<SEC-DOCUMENT>0001193125-13-421071.txt : 20131031
<SEC-HEADER>0001193125-13-421071.hdr.sgml : 20131031
<ACCEPTANCE-DATETIME>20131031165538
ACCESSION NUMBER:		0001193125-13-421071
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20131031
DATE AS OF CHANGE:		20131031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-191567
		FILM NUMBER:		131183349

	BUSINESS ADDRESS:	
		STREET 1:		101 ORCHARD RIDGE DRIVE
		STREET 2:		SUITE 1E
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		101 ORCHARD RIDGE DRIVE
		STREET 2:		SUITE 1E
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d572031ds1a.htm
<DESCRIPTION>AMENDMENT NO. 2 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 2 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>As filed with the Securities and Exchange Commission on October 31, 2013 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Registration No.&nbsp;333-191567 </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>SECURITIES
AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>AMENDMENT NO. 2 </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>TO
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>FORM S-1 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>UNDER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>THE SECURITIES ACT
OF&nbsp;1933 </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="6"><B>GlycoMimetics, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>(Exact
name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:31%">&nbsp;</P></center> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>2834</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>06-1686563</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>401 Professional Drive, Suite 250 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Gaithersburg, MD 20879 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>(240) 243-1201 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Rachel K. King </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Chief
Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>GlycoMimetics, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>401 Professional Drive, Suite 250 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Gaithersburg, MD 20879 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>(240) 243-1201 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Brent B. Siler</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Christian E. Plaza</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Brian F. Leaf</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cooley LLP</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>11951 Freedom
Drive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Reston, VA 20190</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Telephone: (703) 456-8000</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Fax: (703) 456-8100</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Divakar Gupta</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Cheston J. Larson</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Latham &amp; Watkins LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>12636 High Bluff Drive, Suite 400</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>San Diego, CA 92130</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Telephone: (858) 523-5400</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Fax: (858) 523-5450</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Approximate date of commencement of proposed sale to the public:</B>&nbsp;As soon as practicable after the effective date of this registration statement.
</FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:ARIAL" SIZE="1"></FONT> </FONT></P>
<P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT
STYLE="font-family:ARIAL" SIZE="1"></FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:ARIAL" SIZE="1"></FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration
statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:ARIAL" SIZE="1"></FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px;page-break-before:always"></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:31%">&nbsp;</P></center> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="1">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 under the Securities Exchange Act of 1934. (Check one): </FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:ARIAL" SIZE="1"></FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:ARIAL" SIZE="1"></FONT></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT><FONT STYLE="font-family:ARIAL" SIZE="1"></FONT>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:ARIAL" SIZE="1"></FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date
until the registrant shall file a further amendment that specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of the Securities Act of 1933, as amended, or until the
registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Explanatory Note </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:ARIAL" SIZE="2">This Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-191567) is being filed solely to add Exhibit 4.2, re-file Exhibit 10.1 and update Item 15 of the Registration Statement. This Amendment
No. 2 does not modify any provision of the prospectus that forms a part of the Registration Statement. Accordingly, a preliminary prospectus has been omitted. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution.
</B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the sale
of the common stock being registered. All amounts shown are estimates except for the SEC registration fee and the Financial Industry Regulatory Authority, or FINRA, filing fee. </FONT></P>
<P STYLE="font-size:9px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="font-size:9px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>AMOUNT&nbsp;TO<BR>BE PAID</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">11,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">NASDAQ Global Market initial listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">Blue sky fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">700,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">Transfer agent and registrar fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">Miscellaneous fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">125,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">We
are incorporated under the laws of the State of Delaware. Section&nbsp;102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for
monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend
or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </FONT></P> <P STYLE="margin-top:9px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Section&nbsp;145 of the Delaware General
Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including
attorneys&#146; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if
such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except
that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only
to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery or such other court shall deem proper. </FONT></P> <P STYLE="margin-top:9px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">As permitted by the Delaware General Corporation Law, our amended and
restated certificate of incorporation and bylaws to be in effect upon the completion of this offering will provide that: (i)&nbsp;we are required to indemnify our directors to the fullest extent permitted by the Delaware General Corporation Law;
(ii)&nbsp;we may, in our discretion, indemnify our officers, employees and agents as set forth in the Delaware General Corporation Law; (iii)&nbsp;we are required, upon satisfaction of certain conditions, to advance all expenses incurred by our
directors in connection with certain legal proceedings; (iv)&nbsp;the rights conferred in the bylaws are not exclusive; and (v)&nbsp;we are authorized to enter into indemnification agreements with our directors, officers, employees and agents.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">We have entered into agreements with our directors that require us to indemnify them against expenses, judgments,
fines, settlements and other amounts that any such person becomes legally obligated to pay (including with respect to a derivative action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by
reason of the fact that such person is or was a director or officer of us or any of our affiliates, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, our best interests. The
indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. We intend to enter into similar indemnification agreements with our executive officers prior to the completion of
this offering. At present, no litigation or proceeding is pending that involves any of our directors or officers regarding which indemnification is sought, nor are we aware of any threatened litigation that may result in claims for indemnification.
</FONT></P> <P STYLE="margin-top:9px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">We maintain a directors&#146; and officers&#146; liability insurance policy. The policy insures directors and officers against unindemnified losses
arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy contains various exclusions. </FONT></P>
<P STYLE="margin-top:9px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, the underwriting agreement filed as Exhibit 1.1 to this Registration Statement provides for indemnification by the underwriters of us and our officers
and directors for certain liabilities arising under the Securities Act, or otherwise. Our investor rights agreement with certain investors also provides for cross-indemnification in connection with the registration of our common stock on behalf of
such investors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></FONT></P>  <P STYLE="margin-top:4px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">From October 1, 2010 through the date of the prospectus that is a part of this Registration Statement, we have granted options under our 2003 stock incentive plan to purchase an aggregate of 1,401,537 shares of our
common stock to employees, consultants and directors, having exercise prices ranging from $1.12 to $3.73 per share. Of these, options to purchase an aggregate of 26,847 shares have been cancelled without being exercised. During the period from
October 1, 2010 through the date of the prospectus that is a part of this Registration Statement, an aggregate of 406,724 shares were issued upon the exercise of stock options, at an exercise price of $1.12 per share, for aggregate proceeds of
approximately $455,000. </FONT></P>  <P STYLE="margin-top:9px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">The offers, sales and issuances of the stock options and the common stock issuable upon exercise of such options as
described in this Item 15&nbsp;were exempt from registration under Rule&nbsp;701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701.
The recipients of such securities were our employees, directors or consultants and received the securities under our 2003 stock incentive plan. Appropriate legends were affixed to the securities issued in these transactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></FONT></P>
<P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">The exhibits to the Registration Statement are listed in the Exhibit Index attached hereto and are incorporated by reference herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Item&nbsp;17. Undertakings. </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">The undersigned Registrant
hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.
</FONT></P> <P STYLE="margin-top:9px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
</FONT></P> <P STYLE="margin-top:9px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">The undersigned Registrant hereby undertakes that: </FONT></P> <P STYLE="font-size:9px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance
upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared
effective. </FONT></TD></TR></TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>SIGNATURES </B></FONT></P>  <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Amendment No.&nbsp;2 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in
the City of Gaithersburg, State of Maryland, on the 31st day of October, 2013. </FONT></P>  <P STYLE="font-size:9px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>GLYCOMIMETICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">B<SMALL>Y</SMALL>:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ Rachel K. King</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Rachel K. King</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>President and Chief Executive
Officer</I></FONT></P></TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:9px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to the requirements of the Securities Act, this Amendment No.&nbsp;2 to Registration Statement has been signed by
the following persons in the capacities and on the dates indicated. </FONT></P>  <P STYLE="font-size:9px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>SIGNATURE</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>TITLE</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>DATE</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ Rachel K. King</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.47em; text-indent:-1.47em" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">Rachel K. King</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">President, Chief Executive Officer and Director</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>(Principal Executive Officer)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">October 31, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ Brian M. Hahn</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.47em; text-indent:-1.47em" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">Brian M. Hahn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">Chief Financial Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>(Principal Financial
Officer and Principal Accounting Officer)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">October 31, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-bottom:0px;margin-top:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.47em; text-indent:-1.47em" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">John J. Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">October 31, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.47em; text-indent:-1.47em" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">M. James Barrett, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">October 31, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.47em; text-indent:-1.47em" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">William M. Gust</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">October 31, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-bottom:0px;margin-top:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.47em; text-indent:-1.47em" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">Michael A. Henos</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">October 31, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-bottom:0px;margin-top:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.47em; text-indent:-1.47em" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">John L. Magnani, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">October 31, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-bottom:0px;margin-top:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.47em; text-indent:-1.47em" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">Franklin H. Top, Jr., M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">October 31, 2013</FONT></TD></TR>
</TABLE>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;/s/ Brian M. Hahn&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">Brian M. Hahn</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2">Attorney-in-fact</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>EXHIBIT</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:33pt"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>NUMBER</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>DESCRIPTION OF DOCUMENT</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;1.1^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Underwriting Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.1^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Amended and Restated Certificate of Incorporation, as currently in effect.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.2^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Certificate of Amendment of Restated Certificate of Incorporation.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.3^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Amended and Restated Certificate of Incorporation to be effective upon the completion of this offering.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.4^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Amended and Restated Bylaws, as currently in effect.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;3.5^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Amended and Restated Bylaws to be effective upon completion of this offering.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Reference is made to exhibits 3.1 through 3.5.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Specimen stock certificate evidencing shares of Common Stock.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;5.1^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Opinion of Cooley LLP as to legality.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">License Agreement, dated as of October 7, 2011, as amended to date, by and between the Registrant and Pfizer Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.2^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Second Amended and Restated Investor Rights Agreement, dated as of October 20, 2009, by and among the Registrant and certain of its stockholders.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.3^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Lease Agreement, dated as of July 1, 2010, as amended through December 6, 2011, by and between the Registrant and ARE-QRS Corp.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.4^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant Issued to Silicon Valley Bank, dated October 12, 2006.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.5^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Common Stock Warrant issued in December 2005 bridge financing.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.6^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Common Stock Warrant issued in July 2008 bridge financing.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.7^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Common Stock Warrant issued in January 2009 bridge financing.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.8+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">2003 Stock Incentive Plan, as amended to date.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.9+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Incentive Stock Option Agreement under 2003 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.10+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Nonqualified Stock Option Agreement under 2003 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.11+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">2013 Equity Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.12+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Stock Option Grant Notice and Stock Option Agreement under 2013 Equity Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.13+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2013 Equity Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.14+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">2013 Employee Stock Purchase Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.15+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Indemnification Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">10.16+^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Form of Employment Agreement with executive officers to be in effect upon the completion of this offering.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">23.1^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">23.2^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Consent of Cooley LLP (included in Exhibit 5.1).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL" SIZE="2">24.1^</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">Power of Attorney. See page II-4 to the Registration Statement on Form S-1 (No. 333-191567) filed with the Securities and Exchange Commission on October 4, 2013.</FONT></TD></TR>
</TABLE>  <P STYLE="font-size:9px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">^</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">Previously filed. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">+</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">Portions of this exhibit, indicated by asterisks, have been omitted pursuant to a request for confidential treatment and have been separately filed with the Securities and
Exchange Commission. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">II-5 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>d572031dex42.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g572031ex4_2pg001new.jpg" ALT="LOGO">

 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">GM </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SEE REVERSE FOR
CERTAIN DEFINITIONS </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">COMMON STOCK </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">COMMON STOCK </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">GlycoMimetics, Inc. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">GlycoMimetics, Inc. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">CUSIP </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">38000Q 10 2 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THIS CERTIFIES THAT </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">IS THE RECORD HOLDER OF </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE
PER SHARE, OF </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">GlycoMimetics, Inc. (the &#147;Corporation&#148;), </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">transferable
on the books of the Corporation in person or by duly authorized attorney upon surrender of the Certificate properly endorsed. This Certificate and the shares represented hereby are issued and shall be held subject to all of the provisions of the
Certificate of Incorporation, as amended, and the Bylaws, as amended, of the Corporation. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">This Certificate is not valid unless countersigned by the Transfer Agent
and registered by the Registrar. WITNESS the facsimile seal of the Corporation and facsimile signatures of its duly authorized officers. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Dated: </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">COUNTERSIGNED AND REGISTERED: </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">AMERICAN STOCK TRANSFER &amp; TRUST COMPANY, LLC </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">(Brooklyn, NY) </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">TRANSFER AGENT </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">AND REGISTRAR </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">BY: </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">AUTHORIZED SIGNATURE </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">PRESIDENT AND CHIEF EXECUTIVE OFFICER </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SECRETARY </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">GlycoMimetics, Inc. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">CORPORATE </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SEAL </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">2003 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">DELAWARE </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">* </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">&copy; SECURITY-COLUMBIAN UNITED STATES </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">BANKNOTE COMPANY </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d572031dex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>LICENSE AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LICENSE AGREEMENT dated as of
the 7th day of October, 2011 (the &#147;<U>Agreement</U>&#148;) is made between GlycoMimetics, Inc., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (&#147;GMI&#148;) and Pfizer
Inc., a Delaware corporation having its principal place of business at 235 East 42</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> Street, New York, New York 10017 (&#147;<U>Pfizer</U>&#148;). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">RECITALS
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, GMI owns or otherwise controls the Compound (as defined below) and Licensed Product (as defined below) and GMI
desires to grant an exclusive license to Pfizer in the Territory (as defined below) with respect thereto; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Pfizer
has extensive experience and expertise in the development and commercialization of pharmaceutical products and desires to obtain such an exclusive license in the Territory to the Compound and the Licensed Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW THEREFORE, in consideration of the premises and of the covenants herein contained, the Parties hereto mutually agree as follows:
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article 1 DEFINITIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For purposes of this Agreement, the terms defined in this Article shall have the meanings specified below, whether used in their singular or plural form. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1 &#147;<U>Additional Ongoing Clinical Trial Costs</U>&#148; has the meaning set forth in Section&nbsp;3.1(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2 &#147;<U>Additional Phase II Clinical Trial</U>&#148; has the meaning as set forth in Section&nbsp;3.2(b). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3 &#147;<U>Affiliate</U>&#148; means with respect to a Person, any Person that controls, is controlled by or is under common control
with such first Person. For purposes of this definition only, &#147;control&#148; means (a)&nbsp;to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by
contract relating to voting rights or corporate governance, or (b)&nbsp;to own, directly or indirectly, more than fifty percent (50%)&nbsp;of the outstanding voting securities or other ownership interest of such Person.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Notwithstanding the foregoing, (i)&nbsp;venture capital and other institutional financial investors in GMI (including venture capital and other funds, and their investors and managers), and
(ii)&nbsp;any Person that is under common control with GMI as a result of control of such Person and GMI by such venture capital or other financial investor in GMI of part (i), in each case, shall not be considered Affiliates of GMI for purposes of
this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4 &#147;<U>Business Day</U>&#148; means each day of the week, excluding Saturday, Sunday, and bank or other
public holidays in New York, New York. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5 &#147;<U>Change of Control</U>&#148; means, with respect to a Party or its parent
corporation, (a)&nbsp;a merger or consolidation of such Party or such parent corporation with a Third Party which results in the voting securities of such Party or such parent corporation outstanding immediately prior thereto ceasing to represent at
least fifty percent (50%)&nbsp;of the combined voting power of the surviving entity immediately after such merger or consolidation, or (b)&nbsp;a transaction or series of related transactions in which a Third Party, together with its Affiliates,
becomes the beneficial owner of fifty percent (50%)&nbsp;or more of the combined voting power of the outstanding securities of such Party or such parent corporation, or (c)&nbsp;the sale or other transfer to a Third Party of all or substantially all
of such Party&#146;s assets or business or substantially all of such Party&#146;s business which encompasses the Compound or Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.6 &#147;<U>Combination Product</U>&#148; means a Licensed Product that in a single formulation or in a single package contains both a Compound and one or more Other Active Compounds. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7 &#147;<U>Commercially Reasonable Efforts</U>&#148; means, (i)&nbsp;with respect to development of a Licensed Product, efforts and
resources that are reasonably sufficient, as measured by the facts and circumstances at the time such efforts and resources are carried out, to obtain Regulatory Approval in a reasonable period of time, which efforts and resources and reasonable
period of time takes into account anticipated product labeling, medical and clinical considerations, safety, efficacy and regulatory environment, and present and future market potential and other reasonably relevant factors, and (ii)&nbsp;with
respect to marketing and selling of a Licensed Product, efforts and resources, as measured by the facts and circumstances at the time such efforts and resources are carried out, that are consistent with present and future market potential, financial
return, labeling, channels of trade, competitive market conditions, historical performance of the Licensed Product, regulatory requirements, applicable Laws and other reasonably relevant factors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8 &#147;<U>Competing Product</U>&#148; has the meaning set forth in Article 10.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9 &#147;<U>Completion of the Ongoing Clinical Trial</U>&#148; means delivery of the Topline Study Report to Pfizer by or on
behalf of GMI. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10 &#147;<U>Compound</U>&#148; means (i)&nbsp;GMI-1070 and all modifications, enhancements, improvements and
backups which result in a [*&nbsp;*&nbsp;*], pan selectin antagonist [* * *] and (ii)&nbsp;all isomers, tautomers, enantiomers, hydrates, esters, racemates, polymorphs, metabolites, prodrugs, and salts of any of the compounds of subpart (i)&nbsp;of
this Section&nbsp;1.10 that are a [* * *], pan selectin antagonist [* * *]. For the avoidance of doubt, Compounds include without limitation the backups specified in Schedule&nbsp;1.10. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.11 &#147;<U>Dollars</U>&#148; or <U>&#147;$&#148;</U> means the legal tender of the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12 &#147;<U>Effective Date</U>&#148; means the date first hereinabove written. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.13 &#147;<U>EMA</U>&#148; means the European Medicines Evaluation Agency or any successor thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.14 &#147;<U>Excluded GMI Affiliate Patent Rights</U>&#148; means any Patent Right owned or controlled by a Future Affiliate of GMI, to
the extent, but only to the extent, that such Patent Right: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">is not controlled by such Future Affiliate pursuant to any license or other grant of rights by GMI (or any Affiliate of GMI other than a Future Affiliate of GMI) to
such Future Affiliate; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) is owned or controlled by such Future Affiliate of GMI at the time such Future Affiliate becomes an Affiliate of GMI or (B)&nbsp;is subsequently owned or controlled
by such Future Affiliate but is developed independently of and without the use of any GMI Patent Right or GMI Know-how controlled by GMI (or any Affiliate of GMI other than a Future Affiliate of GMI) at the time such Future Affiliate becomes an
Affiliate of GMI. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.15 &#147;<U>FDA</U>&#148; means the United States Food and Drug Administration or any
successor agency in the United States with responsibilities comparable to those of the United States Food and Drug Administration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.16 &#147;<U>Field</U>&#148; means any and all fields of use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.17
&#147;<U>First Commercial Sale</U>&#148; means the first sale of a Licensed Product by (i)&nbsp;Pfizer or its Affiliate or Sublicensee or (ii)&nbsp;with respect to Section&nbsp;9.6, GMI or its Affiliates or Sublicensee, in each case to a Third Party
in a country following Regulatory Approval (to the extent necessary for commercial sale, and, in any country in which Pricing Approval is necessary or relevant for a majority of the population to obtain access to pharmaceutical products, Pricing
Approval) of such Licensed Product in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18 &#147;<U>First Indication</U>&#148; means Sickle Cell Disease.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19 &#147;<U>Future Affiliate</U>&#148; means, with respect to either Party, a Third Party that is not an Affiliate of such
Party as of the Effective Date but that subsequently becomes an Affiliate of such Party as a result of a Change of Control of such Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.20 &#147;<U>GAAP</U>&#148; means United States generally accepted accounting principles as applicable to each Party, consistently applied. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.21 &#147;<U>Generic Product</U>&#148; means any pharmaceutical product that (i)&nbsp;is sold by a Third Party that is not a licensee or
Sublicensee of Pfizer or its Affiliates, or any of their licensees or Sublicensees under a marketing authorization granted by a Regulatory Authority to such Third Party, and (ii)&nbsp;contains the same Compound as an active pharmaceutical ingredient
as the relevant Licensed Product and (x)&nbsp;for purposes of the United States, is approved through an Abbreviated New Drug Application or successor or similar process by reliance on the prior approval of a Licensed Product as determined by the
FDA, or (y)&nbsp;for purposes of a country outside the United States, is approved through an abbreviated process in reliance on the prior approval of a Licensed Product as determined by the applicable Regulatory Authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.22 &#147;<U>GMI-1070</U>&#148; means each of the compounds described in Schedule 1.22, all isomers, stereoisomers, diastereoisomers,
tautomers, enantiomers, hydrates, esters, racemates, polymorphs, metabolites, prodrugs, and salts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.23 &#147;<U>GMI Excluded
Patent Rights</U>&#148; means Patent Rights owned by GMI that cover an Other Active Compound and/or manufacture or use thereof independent of a Compound. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.24 &#147;<U>GMI Indemnitees</U>&#148; has the meaning set forth in Section&nbsp;8.1. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.25 &#147;<U>GMI Know-How</U>&#148; means (i)&nbsp;Know-How owned by or licensed to GMI as
of the Effective Date and (ii)&nbsp;Know-How owned by GMI after the Effective Date that is developed prior to Completion of the Ongoing Clinical Trial, obtained as a result of or in connection with any trials with respect to the Compound, and in
either case which is useful for the manufacture, research or development of any Compound. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.26 &#147;<U>GMI Net
Sales</U>&#148; means with respect to a Licensed Product, the gross amount invoiced by GMI and/or its Affiliates and/or its sublicensees of such Licensed Product to Third Parties, less (i)&nbsp;[* * *] and (ii)&nbsp;[* * *]. In the case of
Combination Products: (1)&nbsp;if GMI and/or its Affiliates and/or its sublicensees of such Licensed Product [* * *] and [* * *], the GMI Net Sales attributable to such Combination Product during such year shall be calculated by [* * *]; (2)&nbsp;if
GMI and/or its Affiliates and/or its sublicensees of such Licensed Product [* * *], the GMI Net Sales attributable to such Combination Product during such year shall be calculated by [* * *]; and (3)&nbsp;if GMI and/or its Affiliates and/or it
sublicensees of such Licensed Product [* * *], then the GMI Net Sales attributable to such Combination Product shall be [* * *]; <I>provided</I>, that the quarterly report provided by GMI with respect to GMI Net Sales in accordance with
Section&nbsp;9.6 shall include the calculations for subclauses (1), (2)&nbsp;and (3)&nbsp;above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">GMI Net Sales shall be
determined from the books and records maintained in accordance with GAAP, as consistently applied by GMI. The calculation of GMI Net Sales will involve the use of estimates for certain deductions above. Those estimates will be accrued and GMI Net
Sales trued-up at least quarterly to actual in accordance with GAAP and GMI&#146;s internal accounting policies, as consistently applied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.27 &#147;<U>GMI Patent Rights</U>&#148; means Patent Rights, other than Excluded GMI Affiliate Patent Rights, (i)&nbsp;owned by GMI or licensed to GMI with the right to grant a sublicense, in each case
as of the Effective Date and in each case to the extent such Patent Rights cover a Compound or the manufacture or use thereof and/or a Licensed Product and/or the manufacture or use thereof, but excluding claims that cover an Other Active Compound
and/or manufacture or use thereof independent of a Compound and (ii)&nbsp;Patent Rights that are not GMI Excluded Patent Rights and are owned by GMI after the Effective Date and prior to the end of the Term, in each of the foregoing cases to the
extent such Patent Rights cover a Compound or the manufacture or use thereof and/or a Licensed Product and/or the manufacture or use thereof, and wherein the GMI Patent Rights defined herein include those set forth in Exhibit A which shall be
supplemented as necessary by GMI. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28 &#147;<U>Governmental Authority</U>&#148; means any court, agency, department,
authority or other instrumentality of any national, state, county, city or other political subdivision. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.29
&#147;<U>Indemnitee</U>&#148; has the meaning set forth in Section&nbsp;8.3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.30 &#147;<U>IND</U>&#148; means an
Investigational New Drug, Application or similar application or submission for approval to conduct human clinical investigations that is filed or submitted to a Regulatory Authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.31 &#147;<U>Invention</U>&#148; means all inventions, discoveries, improvements and other technology, whether or not patentable.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.32 &#147;<U>JDT</U>&#148; has the meaning set forth in Section&nbsp;3.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.33 &#147;<U>JSC</U>&#148; has the meaning set forth in Section&nbsp;3.2(b). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.34 &#147;<U>Know-How</U>&#148; means ideas, writings, data (including but not limited to pre-clinical and clinical data), methods,
techniques, materials, information (including scientific and technical information), know-how, assays, compounds, and Inventions and the rights thereto other than Patent Rights, including but not limited to manufacturing and formulation information,
whether or not patentable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.35 &#147;<U>Knowledge</U>&#148; means with respect to a Party, the actual knowledge of the
officers and agents of such Party, without conducting an investigation other than making inquiries of their attorneys. The officers and agents of GMI with respect to this definition are limited to those individuals listed on Part A of Schedule 1.35,
and the attorneys as to which GMI made inquiries are limited to those on Part B of Schedule 1.35. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.36 &#147;<U>Law</U>&#148;
or &#147;<U>Laws</U>&#148; means all laws, statutes, rules, regulations, orders, judgments and/or ordinances of any Governmental Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.37 &#147;<U>Licensed Product</U>&#148; means (a)&nbsp;the Compound and (b)&nbsp;any pharmaceutical product, in all dosage forms and formulations, that contains a Compound the manufacture, sale, offer
for sale, importation, or use of which (i)&nbsp;is covered by a Valid Claim of GMI Patent Rights and/or (ii)&nbsp;embodies or incorporates GMI Know-How or is derived or results from the use of GMI Know-How. For the avoidance of doubt, &#147;Licensed
Product&#148; shall also collectively refer to Combination Product. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38 &#147;<U>Litigation Conditions</U>&#148; has the meaning set forth in Section&nbsp;8.4.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.39 &#147;<U>Losses</U>&#148; has the meaning set forth in Section&nbsp;8.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.40 &#147;<U>Major Country of Europe</U>&#148; means each of [* * * ] and [* * *]. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.41 &#147;<U>Net Sales</U>&#148; means, with respect to a Licensed Product, the gross amount invoiced by Pfizer, its Affiliates and its
Sublicensees for such Licensed Product to Third Parties, less (i)&nbsp;[* * *] and (ii)&nbsp;[* * *]. In the case of Combination Products: (1)&nbsp;if Pfizer and/or its Affiliates or Sublicensees [* * *], the Net Sales attributable to such
Combination Product during such year shall be calculated by [* * *]; (2)&nbsp;if Pfizer and/or its Affiliates or Sublicensees [* * *], the Net Sales attributable to such Combination Product during such year shall be calculated [* * *]; and
(3)&nbsp;if Pfizer and/or its Affiliates or Sublicensees [* * *], then the Net Sales attributable to such Combination Product shall be [* * *]; <I>provided</I>, that the quarterly report provided by Pfizer with respect to Net Sales in accordance
with Section&nbsp;4.3 shall include the calculations for subclauses (1), (2)&nbsp;and (3)&nbsp;above and GMI shall have the right to audit such calculations as set forth in Section&nbsp;4.4. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Sales shall be determined from the books and records maintained in accordance with GAAP, as consistently applied by Pfizer. The
calculation of Net Sales will involve the use of estimates for certain deductions above. Those estimates will be accrued and Net Sales trued-up at least quarterly to actual in accordance with GAAP and Pfizer&#146;s internal accounting policies, as
consistently applied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42 &#147;<U>Ongoing Clinical Trial</U>&#148; means the Phase II Clinical Trial being performed by GMI
with respect to GMI-1070 under Protocol GMI-1070-201. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.43 &#147;<U>Other Active Compound</U>&#148; means a therapeutically
active compound that is not a Compound. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.44 &#147;<U>Party</U>&#148; means GMI or Pfizer and collectively the
&#147;Parties&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.45 &#147;<U>Patent Rights</U>&#148; means United States and foreign counterpart patents, patent
applications, provisional patent applications, certificates of invention, applications for certificates of invention, divisions, continuations, continuations-in-part, non-provisional patent applications
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
claiming priority benefit of a provisional application, continued prosecution applications, national and regional stage counterparts, together with any patent term extensions, registrations,
confirmations, reissues, re-examinations or renewals and supplemental examinations of the foregoing as well as supplementary protection certificates or the equivalent thereof, and any other form of government-issued patent protection directed to the
inventions claimed in the foregoing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.46 &#147;<U>Person</U>&#148; means an individual, sole proprietorship, partnership,
limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or
political subdivision, department or agency of a government. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.47 &#147;<U>Pfizer Excluded Patent Rights</U>&#148; means
Patent Rights owned by or licensed to Pfizer or its Affiliates that cover an Other Active Compound and/or manufacture or use thereof independent of a Compound. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.48 &#147;<U>Pfizer Indemnitees</U>&#148; has the meaning set forth in Section&nbsp;8.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.49 &#147;<U>Pfizer Know-How</U>&#148; means Know-How owned by or licensed to Pfizer or its Affiliates (with the right to grant sublicenses) as of the date of termination covered by Section&nbsp;9.5
which (a)&nbsp;constitute improvements to Compound or Licensed Product or the manufacture or use thereof, where such improvements were created or made in the course of activities carried out pursuant to the licenses granted to Pfizer in
Section&nbsp;2.1, or (b)&nbsp;Pfizer had actually applied or used with respect to a Compound or Licensed Product prior to any termination of this Agreement, provided that such Know-How is necessary or useful for the continued research, development,
manufacture or commercialization of such Compound or Licensed Product in the Reference Forms, or (ii)&nbsp;Pfizer had, prior to any termination of this Agreement, incorporated into such Compound or Licensed Product in the Reference Forms as of the
time of such termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50 &#147;<U>Pfizer Patent Rights</U>&#148; means Patent Rights owned by Pfizer or its Affiliates
or licensed to Pfizer or its Affiliates (with the right to grant sublicenses) that are not Pfizer Excluded Patent Rights, in each case as of the date of termination covered by Section&nbsp;9.5 of this Agreement and in each case to the extent such
Patent Rights (a)&nbsp;cover improvements to a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Compound or the manufacture or use thereof and/or improvements to a Licensed Product and/or the manufacture or use thereof, in each case described in this clause (a)&nbsp;where such improvement
was created or made in the course of activities carried out pursuant to the licenses granted to Pfizer in Section&nbsp;2.1, or (b)&nbsp;cover a product, composition or process that (i)&nbsp;Pfizer had actually applied or used with respect to a
Compound or Licensed Product prior to any termination of this Agreement, provided that such a product, composition or process is necessary or useful for the continued research, development, manufacture or commercialization of such Compound or
Licensed Product in the Reference Forms as of the time of such termination, or (ii)&nbsp;Pfizer had, prior to any termination of this Agreement, incorporated into such Compound or Licensed Product in the Reference Forms as of the time of such
termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.51 &#147;<U>Pfizer Quarter</U>&#148; means (i)&nbsp;in the United States, each of the four (4)&nbsp;thirteen
(13)&nbsp;week periods as used by Pfizer in its audited financial reports, the first commencing on January&nbsp;1 of any year, and (ii)&nbsp;in any country in the Territory other than the United States, each of the four (4)&nbsp;thirteen
(13)&nbsp;week periods as used by Pfizer in its audited financial reports, the first commencing on December&nbsp;1 of any year. With respect to Net Sales, the Net Sales for a Pfizer Quarter is the aggregate of Net Sales in the United States and
outside the United States for the applicable Pfizer Quarter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.52 &#147;<U>Pfizer Year</U>&#148; means the twelve
(12)&nbsp;month period (i)&nbsp;with respect to the United States, commencing on January&nbsp;1st of any calendar year and (ii)&nbsp;with respect to any country in the Territory other than the United States, commencing on December&nbsp;1st of any
calendar year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.53 &#147;<U>Phase II Clinical Trial</U>&#148; means for the purpose of obtaining Regulatory Approval a study
in humans of the safety, dose range and efficacy of a Product that is prospectively designed to generate sufficient data to commence a Phase III Clinical Trial that would satisfy the requirements of 21 C.F.R. 312.21(b), or the equivalent process in
other countries or groups of countries of the Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.54 &#147;<U>Phase III Clinical Trial</U>&#148; means a controlled
study in humans of the efficacy and safety of a Product that is prospectively designed to demonstrate statistically whether such Product is effective and safe for use in a particular indication in a manner sufficient to obtain Regulatory Approval to
market such Product that would satisfy the requirements of 21 C.F.R. 312.21(c), or the equivalent process in other countries or groups of countries of the Territory. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.55 &#147;<U>Phase III Milestone Advance</U>&#148; has the meaning set forth in
Section&nbsp;4.1(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.56 &#147;<U>Pricing Approval</U>&#148; means, in any country where a Governmental Authority authorizes
reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or
determination (as the case may be). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.57 &#147;<U>Product Infringement</U>&#148; has the meaning set forth in
Section&nbsp;5.2(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.58 &#147;<U>Reference Form</U>&#148; means a Compound or Licensed Product (i)&nbsp;in the form being
sold by Pfizer at the time of termination of this Agreement covered by Section&nbsp;9.5, and/or (ii)&nbsp;in the form used in any ongoing clinical trial at the time of termination of this Agreement covered by Section&nbsp;9.5 and/or (iii)&nbsp;in
the form used in a clinical trial completed by Pfizer at the time of termination of this Agreement covered by Section&nbsp;9.5. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.59 &#147;<U>Regulatory Approval(s)</U>&#148; means any and all approvals, with respect to any jurisdiction, or authorizations (other
than Pricing Approvals) of a Regulatory Authority, that are necessary for the commercial manufacture, distribution, use, marketing or sale of a pharmaceutical product in such jurisdiction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.60 &#147;<U>Regulatory Authority</U>&#148; means, in respect of a particular country or jurisdiction, the Governmental Authority having
responsibility for granting Regulatory Approvals in such country or jurisdiction, including in the United States the FDA, and any successor governmental authority having substantially the same function. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.61 &#147;<U>Second Indication</U>&#148; means any indication other than the First Indication. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.62 &#147;<U>Sickle Cell Disease</U>&#148; means sickle cell disease or sickle cell anemia, a chronic anemia marked by sickle-shaped red
blood cells occurring in individuals who are homozygous for a mutant hemoglobin gene. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.63 &#147;<U>Sublicensee</U>&#148;
means any person or entity that is granted a sublicense by Pfizer under the license granted to Pfizer pursuant to this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.64 &#147;<U>Term</U>&#148; has the meaning set forth in Section&nbsp;9.1. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65 &#147;<U>Territory</U>&#148; means the entire world. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.66 &#147;<U>Third Party</U>&#148; means any entity other than GMI or Pfizer and any respective Affiliates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.67 &#147;<U>Third Party Claim</U>&#148; has the meaning set forth in Section&nbsp;8.4. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.68 &#147;<U>Third Party Royalty</U>&#148; has the meaning set forth in Section&nbsp;4.2(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.69 &#147;<U>Topline Study Report</U>&#148; means a summary of results, including data tables, with respect to the Ongoing Clinical
Trial, in the form attached in Schedule 1.69. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.70 &#147;<U>Transition Plan</U>&#148; has the meaning set forth in
Section&nbsp;2.3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.71 &#147;<U>United States</U>&#148; or &#147;<U>U.S.</U>&#148; means the United States of America and its
territories and possessions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.72 &#147;<U>Valid Claim</U>&#148; &#147; means, with respect to a particular country, an
issued claim of an unexpired granted patent which claim (i)&nbsp;has not been cancelled, withdrawn, abandoned, or disclaimed, and (ii)&nbsp;has not been permanently revoked, held invalid or unenforceable by a decision of a court of competent
jurisdiction or administrative agency in an unappealed or unappealable decision in the subject country, and (iii)&nbsp;has not been admitted to be invalid or unenforceable through reissue or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.73 &#147;<U>Withholding Party</U>&#148; has the meaning set forth in Section&nbsp;4.5. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article 2 LICENSES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>Exclusive License</U>. Subject to the terms of this Agreement, GMI hereby grants to Pfizer an exclusive license or sublicense (even as to GMI), as the case may be, with the right to grant
sublicenses pursuant to Section&nbsp;2.2, under GMI Patent Rights and GMI Know-How to research, develop, make, have made, use, sell, offer to sell, supply, cause to be supplied, import and have imported Licensed Product in the Field in the
Territory. GMI covenants and agrees that neither GMI nor its Affiliates will practice, use or exploit GMI Patent Rights and/or GMI Know-How with respect to Compound, except in performing and completing the Ongoing Clinical Trial and for carrying out
or allowing Third Parties to carry out the studies described in Schedule 2.1. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Right to Sublicense</U>. Within its sole discretion, Pfizer may grant exclusive or
non-exclusive sublicenses under any of the rights and licenses granted to Pfizer under Section&nbsp;2.1 of this Agreement subject to the following conditions: (i)&nbsp;each sublicense shall be subject to and consistent with the rights and licenses
granted under this Agreement; (ii)&nbsp;each sublicense shall include an obligation of the Sublicensee to account for and report its sales of Licensed Products to Pfizer on the same basis as if such sales were Net Sales by Pfizer; and
(iii)&nbsp;each sublicense shall require the Sublicensee to be bound by the terms and conditions of this Agreement (other than payment provisions for which Pfizer is responsible) as if the Sublicensee was a signatory to this Agreement. Pfizer shall
provide GMI with prompt written notice that a sublicense has been granted or terminated. The name of the Sublicensee and a copy of the sublicense agreement and any amendments thereto, which agreements and amendments shall be redacted as to any
financial and other proprietary information, shall be furnished by Pfizer to GMI within thirty (30)&nbsp;days after the execution thereof. Pfizer shall cause a Sublicensee to comply with the terms and conditions of this Agreement and Pfizer shall be
liable to GMI for any breach of such terms and conditions by any Sublicensee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3 <U>Disclosure of Technology</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) GMI shall provide to Pfizer the GMI Know-How and a copy of filings, minutes and correspondence with a
Regulatory Authority in its possession that may be necessary or useful to Pfizer to develop, manufacture, register, or market Licensed Products and efficiently practice the licenses granted under this Agreement within sixty (60)&nbsp;days of the
Effective Date and thereafter (to the extent not previously disclosed and provided) no later than twenty (20)&nbsp;Business Days after such additional GMI Know-How becomes known or is acquired and a copy of filings, minutes and correspondence with a
Regulatory Authority no later than twenty (20)&nbsp;Business Days after made, and after Completion of the Ongoing Clinical Trial, GMI shall transfer to Pfizer (i)&nbsp;within ten (10)&nbsp;Business Days after database lock for the Ongoing Clinical
Trial all INDs and other filings, minutes and correspondence with a Regulatory Authority, and (ii)&nbsp;within a reasonable period of time after Completion of the Ongoing Clinical Trial, but in any event within ten (10)&nbsp;Business Days after
receiving such information from the relevant service providers, any safety or pharmacovigilance databases, in each case, with respect to Licensed Product in the Territory. GMI shall bear its costs and expense for providing to Pfizer all of the
information described above in this Section&nbsp;2.3. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In order to ensure the smooth transition of such GMI Know-How and
development activities to Pfizer for the Compounds and Licensed Products that GMI has licensed to Pfizer pursuant to Section&nbsp;2.1, each Party shall, at its own cost and expense (except as expressly set forth in the Schedule 2.3), carry out the
activities to be performed by it as set forth in the transition plan attached hereto as Schedule 2.3 (the &#147;<U>Transition Plan</U>&#148;). If there is an inconsistency or disagreement between the Transition Plan and this Agreement, the terms of
this Agreement shall prevail. Neither this Agreement nor the licenses granted hereunder shall be construed to confer any rights or licenses to Pfizer by implication, estoppel or otherwise as to any data, Know-How or Patent Rights other than GMI
Patent Rights and GMI Know-How in accordance with the licenses granted under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In addition
to providing the information described in Section&nbsp;2.3(a) and the transition services described in Section&nbsp;2.3(b), at the request of Pfizer, GMI shall provide Pfizer with reasonable technical assistance with respect to understanding and
implementing the GMI Know-How and filings, minutes and correspondence with a Regulatory Authority provided to Pfizer under the foregoing provisions of this Section&nbsp;2.3; provided, however, that in providing assistance under this
Section&nbsp;2.3(c), GMI shall provide [* * *] of meetings between the appropriate GMI representatives and Pfizer representatives and an additional [* * *] of GMI representatives at no cost to Pfizer, and Pfizer shall pay GMI on a person-hour basis
for any additional assistance under this Section&nbsp;2.3(c) at a rate and for a number of hours that will be agreed upon in advance between GMI and Pfizer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.4 <U>Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information</U>. Subject to the terms and conditions of this Agreement and any preexisting exclusive license grants
to Third Parties, and without limiting any other license granted to either Party under this Agreement: </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) GMI hereby grants to Pfizer a non-exclusive, irrevocable, perpetual,
royalty-free, fully paid-up, worldwide license, with the right to sublicense to Pfizer Affiliates, to use only for research purposes any and all GMI Know-How or Confidential Information of GMI disclosed to Pfizer during the Term but not any GMI
Patent Rights, it being understood and agreed that neither Pfizer nor any of its Affiliates will have any right or license under this Section&nbsp;2.4 to use any such GMI Know-How or GMI Confidential Information with respect to Compound or Licensed
Product after termination of this Agreement and/or in connection with obtaining Regulatory Approval of a pharmaceutical product and/or the sale or manufacture for sale of any pharmaceutical product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Pfizer hereby grants to GMI a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license,
with the right to sublicense to GMI Affiliates, to use only for research purposes any and all Pfizer Know-How or Confidential Information of Pfizer disclosed to GMI during the Term (but not any Pfizer Patent Rights ), it being understood and agreed
that neither GMI nor any of its Affiliates will have any right or license under this Section&nbsp;2.4 to use any such Pfizer Know-How or Pfizer Confidential Information in connection with obtaining Regulatory Approval of a pharmaceutical product
and/or the sale or manufacture for sale of any pharmaceutical product. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article 3 DEVELOPMENT, REGULATORY AND
COMMERCIALIZATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Completion of the Ongoing Clinical Trial</U>. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Supervision and Control</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) Subject to subsections (ii)&nbsp;and Section&nbsp;3.1(b) and 3.1(c), GMI shall complete the Ongoing Clinical Trial as soon as reasonably practicable after the Effective Date at the cost and expense of
GMI and under the supervision and control of the JDT (as defined below); <I>provided</I>, that such supervision and control of the JDT is in accordance with applicable Laws and is in conformance with GMI&#146;s obligations under any agreements with
a Third Party that exist as of the Effective Date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Notwithstanding Section&nbsp;3.1(a)(i), GMI shall not be required to
continue the Ongoing Clinical Trial in the event that GMI reasonably believes that continuing the Ongoing Clinical Trial raises concerns about patient safety and/or would be in violation of any applicable Law; <I>provided</I>, that GMI shall
promptly notify Pfizer in writing of any such decision to discontinue the Ongoing Clinical Trial and Pfizer shall be required to provide its written consent for such discontinuation, which consent shall not be unreasonably withheld. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Joint Development Team</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Purpose</U>. Within thirty (30)&nbsp;days after the Effective Date, the Parties shall establish a Joint Development Team (&#147;<U>JDT</U>&#148;) for the purpose of supervising and controlling the
Ongoing Clinical Trial, including but not limited to (i)&nbsp;reviewing and approving all development, regulatory and pharmaceutical sciences plans and all material changes thereto, (ii)&nbsp;reviewing and approving the scientific integrity,
statistical analysis plans and protocols of the Ongoing Clinical Trial and (iv)&nbsp;reviewing and discussing data and results, including with respect to safety issues, of the Ongoing Clinical Trial. The JDT shall be composed of six (6)&nbsp;members
(or such other number as mutually agreed in writing by the Parties) with three (3)&nbsp;members designated by each Party in writing to the other Party, who each are employees or contracted consultants of their respective Parties and have the
appropriate expertise and authority to participate in the activities and decision-making of the JDT. The JDT shall appoint a chairperson from among its members, which shall be one of the representatives of Pfizer. The chairperson shall be
responsible for calling meetings of the JDT and for leading the meetings. The JDT shall not have the power to make any amendments or modifications to this Agreement. The JDT shall be disbanded upon the Completion of the Ongoing Clinical Trial.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <U>Meetings and Information Requests</U>. The JDT shall meet within twenty (20)&nbsp;Business Days after
the Effective Date and, thereafter, once each month or more frequently if requested by the chairperson in writing. A quorum for the conduct of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
business at any meeting of the JDT shall consist of one representative of Pfizer and one representative of GMI. Each of Pfizer and GMI, shall have one vote, and subject to clause
(iii)&nbsp;below, all decisions shall be reached by a unanimous vote. If a JDT member, including the Chairperson, cannot attend a JDT meeting, such member may send a designate who is authorized to make decisions on behalf of the respective Party,
and such designate shall be permitted to participate fully in such JDT meeting, including casting any required vote. Upon prior written notice, each Party may invite additional employees of such Party to attend any JDT meeting to the extent that
such Party believes that attendance by one or more additional employees is necessary or desirable to fulfill the purpose of the JDT. The location of meetings of the JDT shall alternate between Pfizer&#146;s and GMI&#146;s principal place of
business, or shall be conducted by telephone and/or video conferencing as agreed by the Parties. Each Party shall bear its own expenses related to the attendance at JDT meetings. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that Pfizer requests additional information from GMI with respect to the Ongoing Clinical Trial that is in
the possession or control of GMI (including information controlled by GMI but in the possession of a Third Party), GMI shall provide such information to Pfizer and to the extent reasonably possible such information shall be provided within three
(3)&nbsp;Business Days of such request, provided, however, that GMI shall promptly provide Pfizer with any information with respect to any safety issues. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iii) <U>Decision-Making</U>. In the event that there is a tie vote that is not resolved by the Parties within ten (10)&nbsp;days after the tie vote, then the vote shall be resolved by Pfizer. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) <U>Minutes</U>. The JDT shall keep accurate minutes of its deliberations which shall record all proposed decisions
and all actions recommended or taken. A member of the JDT shall serve as secretary and the Parties shall alternate responsibility for the preparation of the draft minutes on a calendar quarter basis. Draft minutes shall be sent to all members of the
JDT within fifteen (15)&nbsp;days after each meeting and shall be approved, if appropriate, or amended and approved as amended within thirty (30)&nbsp;days by a quorum of the JDT. All records of the JDT shall at all times be available to both Pfizer
and GMI. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Costs for Completion of the Ongoing Clinical Trial</U>. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The budget for the costs for Completion of the Ongoing Clinical Trial after the Effective Date is set forth in Schedule 3.1(c). In the event that GMI anticipates that
the costs for Completion of the Ongoing Clinical Trial after the Effective Date is reasonably likely to exceed [* * *] Dollars ($[* * *]), GMI shall promptly notify the JDT. If GMI anticipates that total costs will exceed [* * *] Dollars ($[* * *]),
GMI shall promptly submit to the JDT for approval a new budget for such costs, together with a detailed explanation of the estimated excess costs. Such new budget must be approved by the JDT prior to the incurrence of any costs in excess of [* * *]
Dollars ($[* * *]). GMI shall be responsible for the costs for Completion of the Ongoing Clinical Trial after the Effective Date, provided that the total costs payable by GMI after the Effective Date for Completion of the Ongoing Clinical Trial
shall not exceed [* * *] Dollars ($[* * *]). Notwithstanding anything else to the contrary, GMI shall have the right to suspend any and all work with respect to the Ongoing Clinical Trial to the extent that the cost thereof after the Effective Date
exceeds [* * *] Dollars ($[* * *]) until the JDT approves a revised budget for the costs of Completion of the Ongoing Clinical Trial as set forth above (such excess costs, the &#147;<U>Additional Ongoing Clinical Trial Costs</U>&#148;). On an
ongoing basis, and no more than [* * *], Pfizer shall reimburse GMI in full for such Additional Ongoing Trial Costs and payment shall be due from Pfizer within [* * *] after receipt of an invoice and an explanation of the Additional Ongoing Clinical
Trial Costs included in the invoice. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that the Additional Ongoing Clinical Trial Costs due and payable by Pfizer hereunder exceed $[* * *], Pfizer shall have the right, after Completion of the
Ongoing Clinical Trial, to engage an independent certified public accounting firm selected by Pfizer and reasonably acceptable to GMI, at Pfizer&#146;s expense, except as set forth below, and upon at least forty-five (45)&nbsp;days prior written
notice and no later than [* * *] after Completion of the Ongoing Clinical Trial, to have access during normal business hours to such of the records of GMI as may be reasonably necessary to verify the accuracy of the Additional Ongoing Clinical Trial
Costs paid by Pfizer hereunder. The accounting firm shall disclose to Pfizer and GMI only whether the Additional Ongoing Clinical Trial Costs are correct or incorrect and the amount of any discrepancy. If such accounting firm identifies an
overpayment of such Additional Ongoing Clinical Trial Costs, GMI shall reimburse to Pfizer the amount of the overpayment within thirty (30)&nbsp;days of the date Pfizer delivers to GMI such accounting firm&#146;s written report so concluding. The
fees charged by such accounting firm shall be paid by Pfizer unless the overpayment exceeded [* * *] percent ([* * *]%) of the amount invoiced by GMI with respect to the Additional Ongoing Clinical Trial Costs, in which case, GMI shall pay to Pfizer
the fees and costs charged by such accounting firm. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Development Activities, Regulatory Approval and
Commercialization After the Completion of the Ongoing Clinical Trial</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Diligence</U>. After
Completion of the Ongoing Clinical Trial, Pfizer agrees to use Commercially Reasonable Efforts to, at its expense, develop, obtain Regulatory Approval for commercialization and continue to commercialize a Licensed Product for the First Indication in
the United States. Pfizer shall notify GMI in writing promptly of any decision to cease development activities, efforts to obtain Regulatory Approval, or commercialization of the Licensed Product for the First Indication in the United States and the
Major Countries of Europe. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Development Activities and Regulatory Affairs</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Development Activities</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) As between GMI and Pfizer, Pfizer shall have the exclusive right and responsibility, at Pfizer&#146;s own expense, to
develop any Compounds and Licensed Products after Completion of the Ongoing Clinical Trial. As between GMI and Pfizer, all decisions with respect to development activities for any Compounds and Licensed Products after Completion of the Ongoing
Clinical Trial shall be made by Pfizer. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) Without limiting the foregoing, after the Completion of the
Ongoing Clinical Trial, as between GMI and Pfizer, Pfizer shall have the sole right to determine whether Pfizer or a Regulatory Authority requires an additional Phase II Clinical Trial (an &#147;<U>Additional Phase II Clinical Trial</U>&#148;) for
Licensed Products with respect to the First Indication, and if such determination is made, to initiate and complete such Additional Phase II Clinical Trial. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) <U>Regulatory Affairs</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) As between GMI and Pfizer,
Pfizer shall have the sole right, at Pfizer&#146;s own expense, to determine all regulatory plans and strategies for the Licensed Products, and will own and be responsible for preparing, seeking, submitting and maintaining all regulatory filings and
Regulatory Approvals for all Licensed Products, including but not limited to, (A)&nbsp;preparing all reports necessary as part of a regulatory filing or Regulatory Approval, (B)&nbsp;having the sole right to determine whether to file for Regulatory
Approval in any country in the Territory, and (C)&nbsp;obtaining Regulatory Approval in any country in the Territory. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) As between GMI and Pfizer, Pfizer shall have the sole right to apply
for and secure exclusivity rights that may be available under the Law of countries in the Territory, including any data or market exclusivity periods such as those periods listed in the FDA&#146;s Orange Book or periods under national
implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 (including any pediatric exclusivity extensions or other forms of regulatory exclusivity that may be available), and all international equivalents. GMI shall reasonably cooperate with
Pfizer and take such reasonable actions to assist Pfizer, in obtaining such exclusivity rights in each country, as Pfizer may reasonably request from time to time. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) <U>Joint Steering Committee</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) <U>Purpose</U>. Within thirty (30)&nbsp;days after the Completion of the Ongoing Clinical Trial, the Parties shall
establish a Joint Steering Committee (&#147;<U>JSC</U>&#148;) for the purpose of exchanging information and reporting on the progress of the development of Licensed Product including but not limited to, clinical trials, as well as regulatory,
manufacturing, safety and efficacy issues and, at the relevant time, discussing at a high level Pfizer&#146;s plans for the initial launch of the Licensed Product (provided that in no event shall Pfizer be obligated to provide detailed
commercialization plans or sensitive commercial information except as set forth in Section&nbsp;4.3 or 4.4). For the avoidance of doubt, the JSC shall be a non-voting entity and no votes or decisions shall be made by its members. The JSC shall be
composed of at least two (2)&nbsp;members (or such other number as mutually agreed in writing by the Parties) designated by each Party in writing to the other Party, who each are employees or contracted consultants of their respective Parties and
have the appropriate expertise and authority to participate in the activities. The JSC shall appoint a chairperson from among its members, which shall </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
be one of the representatives of Pfizer. The chairperson shall be responsible for calling meetings of the JSC and for leading the meetings. At each meeting of the JSC, Pfizer will provide the JSC
with updates as to plans for researching and developing Licensed Product and including an update on work performed with respect to Licensed Product during the previous calendar quarter. The JSC shall not have the power to make any amendments or
modifications to this Agreement. The JSC shall be disbanded upon the earlier of (i)&nbsp;Regulatory Approval by the FDA of a Licensed Product for the First Indication in the United States or (ii)&nbsp;a Change of Control of GMI or (iii)&nbsp;upon
prior written notice by GMI to Pfizer. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) <U>Meetings</U>. The JSC shall meet within forty-five
(45)&nbsp;days after the Completion of the Ongoing Clinical Trial and, thereafter, at least every six (6)&nbsp;months or more frequently if requested by the chairperson in writing. Each Party shall have at least one designated representative in
attendance at any JSC meeting and each Party may invite additional employees of such Party to attend any JSC meeting to the extent that such Party believes that attendance by one or more additional employees is necessary or desirable to fulfill the
purpose of the JSC. If a JSC member cannot attend a JSC meeting, such member may send a designate, and such designate shall be permitted to participate fully in such JSC meeting. The location of meetings of the JSC shall alternate between
Pfizer&#146;s and GMI&#146;s principal place of business, or shall be conducted by telephone and/or video conferencing as agreed by the Parties. Each Party shall bear its own expenses related to the attendance at JSC meetings. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C) <U>Minutes</U>. The JSC shall keep accurate minutes of its discussions held at each meeting. A JSC member of Pfizer
shall serve as secretary of JSC meetings. The secretary of the meeting shall prepare and distribute to all members of the JSC minutes of the meeting within thirty (30)&nbsp;days after each meeting and shall be approved, or revised and approved at
the next JSC meeting. All records of the JSC shall at times be available to both Pfizer and GMI. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) <U>Pfizer Reports</U>. Following such time as the JSC is disbanded,
Pfizer shall provide GMI with a written report summarizing in reasonable detail the development and/or regulatory activities performed by Pfizer and its Affiliates and Sublicensees as to research and development of a Licensed Product for each [* *
*], within [* * *] days after the end of each [*&nbsp;*&nbsp;*]. Such report shall be provided by Pfizer to GMI through, and with respect to, the first calendar year after the First Commercial Sale in the United States. Thereafter upon GMI&#146;s
request no more frequently than [* * *], Pfizer shall provide to GMI and update with respect to any ongoing or planned clinical trials of any Licensed Product (including clinical trials for any new indications) undertaken by or on behalf of Pfizer
or any of its Affiliates and any pending or planned applications for Regulatory Approval for the Licensed Product by or on behalf of Pfizer or any of its Affiliates (including applications with respect to any new indications for the Licensed
Product). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Commercialization/Pricing</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <U>General</U>. Pfizer shall be solely responsible for, at Pfizer&#146;s expense, marketing, promoting, selling,
distributing and determining pricing and other terms of sale for all Licensed Products. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)
<U>Trademarks</U>. The Licensed Products shall be sold under a trademark, and marketed using logos, trade dress and domain names selected and owned by Pfizer. Applications for all such product trademarks shall be filed, registered, maintained and
prosecuted by Pfizer, at Pfizer&#146;s expense. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Manufacture and Supply</U>. Pfizer shall be responsible for the
manufacture and supply of (i)&nbsp;clinical materials for an Additional Phase II Clinical Trial initiated after the Completion of the Ongoing Clinical Trial and any Phase III Clinical Trial for each Licensed Product and (ii)&nbsp;for the commercial
supply of each Compound and each Licensed Product in the Territory. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article 4 PAYMENTS BY PFIZER TO GMI </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>Milestone Payments</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Effective Date Payment</U>. In partial consideration for the expenses incurred by GMI in research and development of Licensed Product prior to the Effective Date, Pfizer shall pay GMI twenty-two
million five-hundred thousand dollars ($22,500,000) within fifteen (15)&nbsp;days after the Effective Date, which payment shall be non-refundable and non-creditable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Event Milestones</U>. Pfizer shall pay to GMI the following non-creditable, except as set forth in this Agreement,
non-refundable amounts within forty-five (45)&nbsp;days of the first occurrence and only the first occurrence of the following events in connection with a Licensed Product that is achieved by Pfizer or its Affiliate or Sublicensee: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) With respect to the First Indication: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to Section 4.1(c), initiation of dosing of a first patient in a first Phase III Clinical Trial for the First Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$35,000,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptance of filing for Regulatory Approval by the FDA for the First Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Commercial Sale in the United States for the First Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(D)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptance of filing for Regulatory Approval by the EMA for the First Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(E)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Commercial Sale in a Major Country of Europe for the First Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) With respect to a Second Indication: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiation of dosing of a first patient in a first Phase III Clinical Trial for a Second Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptance of filing for Regulatory Approval by the FDA for a Second Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Commercial Sale in the United States for a Second Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(D)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptance of filing for Regulatory Approval by the EMA for a Second Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(E)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Commercial Sale in a Major Country of Europe for a Second Indication</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) With respect to Net Sales of Licensed Products: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">The first time that total Net Sales of Licensed Products in the Territory in a Pfizer Year are greater than [* * *] Dollars ($[*&nbsp;*&nbsp;*])</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">The first time that total Net Sales of Licensed Products in the Territory in a Pfizer Year are greater than [* * *] Dollars ($[*&nbsp;*&nbsp;*])</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">The first time that total Net Sales of Licensed Products in the Territory in a Pfizer Year are greater than [* * *] Dollars ($[*&nbsp;*&nbsp;*])</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$[* * *]</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Phase III Milestone Advance</U>. In the event that a Phase III
Clinical Trial with respect to a Licensed Product for the First Indication has not been commenced by Pfizer within twelve (12)&nbsp;months after Completion of the Ongoing Clinical Trial, Pfizer will make an advance payment to GMI of fifteen million
dollars ($15,000,000) (the &#147;<U>Phase III Milestone Advance</U>&#148;) against the milestone set forth in Section&nbsp;4.1(b)(i)(A) with respect to the initiation of a Phase III Clinical Trial for the First Indication; <I>provided</I>, that, the
Phase III Milestone Advance will not be payable if Pfizer provides written notice to GMI that (i) an Additional Phase II Clinical Trial has been determined as necessary by Pfizer or by a Regulatory Authority; and (ii) an Additional Phase II Clinical
Trial has been commenced by Pfizer within [* * *] of the Completion of the Ongoing Clinical Trial; <I>provided further</I> that, if the Phase III Milestone Advance is made, the remainder of the milestone payment set forth in
Section&nbsp;4.1(b)(i)(A), such remaining amount being twenty million dollars ($20,000,000), shall be payable to GMI by Pfizer within forty-five (45)&nbsp;days of the initiation of dosing of a first patient in a first Phase III Clinical Trial for a
First Indication. The Phase III Milestone Advance shall be payable by Pfizer to GMI within forty-five (45)&nbsp;days after the end of such twelve (12)&nbsp;month period if Pfizer has not provided written notice to GMI of a determination that an
Additional Phase II Clinical Trial is necessary or [* * *] after such [* * *] period described herein, if a patient has not been dosed in such Additional Phase II Clinical Trial within such [* * *] period. The payment to GMI under this
Section&nbsp;4.1(c) shall be non-refundable and shall be creditable only against the milestone payment set forth in Section&nbsp;4.1(b)(i)(A). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>Royalties</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Royalty Payments</U>. Subject to
Sections 4.2(b), (c), and (e), during the Term, Pfizer shall pay to GMI within forty-five (45)&nbsp;days of the end of each calendar quarter royalties on Net Sales of Licensed Products sold in the corresponding Pfizer Quarter during the Term in the
amounts set forth below, which shall be non-creditable and non-refundable: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="text-indent:6.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Portion of aggregate Net Sales of Licensed Products in all countries of the Territory in a Pfizer Year up to and including $[* * *];
and</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:6.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Portion of aggregate Net Sales of Licensed Products in all countries of the Territory in a Pfizer Year above $[* * *]&nbsp;up to and including
$[* * *]; and</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:6.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Portion of aggregate Net Sales of Licensed Products in all countries of the Territory in a Pfizer Year above $[* * *].</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*]</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Royalty Period</U>. On a country-by-country and
Licensed Product-by-Licensed Product basis, royalties on each Licensed Product under Section&nbsp;4.2(a) in each country shall terminate on the tenth (10</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">) anniversary of the First Commercial Sale of such Licensed Product in such country, after which time there is no
further royalty obligation with respect to such Licensed Product in such country, except that the royalty shall continue after such tenth (10</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">) anniversary in such country with respect to such Licensed Product sold in such country where in the country where
sold or manufactured such Licensed Product is covered by a Valid Claim of a GMI Patent Right. The termination of royalty payments under this Section&nbsp;4.2(b) in a country for a Licensed Product shall not terminate the licenses granted to Pfizer
in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Third Party Royalties Payable by Pfizer</U>. Subject to clause (d)&nbsp;below, at any
time after the Effective Date, in the event that Pfizer or its Affiliates pays royalties to a Third Party during a Pfizer Quarter for Licensed Product in a country for which royalties are also payable to GMI under this Agreement in such Pfizer
Quarter for sales in such country, and such royalties are due to such Third Party as a result of a Valid Claim of Patent Rights of such Third Party that claims a Compound or use thereof (a &#147;<U>Third Party Royalty</U>&#148;), then [* * *]
percent ([* * *]%) of such Third Party Royalty paid by Pfizer or its Affiliates for sale of such Licensed Product for such Pfizer Quarter in such country may be deducted against [* * *] percent ([* * *]%) of any royalty payments calculated under
Section&nbsp;4.2(a) with respect to the sale of such Licensed Product in such country for such Pfizer Quarter. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Third Party Royalties Payable by GMI</U>. GMI shall be solely responsible for making any and all payments that are
due and payable with respect to a Licensed Product under a license agreement between GMI and a Third Party that is in effect as of the Effective Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Generic Products</U>. In the event that a Generic Product is sold in a country of the Territory in a Pfizer Quarter that in such country or in the country where manufactured is not covered by a
Valid Claim of a GMI Patent Right, then the royalties payable by Pfizer under Section&nbsp;4.2(a) in such country for the corresponding Licensed Product shall be reduced in the applicable Pfizer Quarter by [* * *] percent ([* * *]%); provided,
however that if in the applicable Pfizer Quarter in the applicable country there is a royalty reduction taken under </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Section&nbsp;4.2(c), then the royalty reduction under this Section&nbsp;4.2(e) shall be calculated before the royalty reduction under Section&nbsp;4.2(c) and in no event shall the royalty
reductions under this Section&nbsp;4.2(e) and under Section&nbsp;4.2(c) reduce the royalty on the applicable Licensed Product in the applicable country in the applicable Pfizer Quarter to less than [* * *] percent ([* * *]%) of Net Sales.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <U>Currency</U>. All payments required under this Article 4 shall be made in U.S. Dollars. For the
purpose of computing the Net Sales of Licensed Products sold in a currency other than U.S. Dollars, such currency shall be converted from local currency to U.S. Dollars in a manner consistent with Pfizer&#146;s normal practices used to prepare its
audited financial statements for external reporting purposes; <I>provided</I>, that such practices use a widely accepted source of published exchange rates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(g) <U>Transfers to Affiliates</U>. No royalties shall be due upon the sale or other transfer of Licensed Product among Pfizer and its Affiliates for resale, or upon the sale or other transfer to a
Sublicensee for resale, but in such cases the royalty shall be due and calculated upon Pfizer&#146;s or its Affiliates or Sublicensees Net Sales to a Third Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.3 <U>Royalty Reports and Payments</U>. During the Term, following the First Commercial Sale of a Licensed Product in a country of the Territory, Pfizer shall furnish to GMI a quarterly written report
for each Pfizer Quarter showing for the applicable Pfizer Quarter the gross sales, Net Sales and calculation thereof that breaks-out the applicable deductions permitted in calculating Net Sales on a Licensed Product-by-Licensed Product and
country-by-country basis for all Licensed Products during the applicable Pfizer Quarter, applicable royalty deductions for such Licensed Products, for the applicable Pfizer Quarter, the manner in which conversion to U.S. Dollars was calculated and
the royalties payable under this Agreement for Licensed Products. Reports shall be due on the forty-fifth (45th)&nbsp;day following the close of each calendar quarter. Royalties shown to have accrued by each royalty report shall be due and payable
on the date such royalty report is due; <I>provided</I> if Net Sales in any Pfizer Quarter during a given Pfizer Year are less than zero as a result of permitted reductions in calculating Net Sales under this Agreement, then Pfizer will not be
obligated to pay GMI any royalties for such Pfizer Quarter, and for purposes of calculating royalty payments with respect to the fourth Pfizer Quarter of such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Pfizer Year, Net Sales for such fourth Pfizer Quarter shall be reduced by the aggregate amount of negative Net Sales in each Pfizer Quarter in which Net Sales are less than zero during the
applicable Pfizer Year that have not been previously deducted from Net Sales. If, as a result of such reduction, the aggregate Net Sales with respect to such fourth Pfizer Quarter are less than zero, then, for purposes of calculating royalty
payments with respect to the first Pfizer Quarter of the next succeeding Pfizer Year, Net Sales for such first Pfizer Quarter shall be reduced by the amount of negative Net Sales in the fourth Pfizer Quarter of the immediately preceding Pfizer Year.
Any adjustment for negative Net Sales described in this Section&nbsp;4.3 shall be clearly indicated and shown in the applicable royalty reports provided by Pfizer pursuant to this Section&nbsp;4.3. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4 <U>Royalty Reviews</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Access and Review</U>. Upon the written request of GMI and not more than once in each calendar year, and upon at least forty-five (45)&nbsp;days prior written notice, Pfizer shall permit an
independent certified public accounting firm selected by GMI and reasonably acceptable to Pfizer, at GMI&#146;s expense, to have access during normal business hours to such of the records of Pfizer as may be reasonably necessary to verify the
accuracy of the royalty reports and payments hereunder for any or all of the twelve (12)&nbsp;Pfizer Quarters preceding the Pfizer Quarter in which the request is made. The accounting firm shall disclose to GMI and Pfizer only whether the royalty
reports, are correct or incorrect and the amount of any discrepancy. No other information shall be provided to GMI. GMI shall provide Pfizer with a copy of such report within thirty (30)&nbsp;days after receipt thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Underpayments and Overpayments</U>. If such accounting firm identifies an underpayment of royalties during such
period, Pfizer shall pay GMI the amount of the underpayment within thirty (30)&nbsp;days of the date GMI delivers to Pfizer such accounting firm&#146;s written report so concluding. The fees charged by such accounting firm shall be paid by GMI
unless the underpayment exceeded [*&nbsp;*&nbsp;*] percent ([* * *]%) of the amount owed by Pfizer to GMI for the period audited, in which case, Pfizer shall pay to GMI the fees and costs charged by such accounting firm. If the examination shows an
overpayment of royalties by Pfizer, such amount shall be fully creditable against future royalty payments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Sublicensee Requirements</U>. Pfizer shall include in each sublicense
granted by it pursuant to this Agreement a provision requiring the Sublicensee to make reports to Pfizer, to keep and maintain records of Net Sales made pursuant to such sublicense and to grant access to such records by GMI&#146;s independent
accountant to the same extent required of Pfizer under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5 <U>Withholding</U>. GMI alone shall be responsible
for paying any and all taxes (other than withholding taxes required to be paid by Pfizer) levied on account of, or measured in whole or in part by reference to, any payments made by Pfizer to GMI under this Agreement. If provision is made in law or
regulation of any country of the Territory for withholding of taxes of any type, levies or other charges with respect to any amounts payable hereunder to GMI, Pfizer (&#147;<U>Withholding Party</U>&#148;) shall promptly pay such tax, levy or charge
for and on behalf of GMI to the proper governmental authority, and shall promptly furnish GMI with a receipt for such payment. The Withholding Party shall have the right to deduct any such tax, levy or charge actually paid from payment due GMI or be
promptly reimbursed by GMI if no further payments are due the Withholding Party. The Withholding Party agrees to assist GMI in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to
time in force and in minimizing the amount required to be so withheld or deducted. The Withholding Party shall apply the reduced rate of withholding, or dispense with withholding, as the case may be, provided that the Withholding Party has received
evidence, in a form satisfactory to the Withholding Party, of GMI&#146;s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15)&nbsp;days prior to the time that the payment
is due. The preceding shall apply mutatis mutandis in the event that any payments shall be made to Pfizer from GMI. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6
<U>Interest for Late Payment</U>. All payments under this Agreement shall bear interest from the fifteenth (15th)&nbsp;day after the date due until paid at a rate equal to [* * *] rate in effect on the date that payment was due, as published by
<I>The Financial Times</I>. For purposes of this Section&nbsp;4.6, the due date for any overpayment or underpayment determined pursuant to any audit, review, investigation or adjustment hereunder shall be the date specified in the relevant provision
in this Agreement for payment of such overpayment or underpayment after completion of such audit, review, investigation or adjustment and no interest shall be retroactively payable back to the original due date for the payments underlying any such
overpayment or underpayment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article 5 INTELLECTUAL PROPERTY RIGHTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Prosecution</U>. Promptly after the Effective Date and thereafter, GMI shall provide or cause to be provided to Pfizer or its
counsel a copy of the patent office files with respect to filing, prosecution and maintenance of the GMI Patent Rights licensed to Pfizer under this Agreement. After the Effective Date, at the cost and expense of Pfizer, Pfizer shall be responsible
[* * *] for filing, prosecuting and maintaining the GMI Patent Rights licensed to Pfizer that are owned by GMI. [* * *] </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither Party shall have liability to the other Party for any act, omission, or default or neglect of outside counsel selected pursuant
to this Section&nbsp;5.1 with respect to filing, prosecuting or maintaining of GMI Patent Rights pursuant to this Section&nbsp;5.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Notices of Infringement</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Each Party shall give
the other Party notice of any actual or suspected infringement of GMI Patent Rights in the Territory that comes to the Party&#146;s attention. The notice requirements of this Section&nbsp;5.2(a) shall be limited to those circumstances where the
actual or suspected infringement, is with respect to the manufacture, use, sale, import or offering for sale of Licensed Product in the Field. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) With respect to the alleged infringement by a Third Party of GMI Patent Rights by making, using, selling, importing or offering for sale a Licensed Product in the Field in the Territory (a
&#147;<U>Product Infringement</U>&#148;), as between GMI and Pfizer, Pfizer will have the first right (but not the obligation) to bring any infringement action or proceeding against such Product Infringement, at the cost and expense of Pfizer, by
counsel of its own choice. GMI will have the right, at its own cost and expense, to be represented in any such action by counsel of its own choice, but Pfizer shall control such infringement action. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) For any action pursuant to Section&nbsp;5.2(b) to terminate any Product
Infringement of GMI Patent Rights that Pfizer is entitled to bring, in the event that Pfizer is unable to initiate or prosecute such action solely in its own name, GMI will join such action voluntarily and will execute all documents necessary for
Pfizer to initiate litigation to prosecute and maintain such action. In connection with any action, Pfizer and GMI will cooperate fully and will provide each other with any information or assistance that the other may reasonably request, at the
expense of the enforcing Party. Pfizer will have the right to control such action, including the settlement thereof, provided, however, that Pfizer shall not settle or compromise any claim or proceeding that adversely affects the scope, validity or
enforceability of any GMI Patent Right licensed to Pfizer unless agreed to in writing by both Parties, which consent shall not be unreasonably withheld. Any damages or other monetary awards recovered pursuant to any suit, proceeding or other legal
action taken under this Section&nbsp;5.2 will be allocated first to the costs and expenses of Pfizer, and second to the costs and expenses (if any) of GMI that were not otherwise reimbursed, with any remaining amounts (if any) to be allocated to
Pfizer and such remaining amount shall be Net Sales subject to royalty under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Each Party
shall inform the other Party of any certification regarding any GMI Patent Rights in the United States it has received pursuant to either 21 U.S.C. &#167;&#167;355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) or its successor provisions or any similar
provisions in the Territory and shall provide the other Party with a copy of such certification within ten (10)&nbsp;Business Days of receipt. Pfizer&#146;s rights with respect to the initiation and prosecution of any legal action as a result of
such certification or any recovery obtained as a result of such legal action shall be as defined in Section&nbsp;5.2(b), and (c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) In the event that a Third Party files a declaratory judgment action or any other type of action or proceeding with respect to any GMI Patent Rights against either Party or both Parties in the
Territory, such Party shall provide written notice thereof to the other Party within ten (10)&nbsp;Business Days thereafter. Pfizer shall have the first right within its sole discretion, but not the obligation, to control the defense thereof with
attorneys selected by Pfizer, at the cost and expense of Pfizer. Pfizer shall not settle or compromise such an action or proceeding in a manner that materially adversely affects the scope, validity or enforceability of any GMI Patent Rights in the
Territory without the written consent of GMI, which consent shall not be withheld unreasonably. If Pfizer is unable to defend such action solely in its own name, GMI shall join such action voluntarily and shall execute and cause its Affiliates and
sublicensees to execute all documents necessary for Pfizer to defend such action. Pfizer shall keep GMI reasonably informed of the course of such action. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 <U>Extensions</U>. The Parties shall discuss with each other obtaining any patent term
extension, such as extension under 35 U.S.C. &#167; 156, patent term restoration or supplemental protection certificates or their equivalents in any country in the Territory with respect to any patent term extension regarding GMI Patent Rights, in
each case that contain a claim that would be infringed by manufacture, use, importation, offer for sale or sale of a Licensed Product in the Field. Pfizer shall have the right to make the election in its sole discretion with respect to GMI Patent
Rights and GMI shall abide by such election with respect to GMI Patent Rights and, if requested by Pfizer, cooperate with Pfizer to supply information and assistance useful in obtaining patent term extension. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article 6 CONFIDENTIALITY; PUBLICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Confidential Information</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) All information
including Know-How disclosed by one Party to the other Party hereunder shall be considered confidential information of the disclosing Party (&#147;<U>Confidential Information</U>&#148;). Subject to Sections 6.1(b) and (c), each Party agrees that
(i)&nbsp;during the Term and for [* * *] ([* * *]) years after the Term it will keep confidential, and will cause its Affiliates to keep confidential, all of the other Party&#146;s Confidential Information, (ii)&nbsp;each Party and its respective
Affiliates shall use any Confidential Information only as expressly permitted in this Agreement; (iii)&nbsp;it shall take such action, and to cause its Affiliates to take such action, to preserve the confidentiality of the other Party&#146;s
Confidential Information as it would customarily take to preserve the confidentiality of its own similar types of confidential information, but in no event less than reasonable care and (iv)&nbsp;no Party shall disclose such Confidential Information
to any Third Parties under any circumstance without the prior written consent of the other Party, except to the extent that such Confidential Information: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party&#146;s business records; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) is or becomes part of the public domain through no fault of the
receiving Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) is subsequently disclosed to the receiving Party by a Third Party who may lawfully do
so and is not under an obligation of confidentiality to the disclosing Party; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) is developed by the
receiving Party independently of information received from the disclosing Party, as documented by the receiving Party&#146;s business records. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Notwithstanding the obligations in Section&nbsp;6.1(a), Pfizer has the right to use and permit a Third Party to use the Confidential Information of GMI that is licensed to Pfizer pursuant to the
license and rights granted to Pfizer under this Agreement. In addition, Pfizer may disclose the Confidential Information of GMI, if such disclosure: (i)&nbsp;is made by Pfizer, its Affiliates or Sublicensees to a Regulatory Authority in order to
gain or maintain approval to conduct clinical trials of Licensed Product or to market Licensed Product in the Territory, in which case Pfizer, its Affiliate or Sublicensee shall request confidential treatment thereof to the extent permitted by
applicable law, rule or regulation; (ii)&nbsp;is under an obligation of confidentiality and is made by Pfizer to Sublicensees, Affiliates, agents, consultants, or other Third Parties, in each case for the research, development, manufacturing or
commercialization of Licensed Product in the Field and/or is made by Pfizer in connection with a permitted assignment of this Agreement, or a licensing transaction related to Licensed Product in the Field, which obligation of confidentiality
provides that the Third Party agrees to be bound by confidentiality and non-use obligations substantially similar to those contained in Article 6 of this Agreement, and that such information will only be used for the applicable purpose;
(iii)&nbsp;is in connection with filing or prosecuting GMI Patent Rights or trademark rights by Pfizer as permitted by this Agreement but only after the consent of GMI which shall not be unreasonably withheld, (iv)&nbsp;is in connection with
prosecuting or defending litigation by Pfizer as permitted by this Agreement, (v)&nbsp;is in connection with posting results of and other information about clinical trials to clincialtrials.gov or PhRMA websites, and (vi)&nbsp;is necessary or
desirable by Pfizer in order to enforce its rights under this Agreement; provided that in the case of any such disclosure pursuant to subparts (iv)&nbsp;and (vi), to the extent that Pfizer is not prohibited by applicable law
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
from doing so, Pfizer shall promptly inform GMI of the proposed disclosure in order to provide GMI an opportunity to challenge or limit the disclosure obligations. GMI may disclose information
received from Pfizer under this Agreement that is Confidential Information of Pfizer (i)&nbsp;to Regulatory Authorities in order to respond to inquiries, requests or investigations relating to this Agreement; (ii)&nbsp;to the extent necessary or
desirable in order to enforce its rights under this Agreement; (iii)&nbsp;in connection with an assignment of this Agreement or (iv)&nbsp;in connection with a potential or completed loan, financing or investment in GMI or Change of Control of GMI,
provided that in the case of any such disclosure pursuant to subpart (ii), to the extent that GMI is not prohibited by applicable law from doing so, GMI shall promptly inform Pfizer of the proposed disclosure in order to provide Pfizer an
opportunity to challenge or limit the disclosure obligations; and provided further that such disclosure by GMI under subparts (iii)&nbsp;and (iv)&nbsp;is under confidentiality and non-use provisions substantially similar to those of GMI under
Article 6 of this Agreement and that such information will only be used for the purposes of such transaction; and provided, further, that GMI may disclose the following information in the normal conduct of its business: (A)&nbsp;the amount of the
payment received pursuant to Section&nbsp;4.1(a), (B)&nbsp;the total amounts of all payments potentially payable under Section&nbsp;4.1 (but not any individual amount or subtotal amount thereunder), and (C)&nbsp;the fact that Pfizer may pay
&#147;tiered, double-digit&#148; royalties to GMI hereunder; provided, however, that any press release regarding this Agreement or events occurring hereunder shall in any event be subject to Section&nbsp;6.4. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If a Party is required by law or regulation (including, without limitation, regulations of the Securities and
Exchange Commission and the U.S. Food and Drug Administration) or judicial or administrative process to disclose Confidential Information that is subject to the non-disclosure provisions of this Section&nbsp;6.1, to the extent that such Party is not
prohibited by applicable law from doing so, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential
Information that is disclosed by law or regulation or judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section&nbsp;6.1, and the Party disclosing Confidential Information
pursuant to law or court order shall, except where impracticable, take all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential
Information. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>Publication</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Without limiting any rights or obligations of the Parties under Sections 6.1, 6.2(b), 6.2(c) and 6.3, during the
Term, each Party shall submit to the other Party (the &#147;<U>Non-Disclosing Party</U>&#148;) for review and approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party&#146;s
Confidential Information. In addition, GMI shall submit to Pfizer for review and approval any proposed publication or public presentation relating to the Compounds, Licensed Products or any pre-clinical or clinical studies conducted by or on behalf
of GMI with respect thereto. In both instances, such review and approval will be conducted for the purposes of preserving the value of each Party&#146;s Patent Rights and Know-How, the rights granted to Pfizer hereunder and determining whether any
portion of the proposed publication or presentation containing the Non-Disclosing Party&#146;s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder
shall be submitted to the Non-Disclosing Party no later than thirty (30)&nbsp;days before submission for publication or presentation. The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within
fifteen (15)&nbsp;Business Days after its receipt of such written copy from the other Party. The review period may be extended for an additional thirty (30)&nbsp;days in the event the Non-Disclosing Party can demonstrate reasonable need for such
extension including for the preparation and filing of patent applications. GMI and Pfizer will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any
publication. For the sake of clarity, (1)&nbsp;Pfizer shall have the right, subject to GMI&#146;s rights of review as set forth above, to include in its academic, scientific and medical publications and public presentations any pre-clinical and
clinical data and results relating to any Licensed Product or Compound, including without limitation any such data and results provided to Pfizer under Section&nbsp;2.3 and data and results of the Ongoing Clinical Study, (2)&nbsp;subject to
Section&nbsp;6.2(b) GMI shall not include in its academic, scientific and medical publications and public presentations any pre-clinical and clinical data and results relating to any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Licensed Product or Compound, including without limitation any such data and results provided to Pfizer under 2.3 and data and results of the Ongoing Clinical Study, without Pfizer&#146;s prior
written consent, such consent not to be unreasonably withheld, and (3)&nbsp;Pfizer&#146;s obligation to submit any publication to GMI for review and approval under this Section&nbsp;6.2(a) shall not apply to any publication which does not contain
GMI&#146;s Confidential Information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Pfizer understands that there are rights to publish under existing
agreements between GMI and Third Parties which are subject to certain restrictions, and nothing in this Section&nbsp;6.2 shall limit such publication rights pursuant to such agreements; provided, however that GMI, to the extent practicable in light
of such restrictions, shall provide Pfizer with the opportunity to review and comment on such publications as set forth above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Except as permitted by Section&nbsp;6.1, Pfizer shall not have the right to publish or disclose Confidential Information of GMI pursuant to Section&nbsp;6.2(a) that is not pre-clinical data and/or
clinical data or results without the written consent of GMI. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Disclosure of the Agreement</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Neither Party shall disclose the terms of this Agreement, except either Party shall be permitted to disclose the
terms of this Agreement to the extent required, in the reasonable opinion of such Party&#146;s legal counsel, to comply with applicable laws, rules or regulations, including without limitation the rules and regulations promulgated by the United
States Securities and Exchange Commission (&#147;<U>SEC</U>&#148;) or any other governmental agency. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section&nbsp;6.3(a), the Parties shall
allow at least fifteen (15)&nbsp;days for the other Party to review the disclosure of the terms of this Agreement for which confidential treatment will be sought in making any such disclosure. If a Party wishes to disclose this Agreement or any of
the terms hereof in accordance with this Section&nbsp;6.3(a), such Party agrees, at its own expense, to the extent available to seek confidential treatment of the portions of this Agreement or such terms as may be reasonably requested by the other
Party, provided that the disclosing Party shall always be entitled to make such disclosure even if such treatment is or cannot be obtained from the governmental agency or authority. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Either Party may also disclose the terms of this Agreement in confidence
to (i)&nbsp;its Affiliates, attorneys, consultants and advisors, (ii)&nbsp;in connection with a potential Change of Control, to potential acquirors (and their respective professional advisors), (iii)&nbsp;as a part of their due diligence
investigations, to or existing and potential investors or lenders (and their respective professional advisors) of such Party, or (iv)&nbsp;to permitted assignees, in each of the foregoing cases under an agreement to keep the terms of this Agreement
confidential under terms of confidentiality and non-use substantially similar to the terms contained in Article 6 of this Agreement and to use such confidential information solely for the purpose permitted pursuant to this Section&nbsp;6.3(b).
Notwithstanding the foregoing, if GMI after exerting reasonable efforts cannot obtain an agreement of confidentiality as to this Agreement in connection with a financing and/or public offering, GMI shall have the right to disclose this Agreement
and/or the terms thereof without an obligation of confidentiality; <I>provided</I> that GMI provides written notice to Pfizer at least five (5)&nbsp;Business Days prior to such disclosure and [* * *] until in GMI&#146;s reasonable judgment such
disclosure should be made by GMI. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>Press Releases</U>. The public announcement of the execution of this Agreement is
set forth Schedule 6.4 attached hereto and GMI shall be permitted to distribute such public announcement upon execution hereof by both Parties. Subject to the foregoing provisions of this Article 6, GMI or Pfizer may issue subsequent press releases
with respect to events that occur pursuant to this Agreement with the consent of the other Party, which consent shall not be unreasonably withheld; <I>provided</I> that each Party shall allow the other Party [* * *] days to review the proposed press
release prior to providing its consent for the issuance of the press release. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article 7 REPRESENTATIONS AND WARRANTIES;
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADDITIONAL COVENANTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>Representations and Warranties by GMI</U>. As of the Effective Date, GMI represents and warrants to Pfizer that: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) it has the right to grant the rights and licenses granted to Pfizer under this Agreement, and pursuant to this
Agreement, Pfizer has been granted such rights and licenses; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) to its Knowledge, the granted patents encompassed within the GMI Patent
Rights of Exhibit A are valid and enforceable, and no Third Party has challenged or threatened to assert a challenge to the validity or enforceability of the GMI Patent Rights of Exhibit A (including by way of example through the institution or
written threat of institution of interference, nullity or similar invalidity proceedings before the United Stated Patent and Trademark Office or any analogous foreign entity); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) to its Knowledge, the manufacture, use, sale, offer to sell, importation or exploitation by GMI or Pfizer (or their
respective Affiliates) of any Licensed Product or Compound as formulated and manufactured as of the Effective Date does not infringe any issued patent of a third party; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibit A contains a complete and correct list of all GMI Patent Rights; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) it is the sole owner of all the GMI Patent Rights, free of any lien, encumbrance, charge, security interest, mortgage
or other similar restriction. No Person (including any Affiliate of GMI) has any right, interest or claim in or to, and neither GMI nor any of its Affiliates has entered into any agreement granting any right, interest or claim in or to, any GMI
Patent Rights or GMI Know-How, except for the rights granted to Third-Party service providers or investigators solely to conduct the On Going Clinical Trial and the other studies as listed on Schedule 2.1 (which rights do not include the right to
practice or use the GMI Patent Rights or GMI Know-How to manufacture, commercially distribute or sell the Compound and/or Licensed Product). All inventors of the GMI Patent Rights have assigned to GMI their rights in such GMI Patent Rights and all
such assignments are valid and enforceable; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) it has complied in all material respects with all applicable
Laws in connection with the filing, prosecution and maintenance of the GMI Patent Rights of Exhibit A; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g)
there is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the Knowledge of GMI,
threatened against GMI, any of its Affiliates or, to the Knowledge of GMI, any Third Party, in each case in connection with the GMI Patent Rights of Exhibit A, GMI Know-How, the Compounds or the Licensed Products or relating to the transactions
contemplated by this Agreement; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) all necessary consents, approvals and authorizations of all government
authorities and other entities or persons required to be obtained by GMI as of the Effective Date in connection with the execution, delivery and performance of this Agreement and the granting of the rights and licenses granted under this Agreement
have been obtained; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) no Person, including but not limited to any holder of GMI&#146;s Series A-1 Preferred
Stock or any investor in any other round of financing of GMI, has any option or other right to negotiate any license, option, collaboration, joint venture, sale or any similar transaction with GMI with respect to the Compound or Licensed Product in
the Territory except as listed in Schedule 7.1; provided that, as of the Effective Date, GMI has the right to grant the license granted to Pfizer under this Agreement free and clear of any such option and/or other right of any Person set forth in
Schedule 7.1 and after the Effective Date any Person set forth in Schedule 7.1 has no further option or right to negotiate any license, option, collaboration, joint venture, sale or any similar transaction with GMI with respect to the Compound or
Licensed Product in the Territory; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) to its Knowledge, GMI has not used in any capacity the services of any
person or entity debarred under Section&nbsp;306 of the Federal Food, Drug and Cosmetic Act in connection with the research, development or manufacture of Product; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) None of the rights of GMI or its Affiliates under the GMI Patent Rights of Exhibit A were developed with federal
funding from the United States government or any other Governmental Authority; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(l) None of the GMI Patent
Rights of Exhibit A have been licensed from a Third Party; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) GMI has heretofore disclosed to Pfizer all material scientific and
technical information and all information relating to safety and all material information relating to efficacy, in each case with respect to any Compound or Licensed Product, and in each case that is known to GMI; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n) GMI has heretofore disclosed to Pfizer all material correspondence and contact information between GMI and the FDA
and any other Regulatory Authorities regarding the Compounds or the Licensed Products; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(o) it is a
corporation duly organized, validly existing and in good standing under the laws of Delaware and has the right, power and authority to enter into this Agreement and to make the promises set forth in this Agreement; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(p) it has taken all necessary action on its part, including but not limited to action required by Law, its certificate
of incorporation, by-laws or other organizational documents or any agreement to which it is party or to which it may be subject, required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(q) it has duly executed and delivered this Agreement and, assuming due delivery and execution by Pfizer,
this Agreement constitutes a legal, valid and binding obligation of GMI, enforceable against GMI in accordance with its terms; except to the extent that such enforceability may be limited by bankruptcy, insolvency, or other similar laws relating to
creditors&#146; rights generally; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(r) the execution, delivery and performance of this Agreement do not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor to its Knowledge, violate any Law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over it. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>Representations and Warranties by Pfizer</U>. As of the Effective Date, Pfizer
represents, and warrants to GMI that: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) it is a corporation duly organized, validly existing and in good
standing under the laws of Delaware and has the right, power and authority to enter into this Agreement and to make the promises set forth in this Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) it has taken all necessary action on its part, including but not limited to action required by Law, its certificate of incorporation, by-laws or other organizational documents or any agreement to
which it is party or to which it may be subject, required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) it has duly executed and delivered the Agreement, and assuming due delivery and execution by GMI this Agreement
constitutes a legal, valid and binding obligation of Pfizer, enforceable against Pfizer in accordance with its terms; except to the extent that such enforceability may be limited by bankruptcy, insolvency, or other similar laws relating to
creditors&#146; rights generally; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) the execution, delivery and performance of this Agreement do not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor to its Knowledge, violate any Law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over it. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3 <U>LIMITATIONS</U>. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER GMI NOR
PFIZER MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT AND EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS ARTICLE 7, EACH PARTY HEREBY EXPRESSLY DISCLAIMS
ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND ANY WARRANTY OR REPRESENTATION REGARDING CLINICAL EFFECTIVENESS OF LICENSED PRODUCT OR THAT ANY PATENT APPLICATION WILL BE GRANTED
OR THAT A LICENSED PRODUCT CAN BE SUCCESSFULLY DEVELOPED OR COMMERCIALIZED. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4 <U>Additional Covenants</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Compliance with Laws</U>. Each of GMI and Pfizer shall conduct, and shall use reasonable efforts to cause its
Affiliates to conduct, all its activities contemplated under this Agreement in accordance with all applicable Laws of the country in which such activities are conducted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Reasonable Access</U>. From and after the Effective Date, GMI shall, upon reasonable notice from Pfizer, provide
Pfizer and its agents and representatives with reasonable access, during regular business hours, to (i)&nbsp;all information concerning Compounds, Licensed Products and/or GMI Patent Rights, and (ii)&nbsp;all employees of GMI who possess any
information described in clause (i)&nbsp;of this Section&nbsp;7.4(b), in each case to the extent reasonably necessary to allow Pfizer to exercise its rights or carry out its obligations under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5 <U>Exclusion of Certain Damages</U>. Except with respect to an obligation of either Party to indemnify the other hereunder, neither
Party shall be liable to the other for consequential, incidental, indirect or punitive damages arising from the performance or nonperformance of such Party under this Agreement whether such claim is based on contract, tort (including negligence) or
otherwise, even if an authorized representative of such Party is advised of the possibility or likelihood of same. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article
8 INDEMNITY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1 <U>Indemnification by Pfizer</U>. Pfizer agrees to defend, indemnify and hold harmless GMI and its
Affiliates and their respective directors, officers and employees (individually and collectively, the &#147;<U>GMI Indemnitee(s)</U>&#148;) from and against any and all costs, expenses, claims, losses, liabilities, damages, fines, royalties,
governmental penalties or punitive damages, deficiencies, interest, settlement amounts, awards, and judgments, including any and all reasonable, out-of-pocket costs and expenses properly incurred as a result of a claim (including reasonable,
out-of-pocket attorneys&#146; fees and all other expenses reasonably incurred in investigating, preparing or defending any litigation or proceeding, commenced or threatened), in each case, net of any insurance recovery received as a result of such
cost (collectively, &#147;<U>Losses</U>&#148;) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
resulting from any claims, demands, actions or other proceedings by any Third Party to the extent arising from (a)&nbsp;the research, development, testing, manufacture, use, handling, storage,
commercialization, marketing, sale or other disposition of Licensed Products by or on behalf of Pfizer or any of its Affiliates or Sublicensees in the Territory during the Term or thereafter pursuant to Section&nbsp;9.1 or 9.10 of this Agreement, or
(b)&nbsp;the use of Licensed Products that were sold or distributed by or on behalf of Pfizer or any of its Affiliates or Sublicensees during the Term or thereafter pursuant to Section&nbsp;9.1 or 9.10 of this Agreement, or (c)&nbsp;the negligence,
recklessness or intentional misconduct or unlawful act of Pfizer or its Affiliates or Sublicensees in exercising rights and/or carrying out activities under this Agreement or the licenses granted under this Agreement, or (d)&nbsp;a breach of a
representation, warranty or covenant made by Pfizer under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Indemnification by GMI</U>. GMI agrees to
defend, indemnify and hold harmless Pfizer, and its Affiliates, and their directors, officers and employees (individually and collectively, the &#147;<U>Pfizer Indemnitee(s)</U>&#148;) from and against all Losses resulting from any claims, demands,
actions or other proceedings by any Third Party to the extent arising from (a)&nbsp;the research, development or commercialization of the Compounds or Licensed Products by or on behalf of GMI or its Affiliates or licensees prior to the Effective
Date or subsequent to the Effective Date and prior to completion of the Ongoing Clinical Trial, (b)&nbsp;the research, development or commercialization after termination of this Agreement of any Compounds or Licensed Product by or on behalf of GMI
or its Affiliates, where such Compound or Licensed Product was researched, developed or commercialized pursuant to the license granted to GMI under Section&nbsp;9.5 or with the use of any of the information, documents or other materials transferred
to GMI pursuant to Section&nbsp;9.5(e), (c)&nbsp;the use of Licensed Products that were sold or distributed by or on behalf of GMI or any of its Affiliates prior to the Effective Date, or subsequent to the Effective Date and prior to completion of
the Ongoing Clinical Trial, (d)&nbsp;the use of Licensed Products sold or distributed by or on behalf of GMI or any of its Affiliates after termination of this Agreement, where such Compound or Licensed Product was researched, developed or
commercialized pursuant to the license granted to GMI under Section&nbsp;9.5 or with the use of any of the information, documents or other materials transferred to GMI pursuant to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Section&nbsp;9.5(e), or (e)&nbsp;the negligence, recklessness or intentional misconduct or unlawful act of GMI or its Affiliate in exercising rights and/or carrying out activities under this
Agreement or pursuant to the rights granted by Pfizer to GMI pursuant to Section&nbsp;9.6 of this Agreement, or (d)&nbsp;a breach of representation, warranty or covenant made by GMI under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3 <U>Indemnitee/Indemnifying Party</U>. Each of the Pfizer Indemnitee and GMI Indemnitee shall be an &#147;<U>Indemnitee</U>&#148; for
the purpose of this Article 8, and the Party that is obligated to indemnify the Indemnitee under Section&nbsp;8.1 or Section&nbsp;8.2 shall be the &#147;<U>Indemnifying Party</U>.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4 <U>Defense Procedures; Procedures for Third Party Claims</U>. In the event that any Third Party (in no event to include any Affiliate
of any of the parties) asserts a claim with respect to any matter for which an Indemnitee is entitled to indemnification hereunder (a &#147;<U>Third Party Claim</U>&#148;), then the Indemnitee shall promptly notify the Indemnifying Party thereof;
<I>provided, however,</I> that no delay on the part of the Indemnitee in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is
prejudiced thereby. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Indemnifying Party shall have the right, exercisable by notice to the Indemnitee
within ten (10)&nbsp;Business Days after receipt of notice from the Indemnitee of the commencement of or assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the
Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnitee; <I>provided</I> that (i)&nbsp;the Indemnifying Party has
sufficient financial resources, in the reasonable judgment of the Indemnitee, to satisfy the amount of any adverse monetary judgment that is sought, (ii)&nbsp;the Third Party Claim seeks solely monetary damages and (iii)&nbsp;the Indemnifying Party
expressly agrees in writing that as between the Indemnifying Party and the Indemnitee, the Indemnifying Party shall be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (i), (ii)&nbsp;and
(iii)&nbsp;above are collectively referred to as the &#147;<U>Litigation Conditions</U>&#148;). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Within ten (10)&nbsp;Business Days after the Indemnifying Party has
given notice to the Indemnitee of its exercise of its right to defend a Third Party Claim, the Indemnitee shall give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnitee reasonably so
objects, the Indemnitee shall continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying
Party shall be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnitee. During such time as the Indemnifying Party is
controlling the defense of such Third Party Claim, the Indemnitee shall cooperate, and shall cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by
furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy
the Litigation Conditions or does not notify the Indemnitee of the Indemnifying Party&#146;s intent to defend any Third Party Claim within ten (10)&nbsp;Business Days after notice thereof, the Indemnitee may (without further notice to the
Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party&#146;s expense (including reasonable, out-of-pocket attorneys&#146; fees and costs and expenses of enforcement or defense). The Indemnifying
Party or the Indemnitee, as the case may be, shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense
of any Third Party Claim that the other Party is defending as provided in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The
Indemnifying Party shall not, without the prior consent of the Indemnitee, enter into any compromise or settlement that commits the Indemnitee to take, or to forbear to take, any action. The Indemnitee shall have the sole and exclusive right to
settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but shall not have the right to settle such Third Party Claim to the
extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnitee shall not make any admission of liability in respect of any Third Party Claim
without the prior consent of the other party, and the Indemnitee shall use reasonable efforts to mitigate losses arising from the Third Party Claim. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Notwithstanding the foregoing, the Indemnitee may be represented by
separate counsel of its choosing at the cost and expense of the Indemnifying Party if a conflict of interest exists such that the counsel selected by the Indemnifying Party cannot simultaneously represent the Indemnitee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5 <U>LIMITATIONS</U>. IN NO EVENT SHALL ANY PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER THIS AGREEMENT FOR SPECIAL,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, WITH RESPECT TO ACTIVITIES UNDER OR IN CONNECTION WITH THIS AGREEMENT SUFFERED BY PFIZER, GMI OR ANY OF THEIR RESPECTIVE
REPRESENTATIVES, EXCEPT (A)&nbsp;FOR PURPOSES OF INDEMNIFICATION PURSUANT TO THIS ARTICLE 8, OR (B)&nbsp;IN THE EVENT OF AN INTENTIONAL OR WILLFUL BREACH IN BAD FAITH OF ANY REPRESENTATION, WARRANTY, COVENANT OR AGREEMENT BY GMI OR PFIZER (AS THE
CASE MAY BE) CONTAINED IN THIS AGREEMENT; PROVIDED THAT THIS SECTION SHALL NOT RELIEVE EITHER PARTY FROM ITS PAYMENT OBLIGATIONS UNDER THIS AGREEMENT. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Article 9 TERM AND TERMINATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1 <U>Term</U>. The term of this
Agreement shall be effective as of the Effective Date and shall continue in effect until the earlier of (i)&nbsp;termination of this Agreement under this Article 9 or (ii)&nbsp;expiration of all royalty payment obligations hereunder (the
&#147;<U>Term</U>&#148;). Upon expiration (but not termination of this Agreement), the licenses granted to Pfizer under Section&nbsp;2.1 of this Agreement shall become a fully paid-up, irrevocable, royalty-free, perpetual license. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 <U>Termination at Will</U>. Notwithstanding anything contained herein to the contrary, Pfizer shall have the right to terminate this
Agreement in its sole discretion in its entirety by giving [* * *] ([* * *]) days prior written notice to GMI. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 <U>Termination for Breach</U>. In addition to the termination provision of
Section&nbsp;9.2, this Agreement may be terminated at any time during the Term by a Party if the other Party materially breaches or materially defaults in the performance or observance of an obligation under this Agreement. A written notice of such
breach shall be sent by a Party to the other Party and the written notice shall specify the breach, and if such written notice has been given and the applicable Party has not cured a payment breach by making a payment within [* * *] ([* * *]) days
of the written notice or has not cured a breach that is not a payment breach within [* * *] ([*&nbsp;*&nbsp;*]) days of the written notice, then by prompt further written notice to the breaching party after the expiration of the applicable period
without cure, the notifying Party may terminate this Agreement. For the avoidance of doubt, material breaches that may permit termination under this Section&nbsp;9.3 by the non-breaching Party include, without limitation, uncured material failures
to make payments when due and uncured material breaches under Section&nbsp;2.1, 2.3, 3.1(a), 3.2(a), Article 6, Article 7, Article 8 and Article 10 of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.4 <U>Termination for Insolvency</U>. Each Party shall have the right to terminate this Agreement upon written notice (a)&nbsp;if voluntary or involuntary proceedings by or against the other Party are
instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for the other Party, or proceedings are instituted by or against the other Party for corporate reorganization or the dissolution or liquidation of the
other Party under the U.S. Bankruptcy Code, which proceedings, if involuntary, shall not have been dismissed within [* * *] ([* * *]) days after the date of filing, or if the other Party makes an assignment for the benefit of creditors, or
substantially all of the assets of the other Party are seized or attached and not released within [* * *] ([* * *]) days thereafter, or (b)&nbsp;upon the voluntary liquidation, dissolution, winding up or cessation of business by the other Party
other than in connection with a permitted assignment of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5 <U>Consequences of Termination</U>. Upon
(i)&nbsp;termination of this Agreement by GMI or (ii)&nbsp;termination of this Agreement by Pfizer in accordance with Section&nbsp;9.2: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Except as expressly set forth herein, including in Section&nbsp;9.13, all rights and licenses granted to Pfizer under this Agreement shall terminate and neither Pfizer nor its Affiliates shall
research, develop, market, sell or otherwise commercialize a Licensed Product and/or Compound. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Subject to Section&nbsp;9.5(c), upon written notice from GMI, Pfizer
agrees to grant to GMI as of the date of such termination of this Agreement a non-exclusive license, with the right to sublicense, to research, develop, make, have made, use, export, import, offer to sell, sell and commercialize Compounds and
Licensed Products in the Reference Forms, in the Field in the Territory under Pfizer Patent Rights and Pfizer Know-How, and upon such written notice such license shall be automatically granted without any further action by Pfizer or GMI. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In the event that Pfizer Patent Rights and/or Pfizer Know-How are licensed to Pfizer by a Third Party, and such
Pfizer Patent Rights and/or Pfizer Know-How are reasonably required by GMI to make, have made, use, sell, offer to sell, import, export, research, develop and/or commercialize Compounds and/or Licensed Products and Pfizer has the right to grant a
sublicense thereunder to GMI when this Agreement is terminated, Pfizer shall notify GMI of such Pfizer Patent Rights and Pfizer Know-How, and then at the request of GMI, Pfizer shall grant to GMI such a sublicense to the fullest extent permitted
under the license under which the sublicense is granted and subject to the terms, conditions and requirements thereof to make, have made, use, sell, offer to sell, import, export, research, develop and/or commercialize Compounds and Licensed
Products to the same extent and as set forth in Section&nbsp;9.5(b). Such sublicense shall be granted in a separate agreement without additional consideration to Pfizer, provided that GMI [* * *]. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) In the event that at the date of such termination Pfizer or its Affiliate or their supplier is responsible for
manufacturing a Licensed Product and/or Compounds for the purposes of conducting clinical trials and/or for commercializing a Licensed Product in the Territory, then upon GMI&#146;s written request until the earlier of (A)&nbsp;the date that GMI
obtains an alternative supply thereof or (B)&nbsp;(i)&nbsp;with respect to the supply of the Licensed Product and/or Compounds prior to Regulatory Approval in a country in the Territory, [* * *], and (ii)&nbsp;with respect to the supply of the
Licensed Product and/or Compounds for commercial sale after Regulatory Approval (and Pricing Approval, if applicable), [* * *], at GMI&#146;s option, Pfizer shall supply such Licensed Product and Compounds to GMI at Pfizer&#146;s or its
Affiliate&#146;s cost for such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Licensed Product and/or Compounds (and in the case where Pfizer or its Affiliate manufactures such Licensed Product and/or Compounds, such cost shall be [* * *] percent ([* * *]%) of Pfizer&#146;
or its Affiliate&#146;s fully-burdened manufacturing cost for such Licensed Product and/or Compounds); <I>provided however</I>, if there are restrictions in an agreement between Pfizer or an Affiliate of Pfizer and a Third Party governing the
manufacture or supply of such Licensed Product and/or any such Compound that would limit the amount of such Licensed Product and/or any such Compound that could be supplied to GMI or that would preclude the period from being up until [* * *], then
the limits in such agreement as to the amount of such Licensed Product and/or any such Compound that could be supplied shall govern and such period shall be up to as long a time as permitted under such agreement, and further provided that if Pfizer
or its Affiliate is manufacturing the Compound and/or Licensed Product, Pfizer shall not be obligated to manufacture and supply such Compound and/or Licensed Product in amounts that exceed the amounts of such Compound and/or Licensed Product which
were being manufactured by Pfizer or its Affiliate as of the date of termination. Notwithstanding the foregoing, in the event that Pfizer is obtaining supplies from a Third Party, the Parties shall meet and discuss in good faith whether it is
possible to assign the Third Party agreements to GMI. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Upon the request of GMI, Pfizer shall transfer to
GMI, at the cost and expense of Pfizer, clinical data from any Additional Phase II Clinical Trial and any Phase III Clinical Trial of a Licensed Product, all marketing authorizations, INDs and other regulatory filings and Regulatory Approvals in the
Territory for any Licensed Product that is being developed and/or commercialized by Pfizer or its Affiliates as of the date of such termination. For the avoidance of doubt, Pfizer will transfer ownership of the items described in the preceding
sentence, together with the privileges, benefits and obligations associated with the ownership of such items. In the event that in any country such transfer is not legally possible, Pfizer shall (and shall cause its Affiliates) to take all
reasonable actions that are permitted by the applicable Regulatory Authority to permit GMI to also have the benefit of the relevant marketing authorizations, INDs and other regulatory filings and Regulatory Approvals in the applicable country that
exist at the time of termination for any such Licensed Product in the applicable country, including allowing GMI to cross-reference data and information on file with the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Regulatory Authority in the applicable country, and to this end, Pfizer itself consents to and shall cause its Affiliates to consent to such Regulatory Authority cross-referencing to the data and
information on file with such Regulatory Authority to the extent that it exists at the time of such termination as may be necessary to facilitate the granting of permitted second marketing authorizations, INDs, regulatory filings and Regulatory
Approvals in applicable country to GMI. In addition, upon GMI&#146;s request, Pfizer will provide GMI for use by GMI with (a)&nbsp;copies of human clinical experience databases as updated following completion or termination of any ongoing trials,
(b)&nbsp;copies of completed and final clinical study reports, (c)&nbsp;clinical trial master files (or equivalent), (d)&nbsp;copies of completed and final non-clinical study reports used to support Regulatory Approvals, (e)&nbsp;copies of material
documents filed with a Regulatory Authority in connection with marketing authorizations, INDs and other regulatory filings and Regulatory Approvals in the applicable country that exist at the time of termination, (f)&nbsp;copies of correspondence
with Regulatory Authorities, and (g)&nbsp;copies of any then-existing documentation and technical information, in the form and format in which such materials are maintained by Pfizer in the ordinary course of its business, that are necessary for the
manufacture of the Licensed Product in the Reference Forms, which documentation and technical information shall include (1)&nbsp;copies of flow charts of the manufacturing procedures and work instructions related to manufacturing of the Licensed
Product in the Reference Forms, (2)&nbsp;a list of all equipment, including the source of the equipment, utilized in the production of the Licensed Product in the Reference Forms, (3)&nbsp;copies of all current specifications for the Licensed
Product in the Reference Forms, (4)&nbsp;copies of all standard operating procedures for the manufacturing procedures to be transferred, and (5)&nbsp;all environmental conditions necessary for the manufacture of the Licensed Product in the Reference
Forms and copies of any existing external environmental impact studies based on the materials or methods employed in the manufacturing method to be transferred, in each case that relates to a Licensed Product in the Reference Forms and that is in
the possession or control of Pfizer (including information controlled by Pfizer but in the possession of a Third Party). Pfizer shall bear its costs and expenses for the transfer described in this Section&nbsp;9.5(e), subject to a limit of [* * *]
of meetings and an additional [* * *], and any additional support to be provided by Pfizer shall be provided on a person-hour basis at a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
rate and for a number of hours that will be agreed upon in advance between GMI and Pfizer, provided that GMI shall be responsible for any out-of-pocket expenses incurred by Pfizer in connection
with any such transfer to the extent Pfizer notifies GMI of such expenses prior to incurring them and GMI agrees to reimburse such expenses to Pfizer (and if GMI does not agree to reimburse such expenses to Pfizer, Pfizer shall not be obligated to
incur any such out-of-pocket expenses in connection with any such transfer). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Pfizer agrees to assign and
hereby assigns to GMI all right, title and interest in and to any and all trademarks that are owned by Pfizer and that prior to termination have been and/or are being used at termination with respect to Licensed Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6 <U>Certain Payments after Termination</U>. Notwithstanding anything to the contrary herein, in the event that (a)&nbsp;GMI requests
the license provided for in Section&nbsp;9.5(b) or requests Pfizer to transfer or provide any of the data, information or documents provided for in Section&nbsp;9.5(e) and (b)&nbsp;as of the date of termination of this Agreement by GMI or by Pfizer
under Section&nbsp;9.2, Pfizer or its Affiliate has completed a Phase III Clinical Trial for a Licensed Product for an indication and GMI or its licensee files for and obtains Regulatory Approval for such Licensed Product for such indication based
on such Phase III Clinical Trial, or at the date of such termination Pfizer or its Affiliate has obtained Regulatory Approval for a Licensed Product for an indication, then GMI shall pay royalties to Pfizer on GMI Net Sales of such Licensed Product
for such indication at a royalty rate of [* * *] percent ([* * *]%) of GMI Net Sales at any time after the date of such termination for a period of ten (10) years from the First Commercial Sale of such Licensed Product for such indication;<I>
provided</I> that GMI only shall be obligated to make such payments to Pfizer until such time as the aggregate of payments due and payable under this Section&nbsp;9.6 equal [* * *] dollars ($[* * *]). In the event that (1)&nbsp;the preceding
sentence is not applicable, (2)&nbsp;GMI requests the license provided for in Section&nbsp;9.5(b) or requests Pfizer to transfer or provide any of the data, information or documents provided for in Section&nbsp;9.5(e), and (3)&nbsp;as of the date of
termination of this Agreement by GMI or by Pfizer under Section&nbsp;9.2, Pfizer or its Affiliate has completed an Additional Phase II Clinical Trial for a Licensed Product for an indication, the results of which Additional Phase II Clinical Trial
are supportive of and included in an application for Regulatory Approval for such indication, then GMI shall pay </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
royalties to Pfizer on GMI Net Sales of such Licensed Product for such indication at a royalty rate of [* * *] percent ([* * *]%) of GMI Net Sales at any time after the date of such termination
for a period of ten (10) years from the First Commercial Sale of such Licensed Product for such indication; <I>provided</I> that GMI only shall be obligated to make such payments to Pfizer until such time as the aggregate of payments due and payable
under this Section&nbsp;9.6 equal [* * *] Dollars ($[* * *]). GMI shall make such payments to Pfizer within forty-five (45)&nbsp;days of the end of each calendar quarter in which any payment under this Section&nbsp;9.6 become due and payable and
each such payment shall be accompanied by a detailed written report showing the calculation of such payment. The provisions of Sections 4.2(f), 4.2(g), 4.3, 4.4, 4.5 and 4.6 shall apply, <I>mutatis mutandis</I>, to royalties payable by GMI under
this Section&nbsp;9.6 and for purposes of this sentence all reference to one Party in such Sections shall be deemed to refer to the other Party and all references to a Pfizer Quarter shall be deemed to refer to a calendar quarter. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7 <U>Offset of Damages</U>. In the event that Pfizer is awarded damages against GMI under this Agreement by a court of competent
jurisdiction as to which Pfizer&#146;s right to collect such damages has not been stayed, in addition to any other remedy for collection of such damages, Pfizer may offset such damages against any amounts to be paid by Pfizer to GMI under this
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8 <U>Termination of Rights and Obligations</U>. Upon termination of this Agreement all rights and obligations of
the Parties under this Agreement shall terminate except those that survive termination under Section&nbsp;9.13. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.9
<U>Accrued Obligations</U>. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including without
limitation the obligation to pay royalties for Licensed Product(s) sold prior to such expiration or termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10
<U>Disposition of Inventory</U>. Notwithstanding anything herein to the contrary, in the event of termination of this Agreement, at the option of Pfizer, Pfizer either (a)&nbsp;shall have for a period of [* * *] ([* * *]) months after termination,
the right to use or sell Licensed Products on hand on the date of such termination and to complete Licensed Products in the process of manufacture at the time of such termination and use or sell the same as if licensed under this
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Agreement, provided that Pfizer shall submit the applicable royalty report, along with the royalty payments required by this Agreement; or (b)&nbsp;at the request of GMI, shall transfer to GMI
all existing inventory, raw material, work-in-progress and finished goods, each with respect to any Compound and Licensed Product, at a cost to GMI equal to Pfizer&#146;s fully-burdened manufacturing costs together with the reasonable cost of
transportation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.11 <U>Pfizer Elections upon Breach by GMI</U>. If an event occurs that gives rise to a right of termination
by Pfizer under Section&nbsp;9.3 (as a result of an uncured material breach by GMI) and if Pfizer elects not to terminate this Agreement, Pfizer may elect that Sections 3.1(a) and (b), 3.2(b)(iii) shall be deleted, in whole or in part, from this
Agreement and Pfizer&#146;s obligations to deliver reports pursuant to Section&nbsp;3.2(b)(iv) shall be limited to [* * *]. If Pfizer makes any election as provided in this Section&nbsp;9.11 to delete any Section, each of the Parties hereto will
enter into an appropriate and customary written amendment and no Party shall have any further obligations with respect to any such deleted Section. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.12 <U>Bankruptcy</U>. All rights and licenses granted under Section&nbsp;2.1 of this Agreement are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the U.S. Bankruptcy Code,
licenses of rights to &#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the U.S. Bankruptcy Code. The Parties agree that Pfizer, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of
its rights and elections under the U.S. Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against GMI under the U.S. Bankruptcy Code, Pfizer shall be entitled to a complete duplicate of or complete access to any such
intellectual property and all embodiments of such intellectual property that is licensed to Pfizer under this Agreement. Such intellectual property and all embodiments thereof shall be promptly delivered to Pfizer (i)&nbsp;upon any such commencement
of a bankruptcy proceeding upon written request therefor by Pfizer, unless GMI elects to continue to perform all of its obligations under this Agreement or (ii)&nbsp;if not delivered under (i)&nbsp;above, upon the rejection of this Agreement by or
on behalf of GMI upon written request therefor by Pfizer. The term &#147;embodiments&#148; of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all compounds and
products embodying intellectual property, Licensed Products, filings with Regulatory Authorities and related rights. The foregoing is without prejudice to any rights Pfizer may have arising under the U.S. Bankruptcy Code or other applicable law.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.13 <U>Survival</U>. Following expiration or termination of this Agreement for any reason,
Articles 1, 6, 8, 9 and 11 and Sections 2.4, 3.1(c)(B) and 7.5 and Sections 4.3 and 4.4 with respect to royalties paid or to be paid under this Agreement shall survive the expiration or termination. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article 10 NON-COMPETITION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From the Effective Date until the end of the Term, GMI, its Affiliates and any Third Party on behalf of GMI or its Affiliates may not, directly or indirectly, commercialize in any country in the Territory
any pharmaceutical compound or product in any dosage form or formulation that is labeled for treatment or prevention or prophylaxis of a vaso-occlusive or painful crisis associated with Sickle Cell Disease (a &#147;<U>Competing Product</U>&#148;).
If GMI or any of its Affiliates controlling GMI (a &#147;<U>GMI Parent</U>&#148;) undergoes a Change of Control, then the provisions of the preceding sentence shall not apply with respect to a Competing Product; <I>provided</I>, however, that such
Competing Product is researched, developed and commercialized without use of any GMI Patent Rights or GMI Know-How. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Article
11 MISCELLANEOUS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1 <U>Assignment</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Assignment</U>. This Agreement and the rights and obligations under this Agreement may not be assigned by
operation of law or otherwise by either Party without the consent of the other Party, <I>provided, however</I>, that either Party may assign this Agreement, in whole or in part, without the consent of the other Party (i)&nbsp;to an Affiliate, or
(ii)&nbsp;to a successor, in each case by virtue of a sale of all or substantially all of its assets related to this Agreement, merger, consolidation or similar transaction or where a Party or its Affiliate is required, or makes a good faith
determination based on advice of counsel that it is required, to divest any of the Licensed Products in order to comply with Law or the order of any Governmental Authority as a result of merger of a Party with a Third Party or acquisition by a Party
of a Third Party or acquisition of a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Party by a Third Party; <I>provided, further,</I> that the assigning Party shall deliver written notice of any such permitted assignment to the other Party, and the assignee shall assume all
obligations of its assignor under this Agreement and such assigning party shall remain jointly and severally liable with such assignee in respect of all obligations so assigned. Subject to the restriction on assignment of this Section&nbsp;11.1,
this Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Transfer of GMI Patent Rights</U>. Except in connection with permitted assignments under Section&nbsp;11.1(a) to a
Person that is not an Affiliate of GMI, GMI and any Affiliate of GMI may not sell, assign or otherwise transfer GMI Patent Rights to any person other than a wholly-owned direct or indirect subsidiary of GMI that (x)&nbsp;is and continues to be at
all times incorporated and domiciled (including with respect to principal headquarters) in any state of the United States of America and (y)&nbsp;prior to any such sale, assignment or transfer to such person described in clause (x), has acknowledged
and confirmed in writing to Pfizer, all in a manner reasonably acceptable to Pfizer, that, effective as of such sale, assignment or other transfer, such transferee shall be bound by this Agreement as if it were a party to it as and to the identical
extent applicable to the transferor with respect to GMI Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Non-compliant Assignments</U>.
Any purported assignment that is not in compliance with this Section&nbsp;11.1 shall be null and void. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
<U>Performance by Affiliates</U>. Pfizer shall have the right to permit an entity that is an Affiliate of Pfizer to exercise the rights and licenses granted to Pfizer under this Agreement without the granting of a sublicense while such entity is an
Affiliate of Pfizer, provided that the Affiliate agrees to be bound by the terms and conditions of this Agreement as if a signatory thereto. In exercising the rights and licenses granted under this Agreement, Pfizer shall have the right to have
Licensed Product in the Field researched, developed and/or made for Pfizer by a Third Party without granting a sublicense to such Third Party; <I>provided</I>, that such research, development and/or manufacture is performed for Pfizer, and Pfizer
shall ensure that any such Third Party shall perform such research, development or manufacturing activities in compliance with the provisions of this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2 <U>Notices</U>. Any consent, notice or report required or permitted to be given or made
under this Agreement by one of the Parties hereto to the other shall be in writing and shall be deemed given (i)&nbsp;five (5)&nbsp;Business Days after mailing when mailed by registered or certified mail, return receipt requested, postage paid, or
(ii)&nbsp;on the date received when delivered in person or by reputable international express delivery service, addressed to such other Party at its address indicated below, or to such other address as the addressee shall have last furnished in
writing to the addressor and shall be effective upon receipt by the addressee: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to GMI: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">GlycoMimetics, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">401 Professional Drive, Suite 250 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gaithersburg, Maryland 20879
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: CEO </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If to Pfizer: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer Inc. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">[XXXXX] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With a copy to: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer Inc. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">[XXXXX] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.3 <U>Jurisdiction</U>. Except as to Patent Rights for which the patent laws of the country of the Patent Right shall be controlling, this Agreement shall be governed by and construed in accordance with
the laws of the State of New York, U.S.A, without regard to any choice of law </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
principles that would dictate the application of the laws of another jurisdiction. All actions and proceedings under this Agreement shall be brought exclusively in a state or federal court of
competent subject matter jurisdiction in the County of New York in the State of New York. Each Party hereby waives (i)&nbsp;any objection which it may have at any time to the venue of the proceedings in any such court, (ii)&nbsp;any claim that such
proceedings have been brought in an inconvenient forum and (iii)&nbsp;the right to object, with respect to such proceedings, that such court does not have any jurisdiction over such Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4 <U>Dispute Resolution</U>. Except as otherwise set forth in this Agreement, any disputes arising between the Parties relating to,
arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, shall be resolved as follows: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Within [* * *] ([* * *]) days of notice of such dispute, the senior executive, or an equivalent successor thereto, to
be nominated by Pfizer who is responsible for the Licensed Product, or his or her designate, and the Chief Executive Officer of GMI or his or her designate shall first attempt to resolve such dispute through good faith negotiations for a period of
not less than [*&nbsp;*&nbsp;*] ([*&nbsp;*&nbsp;*]) days. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If such dispute cannot be resolved after such
[* * *] ([* * *]) day period then either Pfizer or GMI may initiate a legal action with respect to such dispute. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) This Section&nbsp;11.4 shall not prevent a Party from seeking and obtaining temporary or preliminary relief in a court of competent jurisdiction to protect the interests of such Party pending the
outcome of proceedings pursuant to this Section&nbsp;11.4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5 <U>Entire Agreements; Amendments</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties
with respect to the subject matter hereof and supersedes and terminates all prior and contemporaneous agreements and understandings between the Parties, whether oral or in writing, by and between Pfizer and GMI with respect to the subject matter
hereof and except as provided in Section&nbsp;11.5(b), including but not limited to the Confidentiality Agreement between the Parties effective [* * *]. In the event of any conflict or inconsistency between any provision of any Schedules or Exhibit
hereto and any provision of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
this Agreement, the provisions of this Agreement shall prevail. All express or implied agreements and understandings, either oral or written, heretofore made are expressly merged in and made a
part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by the Parties hereto. Each of the Parties hereby acknowledges that this Agreement and the related documents are each the
result of mutual negotiation and, therefore, any ambiguity in their respective terms shall not be construed against the drafting Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) The Confidentially Agreement between the Parties effective [* * *] shall survive and remain in full force and effect only with respect to any breaches thereof prior to the Effective Date of this
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.6 <U>Headings</U>. The captions to the several Articles and Sections hereof and Schedules or Exhibits hereto
are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.7 <U>Third Party Beneficiaries</U>. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including any creditor of either party. Except for an
assignee in accordance with a permitted assignment of this Agreement, no Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation
(or otherwise) against either Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.8 <U>Independent Contractor</U>. It is expressly agreed that GMI and Pfizer shall be
independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither GMI nor Pfizer shall have the authority to make any statements, representations or commitments of any
kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party to do so. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.9 <U>Waivers</U>. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a
written instrument duly executed by or on behalf of the Party or parties waiving such term or condition. Neither the waiver by either Party hereto of any right hereunder nor the failure to perform or of a breach by the other Party shall not be
deemed or construed a waiver of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. All rights, remedies, undertakings, obligations and agreements contained
in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.10 <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Counterparts may be exchanged by electronic portable document format if mutually agreed by the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.11 <U>Other
Actions</U>. Each Party agrees to sign and execute such documents and to take such actions as reasonably requested by the other Party to carry out and perform the intent and purposes of the Party&#146;s obligations under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.12 <U>Severability</U>. Each Party hereby agrees that it does not intend to violate any public policy, statutory or common laws,
rules, regulations, treaty or decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid or unenforceable, the Parties
hereto shall use their respective reasonable efforts to substitute, by mutual consent, valid provisions for such invalid provisions, if their economic effect, are sufficiently similar to the invalid provisions that it can be reasonably assumed that
the Parties would have entered into this Agreement based on such valid provisions. In case such alternative provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement shall not affect the validity of this
Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provisions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.13 <U>Construction</U>. Except where the context otherwise requires, wherever used, the singular will include the plural, the plural
the singular, the use of any gender will be applicable to all genders, and the words &#147;and/or&#148; is used in the inclusive sense (one or more). The captions of this Agreement are for convenience of reference only and in no way define,
describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term &#147;including&#148; as used herein means including, without limiting the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
generality of any description preceding such term. The term &#147;owned&#148; or &#147;owns&#148; means solely owned or owns, or jointly owned or owns. References to &#147;Section&#148; or
&#147;Sections&#148; or &#147;Article&#148; or &#147;Articles&#148; are references to the numbered Sections or Articles of this Agreement, unless expressly stated otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page Follows] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and scaled by
their respective duly authorized representatives as of the date first set forth above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GLYCOMIMETICS, INC.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">PFIZER INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Rachel K. King</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Adam Woodrow</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rachel K. King</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adam Woodrow</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President Commercial Development</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT A </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">GMI PATENT RIGHTS </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation /</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. /</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation /</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. /</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation /</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. /</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.10 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Backup Compounds </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT WHICH INCLUDE THIS AND TWO ADDITIONAL PAGES OF OMISSIONS. THE COPY
FILED HEREWITH OMITS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.22 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Structure </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.35 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Knowledge of GMI </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PART A </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Rachel K. King, President and Chief Executive Officer </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John L. Magnani, Ph.D., Vice President and
Chief Scientific Officer </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Helen M. Thackray, M.D., FAAP, Vice President, Clinical Development </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brian Hahn, Director, Finance and Administration </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">PART B </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.69 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Format for Topline Study Report </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Topline Study Report Template </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT WHICH INCLUDE THIS AND NINE ADDITIONAL PAGES OF OMISSIONS. THE COPY
FILED HEREWITH OMITS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 2.1 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Permitted Studies </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:35pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Indication</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:35pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Institution</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:49pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Investigator(s)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Summary</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Status</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT WHICH INCLUDE THIS AND ONE ADDITIONAL PAGE OF OMISSIONS. THE COPY
FILED HEREWITH OMITS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 2.3 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Transition Plan </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 3.1(c) </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ongoing Clinical Trial Budget </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Budget</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>To</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Remaining</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jun-11</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">[*&nbsp;*&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">]&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 6.4 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Public Announcement </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g572031st_p73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DRAFT &#150; NOT INTENDED FOR DISTRIBUTION </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GlycoMimetics and Pfizer
Enter into Licensing Agreement for Drug Candidate </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Currently in Development to Treat Patients Experiencing Vaso-occlusive
Crisis </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Associated with Sickle Cell Disease </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Gaithersburg, MD &#150; October&nbsp;11, 2011</B> &#150; <U>GlycoMimetics, Inc.</U> announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) for
the GlycoMimetics investigational compound <B><U>GMI-1070</U></B>. GMI-1070 is a pan-selectin antagonist currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease. GMI-1070 has received Orphan
Drug and Fast Track status from the U.S. Food and Drug Administration (FDA). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vaso-occlusive crisis, which can last five to six days on
average, results in over 75,000 hospitalizations each year in the U.S. These crises cause pain and tissue damage leading to multiple organ damage, a requirement for life-long narcotic pain medications, and eventually to significantly shorter life
spans. While the genetic and molecular cause of sickle cell disease has been known for more than 50 years, therapy for painful crises has not significantly advanced. GMI-1070 is thought to inhibit selectin interactions, a key early step in the
inflammatory process leading to vaso-occlusive crisis. In preclinical studies, GMI-1070 restored blood flow to affected vessels of sickle cell animals experiencing vaso-occlusive crisis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very pleased to partner with Pfizer for the advancement of GlycoMimetics&#146; lead drug candidate, GMI-1070, which is initially being evaluated in patients with sickle cell disease
experiencing vaso-occlusive crisis. This is a major unmet medical need,&#148; said <B><U>Rachel King, CEO of GlycoMimetics</U></B>. &#147;We value the resources and experience that Pfizer brings to the program, and recognize that the agreement is an
important validation of GlycoMimetics&#146; unique chemistry expertise in discovery of proprietary drug candidates.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of
the agreement, Pfizer will receive an exclusive worldwide license to GMI-1070 for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. GlycoMimetics will remain responsible
for completion of the ongoing Phase 2 trial under Pfizer&#146;s oversight, and Pfizer will then assume all further development and commercialization responsibilities. The potential value of the agreement for GlycoMimetics is approximately $340
million, including an upfront payment as well as development, regulatory and commercial milestones. GlycoMimetics is also eligible for royalties on any sales. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;Pfizer is committed to helping improve the lives of patients with rare diseases, and we see potential for GlycoMimetics&#146; GMI-1070 to be a significant advance in the treatment of vaso-occlusive
crisis of sickle </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
cell disease,&#148; said Yvonne Greenstreet, senior vice president and head of the Medicines Development Group within Pfizer&#146;s Specialty Care business unit. &#147;This experimental compound
and partnership are emblematic of our strategy in rare disease, targeting areas of high unmet need to deliver improved patient outcomes.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;This partnership is an important milestone for GlycoMimetics as the company advances its clinical development program,&#148; added <U>Jim Barrett,
Ph.D., Chairman of the Board of GlycoMimetics and General Partner, New Enterprise Associates</U>. &#147;It&#146;s a testament to the progress made to date with GMI-1070, and will enhance continued development of this potential treatment for patients
suffering from vasoocclusive crisis.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About GMI-1070 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">GMI-1070 is a rationally designed glycomimetic inhibitor of E-, P- and L-selectins that interferes in a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed
tissue. GMI-1070 has shown activity in several models of diseases in which leukocyte adhesion and activation play a key role. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">GMI-1070 is
initially being developed for the treatment of vaso-occlusive crisis associated with sickle cell disease. By inhibiting selectin interactions, GMI-1070 may be able to decrease the enhanced cell adhesion that results in vaso-occlusive crisis. In
preclinical studies, GMI-1070 restored blood flow to affected vessels of sickle cell animals experiencing vaso-occlusive crisis. Two Phase 1 trials of GMI-1070 were successfully completed in the first quarter of 2009, with no serious adverse events
reported. The program is currently in Phase 2 clinical testing. GMI-1070 is also being evaluated in preclinical studies for the treatment of other diseases, including hematologic malignancies, where selectin-mediated cell adhesion and migration is
known to play a key role in the disease process. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued U.S. patents cover GMI-1070 with additional intellectual property issued and pending
outside the U.S. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Sickle Cell Disease and Vaso-Occlusive Crisis </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Vaso-occlusive crisis is the main clinical feature of sickle cell disease, causing severe pain, often resulting in significant patient complications, and sometimes death. Currently, there are no
mechanism-based therapies for treatment of vaso-occlusive crisis. Treatment consists primarily of supportive therapy in the form of hydration and pain control, typically requiring hospitalization for five to six days. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About GlycoMimetics, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">GlycoMimetics
is a privately held biotechnology company that capitalizes on advances in the field of glycobiology. The company uses rational design of small molecule drugs that mimic the functions of bioactive carbohydrates to develop new drug candidates. The
company&#146;s initial focus is on therapeutics to treat orphan conditions in which inflammation and cell adhesion may play a key role. For additional information, please visit the company&#146;s website: <U>www.glycomimetics.com</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"># # # </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MEDIA CONTACTS
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GlycoMimetics: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brian
Hahn </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone: 240-243-1207 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email
Address: bhahn@glycomimetics.com </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 7.1 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Disclosure Schedules </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMENDMENT NO. 1 TO LICENSE AGREEMENT </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This AMENDMENT NO. 1 TO LICENSE AGREEMENT (the &#147;First Amendment&#148;) is made and entered into as of November&nbsp;17, 2011 by and
between GLYCOMIMETICS, INC., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (&#147;GMI&#148;), and PFIZER INC., a Delaware corporation having a place of business at 235 East 42nd
Street, New York, New York 10017 (&#147;Pfizer&#148;). GMI and Pfizer are individually referred to as a &#147;Party&#148; or collectively as the &#147;Parties&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, GMI and Pfizer are parties to a License Agreement dated as of October&nbsp;7, 2011, (the &#147;License Agreement&#148;); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Parties desire to amend the License Agreement by including therein certain patents and patent applications owned by GMI that were erroneously omitted from Exhibit A of the License Agreement;
and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the mutual promises and agreement set forth herein, the Parties hereby agree as
follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. GMI and Pfizer agree that Exhibit A of the License Agreement is replaced by the Exhibit A attached
hereto and the License Agreement is to be construed as if the replacement Exhibit A was attached thereto as of the Effective Date of such License Agreement. The representations and warranties of GMI under Article 7 of such License Agreement with
respect to GMI Patent Rights of Exhibit A shall be deemed to have been and are made as of the Effective Date of such License Agreement, with respect to all of the patents and patent applications of such replacement Exhibit A. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. This First Amendment amends the terms of the License Agreement as expressly provided above, and the License Agreement
as so amended remains in full force and effect. Capitalized terms used but not defined herein shall have the meanings set forth in the License Agreement. The validity, performance, construction, and effect of this First Amendment shall be governed
by and construed under the substantive laws of the State of New York, without regard to any choice of law principles that would dictate the application of the laws of another jurisdiction. This First Amendment may be executed in counterparts, all of
which taken together shall be regarded as one and the same instrument. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Parties have executed this First Amendment in duplicate originals by
their proper officers as of the date specified above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GLYCOMIMETICS, INC.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">PFIZER INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Rachel K. King</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Robert Bagdorf</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Rachel K. King</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Robert Bagdorf, MD, MBA</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: VP, Worldwide Business Development</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: Nov. 18, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: 11/17/2011</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">GMI PATENT RIGHTS </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. / Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. / Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. / Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. / Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. / Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No. / Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMENDMENT NO. 2 TO LICENSE AGREEMENT </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This AMENDMENT NO. 2 TO LICENSE AGREEMENT (the &#147;Second Amendment) is made and entered into as of December&nbsp;1, 2012 by and between GLYCOMIMETICS,
INC., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (&#147;GMI&#148;), and PFIZER INC., a Delaware corporation having a place of business at 235 East 42nd Street, New York, New
York 10017 (&#147;Pfizer&#148;). GMI and Pfizer are individually referred to as a &#147;Party&#148; or collectively as the &#147;Parties&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, GMI and PFIZER are parties to a License Agreement dated as of October&nbsp;7, 2011, (the &#147;License Agreement&#148;) as amended, November&nbsp;17, 2011 (&#147;Amendment No. 1&#148;);<B>
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, the Parties desire to amend the License Agreement by including therein certain patents and patent
applications owned by GMI that were erroneously omitted from Exhibit A of the License Agreement; and<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>,
the Parties desire to amend the License Agreement by deleting the Topline Study Report template (Schedule 1.69 in the License Agreement) and replacing it in its entirety with the revised Top Line Report template attached hereto and made a part
hereof; and<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOW, THEREFORE</B>, in consideration of the mutual promises and agreement set forth herein, the Parties
hereby agree as follows:<B> </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">GMI and Pfizer agree that Exhibit A of the License Agreement is replaced by the Exhibit A attached hereto and the License Agreement is to be construed as if the
replacement Exhibit A was attached thereto as of the Effective Date of such License Agreement. The representations and warranties of GMI under Article 7 of such License Agreement with respect to GMI Patent Rights of Exhibit A shall be deemed to have
been made as of the Effective Date of such License Agreement, with respect to all of the patents and patent applications of such replacement Exhibit A. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">GMI and Pfizer agree to delete in its entirety the Topline Study Report template as set forth in Schedule 1.69 (Format for Topline Study Report) of the License
Agreement and replacing it with the Top Line Report template attached hereto and made a part hereof. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Second Amendment amends the terms of the License Agreement, as amended, as expressly provided above, and the License Agreement as so amended
remains in full force and effect. Capitalized terms used but not defined herein </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shall have the meanings set forth in the License Agreement. The validity, performance, construction, and effect of this Second Amendment shall be governed by and construed under the substantive
laws of the State of New York, without regard to any choice of law principles that would dictate the application of the laws of another jurisdiction. This Second Amendment may be executed in counterparts, all of which taken together shall be
regarded as one and the same instrument. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Second
Amendment in duplicate originals by their proper officers as of the date specified above.<B> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GLYCOMIMETICS, INC.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">PFIZER, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Rachel K. King</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Y. Greenstreet</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Rachel K. King</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Y. Greenstreet</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: SVV Development</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: Dec. 14, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: 12/06/12</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g572031st_p81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Protocol GMI-1070-201 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>TOP LINE REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>[Schedule 1.69 TEMPLATE] </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT WHICH INCLUDE THIS AND SIX ADDITIONAL PAGES OF OMISSIONS. THE COPY
FILED HEREWITH OMITS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">GMI PATENT RIGHTS </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:87pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No./Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:87pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No./Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:87pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No./Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:87pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No./Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:87pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No./Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:87pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No./Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nation/Region</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:87pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Application No./Patent No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:36pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Filing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Status</FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[* * *]</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g572031ex4_2pg001new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g572031ex4_2pg001new.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"2P-P`P$1``(1`0,1`?_$`.@``0``!P$!`0$`````
M```````#!`4&!P@)`@$*"P$!``$%`0$!`0````````````,!`@0%!@<("0H0
M``$%``$%``$#`P$%`P8"&P,!`@0%!@<`$1(3"!0A%0DB(Q8Q05$R)!=A,QAQ
M0E(T)38*@9%RLX2T=1EBDD.U)C<YDW:V)SAXH;%3<T2W>1$``@(!`P($`P0'
M!`@"!`$=`0(1`P0`(1(Q!4$B$P9183)Q(Q0'\(&1H;%"%<'14C/A\6)R)#06
M"+)#@G.S-1>24V-$M"6BPM-49'0F-G8W"=+BD\-E=3B#U%75.?_:``P#`0`"
M$0,1`#\`_?QTTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333I
MIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIIT
MTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ
M::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=
M--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.
MFFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG
M333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333III
MTTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTT
MZ::=--.FFG337Q%[HBJBM[IW\5[=T_[%[*J=T_\`+TTU]Z::=--.FFG333II
MITTTZ::=--.FFG333IIITTUI;]L7DS/X2@LX<O\`'?!EZB>-AYI8E<2;%QMT
MVO+8C_<*R%,'#D']HQRBI&0S6/?^C>Z=M['H3(S[*G$AE0;"3!L68V8B0()4
M<HD#KKRS\ULNW"[/3?4W%D:UA+$*6%#\2PY*K!29`<\>4$]-:(AY$N8]A"DV
M.ZRE1!G2C/BAL-7Q"&]E44;>[C)2[2$"/HWQBQY6>SL)U=*8]`R9X9CT7\=P
MW==ZW;J6K9:Z+GL4"8KR"@8U56!22DR'=N:Q*J4'U3KR%>]Y*7)9?EX]=+L8
M#780L-8R+Z6=0+8(-=:>FX/%K%M(\A4ZB"Y0TT:NG-_ZF<>I.-#<8B%T_%A:
MI+G_``X#0N.^;=23OKTY&0ODBN4C:=6_HDI>_5&[7BM8O_"Y'IAO\%_+CZAF
M(4"?1CY>I_L:JGN#N"4/_P`?A>J5G>W$X<_1$3RL)X_B9\9]&/\`S#K[_P!4
M/3)D/?RK@QPCF/&E&9L>&84UE`FOKRM:T@KOP'/_`,$)/0CFJ-O[KZ?U_&\V
MI3^E\E`&)D>H`"!Z>21S],_[/3U>$=?N^7\T:?\`4'"QB>XX8J)()];!5O3]
M93X61R_#^I,0/6X_^7(U*Q=5HZF='%IK67<6L>-5+/PL.-54TNEGV`G^HNPV
M[)&C!51I]<:')B55?6VUM'BE]]@V`Q[>TCXF-=66Q4"5$M%I+,&`Z^G5"%B#
MR5K'>NLL.-9L(.HZ^XYV-:HS[&MR%5.6.H1"C,-O6OFP(&4HR4UU77*AYW"D
M$:]BY)C6E5-!4Q[/.29$,-C(M:/3CY5A0132(ZKA$S.NI>(KV2^>'Q..#7V9
MKA0M1_X#U<P;Z'MCU6JUI6Q08"LGH$Q]1YUMD*(.Q9T%<[>H()%5[[7D8[IC
M"RAV4,7KM_%JH;Z`:KDP[#R'F"5VM=Q$^B9"FV9VWU,=@9$O>XN%4V(;-^=T
M%I>Y&@SVJ?%S=>W\F@;H=A`OQQ(/)4@L&RA3HL:VK8J#%(".8[L[)KP<1B53
M'O:Y2O-%6QWKESL_"LI)I`9&5FK=I*DITP+>[=PK`>S,Q4QK`WIV/9377;%2
M[U^I<M@"Y1-=M=BK=4G%75;3O<%1R%IYMPM%3;?/:.Y=)EM7.T&GXE70Q\>W
M7@EV.CT,2/NH#X<"DX\1\V?+.?\`$A6(47R6(J]8]W;L5*?Q%U%E=,#SNF1P
M-GID!$)J,EKH55`Y,AZ<]9N-WON%N5^#Q<NB_*Y'[JNW#]04^L"UMBC(7BM>
M-+V.S<$L7J:SJFNY&-!CA+;Z'_J%(5!$#;T-E(XIPTJ4]7#JJFALK2OW^WT[
M;3Q1@9DJKSL"4@T6*8[7,>24=M#L137^&7?RNHOM`_F9U4U5)Q\55[G6?,JP
M0(#WQJD#9-_XU]H>MCB8Y/1$K9ER+[>717>K&K>!Z;/()J__`%I@28K8N6N1
M8*Z='BRHMGKK&9M\S#>=/<<6TEQ(/'6YP40<V,\3I\F!:5\9PG)(=%8TAQP_
MT2Q7YY:'(ID@K6!4YC8>F";JK3!!X*Z.9\O,D*<G_JFFRL5]OM&'E<00US-?
M4L[D7L%QLC'`8$&QJ[:U(/,U@,ZQ;/D#5P]26';7-!DIL"7'CW57HM%BH>GJ
M2+K2'.EG6GY0.R-=+QL6,8#4<6&:S)YM<^$\9'4J[?B/BAZ4LNK9259$L*-]
MW`XL*!*^MR!Z,$$&'!&KK^]=QJ[@:LFVG&N1@'2RRA;4^^)/-3EF'_"E&424
M:TR":BK'[!Y/V%9`.@=[Q^6UD0VO%(#IL:V$EC%R$_\`L2%B<B5I?Q';98XA
M]D<]U60SG>!V#1:/VO"ML$X^0*@W0I9,&P;B:6$^E)/AZ@4;J3JM/N#N>/20
MF9A'(9-B+:./(4ML8R5,>OQ`ZGTBY,.%U4A\E:>RLH,,>YPQ@3YC8,=LG8XJ
M/.&ZRU6;BPJP;R\DEA)+EY^39C[$<\:STA-[JQYWI$>V8M5;.:+PRK)BNTCR
MUN2W^3,!PAV@\.9ZA1J=>_9]]Z5C+Q"COQ$WT!O-;4%43E%9:LVC>1ZGI#H7
M.LJ_,&XT%_RUG*VQDM$6OE$B6+85K5D))).HN:06-;>1<MJ[^G*@96%KY+!3
M1CG`DM>1J($@NM5[IP<?'[1;94)5A(E6VA\8@J7K1A(M=25)4K`^H'70^P.[
M9N9[DHHO:&1B&XNDDM7G!DL%5UB&#CUL`X%BM)`",NNJW7D^OHC3IIITTTZ:
M:=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFM>OIN
M;)K^,VRHI'M>+5Y<KA-+*$&4R/8ME)#F-B&`:3!D$`UI@^2-*SNU>Z+UT7M=
M%L[IQ?H:;/AM*Q(D&")V/@=]<5[]MLI[#ZE9,C(J,20##3Q:""5)`Y+.XV.N
M5U5S3J)U5`L2ZC*Q!VG[W%IE,?BB0MQ-I\_QA:R'0&UIK%\B+4RM+:BL%3^H
M1'0@IW(.5UZM;V3%2UJQ5:2G$MM>.(9[U$\@(+!$*?$<ST*:^>L;W5W"W&2]
MLC'5;.823B'FR5XKGCQ+2$-MHL/@?24>86:KS.7K1)#E_P`DJBQ'SX[FD9%X
M^%))6+I-`AU<S]F*)9R8O]I]:HY1K9)+[]@>GJ`]GJXQZ3A@I\;HY<$C^;IZ
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MVE>E;!@E9"*DJ93;NKL#P`U9C5+='^R\H\3Y',M":V&Z-#9,M*A+*6)?Q4>+
MN3J,=I=$2SDS#EL&J8`\@&X<J,BQ]E\S%4LX*?/!VU,WN.JVZRD5HC!3+)D(
MQ4(2GJ\,O#IJ@O*H'MI]5Q]W*^;6/YVVOJF5$T%CN*N?2U1ZF$2_T&?XZQ:K
M8N_R6=>9&5G[;+3[O(:D&2;`EC!*E.A'8V5,ARYT(@_7L4P<>U#CUT.MSACP
M1[K-O(%L#JX6Q#9S4E5Y`\4=*W!G36]VS,9US;\NM\6MD4V65XU'F^]:RDUO
M4UE-PI]-PKN48>I;59;45XTF+R1L[NUCUL"^RV@W-['CQ,?GH[^+YD^YT,;+
M1I,6)5P39*%,F1UVKYS_`/UD:!I2!5Y!E8<W4K]MPJ*C;97;7@5DFQSZX"H;
M""6(L(!]+CX&;`8!!5=8U??.Z9>0M%-V/=W>X!::P<1F>P5`@*II5F'K^H?J
M'&@J2RL';53_`,TH,Y8V[G:*GW@85A*>8L$6&PF6S59^:1!0WZ_-8'3Z_>RX
MK6,C&M:VIJ\V]_FX,XS/ZVQ_@<C)K0"M\=F40#ZMKNT=?3>U*Z@=R*WLLN`B
M:P=M9']5P\&^TF^K,17,E11CU5)R,+ZU6/;=D$;*;:J:L8F2MS#<1;'D;/6C
M?VP%6_)71&%C+9U/[%R-8T<Z,\?OCW6!VV'J[FQJF@EA(]]18DD*(S7Q0RG/
M8U]M?;<FK[UG%U`WXMSI#`]"MM5K*&D$?>(!(AV4`Q=?WS"R/^'2LXV49'-/
M3R6K8=0^/?0CLD,"33:6(8&M;"0#'/<7F?8&"3;8.L?:40K>.60#CLD+55-A
MG:5F7UU$:OXFFD?DK[3@N90U20T_[>^-%,UDN/*;U1::,@EQ1D,$LXF#=-;!
MVYUN#D#[Q$-:G:.?)P2C)J]\K+PP*FR\.LV4AP2,8K<C5)Z5U97#8^C9:+G'
MF#>F4K8"Q+!J/'T<59@Y"Z[`,@)9A>H10,0LIU+_`)3+<L`A7\22([9Z8A8P
MVO9W8EPQ[_UC*UG5K8S<"OHY'J<3O-L<N`W_`.8!CU>1WW],@?5OJY,ZLVA_
MQ.$*?4&P6B>'JGRD_@R.7H<0"-O6!.]<#7DO(^D@1`3UUG&`+%M8X-W(!#R,
M2J28W)3&GLAHSC*NDBJ6[8$8SVN*I4IE(/Q61V>VH[;C6.:_1RC7S\H)L+1Z
M@A?\]AR](D#:/4@SQVT;OF=56+CD]O%_IQ80M*IR]$RP_P"%4A/7"L1,^A*Q
MSW&4.,]]HIG-51G9_P"WQSUVKJW>R+.QS[H<)G(O&U1!9))AR1)#8%K2:N4I
M/RVOASVO&X*?VB(NI[IV_&3LCY%?(JU+=19QGT;F,>K(E6K6./F2"&ZC6_[#
MWC.M]U5X5W`,F2FX:GGQ_$XJ+/H$'B]=SSS!2R5*#RMKL)UXYKZ:TZ::=--.
MFFM!?Y!NW_3#.]^Z=[Z2UJM=)&YKW0%:-["P@2IP7L>J*CXXBG8J=QL>]&M7
MT#\O/_>EG_JQ\/C\R`?L)`^)`UX[^<__`+@H_P#7'XC^7XJ"P^U06'503`UQ
MFYQC&/?YOP+8GLWT,L$,*+;R;*=*E\M<V1TC-CV46LT$^VDO+X-63%!->Y[D
M(,1G*U/:>Q,%Q[)"BKU`2?*``,?&,RI9`HZ^5BH\"0-?+GNU&;,H@N<CT2%'
MG+,3F9PB&"6,YF!R17,F55C`NN/@,UA&K#W44NYV=,5T*[HCS=1'XYS%H6ZB
M5!LJ"MRMK5WW)E_47]J&+;S76U7G8,Y"`:6<>.]4Q&[ADYYYX!%&$XE7`0W.
MH4MZA:Q62E&12U:^G9<RPQ%:L-;%.S8':!Z7=U.7W2H\;*RUHQJG+A#2%I=+
M,JQ+'5+G-U6-79R0-<Z'5WT.FQ=/+B2(6%PN>'%->VL&SC</<;29<!V8N!52
MV%<W50+^X>>-/$ID_*DE<U&(Y%<]5:F'?BYMR%7OR+"0JE3D7`'FO*#Z918(
MV\JCX;#?6RP\_M6+8KU8>)2%-CJPPL4E?2<)R7UEL>0PGS,3M.Y,:M#31I)C
M6KY%C*LJTXKR;6OGMAW%N$UO!OX5O+G2[6GOX-K/T-G9N+9$DQ1/,55,:0-6
M^+LS%955`JA;05#1*KY2A4`*R%0BK"`,0!Y0IF=:W/1V>PN[64$6,O*'<%UL
M5V8NEBNUC.3:60%C+,ZQ!OK/<<[V\B$U57-HZF*6;<6U6EM8#";UVUC/B),A
M#;,T@!D@8NBBMJ6+9N]R$_Y4,'S]C\')[E@4/^$M6QW"JK<1/TJ#!V0[V.WJ
M'AM'F+Q`V^%V/O.76>X8[TUUEW=.;0?.S#DHY6@%:*T%(]7>?NUJGD;[>39X
MC-65M4/V&(T4"YIF<@U]+)@2`RHLRDEKG=*VPB0+.VA[F96TA8%M/I)T59`4
MB"/Y/"%C->!A9V2M-OHWXS(WHE@1!##FD$JIJ#,'K2U6@\RL!B3MR>Z=IP'R
M<8Y6)FI:@R50J00R'T[>05W&0RUFNVRBQ.2^FKR44"5SIM=R-G]"DBRY#V59
M&6HKX6<LMKIM3G]1>6M@ZPJ67_\`D'[U?V%&!T-LE8;9S*QQ8HRR6&$-A"7Y
M(P^VY%?%<>BT\B76I*W15$-PX<4#&8Y<2\,0I4D@1X3=S[YAW<[,W*H7@JU-
M?;;7;8[<D%GJ<[&K''EP%@JY(&L#JH8TP_!VVN(UO/2XRI[27%LI%GGF[FBL
M=RR/(=(!*H[<=5-5+FXH;88C@5DU2E"QX2H3S2$DJ]]P:62OA:*@5"OZ3"J1
M!#+R'E5UD&5@&"(CGK'?VGW7*2VX6XYR&5B]?XBML@`R#6X1O.];@,L/)4%6
MY3Z6K5IZR5%0\:P@RZ*%3R9+;:"$CVUK9?YMS-/6F4PH`8II:V)6.BI20FO\
MNSB$1S?'*NM1R&K86.X'$_S1"@$1),0#R]5OD!O.OQL>RN4N1J:JF/-1],\G
M8J9"@$\B./H),[EI$72#F*TS,`E:^;;%I\W165?5OMFXNYF0:FBL*^*&M'?Z
M#C_4S&U]57,,&(R<91B:C&)Y"8-B8K=FJRK/5"H+K;%+<?44%F!);@EJ"6,%
MBHD[GJ2=;!/<^1@4FAGL.+12RIS]!V5*V4!199CVMQ1>2H+&@;`2H4:M.??X
MK92;BGT5/%AW1KB1`KM)Q87,5FZIX`*J#;PK6RQV4M:_$<C5K(4X9CPGUE/<
M>M"I&F$(Q@WY=>/G82I=CN6H"`E+^;5,>14J++%-M+2"`W.RN8Y(`21KKLWM
M7='MQ<ZI5RC:56W$-2Y"*$5U=J:76C)4*P+(:J;HY<+68!3B2@H-!D^4Z+-W
M][!NE-)J+BMG4\V5+SNLS-RR#:T.MI)AW-=94]W7F$<**-KPO&\1VC,QS4W&
M1D8^7VJS)QZV2`RL&`#UNLJU;`?2RD$'?>05E2#KF\/#S>W>X:<',N2V61U9
M&)KNJ?B]=U;'ZDL4AEV!4@JX5P1KI'\I$L)/-E469[U:.3'6(PQKDC`5_P")
M].M$*.*USF>CPX[3$7L*"ZQ@HJJK)A'J]@_-/=@K7L;A(W!GZ=S.%UXNY)CQ
M;@WQ0""?<ORZ:ZSW76ULP&'&2YA>/=8`#U5A1)Z5FROX6L9"]=>O']?2NG33
M3IIITTTZ::=--.FFG337$?FK[`^H,GS[]/Y?&:QW^>\6@VL;Y\^-$^<]-MO^
MON'IOE<?*5!S.7EVB)#L:45MS6>71)('+;2!=3)1$C.N+*-)8U(%$#^/Z]:K
MV7\C'U]A)>7T7'V[M/K_`($R_*F+G;OEJ!\U2\?H-WF[#@/D#3\N<,T-#GJ6
MLC0[7B[<PLY8BL(L/\V*VS)23R29L8Q.J:KP4]=C]NL0Q_Y(_P"4VAR5?3Z:
MB#9[J_P'#L;_`""M^>[-E1F.0\;S?OY'T98RHP8Q(A*O9\*9ED"F"959#GL9
M($KWF1JM]5X+^K6;K?[G_D!LET]5Q7LJ;2<SW4W156]XAUGS]/K\G\6;F/\`
M9W#7#?$>0OM16U\.XV&=Y2XQVEVZ;*GRK"9*BUS]'5DC5PU"M=4XKX]/X[:S
MEK/MKZPN?B6SYQ1QOG_<N^V.5N*[FLY`Q43/:7#\18_9\B4%?E@7FCP^YXOH
M=-'GYR##C:G40AYF[`BM'+CR;*O.UJG%>4>$:LO3?4?WM&KM)R?GN1]L+(O^
M(_EKZ%'C-1\DTD&SP=WSCR9<\7<RWUKFZ65H==/D\#83.RM^S,#M["60S5BR
M#2(3A,?32%Z?/5MA^[OIE]O$H9WTB;/<%1=#S@/A3[)7Y'G[Z3]<:+%,X)?@
M.)&<992MJ8)B3KG>ZZL21F8U1-VB9A'TAHK@3'EKJO$?#?X?#6X?Q1]3_4G+
MGTQRWQW]'44CC;&4%G]"Q?GF/%P+HU=SWE^._IG=<>6^PN=>9A5Q6@XIH*JC
MJHN7>T$VXKK%-`Z1.#):.`U:R@"1KKGTU9ITTTZ::=--.FFG333IIITTTZ::
M=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--
M.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--:7_
M`'IR[R5PKP,#7\:6"98L[E/B3(;SE%<B_>MX3XIV&\IJ+D7F%V/:*0"X3$9R
M64WG*$:O@*_\V:(L.,<;FKE$G7+/8_<7U)3V>/#EN=)&M>W&\3W'SM7K\DWF
M4;_(?HM5]$[[`[^D."ZASI_'@\AQGGJ([9=$:G`]E[_E2M_8'!AC:OXKX_QZ
M:UKF?R._RC753>9K.4@JK8Y[`?2;1ZBQ^?+(M/H-WHN2LM9?+<Z)&-''"?7X
M?BNU+!N@A<C;*<Y3%\'C\4:KQ3QUDJF_D;^P=[>:JWY(W-G\??/VAY*F$RO,
M,[YNDZR]XYI:_@.IML7Q=<TNDI+6',F\J\J5]_.6PF0WR'@@!I83X\R=&*E-
M.*CIN=9IX!^Y/Y"]5SMP)C^;.(O\2PW-/-'$^2MCU/&%W#=QB6%_'Q`YUYFX
MZW,BS?*D4,;1\LZVLG9RV,]212UMO0R2.D!%Y5U:56-NO^G5H;?[(^W)%M_(
M7G,GRI81]9P/QE]$<P<5"QW`V>U^5SZ<,;N7`P'%VFJ]9FLOR3F-7R/E9<89
M(5K#T#=4D25=9FW%7C;&+350J[$ZO3:_67VIQ;SE+XSK.0['F/E#([[C+&X3
MYIG<`5F=-]-\-:3@ZNWF\^DY7(^>JPQ,=(S'(-I;5B+72XU#6?XLVNFQ#3[,
M1>JZI"D3T'Z;:P_.^_?NF-P[QCJ>!]D[ZZWFNM@KRW0C^5;WC0O!MH;Y@Y7Y
M,Y/Q%0V6>EK^3[WA?296)/@9`9H>GE3P!SUC:/E6H2BIJO%9WV'VZ_0WQ7H8
M.MXRX\U%9K)&\K]%B<O=PMM,IF9R9KHUG2PI@M)+SPZ^I;02KEADD$@_BQEB
M/(HE$Q6*U*ZC/75^]-4TZ::=--.FFG333IIITTUK;]6>7_2<WBB*[_(Z#Q1W
MCXJ[WE[(OFYC.RK_`+U1/]ZIUTWM/_WN)Z>D_P##7"_F)/\`TX8Z^O7_`!.N
M"?++9CL)@KN3(M&LBV>O;)24#4/:(3,KP*%33#:NOIKQ[!B.QS1R0#:Q&L4*
MDCJ%S_?>T<!GY%"A9*UQ!3_XYE;`5EE\#N"9WF&Y`?'GN,6GM&'EV&R%LNF1
M;L/2[>)8W*EG0B`R@"!QY)Q)K&>XJSV=A#+O`6%_KCTP[Z5BY4G14F?RM/-J
M`:.N@[QV34NQU6ZGTC63_P#'JD]8R!$DB_<)["&;&2'([MD9+Q@%:\,/Q%@"
M,[L&*$U>I]W74&E/6L#EV4^G60"VLK"]O86%2&[P'N[D:A8:";:ZZ49!:JY'
MHS==D-7%GX:EJA6C+ZUP9A6,IPESE85(T7#9*@GMN5JH1:SA[CM(_M;G&W]G
M%%#Y$SN]TMP]JF"($@DHGL)[55.R-<NJL_$VCDU]UE?#D>61=/U\%)-+U(O0
MD@*($?/70U?@:&X5XF-3=ZO!2N%C1/I>HX"Y-61:_4!6+F3R\(.I+2EDVM@:
M[`>Y..P/"OK*[/)?.M+&>^=3VQKDSZZ*2D'+@PX<>)'&&F(`$)H(<2.,+?$<
MF*%IK%#!`5!15`A0(90NYY022Q)L!+<G=B=S#G-9D7'+0VE7*V-83R=FY(Y<
M\1Z8*@*B@4%53A56BJ($AQ;Q[K]#6#D5!J>GAP#1#UX[V8*%6RCYZAJ*"DF+
M'IX5I7QJ2LO)=E*ER?QJ*"^7'7V5\M6]FR=U[CAX]I6X.[L"#Q$D!W9V$L5)
M9E"*J\K6"G:Q-0^WNR]SS<</C&JJI""HL(52:ZTKK:$5U%:V&UW?CCUEU\U-
MD0,N0*C<YBCWU\MCJ*C6Y;,UI_\`-LQ>5[Q:/'%M$CRV:.R>EPZUMXUS);8U
M0T-"M:>,^0@R!"<CC:>R[`RK\?'XU/B6VL/3=3Y+`LC@OEXJ5'"PPU=C!9#,
MH`Z2G&[O@8F9F<\BKN./CJ?7JL6+:2T-ZK>?FX<BRH<DMI4O#(KL6QU7W>SU
M-A:@?J>5;?/_`+<65J:-O(?(UZ/0#)^WTU?23:VPT-BLVKL),Q631!:`\P+"
M1^ZHX\8.RLHPL2M&%6(F1RBMO1I3AU8L&""&`'E)D*8;P5CI*<ONG<+K$.1W
M&W#],FVO\3DV"P>5%K96L;DC%H<*%9U#)XO6M6A<,Z>RN@-EZCC:@T26*G%B
M;?819U]"%$K%%^QUA*^6-8>>V%'*=^/#+,!(CE5C1>L;"(6%^]8M5!*59-F/
MQ@VK60AEIY-(W>MAYF"D$3,DB,FKVOGWY0%F1@4YO.10]RM8H58]->)'&NZL
M^5&=64P%XJ&Y6S69:[JEETMG7EII-",()SY`(;$%'@PJ(->4D2UKQUT27-=2
M",-L:CC/(CG.;)(OD\N5;ET6Q?4P=+"2()ZDL3NID@<B#RM8#8%1T&!C]OR\
M?EBY"&JRD`-(78*M84\74*I;TP0%H4F20YW+5>'RM-S$6QSE-96\.J69;3J2
MG98+$IZAT^E)H"R@19<:6F>]MLJS)P8KP13.*1?6U?-[X7[2F4ZY-ZHUO%0S
M1+-#<(D$<_+Y5+`L(&_0#)J]Q6]OJ?!Q;+4Q^3M6G*$3DGJ$@$-Z<OY[%0JA
M)8P-R;?L=AC=NU8.YH,EJF747-.J#ONL!E.1A$U,2P*]U)R)A04QF6,.SKB-
M''O:RZA3'O$J^D:D>/(KP\W!\^!9=24+\AQMLI\A'U4VEMBI$FIZV4`_48!P
MK^Y]K[M]UW>G&R!:M7`\\>G)!M#'R9..$/(.I`7(JO1R5^D%BNO>LX]%@-5G
M'0[:?;YR^?*L\KH/Q3P)DV'`L9U+;T5W4-F'-3;3+685AVL-%,P4EJ$"I8YX
MY7=%B=Q;N&)8'14R:X6Q)!`)4,K*T`-6Z^:MMB5V:&5@.,[EV5>S=PH-=CVX
M-TO59!5BJLR/6Z22E]3#A<GF"MYE+(Z,>@_$I+->:\Z*6Z7^WBU@OVMIW:M8
MK7$Y0X$+,2$EK`!DT[JYBO\`VB1((OZ?F((GK:OG?=Q5_0["D>H:?-'IS_D9
M43Q)L^,>H`/\$B=>T>VVO_ZJH6SEZ`R1PGUHWR^W%N/-13\)]%F/_P`="M`U
MVNZ\1U]5:=--.FFG336@W\@H&RN,,_%<-2_E74Z,T3?'N1\BL>$;.SY,)CD<
M]Z(K5D1O)/T]P>_L;Z!^7C%>Z6,#$(#^QOL/\&_W3T/COYSH+/;]-9$\K6$?
M&4('BO\`XE_WE^H<O&,;`Y>Q-G%5C?\``>,.4>1*B$L=BN2ZP%C]'V64E_A.
MM+YJMIM&L.2@G3IC$>%%]YU:CW^ID^IV>^M__EC*HI8S_+:,-;!/%/J3DL\5
MV/TK,#Y_`%/N7$OK_P#E/M^7DHL?^9CMW-J3QYV?1;P:/4<2H\[Q)Q=HHS)Z
MK3&(S\*FCV=`DN2%D^#1UX"4*,N)TW6VD#,19%'H,O&NI_XX)SR0+(Y2&>H9
M'AM<9BGWP_S'*O`V+$\_*!6I<AD=JDDK#HH"CDL\]FUB[_A6(]*I7KY$<EK4
M&OSLUS+4#794E]G%;":[79F/!XR+@^/@[VNN;(]K,R>3@7.E+8&ADH[7\&TV
ML7T:C,2V9^EK(+'9G8U"M*5TTZ**;'<QA$.-.M;G]Q;M]B5*BVY;(@$\EE:C
M*..;,?/6VPXC=6DCB=;SL_95[Q1;>]C8W;DMM+%?3?B]XBVIO315^ZN2"QL;
MRNA`;FHU=M'N>$ZU\B'/PW(5]FC3()V$6[A!LC5\JN_.J3U]>.J:>J.Z_H9:
M>LJM]<EY4)V\6]L._![Y:`]=^/7DA2/I)4$&&D\H8<'7<=0!'4ZV6)W;VI0S
M578F;=@EE,^HH8J5Y(57A*'U*WV,0Q;ET&H/)IF75D.RII<R7QM%?$CYYIR1
M@QF#-XEE_EA=9RO3+&A%&1$D^E`A"TGL9XLZN[6#34:[P!W,R7B2=ND>4;>(
M\LR3$'?4??F&5>+\5F;L:D"N2`(.YD<S##H?-$*H;D(&LM\.Y_8@SFQPN]RD
MV7C[_)3I6<@7!)P(,W7T5:W<4SJ^76][.J-I#QI<B0C^Q98@N:YKR,8U=1WG
M(PVR:<_`M49E=P#E8)%;-Z32&\K!`5`C92=H!)UTOMG#[FF%E=H[QCNW;+L9
MC4KE@K75KZZ<67SH;2'9IW<*006`&I2OT5UK<#2U6(S+JZ9O;&^U>SAU)1Q!
MEI:ZPGT%(LI\V2:+3UMDL6QJI2A,V.62*,52,<JM)=9C4X?<'NSK>5>.J5UE
MA/F(#M$`%F$I8LB0I80>HCIS<KN79ZL?M-'"W,>RZ]4(`**S5I/(D(K1;2_%
MN)85L6!V:RJO#VU=:I8R#GII^?D$LITX;&Q#@C)7U+#&=*>QJ2$7\`)9"HTP
M#(17N8YWD7K.MSZ;*O34!Z[!`'4$RT"/#J0.A$1/\NM5C]IR:,CUG)JNI;DS
M="!Q23/C]*EMF5I)()EM77LN8^,M`<D8/%XXT.5;"FK;!WES5P4G$;*L)]O(
MJ::&&#&C!@59Y+QKY@:(B*UXW(Y'8F%V;NF.H9LHEPD<34K&-@%#,9)E@L[&
M1T.VMAW3W/V#-<HO;PM;6AN8R'5>6[,Y1%"@!49B-U@[$$&<,WV1RU_C)&ZX
MUL-#`DQXW[=N\_*F/?:91;^VK[^R9G9M1<Y9SOQX,I\=`*\DD[A>2>96G"NZ
MQ\S+Q\T8'<UK929J<#RV<%*#F&6SJ0#,`"8V!4ZY?,[;V_,[6W=^Q/>EBKQR
M*RWGI]1UL;TV1ZNBDKQ)+,1.[!UUCVQ=;2G+^\V-A%29+G6+X-S:Z:J\I<Z<
M$LV'&%RI`OLM/9"B5,*K"C;",-DE;,K'M#"*3K8U>BH^Y53``E51M@"`3Z!2
MP269SY&)7T@06<#6EO\`Q-G_`#3NO)F;B[VINS`LH&6ME3<0E=2Q8H#>NP(6
MICJZK&5"<3@&3.EC9<0-UR5C`,,(X2I3)-XOV<."T!G$DQ!@U_(EJT`7$+Z6
MR$8KW-3R7%K1X[@J#[EJ*;#T^J+ZR9&QFNFN3`F)@';6QNLJY=FLN8#*3,RJ
M!((/#EB7JL&2(NR;N*DGB&@D@3K>WX_:1G,A>\0@`G_'/&=)!-CJ^-^1]#HP
M\8\_2:)UHU[G>+3"%4"<Q'(D$2L5YN!]XD'LPW!82#!!WC$V(")Q^PFP_P"V
M9@>N_EF&'N@RI"M!$AAM/<MP6MLY_#D!2")^Z6"6ZV=>1:^D=.FFG333IIIT
MTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ
M::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=
M--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.
MFFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::UJ^L'>'
M$<E_GZO#0T3O8JM:@^QBKY]WHK$\?]?U_3KI_:0GO`$3]V_\-<)^8QCVTQF(
MNKW_`%G7&R)GJS5/^?\`/3*\7[;<<LBC6D(:1X48]*QOS5+M@&JXFDU$-6S8
MD8[7*V>7WN)V>T/=P!>SODVXB]PR48^HF'*G<D-_QH4ABB'8D?R"(V+?4?E^
MK"Q^XGLV#:@]"WN(#KLH*?\`SK+@H+;5\RANEAY$[A=T7&UK:6.C$MQ=,-IS
M7A&[&^AMITMV2K+=AO).A;(;=VE-DJ:9K(.PDBBCDNES%E5`@?T-/$&NRJJK
MQCZ-$5+6/30\N,+45"1Q5K&%9K!8CBO&PMOQ<ZT63D7YR_B<H'(>T^M8O#G+
M9`L-D\W2E&N6Y@@;F_.E4V#UC5V<292;M+0<>JMPQJG*)DKG4VM3'RD\E@;-
M@%20Y=;(RN-CQE_Z@8>;&L_.38D8,()`_P#_`!WHN)W?+KPJIN0FV[U%16-@
M@.>1!%EA/W5H*0J`DE3_`##6R]M]NN[ID!,>T+C8_HO:Z"EN1J`K!4TT`?\`
M$4,MLO:0%5U_D,YAJ[CB?)6T5I<WK]+7Q:J%03)]I=?LK+"#4W<VAO+"'`F4
M[Y0@N;<5\E7JC>P?!6$<SNJZ:VGN^722+::K"Y<!5Y064.JDAH_E=?MF0#KI
MJ,GVYV[)7E1DWT+6M;,[\.2H[5V,JLD@>>MIV\L$$C5+Y0FU6L@UJ8=-#796
M)7LD)16;3>^HFR"-$X$M*XY`D97AB(&'(&&-)=Y'>Q8SR$)U-VM+L1W_`!WI
MMEEHY+$,!XCD)W)E@2P^D'D`!K']P6X_<JJ_Z3ZR=N5)]-YE&)B&XDCR@<48
M*K?61P))U?W`-+JHU_&K[RHDMXUW,:THM7`*<):%]7J7VT"JL21HT\D@4I)(
MJ^+'F-3R`WNC3HQRO+K_`'!=B/0;*'']3H*M68\_).)99(B(+L5\?%9V&X]G
M8O<*\Q:<NMAV++5Z[E)!KX6EU1B`Q(,BM%<?3X-!):4KY6IB9#7CH,128ZXO
M]P;!5<NH4T*47+92%%#8R"2F.C5"1:^<.MDEGJUII$,DICVN`U5;?8N*^92<
MB][J:Z!:P;<>I820(W:2.:A.@8*00W6.FSN-?;<D8>)5BY5V6<="DJ352H#$
MG9(5A4QLCDR&P$%!M9-?B;>/;306]7$K'Q'?N<><0HS,B1XDJY<V4"?7SEB$
MA"98DC@<%#12*,*$8K&#ZSK,ZEJE:EBP;RD=))"[$$3/E#&8828,DZU-/:<E
M,AUR:UK*^<-(/$`ON&5H*CD57CR4PO(0!JY]GS%F5`&/(XSIM%=GHPU-E8%T
MFGH1WMM!/%S,7PK,P>N@_N4BPD,1"A<LA[8CGN[*U59B879LKD67*>N@.64<
M$;BI!<^9P3``Z';S`#KOL.Z>Y\`H$LP*K\LU!&8VVUBQU(J'EJ*KR+$;J>1"
M$GIMC67G\AR+07U[QS-DY3>UT>_NYU6[6PY-5)JU!)H8,BAFQ]/131"+`A@.
MGY4KR>T[&)ZT,R2S9ID9G;<BNCN2BWM[%%#>F0P:0Y#@HXF21Y5\"=X*G168
M7;.]X=V7V1VQ^\(MEC)ZP*%(-:FMA;6P!55;SOOR`\O(6#$Q(ED>&QR&TT&M
M(^)'AV=M(Y2@*&)'J!YBA8ZPA7_(N4E3:ZF/-L9(RA4<F?-KXKFN.\BLVX>I
M7B*FMW)5109);F^Q2FP!F"HI!E46QAY0)YPUWO4#.0E!(`9SEK`""JL<ELR:
M2RH7L8%8:RRFL@N6CQJ9@)G'RQGR0(VGY<P5K2N::ND188];Q]R#3WE9$M()
MUJ#B_`XRHBD/%:V)*9'8=!A0BA;7$1D[AR`,OAVJVQ!/IW5,K%2.0WOM`#>9
M22LM$FG<;4M[+P9A%7<L=TW4A1=C9*.H=3P(XXM!+)",%#\5Y%1NGQ@,*<\Y
MX0836D;<Y\Q9:0JX9I12;KY].="2(NHM9TIT)SGHJFJZI@T5?6^4U7/'Q/=2
MW]`L);;@XB3`'I98&Q10)VZ/9/B$.Q]3]OJH]WTJJ[^K62>*@D_B.W$R1:['
MCO\`552!OQ-@)*]I^O$M?5&G333IIITTUH5]_O:+C?+$>Z.QH](0CG2UB)$1
MK(B.7\IT^#9U[8ZHG]:R(T@#6]U((C/)B]_^7HGN=H$R:O"9Z^$%3/PA@?@0
M=]>/?G*0O8L=CQ`%YZQ'T^/)76/CR5ECZE82#R^N8<6NCOT[94.+9VW&.^P5
M$$B5CQ4>)T.[Y.C:3E&Q_P`?!5P;*MO<Q:R(N/K*^'$_=)(Y%D@HU;&'[O4J
M':UOPI#&I,JJUCYO-:E5!2@<RQ#*ZALAW9N`*U2UK&/`,JJNA/Z@&5<BSM^1
MCUCR1719D90MRV],(K+94[)A55HGJL'OXUT5KRMN91P9,^QO)!H,<B2"RY33
MQX,F7GS/':DKJQLFWK+@$4DEI7NC$`C13D.J`>J%E-)E)D6+6M"AB(`$$@/]
M,F%928CS`[K'F&R$:^W$J>Y\MRBF23(4FL^?BDNC@3)*E8%G+R'S6`Y;CY34
M'X>Y)A5E;6V^>AVM>2SMF3"7L\M8[]O!)@GG%FI#D5(DA!@I&="<%J#1GDBH
MSMIVR\5>\XUEK,F2R'BL<1RW(($2&W+3RG>?CKI4[=W!_;.?50E=F$MBEGY&
MQBOE!4L6XE!Q%?'AQ$`3TUB_(89U_HJC/:)LVLC2I!T(^O=7UYI)#$=:1'$G
M@S%>%A["]CB<^6\BG?*17M_IDG8[:YF?^'QGR,:'8`=9($>4[%R8"DPL0%V_
ME4ZY_MG:#F9M>%F\ZZV8_3Q4F?.OF%2B6L`)<GD7W&UC@Y0QG,F%Q.NTV9F\
M51'Y&JD%S^D<V]LFO@S66)8X9=89W[A#).CO&03E9_4[U`[^3O<T>JS>RY^;
MAU9299_&..:>0;CC)##8P=C^MNGE)Z#M?N?M':NY9&!;VY?Z;6QKM^\;RMR(
M!4^92PW&W6$F3R`OJ0+;\7\MY_F?)WZ7O'?(=Q+NA21_F*$\!&0QV&7V+G2)
M4:MMJBL1!16.8X3V1V.8Q[OZFX"G![KVBSLN77Z?<<9`L;;'>'KV!*LV[&9!
M)!(UMW7NWM_W)3[H[;=ZW9,VTN".4%?*&JOW(5T39!!!"@@$[C(&^XNU.RW%
M?QQG"QZ;"<:*!EG;V<88H=56US5L)>GL;9\@UC/-/)/*-J(4C),>/':X8CJY
M[M?V_NN+A8+=RR07S\J>*J=V9M@BK$"(!Z""6W*P!NN\^W^X=T[LG8\(BKM&
M!'-W``15\S6L\EF+%B.I#*J`A7DG%W,7/.>E/'D\K@J34T=6*'0OTNBC:!9&
MKD9NLAT"V)'-M:R%Z304'Z_Z)2M>K7,14\WMVO9NP9*@Y>7D/5>Y+<$*16'8
MO'TL>LS]/S\`>>]S>\,*PCMW;L.K(Q*PM?JV"R;C4BU\CYT6"L1L\&"-I(L'
ME'-YXSLO?8W/R<O8VF9I[:?!&R\L/V1HXU9';6PYDFVK$2(V)61O:J>YY`M(
MCT0!3"7/[5DY`%M&;8+:DM90?*.6[&2`K;RQCH`8CS!3K3^X,'"<X^9VREL>
M^RA'91ZC<-D'!277:$6?J)4-/E9UU,<6U$A./>59[Y'LE2X]-GH^<F'DV-^0
M1#/E6=G!JI=EL)MC'6)/<4AQ,\227'<Q%D_H^G=KE_J.)6!Y`6<N``G2%!8+
M6%,B`"=EXSY>DGM[&?\`HO<;BTV,J5BHDM9$R[JA:YF$,26`@L7(\_7'<232
M4#CU-:%CI$4Y(+4":/#=[8L8(I$<-=5S8-80-:""!TIRA;%BMCO0SF,:P0MB
MZWY`%MA\I$[R>IV)+`M+$GCOR:1Q!)).CKLQ,,G'H`+J2NQ"[@`$!494(4*I
M?8(@4\B``JSU4&BV=_1TMW(AU,RHUT'?8S1'(ZJKXUQ8R<MG[*GOH[@1U'@]
MFN(@AA6!&#6EMX[9)VNKY,E(=EIOPL>RZ@%T>DU6(/,2JAW#(9/WM?JL60$^
MI6>*D6*O.;'7#[IFU8N64JMKR5R*+3Y%#L:JV2P0/^'O]"M4L('H7*+'!I=Q
M7NC\1R7OY3N(IZQM)8QF5Z7=(0F6_=Z:Z+*YRD3*S50\M"AOJ]-#0[6206SI
M5NWLBDD$"H4;Q/OA0.THRMZE9)XM]YQ98Q0&0V$\D,2IKXU_!0>6O4ORH<GW
M#96]?HWKQ]2O[KFCDYY9;EJ4<+5F&6XO=_B=EX1UQZ\@U])Z=--.FFG333II
MITTTZ::=--4?07]5EZ:QT%Y*_"JJN.Z3,.@3R"(Q'-8,4>+%&:7,ER3/:,(`
ML>8Q7M8QKGN1%FQ\>[*O7'H'*US`&P_:3```W))``DDQK%S<S'[?BOFY;<<>
MM98P2?L``)8DP%4`EB0`"2!K6"P^LZ>6,CL-A-1K&!D-BGL#,="IHSW]T\YE
MC31-.M8T:IV>V<.(]'?T=O/LU>IK]HW(1^/OJI)$@=6/V!BG+_T2P\>FN`O_
M`#'QK`3VC#R,D!H+'RH/]YD%O"/$6!#X1.VL-[K[%W>2J\O?6U/A,C0[;/2M
M;E9UC,?IG7^:@RLV&7;4S\Y?F-(CA%J8;_[L,3R!,I&L[">U=U@>S,#,MMQZ
M7ONR*+!78`.'!R'A6YH(,HPV8P1!.XUS'=_S.[OVW'Q\S)JP\;#RZ#=2S-ZO
MJ5*:@73TK"2`+4.Z`D,6`\I&JGI^3/HZEIMIJ[':\3U^8Q6%G\F2)N9M!Z"3
M9Y*"VU?9%AU;<+;RE)5/IB"&]Q1LE/?XM_K$7PBQ>U^V[[Z,2JC+;*OR!2`Z
M\`MAXP"WJJ/-R!(@E1OT(G(S^_>^,7%RNXWY7;DP,7#;*+5.+"U*\^15/P[G
MR<"`20')@;JT2NLY6^B>.<EHM_>;#CVVSF7P53R7<>9`,,')V9IJA.*N!BJ>
MT).*RM(U!O48U5W9CW$1R,NQ.T^W.Y9E?;Z*<A,FW(:E>O\`F+$@DVLL#D-]
MS\0!UB[C[C][=C[;=WG+R<*S!Q\-,I]Q(I<M!"BA'Y'B1!@;P"2"!<MA]'\P
MY&QK:[49'#3BV<;/2JH<:V'0/T`]+*#7U(:-\K27$^ULYLYZ,_$C5QI0?>%2
M"8TC'/QJ_;79LRIK<6Z]0I<-*\^'`2Q:$4*H&_)G"F&@F#&??[Y]S=MOKH[A
MC8CM8M90!Q7ZGJD*@KFUV=V;;@M1<<DY*`03>M7]?XL%F&AWV;T^"O#2RP&Q
M9D,\]A9P!L(>'"ADBU>JLI0VO1?6"J(16?U=NW6#;[.SFJ.1V^VK(H`F00-C
MT),M6!\S8!K:X_YF=J2\8?>:,C#RRQ6&4M+`25582UB/@M1,;QK:ROL(5M`A
M6E;*!.KK&)'G0)L8C2QY<.6)AXTD!6JK2!.$C7-5/T5%ZY.RMZ;&JM!6Q200
M>H(V(/V'7HE-U632F10P>AU#*PW!4B00?@1N-3G5FI=.FFG333IIITTTZ::=
M--.FFM!?NC^3;XR_CJR#--].<N5F=N["*Z5E^+\XQNHY:V;&D]:OSF&@';/_
M`&]KT5'V$UT*K$YOB22QRHBM7*C-TUE'Y*^VOEW[EXXC\I?+_+^6Y0SGA&;=
M0:V2^%K<=/DB]B4VWQMDR)I<G;,5'(@YL833(U7A<0?9ZM492I@ZVIZ:IITT
MTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ:
M:=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIK7GE?Z0QW
M%F@J\82JT6LVMX@F5.;S4(<N3)E'#(D@@_U&22>:^'%>=P(@)9PQ_$I!L&]C
MG=%VGVUF]UQWS0]=.#7]3N8``@$_`"2!+%03(!)!&N*]Q>^>V>WLVOM;5WY/
M=;HX55*"22"0O62W$%BJ*[*L,P"D$Z[5OUAR]R!JJ'&8CCC.Y"\U4.]G9R+R
M#+M`DMX^5-%'H_Q'2$SLUIJQDICWC_;R/<-5<QKFL>Y.DL]I=G[?B69N=DV7
M45,H<U!?*;`>$QS'F@B>8$[$B0-<11^8WN7O/<:>U]IP:,;+R%L:H9)<%Q20
M+8GTVE)!(],F-P"`3K%^OYT^HX%5P[=1=)1S*OF$FGG+,RM3!+78/,8ZF6_T
ME]HY<W(S1^=3#B%:V,V8ULLG<33,5OMZVF'V'VK9;F4/58+<(((L8@VO8W!$
M0"P?42-^/E&\&8UH.Y^[OS!IQ^V95=]38_<S:W*E%*X]5">I;9:6I;Z`"`O/
MSF5#".6K[E/^F@<L[K`V7)5I'J*GBT'*N<V\#-RSYW106R_P+?.Q@192FI]'
M66(D5H$2<I81VD1B/5J=8"#VPW:*.X58R&Y\HT/47`=#$JY)'F1AX^6&!$QK
M;V-[\3W'E]GOS[%QJ^WC+JO6IC58O+B]8`,I:K#Z?O)1@P$D:B1-O]!`Y/Q_
M%53R.RSEZ7AZ1RQ'U-E1CCY,=7`LZN/*ASK:7B]`AY)6W@488,AJ(P:^P8G/
M&CZ/@^WF[7=W:[&XI5F#'-8:;.15B"%%B0/*9!'CL2`8NJ[M[S7O^-[>Q\X6
M67]L.8+6KBD(KH"K.U%DD^HL,K#8>8*2LS.$^F^=+ZVL,Q7X[-;ZSH,T+67T
MBH(&(E93R7M;!%8S#7-.V5960?(T9*BNL@'&Q>ST<GAU;G^U^PX]*Y5EUN/5
M9;Z:AI/)AU@!6A5,!O4="">D;ZD[1[]]W9F2^!1BT9E]-`NL*0O!#](9BZ2S
MB67T:K58`[@[:S]Q1]-YGDB_BY"?52<KJ9T'\^!`ER'O%-&K)I0B:"R@T>@A
M2)T:JFFB_DUX@R1P9/J*1\<K6\]W;VOE=MQSF5N+<56@D#ITG=2R$`LH:')4
MLL@!@3V7MWW[@=]S%[;=6V/W!TY*I.S#S$"&6NQ2P1V3E6%<5V<6)1@-F>N8
MUWFG333IIITTTZ::=--.FFG336N'U4P9.(YHR-[H6]HQM5/)7C<22YC2"1KD
M\B-[_IW1R?[TZZ7VF2.\*1X5O_#7#?F(%/MIU8=;JQ^_P^>N,^:9&KX?'^UK
M!@F66.T5XG'U*P]0*IUNQL<CQ(85T6=EJ>BJ!X/"3X+F7IQ0&R)EH:/4QE-8
M$D21^TY):Q\C!ME:KJU]9H;E76+,@<8L9F]6T&:@7A4#7-QK"J?EW`"4U87=
M:`K7XM]GX:N4"77-3AD.6J2M/P^.RD7L*PSVLF,G*YGL6CY?*T<\=3!F3RE6
MIS%$.KGVM77RXTJ.(-?`JKUK)0+-M-7SW0F_DR!A:H9`4&=PI(8Y%FRLN^MG
ML10.=K<@K$$$R678KR(GR@G<&5!5F&L;M_;\2Y:Z;7)]/'K",Z*00`JI9N&X
M*W$<F"CBRPY6Q$)S'@\?>2H7(M9%8Z<+_$[&5))-L620QE@`F3R@JI8;%E:D
MHCK`LIT($`CG/>0RC55)WTN?F4*^-:_E/K*!`@F2!+`CE&P7D6&T">FNG[/V
MS+LJSJ*QS7\,Q/)@0.(9B$(;C)Y%BBUF268@^:=?,76PCW,.GL!3JT%E)K(4
ML<:/65TNKIY<18)YR^K'Q!5[1TCG5K0I(`1\-Z"1>P8Y`=%FVN*3?659D#$2
M6(9@9`_S"3YO/,$!M_YF#<7VNBI\I,:X.B6,BF`BE$(XEMJ0%^[FKCR4E#Q_
ME0IG`V]IN,MFE57X^EG`J!_C:0]C87KI5R":T5@<;8XK(\0PGB>@CE>)R'*4
MJH)'.'Y:(=ON[IA>K9<ZLYE``L*1L-^(/S`G8`;Q.NL;O&-V'NGX>G&J=*A%
MI9K)<-#$0&*D1LQ(\Q+$+)6;FV-?=ON,SSYQ7-FI0UDJCAV556V0"[#CVY]<
M88:JY\%&6=G[4<1J-D/1`$&Y1D:CE7K%PK*!3;[?[JJ_B&#$,P/IVKO++\'6
M>@W!W&L_N=.6<G']X^WG;\'6U:LBL#=C/L`C^+5N!LQ\I'E823K)_(F/T_)=
MUGLEQ]2FJZS51A<DWQ5=,=GY6AU\0%SI+"TLG^D$6'2,`",!5:-\5QI`F-\"
M#<[5]NS,7M=%F9W%P]M)]%.G,)62J!5ZDM)8]0T*29!`Z'O?;,_OV53VWLM1
MKQ\A1DV'?TS9<H>UG;8!:X55V!274""";3V')]3FZ2%QIC:#,;F/DH;ZV[TU
MA#L7DN)'[A83)$9E6LF''_9@S)1'`"5A'.AA(]6*_P`$ZS,/M=V3>W<\VRVA
MKFY*@*^40`#R@GD0!)$>8@3$ZUG<^_XV#BIV+M=./EIC+Q>UE8ESR9B.$@<`
MQ)52"2BL2)C6/]S39FXP^*TT&A?C[RTC2(!X]"Z];6V`@2I`+*P:2--A,CRS
M?N<GQ44AIU$<KPHP@A$'L,&_)ISK\9[/6H0@@OPY"0"HW!D>4=1$@`R"0=-W
M;%P,KM.+GTTG%R[%*D5^IQ8`D.TAE@GFW1N4,Q4!E5EEN"I)[2\UKAW%8"\J
M\OH8.3@WF@T\:5H-">S;6H\#B7DB$Z2XX'M(-8B!];8Z*C(R,8*[ORK512"C
M&A[4-A5$(1`L[^4&((@\IGEU:28_:#M?EY)%M8RZ\>Q:5LLM!LL+<=IL*S(,
MCAQCAL$@+C."VIH"$B0ZLDJXK30:JS2361J.V!>VTV:T->4=75TMK(O3%ER$
M6,CF3G@E.<4@4<5#;.SUL@<W8"E@66&+*54#?S,RA1`\WT@K`#0..AI_#8;&
MJJLMDH51I45N+'9H4\41S82S>6185<EBH+<J,MA"T`+.'IV%E4MT.OL_WJM#
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MVVZ\/U]6Z=--.FFG336D?VYG`[',<=Y&1.F58=/MAT9;.`5X)L`5C';%++A2
M!N80,X`R*X+FN:]"(BM5%3OUW'L?);#RLG,50S54<N)W!XF8(^!\?EKRC\U\
M%.Y]OPNVN[5KD98K+*890P@E3X,)E8WGIKC=H.1C;*RFZQ7.H0V;IVQ%,'%C
M2(64J8#YV?S]A/@3028'_2"JS'AD;>;.#/\`PI%>Q(\$QD>0WM&/VT8=2X@^
M\*17$D&QC#N`1!_$,\Y%:J4Y!SRL40%^8,WOC=TO?N)^Y6SE<&"@K2B\JZV9
M6!7\$E48=SV+9P:L<*6:6:>XNSX])KJ7)F;`@1WP)%S8P3/L57_$O<V7/#!>
MXDVQU?%&N(!1U=H]8,F+*6.V/"<WL\D?=<@XN&^6.3-R"@[?YD0)Z"N^N9>L
M<E9>19P=A+[?PESNY5=N?@B%"[*>7^3,L%W9KL2Z(JM/INC\`E1&[53;;FYG
M79*=Y35V>J'SH-#G:]\P$25'JA+#6W\*QLB7H'3'24&R\CBG+&`KA3VD\%[P
MX6!2E'K"&R'@NY@D%M^/F@)$2:B5Y'>LB=9'=>[Y5V6<4DIA5EEKJ7D%(0<>
M?EDV<I@7J'XK*W`QK+W&=L'$XR1REH&!T0):Q39?._\`L\["R@S)-1`EW5Q$
M/._*@DEQ_9X1B&8JL<I615<).M/W.EL[-':L>:RLAWW&Q`8A5($&#$D`[[%X
M.NE[#DKVKM;>X,T"]6@U5>4R0Q12[@M*EA,*6&QY"LE=5)F^X)Y.V3[#?\8#
MJB:E?QSS^.;=:1P9\:1+-%L9U#-B28TRXLY`WC*XLHB#]3?-6^3W=1GM_?NU
MX7I]ORBXJW`N7E((`(#@@A5$$0HF3$[:G'>?:/?NZ&[O.`*SD;%L9^$,"2&:
MME(9V(()+F($Q).I+?\`*%1BM[4?/7S7R6"9^^1[?_J1QWROQQ<-BW+968_>
M(DZCY"JZQLZNTM=3(4<0D1H([9J,?^2OBK5D[?VN[.[>_N+W-BE?3*^C=1<L
MK#\2&I9H*%H+!I/&1QU%WGO^+VKO-7LOV)GAO55_Q.-EXSP\U<U:O)1>2VJD
MA"G%19!]3:-8OX[YNT?'D+B1=WRGS+I_G[36FM=8T5'QT3>;_D?75]G'A6<7
M?:G03IOX-<PT^(6NAUI7RVP0#<V,,I6G?M.Y=CQNXOF?@,3"J]PU)7#-=Z55
M-94E356@$F`P=G''D3+$#B-!V3W9G=EJ[:>[]Q[I?[,OLNY5UXWXC(R;E8*X
MR+K&;BH+(:DJ)<5J"*U9@YV1Y4Y&XQXYEGK^-^+'R)U?8R5D6^ND6%I)\XR`
M2OA3*9C6CK8`FR'#<V5_ZN)KFO\`!RJJ<SVGMO=.Y(+.Y9<5LHA:P%&\R0W\
MQ,2./4P1(UW/N'OG8.R6&GL7;RUR6&7N+,9$<59!LJB8(?Z5!!@G:TYW(4CZ
M/J+2#H:)^4TM(L%U-I\C$=6YNSKSQ;#_`).^KVS4A2:V!)>]"F:4;6^UW])/
M^#K,K[<OMNY+,>SU<5YY)8>3J01NIB02.@@]/#KK6V]Z?WSC659M)Q\^KCPM
MI'&IE(;:Q>7$JIF2".IV/36G53J[.GLJRQK[*57V-2TU@^?&.ZJ2N<\CO8^'
M/F,E'A54E82QS33!.I0%8@6C9Y*_LK<2JZIJ[%#5O`@CE/V@0"PF0H(@@R2>
MGF6-W'(QKZ[Z79+ZY;D#PX[^#&2J'CQ9V#2I'$*)G.',D:!^)GMA6!?66&TR
MHW:^+`CR:>'-CU%=6GD29<F`2+,RO&A+&>LNYLO?:"3S$PT<ZR"%;H^RM9SL
MP[2&KHM^[)(8@L6``!D670.-:0AV)5EX@:ZSW/73Z5/<\<&N[*QQZP4%%8(J
MDDE2&IQ2S<[[>5HW4,C\V88+C37CDPUG@A%67"9>$_(9%C5MCGY%0.D@7E76
M5\7]D!P=EZNR>'][K0U<R0=C6RX9Q^QC-\R`JPK+"#QVDD.&+%68GD<IV`/I
M.74`^1U,$\BEI5U]8(2R^IN`%:LH*UL1%'IC`J1BOKU+4[,`+*G60.HOR)&]
M_)>?TDZQ//N;W+4]=9B+)))F!L<`O-?')[BT(-$8=^IAY<$DIBJKI%@V03_B
M7R=Y9[P;CVRS&10M-=K%=H'&W\-<%7X<"Y``Z)Q'37T#^6J<^_4YUMA?*NQT
M5P22P;'_`!V,7:.IM6I6+'ZK`[==SU7Z\FU]$:=--.FFG336*.6>6L]Q1GY%
MG:2J_P#<G0+"?!A6$]E;!#!K&#?9Z"_LG#.E+E*-IQNFS5&1R*\8`#/+/'CF
MVW:.T9/=L@55!O2Y`$@<B2WTHB[<K&@\5D="S%45F'.>Y/<F%[<PFOR&3U^#
M,JLW%0J1SLL:#PIKD&QX/4(BO8Z(W*DO\G%N8\AM36:^YA>PCHEO`XMS,&).
M$*083C1*ZZY<!;QHQ6-\V,E-9*&QJ(5C'*Y$]8'Y7TJH]9J4?Q4WN2-AU*XY
M4GPE94GH2-?/#?GWDL[#&KR;:I\KKB5*&`)$A7S`X!Z@.`X$<@"3J?\`_JF5
MZP(V2,AOH\IJ@')1W&V1<\*/<=KCE$O+S',/V#W4*M;V=^GEV_J6/_X,<<DE
M;L<IO'WUF_3;_E^F_7]WAJ;_`.'G,"@/C9BV;`_\+3M,[D?C-CM],?*?'56_
M^J?A$%C29'=O,)D99!%X_P`:-.Q"J'R5J\W)XF,YB]AHB+W5$_3J'_X+6+;7
M8_$S'WMGPG_ZVZ#XZR/_`(?D5!RQLPL(G_AZ/$Q_]?=3\-6KO_Y'JO59;39Z
M1C-T50QXTI%7!Y`80VM;-!:TSR'3F6;XB%:0`O>]@CJQK551N[=ER^W_`);6
MXF55DK?0))'^;9NK`JVWX8?RDCJ)^.M?WG\\L?N';\C"?%S"0`?^7I`#JP=-
M_P`:VP=020&@>!Z:P'Q%]-6'!>9G8GB*1L=)43-CKK^'GIV?L=/`J\OI7A/4
MXJ%2:&RH:NH=FHP&#]M8:T&8RR"_W`D:QO0=X]L5]^RESN\"FNX4UH7#A"UB
M;-:60.S<R28<(0.(V(G7'>VO?M_M+`?M7MILF_&;*NL%;5M:J56P4H6NQJT3
MT@`)J:T,W-MU8`258;Z3ML9C<?4\>Z9F0PL\L')2]?;US#9<-P9;$E;&L:G,
MXBT!45TJ,#QA%ER(R"BA&KB,$UJ26K[:IS;LVW(J.9>LV"M3#E1'(JSVJ68$
M^8*&EF,`DG45#>^LGM>+VS&PL@=LQ'*TFYUFH.>7$,E5#A%(6$+LL(JRP4#5
MWNQ/V1[KN?&OZ&C9I)DR%H9(-I?D!9@CMDG2-.$?=2U="GFG2Y+1JQK#FE$(
M[NXSUZPAG>S.*5M798:E!0&M)4F!((J&X`59F0%`'0:V1[5^9_*VY+J:A>S+
M81?80P$F&G(/E8L[1`#%V)W8G4>=2?9$ZI/"G6M#J@.A/CSA2-CLQNMJZ!+(
MM963PIR-!%-BQG2'.=!+'>!.SW>M[5<KJ5W^S*[196EE3<I$5U^4D>9A]R8)
MCZP0>FXU?;B?F?=CFJZRG(3A#`W7^=58\58?B5#`2?NRI7J>)!,R=_O/K*EM
M6Z+9\2QMD;-Z#/:&/<S853J?1:YTCY><FQK,E-=WJCB=_./VGC&5S6O5WZL7
MJ_'P/:-]7X;"S#0MM;H5!9)5]G!7DJ;]#Y"1T^.H\SO'YC8N1^.[IVU<IJ+J
M[`[*EL/69J8.4LLA>J_>`&`9W&J)S!],KR]D:/!;^IT&/F4')X^7KBG@9VP*
M3?2*^QF7@LI)AP_\C9#D$NA`'%G&GP6PHZ-:]%8GBL_9O;']'S+.X=O>NY+,
M7\.K%Q]T"`OJ`GA(XR64(W([C?6'[F]^GW-VVGL_>:[L6VG/&8Z+6Q.058V"
MDJOJ\3S"A+#97Z:P""-M95XX_D/LL%A\QD8U#?2'4]2!)9R\9TL\LJRG'+*M
M)SCM^@8/D*?<RC.&J1P,1'HUK&)V:FH[E^757<,ZW,:RL!W,#UV```A1'X0]
M%`G<].IZZZ+L?YV7]G[1C]M2FX^E6))Q48EF)+M/]179G)(\JC<``;#5]&_D
M]N8IC1I>:O(YQ-[^1>*J(,=KFO&CV/*3Z+\'O[$3Q1KD_P!>_P"J=8*_E=0Z
MATMK*G_Y.Q/_`,QZV[_G[E5N:[*+E<?'$K`_;_4M0&_RBVA#K$9F[QLEGZ/8
M3BBG9W<C4=X(I/HD;$)V17>/DKO']>W9._5?_@KJ"\S;7Q_]>W_]GJT?]P.0
MS^F*+?4'_P!B)_\`[*)^775XX7^2C]^U5)3WT5M#$LCH+WZ?#U^4JI!RM8L.
MMD:>'S-L&9@]BY_@&9+@%@#/XMDOCB5YQX>?^6?X?%>['/J.HZ):;&`\6"'&
MKY@=2JL&(DJ&,*=GVC\]?QG<:L7,7T:W,3;0M*$F.*FU<V[TBW17>LUAH%A1
M9=>J>8T]3KJD=O3F(X*F/#F1)(UCV-3:0R*&PI[>$Y5+`M:V0U1G"_\`5KD[
MIW:K7+Y1E8MV'<:;AO`((W#*=PRGQ5AN#KZ&P,_&[EC#)Q2>,E6!$,CJ89'7
MJKJ=F4]#\H.K@ZQ]9NG336(N<>?.%OFGCJ[Y:Y]Y.QO$O'&>$K[36;:ZBTU:
MPJL(0,"$AW_E6UQ,0;FQH,09YDEZ>`A/<J)TU4`DP.NOS`<N?S/_`&K_`"*V
M.QXQ_AVXG%Q;P7F'RJ_E7^2/Z;!"P?&.#JAHT5I;9ANKCR,]GWPP*\@WSA6U
M\H^S_P!GAJB&:$D@#J3`^T]!^OPU+P1%+VG8`D_8!))^0&Y/0#7/KC;B+Y:^
M;ME8\MU99/\`)1]GW\A;/8?:_P!@5%]HN%J/028SDER>#N#[ZX;H>29$(YWL
MB:+13H\5C1L-6E>%WXZ?47Y7?]J_O7WPM?=?<Y?LGMQQ(-B3EV@]#7CM'!3U
M#W%=OI1NNO@[\^O^_P`_+#\K&N]O^QO3]S^\ZR59:+..!CL.HORU#"UAT-6,
M'Z^:U"(TL.`.`.0.3(_/GRAR@?\`A\^[A2'E@;'CZVMQ_"7,UO-EC<^GT$1J
M29_S_P#Y#(.[\BNM(\W)/_0:#L3/5R<S^:/_`&Z^_?RU:SN*U?U/VLI)_%XZ
MD^FO_P!D4[O3'B_GJ_\`D@Z:[G\A?^]#\I?SO2GLS7_T3WVX`/;\QU'JOX_@
M\GRU9,GZ:_N\C>/2,3KJ+P9_._SE\B[S._-'\WW`-G\_Z^T]4/$?8'&U,;1?
M/?*L/^TP&BF-S?[I`BQI(7>X\[/EG`#YHLJMJV(J)X$#(GPU]<M5_@ZCJ#U&
MOTUX#D/!\K8^AY"XQV>8Y!PFI@"L\YL,;>5NDS=Y7F[^$NLN:F3+@3`]T5JJ
MQZ^+D5J]E14ZKJ`@C8]=7CTTTZ::=--.FFG333IIITTTZ::=--.FFG333III
MTTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTU
MSD^I/N2GXC;%BY24^<\DH@(KJ>'66MSJ2QICX%E)H66\J/35F.HY0B`/=2_8
M.?9,_"@#*HI9XWI/M7V+=W<ELL<0!)Y%E6N1*A^(+-8P@BM8*)Y[")16\/\`
MS!_-K&]MA:^W-S)8@<`CO<0W%C7S(1**R"K7O(LM'I4JW&QTU()_)1RB`02&
MPW***4S`B:E!QZY#*YGN52JV'Y1VJQ[$:Y41BH[OY)V5>NO'Y9]J9B%OQ8`_
MQW;?OW_CKS9OSU]P(H9L3N$D@#[O&W\=_+MX?`;]=M1C?R.<LA1BOQ'(S%>O
MK:W\'BY[B%1PVN1B-C_^:X[&K_JWR7MW[]T2U?RV[0>E^-^V_P#O^6KV_/'W
M(L3B9P_]'$Z[?+YC^_7HO\C/+8GE&F+Y&,HNW=T>JXV,QSE[?TC<D)$(O?\`
MW?HO;]%5.@_+?LY`/KXPGXM=_?HWYX>Y%)'X7.)'P3%/_P!+K%=G]?WEYR=4
M<HOS>\RNPS(_"):%S.=TIK5)]';9FTI)%)G).>\8]M%L(<ELDQ'L9)IHHR*P
M?=R;6KV=11VM^U"W'MP[>J\W3C#*ZL&</NI#+``/&QR).VN>R/S+R\OO]?N`
MT9F/W/'&SFJNTORK>IZS74:]G#(P8D@/16K0LG4:Q^C_`*:Y7EY6USF2W=O*
MH*^XCYW66Y*G&I');/'#MI8V9:D';5TZ;&B-$4PK_P`617*QJ*CWHZVOVU[8
M[2EM63=CHEC*7K7E9/'=1]XW%@"9`-7U;GH(ON]\^_?<5N/D86-F6V4HXKN?
MA1!<A7(]*OFK,!!89&R;#J9DB9#[%T<*.&T#@*2)*%)$P=Y=:/5I&84P6J9D
M;0;G3QQ-',B^3G-"BD:YSFM\G=^I!F>S<:PM4<AW!'TJE<]?%*D/0QUVZ>&H
M6[9^9V=4J9`PZJF!'WEEMT21O%E]H$,),+ON0).O4K@#Z/65Y_Y%PE(EQ5$6
M3$%@<FZ/,4,=6'?'+(X^DGGR'%7W.>5WD8?^JJY%<M$]P^V^$>EG!#T)MLD2
M=IBX`#P@=#\MM5L]F^^?4Y>OVEK%@D#'IAH&Y!.,2QGS2=V'C.Y1N+_JO/\`
MG)I"\8/A!'ZS)G$L,>!YIBE>:'$_Q2PP98@7C<14$CT"Y&IV[*KTZ-W3VGD>
M2\97,].<6';Q/J"V3TWZ_NT3V_\`F)A39B'`-0$'TN5(DS*CT6QRHB=IX_9O
MKPNU^J..K.)IM/QWJY[:UU$E/;YG>6]U^/`S%A8NH(((%N/97(*(C[>3[8H+
M2%&D@,K9/FQ$\:_@?:G<:CBXN34I;ER5ZE62X',DKZ:EO*L,48J1Y8/6G]5_
M,/LF0N?GX60XK-?!ZLAWA:F;TU"N+W%9YM*+;6K*T/(B).L^M;=W,3.8K##[
M?4:B28TF<>IH,=D&P[^%1MQN8J(M+,F\@MEP\MFK*V?^862.6>7>$5!B"-K5
MOM]HT_T8]FKOHJQ0(')[+)0MZCL6`I@NZU^4*5"U#<L3J+'_`#(R3[G_`.I[
ML3+R.X,26*5T4Q8M?H5($9LF5JJ:X\RX=GO;RJJ@'/Y?Y,-H)OD[BKEM6^R,
MQ7,)Q\Y&I+42`+_[GHYPU4S?+Q17-5>RIW_3KGA^6.$VWXO#\?\`X]X=?_,U
MVC?GQW11)[=W*)'CC>,0?\GIOX=->8W\F6QE'?&#Q?RJAAN1CV&D<>`_K5'N
M<UKBY!K7N$T:J]&JJL1.[NW56_+##0<FRL2#\KC_`/M/V?'PU1/SY[G8YK7M
M_<>0^)QA_&GPC>.GCJ:3^2/D%Q"C9Q)RRJB,HU+[<"H/5ZU<V6A6XQWE%0G9
MKGHBHG?].Z(O:S_X-.W0"<S#Z?\`R6?L_P`SK\M7_P#PY]Z+%1VWN.QZSCQ$
M=9]#I.TZV2^=?M\/)$Z="W%/>9,4>02/-#K(,*#<4'J<$;+[\VJ!$I=-A)3Y
M`Q29D8(95%)<UTT;H9VRP<U[C]C-VVM7P72XD2#625?KY88EDM$$A6)6U?H(
M=2C=U[(_-A>^7/5W:JW&56(87*JO7$`6<D`2W',@,ZJKX[0;0:G%B=&>O-]>
MWZ=--.FFG336N7U*WRXL<WLJJ[3YQC51$<C7$F.&USVJG9S$<].Z?IWZZ3VK
MMW6?_D3_`,-</^8(GV]'_P!D5?\`BUQ`VT^77Z^ZP\>RNY==EUKN+ZL45PK+
M86-;QD$,4T_,#F2*XMIJ*G95LK7V`YTV)7.@W$E\A#(C&,]SP:TLPTSF6M;;
M9O:?+6#?)`>`>*-65QT*JS\JU"\=R?DWNU]E/<[>TH]K4X_'$0"&N9<4`%J@
M2I>U+U?,L%CI6:[K"X?8"CXVQ+H+R@JH\^M'_E%X]V<G437R*>REM]PK3:<1
MFF#@.L7-&UK]34"!GJQH'RE%[B(T8YLVI<>BRUE8^E7YPVS*-N->1$\?_D%A
M-SR%GB))QNUW-FY=..CH/Q%OW35[HQW#WX9;CRV@Y=(7&J"FSCR:%7*_+&LC
MT4].-LZP55D<TX$>'$K5E6$6UG($]](DAB6[8?[XP3"N(ZF>]MG7E8PX'!0B
MB;J>TXC7U_U/)E\RV228!42$`)6>/2/4`X."58&)UT7N/N*8=W]"P0*^VT$!
M0LL':#82%?CZD3/H$BVL@.A7EQ%?XG$T<:=O]&TEAE:.%8!DTM6V,Y+:14L"
M<RS;21%%,2H_/-&CD$C(]C':]S2",/S>N/W<DLO;\;RY3L(9I\H:1LH,<HY$
M&2AB05,#69[<4*C]YS07[=2K`HD><I!/)R.7#D54B%L4$@JZR=5:YYIXZY-W
M4&7NN/J5H01(L%MAA5ETUHP42<1PPDGF-(A2IB2&%\'!9'6.OFA&]O6UL-/9
M>Y=LP&3!R'DL3%L,NXZQ`($1,S.T'J3E97NGLG?N[I9W?"JXJH7E1*/`;H6)
M*EIF"`O'<,.@'WEWD+!\.W>*RGSAR'K,#R?O)U3[ZO;\4RMSQ]IL]>69:M,I
MI9\>FER(X?W)K"^5?&E2`C:X97#\AJ-V?MV?WFB_+]RXU61VO'5H:J\57(ZJ
M&]1`6`/EV\Y4$P1,&7N3O79_;&7B=N]C9N1A^X,QTE+\0Y&-;78Y3T;6"$@<
MH,UJ[*)5B)7CAFNW/)O%L6[N:KDSFV%C8'.$6CY9SN&QX>0-98V@8<V7#R^1
MN]3>6<+/\61DK9-9&CG;[3/<1"?E.$C!;JS![7W5DIMQ<%LUL$MCO;9Z584D
M`O8M:J7O/)78C8"(X@R>7H[OW[V_7;E8^?W9.UIW85YE>/2,BYG`8K539;8R
MUX@XM4JL)))GU"L+MCO^4>*\_5UI\#PG<5MCNJU;\+M_7VL'0U0[*".Y"EKF
M$)Y5Z`(<@PJ]TE$4+_\`A$S]>2[?VKNV1:R]PSD:JAN!](J4;B>)XOXS`)CC
MU'B=>B]Y]P>WL+'K?L_:K:[\NOU!^(5UL0,H<<ZI\L$D+/+Z3T4:QC!YCG<Y
M2)>1W-152YL6(D2@T>,A?XQ<9IPS!:^N'%A$*"RDV8SKX1F@:9SV>EKGKW\=
MI9V9.PJ,O`=PA,NEAYJ^Q\TG=0L;F8C<@>.AI]SV^[7;MO=ZZVM58KMH7TGJ
MW'E`4D.6!V7CR)'$$^&K\M0YZ]L*P,LTP\&U6J715TQY&#G5DK\,,O.NDRWP
M7:-KD1R/>0DN&Y'_`(E:15;X]0DY%"VD!59.7`CP83#P)X?(`*VW.T;ZX"WA
MA9CXZL6=+.'J*Q^I3Q!KD\?5\9)+IOZ=#&(V$VT--EQ1B.04%9R-6P\G*R%S
M\43KC45;7W)K2!DW6<.AEDT\@%4-DV;*E4MNV("61K1O=&AOY[!?\%W:_M\J
M,2!8.9\M;>7B;.)<<`6/%56ROD4!)')QVG=:QW/V[B=Y`L;N(8TGTP.=J><L
MM/):SZI"`.[O1=P6Q@%)2HZS#F-F"K5AEKK!]B]HZTE))86EU];F))[1N)XQ
M==-KIFBC5<^(MAH7:AC9AB$(V!:.,]CY'4%.!;F&4+]08>:MG`7U;^,A"P/"
MGT#Q``-E0`(7@UM%JH:RCES"FLRERU$OZ&+SXM8$8>IDG*`=B6%.06(+[>_,
M363])QQ8MLDF)2:QV'J!14E-JY>1C\H\$\@T%E4AE,'('61W[^4&*A&J45<L
M43U_M(B<=[HFO&R:^,<Z?5:8Y"PT953JT;<CZ2EHV+\B.NO2O8(6[.P;Q9R]
M+)]!`)X&D9?;\BMD!`/`?B'5)W%?IJ3Y=NZ77@^OKG3IIITTTZ::T5^\+2\H
M\)C+G,,0NDJM6L^A`YC",DW$6*A:Z(1A""&\<N4UHW(YS45KU[JG^O7>>P:J
M+\^^G*VQGIAS\%)W/ZAOKR/\W\C+Q.SXN5V\3G5Y'*L?%P)4;P()@'<=>NN1
M6OR8*J5YT:QSTME965]QPDII!`41+-*2/%OY\>4(5-9\+R5L**ZB1CO"DN.,
MDROG190'.]@P\MK5B^1>JA+HZ_3R)0$>9<D<+:V8`\20EE;HVOFON?;DQ[)Q
M(.+98UF-.P@OZ8%C`@(^"?4HO16(YJ&MIMKL0FCYL]MG)\:YSY;)(`+%;)QI
M43R->3+&(^#;[#4P0QU8[1::ME205%?7Q*4[!27D+Y)_>--DK3DUFC("^H5B
M`?I`,K6A)^A&"FQW:T2H`_PKBX+9&#<N5A%_1%G.2-[&8<7NM4#_`#+5++37
M6E#`,6:?K;,VDXGF[JMT'(^51G[:Z2*_TN8M!P"7&>LY4E6GL)[57]JUM@98
MSXS2*LD-2*.K8@2*%WKTN-W=,"VOMN5_F041UGBZ@;`?S5C?E&QL)\[#D)ZC
M.]N6]VHN[YVZ/0Y"RVIPI>MR=V;^2YC!4'S"D+%:L4,7IP2>#'.#&Z&+G]=E
MM);1V2,]9)+F6T6QF$&>P=07,-4LZ>P_.]A"(\WA(5AB,0*?HF#WY;&4YF.;
M*<NI##K`4@;#FI\K"(`@;;`\M;7V@U-;CM>:M.3VZ^P36TLX8D%O3<>=&Y23
M+0T,PX]-7!9[/A#B?:6:X?BQ^A6M0=8<^[L'6)8\TLU);EB08Z1&R(:-E,5[
M2^_]1-4O;S:K\>K"[YW;"7\=E^GR\P%0B1$;DS!VVB.ICIMF9'=/:?MSNEG]
M([>;S7Y"<AN1#%N6RB)7<3/+H.74$WCLL[=\_9K%;3EGD76\:@I(U@?'<<X1
MU5G(NYDA81E=87$^@=&U<3*9\H4!(0!484!2MB>!D>Y</!R:/;^5?@]HQJ<E
MK"!9=;R<U#^8*'FLV/,B1(('.5@:VG<\+*]Y8&+W7W'G9.`E2L:,;'X5"\B0
MK.U<7"FLCBW$P5+"J&DF@\1\'V''VXJK.=S%J(7TCF(&E'3AHBNH>*^2JPS;
M,$'+7^0T#;.#53H<@;6-<%\1LY`QWD\):O,[([QWVON."]5>%4WMJUDY<_/?
M2PXDV)8G$L"/B&XRP$I"ZP_;7M*_LO=J\B[NF0GOK'2T(*SZ>)E(>06JRFSF
MJ,I$`@IZG%"T62QL#D#Z2V,S3AI.8N,,-I)-84\>^L9F?-07AFP9X#-1EG3$
M_(2N)Z615:]I%8AO)?%4=Y9_;_;6$F*;^S95]2L`4`?FHD$?2VT[EO"8C?6F
M[S[Z[I;W`8GN?M^)?962+&:LUV'BP/U(9X[!8(,<IV@S=G-&SQE?09VAP6?G
M<>9O=T%?=EE54KWW+9#`&=)_?;1Z2;-HH39C!M&#\:6T!W*Q[!.\%Q.R86;9
MD69'<+%R<FBPK#"%B1'%=EW@F3R61N"1.ME[I[IVNG#HQ.S4OA8.92MA*&7F
M#/J/N\#D!"\7"L2"%,:UQP?$$>_BWVKG:ZOB8C*2@FD-:4=3KIA$1H2)2P!`
M>E9-GRHC?*QCH)/6K$DQY`W%>WI<_O+8[UXE=+'.M&W\U8_WC/F`!^@SO/%E
M(`UPW9_;29E=W<;LE%[3CL"=PES'IY%`\K,0)M4#:.:.I8B8VTJRO;6,.-%D
MUE%F#K%R<6OE0F3\^6%W;'GY414F9T&H#%D**77E&T)V*B0I'DQ'-MP5JQZ2
M6(:^T382##SU%G1RDB5<&0?K7>-7]ULOR\A516KQ,<Q2%*\JRO1J0>58M"F'
MK("L-JGD2+5RF0M+VXK05L8);"3;EN(5<LM8^;9JV#@V=GJF&L9DR0S%7.2D
MR9&@+.DV`*4$5Y&LBO&%G65EYE5%+-:2*P@4F)?T]U6N``/56P`5!50VE@"7
M!8ZU_;NVY&9DUK0H-S6EU68J]:%9[I9F/H/26;(-C6+0J$@5E5&NAWQF>/)Y
M3E.J3RY63CY[!5F+E6M)*I;6UH*;.<L5)-69)O8\T6[OHDZ[\T:QH7SUC*CG
M`<]WG7O0,O:@+@!F&RUK`K!E5V?';TQ&P])2M4;SPY=&C7M?Y7NEGN%CCEF[
M<M..M!>LH[UI5F(;CRW89%BV7S`XFPIN4)/5_KR77T7ITTTZ::H>FMGT&;T-
MZ(+))*6CMK8<<KWC&=];`D3&!(00C$&PK@^*N:Q[D1>Z-5?TZGQ:1D9->.3`
M>Q5GX<B!/A\?CK$S\DX>#=EJ`S55.X!V!XJ6@D`D3'@#]FN#6T-R3]5<VZW#
MDM$CY'"SWR=O)0/_`#^PL<E=RJLLMM8\QF1\[0V0)4;-4HWD%#4CK.4^18$(
M1/?,)>V>U.QTYP6<R]8J$[5BQ0T<O%W4J;K"`6CTD"U@#7Q_W1N^_F'[KR>T
MM9Q[;AO-YCS7-385+<),55L&7%H!*I)R+"]Y9M;P9[/YC(4XJ.BIHH*&#&:*
M*P$83[8%3*DDF?NY91&BDR+"-:F(I'D1_M]CE548C7+PV1D969<;[W)O8[R?
M*6`CC'0`K$`1$#QVUZOA86!VW&&'AU*,-%@0!S"$\N9)@E@Y,DS,G>-S6SMJ
MSR)!+`<8,KW1V6%K"C1E\)!QM;67/<8/(9&L$@Y(45K/U143R[>J!3<J@5R5
M@PI)Z#ZEZ_K4]?U=<QQCNY-P462.3J!U/TOTZ[0R]/U_3"D5L-),1SPTTR49
MQP%"$4236R#"\4EPE<Z'X0Y$D:LD!>USFN>J]O!>RK<MC\3!<((,[@@>!Z[@
M="-OUZL>BKFIBIK#((`!4D=5^G8D0RF2)^&H,FISKD5AH]<\IQM+'.:#":PE
M0UST0/F0+9`[RC(Q0L&Y2*9J(-6_IV'5;<CJI;B.HD_5_#BW6=HZS\:/C8)V
M8(6(D$JNZ?#<2+*_I`,\AY8\%EY<)D<`Y+3Q4'^:2,:95-C`EMF?B^$2;ZP"
M0[HLV`-KG-:]%>\:JGZ]_;<EA9N,&>,PTD1.XWVD']@/[([*E1!9*QS(+)`/
M*-FV$PRQM.Y!\9Y>/"4-C$>T?H.WPD-$I&.&4*"<:JE"DI_8/_;=X)XJ1'/<
M-O=O=@ZRA.TR.GZ_YA'4?'PVD[[FA%BC<#BW6/B(E"#T.QC:=RHD;#P:*(H'
MR1"D,EPG*0Y&J-7DK'M18=BX87E9ZQ/>T9_!SOT[+Y(Y'O6JL0W$QP;I_O>(
MWC[1_"(&J-6K(74,+%ZG;Z#]+0"=AL&B?MF3J4+'/$.-HFA!+#-"*2\@.\(I
M?'^P41V`"V(TXU_[KP;V8B*C59W:"\,K@DR4*F-]_GM)F/C/ZYW:-D>IP%A;
M`X!V\I/@08$2/"!MX1LDZ-I8[Q$BA*(,UYQ@:DEZQSQF=VSH/N4K2`-&D(OI
M\7=U5Z+Y*Y4(Z,D,"'(++$[;@^!^8(Z_P\!*`R$,@(5R0-S!'\RS,@@_3OXS
M,[GP9:N9+=:6=556=N![GP["TK:XA3Q58V..2"84!#0YT9K6N[A[%\6^L@W*
MGB*H]5$]*IW6D]0I.QZP1,$'Y[>((\;6_#VV?B+ZZ[,I>C.JDD=)!()5A_L[
M_P`K`Q"^VCAI+0QXE3&*I1>PC:BH=(`9P>\:P&[\4BSH<USE>]!-5J*[S1.Z
MM4E"7X0I<B/\30=]QUV(Z"?L^,5`K%G-UK5I$^1)!C9NGF5NI@1O/6"T`U'3
M$$XQ:NC>)LQ`V`/VD4O\&V8\BHV*,8TDD@62QO\`@;Y^+D[)XJUKV7+?<#`:
MR>,@\B)7Y^$K/^N8-K8F*5YM73QY0PX`\7WZ`;E6CIO^J`1-PJ&M(T\^-%IX
M[YT<[JL3*R)/67(0#&3ZF0Q`&/YM`Y6!<Y%(C7IV5$)V=;9D6"$8N0I'+S$0
M)V8;@==SX;?+:2K#H8&Y%J#.IX#B&DQYD.Q/392=X/P;>GNKZEX`E2@I"Q%"
M<;(1JN'+!)C-<T]A53"L`AP_C_J9CG-\W,5%5ZK_`%DO]2X,1ZCAY&X8@@]`
MPW@ST/S\/`0FC&*!O1J-<$<2BD$=61C$B/J$B8W)\6M_*Z[0<)Z2/9T[3RLI
M9`,UM.<I'"/24D.7+3/G*1Q7/#54M=(_QVR572H'H2HEM+!?$6KR<O#Q^^8Q
MJN@9:D>8#HS$#F/FS$>LGTO/K)%@?U<+MW<LWVIG+D8H+=NL!\A)@I6K'TR3
M.R(K?AK?KKX_AK`U1K./U)Z\JU]!ZMG:V\N@QNMO8""6=2YF^MX22&*0"RZV
MJES(R&&UXW$%[@IY-1S55.Z=T_UZ::_GL<)5E=]X\48?^3'^4;><L_:^WW?+
M/*?&GSW\AQKH'$_S=C97%HZ>=HKS<3J0YY-1A_"Z&C*G/UK9UBO@V:2>CS/%
MZ!^6GY;]^_-/W,OMCL#T57^DUMEES$)74A56>%!9R"Z@(HEB>H$D>4_GA^=?
MM/\`(+V-9[X]V5Y5V'ZZ454XZ!K;\BQ7:NL,Q5*U(K<M:YXH!,,84[2<E<L[
MWEROSN<U\G.TW&V(:$/''`_&6:A\>?/_`!C$B%*6O!C^,*E[Z^785[C.4=K<
M$LK-KU<X)8[7>I/TT_*[_MV]A?EGZ?<!5_4_=*B3EY"@\&\?P].Z4CX-Y[8Z
MV>&OPM_/G_O._-O\\#=V<7GL?L-R0,##=@;5G;\9D^6S))$2GW=$]*O'6/%5
M7*JN5555[JJKW557_555?U55Z][)),GKKY$``$#IKRJ(YKV.:US",<,C'HCF
M$&]JM>-['(K7C>U51R*BHJ+V7IX0>A$?:/A]FJ@E2&4D,"""-B"-P0?`@[@C
M<'64\9S!H\I@K+A749K#\]?-5_V;I/E[G>L=J^)Y`^TE/R\!.>&7I.%M'&66
M1\291.=!BR'>[]N(;L1/E[\TO^UKV5[Y-O=O;/#LON9I8FM)Q;F/_P`=H6.!
M)ZV4\3XLCZ^\_P`A/^_G\S_RK]#V_P"^?4]S>R*^*`761W#&0;1CY33ZJJ(B
MG)YB!"65==8MS<6Q_C/Y<^%_HO\`CAYPYNXE^:OMG[/IOF_FOXHYFF5?(^)Q
MF@BZC.5NW/GM`ZRFP=!4'K+DPZ>W<&/HH[5"\TUZ*6(/\U/=_M7N_L?W+E^U
M.^BL=UPK`EGIMS0RJNK*T"59&5A(!$P0""-?N%^77O\`]N_FK[([?[^]K-<W
M8.Y4&VDVU^E:`KO6ZV)+<62Q'4PS*8E200=?OMZYS76Z=--.FFG333IIITTT
MZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::
M=--.FFG333IIITTUJ7]J\D6?%'!.AV<*/)L8D:1`JYM+".^N+>'OI@*>IK+&
M]$9DFBS!K*8QUJ6*QTXT-KH\=P2&]P^N]D=MJ[MWZO"L(5R"P8B>(0%F8+T9
M^(/IAO*&AF#!>)\X_-3OF1[=]H7=TJ5GK5E1D4\38;&"(C6`S7468>J4!L9)
M1"K-R'+;Y_X6GZ.Q#SKR=/%J-AMJRMGTD";!`E;30X0QBITK:J`Q(5;^%7QQ
M@JJ^.-L6MB.1C1^Q4<SU7W!WNO&K/8>UJ:L.AF#$$\F)^KDQW:22;')Y.V\Q
ML?GSV;[5NSKQ[N[^XR.YY=:LBLHXHJ@!.*+Y5XJ`M-:CA4A@+.XW92665ZI+
M`(25`"QTE2/$0,B&+L$;/P7C]:BC!\6.:U'-4:]W-5$<J</P"^0F%8[=9!/S
M^?7[=>K"QK(<`&Q!OT(*C8>7I`$`Q.VY'4Z\RFP7&;+C'>`4D,G_`)=5*]T*
M2]B=XYNR?W8KC^*M54>K6=G=G/:GE5?4`X,)((W^(^(^<?O^`.J6"DOZE9(5
M@=M_*?@?B)Z==MX)`F58LHB,KW/:GF9OK:[Q<)#+_956&155HG]O'R17,[(G
M=.R(]EQX@^H/A^[KT_0_P-@-C123L3M\)Z=?@?CN/C\1X_)D/3S\D1X?6K3H
MUS)`D17HU'$\O!?(A.Z>3?+R3NG_`)ZK4*HV\#X>'Z?I\-6\[")\1X^(_7]O
MRF?UZB/]2D;-1A7Q_<0)`.<]KV>3FE?'85_FU4,!B=G=U>UJJG?O_6M!/T;!
MHF?[8^7[/X:J8D6B2DD1^^)^8'7K$[SOKZZ,1711,,TT>4)3L1Q2O%!=^JR4
M&US6-\V^CL5J)W>CFKV\NW8&$%B(8&/M^'\=OUZJ4)*J#*L)&YA?C_#?X[&)
MZ2K22WR%(YSY+U17]RHIBHP;/)R'4ODTX$&B(GZ*Y&)^J*U%<ET(%CH/V?ZC
M^G7;48-A>3+'Y[G;XSU$=/EUVW$:(0T5JN<CEAR6EB%?Y.4CQO:JO5'+W8R0
M`BHYB._I<C.ZHB_U=4<*Y_VQO^GR/]OZM7UL]>YGTFD'[/[QU'QC]>JH62HA
M+76SI!V1HKDICQWA58WN>A1/[HJJ:#*9V_I\W(UBHK/T\7-B59/J4P"3Y@?&
M-OU$?Z_AJ=GA?0R>1"KY"(VG<?:I^T[=/`B,>%,'7*?\1@)M7*5UHUB(*2@3
ML$Z)-E"$U&%\^W@^1W5Z^+>_ZHJ]46Q#9QY2CCR_"1U`_C'3KJYJK11SX@6U
MMY_`P8AB!U^!;KTGQ.H2'$QY)003DH#2'1%CRCC]C"$&TI5CJKB%5HE5?`_B
MUSO!6^2JGFM2I("$K^(`F0-OU_VCY]/#5`Z@FQ0_X,M$$B>DF.IV\&B3$3(G
M4TYLT+QP/R@)/JE?+A%:-A"E"V*^4,`B"<YSU[-[HQR/55<QJ*C6]DL'!AZD
M'TWV/VS$_P"G[?CJ\BY2*>0]:O=3&Y$2`"/X&>H'0:@D((R,F0!>N!X@=:U[
M9$@I&*)SVF.]K6`:V&YA?Z/6Y$;YJG9$1R-N`*REAFS?B8`^P>.^V\_#5K%6
M^]I$4[<UDGIU/AY=]H.TQ\8D+:M;?1BY]'SF+&G+HLI80'BCVM/9#C&;'G5!
M#CG.8<\$[Q."5Y`2!.>&0,HB&$22FPX[#(\NZ\+`9*LLB0T1L"`9$$&&4@A2
M(<FC\8APP7'%_4I98#HP!AD)#;E21Q)*L"4<,I93L'\T;.\N*ZURUP>/)_Q?
MVPF>D$J,VOE0+6?62($$<LISCI2Q`1I,:,0A7USC%B-*4`0*WG?<^%13:F52
M"/5WW(,@J&!,0.4DJS`#G`<@,S:[3V'W3+R:+.W9)5OP\KL".)5V4JLDGTR`
MK(I)-99JPS(J1M+URFO0M.FFG336O'U`%IN*9?DGZ!O:&1Y?TJHW!F>3#)Y*
MG]0G]G-5.[D<B*B=='[68CNRQXUN/VC7$_F`@?VZT^%U9^R&Z_JUPKUU'87D
M"/OK"M))?MX&>D;*D(204Z<CU61JKK1<?V$6N/[H;MA8,B;"OFAL:^PDU=B9
MH)+70Y@>O>,.^NBP]OK:!0SBMMH]%K&5+02-_3'+'=2CHKH"RGFAU\C=RQ+L
MNI>\75ECEI4;TDD_B4I2RS'8*97UFX9M;K;78U5C!'!JM35N5=?>AFOLH\IY
M+)9U?+M+&6^)&_R&\RIF$ADGG=`C!B\8\>R9#&,1:R5+G&`-6RG.8[\;)MLQ
MV05,(JXD*!)X+9U@29OM`)/G55!,H)'+!QZ<Q;3>C3?S4NQ@>I929!8\0!BX
MQ(`^Z=[&58L)!]/+]CGS<P)8Z#.Q0R]544$=;W+6HX]3,T=311HE9&NHLJ:>
MM$ZEC,CJ2/1F,.&PA/.8CC$5"Z:O(7LW''R"1B/8>%BRP1F)8J0`3R,P;0"T
M"$A1MTU^&WN7GFX*ANXU4CU*G`1K4K`46`L5'IB)6@L$!,V@N?-.<;6,S(V3
MXWC#LJ&SA$!/R=U4!TC4>9C*!0RV`.T[;`WO$P9(*@>C6M8-!]T5EG<ZTS*N
M>ZY"M(L5BG3SR)$0(,AI^)GQD[%?;VR\U^5\.Q"&I=!;U^[@P9Y&0`:^)@`+
MQ\,H\CS>%^-M<^!C.,4(6ABBC.J-C>.DY^%:%%^XL@@K0FC6DL4#U^[QD&<2
M21Q?:[P1/+5=MK[WW/#%F;E;6&>5:PY7I)8@J">FPA1$;].@[Y;[6[%W+T>U
M]O\`/2H'"ZR:U>.7$*"'(6.4,Q+$MRVZW?<V>J^@N-R5_+^UU/#?&>:O@R8[
M>(_V;*6FSDL`,286"&3"_,CQAB*V2XHR#!'>Y'2%5'"3K#IJQ?;W<O4[-15F
M]SMK(/XCE8M8G_-)!@G^6""2/I\=;/*O[A[S[$:?<V5D=K[#1<"/P?"E[S`'
MX=05Y``$,2"%4F7)E=6)C."<90<AY,W)_*VKH]".]K-CPEN<1:6F-#0T,ED2
M578'=2[P]P345ED!@?;-,P=@0DJ3YO>*0U&[#-[]FY';KE[7B5/C^FU>35:J
MV%W$@VU!0O!E,PHE`%6`"IUJ.U^T>UX?>\9^_P#<<FK-%RW8-]#O2*ZSQ*X^
M0;"_JHP"RY`L)=Y)5Q$SR5]%\ZU$O28OE"DQ=S;UQ+$]8W3YJDDQ(H'R%+`2
MMN8\44@REI2F=%EQ5<Q/%2%*C4<C[.V>W.PW)5F]KLO2E@`W!V!)B#R4F!YH
MY*V_@!/2_OOO?W=C67]K]P58MN166*^K4A`$RO%P`3*$\'61_,S1(/CDG1Y<
M/$N9E\;<:1N.O^ID1]/O'T5@"3:Q3#?)>P*3"!DV<6GNUBRB1G!1J'<!5>%2
M-56U[9C91[O:G<\HY/X4\JN0(4C;>)"EEE0T])V,:IWW.[>OMRBSL6`N"<]>
M&1Z;`N")VY$%@CPY4K'(KNO(&,%<=\,3MW,N)EOL:FEJZ^``ML^[BS0K=0J\
MSVE'4_N5D-EJC#2GA&KRCD#:-[XY`O\`4%V^[CWM,!$2FEWM9CQXD'B2/YN*
M^78`G8@R`P(EAR/9/:UW=[;;,G*KJQT0%_4##FJG<)S?S[DJ)(802C*>*FX=
M]8"LHD'.4%0U>/X\./(K*2UFAF"O7J5JCFZ>3(980!:J';P76%59)&10'5WY
M:"208JX_;ZS4[9.0_P#\\"Q#,H(*_)`.)],J>%B3N(X3Q4:S>\W+?6F#A5__
M`#F5051V#"S?ZK2>2BT.ILJMX^5I]3CS9CBZ;4%O+"6`T:TMKZ^+75%AZHY/
M\@Y$M$$3_"8Y8<LDR5:<KX^\JXH_[DR562X9GS'Q6`(0Y-JEPHK!4JF/6"PW
M\E*_^:9$!:+%9CLJNK`('+`*.>MQFR[V1ULLS+BJ-`/J9+P?0!4EBV938B#=
MWJ=&-IK"%G;;/@M9D/F'#5D:;(EP:58]996XA++IM-NYO-O&%IR'=T-P:7(F
MVM)!-9QZ"O,Z.(9JNFCRQD(R4GKY'OP1^S7VLH6QY8+T9*AC7K2K*``K$*;7
M$DA[&0@%=_2/:)MJ]SXF/6S-35"LX$I;D-G8KY-E;DEGK4NN/6Q4!JJ$L5F%
MGE[==>&Z^K].FFG333IIK1'[T=&3`959)8@Q1K\EA(;-=7#C/A1U@1I7M)<Q
MI=&T;$FM<_\`-&^)ZD<I6N&CFKWOL`-_4+>(,FN!$S)DCZ2&\-N)Y3$$'?7D
M'YPE!V;'YE0JW%CRX@<1Q!DN&KCS`GU`4B>0(D:Y;W!YOYU=FX<6+(SVBPW*
M.YB1HC*0H*?89@'.^NJ-Y1/S\*/GQ'M8-'%J;A`B;5W5(_\`%*#U"C.%ZK2J
M>FV2Y(R:[Z*B3REJW.+6U3\R7A2S65R>==OG#26GY]R7M]9,&I5.%?B9=X`]
M,A+JAW"Y,BOTU%8+K6M-W$"J^@^FR<5K*^CW(80YUC6TDAWXC"2I4D4:RGUD
M"0R"EC:LG28431V->5D.(<16RX$=H(S%_0@RQ`3:"@N5KML'FV`E0Q$PL`E%
M.Y!'%S+?`AV2KY2U![J*F\HDD!F53QY/R*BUE/$,#SK4*H_F5JTMN:CLK&VX
MXY,,.>:WMJ^YA2+:&*9&GV`:BG5ZM@P(-79871=X#AR22H\H+7C?&+%80CQ/
MZQ;ZJZ>Y8JE0E+(0I((!9O$EA:F_E"E3!#!R`"-9^)??D=CSW5S9DI:I=00S
M!$_E54;'M\L.75P""K5@DJ=8]J-589:W;I*<D1EC&D2"Q;8KS2X+H[9\B$\,
M63"N[.#+)-N)R0U<Q?(8XT\CE8Q8OHV-V)7ET_AK@?2(`*]#,`R054B%'+YD
MUC<\N6EQNXW=OR1G8Q47JQ(<R5CD5@%;'5BSMPD;@+<Q@>GPV#R-K@K2RN>0
M-3Q7EPEDV5C(@@-?ZB4;33QF:^+/92,DB)%&K3&_+:Y2*4A'JQB.<U'<[F5=
MPJJ3M^)EVD!0"0B#@(W'*-_#CT@`28Z=IVW([/D7V]Y[AV_'#,[%0;+2;6!V
M8)((&[<QO))@21.8LO!'ON<:.RL=%2BQ;;(L^BH*F=%E6@:*M.V2&MLJG\I"
MT4.%!"P!E.1A1C,KT]O9>VFRK#V_L5E5=;G.XPSL"%YL(+*T>8DR1`@D1MKI
M^WU+WCW95???4.U>H6KK1@7%:F0C),UJJ@*W(@@&?-X4?FY:CE.%C-_GK6-C
MKR;.UE/*KK#SKZF.>DMY-G!L&VT,AHL"U#4H&6T)7C#+`PJ(K2-4#I^Q^MVI
M[^WY"&ZA5K8$;L0R@$<3!*\I60"5,>'FUB^ZSC>X:L7O.%8N+EN]R%6\J`UN
M65N:R%<)Q?BQ"NH;H1Q-J\A<GX#=.G9R=08[:Z_)P8<=FQ5\X0MT2M@$!-%-
MC0I<%I$G'<4(SF`\I?%IW*-K1.3*[=VKN&!QR:[+J,.YB?3V^ZDR""0>@@D`
M@#Z=]]:_O7?^S=W+X-U.-E]SQD4>OY@,@JL,&"E9Y&5#,I)V<\84ZU*WVZG[
MB7$A7-?"H?VE8\8=,-SXU;%9-E08,EYB?C29\@$2>V&Y_P#7ZPUTMQ!H,\8#
MF]?V_`KP59Z6:SG)Y=6,`D1N`)'+PDNH!E68:\W[QW>[NUBU9*)3Z<#AT4<B
MJF3!8@-P)WA:W++#UH1DGCK,.A<5\E:.?4K!9<5U93TL>8-\2PF38Y&Q`,;^
MWYFD<=Q-)WK0^3QQY!F(=CQ@7UMUG<LH/W7&QJWY%&9F(W`!W/5VCR><[%@/
M*06W.][)V\U>W<_-NKX"U$1`VS%AL/IJKF;?NAN%9@'4A#Q&%ELAS(#J^9/D
M`6U;%)#C(E<TSTG$0=4L+*(76:TY#6`)8_Q#%:9TZ#(KR.22V,69N_2*6>HB
M@\)D[^'U39]W6(!4\@(XLM@''D$Y;UULI]&UV'J05'EGS&$XTS=<26#C@Q!]
M2MZ2>81K;YL9LJCI\H>+(D"D;;G?.X2XEJKHL\N*S&=XPVT?)#>SWK%HKC8Z
MD]I:@0SW6Q8\9LLA4"C$P*T6^ZU7`*T8#VJ.H]1WOJ-GA+K76$K,?=@L4`Y3
MK;76V8F-CO6S!\ON]>.[=&-%5>+>*=IBM[K6MM62;BJ"QF"`:W;^,"@3EJ=Z
M/P0(5P`R8]>[*_\`,SA'YT>^?9MS+R%_=&1AC&1+3PN?!6*=J"]"KP_O4-_1
MUY<C$P3ZFPC%V7G_`"S)'#[N9X[\M>K?E:RCW(_#@`2`0OI;L#W#S-Z6_.``
M?5BZ(YCCPUUNZ\AU]):=--.FFK'Y.DCA<:\A3"N>T43#ZR25PT\B-&"@L"O<
M-O=OD]&L7LG=.Z]9_:U+]SQD7ZC?6/VN-:GO]BU=BS;6GBN)<3'P%;'7%OYM
M(\GT+]*08Q&)8BNM9.KBQRHD@$Y.4+M\:*I'N009,AK51!]W>8GN\FM3_B]K
M]R@#V[VRQQ]T4K!GH1Z"R?L'Q\#XGP^6/8K%O>G?:4(]<6W,I!W#?BW@;[`G
MX>()D?'$OW[]B\_</<C?(OS9\O9/C&_^@/L'?<B9_,WO,(M%_@/'>,X^HHN@
MW<_4Y_(NAZ#0D\IZ+'"$S6L01G*CRJQ@?.\JUJ+:\;'"^O:>K$\1Q&S@SUC;
M]WV^V]MQ:LO'OS\XO^$QP3QK`]1N9@UD$1$[S\YV/TZM;O\`D7^TN!/C'[(Y
M1Y^^<,+EOHCY)Y<X[XVS=VW/<EUWS1]#X#D3:Y_-IN^/CWTN!J;.AK(=H1"C
M#.(&-(0+?:SS_%'COFYM6-:UR*+:W`G<`F1##IOUD@_`D=2<VGM/:LGN.-7B
M6.<7(J+1Y2Z@`S6W7;Z8D;;@-$`:V_0G\U_-G&WPY\\\YX[B3B21]%Z[7?35
M-S1A;1=@N'R5-\L7,W-ZRUK&5^@C:44F?>6U,$"2YAD5LOR57D\2+;9W?(IQ
MEM"HUC<PP,PI7K`GIT_;'382T>V,+)[@^,SVIC(*BC+QEQ8/*6,$2(8;;[`R
M3N?T28*UE:_COCW73HM?'NMUB\CJ946,1RP8UU>YRET$P,`9VE,2OD?N:L!Y
M+V14:Q'>7B/K=UVEE5S/'B"?L(_^E/ZXW,[G7(7XX2UZQ!<V,HDCJK=>F_(?
M8)V$;+J]"5D:*XLFOE"$&P@+*;63V+^%-:B*Z7&_,?(8J38D@2^#5\2>2(OF
MA6N>H6LP"V`EE:.0ZCX&(Z$=?#Y1`U0T)62]#`*Z3Q;Z6_Q#E/U`C;QF-^0)
MT80D>.^+(D.<]!POS'(A)$<(WLBFK+=503G%=#0_I5%;W1CF-_T\!]"`S<U&
MTF/`GJ&7]<3^T_$Z!F1#6[;PO+J0!L5?IO$QTZ0/@NH/_,QG/*UWXO9LN`0'
MG)-$\8P_8>O?)8_V-!8!>YS&^QSD7]?+^EI6W>5A'7H9VG?HT?$?9_<;/O*Y
M;Z?J6-R-A)6>L,)($S\]@P@1+"8^--BQ&`(-8IV.AD;)/^16^:-'&<1(C$,Z
M![O)A7!16-5_@KA]ANN>M`ZLTS(WV$-\>OCXB?A,'?5M=UIK>NH`KQ(XF3*S
ML)C?C,@P($Q(V/R(DR)[!E8.:_L-\(##(DUAI0_&%8U4EJC9*&PK6?HQZ*_]
M%(BJWV,/P>")4>)C;;J&'A^L?9\"K%M<JP#';B)\TD>5D/B)CH=_YNDB.,O=
M@VK'=*]I&*.+ZAD8&S:1WL"@%&(+(MHPJ]FC5?'NWLQ4:P:VD;DS$#K\5^,]
M96/']O4ZN#2!L6D["`8:=Q$`0\^'RVV`UZ,.H:5SJT2G$1I9J1)J>PT9OCZY
MU45OL4@R`:CB!*SP>Y5\E<BHKW%-T1:8(@2/'X-^OH0=OX"KKC!IH$H9:&WC
M_$A^!&Y4B#XSXGW*''`YXCRC*5B1XRO>`[)+JIZ,)'G,4#E'()!*UB"<]?`@
MT;V5S5&UE$+,)4"#)ZB.7B-^DCK'0_K)K8J(>+L>0@3!GAX-ML>)B)V(CJ.(
M"4*7%)[V.`R<CHGE($5C(4S\ARI#M(\EBHL64I!N\R-:C%1%5WDCGM*4HXXF
M?3WV\1'52/$?`?LB`0L6Q#S$"V1O(XM/TN#X&1N8CXS)#>YQI3"/4L;\.:DD
M3+([7?B,!;A(=\.>,K7>(_R8[W=U>UH2=U<CO)%>VE80C8RD&!UE=I'ZC\-Q
M^[5;FL#2R\;>0Y'I#@GBP/A(^(@[D&9(QGR3*<^)019`W"8*1K^P2QU#^-8?
M]/-6Z9'$]@T<.,HW>Q`L51L5R?TL16HFT[8H#V.IDD5^,R/6K@GY^$]3'4[Z
MT/?+":Z:V$`-=L1$-^&NY`?`>,#83T&VNL'7DFOHS5B\H?\`X-.1/_S%UO\`
M]P+#IJHZZ_GV_#8GN_B4^+CIV]8_JK[6$[]?ZO,U1Q\YG9/]J=@.[K_LZ^M/
M^S3_`/&GE?\`\%O_`/;8^OSZ_P#RF/\`^(/#_P#PEP__`)GS-9?Z_3O7X0Z=
M--.FFG334K]1?_L__P`/_P#_`-E[K_\`2WC_`*_(#_N3_P#QW=__`/7T_P#S
M+1K^D+_LC_\`Y6_:7_VED?\`S=E:_8A_(1]D%^+.!XNURN$-RYSARER#CN!_
MFGAJ+-_;C<I\\\FS"UN*SLRQ1'.J\W7MCR+.XF=O^7JX)U14>K.O#]?42+R/
MR\=:A9/^-+ZTY6J&;K[%_E'^R8W-%\$5A.R/QEN,]\V_/W&<PXO/_&<1E8F+
MOM#LZVC([TML]%,DRK!K/883%>K4:KR4?2!'SUE'Y=HOY%OG'Z$3YZYYT\K[
M4^3M/E+2_P"+_L2RAX##\U\2Z.D1CG\4?1.3I9E'`Y#B7T5W>EU5%5MD/D-4
M=@!J/0H6AXD2-CK"OS-]SU_&G+7\DTSZKYDT`>.<M_)[BOESA63H(%O=Y_C]
M_)?#W#'^#X@<BBJ);,EE+C=Z(Z?GV+A0`39[4-('[6(K52L@1\)UUSYDY?XX
M^?\`BKD+FWE_4P<3Q?Q9D[K;[K5V(Y1XM'F\_"+/LIJQ8()5A.,T(E:&/'$6
M3(,YHA,>1[6JU8`28'76".<OO/Y7^;N(^.^:.:.3$Q67Y>C4I>*,_(R^OL^4
MN2+#04T:^K,[BN(*6BL>3=!IUK9@GR8`*ITF`KT24T/Z]FJA23`UC?Y[_E!^
M0_H[D^+P?G-1O^-.;K2JF7V<X?\`H?AWE'Y[Y!V=%7#0T^WPE)RUE<JFWBP(
MZJ60RJ)+/'$UQ"C8QJN1H4($^&LB?5'WK\P?&\C'TG-F\L!<@<C?F?\`3?A_
MCW&;+ECF?D%E<]C+"5D^+.-Z/3;*QJZ]S^QY[H@X`7?TO,UZHU6@4MTZ:DOE
MK^0/Y<^PKK78SB#;74+E/CZ)$L=[PIRG@]OPWS5D*J>98\&\M^+^3:',:UV=
MF'[#'91HTBO4KVC]R$<C>FA5EW/37,[^3CZTY8X@^J.-Z/C7?:K/TV&R&5U&
MFS%->SJ^CTUG-U-I9EK]!6QBLC6,>71UT<+V&:]%"9R?Z.7K[^_[9?RG]J>[
M_P`K.Y9WN3`Q<C,SLR^FFZRI7MI1:$0/4[`E"MKNP*D>90?#7Y#_`/?%_P!P
MGY@?ES^?79.U>RNZYV)VSMG;\7)R,:J^RNC(M?)ML->16C!;%:E*E8.&!1B.
MA.M^ONCZ;'QY\83>4./;^3677+%5E:;C2ZKI2Q;*,_<Q!V[[:!("Y#1YM=DP
MRSC*-4<([&*BHO;KP3\C?RR;W#^<R>U_<&.MN%VFV^S,K=>2'\,QK%;@[%7O
M-:E3LRDCIKZU_P"ZC\\J_9W_`&TV>_/:&6]/<O<%&+5VVZMREB_C4%QMK93R
M5TQ%N=64@I8%,@QK5KX\YAUW-/\`'E]$?]1>9-E5:;'DY&K[#E27)M]/J\YG
M2Y2KTD6R&X,G]\G#ACD2Q-&`K9'J:K0N:]&JGJ/YP>S^T^S/^X7V[_T[V;#M
M[9F#$=,%1731=<+WI9#(])2Q%;$L"G(@N")UX/\`]N/YD>X/S,_[//>+^\_<
M?<L?O7;3W"NSNCM=DY6/C_A*LA;!#>O8%FY>*,+.(*UD-Q(RA\N?0'$/S!\7
M<?;'DGG#2\FY&^WNFSE)LWY'9F("S?)MI'^,5]7:`DZ05/6)12G,/):QCBO<
MC$:Q1MZY?\T/R_\`=_YG?G/W#L_MOL>-VSN^/@4W68_XC'`*16/6=T(I-C^J
M@*H20H!))#'7??D;^;WY=?D;_P!M?:/<OO7W3F][]NY?=LG'HS#B99*VS:WX
M:NNQ6R!57Z%K![`H+LP4!2@UE@?\H/QN;D"+Q^#D:88DN>"K9KVYVT;A1SY+
MV!$,^@*(:CB^\B,=+]/X3/U<XR,17]<HW_;#^<2=@?W`_;D"I67./ZR?B2H$
MDBH$RT"17R]0]`G+;7?I_P!\W_;A9[LK]IU=YL9K+5K&7^'L&"'8@`&]@"$D
MP;>'H@>8V!!RUZNOY/OCFBY#+QW)Y%F23QK/]GG:VNS]E/PL&>TR1BM+H@,<
MAX0#_P!+YD<1H2(BO]O@BNZIA?\`;'^<.=[>'N&KMR*C5>HM#VHN2R1(BHG9
MB-Q6[+9X<.6VKNY_]\G_`&Y=J]WGVA?WBQ[%O]%\NO'LLP4LGB0;U'F0-L;J
MT>F`6]3@.6MJ>7>=>*."\0O(?)^RK,YEB."&NF*I;"3>2Y('R8D&@KZX<J;<
MRY0&*1K8['H@D4CE:-KG)Y9[1]B^Z_?/>_\`I[VQAVY/=!)==D%2@PS6NY5:
MU4F"7(\T*`6(!]X_,/\`-7V#^5GMC_K#WQW*C#[$Q`K?>QKW92RI176&>YV4
M%@*U("@NQ"`L-:.'OY)?E#FO80<'G-I:4.FN)+(5##VM!+SL:^FE>@X\*MLW
MOE5GYTMZHT`#F"8[U1@VN>J-Z]*]X?\`;?\`FM[+[._?>XX55_;*5Y6MC6K:
M:E`DLZ0K\5&[,JLJC=B!OKQ3\NO^]'\@_P`R_<=7M3L_<K\3O>19PH3,H;'6
M]R85*[9>OFY(")8Z.Y(5%+$+K1;[A^Q:W"_;7!=-4<G[O.X[B"^J&\\Y^CDZ
M>!228\BTI=)ZYU/`(*'KF%S4OLYK1G3Q<H_]>[>O<_R1_)[)[Y^2G?,W+[9@
M9'>.[T6?TNVT4O8I"64RMC`MCD7+L25Z<ND'7RM_W0_]QV%[6_[G?:O:NW=[
M[MA^W^P9E`[WCT-DUTNK759!#U5D)E@X[P0%<02G61K,_`<JATW\BG*.LH?I
M;5ZMM[QM%UHN'9V<V$"#`S>CHL19TH)-E9/3)K6T,._B'ALC,27YR%:]&.8=
M2<9[]JS^V?\`;OVOM.?[:Q,0T=R:@]P6['=FNIMR4L*HGW_.UJK%L+GTX65)
M!0+Z7^4V5V?OO_>)WSOW:/>N?G_BNRKECM#X^6B)C9%&%;2K66?\+Z="9%+T
MK6/5EH8*5M+[$\T?R._*?!FKFXC4;:PO=34R'1+RJQ-))T:44P:]BPK2R&^-
M4"GQW=T-'9()("Y%:1C7)VZ\\]F?]N?YJ>^.U)WOMF%71VNU>53Y-@I]53T9
M$(:PJ>JN4",-U8C?7L?YD_\`>7^0OY7]_M]K]Z[G=E]^QWXWU85+9'H,#!2R
MR4I#J9#UK8UB$%756VUF;B3ZIX&YNPU[R'Q_R%43LYDX9Y^Q6S]U'99")%BF
MFGDZ2KM1QIE;#;$C$(V0YJQBM&]1D?XN[<9[M_*SWY[)[Y1[>[_V^Y.XY;A,
M?A%J9#,P4+2Z%E=N1`*`\U)')1(GTC\OOSZ_*C\SO:V7[Q]I=XQ[>S=OJ:S,
M]6:+,1$5G9LBJT*]:!48BR#6P5N#MQ,8.XV_DK^2N4^1(7&>;W%K%O;FS%39
MN=H,S:TM#I+229(\*#5V4H?<,BP,Y&QVS!Q%,]S6,[O<UJ]Q[D_[;/S9]K^W
M7]R]QP:GP::C9<M5R66TH!+,Z*=P@W<UE^(!)@`D>7^S/^];_M^]]>\*O979
MNZ7U]TR;Q3C67XUE-&3:S<42JQA*M8Q"UBY:N;$(LNP4[[=>#:^L-4F^*4%'
M='`1XC!J;$H2L7Q>,HX9GC(QR?JU['HBHO\`L5.FFN$7P)_)7Q;P7_%1\"<W
M_>_T#=QM!ST#<Y5W+?(J:'42;[5T-[ROI5=KM'"@V!(*#R.+(&.:3XH<H@11
M>9BB&ZFI&4ER%'36UO%7\OGR)R=R?Q]Q1;0/H3@R^YDGMJ>#[OZ6^;^7N!L/
MS3<&8XT"CXYV?(.8J:&RT%Q%;[8-?*+#G36JC0">1S6+75"C`3L=;.?5?VI\
MY_%^9S>AY[W)J.=N[I^9XUP.7SFCY`Y5Y2TXP?DDSW&W&.)J[W:;&QC@5KSK
M$AO!$8]KI!!-<U5:H%+=-83X'_E'^6N=.5ZC@62SF7@/G+40)EKAN)OJ?A#D
M?Y[U_(]77`6392^.&\A4=92[@M;&:I9$2NF'G!$BD>!&-<Y&JE&`GJ-=%NFK
M-.FFM!?Y,%&WY)V#WG:%[-7QPX*/<C&'+_G%(GH<YRM1&O&KE_U3_3_XE]`_
M+&?^KZ0!(]&Z?E]TV^O'/SX('Y;Y))@C)QH^9]=-OV3K6?A(GKXHXKEQ9325
MX\!GVA<HFO(I?4.1'*KA*^,X+?8YB=AHQ$_J=W1SG-Z?O@GNV6KC[S\0\_9T
M/7?Y]9_8-<'[4/'V[VZRMIH&%7&TF8!!VVC<CI'B>I(R\(9&#;*7LH&2?QGN
M5J%5SW,][V/$]ZH5JA?_`+?%?_C[/=IV()X?S$3_`&?I^@UTJJ0OJ?R<H^/S
MZ>.WZ>)^^;7.-&9Y^A2D=%\A*15?V\1N`[V([UG1J#<Y%<BJU/)JN8GBW`#G
MZHW_`-/V=?[=]`02:Q/`DQM/V1\CT)W^8D"/"N,\;O\`A3T>M5)X(TS$15$-
MC7M\?%%(1%55155R?[U5>J^6?MU0EF'V>/C\!^_4X\K>[;`;GO,XR,DA-'18
M:J\/=PD7\DKRB,C'*YCD8JKW<W]4[I8!_P"6>D;;[_PZC]>I&8?YRR6G<$>7
MITZF0?$&/B.FWI(D=TJ(A7$@PI@4,QY'K)42*T@D\_QT<62-)#$<C5:-SD[?
MHW]'=4YMP,>:Q3'P_CTV^W]?35?33U$#$I2PGXQU'AN1/A`/V==>!@*K_P`0
M9'NF`D.=$$P)G?D-\4(10D4:*!&L&INQ$:QS.Z_HO?O4L(YGZ"-]QM_?\-M]
M4",3Z:D^J#L(._CL8VZ<M]B/AJ6*BG'^01#$52N9)D+^6YT@Q'/.XCY)%422
M%&[_`$8Y%[-[^*+W<ZX>4\1'38;;#IT^&K#YUYM),[G?<G>9Z3'P,^,>)F!.
M($:"EM:^!->8H4BH\S(KG/>,;HZ'4:.FQ0/:PK%\&N[HJ=D];TM,,>2?YB]9
MVG[8\">G^L:O4LJ\;!-+$D1O'@(F/,!`(VGY>4B(V*8S)XY!&,DP`#4"%DD]
MJC"]6D!&#V<-JM8ODC?Z555[JB.1W5"RJ5*@\&.^W[R=5%;,'5R`Z`1),P/`
M#I^GQG4;\F0XKKJ$V.,P?#\J,(3R#:B-$+\B0%_L:0,LS5>]7.1?9^OZ.1KU
MMXK'H/)4]#^W8?9T^S]FKO4<M^*JXAAU`$CP$D?`G<[]=^L'4VP:USY%4>0!
M(5C6@E.26)SE8<@6O$Z,T:%<R4"0KFM55:CD:J*[]47JTGU`+5!YJT;?#Y_*
M-2@>BQQW(]*RL'S#QC:.NX.P_>=2Z-1PE:P9H=Y6^]\EQ%>KY0@H1Y'$4I'*
MR0`2^'CX>+AHG=5;W\;IAMX:AHCY'^[^W]]D2L`%<JN9^8'69/4#PC<?+I4W
M)%]%9;I'6+6RU)7788KBJ)TAK>WN:)[R.<-S'M?XKY+[&*O95[*Z+S<FIF;%
MW6?A^FWV']DY%?"O)CC0TK8!TGXQ\-YCXCQ\99]?)6R6O=)=[O6Q]'-<]&B5
ML/W&C"9(+'CR41_DHVN16H,K6IV5J-5+A8GI>I&T^8?;$[`D?/YB?'5AIL-_
MH\O/'D;P\LD"2`?D#X$#:(B__EPMB?6\E29SRD699V<CV%<QZF5MF(#BM5#.
M<UON$1.S6(Q5153MW1%U_NH5KB8JUQY44?9Y9_A'C.MS^7S7OW+.LN)/*QCO
M&_G`GK\0?"-;K=<1KU73IIITTUKU]/\`Z\36*>#7HZWI6KW>K'M1TOQ\Q>#5
M(\J*OZ(Q6N_U5%3MUT?M;_WNO^XW\-<5[_\`_O;LVG[Q/X^'C/V;_/7&J+.B
M`IN':FH@U]E4[[<5>1UE!6NS(:[25=HSYLH(9G66&K:2KK]3C9M[,FTUC%05
MA46+WD*0A"2T/[.];M?F77,RVX]#65NW,LC+^-<CC:S,:[`JK8C2EB0```G'
MY?KNK3%[7C8R)9C9F6E-U:^D%M1_Z96IY4+6BVT-8]E%B19382S,Q:SG;E6]
ML6)70([YTV>"+&_<#)"=/FR)/KDP:^P?`H[%+D,B9,(%8SAP71U,0CA/'_SK
MHF3:.;M8W%:R3`F`!L2)8<8`GE+3``(/D#X-#"NNNE.;W!1R/'DQ.ZJW&MN8
M):.,5E>18J5^]->0>-K,>CG:NJAR&&UYL05N?CCL0P5A!M(S94R/$B6]=A+J
M.ZR]Z^EX?(:Q3!,Y0-.!!Z_N=1QJZK7$88O\Y@F>)@$E3:IXQN#OR#*.7%IW
M78L@9UV1CU,#W(XA],!@O$.)8`.N.XY3Y2)'!E8\`Z<<7P+Z=$(L=TV;7"HK
M)RB;W*X#?37CMWDD@9M[>*<M?%@N.X)?=_S,V&!2&*&8V1M+,>MQR"JQL7?X
M]>.Q])2))B1&RNT`,A7GJ<RVL\.3HM-FW6-EYDD>NX)55+$'EYGJ0LS+:'SG
M3:*BVVC)=[7BS+R6PP@CW%X&PT(03I[H\22Z$D,<Z.P?A;)_0U\AZL:-6J-R
M(U$T-V/D86,*,'+M!))5"$)`DB9@_P`O78=9D;ZZ[%S</NV<<ONO;\=@@`>P
M-8`S0IX\0PCS]`6,`1Q.VKMT<ZKY/WN1_9-%49S+$'14(,M1233K>LM!PQ0#
M1ZZEDF;(9*=*`4P3S?`$U&M&\K7.:U<3&2WM>!=Z];V90+N780K+,@LPVB"`
M0LE=R!UULLZW'[_WC&_"7U4=O(KK%59+.K\0I"H3,R"RL\+9LI82`<F<_)EN
M3JS;9ZLF5>0MN)]S"RU'+40RU4B@E4D0=6"S;#<^9%7]SK'@!*:(C?,T="*C
M'(5=7[?_`!7:[:,FT-=3ET%V'\P<,>16=CY6DK(V#1OMK?>\?Z?W_'R\+':O
M&R>VY:U5G8H:S6.`;CN/.A56XD2R28/+5A$YER-WE<SQ]=4^/Y+DY[)L0N[D
M1"6?[)<(LZ9$KH[O.#,M:Z#%$!C&JHVND*U>ZM0C.M@.RYE&7;W&A[L9;+O\
MH'CR78%CU"DF2>OE^<'6F/NCMN7V^CLV55C9]E&-OD$%^#^9@H^EG50%`&TM
M'A(UJ[R9R5>V;JW,:6CS6:KZEKI%96X:$YL"<"$QR5Z!E78+-#*2`.8"L5S&
MM'+C@0_M84Z/ZKM?;,>H-E8SVVV/LS6G<3UD*5C?B7WW4MQ@A8X#OW?LS(->
M!GTT44U[HM`\K!?I@V!Y\O-:I`AU3GR#.#DS@R,5&ZW2VL1E5FJ3-7<:;;B!
M81ZVSE#"&T+(BES69I9JUXLRV//`1QI0^\A\555XFD)J^_,/N<:D\\E[5(60
M643Q@\W827E2(4[!^A(&^]I(P&3GY"BO`JH<,X#!6(`<D&JI&XBKC8I+./,:
MY)4,V"G:&-"#-AREA54AYYP5#<65!4%KVP/:EJ%U?7!W.EG/K33X4@I$8+WU
M<F+8>+@?EQA[_P##.Y6Q>3*`#*J[3/TF6-2#D`P`DPX>O9N#'D3FUU*]5G"M
MRS"':M"O&>8XJ+[6XEJV)@<JFKN@IZJ+.W`S`S&VO&K<"N#T/&7&_P"Z3XDR
MFN:^-O=/OJ_=5E2,<H[\[::2@Q4:%.*\XYR5HC1E(-AD8^.DJV510>!I%E]W
M$$,I-25&IFV'-4>UF4`%>95H)$B7*#)V_+RQZHRC3BXW-@R.HR+<A<A$$GTW
MMKH6NPEA9Z0>LD!H.VW&<R&OT-3@B2:\DR+/R0I;(I,BV<"/)UOSN.-'FQ:6
MNB:J/'&)'BC_`+N>0-[!K^(T;$(CN0[HC_\`3KLX8(5LB?4@D5YDD%B:R>A/
MI@$$^>3$>D=AMJ/O6I*F0VJ](:#3R`-W;0`PK46@1(7UF8$#[L`<I[2]>)Z^
MI].FFG333IIK17[I*462Q2@F$"9;TJ,A17V;9U@K)U`5C(*4D29=_D1S#8]J
MPV/E-<B>ICRJQO7>^PP&R[^0!'I]3Q@;.-^1"P1MYCQ^)`G7D7YN,R]MQ2C$
M-ZQ\HY\F\U9''TU:R08/D!:8X@M`URKUNI!F^0.-K?5GL&T:U^HSVZDJMJ2S
M#D==><T8?4'(W11H5Y,M*.AO23'CE#'.*6-XE8A7.;UZMB8C9/;\FG$"^OR1
MZAY>)LK7&M0>0E0K.H4%25`.QC7SSW+N"X/><')[B7_"<+:\@^?F*;K,ZBT_
M>A;"]==A<AP')6&'(D:M#7T%CEYIW6KZP]YFHA&S7-!7SDE2J&BF:W/6]9;B
MOL=:%R6\N@5MO5N'-L(,RN@11H@48X(<W#R*\I!Z7(46MMN1`9A6ZLO"Q?4J
M4O6\JC*[N?-/)M9W+#O[?:3D&LY="GELK2:ZVNK='%E+FG(<575$/96]5=:^
M6"BS5%?ZW*WE1:YB[D1;"FL\O5-C6\VSOZN9$ILC>3;E]BPW(.Z'+9:6MP8[
M?R&C*A?%'(YS$*VR_'Q,NAZ<JL&MT=I4*C`M8H6(IJCBJ@;2(Z;&-28F9W+M
MV77D=OM9;JK*DAV>Q"$I=GY`Y&0&YN[,.0#3$R1RUGW`;"A#6Q[_`&/&?'MD
M>MA5(&V,RGE0KFYU#62;(S'(E]$H0H6VT2%<Q\=&^:JSP9_2YG/]PP\AK3CX
M65D*K,Q@,"JIL!_*6/E2-CTWD[SV'9NYX:T+F=TP,*QT1!R9"KO;NQ_\P5B7
MMF"L3M`V(N?D#+3.325N@XBJJB5$NX,0,W+5;V0I.>MI-65"5C:J:RM'^W2[
M,2,]J`D@_I5&2!L3V)B]NRD[6&Q^\,X>MB18VX=0WU<ARW"^$J?BI.VMAWKM
M]O?FKS/;5=35VH`U2>4UN5,KP;CY2XB>++L8=0)U5N+'P.-F;W5Z"14WU[7Y
M6P#`RE98@FU,8EQ:IG8XKO15\U((;R&.TDPI(1RWHP8F&(X?9OE#W46=R./B
M8X>NAK038P(8\5YGBA$E3Q5E)7<D@`[ZR?;QI[$N9W'-:N[,3'8+2K!D!=_2
M`LM5N(L4.R,`Y@`,Q6!,F35XWD7CG5X2R`;*562/'OJF8:7/OK60*UG?L&BC
M7+4A,F/C7,@T80RQ8XRUH2N,\3$8<,>08F;V[N56?41;;<"C``(HXCFA7>)4
M<B0Q(<CB"95FB;N/:^]]CR.T7@X^/C$6(26L<AV].P/Y>4.2H!10:E)8J(=4
MQ_C^$+ILP=A=65";+"4D^TN\SH(E["L1LL*PEH:ML0"%"#1?DS"QW$DRH4<3
M?,CTFN;ZQ[#,[[04-="V#+.RJZ%"NS<05.Y:`#"JQ.P'`;G3=M]IY0M%V592
M>W@EGLJL%BMYE+E6$**Y8K+/6H$L?5(XK.['E(.NC3@1Z3!*6$"35YS43<K"
ML;&["6J&:-;?Y`QPS'&05>*1">%\A@HK!(5_]2-6/#[4<-U9GR(8AG0.0%\V
MZ\/#J0TP2TP/'4O<_<*]RK=$JP^2`I5:U*LU@*2']38G90R$%@$"\CO&L&:S
M>7W(C'TVJL@K3SI>G@LH`0:H5='C6^0ARL[,KH4S,:H@35&CK7*$Z!51N1W9
M'=^R[[$P*.V_?8BGUE"'F2TDK80X)#U_4C;B=]M<EW'N^9WL'&[C8/PSM:OI
MA4"@/2#655JK2"EJF&C8SUG5A0)K)KY!0AM<U3-CPWVTXKYD:OIR;C*3IUVQ
M19G#86?:&;N:")8PQ.G"+)L3JHU1Q1C=GNA0!24MND\1L2WI6`+]=MH4>D[(
MQXD*@WV!(T]-HN+,HLHQ0J\VW"H;Z6:S:K'QV8^O6EB`V`M8WEW95.3-5,47
M(W!_'Z"'766(Y$J=1L*4=>W\/-Z;>W^1CUF)>M6./%@V^&X[QE,*TC#:U8UA
M-/&5WF!ZKK,1`W;<[N$EJK\9DK:=W2I+"UOFDE;;K+"C'ZD56Z,-;[N-I7O?
M:>S0$OQ,U+KD"^6JW(LI"4>0`*^/C44"U1]-CO63*$ZWK^-G%/RM*,<L@R`K
MJN'%;-DW,@D83)G.[G"@LN<_1,BUI$[.8.`^PK_)'>$LA/8T?!>\X':0%`$L
MQ,!1.V+N>+M)^;A'^*`03Z[^5Y9_<3,Y8PB`<BY($]PV7G76`OP%9LKF8L8\
M@O6'KR77T9ITTTZ::L/E.,LSC'D:&A$"LO!Z^,AG(JM$I\_8"0CD1KE5&>7=
M41%_T_TZS^U-P[IC/$QD5G]CC6G]PU^KV#.J!CEAW"?A-;"=<7OG-K8G.WT=
M,+%=)B/U>V6:$#3#.-J\EV#0V()7O"T<VO(%KFHUJHB=E5R?U.;[7[DE^P]M
M0&']&J)B/\D>4B#L9_T?'Y:]D`5^[^^6LO*LY-_("9_YIH8&1#*1M`_6-R-$
M?Y3Y\WAW[0_C"^VM)1[VXX+X$V?.V(YMW''.0TFQT.`;R?A8M=D=U?9[-0+:
MW_9S.>]"R`">B_BN&T?FX(R>9=P'HW47NA-"EI`$A0PB!&^QF/A\9U[YV1QD
MX>;AU6*,RQ4*DGB7*$F3.VX*S\1X1KCKK6<R<A_QT_S(9V%'^R^1>-I'-?R5
M9?)==]$!Y6VW)L[BNSV[+\EY2UVKAEN61]+"CLM9((L5I(P?5^4QCQN5->ZV
MOBY/I^H:B4X\I+%9$$;3\/AL1MK=UOC5=R[>;OPZY(2T6&OBJ+9!Y`P8'B-Y
MW!@]3KQ]=_(?*\.R_EZG0<1NIV+R7S?BMI\_4=+D=-9,OMQ]I[GYTV'-5/E(
M\6)(+;6=+*XGL&3XL3\@\57*T[6JOZ4R<:T-E'B6K"`@_P"^5,C;?IOTZSJO
M;^XX[)VX<PES6D,/E2'4`R=AY@0#,Q`Z;?L"X;KIU;PSQ+%=$],R)P=QHR9%
ML@L:Z57"P>>69%,PXV%C6E#)\FO$YJ*-[5;X(K587IJ65JJPTCZ1M(*M$=/@
MWZ'Q'G^36Z9%Q0`_6=X(>LL3U^*3_H\&ODU,>0"/%EB,R;(>,!PR59XQ#%$-
M];[G@&JO'8QV(T1&]G^\:JY[U3Q'.+E5BZ$%!N"/'XQ]AZCI!Z#QPVQF=%2P
M$6L0"#X$CRS'4,.A&_(;DQ`\QX=I$DU\R%#6<(QB`-`.)JM;(8U[940GB@X[
MT/[%=X*B*]'(K4[]O=5GJ=61SQ($R/AX'X[?I_LT2K(J=+:EYH3!4CQ\1X#>
M9CQG;_:GC-G!=)C2`F>%0`-)"=.Z/K'%8D2R";R1[YT9CVC\E;Y(T?9ZN[>(
MHP:VAE(!D@$?XO%2/@>OZ]OB97%J\D<$KQ!(/^"=F!\6'3XP-R8A99SO!XB]
MW"?`;YG]KVN/%.J-<DTIE\0GJ;/V)YHB^MBE5?\`S_(U\3(ZANGP(^'R9?#Q
MV^4+9)5@>A3K/4'_`!$]"C3OX"?G+3+%:R:K0BB6<":!\]82D.-\J$\R2#5P
MU5B^N7`?'1X_7ZR(K47L_NUC+3]'F)6Q3$[;&(!^PSO,C[.IO!`MA0ME+KRX
M[B5F2OR*Q(B#MX[`0HUG7V#7CDPY)Q-83WH4OX\IXO6P0)+WHXT0$NL5_=#*
MJ!-&3NKD[JA:M59695@#X>(GX>!(;X=0W[J)D4W"+%8K&\[$B``?$!EGZOI*
M^/\`B@O(\R2&RR-]SC>+I2,4#*^W&5H@R2G1@Y$>/*B@1KG=U\B(I'?U-_MU
M``(X=(Z=96.D="03^S;IUL+%PPL/FGK$<7F`2>H!`C[=SN/+&&EC^,:,&&I!
M!FD\&CC_`),ROD-B?W()GE&T18$\;W)V5Q6.8G?LY55KZ'TN0<GS%?C`(GJ/
MF/U&?AU%P]?@4594.>@EE,;J21!5A]HCX]#]8*='#%=%`R2*0AFP!N$\G[@!
MQG+,KS@[^`WUIFN*K_-CVN_K9_M<VA-;$\S!$3\C&Q!_VAM'ZC\""W(JFL<E
M,\1'U"=U(\.)DS(/B/B"J=0,")6F"&&25^243OR9E2](XCQ"*C'".RM5J/1%
M=YL5K5:B.:UHWEY<CL2T0#L&W@_K_?X['>OGXA5W0),D;E#`(/@>/7K(@1N`
M%Q[RJX'[=F`(4(9D61J`EC"8439E<O&FO?635\WK[RB8]Z.<OFYJ/1$=X=N^
MQ[3R]6UH)0A#)\#ZU?(?9_=\=:7W%Q]''0$"Q3:"!MR7\+=P;YD;[[Q,3$3U
M7Z\GU]$:L7E#_P#!IR)_^8NM_P#N!8=-5'77\_;X8_\`Q1'QM_\`O9?9G_W$
MQ/7UK_V:?_C3RO\`^"W_`/ML?7Y]?_E,?_Q!X?\`^$N'_P#,^9K*W7Z=:_"'
M3IIITTTZ::E?J+_]G_\`A_\`_P#LO=?_`*6\?]?D!_W)_P#X[N__`/KZ?_F6
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M"6\/#]>M[.)8.9U?\Z_UZ?E\$6;R)Q)\=?,S/C>NT``O'0\,;FRWW_B&U_&\
M:4QP@6MGRG`KZF[L(B-E,B!BQ2/0+_!U/'5I_P`L1TG?703ZNXW^1]S4\1WO
MUF/CV!%X\YNX^U'".LVNQ?Q];YOG=+1L;`#X_P!;"O<W=LUU[8._%%61)+OW
M<:NCECR!*YG5=6J6'TZY\_Q[0*'2_P`D'\OVZY.#%E_3>3YTXIXPS"78A$OL
MA\>CX6QFBX8B8M)+5D5F'VVJL-#8S71/`$ZX$1Q_(H6^+5S_`$J/"/WZG/Y/
M8&=H/K7^(CD'`"!"^J;'[>K>,*"52L:S5Z7Y9T7'&\G_`%)G[U(S/RK7CBBS
ML.!:R$D><:OLAQ3,\#$17-$^EAX1K"Q^+`?7WW=]ZU4H(I8,]Q!HL#ESF:UP
MJS:U4?)Y?,RAD=W:)\:]STPJJG953S3_`&KU^@B>Z7_*'\BO8>542CY'=Z<J
M\#J^-8;[[E(\9JMK7]FOQ]N]A5?]Q/\`W5?FQ@W*EM.)[>R<'%+`$59U*XF+
MC,#X<;\>UCXD<A\=:O\``FHU/U?K_B?Y,T57,6AX)T^NMMNR:OD*TH:6Z70)
M"G"7NX#*?.U*T8_-$[.E^*?\77I_OSM?:_RI[1[U_-CMUJ?C^^XM%>-QZI;9
M7Z7)3XFRZS\28\$D]->%_E-W_OOY_P#N/\L_^WWO%%Q[3[5SLNW-]2.-U%5W
MXGA8O515C4G"21L;>(ZZV#X07_IW&_ERX,<U@(]7D^2M)2Q&)X,'75J;RK]@
M1_HC1$K+JM[=D_X4;_V=>?\`O;_[H;?RD]\`EK+<O#IL;J2[_A7@GXAZ[OUS
MKU[\LI]G8O\`W#?E:P5**.V]SR*$&P%5/X^J5'@&KOQ_W:P%R/\`_BE_GOLO
M9?\`Q':[LO\`N_HY._7_`.+KOO;G_P#-C[@__!S'_CA:\D]Z_P#_`#\]G_\`
MX:97_A[EK=S^3CA7B[C_`.(>)39#$9RAG9'682FJ;2LJ84.S=7VF1OTM@SIX
M`LE3UMI,04B2XSGN-)&A'*K^Z]>(_P#;-[U]T=__`#M[LG=\W)R*,O$RK+$>
MQF3FF15Z952>*^FK,B!0`J$J-MM?47_>_P#EA[#]I_\`;#[=?V]VO#Q,KM_<
M<&FJVJI$M-=N)D>J'L4!W]5T6RPN6+V*'8EM]0?N;A?B_&_QK<6R\SB<Y3V>
M>#P].AW,*H@@NC3-%4"#H),RV&%L^66\)8D-*]A'-*7Q<J=V,\9/R.]Y^Y^\
M_P#<EW2GN>;DW8V0W<$:MK&-86FPFI5K)XJ*@@5(`*K('4S'_P!T/Y9^Q?;G
M_97V#)[)VO"Q\[#7M%B7)2BW-9D4@9#/:`+'-[6,]O)B'?BQ$JL:[_8G^9WN
MS_CDI?RL:VCE_/G%TS,.Y7>7_I=(W,J/6MN?\P[C*`L&0*-3CE-(UPE80:%[
M">_KT+\G_P"C8/9OS&S>.9^.7W!FK=^!`_&C&4OZ?X?<$,"<@I!#2&*>8#7C
M7_<9_P!3=U]Q?DSVSGVW^DV>T.U/C?U4G^F-FLM?K_B]BI1@N(MH8%.+(+(1
MCK)/T-\S?9W,<+#Y+E*[^),G<I:!E<<SJ"U3";64>'&(JU>7FLI6S;&N4;V&
M?%`PC$>(1$1KF-7KF_R]_,S\FO9UV=W;VO1[VR\/TBN6MM?XK&4,P\]ZFPJC
MR"H=B##,ID$C7<?G#^2/_<E^8^/VKV_[ZR?RQ[?W+\0K=O>BX8.:Y13-6,XH
M5[*R"&:I`PE$<`%0=7G]=9+T?:/\=E=M:C.6.HNVXJ+R8<%=#E0=5H0:/.5M
MT>R(:$%UY&*81&#=)&JJ'LGBU/Z>M-^4G=N?Y,_F)D=ENR:^UT');#!=E:BH
MTW/6$`8^F0""0A^J3)ZZZ3_N%]O>E_W)_D[A^Y\;"N[_`)/X!>Y,M:,F5D+D
MT5WM82@-RE@P4V+ND"`-M0LK^^57\F7VXF%CJ'25GSAK$QD2N`QBANX6'XH3
M.QH,8;6C9ZYPPL$-J(U.R(B=NK^Z_@<K_MI]D_UUN7;;?<='XAG/6MLG.]9F
M)W,J6+$[]3K&[#_5.W_]\'YH#VHG#O='LO+_``:5J!%Z8/:OPZHH$"'"!5`@
M;`:N/^(G'<`:7B#:7>@JL9J.:2[2W9LW;")5W&E@9Y\:$2G6*"Z9(D1Z:P>^
M04YQM3\B8I6E<Y1,1NM_[N.\>_\`MON["PL"W,Q?9@PJ_P`/^'9ZZ7MEA9R-
M9`-BC@%4GRU\2@'(D[[_`/)Y^W/RB[W^7O=.Y]VQ^V9_YE'N=HRSF)5=DUXY
M1#3P%P9EH<FPM8H^\MYK8S>FH7?6!PS\B:?B_P"@LCQ.WB_+T>X@Z[,<MZ;C
MF7GVR*"<6!+2R6VG1CD!4@SZE?)'"(X4$'9ZM&UKG]_![_>7YN=L]S^W^[>Z
M_P"J96=@V8]V!3F+;%JAEX<%(!L-L!#8`UK;2Q(&OK#$_+;_`+>>^>Q?=_M[
M\O\`^A8':^YU9>-W7)[<^/RQW*/ZGJNK%:EQY-BTL4H2&A`I:>4'%%YK_B+D
MCYZRO*^4X3YVX.U.HE0^"N<\;6YV7JZ%FHG"BS[FBNX@_P!U,T;]*,TR)-24
MJC>K8<UR":U/JWW7@]H_.WVY[A[K[4R^]]B]\8N*K=S[9D/<M%OHJ66NVMCZ
M8GT2M;U\-Q-U(YDZ^`O8'<O<'_;![T]H=@]^]O\`;'NK\K\[.=>Q][PZL9\J
M@9+A;+J+D'JGC^)5[JKQ:8;CC9)],#7Z)$F1'2WP$E1UG#CBF$A(<2RQQ#E,
M$,I\9'>YL<QHY&->K?%SF.1%[HO;\\33:*AD%6]`L5#0>)8`$J#TD`@D3(!!
M\=?L8,G'.0<06)^+5`Y3D.81B5#%9D*2K`-$$J0#(.J;H_\`W>OO_I+:?_0)
M^H]3#KK\<7SYDLYN?@__`.#%YK6U$&^H9'W+=VLJILHXI<"7,R^<^I-52.E1
M3L("2.%?4D60C'M5KG"3NG;JFIR89_LUVS_GNIJR?_$_]8WTJ&`MWQS28+E#
M"VRC9^XY3?83E/$WF6U-%,\??67%3/!_;.%S">MY&=_%[D6NHZ_K&L?<$GH]
M+_.%]0V/-+8\GE#._#7RU+^/!7XA>$/A?43]V3Z3N^.!2448K2;RVRNAWIXG
M_,I$9$"5WI<C5IJI_P`L1TG?71;ZUR?R#I,[Q58?8#.-HU-F.<N-+CA:ZY`O
MTRMA4_0*7*#XQ;QW?1;.GO![VQM?(,2)`.IIS%()XRB4C>JZL'+^7X:VO[_[
M/]O^O;_R]^W_`/+IJFG337/_`/DT]7_A,TZF_1B;3C155"*-4[;>F551J=T+
M_2B_TJCD[?U=OT[IZ%^6$_\`5U7'KZ%W_LFUXU^?7'_X.,CGT_%8OC'_`)Z?
MM^S]>M>>%W"B\4\802H))[,-0F)%>)P@.BE@@0*JH6L"@QJ_Q>B(UW^BJCN[
MEZZ+O4MW;*L$^F;W$SO,GX[_`&:XGVL5K]N]OI:/6&)62(@05$=-OD>A^W?6
M33.*#S9Y">KNSW>31R4<BJU#$CJ%Q/$O=/'S'W<OBC53O_2FL`#;[_P^R?E\
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MJO(&%'2-H_3]/'PU3@1+MUY;S,S_`*?]7CJ-ZR@"`I$23$E>U4:B/'';)1?[
MH&"_(?X28:(Q6.>[R5$:_P#W.ZMD,Q`V<1]L?'IT/C^L:NAD0,?-6T_9/B(G
MJNT29Z'X'7EY4:$H&6`C0D41`N>)P1>3'&4A`D(1Y8Z(4BC]?BB%>OFO9/\`
M2H4E@Q4A_'Q^'[?C/ATT+0I0.#5M&T#QW$[C?:/$[ZFU1"`;/&9W[E&/YF$H
M4<_UQV",M@_]2N>\9^[B%>B)^B*O9R*KK.C>F1]V1MO\?#]G0#4A\R>LI_XA
M3N(\!!Y>/0]2?U[[F8B3A09!BE:V0&WJSQY0^[0H-\IZM(JI&8)J-%(!YHC6
M,3M^B=T1'.M>LV*`-F1P1X]/M^(/Z=-7UW+586;S+960?")^R.A$]!_:9B$=
MLV%_CEBHXRH[W0)Q(XO,"HP\ET62YO9SHTOW*YK_`#<UJN_VM=W;8ZE'_$UR
M1T(GKT$CYC]-]7U/ZM7X*^%\58@;=3!^1F09C]1D>T>0D:LM2#&04`BP;E_=
MQ9SVD*K$%+%(>QL@3XJ^+41O]/=>ZJOEXH`=J@3+"5^'ZHZ;_I\:@EDKR&`*
MH>+GJW7Q!ZB.FWV^,3#@0ZLM>8[UF9JX$1S1&8130FD?W>QBHI7@E"5C.Y1*
MY[F=T5%=X]6\GM#*/+E(>HZ'_1\C_?J0I5CLC.>6#:#L>J_Q((V\PW(^<:DI
M"*R02MAE69*K)!B5<^([VR#`0;#.#YB56R$&,?\`1XHG9$7^GQ7LV]=U%M@X
MHX'('83\?E\_TF%Y#FBH\GK)X,-R1UB1U@=/U[1TOKY7LTE[#DT)U9^::UMI
M?]H*,&X3;.,T[U<Q$8A/R)'^B_U+W_7NJ*O6![KJX8>*R_0$4=?]DQ^X:W'Y
M>9`L[GGJ_P#FFQSL/#F)_7)^W6[W7#:]8TZ::=--:W_5+/9Q05%[=DTF?<O=
MR-1$;*>O=5<YJ*B+_L5>R_[?T[]=+[3,=V'_`*I_X:X;\PQ/MPCP]>O^.N*O
M)&INZ+CWBC:QF6[KK-:./HX$.[=I_P!R=,S=3\NVL"&=VYK:O1("0V",8U>Q
M(J1W-_$5\=!$=[;VW%HO[CEX3</0MK*$KPXP[9RDCTF9)$DG^:?KAI`^5N^]
MPR\/LO;NZH+?Q6/>+%6SU>7*I.U.JG\0J60>(`D<>)'IDIQ8T7544:VL(ZTI
M(]QAM(5]]AREBTMG+LL!MKD+`2*XUU*H)%989BHM;+-W#(=Q'-6V[I+S1560
MTY<C$O:FL^O*9]0X6B64+;4ID$*'#!V5+JRU9#U\0'\I48G<<2O)N4XA%O:+
MSZE!(1V;'O<05+FLHU2/;C7!+E:JXV%J_.':W(EIHH#85S66,Z);#@#U$U\*
MRLY@!'T^ZA(X!:^NY>U4&NBU]'4P83@)%40AC]37J,CQ]9#U8SEJ;54T\N`E
M5!A*CN"<>LL2S,T\I),D2`=8561FTA,K'=UR0@M;BS,`;<A=BJYERJ%K2M"O
M"`!Q!XDKK8+)\@2=+H+";M\AQQ?@'^_EE:749ISW_M)IXX$?\1:^WKX+3NK:
MC\?^\)%(C6-<YSFK[>=S.WKC8ZUX-V36QX`(C_S`29E28Y-.QVWZ#IV?;>\O
MG9KV]VQL&Y!ZA-MM7\A8*(XNJSQ3CYAO`!)(/*_[F.WE&DH+?CO.9RBG9T,F
M-I,/%2%GVR(M3/4+[&G:844,N)-B2FC>Z,6?&\U?[%:K$5-?2W]*OLI[C999
M7804M,O!8?2T3!!$^8*T1'76YRD'N#$IR>R444VT`BW''&N0C1R20`592`>)
ML69F(U2>,J;/\9\CT<S8R\__`)?1P+6?'S%7.K+>RK;JAH2SE!H+.N=8QZ)\
MHE&"9`828Z4T1RQ_5W57-F[G=D=T[;8F&+/P=C*"[!E5E=XE%:"T<BK0O&0&
MGPUC=@Q<+L/>ZK>YM3_4Z4=A4C([)9766BQUY"N36KU@OSAF3CXBL1>3<SI!
M<@XPE"F;AZ_-W.H*7.6A+^V?O<W7NTE5H,REK.!)+2.%'*,%,TC7'(]K`&5A
MA&?"_:\K&./FBSU7IM5!S7@OI.>#(_$$<MP381L-V$@J,JOO^!G+F]K-/H59
M-#VDU,;'_$5+ZJ65<V!-<`A:`1R)A&AE8XXS'"MM9##(J]-GI.6C):K*LXKW
MV-GG5;1L/751<ZC?)NGA4U2)TJ-(4;@G[`62#P<AMEE=[IJ)6VJP91XPI\JO
MYH+<_P#`68\6$R/-Q:=M'V_VKDWJ'QLBENWKSE@>35_=RJ&K_P".JB`NK1Q;
MR<T@\LD:#FIC))\_`+F=!28\(85==V-#FM:2%/KWS*X^6FWCV6<+U`DMD1AB
M(:*BRB&<)SF.[IK<?LA*C(L%M=]QDJ'>N08(L"^4[B"2`WE"@[C6\S?=0#G"
MI./=B8P"K8U=5W%EY*:FL/-8!Y*`63SERI(,ZUKT?)&WM61<[I;1A<U5OP=;
M+JHD:FK*6UC0?SZJ2$]<6NF5!'FBV3%(Z1'(5.S6L>U?+MTV-VW!J)R<9(R6
M]4AB69E)A@0P8-L5VA@.LCIKA<[OO=L@+A9UDX%9QU*`(B.%Y(05*LAD.)+*
M6Z`$;ZQ+6NO8K%BRG]V5L2,Z4>):1J2F1,'M19%TJ[;GLCEHS*^UP]Y^(=Q)
MHAECQ6HB.:U7-V]OX=SS4;L3`*EF^]K]2%YV6&5M7D(4D%CX]>;H.96/3L.U
M:B2&%:?\/>*9L].FH!7H?@Q+@%4`W`D7ON3-S&4X\X\8UXM#?7N6V%M#/%/7
MRJS`8W.Z"MX[-H:TQ%F0M'O+39V]\Z-(?^4R"L(TAONDKU@X`_%9>1W$[X]=
M;UJ000UMCHUW!NA2I:ZZI`XEN:KLNMMW=Q@=NPNRB1FW6U7.""I7'HKL7&-B
MD\EMR'ONR"K'F*_29QR<ZW+XW>?_`*YY>.XTXT8%W2E`I$TZ5:$E;SYX(<%?
M^XUL?)(>,[Q;)_:),@ZE3O.09%&U>+[F%_H5K0H8HT_1RVJRX)AC9!_E]0*(
M_P`N1.O4.Q%_^K<=)<UBVN/\WA)R.VDA>2BF1T;T69I_SN+<0>S_`%XIKZET
MZ::=--.FFM'/N4B)AZ`#_P`=X7RSF.`\:-)0X@W>38YJ,F6-1$<S^_V>PLN*
M(C%5KSB;W>G=>Q!_QUC"9@`$$B)6SX!CX=0K$>"GIKR7\VV'](I0\>)8D@@&
M0'I_Q,@\=P70$;%U&XY3<DX&]UL;,$H(H)4(5+*0A8:U*Q(SUW?(RR*E\>HM
M=5&KY]/'D@18SI!FL802CD%:GFOK/;.X48C6C()#EQUY2?NJ8:66LD,0=X'0
MRH.VOG;OO9\SN*8YPE#5"H[KP@?\1DRD(]P5D!7REF`!7B[#?4WC:_E?.P(]
M!>96)O<Y`#)AYT$ZROLYK,A'FE(4]7C]U11"6-;1%,WV.J)<>RJ'&:KTB->Y
MSNK,VSM.38<BBUL?)8@N0J/781T:RIC!>-O45DLC;F1MJ7M=/N+!I&'EXZYF
M"@*U!FLKNI#$DK3D5@LM9._HNMM)()%8))UDIN2`96328GF$4P[4D,JP9CC+
M6'EN@P3B8R'/EYW%#M'"C.>!%(&,JA[^TJ(G]&L_&,OD%^$4&W(O?6!)'4![
M..^^Q._0?'>CMJ.1:<7N8M._`58MQ;BI^EC71S@2NZKY?J:.EHW\2=6V:02I
M7ABL>]]/.SHY5?`TU>VX@095O!AV5J"^C3:J,LB+=U#+M\REM`2(QQ*!1'+F
M8[UV5>H.1?\`F#P2AXDA254H0QXM59Z06Q"K*0TJ-9F5W49'HMP%8/D:L%5M
M7FJEU5G%@9!R2^D7EZ+5='4IQ=L=OK-"V/*F6+)6698.>:UDSI;LS$&AX%8M
MU"#/FCKX-;LZ+3U)+"(AE82Q%(<JSIP2N:[8BW'+!*XM*_2`.9V+<3`DM6Z,
M$:)"%1]W6P&M*V/FA&MOY8X?=RQ])=U7FH9@JK?7:AL28-BL?OK58@Y?J<=N
M4J0U\9US4#N;&!?S*ZEXICZ+7VS)D4Q:G:\CY5VWQ=KQOEK!\7PK@QWNO+>2
M,D]T=D9@O9I[LW`]8V-P<HI0,UY2M8(Y54V>E:MU@F7)^ZK4BL,6)CIL;MG=
M_P`,*:S;4MKK853$%MS\@2E^35Z]#XM31%84^O<X:XH*PO+T'!:JD:R+,+>Q
MOPZN2O[M,XT?QGQKHG$`!DK+Z_=W^_U6FR;[FN`HX%JRLB5E78)&641\1J>H
M>X8EYYIZ9Y./*+O6N3<P]=255I9Q)EZR[.Z<N(#]2]G[CB#T[3<O"L^=L7\+
MBVR!-5V19D76T\U$5W"I*JK.'J,:QY;&EYFRE/E0ZFELV75-)AK)Q;JPE-=4
M5U4ULH&$RALZ^:"=`90SK;]PG6WNA1#M&IX]BP+4-+SDRJU`>YU]%P8MY<E9
M68&VP/!!Y!>"UPS">+5EO*FHLP,BPM7C56?BJF6:.)1ZW12,>DU\@R^FS^I9
M=R1&`YI>$'.RF@SMW^[U50.OD2%GSW4T<`X9)&GW)(M/29S.LR<-T?,V>D?8
MSLH<OG8AM`@C&%*/*_'5INI6R:/1>XL!Q7D3,)5+,[^H9=4@6`0A0E@45>4K
MJ!,++_$UXRHS%WX``3;D$(E57HK%36\FI8S8+0JE;'LX0^KYEYV;$>\),=O^
M0'(A'SK+&OS<#&!E$CL'^T8B\D\%\BVFHJ*.(1T8MPZQ"&RF(>1&C@CN%Y8"
M9*.)%V/C_!;.9L(GZK5&52J,Q\PKX$HO%69FG6WLP;:R4.+F9I@\FH]):`2`
M.%%AP,E[4K!*FXVJMK\WK1$*S"L&\D1A!?QYQ-<8*[C#9'@[&VA[/D#:T8A@
MC0&$RQY&#R^*Q]G^)%:#\V!0LLQ-[(&6)6IWK7_36)_J.6F10=S6IKJJ;J?.
M!:]MBR9XO:4/\R'5MP[Y6H/9>W6X>6HA;G6_(OK``7[HG'JHI;B`OJ5XXM`^
MFQ8UC[(<1\@NU&/6QRMN%J[#/2YDYN:UD=XY)+J&[]ZFVUE6Q`N6(9ZS)<F6
M8:*,3WN>KO\`78YG=^W?A;O3M0GT7`'.L[<3Y0JL>OTJJ@[D`#6F[;[;[R>X
M8WKX]@'XFLLWI7#<NOG9V4#8^=V<C8$EIUT!^.!.=O5D-"B0G.A/BR4#(`.:
M4X^:Y+ID;W:71LFQW1Y;6))$VL"16JC80_'VE\]]YD#M_"?O-Y$@Q'X8081(
M,B>)YD>+GH/9?RP4GO',#[J5@P0&)&<>0FVSD(:.0%0,&*ECDW4_KRG7T+IT
MTTZ::HFFJ77^<T%$PK`/NJ2UJ6F(U[QA=8P#PVE>T;F/<P:F[JC7(JHGZ*G4
M^+<,?)KO(D(ZM'V$'^S6)GXQS,&[$!`-M3I)Z#DI6?U3KE%DN,[7B7FWD.QD
MM?'+L5FV<&/,(UTD&JNKVPT%MEV%C-BML84X$B1*I)?Z)9Q([AHQLV)*C"]:
MR^YT]W['C5KNM,*2.A15"*^\P00%M7^1B#)1T8_.G;>P9/MOW7FWO*ME<F4,
M=Q<]C6/5M')6!9Z'_P#-12(%M=E:YU#-&P(W*)!!CPCH&2*0S\F?G9/]DU<5
M4_[R?5OD-(WNQ'()J]U\>SB:+BP8\3YB1(\`XWG[&B/M_=UH=#6.:CTU4P9!
M+5G8J?\`:29&TQ.\;M!)*#)DC=*GVB!1BU[K1BR&,?&]CEK[PT<R&DJKWM=[
M?ZFHYS?Z5:Y7=KAZBB5"\NL>(/\`,H(V^S]\ZC/HN\6%O3CB6@P1_)809)\9
M^8V(,ZGWQ6P*<L,!E#^*]CECN(U'LGL_LP[C/R')%675V';P(-%\F)V5/)K4
M:Z,6N]P<S)G?Y'JK#>&'@?'^$[T5U8K5"($2#'U#97K)CDC="/#;J!!IGG,,
MV'^.UHCM52-"L5B#%=,>1LFN8CU86O?.B=B.9V]9G(YR]D]KTO\`(I;D97XS
M_+X-\X.T]1^P:B!L8(*P`P\(V#B97XKR7<CH3/3S$?0N)7QD/ZCGB^2M=!E/
M$-LB(BNBRX$H0F,61/JY1>XWO;_2B-[,:C4&@@6-QD!OB/`]01/0,.H'[?'5
M5+4U\X)K_P`)C<=&4@=64G8D?J$0)59!&).="++0+?*0/NY\:R0(C%D0+9"-
M?^/*8I2.85S?%B(J/<O^IDOXJ>/,">GQ$]"OQ'Q'CX#_``ZCYL.9J+<>OP:`
M25>>A$F#$#Q/BVA)]@Z,IYKO8]II+FN#&1TJ#((UXRUTR&1Z_P#(6:*O?MW1
MSD7Q;_J-`KK#<:^D#J=B/`@_%?\`6?'1KKBG.W<R>@W4G8J5/\K_`+S,#^77
MEOXS%8>37E?$8QTR('V.)WA';_S8H\AC@E$:"\CS,3R>-BH_S[?U/<\Q\JL.
M9V/VCI(WZ]#X](\`*#TQ#.A-8W`Z^4]0#L9621N0-Y\2?IXCV/<D`Z^R&0+R
M)Y#]1#D<-*Z:R*_N@G26.:$B)V1A.S?!/)HNBN"/O!LP/[/YA/RZCXCQ\=&K
M8$^BVZD'[28XL!\_I/P.T#9=0R/B,(2SDAD@4SQN9(B&*)L68-Q7V-<>.49$
M:\SR$5B/[M:Q53OXJ56U',@5*08\".H\"#^SI_&-49JPQR'#"2-P2(83R4@@
M]=XG8`]8+1-'CPQ3V3&G]]4YB>31#\#LC^^..;4RXK'G6*Z$,RJGL\U_ML:/
MNC6-98K.U?"(M_=,$A@=IF/#XDGQF]DJ6[U09Q_D-XD!D(WX\0?&>@"]``#$
MKADDLD33-$P[8\1A7+X?M)E]E?9Q2*Q$(&$Y4<9JJY$$151&=E\C/:0"JB8D
M_P"]XJ?F?#YCQT6ND%@['B&@3_@.ZN#XA>K==CX;S4)DB3%602;6D%</03GS
MHK$8QED!46!;,<\;6.9:QT>US4[.>YJ*WN_LT=B*K`!&!I^!_P`)ZK_Z)_9]
MFYGMLLKY-;61DF/,!_,/I?I'G$@_$C;?8>&*XAF28H?4:0)EE%B^M%`>S!$\
M+6M>UY!$C-F`[*C%;X/;V\6JSQ\Q@+P8RH/$GQ"D^5OG!\>H^V8M4DN+*Q#,
M.0$;%POG7J".0\(@CH"(FU(^6L.8[FDH\]#4-#!;<2J^Y>'L:+77D&SHK&TG
MR7$[%S$!D^:.L[M?)NK-J?CJR%&ER^LMLJOLU#WY#3>W$%9V+*58*!_C,*7Z
M+6GU2[(FM>G;[_<^55B82QAIS*O&X6Q7K9V,[U+R<5=6OM'D(J2RS72_KS'7
MO&K1Y`@3+7![:KKH[Y=A99'20(,4:L0DF9,IIL>+'&I',8CS'(UJ>2HG=?U5
M.F@U_/3^!M=Q[6_,V(_C2YUV:?'_`-Q\`<^\R;VDXU^J\[;\8<>\M0^78--!
M!BZWE`R28V#VL<M0GX)+6"ZOLW.:V*\[#(8'K/Y+_F@?RE]X_P#4KXGXW$LQ
MGQ[:P_!Q6[(Q>MB"O-36(5QQ8$@E>H\#_P"YS\AQ_P!PWY:M[)J[C_3<ZK,J
MRZ+C7ZM9NI2U%2Y`5?TG%IY-62ZD`A6W4[);K$[GBS82>/.4\9HN.-Y%"64N
M7U44,>195P2*)UWEK:#)GYW;9MSV_P!-E33)T+]4:\C"=V)^J?Y?_FG[(_,W
M!_%^U,Q;,E5!LQW^[R:?]^HF8\/43G6?!]?S_?G!^0/YI?D9W3\![_[;93@6
M.11FU3;A9$=/2R%'$,1!-5HKN6?-6-6UUZ'KQK3_`%_1.FFK[XQXLY(YJN;B
MCXJRA-.[,!)+V^HGV<++<9<9UX(Q)LJUY1Y-N?#,8N)$@A>=T9[Y%L4+%?'@
MG1%Z\?\`S,_/'V%^5M34]YR/Q/N#C*86.5>\_#U-^%"G_%:03_*K';7TE^1O
M_:I^;?Y\WIE>W,/\#[0YQ9W/+#5XH^(I$>IE./\`!0K*#];H-]89Y=W7'GT5
MRW_&Y\%_%]_H_M+E#YO^\J[Z>^@^3^#\'<%X(R5/>;3)NT5?F=C92R2+_-XB
M%5F))T1V1:F6T"N`12E;%%^47YA^\K_S!]Z9_O'(H3&MSK0WI*Q<(%1*U'(@
M%CQ0%C`!8F`!`U_09^3?Y:8OY._ECVG\N,3*LS<?M>,U?KV(M;VL]MESMZ:E
M@@YV,%7DQ"@2Q,G7]`2\HZ73TMOF])45>@SU_6SJ6]H;N!%M::ZI[.,6%955
MM5SA'A6-;80S/$<!F/$43W-<U6JJ=<;KT37(:-_#3QYQT6=4_*?V1]Y_&G%]
MG/ESB\%\#\Z5DCAZA6P(IIX>/,MRKB>2)'&<>29SG(&EE1(H%7L$(T1$1J_U
M">H!.MO_`)'^!_G+XN'LK3B:BTU_R;R?+CV'+?//+>QO.4^>.6)\17K#-N^3
M=7(F7<^%!\U_&KXWXE7%7NH8PU5RJU1F+=>FK[X-^7N-?G79?2W(6(G:N1;_
M`%'S(7GCDQFDM8=E7P=@N)RF%)'RD>)4UQJJ@2DQL5_XYB2R_D.([V]G(QK5
M"28^6N</\2_`%3-Y.^\_Y%[+B6?Q+I_N?Z+T#\!F-'F;/*:N!P#P\<F!R.IO
MJ"]#'NJ#0<WZNKM=C8QRB%[1SX3U;_2B]-7N=@OP&MW?K;X,X1^PI?'VMV,_
MD;C#FCB"392^'_HG@C;3N,><>-/WL8A7M90[&O#+!8YB_&!B3Z:UB6-3+\4<
M^.KT1R-6JQ7[-8:XC_BZXYR/+V&YYY[^@/IS[8Y2XGDS+#ANP^I-]GM%C>(+
MR=&6"?7X'C#!XW`<?0=ZM>]P&7LNOFVD=CE6.8+OUZ:J7,0(&L@_4?\`'AQ#
M],<B9?G:MW/,OS?]+8O/GQ]!]&_->X'Q]R9)Q$B42>_!;0<^HT>.Y'P[;(BR
M15M]56`HIW.?'4+GO5S5`Q`CJ-2GS-_'1Q1\\\I6OT)J>1^;_J/Z8MLR3$L^
M@/IO<1-YMLKB)$D<V=B^-:>FH\MA.,<Q:31,+,#25,,TY[4_)*5J(U&A8D1L
M!K.7"/RQQCP%L.5MUBC:B;I.9+MM_L9NEN`6O>:VSO+=S*M@:^#^%&+.T!W/
M:Y2*J(Q._P#3^OI'O;\TO<WOWL_:NQ=Z&*G;>S4>ECK364\O"JN7EVY$+4H!
M$1YMM]>*?EA^0WL;\I?<??\`W7[9;.L[U[DR1?F/DVK;YQ;?=]T%KKX*SY#E
M@>1,)OY=Z-Q/\;<*\,<Q\A<Y8J!=AVW)'[Y^[CL+,$NCJV:.]!HKD>=KF0([
MZP<RRC,544I?$;?!O9JJBYGNO\X_>GO+V=V_V/WJR@]E[;Z7IE$*VOZ-1IK-
MSEB'*H3_`"K)/(R=:WV!_P!MWY9?EK^8_=_S2]LTY*^Y^\^OZHLL5Z:ADWKD
M7#'K%:FL-8J[%VXJ."PI(U3+/XEX9M.2.:N4B'V<70\^X"]XXY`B0KZ,"E-0
MZ&MIJRPD54%U40D&V\*()6&<4J-,KW>"H[LF3B_G7[RQ?;?9?:ZKA-V_L'<*
MLS%9JF-@MI>QT#MZ@#5S:RE0JRO$3M.L'/\`^V'\MNX>\_<WOJQ^YU]W]V]H
MO[=GHEZ+2:,FNFNQJD](E+8H1U=G<!RQXD-&K2N/X\N`KS@3(_.4V3OTX]Q6
MQL-Q3E!I88]"ZZLDNVR&S;-:1X)$)$OS^(T`Q4[,_J7M^NVP_P#N%]_8/OS+
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MDIK4$&\5F/"`%3[;$T"6(BN9';[O[*>:]^WCU=[2_,SW'[+]YV^^^SC&/>[3
M>6%B%JIR"39"!U(W)X^;;YZM]_\`Y)>S/S)_+6C\JO<39H]L8Z8JH:K52^,1
M0M4V-6ZG91S\FYW$:IW)?R5PGR[P]D^$][GY5UEL+2TE+C[59[HVMS[:"HC4
M<.PK[Z.(;V3CU\1C9*.&Z-*[?W1.1&HF1[:_-GWK[1]X9?O7L.0E/=,^ZRS(
MKXS1;ZMC6LCU$GRAV)2"'3^5Q))PO>O_`&^?EE^8/Y<]O_+'W7B69/8NU8M%
M.';SXY>.**EI2RN]0(<UHHL!4UVD#G684#6;B_\`BE^8.-]C4[6>7?\`)4[/
M2X\V@JN0M!76.?KI$(C3P"$K*BCI4LD@G8UXQ27EC>345PG=>E^Z/^ZK\SO<
MG9[>RT#M_;:,A"MKXE3I:X80P#V6V<.0V+(`\'9AKQ'V)_V#_D=[)]QT>YLE
MN[]ZR<1U>BK/OJ>BLH90FNFBCU`AW"6%JS_,A&MH.4?EKC+EWEKB?FC5FT[-
MAPU-CS\@.IMP0J9YXMO'NA?O$$E?)+.9^9&:BHPHN[.Z?]O7F'M?\T?<OM'V
MGW;V9VH8I[/WE"N0;*RU@#5FL^FP=0IXD]5;??7NGOK\BO9/YA^_^P?F3W]L
MX>XO;EJ68@JM5*2R7"]?50ULSCFHD*Z2NVOF7^6>,LC]#;;Z:JC:=>2-]2+0
M7HI=O'-FVP7`SD=5@U3:X1XY_7EXW]3I#T[J_P#3^I.U>Z?FE[F[M^7N%^6>
M4,7_`*<P+O5J*UD7<IN/F?F01-S[!!_+OMO9V/\`(?V/[?\`SA[G^>&`V<?>
MG=L4T7AK5.-P*XZ^2H5AE:,6O<V-_-MN(ULYB_BQ^8N7=E:;L;=KQQ>WTL\^
M^'QY=5M;3VDZ81Q9\UU1;TMU%@29Y7*\OXGH$]ZJ]6*YSE7TGV=_W2?F;[1[
M-5V)CA=QP:$"U'+K=[$51"KZE=E;,%&R\^3```-``'BOYD?]AOY'?F)[CO\`
M=*#N?9>Z9=C67CM]U5=-KN9=S5=1>M;.22WI>FA)+%.1).8N+_A3YOXGXNW'
M$N>QTFPSW)E:E5R!:7MM+EZ?50A,*V("9=0_V]\$%>IWOCBA,BB$1RO1GFYS
MEX[W/^>GYC^Z_=&#[L[AF+7W#MEGJ8J55JM-#&.16MN88M`#&PNS`!28``])
M]B_]J_Y,_E_[%[I^7_:.W67=H[W2*L^V^UVR<I!/`/<GIFL5DED6E:E5B7"\
MB2<,<4?Q6_,G$_(E+R+#-R!K9>7M!766S^QT%;/S=):QC?E09R0ZZBJI-B:O
MF-88*23$'[6-<]CW(B]=G[K_`.Z;\S/=?MV[V[<.WXE.54:[[<>IUNL0CBR\
MGM=4#K*MP4&"0I4'7FGL'_L,_(_V![RQO>>.W=NXY&#>+L7'S+ZK,>BU6YHX
M2NBI[#6X#H+'9>2@LK$:RMQE\]:]GUAS3]-<IRJT\V=!K>-N$ZBHLI4R-1<:
M0(D:3.L[(9`1FANKRT<]S@*CVQGNDJUSVF8Y.5]S?F%VAORI[+^6?M9;%I1W
MS.Y66(%:W,9B%1""9KJ2`&V+@5R`4(UW_LC\G_<*_G[[E_.[WV]+Y5M5?;NS
M4U6,ZT=N159[+`0L6WV22A!])VR.)9;$;6Y,R**=$E0C^7IF1CQ3>#O%_JD"
M<(G@[LOB[P>O9?\`8O7B^OI;7/W"?QD_-7'7&_Q1Q7GG\C+E_@;DBTY3X'6P
MV#)=F[46]1OJ66FXFI4"335GX7)%CX!1D96O]2^2^OLYJXL22?CK8[ZC^;N.
M?KW@#D[YLY;70MXXY;H19S6+E+=*'0I7!M*^W9^U6[HLY(,C\NM'W?ZG_P!'
M=.WZ]^FJ`E3(ZZQ9]2_!/S_]<5G'+^1(VXR7(O#,@DSACGCA[<WG%W.W$\V3
M%CP;(F+Y'S)06,>#=1(K!SZZ6.953D8U3Q2*QBM:JK%>G36(>'?XMN%^.^7\
M=SYRKR]]._87+G&7YS^)-/\`6_+[^3ZWB&=91RPI]]QOAJF@R&`S^LE0#*!;
MEU6>V8-504@?DO=JI<D0(`^6LUU/Q+Q53_;VJ^^(VFY7)S!KN$JG@:QRDG?S
MC<01\E47<:]!:5^`6,@8VE))AC:XRR'1V]R$8!IS%*]JG(\>/A.MP^FK=:D_
M:^#N>2N!]'D:U%C1)AJ^?/O`A+-D9HM%/BW=7=2*L,27*L<\R?7M!:_C,?-B
MP#DE`&9P%"_K_9&?3VSO]>9;NZ@@*3`?D"K*&D`/!FOEY6<!6*\I'F_YJ]GR
MN_>T+^VT>6IBK-8`6-1K8.CE`"6KY+QNX@NE;&Q%8IQ.FW%[)=+QUFJ">T46
M\S69I<_?Q0$CVBQI<.!%*S\:4)S03J^Q!X'B3`/4$R$9I@D<,B.7M.Z%+NY6
M9%<FBVUG0F5D$GJ/`@[,IW5A#`$:\O\`;XLQ>R48=P"Y=&.E=@!#P54$01LR
ML(9'4\71@RDJ9UD!L1KWN.WP1`L5QAND-&)S540T<P"_TF*,XQ_\*>7Z?JOZ
M-[:[F0(/CTV_M\!$ZW`K!//;;J)V\!T\2#'S_=J9:96.9(<4+C+(>)["$![#
M.<-3L\P._N2$(%'H]SFO:[P_J5?)6MMXSY8,1\_LZ^'[NORU*'((<D<N4'<2
M=IZ>,B9F>F_6!X8P;Y'@9\)JO]J19"%"\?D1J^MH7^Q/Q)"F[!>PBM\7?TO_
M`$7JI)"RO+YC?]_Q'B(_5J@`+PQ23,&1^[X&=B#$'8[:A@,25'&QHR+_`%^T
M0D>+LXCU&([/%ZO_`-&,55:U6D5[$;V<OZ)5E"-,_IX?IT@SJU&:Q(`/Q`^?
M0_ZAO(`WU'-*<1@$>C4(U[VK)\W^XRN1'!&YSO+L\:#<K516]T3]&J[R=U:$
M@F.GP\/T_3X:O:PD"?JD[^)^`_5X?WR=2SN[V*)%(/Q:QSG-;_:1_FY&^I%<
M[R[,&U51W9R*OZ*JM1_5PZSU_C^GZ?+49W'$2/X?J_8.N_P\#J?<,@B%CI(&
M,4A@"L0K4*)PC>LP&/\`^[])4&550B^/K5?U7P5RK&""`T>82/[#_J\?MC4Q
M!4E.0"L`=]Q!W'P@P>NT>)B9C.$0C'#*\$.37"<T:%(9DF=_S*,8`'BU1,/#
M=[%\D<B.:G^Q6JO5`P!D`E6/R@;=3]NWZ'5_$D0Y"V5C:29;>('A*[_J^S7T
MU@)7P9(GO6>@FCF!*QK8IVQ?`8F)XN9[D-&8WW#[(GZ]U[JJKT6LPRF/3\/B
M)_N/0Z/<LI8I/K1#`]#$`>.\CZA_?JJ"(C".AG5Z4]NU\N*T;V-!'(]R*X@G
M/:!5_#5KQ/&C6*]41$:GDU>HB)'-?\Y-C\3_`!Z[&?#4ZM#>D_\`RUOF$'8?
M,=/IW!&T_#<'4O':R572O80))E8\18RN<YA)$,7M(88G?TE+Z^ZE:BM_I;Y.
M_I_K5:MY+!`/!AO\C\_A\/[]M6(!90TD&VL@CXE1)('B?B-NDG;?46P7N]EQ
M"8!\6:B+/@C8I(T65(_[V&\?]MKD*U&O:K%:X3E:GDCVM>M*^AI>>2]">I`\
M?[-^OV2-77=?Q50'IO\`4O4`GJOAUZ[01MO(!,\"&^%:OIARG`@W<)H0R2(A
M@L22%##5/+L`_B95&][&M<J.7P\?+JPN'I]<B71ICIT/[1\1^^=3)4:LDXP8
MBFU(!.XW$_8=]B1'4Q$ZM^XO&4]?!K)\1[+X<P<3,1X@!1IMR='2)3H3CF]`
M!1(H6'EFFG<*+#B@*>208V/=UD4T&ZQK:S..5ER22%&PF-R23"A1+,Q"J"2!
MK#R<H8M*8]RD98;C4``&<[GC)@!0.3FQB$1%9K&`!.L^?.?'US63;KD6X;'A
MNU<(BBB1HQ8L:=(LIP[2?;5T20($N!0L](8T+WM_)G-$^:]@&R!QQ\_[D[C3
M:B=MIEA4W4F2`HXA21(+]6:/*LA`6*ECV/L?LN5CVV][RH4Y"F``0&+,'9U!
M`*U[!:^7FL`-I"!U1=KNN2UZ+ITTTZ::UO\`JG_\%)$_WZ7/?K^J*G:4]>[5
M1KG-7]/]415[==+[4_\`>P_]4_\`#7#?F'_][I_]?7_'7%+3Y>YUO%N-K,U7
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M*+N.QLJ=>0@6!U`&LN?LT*6X,F7@.0(+U`L:73LOL5J8;XWYP+)(\*WL^.:"
MV8K;$+7(^2DHB.:CO-7N>KM/ZSH"B9&.PF0W&RLS!62JW.O0_P`O$?*(CH_P
MM5I#V86:AB"GJ46K'(-"NV-6X\PF6YF1,R23;]Y7/SM;'+3)8+769#MA3I?[
M147-!H9X5GKC-W%H+D$&EW,>P<(L$T:S@QKFL*&5#7S#*$')HL&1:1=Q]58D
M#DRN@,>I474EJB)#!D9JW#(^S(3AY=#85"MB\_0L)XL>"/78PY>AD"MPJ9`:
M#64MK6^HI95NEBK;UE66I#R[275_BPAF\GV-W&2!1&\[*Y6$6^E1/8")0:?-
M:1\!)SY=HV--`C&6$$K%9UD5VU!14C2Y'13+#RK/$'<NCH&XA4Y*9-=@,ZP;
MZ,AG;(LKXU`_58.-9\S\381(6NVJTU^H7M"NL"ZEA&I^EX\O&0(]Y+LM!0PY
M%7/%3OH:#':+D7>P6RV1S%H*K7:3+YS3\=9,$D*.TAEBK-\60ZI#^QQ`1W]Q
MH-AH1:['##ER>Q*:C$P[5H[I=9!^Y'+CN]O&`&GQ>R98I7+MLNIJ:M@GIUT6
MY.0LP36EUM55N-2"O_$MP]2!5C\^19+XKL/H,O=5UM7:G8UYS2SG%L:+C/B2
M(3+3SM(:)H-=&T_->]N[JBAS40LZ!40$FG&XRL>DAW<N#9G8^70U-E5+*`!Z
M;7Y!Y@=4K*8U2JY&RM8_$'C(X]-M1VG-[?E)DTY&4CEB1?7BX8-+'<67"W.R
M+'K5M[*Z:_48%B#S/FL&=FV`2+4VL:.4MO4C,.NC60=!$N\B^P%96TCC:W<.
M3%Y=_P"H%D$+4FQ(\L8@&],R+'DC0<;85Y):;JB0$>)(X%;(XJ+EV./Z2D^5
MBI)')'93+:>[!"<<;)52UE8(4,+!93R#.<9X(S/Q#!1ZB*X"MQMK1UXUVV2J
MT$"4V19QAAL91:P9B2B6)EDVDXVGL[:MS#`,GZ/0R(%IK(<"+7U]W*;-+!D!
M`$36%8W)%V-8G&HS6`W2-E'!59YA$!6MG9WJ7B'5F8R"<!L?-IL%F0H%[%`2
M2QEV-K.M4<K;"KW)6E==[AS6ZHB@,!D\]!9PH,*IL<[I-5?Q)T.;?UE+K\K1
MT>*EU4SW1L?<3C8/DRVNN0F'8LF]1IX\.K,5E>-3&CG*[5KD5.[75VU4XY4A
M&:NQFL#"#8H]6E5ICRU;%G`-AXAE`W[X=]528U]%^1F*X:Q4NIKKH9&D4NQQ
M\IWR9\V1#*E1(I7DR.QM2[D<AU_H%QSP'6Y^?%>$L/5:72_]1Y%*7R-);-R^
M;L8>/P%385DB4\D8Q\_,?',JO"K7>+^LJA>W62>Y=P:RLS-:)Z(8=(=U-EK!
M@(8"Y9&S3TUKLI^]4\5['V=*;E(*W6V_B2AW/*JIEIQT9225+8SE6\RP8.L5
M?]&.3)-P?0W\:?>SY%@>WMY4R7/L[FZLB&=,/*.>?XOFSIYVM:YYRHU2HBN<
MB=DZV_\`6^UI2,?'*UUA0J@`*JK$`0.@`\`.GAKGO^EN_69)S<Q7NN9R[EF9
MGL8GD22WU,QV)9AON3&M[>.DC_\`B&IWA-`DF_>LU%ER8*4DAKS5NV^>:Y\5
MUK5ZNXDV*P948K.YZZN8-45@GRD1SA\%W+E_TZX(8+P<@'D-C5EF>+5J!((.
MSO/4A>A]=[($_P"M:V0HS>K4"5],[K?VU8YI<Y;B01YJZP.BFR"5[2=>)Z^I
M].FFG333IIK4OZVHHEOCXLJ9!991Z.GW5_+AK-;6'D0,UFGZ\H(<\U'HH8I9
MIF:CM1DF&>,5BN:1KFKV7KO:%[TYA5&XL[U(#'(`N_IR1R0D`.?I8,#!!UYO
M^9.'5E=L6RU!8E5618R\N)*U5>L0K&NU02U2[,C(PD,"-M<O[K1Y6IDUTH>4
ML9Y%CTUR=G^<XD3Z]T25I+IB'A#^>IP7C`3D.U(JG](I*O8-_9`QT'ZE1C9=
MRLAN51+*/NK3,A%V/XL=?1K&TD;D=6GP'*SNW8UB6+CV.W%'/W]`X\3:^Z_T
MUA`.3:?-Q#2%.RIQLJ1L^-8%4CC<=7`HEO%E4T<9]9QWZC60LI5X:VSHI'_0
M8I8MU5U^/KXA""8K?,PIPBN?*(1V<N%W.RV!DH70AC%=VRFQK5>/Q0E6-CL`
M3X&LB%`UJG[KV&G'EL&P56J4`-V-!84I0]8/]/)%B+36A($2RVJQ-C,;C?R)
MCY<"PT!..KVTLJ10;%*8>@P9VVH0:L_*5G)@-%\^(>PC0M"]9!8B1'.D0U*!
M@G!'Z5QAV[,1UQQDUI4\U\N%HXDUBA0?^+@$IL&Y;-#$ACRUG'O?;+*7S&P;
MK+ZHNX>ICGF!<<MBL=NE@MGF9.$LG)`I5>&KGXFY-S&NW57Q+F>,M'*/9*RD
M#EK'59&[X[L68>7_`([*T=O12N"8L)EC4.B&4EC&&RUDM"YWY!$1$;B]W[7E
M8>`_=\K*K"KYO4%=BW+ZHYA%891,-(A&)K4GZ1XY_MSOV!W+N]?MS`P+V>S[
ML5-=2^,WH'TFM>L]O"\D@S:H%S!2>;>%W:7E/A^BU,_+<<\6U$G0YE\D-OM.
M,).3@:C'V;##KK"10W5OQGL9=4^$!ZM).ALC>1AHD8CD5CUP\7M7>+\1<ON6
M4XQ[8*UWBPI8L2`ZK?6&D]$8ML?,.HULL_W#[9Q.XOV_L?;ZFS:"0]^*:5MI
M:>+&MWQ;V0J-C8@66'D8B#K!J<N\+W\7+SYG%O)$R]W9M`]!S-=QQ8VQ7DQ]
M0*XF7FCL>%C$LIEI&PP!H=SS/_+>61[F+).]=[_1^]X[VUIEXPQ\<)TKN"_Y
MC<0J#)$!3:3$`<87B>*C7)?]2^U<VO'NL[?G-F99L^J[&9S-*!VLM;!/(L*%
M'*6/,L_(>HY.R^'S>$Y#CWDVHQ,R@W,$\O20<9:SN)S6&FK(.MF;.1:U`I7!
M?BVFAZJX.!PUCHUT88H;D_'\6,YC.R<_MS5UW7K9@L`AL47PA-8K"M&5]1K4
M&9ZDO]4D]YVG![1WNNVW&Q6I[LA-JT.V&6M5;FO+H#@?0+G98X_2%J(X0!A"
M+S_Q'3R:_`1^-97)U32MSN0RC=/R7QOIF0I@-"'#3X&35G&M;NX$N)<$$0HH
MD@3)Z$:80VN)UO6]O]XN5NX-DC%N?G99PHN204]4&S[YJB"L@%@>,$$P-<G7
M[S]MXMB=F3`;/QZO2II]7*QK>+"P8[+3_P`*N0K*\$A&`LD,H!;5QZGE7C/.
M-FU&9XZ/D;C\83=2SC'79N+;VZ2BQTM\S;[K4<8Z"^L*F'.<]LO\>P4!BQW-
M<PHE:KL;%[3W/)XW962+J9^[]>MRJQ/%UJ2]$#$1QE)`(((/3.[A[B[#@A\;
M`P3C9/$>K^%NJ5WDCG4^1;BV6,@:>?&SBQ4@AEB<?BY)XXCQH]P_C^]@/G74
MG0U]62QX1-/+#@ZC4<AFMQP9W`,5&4;;R?(CQ!(Y1SA)^"Q/3#<UFQ/;.Y,Q
MI&16P6L(6C)B2B4A9&6?-Q`9CU4_>'=Y.E7OO8T09)PKD+VFQ4+8!8JMMN27
M"MVX?=^HS*@Z6#[H>6H@7G0TN,U;:6IC8B_APIFBQ?'L$T^SX:`\8=W3Q>)J
MFQF%!P&9[C@JKE'E$,AI*2F.E(JR!JYN%D79N(7N>^MG6NRX@+D]:F.0P$Y?
M0LNQ("\?)])UM</%[5W(58R8ER5/?1C*6;"$#(08:,Q';SN$>2`6?F#8/.LC
M;V@^2R:>./41QTD5TJWLY:1RIQ>C&S8.UK;@SOQP_-SHS8Q+S(@<P2?T)%<0
M"IZRD:O'9'NX8K'%;F0$43]_T-;*-_QDSQL._7E#=0#KTO#_`"W;N"#N""I2
MUKF#^$^I;U<[#MD0;*5('3AR2(9AK-O"OSC-XET-?.C+4#K0-7\MT>QK'2C,
MBP-%%K(PZ[.\:8&L*YI]3*(:7)<>2YC`B1?6-B-T?>_<J=WQVK?GZAZ2&C<H
M6,O=:W1%`58623U)UU7M7V-;[<S4NK](4#ZH9),+:$`6K%QT.]KEG;DQ`5>B
MB-N^N/UZ7ITTTZ::=--8NY4XRK^1Z$\7M#BW\>.1E192PG+&_4H)3JVT9#D1
M)IJF5)BB>JA,*3$D#%+BD#+`$K-KVKNEG;<@/YCCD^901/0CDL@CD`2-P58$
MHX*,P//^X>PT]\PS7Y5S`OD8@D=0>+\2K%"0#Y6#(P6RMEL16&N@.'N70*-R
M3.Q1$$9JO+F+)?R1@)&-()-*&J6Q--$5WO,Z)&<=R^U1"(KNNC;O/9VVX^4[
M?SKM,@1+0!X#DT=)(UQ">V/<J0>7F!!ZU-N`03R(3D6!\S%%Y'S<58G4,?"_
M*8_5VD*JC[L_J3./8^*\2"+`>)\UPUA%[=U8B)V[]D5$:SQJ>]]J/AU_W^OQ
MZ=?G_IFT>U?<*Q#;C_U72(*QR^D_#^X1`?PKRJH!@0KW#8)T+P>S*E:L4AWG
M8Y4-,54_$(55&K51[>WZ(O=R.N'?.T\N4;S/_F=8CX>/C_JBQO:ON(H$!/&.
M/_DG:9\6\)V\1^LS,BX:Y4[&;(,LMA@CC%22W,.<5@5:\!/:.6TS"B5.R/16
MO5J(CE7LB]6GO7:MBH@@SMS\>OAXZD7VO[AW#GD"(,^EN!T,@S(^/7XZ^/XH
MYC?^I"2BDCE::.7SR*$61X.AO.SO/\%]T?Q<1A$];V,1OCV5S5#NW9AT``(@
MC[SIUCIX'H1N)F?'5#[<]SGJ6)4R#]S,])^KQ'4'8@1'4$;AGE0GH[$8/T3#
MR@O"/-L>'\ERD,%KW3E<L8C_`/5J^2_JO_I.[AWKM0G;JH&_/PZ>'7]/AH_M
M;W"W&#'%B1'I;3U'U=/E_>=>&<-\IH5W<3?4>,:.\;FY9T8'J(JQ""$M@]PU
M$C_[#6^3!L;X*U&JK5J>]=JCKN"#_P"9)^/A^WXG?YZH/:_N'ET\I4B/N8$=
M"!RVC^4#8`1$;:G)/$'*4AR%[`#(_)!+=)"S/M*LD+F.>5G>P<P+I7@GM\6I
MYJB._P")._5B]X[4HC<K!$'GT/AT\/#^[4K^V?<#GEL'Y`R/3F1X_5M/C'7K
MUU;DSA_EMXU*&HG,,XT]OA"=@(Y&A*G@UJ-->+$6&5'*K&+Y*-.[5:C5\>LE
M.\]H!AG6('7U3O\`J69^)\?MU@V^V?<A7DM3AY;Z?PX,'[;(XGP&\=(C;57A
M\/\`*YHQ&R!DA.,(<60.0/(RB2&#(P@YQ%!:D"LV.C?$;^Z/5/\`B7R:UW4+
M]Y[2KRI#09$>H(^6Z]#X_NUDU>V?<35D."A(`,BDS!D,8>.0Z`]?CN`=4:;P
MYRI(<LS]HMWRR^J-)C#;QX"/*CB"@V'*\VIEHG]2([U(SQ145&]F.5G4R=Y[
M2HX<TX#<'[XD'X#R#]L_OWUC6^V/<-A]7TK388!`_#`$`1)FX_LB/AL8U-0.
M,^9(AXS!Y^Q%%%*(=K7'X_.*.,S3!D@:Q=*D@\>2(BJYKG^7?MV<UR*Y;;.Z
M=F=238I8B.EPF(@_1`(^S^[4E/8?=%3J%I<(&GKCD"9!'^;)!!\3/3<'?5+;
MQ5]!1XLP8FMD*89*X,4M'AT#^U^1"B:9SN12(]X2N;Z$1&_C_JB*K51K9?ZM
M[>9U)V@R3RMGEL-ON?V_'[=]8P]N^]$K95'*05`-=$<-R)_XD]#]/3CX;;"O
M@X@Y2OBDA7E:2)#LSU[;)T\N6#7'9!(<@Y=J>AO+&^DB8-S6&APTB+8M[A)(
M`,AB+CMWCM6.`]#!G4'C'J$B8V4.H0?)FY</J"L0!K-3VS[@S&-6765JL*\N
M1J"GC,%S78UA$0&1.'J#RLZ!F;6WV2R55C:IM96->0A7MD65E(:%)UM.0(HZ
MS)BQQ``SP`!@@A$P<>+&&,`!C",8V\=F9EV;;ZMNP&RJ)A1,P)D]22222Q)9
MB6))]+[;VW'[7C^A1)8F68QR=H`Y-``Z`!5`"HH"(%50!='6+K8:=--:._;O
M\<GQ_P#R&81</]0\1TVPD0HDB-E>0*Q&T'*.$?(0BJ?'[J"+]VKA>TBD)",L
MBLDO1/R(QF_ITU<K,O37YF^:_A_^33^+S)'RF>SHOYA_XRJ,_P"Y?]">1A63
M?I7@.EAK[WV?%6AHOS-UD;"CAJ1(]EDRS(HVH][J:`USBIF=N[EW'L^=7W/M
M-]V-W&EIKMJ=DL0_%74@CY[P1L01K![QV;LGN;M=W8_<.)CYO:,E.-M%]:6T
MV+\'K<%6^()$J=U((!U@;A=_!OV;62KSX&Y.LN3M-6Q32]?\:\US<U@OLCCI
M802/MQY=]E/J<']!YBF*`C'2X,N':QQ-:DE94ISF)]M?E?\`]X>9AJG:/S2I
M;)QQL,['0>L/_7T"%L^=E7!]]ZVW.ORY_/K_`/)M]L[BUON+\ALA,',8EF[5
MEV,<9B?#$RFY/1UVJR.=<#:Y-EU*\S;+YB^+[>%F/J_377.GTK93(T#*?QV?
M)&B32\D3;^2=&5]#]#<UY-+")QZLU[58;/Y?\F\>CD41YHG.&G,_FE_W;^YO
M<GJ=H_+Y'[1V0RIR#!S;5Z;$2F,I'@G*V#_F*=M=S^0?_P"3M]C>R?1]Q_F]
M95[B]T+#C%`9>V8[#<<E,69K*?&T)1(_R7$'6W/$W\5_\B_\H-+EU_D&T43^
M/;X+J"Q9^$_CI^9H<3'7%K5"*P\7_J6P#9,2OM)3'N)(F:#]WN%DN(YE;5%?
MYI\A6VVWVM?>S/>[%F9B69F/5F8R68^)))/CK]&Z*L7!QTQ,*M*\:I`B(BA$
M1%V"(B@*J@;!5`4#8#7Z?/EOX_\`FSXLXUA\3?,G$>3XGQL?TEGAH(2ON]-8
MA&H_WO9:B<^7HM?>D1[N\NQDR#(B^+5:Q$:EFJ%BQDZV4Z:IITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIK37DOYRLG7@[WC%D6("8DD4FH_.!5NSZRS%ER
M?V9LF!/KK+-RYAR2?VHZ`2OL'ND0C"&>7&/VG;/<E?H>AW22PB&@MSC8<H((
M<``>H)YIY74E49?+^_>Q[SEC+[!Q5&D%.03T^1)/"596J8DMZ+<?3L)>IE#V
M(^)V_/?/34<%9P"A;XN"\EADO:UX50@D5&4357S<Q&O<KE7LY5_541.MM_U%
MV#ZN)#?99X_^GKG![*]X#R\P5\):F=MQ_P"7^W?1?GOGDRB*:9&8:*]"1O7.
MR*M>KQ$$9I52B&B,>UR+X^+D5?\`=V_5_P!1=@60JGB>NUG_`.?H?97O!B&9
MU#*9$-3\(,_=C^'[-/\`P^\]^[W+(AN[M<%[&S\</S"C_,:HYV:-XD17.[?H
MJ)W_`%\OT[/^H>P<8AOV6=?_`(L:?]&>\>?(LOP^JCI_^J/Z?'4V[@;GUSX[
MV28K$8`8E82TR!&#>%%1A!-'E0>"*Y?+Q_K_`-SE=_MM'?\`V^`00>O^&S_Z
MH=2'V?[Q+`AE&P&[TF(\1]T/MC?YZG:[Y]YL-_59VD>,1#M>I03\BCG!4H_<
M)K4QDT+/8-SNZ^*]FI^B>79>H[/<78U_RD)$>(LZ_P#ZP:FH]E^ZWWOL56GJ
M&IZ3N/\`(8;[_P"O59D?/7*KGQP1;U@8?M0TQ2VF>.I?'N@VB0>'B-$8345J
M$>,Z(A57Q[IWZA7W%VF"SUR\0/*X_P#VIV^4CIK)?V5[B)5*[@*IEI>LS\(B
M@01\2&Z]-M1/_#MR4QRE6]D'<K1-_'_?<TV,U6]D>Z.,G'+U`A%[N<GFOZ]_
M]JJJT_ZD[81'I@?/@\_K^^WU=_T1WT'EZS$P-O4JC]0.-M/COJ,3Y^Y.$[WQ
M[CS,B#1K77&81?-',:IFN_Z=C[$1G=5557]43Q\51.K1[A[61Q9-O]U_V?YV
MKF]F=_4\TMEA_MU?M_Y8;_H(U&!P#R@"))AI?N]4EO@]4N,NJ_HWQ0S$=QLJ
M"/V_U<G=?T_U[?IU1O<':V8.:]Q_LO\`_5NFKT]F^X$K:H7>5A_CJ_;_`,KL
M=>EX$Y-0((R6[2"'(4ODZWS'M$JC*O=A?^G32,'[5:O@WLU7?KV_5RK3_J#M
M?(MP@D?X7_\`JW[_`/1I_P!'=^X+7ZDJ#/UU2.OC^&Z3X=)W^.H9.!.49)`2
MRVZBF,&Q4>*\S#7@,,?BUR''QLTCC*KE12)^J_Z_[>JCW!VM04"2D_X7W_5Z
MW[M4/L[W`Y%C6Q8!X65;$?,8LS\]?8W`G)T2/)CK8BEI+%W.I+C+HY'B<P@@
MC(WC@+F]B.<K7-1B=D3R3_3HWN#M;L&XQ!V\K_\`U;]/#2OV=W^M&0N&##?S
MU>&X`_X8>/CM\]>B\"<GD`L;]V$YG9BL(:VR[S`];%1@@'=QJ0PQ*]&JYJ+X
M]D7]/U<C@]P=K#<N!G_=??[1ZT3^GPBK>SN_E/3]0$?$O42/D#^%D#IMT_:9
MN["\`7'^6)J>2ID.Z2%4P*R)#=*C69IS8SA&2!)_"SF8JJW,QI4=D@L0,8AK
M:8@WS#>B)&BMP\_W#1^$_"]L5DY.6)@K$[2)=V+D&`Q8"M9"#D[/K9=H]F97
M]1_J'?F6WA6J*LART0>)XU5(M0(#%%4M<\&UN%==8VRZY'7H^G333IIITTUC
M;E?#EY"R!<\!8B'6TIK!C9TB7$C%'`L0&F@=*@AD28Q9%?[6"(T9$&5S7*UR
M(J=;/M&>.W9@R6GCP8;`$[@@&#`,&"1(D>.M%[C[0W>NV'"3CS]1&'(E0>+`
ML)4$@E9`,&#!@ZTV-\/"/$=!++$L9]=*JGL9?YL2NA3*S(4\AGF'A)CFE?`P
ME8U")V>UP2/14><[B=FOOHJ_,`\N0;Z'ZAK&'_RS\;7VZ;@=%6/+V_*97J-+
M,.!0I_F5#RLE*$;8/4KCU">HXDC=W+8*YLXU)PLL33/K!7-I(W65H4]=SE4B
MCFW-CON48L\<)."O5('"T+YSWB:Q$>V0P2H@`L8S?=C[D.]SBABE0HL?Z;)A
M1501/XK:4X[SM!/U$D\C[K[$WM7CGM6+<ALNJO9ZHY.V1EAN/X""%L]0D`;A
M@NR*`-2)&UST1UC07&!*7.CJ9%9+MLSH,I;265RXV+Q]-<HG\-UDQR0\41$.
MX$E\EKQN,Q'R>S^NO7!R7"Y%.0!D\PP5TL43ZAN'_P`LL-[.DJ%WXF%VUYN_
M=<.KGA96&3A"LJ7JLI<\?0&,W_RDK>6@^8JQ>06$V;ZG@\UNIKQ5+F)C)DLE
MC^?456[H!U.KJ]?:K=G+/KP\%2<[ILY=FA@F1V6,=1#CG;ZT"KGMZL/8_6HV
MM7@H$,U3\JVK7B(/XH.CJ"5)0R2-YV.I5]UG%RY;';U&+<D3(K"7)<_J$LHP
M#7;6Y5746+`5AQ"R1JZY7.V(S@H&LIN"\8V"I+#SL/QLK5V&4LH,.5?1NUDG
M$.CKH<RYKJHO[?)C18@TEM(!KE*P2/Q$[!G9);$NS[O4VVFQA8I(0^7\0A(5
MF'-69CQAH@F-C9[O[3@JG<<7M&+Z4MYHI1J6538/-^#M56=4/ILJ(.89`>06
M;SXHU>;Y7/L]=:P=O2U/&U;2WO(VXVV_S.O6C'52)FLJ&/NM+PO^ZZ8T"9I)
MBM:\R*T(4C.9XLCQUPN[8F3VE:<.IJ'NR69::JJGKY<@*V\J9/%)"+T'4\@9
M+-K:^W>XX/N-\KN60F75C8*)9DWWY%5WI\"UR>>W!YVE3:^Q/TKP(@(AQ1?\
MQ<55E1/N\OQGLME@881YI)LG8X2A&>KLL_"XY@D*)O#4FVBQY>0C1B,,V0^4
MUZH1?^8+Y.VV/V;NMMRT96533W`GG`KM>&5S<?\`Y9"DBPD1'&-OI&W-YGN?
MV[CXSY6!@965V=1Z7(WX]8*-6N,I(_!%P#2%(;D7F&^MI-=SO/N=32\C92#Q
M3<[^.&?(OK:@LMOG-7QK<7>IL+6QF63<U,X'@UL"T:4#FC*^.(P`*@VJP0B>
MN#)]OY/X;&RWRTQV*A%=:GKN5:PJA>8RBQ6#N)()WW)$YF%[RP?Q^=VZGMUN
M:@<V/6U]5V*]EK.Q?TF[>JJ\@@$J"JP!"J>.Q4V9QM4\,2.8\KQ_C\V&K$6N
MY-F\<:&IQ&NXY&.`B%I)6MAX*ROT!.*/\11U9(L<WF%K/[9%1G-UIW.[O0[-
MEY%UK.9H%R-;7=O]0K-JI(^J7#,(8G<;]O;;V+&]K'W/V_"QL=:P5RFQK$HN
MQH7>MKEQVLACY(J**TJ!Y6VU=R?*64Y`M5QD;B]&E6':CL+]O,.&LY%-FHE+
MB,=:7%@M=P/,>:)+RT:L>BN8DA"L1?Z9<ESW]5E]JR^WU?C6RMI6$_#VJ&<M
M;8JB<H;BPOXQ'Q10!Y]V[W!V[O.3_2Z^W^;B_*S\;CL4J"44N[<>WM(-(J/3
ME(\+'),:5S5D(5C:'%@;>1=5]TDM9(]OQ^R/83A[0VW`RK8GS\8,E96OLO>@
M4CH/UN6.YWI'ZNK4[)F/6BG(04,D1Z5L@>F*CR_XL1%:Q,S/FCD9U)9[J[;5
M?8ZX=K926\I%^.`S"\WCA_\`.X@S<W+CQB#P)XKQU2G<H<9/E#P3L3>B\J=M
M18P(V]PI050/\2O\,2HGS3\$"M"6-1C[`HI;$1TN)-DJBM=+`I&S#M7=`ASQ
M?6?/R!-5HY'U$MY`#*X\6L`*_P`K*.O!H.,?<'8&L'9SB7":N#*,C'(0>C9C
M\&8]O#\DI8AQNZ6-T-B<AM;P;4UFAY,I+"FS8JN?%K\IR!9W<W24DB*^KF<J
M9*/:55;$HN)\//MK4DS,Q5]LE?Q(C4<QB,(8BKR7?;;<?MCUW6EZRUE2J$8'
MD*+"K$OD6A5AVV7S-U,A1KT3VEC8^9WZJ[%H%=JI3D-8UM9'`Y=(9%%>'0SO
MRJ3=O(@D"&=M=ANO&]?3>G333IIITTUJY]7220^-M1*#V0T;BSG62%ZL816$
M!Q+IB,5&$5!/_J3_`$=_2O\`M_3KJO:2A^YU(?I.7B@_KR$UY]^8MAJ[%D6+
M]2]N[@1]HP[?CM^W7%>RAU5+1T^6DPDE2H<2[APJ)EJS3.H:^=4-FYS+BO#R
M`AU\;)U=Q%CAD=BHXX48%CA-$]/;:GNOR'RD:%)4EN/#F0T._&)K-C*Q(VV,
ML09&OE>^O&Q<2KM]B\K%6Q5KY^KZ:LG*JH6$@7"E'15;>66%!4*=4J,\-737
MJVY&2Z_3EB-H*N6=M)8LD"TDUK]G:#@LHI,*JJ(,66.K.'WQ[,LB<*1[(\9_
M>5@UMU?H[65`\F`Y".`^[6>0+,2IL!@H!65AF&L="N/BW?B3RHR"/30G@TBU
MOOW"BLJB*'%3+R6UFN5Y1#K*O',/-5<:#J99++*46/J*N^M[ML.?/LJFJ%(`
M93R2K+G'LGB)*A`!'9&5)!RL%V8UKGIJNY/DVLV*@6V^YV15D!6:"(&PCHQ)
M)V`)WF-=#V.K!QJT[A8;,?$QJTL>R&9D0$&2>3%HFM54+YF(78`G52X1N@[N
M^YZPN$J0<;\H<BXS1CXWMR6&H2#65E1N-*':X@-A81JH&3F:BPM%*R;6E8T/
ML"(?B)`(^+OE#8&/V_/SW.3VO&O3UEA)9FJ0UVP"QL"!8XN-X)/FY1D>U,M>
M\9G>.T=HK&#W_.Q;?PKEK>*(E]HOH#,$%+6L\BRHB)55A>`.#ZKC;1!LI+Y-
M<'"CI/V_UT5X1*YN;N83KIUQ7UC8A9-K;0K@^F2NFV86CMXD:J(5C22$#[M[
M;W/'-0"L<@V3YEWYJ>/$M,*I7AS5#-;%P"0LQR>-V+.6]BZ##6KC%=AX^DZ\
M^:IQ)=U<V^F]JQ<BU,P#/QY63EQ:!M1P"?*3]!$L15>B4$VV,=<P>2'.6/XX
MHSY3XYK:FDRE`P\1Q(DB2)53VB>O;K-RCC^MW!<M:S6720L<P"XF8GBP$PT,
M`?`C6I[>N:,;LS]N>];Q79#.3Z1(J:`)@NA/$,A*,R_S*=9PX:QO(V@YMHYF
M8)H*31YZ_#HIFUL##'(PN%A1<:'1?]0=-8?F5VSD6(GZ&.6`S\I22#$:DY6J
MO?1]ZS>VX_8[$RO3?&LK*"H=+;2;"GI((:L#[DASQ@`'TYUUGM?M?>\SW739
MV\W4YU%PM-['?'QU%`L_$VMR6\L/Q*FL<Y9F`NC5=H]%PE=_0W,EQE71(B:F
M3I87%4DUQ!=4A?\`N%!E[&+4U3V`?56^LTP+,=&=AU_$,J1V#4IP.%CWXW?*
M/;F%3ER?2"&\!3R.SNI9M^2UH4-H(\P\Q,*P.9B9OM3+]Z]TR>W\5_$-:N(2
MZ\!YJZF")MP>ZT6BA@WD;R!2SH5L^YB9*OL("2*N4&'`)$69"BW,.)+E)(AS
MAK($67A;(=<0LU?)Q"M<,!7KYHJM1B9E#Y=E;<7!=I@E20((VVM6=O`;D#;X
MZUF57VVF].=;"I".2BP`F0PD%J&"RVY)!"DF9B!:MY9Q*^\#(,M7,S%K6E?2
M-A19]7''GC4M5$H0Y^/.G6I\U"JP0I5>"!)BKZY<4Z.5RJ4A<NBI[*"J\ERD
M8<I(8\^3%RY`4.6E7+JVZLL1L!K\N^JG+#MZ;=OLK/I\0R`5E$6L5AF<U*@5
MZUK9-G1Y))9FS[@(Y#<D\6O=36$BA!R5Q;'ST<?83LKIZSES&Q9>DTE,TS!R
M'WF286NAV+1(L$C3"4:?N"$9S_<&"]LRAS49!Q;RYZ^HC8]A"(T;<;(=DGS#
MB9^[@]AV9"W?>WL:G;#7.Q!4!MZ5J9E(:VU)@^I3-26Q]V0Z\?ON0[9\9L:S
M&P&L[^/[AI')W5BK_7IKAZIW&\C51%=_O[_[T1>Z)X?W,DYK3UXI_P"!=?5O
M80!VQ`.G.W_VKZOSK`UN-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.
MFFG333IIITTTZ::=--.FFG333IIITTTZ::=--<6_Y"/X+?C?[RMB\JP(ES\R
M?4L62VTI?I3@I@<YK#78G=PV.XHH1JRLVYV(YR?F.)"NVIV:.Q&Q/%6I%L9=
MNJZRM_'K_#Q\6?QQ5C+7B3#$VW-EA&(W7?1?**Q-1RUH9DYBNMW5MH2,.#BJ
MFRDD(Y\*H#%:9KD_*))(BE5JC.S=>FNIW35FG333IIITTTZ::=--.FFG333I
MIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIIT
MTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ
M::=--.FFG333IIITTTZ::=--<Y?O2H)H,=`I:ZN9/M;#E/!QH2+9"HFPK5V"
MY/?4Z`]UX^^`/+3&CL5(-"'<V)ZQ,>][6.])]@7#'S6OL;C4N):3MRE?5HY(
M%Z'U!*08'FDD`$Z\/_.'&;-[8F+0@?(?N..%\PKXO^'RN%ALZJ*C%LB6\G%0
M20#ROV8J:')+&B!E2;@D.0^=-C55<]&*>D6"Z6D$D9ZUQK`TGQ:$44S4]@F>
M?]#/#U;"-SJ'8@4R(!8^#3$SOQCJ6'0F-S/SUW1<6JPUU!FRBI+,$7QKXSQ(
M\I8G8!#U43L(^N2H(VBK941]AHH,V8:7*%/;%F9R%;Z`<N'EA`@2ZD\RP)/%
M,LK&-)C/6HE',(';_FF+3[X>I:AXXS*`!$ARJ0;)(8`1Q1&5AZBA2W\AT/X8
MBFBQ2^:KL6(:&J5[)%0"LA9BP>VQ74^B[,J1]X-7>1M!DL+I;F]C$6'=9G29
MVCH8%0:*3969*FVT4RND1P2;.RK8M#!CLG.G0V(490QVQU60X;4Q`<C,SZJ:
M#YZ[4=G+3Z:\E0,"0JL7)*\6V(+%O*#K9,,/MO:+\K+4^E;1;776J$>N_![&
M4@%F45J!9ZB"0RH$ERHU<==16_(?R=;YWBNH_/E\;\OZ2YYYQWX\QLSD&@UK
M+IV?TM;*E@BMMP82EO(CV5IF&B#;7,+W</Q4F-9?3V[W:F3W9^*9.&BXMDB*
M7KX\T8`GB;65@7!#'F1UZ9]&'D][_+FW"]O5\[,'N=K]PHAN637=S].U"0.8
MQTL0BI@R`5AI(CEK%LN/[^+AIM]+L:\`'.J%'46"EBW<BML=JMEG*=U;7+*=
M3KG1V[*R#":4M-*&LA2N%ZH[G]1A=PQWSEQT5BWF\PW4%:N+M+1RY\2[-`L4
M\8F6C@>Z=ES*^TMF6.@3R0C2'*M?RJ3BL\/2#BJM)-#CGR*\4)N&'27:\K\H
M&AV-L6$6LQ1]52LCLS%A-I3EFBGCB5?[I"6IATC(@7R90G&&:"R6#\0CS-;U
MC/?1_2<575`X>T(T\P&$1+<3R+2>*F"&X-S`6=9M6+E?]1=P>I[#2:Z#<D>D
MS5DL&`3F."U\5+L"P:L6)Z9+`:S3\P1$R60Y/Y7W]@T7!%9Q[<X3F".4+ZZ@
MY=V;J:F6KHLI"DN!,9I:+2'LWR+MB1U&\C&L$URE?UI/=+?C,S%[3V]9[\V2
MMN.9E\>ODW)K")'!T"`5&9@R8@:ZGV!7_3>V=P]Q=Y>/:%>$^/F`CC7F7\$X
M5TJ8;U:[3:6O'&"0`H/(ZMWAB5FHG'-_G(KZX.OI[(,G:PF2!6,Z;15%)FX%
M9-B3Y\>08V8Q=[;&%/`\1G?ED!*\G>]J"R>])E-W*O)?D<-U(J,<0&9G+`@$
M>>Q5!0@CRADCR[X7M:W!K['=@UE!W.JP&]9#,U:5U*K!F!)JHL=A8I!/,I9)
MYCC90[#*TVFA"L(2T5O90IM;1V\R?^[Q,[H"SK6%7:2;11,S&_<!TMHV(0!6
ME:V&=0S$]GH(,N<:\N[%8UMZE*L&90.)=(4E`Q<QR7D"(\PE-N0(U2W=OQ<]
M%N3T<IT9:W+<UKL+.JVM6*ARX/P*F81N-OFX,K6W@35=5J30;&O06C$,M"P)
MH7E.J;!U2]EJRUGGG6\B9;6)A%266.X3GG1Y&.(K_-^3W`6W8@LK:<:0^QV8
M<O+Q`"@*`1Q!F!`($0,'L[48_<#5>D9P!K@KYD;A#\V+.6=B#S*D$M+`F9.]
MOQ8MJ/F[DYEA5G;9KA,T2+=*DSU66<7E?-I04L*+9.C,IVY4+I(CQ@C:PICK
M*<\CI",%P7O;TCV/%-;CTOQ#RNVS_AWYL2)Y>H8(8F0!P@!9/KOY5_B5]U]P
M%U;>O^#JA_-#5?BZO310T!/1'(,H`!+>H22\+VXZ\.U]7Z=--.FFG336JGUR
MU7\6[%B.:Q7\1\^,1[U1K&*[B'3M1SW+W1K&]^ZK_L3KK/:!CNM)_P#LS$_^
M:$UYW^9(GV_E#I/;>X?_`#';KC/=Q85I,'^XLF!A@K:9;(-9)![YDIPS2G5-
M,<\:;'#>V]X*/$C247Q!%AR3$[#'VZ]IH9ZD^ZXERS<2P,`=.3`$'@JRS+U+
M,JC<Z^7<NNK(L'KAQ4M:<PI$L8)X(2&`L>P*BM_*B.Q\HU8=9%G::QKU@0X0
M#SUIX5760EF,A1ZT+(M=$IZ:!82BPX=1&B,F&B,4OC'"3S?W_5W6?:R8M;"Q
MF*KR+,8DL9)9BHDL3Q#&-R('PUIZ*[L^]/15`S\%15Y<0HA0B*Q*J@7FR"85
M3)^.I+D;1?ERV\<9R4"-2C3:9X1).]E4IMIR#%S-,9L_U9=T^WL(<*182H=0
M$:1G>@SI!&.=+:B2=MQN"?U+)!-_W;[5!A72781+PH)`5K"9W`4$<-1]\S?4
ML_H>"P7$'KUR<@UF_)%2'E%7)V"EG2E1Q/$EV!-@&LX8^RIN)<Y)TLZU@4NH
MFZVET5S9P-#JK*(;<ZI?QZW#4SX_Y:OJ`:>"UTZ0A'!(7VE<SP$Q":+,KO[O
MDC&K1GQ5I9%4I6"*J]S:TQYN!A1$@0`9)CK.V7XOMO!;/NL2KN#Y*6NZV6LI
MR+MEH2.7D%J@V-)!/)B(4!LH<XZFAW>-J^9!VA(6GMEA9C9"!*C%SD#8C&>F
MLLA$:1KS2)=1(]YZ4Y896S*?R\G>;'-75=BQ;\#-?LI6<5)>N0>9KV9;#\`P
M@6`,.-D>!G70>[.X8?=^UU^YQ84[A;QJO`(-2W@%&I7Q+(>34,4(>F9,@@Z;
M9>/;6V8^9ZYHY<:LD5UU&B2@VAIT.0Y*$S)!B5<7R?5PU(L=\T87JWLQ51_9
M%5>SRFIIR^Z6R#:&4D%0"//MYC]1Z\21X]->7]O3)R<#L-`#+04<`ARRG[LR
M2@^A9XFP`QMU\==&>6;2!\\\056(I+F`X6[9[^0M(PM-0VV>J"`!9U;=(A'%
MG-@:VRF1JF*.*T3XD:4Z0X)'F>Y/..T56>XN\/G7HTX^U*>9U=I*MP\)K4-8
MQ:>14*"`HU[?[DR*?97MFOM.):G',$Y-LI6]:0'3U9EN-S,M*!(**Y<JQ8D<
M_-O52J:PJ?V*5H&T#]+CZBVC5MA0!HL>//3;"_OI<!LR.^`PUY=2E(8;3!EL
M>B-]<=K@]_0L&U+JW_$"O\1Z5C*2'+6<P$0&#/D40#!6-Y8SKQGNV/9BW5_@
MVN_!_B*4<*U8KI]-FLL99!6;+#)')7!VXH"NKP_>UY7X['*NG6C=O`JJ`NHJ
MIM$&(R^4LY\.EU<)E98DK4G3`5J@L11IC&BE>HRJQLOP3#]#^D]QX4</P+._
M!@\\-I:L\AR@<I0LNZRN_"=;+\5_U'V0691L_JR5UFU&K"^I+<4N4*Q7DP7C
M:%<0_%]A9&L?PFI6S&YZ;,4=1/MGR(4])<.$.GM20WQ88C$"]1Q8FHS97P9;
MB^0X,B.&4H^PB.+L;#ZB?B46;E2"()Y+,F/B4>&6-V!9)W$::H>A;^"M:,9[
M)5I"A'XPH)&P6VHFMYD5LJV$>5BVS?#XK0>LX^!)D$`2MYDXB_=UFN9"F'<G
M(69KA1PA,QDV1,,58YW!>-I$"LEZIXB[MY;O!J.)D,@D-A9'&-P/N7))/0`"
M1(,3Q'4[]][96\=RPDL)#5]TP^?*%8_\34H`!\Q8GBW$@'CZAZ+MVVXQ;XXR
MO3R8[_VAI/U'X>/ZZ:X7M_;5S>[>_9?]O?\`U_7OUX?W3?-;_=3_`,"Z^KNP
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M'$J`1F#7V'>%%,C0@#5$T/TC]0PITZFS7"\33WT2;LX]I3QL;KX3\BF/K==+
MHQVEQ<Z>GR6G_P"K(:"/-JS5=FYE9'D^A[9YB1G'II"_'5=Y4^EN9\D2]?F>
M/XAWP4XV;74,_C_DZYG2*77MP)=%R&;1PW4.6'09F5I[.L?522P9Z2J@AR&:
MQ7!970`:I3OH?ZA6;)ENXGKX62BW33`M_P#I_L;N=H,C7:X^>N9-%54NV+8,
MMY-2P5C#2<&(Q[3M8%DP*/E-:0OQU(TWU;],2O\`''7?RY?5#VT];#Y"KOV_
M3RK#,[*SWT'&"?2OB0Y-=I\E%BSP64D\8SRQZR0LM>XHDEK6D#XZG]9]/\Z4
MFWC9ZNXXKY6>D<KZ+&V^C)A=^X6'SU-=[NNHBW!95I356CG;JHSD"RB3H,D<
M2&&8@R`,\T52M`!JFF^FOK"EJ*"YNOG)UDRQS6FV=U54E+IDN:BC@5&I-35\
M&)"L],EOI'6%?7E)`,M?8R8A##%#'+_'"2FD#59G_0OT[5PB7<GB:H-6339&
M,"!&Q/(Q;+*1="#E%V@TM^6+/G2-%684>'@S)4.#!C2Y8+-@!.88D=2UT@:H
M<KZL^CX8Y[5X(275&EGBY7D$.:W\?.W-?3#F/M-):YR4!MKE8&C@R*Z=1"GS
M@QBL)*CRIT?\=)3VJ\1\=;Y<?W]EJL+CM-<5<JCMK_,TEQ:4TZ!(JIE786-=
M'E3($FLEFDRH!HL@KF."0A'C5/%7N5/)6K-7=TTTZ::=--.FFG333IIKFY]V
MO?\`X]6*A?R4C\S<7$=&,0360XR8CDET\D9"B>UQVP5*9C4[N<5J>/\`5V3K
MTOV$!^)<1$X5^X\3ZM,3\I@'Y==M>&?F\3^"K,\N/=,0P8\H]#*Y$2.O&6`Z
MSTWURUM5(^;&TE@V)83T),#GJR20,^#:74*428:TLT&JF6)0620A1Q/*A'VX
M$_H<&+)\/5:H"'&KE:X',B054B.*_-EY$D"!6>O)EGY\R.7JKG7!7N\PK0PR
MNZF2[1O%;>F%!,FY1L5K>/N(HDG3YZ3Y=A,I9=1*LK._$5UC('$CULFM--DP
MYZ-=)LYEP0[F!4ZOER9+&HK_`&]^J9U_IUKZ85;PX54.PDL#`(Z*%C>/*JD[
M1JO:<06W.+F=L5JBS6`\B`%*EB&ZLSEB%Y2[.!ORUCRQTT_DS24\2!&B5X*]
M^2_9LW9[Z7X9OC:YRNA@Z20M;G7&<B-+<NFV$@L@K9DM_<2(C@"ZV->+7VO&
M=["69O4Y.M0\]RV(4')X_P`/%``.*C?HQUI+L^[OV=572JHB&GA4V0?NL5Z;
M%M/&N?%^=C%CS<^6)1=;/8/F2%\Z66+CTD^2.N2O_;&T*6EX69/R6?E`I-]L
MYDFPK`UB7<&M:R9!8<I&$LP#"AO3&\'<OG]E?W)7>UZ@V\N7/BH`L<%JJP`Q
M;B6E6@`A"6CDTCO^S^Z*O9%^*F*["CAQ]/G86:FLBO(O8L@3U%6'K#$@VJJ\
MN*0<4?6JTE#&J(.9T4NV_P`^N*Z]KS&BUK`7[8.RHG?Y?2NJP("MK+JP&3SC
MG9!=6V,<P&M3L-KMM[1]?(9[,JL)^'0J8)E)K;[MN1EF41N"W-"K3U(YS\Q_
MPN&E5.!>UGXRU;%)"Q9QOK^^3@(578&585FJQ60`;`W!QEGIO+/T/I<A:6]^
M&KO\UCGS+:8\-EHYSHPIP#0Z.-)"%Y),UCY'X9$>X86Q7*Y%\GE'C]TR$[1[
M<JS*DK-M=MD*)""8(+$3L-N0ZGE]@.9V#"M]Q^];^V9%MPQ[J*.3M#6M`8%:
MP0-V\W`R0.&_4LN:/IO<Y:%=97YN8VHD<;<?1*N1GPP3PSU&XND"XFG`2+$<
MKF/P=,=?829*+)DFGFF-(I&*U=)[7P,MZ+?<IYCN>0S!R00U2SY#)_\`CK#8
M*H`"A(@SKJO?O=^WU96/[&'I-V/"5#6%*E+WB;00/_K=#N7<LS6-:&)$:T=E
M+?\`&-_4#SUA;W*U,8UA26P[BHM*BWL=!L*R9:9>32S`18<Q:S/JZ+-B@F-A
ME@G1R>QS@H[ND_#]TQW.0J)S(5EXLK*$K8*X8$D<G\RL5Y!A&PY1Y-8<SL&9
M4N$]EIK4LCAT=':RY2]11@%/&N4=5<(:VG<E9NO=0ZBZK_W[.PCQ6SK.RAK5
M3W$-;9C0->P%G0/B*5K;8D"5`&Z+8#&T<R)+`5?^\[,Q,![:+/0R6!*JIY#9
M73JKS_+()Y(3*LK#PWV/=JL;*I_&8*LH>QEX-N]5FP>N)\_%E!2P`!T=&/7:
MW*P3KROAC'7V+M!E@4[(,HGFPU[FZV2B,?(BL9V27D8L>7';XC(XM>J>TB_@
M(I<FTBBQB67\/:6D>".1X'X6$J>HA^@^\VP<=3E4JJH_XS'"<2>ME2GQ'QI`
M==@2:XY,?1\V_GQ3-#&Y6U-F4DF5%=Q=B:J,X4B78V7B'F?/P(I'0'O/-%4O
M#-CJAW.5CU;)<OZC+X^?^]T9NTU5"`_XJUCL`O\`RSD[[#EL=NH\OQ&O8_RK
MM5/<61>Q9J_Z?0@@EFVSJU'EW8)#+YCL8<_RM';[KPS7UCITTTZ::=--:O?6
M`4?Q7MC*TBMC\2<Z/<YOB@V-)Q5H0JIGK^K&JA.S51%_J5/]G74^TC'=J%VW
MS,7_`-NAUY_^8RS[>RVWA>VY_P!G_*6#?].NN5O)HN()M7G+&->V.*@V`SA=
MF;BD-H(AH4>%#B:3D"5<9X;K"/$'($L))4J&%@1A40V#:QZ]>K]K;O*6V5M6
MM]BQYU8(0224J"OL3!Y<58R3)))U\\]^7VU;CT7UW/BU."/2>LV*5"JMN07K
M'(`$<.;HH4+Q``!.K5L.)N2I>))=\9YA_*U+N*DE1:Z/#OJ]8N>R]H"QS/JK
MJ"-<P-$EG-/XFL3)`_Y>J\Q,5SC/].77W;MB9PH[G:,2^A^2I;RKYNI#[N5*
M<0-D'+>R"8"CEK[O;G?;.U'+[#CGN.+EUE'LHX7>G4X:J%K#K;R8P;&]/RU2
MH)+'CCWC?B_3XTLG;;FH;EI#!"NB"NJO+TEE@QY:'$#KM'9!>P[',LX4-9$<
MKB&+&`+V([N4/;8]S[IBYH&#@/ZJR5\K.RV^H3Z:*=OI)@B`"3$;'6E[%[?S
M^UENZ]WJ_#O`<ATJ1L<5*HNM8;[,J\E)+%5'*998ALEZ'46;+N%)(Z.ZLVF?
MP\61LH8:N\H7L-J!\H7XP09IHEA?#K2(%7#_`"(-:!Q'?I%]BU*8^+5Z#CS<
MJWM(K)97V3T$DB0G(3O#N0/YXU:+,SN&0,NICZ?IWUT`WJ$LKWM_%V0K%6L"
MF-N5=2EC_E\M(O)8"7%IGZH,B1Q%9L?6RJ@CRPIML21?R+.OTE=*<IK6!?U1
MR29M6-"A8*,BQGJ,;3,0_;&%*9%Q`[PIY!MB%A0I1ALI1AQ6PP9;S"25.B=]
M0Y5F'CAF]M6`J4W5G)L+K:IW=;$)9ZA*@)]V>*AAJ4XEM*+%&^?]#90JBQJX
M,;86+1QY'Y\X\Q,Z]M+#UL&<C"U%`D[\<Y&#:D@B,<!'H\WDE_=ZK\T=QQJB
MZVL:QN(`'/S&LCZGB0)V&S1`U%[<R,3M3=FSKUJ?'1;F@'DQ;TCP6Y6W2OEQ
M8@>8P4F6G63[/?OYPOY$;8QJR]L9\N,*;5V\*A6'/IAV,2UFN[V8XDT4X(WP
MJ\*-*X;&DK3`:@7R7LU=7;QV+'#81:NM0892\AN)4?3(@^9SM.UJL9"@[^_O
M)]VYC5]S6NZ]V`9'6OBR!@[?4`P8#A6L&`#0R#B7(QUB[BQBP#8/1AGWP)L*
MR!;Z6TJXT*!N:K:3!1PU#2?E`/+M:*FA_CR&1R-?ZPL*UI1-<Y-CFTUO8,_&
M*ULK*516)-35B>70@*S&1(B21L=:7M63?72>SYH>Y'1@]KH%6]+V`"3()>M%
MXL%,PH8!E!.K&?D=]A-M%+QYFK6['&-#F9J#F,KI)<2YRM-36&4H*:_BUQYL
M4LN?)LY+)L48`HT#"%8QRL`_K/&9V_/P2.XVI62"'+V("KLPL=D)`,`*"K$G
M>`3NPUJ#VWO/:.ZJW9:++54JU2U56E7I1&IK2P*6!+%F#J%7RAF`,(=;`W'&
M%-0V,.5R%?UO%=I<15GQL_KU21I(]B^Q=&*&50P(-S=3+,3P.8"7^.`!PHU[
M'=RN8/G:>Z79%93MU;9=2&"]>R$1.SDJH7?=9)!V(VD]GD]@Q<.Y;.]75]NR
M+5Y"N[>T-R@@UJKNS""%?BJL((,L0NTN4)Q&RZX_IJ*1;WVAF<D</2JG9D@U
MM%17];$Y$Q,]4A@_=["SFR(JUQ0=BCC'`\1`%%YL[MY7+'=S1D79`2O'7&R`
MU<EG0FFT;GB%`,@[%@9#`P=>@]N;VVN5A8N&UMV:V?A%+RJUUV*,FAO*.;.Q
M'$KN%92"C+(G74;!04KLK`BM>I$23<'\E3LO>9=V,Q6]NR?\"G[?_%UY9W!_
M4RV;Y*/V*!_9KZ"[/5Z';DKF?,Y_^*L9O[=7CUA:V>G333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333I
MIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIIT
MTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIK0KZ]
ML,Z"+1EU4*U?05O+?'1+)]<4<25(]V'Y*_#6!,2)+6.9)Y!":1[>[2N3Q<U>
MR]=_[.KR6>P8C)^(;#NX\MP/O:9D2)VDQ\/`Z\>_,N_"2NINXI8<.ON6,6XD
M`F:,KCQ:#!Y0)(V/0C7+?E9V!6_6%6;X-%8_@"E"SNQI)5568Q\5[Y=%E3W=
M$RZHX4]*>6LIHS%&;VR#O>K3DD=>J=I_J'X?G;CFROE'.M@S63LU@5N+$<AQ
MD`B`H'E"Z^??<1[/^,]+'S!3?P!%=U91:"/-72;*^=:MP/.&(:6<F'+ZH/(W
M"O-=/7MJ\YQUH]EB85C$U!=7A8-5MXEA851`ML*Y)=';N9$@UD"T*&O#8,CJ
M:4`YWL:1!,ZR.V][[)=9ZN3DUTYS*4].TM40&F##+N6*@N4F%*J#$G6'WSVK
M[JQJ1CX.#?E=J1UM-V.J7AF0CDLUOLJ*Y6M;`LNKN0&XC5L567B<?Y&?'U$B
ME),@0XU2EDD2NRQKDDPLB]X[PU9'9%BO0D^8YK6EC^^.I@>]5041CNLJ[*?N
M&8K8H<(S%N,M9QB$NM8R>@\#!@\>KG6!C]OK[-VUT[@:C8BA.4+47DFS&QU$
M`RS="O)97G/&L'5`_)M)(MG>Z<T>,6U!3Z73!F74RYJJ"ALJ>]@+QO40ZR-,
M\6CT=7^*]5G"3V>PG9'B>]<CC4K448H)"%D2%"L[AD/K,6(_D;D/(=H'0@:P
MO4R+%RLO/*JU@2VT-872NMDL7\,BJ&Z6IP/WB[R>JDZL.UY`2[Q-_E-%$FL:
MW8AL<C7I,>Q,GH;*V@$MJ,3"R&S04]FV.PDP!7.C`L8[)#6.0<AW6?5V[T,Z
MO+QV6?1BPQ_F(%/%CM!99A2-RA*R)4:U&1WK\7VJ[MV:K",H-2O+_)L9U+UB
M3R"-`+J3Q6U0X!ASK8',\H6'"^ZY>E9R#^-R`?*9"KS$A;B':U%"(M=9CMY$
M6=%(0[M5=1V#B1/0J!A#8]&)[CB[<]D]KK[U@8:9+3V\76,XXE6?=>((.WIJ
M99IW8D3LIUV6![@O]K=W[G9@IQ[RV-2E1YJZ5@JP<JPW]9Q")Q\M8!CS.NK'
MTMA(Y-HSW<.REPM'7?N)J$E##J'S\YK+>5F(HYHI@_PK>P@CJ('J0[&%_)@'
M$9/9((]K,[&K7M=XH=0V,T<^1:'K4.8C=0>1F#$,"NR@$ZK/N?OV(<NMV3.3
MD:S6$Y5W.:@&##B[+P6.0#<ZV5O,Y('BMFYS89JPK]+2/JR1K>!)BPFI7)'J
M]3EX$>LJM1%J4.YQ*2RL"R%4OI(]8">#'$,(:-K:F3AY*V8K\P4()\TLCDLR
M%H^H`#:1YMS"DZMHMP>YX+TY]7IE;5(7RPEU2A$M"3O6S%O-Q)]/8%G58H/%
MV(Y%+H[&B@<::'8Q94,<'7DRV7N;:I_*A2)U]9:K.W4HAZ,*U%C-9^.<DD3)
M_MD1U>H"B<'([KG=M&,M]F572P,U\W56@@*M;J(;S`>8!3PA6CD#RQ/;_:>]
MMG/ATX%V36RA;C54[I*EK&NK<DUC@S#BQ8"R72>#*5S?_C&)SFZ+FM3N\MF=
M%`GI&C64$UAI5C/CH29.LK>32L#FJ!9\@0UC),FQ&C<OD3UHQW;1?BL[)P!D
MXM%MN,RR5("3.P50WG>!,\5:>@F1KK/P':L'NQP.X9F/CYJ/`92UL1YF9RD5
M5\B!QYV(`=SQ`,;5?.LS!$Y;W-=Q]D;W,'JN/LW%T*Z@4%'V=B[FO',5T>MA
MELFU0HBB.OXSI$EH'F_I>UJ>+>4]R)W`=HHL[C=7:KY#E.$^4?AK.K&.4[;P
M)`W!ZGT/V3;V=O<F71V7&NQWKPJA9ZH7S-^.HZ*I;@%AO*6;B3L0-AV<Z\5U
M]1Z=--.FFG336M/U6I&\.<E/:(;VLX;YN<0CD=YA1.-KKQ<-R*C6*1_9BJ[]
M/%RI_KUT_M.#WK%!._XW&_7]\O\`KUPGYB3_`-,9Y`!`[7G[_#_A7Z?PUPRY
MW,,]U'J([59^WYC&>F(VY_9FH)<I0K(T=7HK.M#4<<WI)5S,`:B!&?8Z6(09
MQ.:Q0(ONW85*T&YOYK;)/'E_YC0C(K%KEA5(M)X4L"ID\M?)'N]E?*7&0?1C
MT0.?#;T:YM6QU"8UA+NK4*IMRD(=2!PU=7,>AF5=*(-4T5<,VNHL^Z33MMJX
MC0Y&G/)8I9M#-J9N-=*6OCN-.MI+J]RQT<<;FC>J8G9<=+;R;98BEGAN)_S&
M`V#AA9$F%K7GO"D$C6Q]SYMM&*%QP*P<FNN4YJ8I0G=JV1J9XJ6LN;TSQEE(
M!U<67^H^7H7'`JW7W,G?P]!,N!RI6F@T\K0+31DJO2*'90X4:)=1',FO21)E
M13ULZ&J*%/QW-(7'R_:O9W[D;<-!CO6JP$+!.1Y3*DDJ=ME5@ZMU\T@9F!^8
M/N6KL8H[G:V95<[R;50V<!PCBRJ!8/,>3NC56)NOD(+2FG^CLMM,H2H;@9;Z
M^P"2-*L*J6N%NJR"RS8ROJ%K<Q^=DM`"HB27L)(DU\/WB`+S15<X?5V+[;RL
M'+];\0HL4R`P]56/'=I>+$+$;!7:"3'2=1]P]\=O[KVXXPPV-#B"R'\/8JAO
M*G&KE38$!(+-6G(*LS)&K6XXX9K^98MM-XJTEZ&[6PC&9D]SE;=]>HYX7&<R
M?LLS7Z3/0Y$NNK'>B;;C@14(Y&.5HWD83+[EWJSLK(G=JJS1Q/WE5BSMMM6Y
M1R`6W6LLT;B2`1@=C]KT>Z*[+?;U]PRN8/HWU/QAA/FOJ6VM253RV7"M)V)`
M+!K5R^%NM]&^?:&DBK&-7X/:6]A*TM710<[%'0Y9DB\F/MAQY)+"FCP1K_4Q
MLH_K<C1O1Q5>/*RL^CM[]QR+S(;(K4!&<N>=D*.,B&)^/$3U&T'7=O[1E=YK
M[+AXB\73#O=C:M:UCTZ9L;F`2R!1X!VC93+2M:M*C'8'1.B6.UG;*=G["'^=
M'QE"5(ST<=(LFO=:[,,>0>NFUUJ5CDC52BD,=(1R>E[.\%5V;W#&YUT+378I
M@V/OTD'C62`0R@[V2IXQN#K*R,;MG9\WT[\M\JVEUY"BLQU@KSO`)5E<CRTP
MPYR.)&LEQOH#BFG)!T,?B:DC:BJM:NY@UDZMB:*?4SUA**QDKJKWL.)`FU(X
MT48X-6PCP_EJPH2$:U-:WM[NUP;';+L.(Z,I8$H&$[#TUZD-R8EG(GA(8#6^
MK]Y^W<5DS4[;4O<*[$=495L9&XPQ]6S8*R<4`KJ!*^I#*6`U)\Y?6?+D\,:N
MQ^F3C+(EI:W3DS^8"[,!@0BB>J,T&GC19MW`R$>5"?%0[!RV6!'/BK%B(-/9
M?V+VCV>MC9F5?BLP.4YOYR3/\B$A380>4$J4$-S>=HO=OYC^Y+E6CMF1^`[:
M:EM].H>D%6/_`#+0&L6D%2G(!Q89K-=87S6SS#0K:X2EOJ>">Y+&T%!H*IV=
M_8YUF2BU].I[*-33+%('XV:ERF^)9(DC2$$)W9H_ZE7*[-D>EGOCW,$!K=&Y
M\@O*MH4L!,N!T4R)(W.L#W-A_B.T59>*AM9;J[$]/TV?T[DE@A;C%3'9F'%H
M!V7><J?,\L]K6\,6*/\`S(M1SSC:6OLH,<9<W(K9MWFGMK<=[@FN09[/V-5+
MCJ:P<*0^8LI_M(AFH?4^YD6FS-J^EW[?8Q4GSA@K^:R/*7<,IA)`7B($>7H?
M8=CY%':[YY5U]XH164345:RKRTR"XKK9'7E80Q?U#R;D.?<?&O>3.0'$9ZW>
M<]OC_5_PLLIC&._J:U?ZV-1?].WZ_I^G7A6:`,EHZ;?^$:^M>UDM@H2(,M_X
MFU<_6+K/TZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333III
MTTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTT
MZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::
M=--.FFG333IIITTTZ::=--:-?7E3%MX&3A&:5GY?-W#0%>-OGYNE@UU<GD-/
M-QO[4I6M8C5<XGBB)W_7KN_9]STV7.L&,')/[#6?[/V3KR7\RL:O)IQJFD<N
M[80V\9%R_KV,`1UC7%$!9NHY?99$"X$A^HN+RX0UO$D)6+7Q;;8OIK%]B(Y>
M3*`<LZF@/K/5'IVG2&]2/]:K[<P3%[/Z0,KZ2JL*1RDK7R$1Z+P(?G)LCF($
MZ^5$:[N'N47L(?\`$/8\N#QXA[N#<@3E5AC-9JA:>0J))XDP-KN=?@]?26.4
MT]UEM%$B2)I++/2[6LD.MK>^/`2TDW/Y<G)7<Q:6A&%U9*CR9G]Q6@:XJ*[J
M["P,//PWKRZDMQBP$.%8<50'B%@6*.3$\U*KM+;:L[KW?N?9^Y57]NR+<?-5
M2Q:LNIYO85YE^1IL;A6`:F5GW(0%I.LAZ7ZHU8_V/_J1Z[B/$I`R4E4M/FU=
M(E6<*190-3,RU]&LL_\`N%?&>$4<<H<8[%CO'[/8IFNUV+[4Q#ZG]-E&+D0S
M/L%(4H+$*O!,DE209!B..MWG_F%W$>C_`%R+46H&:TJW+J66UJK`U?)1`4.$
M8<2)Y<@<4;?FO+\B*/\`+P5CE:JL9,E%L<M=R:V3:VS*QAOWBPQ=Q-ML[&4=
M]HGRH\2)(@M#V_I>C57K;8/9,OML\,A;;6($.H8*O+Z18H5SY$XEF#$^(G7.
M=V]U=O[W'J8;X^/7R):JPJ7?C/-J'9ZQ%EA=41JPO@0-4V1P["L>)+/ES":9
M='G,R7/CMJJ[X]TV32*%EYGXD\<6VG):X+3VAK<P6.%"N23S!8SU(C([_.5>
M\V5=W7M&?5Z>3:'XLMR62>+D2HXVHH63+5A`29W81`_MBJ[VW9[E[1?Z^%CF
MOFCXUM,#U*U:';GCVN7*@A+S8R@<=D,WG2<4V/(FOY8U9)>5R61S<')5%G<Z
M@UG3UGNN:C02Z6."NST*[OBNG-J9*-:%KF,&GL]GN>,@<&[NU7;</$Q`+;LR
MUK&54XLWE9`Q)<J@CDO7<G:.((;:8GMV_O?<^X]Q9L?&[;0E*.]I9$ETL:L!
M:U>P\N#;`$`>;ES(*XVQ>_X]P%M/T$B#J>6:XS;"$D9"-R%%9*Z,*VA+&E39
M5Q>,EUT4Y"M[1JPIQ.4:H/R(UVSS>W]Q[A2N.K58E@@S_F.NY4R`%6"0!]3@
M'??8C1]K[SV7LV2^:Z9'<J"&6/\`)K;8.L%B]@*@D_3464\3QD@Y[XM^E>)L
M3<U"X+BFC//M'I1WY'4"5J1:ELB'"S8TM7'F:#22\951VF++>6"&3:%.9HWB
M496:#NOMGN^=2_X_+L%:>9//REH)?RP$06,8"PY"!02#(/8>WO??MSM636>S
M]NI-UGW=A]/C"2JU>>6LM-""2Y-:O:78*5XL*9I.>.8MOR749[>;I1YL6@-B
MPY8ISYSCR(=X["J%4P:"@@%J;>Z@%43W)-AN9&+XC;*D=G*^7&[!V;![8^1@
M43D^GZAL`#W$;-R+N>2J=QY6EAOP7:(,[WA[G[MWZK"[OEQ@BXT"HDU8RDAD
M"+76I1[%,$\T(4PHL?><:<H4<G.7%'/E%#&2RJ_S=3,/&B$S>=FT=R2+6S[8
MU<`>ALY-=#E,"`8O,(CL8I0O&O@W9]JO7)ILK0$\6A`">;AEE@L^102)),$@
MF&!WUH?<&(^#DU7.0/4KY6L0OI5M6\*SE1ZC%5(50)4,!R4@QK?SY>E$L.1[
MV_DMEK/T/`7$-E8NLI\.TL'S(O+.5SI26,F!&!#)82OV/\DZB51.,=SFM9W<
MK_/O=*+7VRO'2/3K[AD*.(*B#CV/Y023`Y<1.\`23X>R>P+&N[Y=F/R]:_LV
M&S<F5VD9E-9+%0%+'T^31L68D`;SV]Z\-U]8:=--.FFG336N'U,SRX9Y0?[%
M:@^&N:5<-&C<TR.X\MF>#G/;[&(U7>7]#FJO;LJ]NZ==+[4/_P`^L41US<;]
M7WR_IOKAOS"!/M?N!GIVO.VVW_X9_P#7M'[-<.>9,U/MEKK^KKDGCT^?H:=X
MXE3'MX@]QFZB!1B'=YX@95+M-;95]9!6IDG'5DJXQ3/:?L-[!>Z=FRJZN6/:
MW$U6.V[%3Z3L6/%Y#5UJS-Z@!<.P4<=P3\E^Z,&[(X9E"<UR*:T@('`OJ1:P
M+*R"E]S*E?HLPJ-2%R'A2%OS3<<3=AFZ6TY#T^5X>F68Z/00K#DB^-$T)K*/
M;FRMH-^-H)<?;:0>EF2CH!K63H;I#1C=YC>Y4P,7N28>2]7;JK<Q%Y(12DI!
M7U%^\<&I.``G=6B3L1K<9_8[>YX-61WO(Q^V6V"NQ6R;"+"P<U./0K87V^JQ
M;C`L3D%4RI)&0:#*?-%9@Y0JC5WG-!)(IT^HM_QZFBK;&XJ5!"LZ:EAEM:.K
M25:RT!"ALDN_"B&>Q[8PQ>;SZ_(R_<UN>#=57A`$!EEG8*VZLQXLT*)9B/,P
M!!8F`NYP^W>P\?L[+C9%W=68,R/"5JSI"NB*7K27/&M`WD1B"$59+VQ=[[-[
MX<NKRF#S:7L5C0P%LK"CNIV1N(%:Z7;9"525Y\SFH[<T>*"M>Q(4]T8Y$*[R
M:Y3,R:.WY/;R+<O(L]`[GB&46*3"V!B'<\P2X/).0$#?RG`R^\8/>%;'[=AT
M?BUV7DU;M2ZKR>DUJ:JAZ1"U$<+"K'D=B6&O=OL=I+=;T\K07+Z2,Z0^332I
M2TU:U0S'>R"N5B!JZN'#C>]D9[2Q$1&G&4CD8^0P'14X6$@2Y:T]<Q#`<FZ=
M>9+,28+;-X$`2%+<7D]S[K8;<6RZW\(LRA/!=FW7T5"(%$A3*=&5F(!<)*1)
MMYF*3YAO<]/GYB<S(W9X=O%VJR93WLR+1?\`LV,(M8>BEG>9`-'Y?CHYB-(Q
M&C(Y+G2C*O[I1DJMJ>LH*FN!_F?S'S!@(F>OP,D:CKMR^WXG8,O"=\>T8UA5
MQ?)VICR@%363/&/ID00`&(O2KV.EY)TP(.YB5/(8QJQ]D6XK&S;JI>("NL)O
M^6JX&WMPA$>*THW&D$)Y"`QK#(1(V';AXW;,4V8!?&/@%:%;?8>GO4I,-!@`
M;L96.6TQ^Z9_?<\5=V6O-`W8NO)T@>9O6VO<`%)')B95``T^GGREH_GRVG0,
M?'Q&PK+/0!KFUR1\[)OP`C.CS[>1M)FF.'/["EI[&M*Z,Y),:6)YT`UJ(0;V
MMY^^_P!PTUMF-?2U59,RX0DR%%80<ZV96\WE93'(G8@GL<7$]EY-J=L3$R:[
M[@O&*C8`(9S>UI%=R(RDIYE<%N`'F!`I/,?S=QSKYE5>\<\TX*GFV53$;29K
MD>W@X>VAU,<:9]VGKM%*CSX\>]JY#2L+^7`<2<)P@-D#4?DZ;LWN7N6&CT=R
MPLAZU<\GI4VJ6/GX%`1*L((XO"F6*F=8WN?V-V/N5M>7V/NN'5;96/3JR76A
MP@'I^JMI#`6(9!YUS8.*!U*R;,^D*JPH<3`S-IES2Z_1ZRML(UY<1PVF2ET.
M,AOI(D]]]GI@,\2XD2[`;&D-:#BM<Q/9'1BN:F9[:NKR,YLJJT"RJE@54\;`
M]AY$<'!?B`"8"%M]FF-:SWSC78?:4P,C'+47Y*L+'`>EJZ%]-6]2LBLN2P$M
M:$!'F2)&KFX%!,K+#A$%PXS;;6?0&"U<V=9MF/MK",.PH*F@6WA#KHU366<P
M=-*4*Q6"A$@A$42K[$*?&[^R6UYS4QZ-/;K:P%CB##L_$\BS*.2SR)8,2#TA
M<_V<EM%W:4RI_$Y/><>YF;D78<JTKYJ%"*[<'X\`*S6JLL\N3]W<DU&Y^`B?
MZ=YCOU_WNGRG+_HB?[5Z\$S/^9;]7\!KZ][:(PD`_P!K_P`1U<G6-K.TZ::=
M--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.
MFFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG
M333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333III
MTTTZ::=--:#_`&W;+3YC.R6QFR7)S%Q2=$<48FB=4UNVOVF52N:)Z-=4]O!R
M^+O+LO?_`$Z]`]CU>ME6+,?\%>/_`(HU)_\`3:\=_-?(.+V^BP+R/]3Q#UB.
M"WV3OM_)T.QUQRU68MLMR.PM1F)M[&B7$J[Q\2GS!=&DS%WCCS(<''T_Y0).
M1B"@3!CN#QYIG6ER22)D=I!E7KV7$RJ<KML76K6Q0+86?A%JP";&@BPR":P5
M'"L*2Q!&OF'N.!D]O[WRQL=[JUM-E(2HVS0\E5I20:0%8"YE=C;<74(&#:NV
M\X5I'SHDOF/F;C7A=D1]DDFKM;^RW&N+GXY(UXDLF%HI=S`I9L-\Q[2?NHQ'
M$"6!S/49ZMZQ*.]WA&3LV%E9I/&&5!57S,K'JL%+`QMZ9()5IE1K99GM7$-J
MV^Y^Z8':@O*4>QK[C6(LY?AZRZHR\B#ZP#!70CBYC5PZ>5PIF96;+DJ'1WUM
M05UG&'=65/G&@D9T`"SL]KI[=2>RJ(4#'1CBGF58UE,+4O$UT@AE*9,;%3O>
M4EHR[*JZ;&4E59Y#DP]8X!6)L(*#=%%@/E`A=9N?9[5[?90W;:;[LFE&`=TK
M@U@%J[F]4LBK2"+&\MKFDJ"[-R;6.K!*RZJ%U7'F3R5=.ST67,NKT/LW-MIJ
M^9`NH:V8Y]O:SQFL9L6*.QDFB50FNE%:P9D5S6=;*KU:+OPG<;KFKL("K_E*
MA!4\851`!)10UA\H)(ZG6DN]#+QOZAV7&QDMH5F>P3D/:K*Z\N3NP+,`+&9*
M0.9`5I(&M;])>ZN_B4;=#LM+K(P;7/OCNL-!9%CUTB1:5S!R,_6SWR(#`%CR
M(Z]HXX[G,>(K$:A">CI<:C$QWL_#4U4L4>8020%;9V$&9!ZD]"#T'+AL[+[C
MF54C-RK\E!97'*QB%)98-:M*P05^D*2"K`"6X9FN>0MQBN6.0YF+TVRR4HN<
MST8EC&T;F3U#''=M956SAR*^+;5Q0&-V;)CD'&>/W(YK&%8[2T=NP<[M.,F;
M51<OJ.8*;;\?,NQ*F8Z$%IX]2".HR>]=V[5[BS;>U7Y6-8:*P6%OF@<_(\%0
MZD%OJ4A2.4@!@:'2Z*EV\V5HM_F\AJ:>19QH4LK:IN3UU]HKZVJ*Q(L"\SD>
MM`<SB^*'D6,21V&9H2=U:JI/?C7X-8QNWVW57!21YO4K1$5FDJY:-NBHPW!8
M:Q<7-Q>[6MF]YHQLC&:P*3P]&ZRRQT2%LJ"@F8Y-:C;,%,P=;"XAGS[M=+";
M+J+/-0LA(99W%I'R49LI9MC;M-78ROOLD*$ZUN\R\A5,>36F..`C7/\`%!/$
M[G<[_J+"QFX.MKW#BJFPQ`6#84LGBK[0%<`M,=01VG:5]F=USD%M=E%6,W)W
M%(GDSRM"V4A>=E4GDS5,PK@M'$J?A?G>DK>6HNGXZ^B.,-I^/;/NK/&6VGJN
M.N0AV-!'/;4U*ZCU11T]Q7PYIAE?!;)KF1H[?%8[7L5>@]QWV]H.+W+MV51*
M<5L5&NIAR%9N5?F4D`CEQ<L?YB#JC>RL2CW(O<.R=[P,KC9ZCT/:F-D\JP72
MOT[3P=58@FL-6%41P!$ZPMS./2!Y$S>;O,EH:>YSE5%KJ\RTDV-IC6^AE.M9
M;<7,E13P[6O'$F,`L<,661SN[`/:5RO7=]E.,W;K<FBZMZ;7)(Y`H%0<1Z@!
M!4R">191XL(VURWN@9Z][HP<O&OJRJ*PJG@PM+V'F?08@AU@A>*HY/1"&,ZW
MJ^74%$Y!T&?"P`69'A/CC*EC0B%)7QK*HYIS3;\-<LM5L201:,LP8BR.Y"#8
MU5>]?)4X/W3+=NKR&DF[.NLD]2K8S\)C:>'$D#8'P&O7/R_XU]YNPE``QNTX
MM1"SQ#)G5>H%GS%1:7`+;D`;DSKM[UX;KZQTZ::=--.FFM?/I-@I'%^\KS".
M\=CQ3S#%>4+6*D=J\?VSW/(Y[D\$>UG@U41W=SD1?T55ZZ+VS*]UQ[`0"N7C
MG?Q^^7_7KB_?85_;^92P8A^W9HD>'_#N?]&N0FOYXU]Q2QYE4VGRU22H@2[N
M@QQBYFA?#+6PPDU4E])%%)N@"#+$R4TD@[(XY8I03*,Q`B]AP^P8=-Y2WG;=
MS(5[!S>9)],<C"G8\8`)*E"LJ"?FGN7N_N65BK;C^ECXQJ5K*Z":J^)51ZI]
M,`V``@."S!0ZV*W%BJXR*TFRAFRQC,I3-/9V.9N+0MA`#F=+.ADJ76!3P#)8
M,I9<DC1SQB5Z,(P,]@E>!.^S$83C*4<UA0ZK!YH#R@`B.0&Z$QM-9,-K0,#W
M2H]O<BIY9JG<LHJM92G(E3R],D@6`3!"W!24UC/)WUEC=C:4]]!GRH1;^51:
MFC)MZB5(RL+C6@K9#;9M9:0H=PX[[.:19HV,.V6-W?S<KP/;M,O'KS<-+L=E
M#BL,C>DP%AN=AQY*2L<0.))'$^`AAK0]NS+^U]SLQLQ':HW&NVOUT)J7%K4\
M^+JKSR8\P`P<&9,H1?\`9Q)L4TK1+5VUI1S*F'2:?-YS-YV6&_F;0K8I.4QV
M3&QJ^0(.=,0%@_P0,Z&K3*I$(<K=?4Z,HQN:)>KED=W<%!7OZ''<B7@IXJVV
MT*#N<BNVMFS3799B-6$MJJJK86->8.6&V4@5$K88XV)#>:789SE<>0LOA+?G
M#3%!;20.MUR5.&JJ`4VDMY>@F0(&UCC98V[;+.YEEI'<]T=K(\ZP(!'C4!'H
M_1+W%\KN"=BQ044\?48LQ9%"`FH[+Q=^)B9*H&@\@(ZZSLE7;^T6>[<\BRP<
M_10(@2US8RK>!R?E74'4DJ`MEA204)G6?*VU%82/EJ-=0:^WK%P]IGK(%9GY
M;+GPM*&O%'E^V:KH+[ZNE-25%G`8C%,WQ<GJ<J==-E4WUKW5J&9+/75U+../
ME<R-M^!'E93O'3<:X/MV3AW/[?KRD2VC\(];!*V#P]:@&6\OJ*?.EBB.0@^4
MZOSD*@K^$)3($PEC)JSFI;\^HK`:0IMA2R;.;#K1P!TR`.6NLJZZ0)HL@PRC
M/+FM>-3.14P.W9%G?$]1`HM`9`C%(K8*"T\I`*E9#`00J0>.MOWO#I]IV^C:
M7;')2PVJ+2;JRS*O$)!*LK\61F!#/:"O,[*3-S,G`M]/M@&=K'UIHNV)E:F;
M-E60Z"T;<\?X'.AG>`#S(0&!8Y[T)^617O4RK'5RK\E,NQ,7!(_"<@:O48`#
MFO&VUXW`.YVCB($>:-,7!M[=3;W#NH)[EZ9%YI1F+"M^>/CUAMBRCB"3/,R>
M4I.L+UF?LN5-;.N]`M@*A=$J[C13[.GR-?9Y?#;3.6J65'3#OG6=W;&K+F"*
M-7`)Z#FGN$BJJ.*_K=VY%7:<1:,?B<B65`K6%7MJ=>+-PXJO)26<B0%GY#7+
M8^%?[A[D^5F\QA\4>QF2E7JQ[ZGY5IZG.QRKJ%J4\6:PJ#U8ZOZUV%S63XL/
M*3)F?@,,VEI:NGL;*%';5VDAL^.PS(<>'&N9MN]'$,J"(\\DYS$8[V?IKZL.
MBVLOEJ++(Y,S!2>2B#$DE0O0;@`!0"(UN<CN65CWK5VYGIIG@B(S*.+GD)X@
M!V?JVQ+,SLP/+6Z.$Y1?J]+QA4:C/Y:XUT;EGB2%+W$&O9`M(DVNT-"%\",:
MM`X=Q65]:,$(DT_D,DR01HS()T;W\5G]J&)C95N+9:F&</((J)E2"CF3)\K%
MI8*-PH$K(;CZEVCW`>XY_;\;N%./;W)>Y8:M>J\7#+96.(*B'55"H7:079@&
M"FOGUWR2(W/P$1.R=YB]D_WK.E*O_P`E5Z\?S/\`F6_5_`:^E>W;8:1_M?\`
MB.KCZQ=9VG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::
M=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--
M.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FF
MG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG33
M3IIITTTZ::=--.FFG333IIK1W[!N'YZAJ;EM34WRP>3./S+5Z&&R=0$&F<WS
M#EMXR'B')"B!<XZH-ZE5XVHU%[]E[KV=2,G(>CF]?+%M')##_75'$P1).VXB
M#KR;\S,DX6'7E"NN[AGXYX6+RK(]+(DN)!*@2VQF0`/AKD9R+RGJ[!YRNN/P
ML?*_=((,M227P*6ANC/80M5:4V=3/U95?^4Z7'D&`YTZ$_W#55"=@_7^V]JQ
M*P`$Y9HXDV,)9U'\RL_-ATXD`^5A!ZJ3\V=[]P=QO))MX=L;FHJK/&NNP[E'
M2KTTWDNK%3ZB'DNZL!8UA"LM97EL8W[E77%9!J_WB(Z3-\=#GJF8*78U<B/7
MB;_[;KI%2)(@2#(2;"&D9WD0<;SSZWKQ+!4W%J69N)@>1V$!@3_*0QY$$!6/
M+H6C47U7]RI-Z<Z\FM$YB6^\K1@60A1]:E!P4@FQ!Z9EEKFS<==S+>#"K[.3
M^0\,2KM07]EH*C0/N=/R#();R\H1611C&(E5_<AD?'$UY0.C#56RE5N;F4)3
M8UE8@$LI149.*4CB+.O^+9A)@'D=TWU?:\NW)J2F]N1"HXL:Q+"]N0>9IZ``
M%-T)425-8VLVNZO=95UPD21$KI=6:=:R\:1^;IR5>`GT]'-@5N0E22V$`PZ;
M6"LG'I2`L%,,RL]3O<-W6'9Z5E/-2PM"J+/.W*X,P)L``/FKXQ:"D$3.Q&ME
M2;Z,GTG5&QR[F@FI.&.R5LJTDEE/"X-RH*V<@T<3R!U</,^5K^*:.S@"$>KT
M&TLZB+=PI5?73%P%-"TE-)!03``GVCJF;N2`?9?BJ]JP:9`L0B++8O6/V3+L
M[M>EC$/CT*Q4@D>JQ1@7!(7D*MDY1YK.1CR'6;[I[=1[=Q+*5!KS,JQ`ZE5;
M\.BVH160&;@UY!MX2/3IX"9L&I+.55#NN1.7<(<M34R;C.YTN5O$BV!@5FFI
MVW*P56S<`YJ[-Z.21T`ZO1HXQ7`D]E&)ZK?DVY&!VW#SU#NJ6/S60"4;C/ED
M2Z#S"-R`R]2-18.-A]W[WW+M#FNNRVBLU60Q"VISX^>"5JM/W;3`4E+/I4ZP
MQ)'8ENY.-KZQ^7LH+KO+9O.:JM;*_P`>TL5E/L).GU$U7^J/(K%AE>R4991O
M-J-"(HU3QW2FL4#-L86U-QL=ZS'-#RK"(/$-('$<1'4@]>7L6]LMNUTUG'O3
MU*JJ[EGT[1PN-MK=`4XDAVYM(A59>F113:["5(H<'/:G\6=-:/L*$ZV-`M]7
M"K0ZW8O5Y8Q&-':2AHKAM:'V($3GN&,K5UQ2S/N+V65<E7X\96LMZ=?C_*#U
MWCD0`2#K=K;1VC&%5-&1Z;/&R\RKW*HNNZ@_61N/+/!22H8:MC,9-]@Z?IMI
M!/;LJ9!J2.EP&@K';?:5LZZKPS;R/7!GGL*F%">`ER=9$I?2H(KD&Z254RLK
M+%87&PF"%P&/'FWI5,%)"EH`8F16(7?D^X4:U^!VXW%\_NB&T5L:QS%:^O>K
M.H:P*&+(J\3<W)O+PK/$V-JJ<><G\I)IEF5/(6E%>Q+A=%.MI5U:LJZ2J(<L
MZXDV,&S8^OD!#'%(()6Q.ZB&T86N]H&/A[CVOM7X7A=C5''*<`H5>3-$*`5W
M!)@'S=3)(AB,CLO?_</X_P!3'S;QEK;ZC.7?A6DEG+*WE(`#$0G0!5!Y(#T4
M^=]O#V?(>O\`P\AF\TRJX[RXW6%)1!H+#3-F<QX,L>UT<""T5/%N#QQ-D%!$
M$(0'RW-52/1[U\X]QX+X7;:>=UEI?)LV9BX2,:V50GS%0=@6))"@["!KVWV3
MW:KNG>\GTL:B@5X50Y5UBMK>6;CD/:JP@<@<BJ`*I<CS&3KL_P!>*Z^I=.FF
MG333IIK!'T.C?^F>]>]6HQG%7+BN<J=E8BX6R17(]5[,1&]^_P"G6^]N?^],
M<#K^+Q__`&JZY#WK']!S">@[=F?_`#.VN`-F9(%C7%A,:U:BF,M?'GPE<-]5
M^WOE-A,!+;+68&;E;*PA$8T;V_B'7Q155CF_0E2^I6PL/UON0?YIB9$018J,
M-QYA]NOC3(84WHU6QJJ/$,O5.,\0&GD&I:Q"((X-MX$4L4@E'-A,@1QI236R
MP1VRY1Q'JYX&@H[G.'FV,QT^:2`DFN(&1(8Q+.(YLKQ5"$04I47HQL)]=8)@
M2&!\RN`!`F'!`)X-*3L)@5VQ+4%*C\(\@23*,(K>HLS<FXS659@/50BR#R8+
M7]+EF<GYVT=&K"S=[08F?$+#KJ*MUB:#,RF4\:0^:X?X%H6]R5/4N$R,DABR
MZUI%17/C!8['QLL]KR5Y,%P++P06=J^#CD1'5>%C-);B>+QT#,1F9_;AW_!L
MX5EN\4XC*56M;O4J/`'E]+&RE$("\ASJ#=36H.1?GNHT7(?($;BY,P5*\UQJ
M["DOHF=/55&>XWK;`N8%`M5N%C&M("P(4XL1'%>WQE-8C$!($U=;[ANQNW=N
M/=?5'J!*PR%PS/<1S)7C/$R5#;?RS/)3K=^R\;.[UWE?;XQSZ)LN:NP5E$KQ
ME8U!7YP77BMA221#@1P=1J_^8>5*'80O^F'#<V,7A_(@K\Y4P46OBQ"0:>.G
M[>S/QY1H[9%+7QGPF`B'60LIKAR#M&1[/3K^S=IOPW_JG>E([Q<2['<F6._,
MB88GD2PCCNJR`9W/N;W#A]SJ_H'M=U/MG&"UHOE"\4'E],$B44<`J-RYCB[A
M6(XZO5D*_LJSYEKC@N5;78ZW_;'SJ6$V$^2[$U\2.2+(KE=,L(P'R!^MY1/1
M&HGZ-:YQ&=3:^/5;W2T%):Y>4,9CU23(.P)@R`?VD`'S_'JS,BCL-#BV$Q7X
M\D7C/H*H(*^9@)$$@_J!)'0"@#2\PY!E;:2J(/,O'CKO4Y+/1`I3R846PK_V
M#8:,4&H<,#5F!E-DM@2AH>#8!9+5@$?Y,\^R&N[-F>K4+#V7)XI8Y/($@\ZT
MEM]B(YJ89"4EHW]FPTQ?<W;/0R&I'NC"YVTUJ.!4,OIW6A4@>8'F*W'*NQ19
M"`R-`M'IX>_V&7KJU\.QI*G5Y!V>K%T.PK=!9V;[B=E-M:7]-$AQF$,>1``H
MO>6-%%`:Q2.`[WO)Z#C8K]OP[;+96]ZK.;<*RBKQ%E2HQ)Z`F8!8M,<AQ`\;
MSL^KO/<\>BCB^)7D4^FOJ7+8[<VIO>Q%42256.15!7!8H>9:LR:*KQ>2I\#3
MQ*&3!DT]>?2ZJE#8B%?:Z(8E7%$*:]Q;E*#/RU/'K&'>5CD>60JJZ1_3`F1=
MFYC]PN-@L#D)6Q7R5D<CM]/-Q!>`.@7HNLI\/'[7VVKLV*M)I:I3;:@8"RX'
M@`&W?TZSR6H,2#+/U?:U0VLG-RXMF,)EM;2.<N>BV,@[Y%!F;$$DRZH:!;&G
MBL[FFS@XM1.`1[V*LR1X$18ZDRVJ7)0U$CT4(YD`0[@@>GXCBK.6L4B/H61Y
MHUZY-F#8MZ@_B+%)K#$S74P)]41#!W2H+38I)_S7@^3EL1P%#L8>ZXFMVF'Z
M)O,7%]78/DE9"$DJ99)9R(E=`DLA'0UK,5\IL<;"*T<17]F()Z-YSW`];X&7
M2097"O80)V"\021(A1"R8W:-Y&NU]G57U]W[;E`C@W=,5&D\1+-R(53Q,NTM
MQ`.R3`XF.]>3_P#=^!_\]_\`T;)Z\!S/^8;]7\!K[#[=_P`FG_I?^(ZN+K&U
MFZ=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=
M--.FFG333IIITTTZ::=--.FFG333IIK\_P!_++_*!]&\*_0/`7\<O\>."RG(
M/W)])0':)E[N!?GXSAS`O)<CCZ.SK&R`195K)C9JUL"EG.="JZJK(<D>6\\<
M*M2(@(+-](UJ'8\^_P#PA'^.KF[@"P^L(O'W\COSSSCOZWC[757R[Q%))R3Q
MM9V@S3Y4JGBY/CW!V02U=/!E38Y+"+.IYPH98Q#P#E"56KHJ8&-FUM)PC_*Q
MJZ;^47^3[@GZQYFX@XO^1?E"HX:_Z:Z+81*#C\.=O.1H^:8D/4\@6<\`K,]O
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ME^-.;N+.7B\3<#\Q[/,:O&7=+NZ*DW6+X\OM-1Q--51);B1C@FP0E)`FM`4H
M%3NWQ<B]-5"GD`WQUQ(_@E_FD^COKJJ^R`_<EUCY5IP=PKD/I+#SLKB*_!"-
MQ*.!LTW<^1'A2I0[*."54UQ`R%[>M)#FK_L[4&I+*PL<?'6MO\2O\S_\C'V]
MKOM7-\P\D<#X&/AOA'DWZ&X.TNPP%5@,+@=8W0TM?@]MR3I!FL2R.-\_"LWE
MLB%"YKHH'F5'=NRM5=%6(GKK]!ORS]S<?Y'Y<^9+'[A^UOC&WYXY=RFWNV\@
M<;<I9*CX>Y99D=5?@M;OB>9<&H`W%'F:0,6-8E$)K`30E1WZ_JM=1E22>(,:
MR!7_`,K?\;%KQGI>8J_[>^;I/&V/OH68T>G;RAG&`K-!9L.6JJ'UY9;+<\VV
M!%,2(P4<GY0@%>+S8(BM:IP>8@SK9O"_1W`/)G$#/H'`\T<8ZO@YU7871>6J
M?;9^3Q]"JZCV)<3+/5?GMIZD=,X3VS$DE"Z(YCFF1CFJB-4@@QXZPUP9_(G\
M*?3%UJLYP%]9\$<KZ#$UUA<ZBDQW(F?L[:KI*ECB6MZM>DMDJ70UK&]SSH[2
MQ1(J*XB>2=VJE67J-<AOE/\`FWC_`%=O/Y/.'1<Y_&_&^EX>NN2Z3^/O:R]C
M^!2<O9?.8?E;1Q>7-,>YT^AA[7&8^/DJZVN)])#'#!5^\KQ*Q6]FKS7`!@_/
M72;Y&^IBYK^/_C'Z+^XOJKY/T]FM?I2\A_1W$6YHJ[YKT$D.YT]72IBM/8,H
MZZ60%7"CP"A&-#%LXYQL:]R?JU8P\T*#K8OYW^R/E3ZUH[O1_-/T%Q3S74Y@
MK`Z8N`V-1=RLXXK2/`_0589#;2E!*8)ZA+)"(9D8Y1N=XN[-4*E>HUC#"?R9
M_P`>_)W+9.!^/OLWYQV'+S+%].'"T/*N3GW%E;C(X+ZFD<*Q6%?VB%8K?QX1
M9!E<BHC?T7IJI1@)(,:WDZ:MUP9_DU^^_I+Y@_D7_B;^;^(KS)UO%?UORU.R
M/-=?>9"%?7-K2`W?&=",6?NY$@4C.2$KM/+:I!->JO<UW;NU.FI$4%6)ZC70
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M6>,!Q"*Q7J"?'I]S8UA0C1S72#FLH00"$U4<8I6C1'*[Q7T/V'`S79C"C$OG
MY@M4K3\`%))/@!.O&/S<+'M=5:++MW+%`/P8)D,I'Q)954#Q)"B28/%N]C1:
MVP_`LG'D9*67UWM"LHAKD,&$9DYCX<8+S+"N($2:4L92)%_-+&0#G>LY?/VR
MAGLK]2J!E@>1HA22(W)ZJ2`#'+B&Y1*B/EG,KKHN]'()/;F/WE<RX53RV`)X
MNH8E9X<RO`GB[3`J9%OD[Z)3MGNE6ZF@V,/1P#MKHSHRRBP*N_@^LLB85XGP
MH\T7F-DL!W$"9BF&1B5N6G+QS=QBF""A$F8ED/0>)4P>)$,IXD'5F,^3V[,7
M%#ELF59;5/$1)5+%@DF.*N)`=6)1P64@5#7TH)\D>RIJN-99^+=4FJTKHF.+
M+6HT-'B]63-O8.@_%M!9Z_MS-$%WM,Z%/&\+&C:8+4CP[FK4X5S%<@HU:38!
MR1K*^?URO-%W.PY)#&>+'4_<\5;G'=,6M7PUM2ZV*2>%E=%WI;5PXKL<@*9;
MA8"H`#(-9@X0HA:M-3I>6H(H.`XGKH-[R9H[*G;7U,[>0G1;S+_A5!R,L[>P
M2]ECDK$5'NER(;`)W28JCTW?,@XAJQNT,6[AEL5I16EA495Y8>51Q!'+;B&+
M?R;]-[4Q%[C^(S_<:!.S=N1;,JUDXHV0L65<4/F=O48-PWYL@3I88Q7S1N+;
MEZGEZJ2=4HH]]6,K(SJ>LJ+6R>[153UU>BK(PALG7\ZJAB$>0)!C?ZV"$[TC
M11[;LF!3V>X8BC_B#6W(\F91Y&^[1B=D#$D`R=R2.1WY[W3W;)]RXK=QL/\`
MPBW)Q'!$=OO4^^M4#S6,B@,P@&`JGBLK$IY5M*YIW>GC5QY\JIRN:A"\Z*O%
M329;H%]$(S0U0'2ZR6%8I"LDC.C3O'_6B?T]4N2I>R8^*[!4>YS]9Y`2A\C&
M&!F((VG;QTQK,E_=69W"M&>RO'J4?=J$)XV#[Q!*D<20P:&(WC;6Q.YI:.PX
ME'SIGC5+[K`U^?RG-E?1JXECG*C.6#GY&&?\2>YEM:UY7F@I.$@%GC%#:YW:
M*;QYS`OOK[O_`$')#^AD,]F,6Z.SC[P[CRJ=FXF>!+F/,L]OW;%Q+O;@]VX1
MJ.5AI73G+7NU25-]RIAO.ZDFOU!Q]0"H$_=O&G5;G"\EZ5`O/GJ])L6SJ+^Z
M874VU=1Y?/ZG%6U#9"KG1Z\1;&=!MQC"XO\`S,V:=&JYR$.YG96Y([9C2!8W
M$JR+]VI9W2U769.P*DF/*JCPA9\QHP6[[G<6-"!U9+'FUUKJKNH>M@L*"S*X
M"D^9W:"3R<BI;F[)..0=/3MJ&M=,_P`>I!`FOF%@7MH5QBL0#$@S)]U=V,Y9
M1$:OY4CR>UJ?TL9'@T!%!N?F=N;2(!1>F^X"J%XC^40">I.1W;+-SD8U0J'F
M]-`&Y%;',G;RLSV-9R/\[20.@$O&@)#&M*)X8TTEBDS?_FN&04989K.?7XPD
MNO\`_58N8AT@!6R$]PYEP0?CYLB#5;F?F?7,E.,51U,A0;(/4N6)KB"M8/0N
M=65T^DOX52JW%^61R@@<2S+02O05+6HNGD'N*Q(K76\/QQ$46VV,U['M-,XP
MQXC%*8:DFK$YSSCEFM`U6J^.^3*,P<CP:TK6>/=7C>B<+[S><&E!T7*LV^$X
MK[3\8`)'A,]"->L?EA5Q[IDVF>38%())$M&?5YH^$E@&C<".JG7=_KP37U]I
MTTTZ::=--8$^BCCC\9[TQFH@@\3<P&*=[F,$$8L-/<]"O>O9B/3_`&_Z=FKW
MZW_MQ2W=,<+]1R\?;X_>C7'>]V"=@S&;Z1VW-)/@(QVZ_IX:_/U(K:C,9&-3
MN05VZDI[*/.D08\VLIE*N7_=65N=F6#"V4>IIC:`$"*V2AT1!A:\S>[F,^AD
MMNRLLW"4YNI`)#-]?&7`\I9N!=N,=20/$_&3T8V!VU<8Q<:JV#%0R)/I<^-1
M:6"(;%K0-RZ*"PW`CP99X5+)")C[*;KV51`0K5QCN#11)T)*W:2@U`X1)=G:
M/JY*T\E"L?&@+*(_S;)"BVV(MEX)/%*2TE8'F(/*L%IA5Y#U!!Y/P`@J=7TV
M/5BLJ@V6Y(2%>3%:LO&\A`LN_!O1:05K]1C(L4:SEB-535,8>ONJZ5`H\XZ/
M.0]1^22XL$FWQ2T^7K"/GV\J98"L@C9Z'HUD8(7R7,<*,1%T.=B77/\`@Z&#
M7VR(:.(A!R=ME`'&3/4DA006&NM[3W'$QZQW/*1DQ*(:4DNW*PE*D\SEF#`#
MB8"JI<@K6=53@R=_U&7FWBB@JXO&6UY4SU+>TVEK<Y=TN?C&Q&GL1WG',N1-
MN)!85'IK0!GH2-(CO=^;Y^A6M\6Q=]K_`*;^![MD,<K!Q+&5D9U9SZJ+QN`"
MB612-F!'ECE.YR?:5H[Y_5O;N%6N!W7N-*6):M5B5@T6L+,9BSDK7:X)E64G
MG/"!`P(3":"#,G#UL?\`PN[;61(<S/Z#^S'H4AYN97R8=?6P($6;$X_LK#0V
M"S0-6O-+BQ8BAGE3N9>@&?CV*IPSZ]',D.G5Y<$$DD@V@(G$^<*S/RK'TZXY
MNT9M-CKW(?A<O@%:NS85Q4RE555##'9K+.:_=LZI7QN;ZM6[5BTEA1_/,&%;
MEJ",X_T9:2QEZ:'/A0O?FJD5<XU-)6+7PX'[L,+'1K$JB\O%6^4D(6.R+3C5
MW]QL=`X_$)R`0@F':8822>,^9!/Q\K$C!QUSKL3LM-5IK(PK36S6JRK-2!90
MPJKSXCC:8F(EU4',_P`_<=ZRWY9BW==*7"U?'MN/>76[)*,P."Q\=,8BXN#:
M/BR++D*RN:>D-6>,QKX1_&4X3G^Q572^X>Y8E/:#18/Q%N0GI+5`^]L/J?>%
M9"TA68/Y88>68C74>S.R]QR?<:Y5#?@\?"M_$/D$F,>D>A]PKD%LAG1&JAP:
MVBPJ3)U6Z3E+CF]W?)FDSD"+E7<BVEL+$>4W42Q5]-HM)$R3LX&JDAK\W3R-
ME*REE+0T&0]R'D)%'V!)>YT%_:NY8^!BXV2QN_#(OJ[()9$-G/D"785BQ%AA
MT',^90!EXGN'L>9W?/SL)%QSFV.*/-:P6NVT4^F$(6I#>:;7Y5L3R;TQY+"3
MB_36U((D%DFFA2HX)='%L89YY8S[&$%9T1!`DU+Y<RM$XLH"N50O*P8T3S]K
MNS=KBTWD,5=@Q5B"`#!,'<-`.P/B!)Z0-<_GY.(I0/4C(K5AE+$<E'(0"A+*
M)*SY20`-^1VL>VN`$M+.>Z3!N(EI%?<P"NJ(5=$FUCL["%7C@UI[!!9H^>6C
MD17581J2".(UC5\2#>_.II85+7#(ZGB?,20W,S)`\X?F&]0F&+2=P0-5DY*-
MD67$I;78O-3P559?34+Q4M]T:_39/2436$"C9E)V(X(T3[?F#B&3-J@SA3MG
MFXT9&L[KE=&'D//3)^EBD>8D.W!HJ?QK7S/)TV.SUH!K(TN4B<YW['%/9LQ$
M8JRTN3_\D3T7`0^*E&\_'Z3OR)9$UVWM#..3[E[9996'1\JH#_Y#:,FMFM!D
MJXM3[HO)=1Q"`5V6:[V9/_W?@?\`SW_]&R>O`<S_`)AOU?P&OL/MW_)I_P"E
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M,L+Y@!]I?R5?_"1_FHP$EVO*?S#P^'*H]&.\>1Z++X+7\=S7*].S5!O*6`][
MD[+X^7;_`%ZIXZ3Q1#K$G\<7,/)W\I'U5\(V,>JFVMU_$I_&SMIEQ6Z2&3\"
M7]F2?W[B'CYY1R$:&1/)!S^?M4(_OWF5,A%7^AR=-&`0'YG]VL<?Q=93^%[;
M_P`8WU;JOY+[GCLGUM.WW,\[Z'ON1[R"'ZVJK)91GYB3P=#T!S:J7K3V'L(Q
M*N+)=+TCY,>R8435"UJK\PXX=/W:R2&K^`]1_+G_`!T8_FV\!J/XP('\=F>+
M\%/^F+;1%XYT%L29?"$N]E<L+!]]F6_B3@O#;-%%<:'2QFL_%2`)6J>;@8^N
M=]4ZHK>$<=_(Q_.7C?X_9&63XQ+_`!/<\6?+%5Q5/%/X6JN88_%T%M8'(%JY
M$C.--%U4NU9%9#>L<#CVP(R-`)XV-5WXKR^KEKE_R#IM]\?_`!M\,\]<:5$I
M[/Y`_P"*+Z0^&M.6"]P5DZ>L^BKX<>Q=X(GOGCRVEK8HA]U>YHU[?HB]-7=6
M(^#3KIUQMPC$^:?K;^8WYXB#&)O"O_P>_,\>3AB\59^_4WS9P:34F7Q_1'SM
M1+FR'I_Z9E[_`*KT\=6DR%/^U_;K6G!<.<>_0-'_`/!8.&.5\_%U?&O(%7]%
M5.URTU2M@:2@@_0LF^DT%C^.0)W5=N2H8"4QCVJ2.][.Z>7322.9'76__`7\
M;WQ)JO\`X2?]E_/M]\[<<V7`?%GS91<J8KA251@-QG4;36Y/@6'9SPY1_>L_
M""7<VLF+#5BQ8LN7[1#8X8O!JA=O2!G>=<=M1&WF._A\^[N,N.#W-=P1B_YK
M8^5Y*I8I[R=2T7$<3'6U9G8F@#7F6:?(EW5#G6SD5_LDS`Q/ZE,YJJU?MS!/
M7CKIG6_,YM5]7?QK<J9[[M_@VXEU^:Y`S,?A7/\`Q[EMKQOHN;\+./0)?\5;
MJ!#DZ*+<+J,<DRDAQM$V%)ERK>3`(\YC.`C5G+8[-^O5[?)=5\NY/E#_`.$Z
MX2PI>"\QREG+;Z@C?-N5G4V$I=M09.NXF^FZO4UW"%8>+&MZJGKZM@PV$6A:
MP88W@AF-&K>]=4/*$ZZY\Y1_'=GP)_\`!K,C]F3"5_\`'=9+],V7)J6LJ9`X
MZG\HQ/H/D8$,?(,N(4`@U<>":E%(*5[71Z2;9O:Y@727I35_B_'ZM=S=?QS_
M``'Q.?OMO-_,'T1D/FWG/:?QW<E93?[O@;234^4>..+]1665)J-H1./G,XLF
M;VL_*IWV-<:Q:XOM@)`$RUDF>YMJ,&R!(D3KBYA]GH_XW,;\03>8>`OXB_Y#
M/ES/<U8&1P5RUP).H7_4LBYN;&;=4^H]48E#O;;15+);GK%TN<LXD:U#"B32
M!F,B%8U)'(G=@?W:_H)<??0'!_+&QY*X\XTY9X^W>]X:MHM#RWC,KJZ:\T_&
MEY-)8!BT^XI:Z7(GYJS.:JE,:&6P3U='(B)W8O:NL8@C<]#K\U/\W'_XXW^`
M3_\`>`L__P#:G"?34M?T-K5'^/7XE^6?J;[$_P#A$FR^A>&,9RW>X+Z#Y2R&
M%D;.K#;-Q<+7:#GJZT%MEFG1R4>IESLW`<*TC^$Z*D5J`*/R)YAJK,P58^&N
M/>3T`K;^)C^&_)_0=_L`_",G^2SG6F^I"5\JW92PLU"V^*M\W7VY*M%,"&+.
MW6UFQV#_`+C"(<T=OY`QJE-2?SM'U1K]0W&-)_\`!]N,/Y+>!]A\U[?CO%_2
M5)\^\CW>1A?,&H/_`.'8N'ILY83]1<<MR^+&SL8+7P^/X]C+5E[-#&+7PUD3
M!OE"@$1J$^H4WZ3K]!W#'-_$'T5QY3<L\%<D8_EGC/1%LP46ZPEW#T.9MC4U
ME*I[84"V@$+%D/K[6$:.5&N7P*-S5_5.JZC((,'KK*?35-.FFG333IIITTTZ
M::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=
M--.FFG333IIITTUST^^*V)<<<)5RV52LG\B\>Q!R+P\P%56$D46["Z]D+7EC
M3C2\Z%[Y\$03!,:QC1V#(PCFN3T7\O[7I[EZJ<Y7&N,*`6:&J\@F0`_T,2"`
MA8D$:\5_.*BO*['^'M%</G8P!L+!$)KR!ZAXD,6J$V5@%2UBH%8$@ZXY;-V6
MGRYR!98R!RD0==Z2L@6<J6*E/`_(511Y$6UDW$NS"[R4+$=(<]`_Z(U/9<+\
M56JSQ!'6=U`Y`QU!4*`?$[06U\Q=U/;[K'X!R&V6#Q8D(5G8$.7+*9XB6)"?
M`2/[I65#*;*29[UM*"9+?,DD.61,S3+O01DD8>JDP"1CPID`=027<$\3,E7*
MF:'P8,KY,GI6W%\M5^ZL40(`#\4,6L#((/(+6-N-?'E)("P_B*,85=NL<_B*
M6;D226J]2P30A6"K*$+W&&#W\@L!6-F;2:RGS7&EI80($B>76T^MK*;.MI;:
MYB:B#(B6L[12]".T/*GI11H,&09X!R@J>S:`0W")[7MT8Q+LKN:UV,%%+ULS
M\E4H05"!.,#F20`2IA.1,B`>L;N6-@]BLOI1G;)JN5*N#N+5*NUALYDMZ856
M)4.O*T(H*GD17\Q5:#F#YPLJ'#0I![CACE#9:#78X%7^/!YDIMPEA(/KHK)C
M9YK+:X6LU#?7%>Z<)H6`:,3B*QCL?*MQ^S>Y%OSV`IS<6M*["TG&:J`*S$!:
MK6KW8<3/(D@2=9>!CYON;V,^'VE"<KM?<+K+J`D+FI?R)N$\B]^.ENR$V#B%
M"J6@'5W79T=1D9=A-GQ%M5MZF0D%%27=CEV6\CZ!1V+:]/6/09Z9=-KJI[2O
MCQXHSHL%?R/(758>2;LP5UJ?2X,)Z+"U%-I_D<+SL$2S%?O/+!X#N6$N-VUK
M[77\1ZB'C]5DMD"R&X]+*VL%=1DJJ!YI\\K`.ZWOMYR5:29\94JZ_-#LTGD.
M$-A70K&0"SA2)!G07Q;*#(,R2XL9'R)BA=$7R%)5'544X_;\6I5/G9^,1L2`
M5(&\J0.,&`L\]BNK&.3F=XS\AW4^FE7/D2`RJQ#J2>,,I(8E99^)K,K9OL%\
MOF%QWDMWSCR$\E?@LUB;WC/1YJ;!BB)SK;OI,W'B9]U.(2#?2YNX6QD2+(;5
MDH^4U6>1%-VY[W2#W++Q^Q=N`;/MO2Y'!/\`PJ\G)?E_B=>`"'RPIF!&NT]@
M,O9.VYGNSO1*=GHQ+,6VIE`_'OZ=0%?`"/3J?U6:T#E+B);E&.L'J*F+ER9Z
M7(_`T].4,NZK"?GE@V];4YRBK"D-(N5+*FP,!-EG$ZOCO(S\:2Z6TB&66YFR
MS\2Y\L9"#EBN"%.TJS.S;!=@;0`>9`,@)''A.C[/W#'JP#A6-PSZB&=3R*NJ
M5UH9+RS+CL6!K4D<6-@(?U"+1;H*RJG0C6ME+))D!BPZJ^=7F2QPLYXM#$73
M`J>YHLN36SI3"L"=WMC@.P\=?RAQNLS\/;;65J4!`2621%H\AX%MB`P$2-B0
M5;R%M:T9N/CVJV38Q=@%2SB>6.T6#U0FX)5B"%8RJL'3[Q:]6M%(6ED1J.U#
M&<"J>'PAE_'+*5M305,L7XEV,<=MI6FCQ4<,["D$40U.)48]7.RG`N4WTD\G
M!WWCS.P,KOQ8$[B`03Q.XC6OK9L5UQ,@+PK(\I@GR5HPBR!S4@2&!((!==C)
MZ`_&DILG<<DD6MCC9,QN/M8EU&?*,\M;-Y2X^'7Y,RV;&2P?X>Z(3LT3G1BI
M.4RJZ00[G>>^]$*8.,.1D76*5,?4*+IL''8^I(Z[CCQ^D*->R_E?8'[MG$UJ
M`V+2X<295LO&"TGEN/1@[`E3ZA?=V<GNYUX+KZ]TZ::=--.FFM8?JPTE.)N2
MH@U8V-(X+YZ>=SA/7Q,#`G2,OY'BH0M3WO[H[]7?[$7Q7KJ?::K_`%?&<_4,
M_%C[#:)VZGH-<#^8CV#VYGUK'!NT=PG8]1CF-^@ZGKU_4=<(K1[9#AVUM$_,
MHJE*LG^,&DE::^O3+&M79]+F$53/]14ADE2&>]D:%$5$9VD1U?[U4.(-5+<<
MA^7G`V11*\^)^(Y!08+,W7RM'R#>0Y&3DKRQ*^!](DS988?T^:F=CP+,.05$
M.WG0M3\ZC-)9O.[]MF3#&/<3YMNR-61F1@1BK8VIY#60VU=3##(DRT8]&BC@
M3^@?J1HEDR9QJN(Y*@`4!98R3LH&_)B0%VW)ZF9.H<*,[(+GTVM)+LSPH@`\
MG)\O!%!9X.RKT'&%U0-SHZ[6S!8W.#R[X;UW61S-5:3--:%NMC%)C9I[^QK:
M`,.OB3[5(788K`R&KX2C$B(_\A7Y&!C6XB',R?5Y_=6.RA%XUGU`$#.22%G<
MH(=I/3C&'W;.I[E:.UX(QS4?Q%-2.UKE[QZ+&QEK"JK/QV%C<JZ^*C?G.;:.
M1!XLI&6-7!&VWL]O638EC1TEQ(@7O)6JA.)&LBLC2(MC#QE!=L$1XAL4B`4A
M$5DJ0G?1WJ_=;_3M8^BM!!#LH*TUG=1((-CK(DF)@;HNNKQ'I]O8@NQT`R;,
MM6#5UN5LRKED,8(9:*[()`$\9.UC[YIY\F`Y#X_%RM!)*6^*-V?M[43)HXJ:
MR54R@V]82OFT99,*I#,8^;0RU*1R06NBC;[`-1FE]OHW;NX'M-D?AP>:KM/I
MA@5:0P!:(6U8'F\Y,-OU/O&U.]]F'N*DM^+(]-W'(#UBA#J5:LE4#`OCO)^[
MFL"4$:>YRO@V0OGBK=,SK(\S$I&LCU[YSY,2+-'E(WJNP3;`<%U@!TE"M&!0
MB1S$_15[!=V.38]1[E;QLY"^5!B"1ZA\I`F#$29/_B'F>#33>O9,<M0$;$AB
MO*0&%(APS!>0F0%@;=#])W8YWU$3A/#4W%L#2PJFJMPV%QR`:SDTD*;0W\@H
M"Y#/V4*N?9&L['36QF):*AW)"`,797B<15XCL.*_>\]^ZV5,]J$+4%#$.@GU
M'4GCQ"+/#;S$GH0->J^[\^OVIVFKV_3>M>/:&?(+%%:NPD&FME7D6:UR/5\Q
MX*%ZJ6UH]M:PU5;/M`AFEJ)>ASI->$F@+GZRAKL="M)(H9!252&\%_,LO^>:
MX,=J3T55>UA`MZ[G"M6VD5,5%PK?TSPYLYL*B9&\H%\NY\OA(;7DW=:&Q\G\
M0@<XS7U&X&PUI6M*N0I!\L6%OO/*OWFY(#*-3E&^%N\N&?81I3--34M(343I
M,BEF@MX-A5Q4H=)^[UJI4AG`O0,2V(QXU5[PR$8GO,K;,@/@91KK(_#.[<``
MPXD,>:<6\Q!0_=@SM*SY5F7$:GO';Q=<K?CZJJS:Q*,'5D'IV\U\@86`>L01
MN5>/.T6N.'*`9]7:2!LB3[\EC6V4HYHS*/0S&NB5;I)1^$5E'I`H6IL'.:0Y
M([0D1&.B#1<HNC#U:AYUKXLH$\D&[0.O-#%B=`#R&X<ZUZUV(QQ[V`K>XLK$
MD>G8WE22-O3M$TV$@L5X$`&L#6ROSRR=7\@\.PCSO181.6>.X5R"4`L<DMT?
M2"KEALA&.=8=L=K0R3.9XM<D&0GZM\>_,^XC79V[-=5FLXEQ4@S$I,S`E1NH
MG_$OC.N[]E"ZGO7:ZG>+E[EC*X((+1:%X\23Q<^5F(V/IOX1K]`F3_\`=^!_
M\]__`$;)Z^>\S_F&_5_`:^S>W?\`)I_Z7_B.KBZQM9NG333IIITTTZ::=--.
MFFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG
M333IIITTTZ::PE]`_-O`WU7QQ8\1_1G%&+YAXYM)$>:?+[:G#:18UE$1Z0[B
MHE?V[*AO(;2O:&=!-'EB:]R,(B.<BM5!(,CKKGQD/X&_XB<3375%3_#7$TR%
MH)5?,L3:B5M-G:M+5SDL8+*V[UNINKBDC"E-:KQ0CQQG1J-*CT1$Z:N-CGQU
ML!RI\J1^*8_T_P#2/PGP[P7GOOCFO'5%=_U!Y-9I8^6W]QFWU,6@@\ER:.:^
MQ6FKZFO\!K$&,B/&/NO;R7IJ@:8#?2-:B_PN_P`:?)GP-B_I'D#Z)N.,+SZ9
M^N>:[3ESDY.'HDZ/QUDJMTBUL*'$99UG5T\I84"[U%Q.>UD<4<*SV@'[&@0Q
M&KG<-`'0:V)Y>_A]_C*YZYAE<^<M_&?#FRY7LK,=U>::766M<#3W`W,>ZUV&
M:I;:MR>QL93AHL@]I!EDE?\`VY7]UZ:M#N!`.VLZ?2OPI\@?8/'^:XN^DOGO
MC;E3#8OUIB::XI5K38D0H8*Y(V+N<X>FOLE#?7Q1`("NE1@E"$;'M<T;$:T#
M,ID'5,X:_C\^+OGKA3>_.O"_SEQOQ[PWRI47%#R9CJ.KD=N0:B^J)=!:0MG?
MS9DO4:9AZ6>>*UTR:9X0%<T:L1R]-"S$R3OJAW'\:_PCH.,N".&KOYAXPM>+
M_F+1%U?`>+G5LV13<7Z`]J^[D66:&^>IQOD6SU.1AGF$1Z)Y-5$1$:<VDF=S
MJ]+CX=^2[_DKG'F&YX*Q%AR;]*\7R.%N=]E(CSUN.3>*Y=3544G$Z1[9[0%I
MC5%'$CJT3!$]8&_U=^ZJU3D8CP&K6SW\<WQ!DY?S=.SGS;QW42_D%M^WYH/$
MBV:/X<;J;4UWH4R/G9/0'[K;2'G+[O=W>Y>W9/TZ:KR;??KK*&?^4/G3*_16
MW^M<]Q)E:GZ0Y(R<'#;GEZ*&8FLTN1K0YZ/`H;$[Y;X;H,4.3KFM1H6N[1!_
MK^B]VJ<C''PU;''/PU\A\2XSF7CKC_Y[XTHL%]#Z6\V'-^-)0CN<UR?I=*+T
MWMKKJ:^):0+,UF-$0K7,0:]D5&HJ)TT+$[D[C6#?GS^(?^-7Y7Y-9S+P+\?<
M38+DZ,8\BKV(XEWH[/.R9*.::3DFZZYOX>0DJ-[F(2K%$>T3E8U48JMZ:J7<
MB"=M5G2_Q4_QYZ_GO5?3^A^5^.9W.VYKME5[#?C?I($K21>0L3:<<[A]Q2UM
M]$S,V=JL5=RX$Z4^$LHXSN>XBD7SZ:<W`B=M7Y9?QZ_$]S\RTOQM;_-7%]I\
MQYHDB1F>'[&D?-S>9FRK:SO2VF;/)DDN<_=?NMU,,R;#E!EC625K"-:]S5:<
MFGE.^J!\_P#\9GP+\NXCD#CG@WY3XBQN-Y7KEIN3:B5GW;)^^H^S_'/ZZSW4
MK36]_GAN(YS*^3()#&]RN:-'*J]-"[-N3K%G#O\`#%_%QP%RQ6<X<2_%?#V4
MY0HK/][S^E6+?WX\W<L(I8]MF:#3WMUFLW9P3+YQ3P8<<L1Z(X+F*U%1JIL<
MB"=M7/\`(GPG%^;?IO[P^GI<S#@T'V7R=EM"/*<=T%Q24=!E,#%T8Z>ZU,R]
MN+69I>5]U::Z=8:*:!L.N:3T`B1VL$XA6J,T@#X:V)Y9^2/FWG7E#AGFGEWB
M#);SE3YYNB:+A3;7@)A+KCF[+8U-L2RSQ(\R.`4A]C11#*I&$3S`W]/]>[5`
MQ`@=#KSQA\C?-G"]_P`[ZGBSA_)8G0?3NCDZ[GVUI@3!RN4=+,=?/E7&F<>8
M=A99G:>>JJ)!-_YI_P"G^G9H6)Z^&K&S/\?'Q1D/G"X^0J#YIXKB_,]]8VES
M:\,2J!MMBY5S<3!V$ZX2#<&GFC6[K`+)`I0B,/'.QI`O8]J*C5>33RG?5C?/
M/\6/\>_RE"Y"@_/_`,J\9\>?]5LO;XC?V,8-W?7^BQE_'+%NLD;3:JXO=%!S
M5J$JH>#%E`C%<UKG,5S&*UH79NIULSP!\\\*?+'%M!PG\]<<Y[BCBG+'MY.>
MP^6%)#2U1[^VF7MP6*.7)EG1UA;V!I!.[U[D(O;LGZ=-4)),GKK,W35-.FFG
M333IIITTTZ::=--.FFOCG-8USG.1K6HKG.<J(UK43NKG*O9$1$3]5Z::TEH?
MNKCZ]XRU7-__`$SYGJ.%*>^QE+C.4;>@QH<_S%$W7)4/BVAU/&-7%WLS8R<E
M(O+*-,'-N:RF254213(K3C(WNU=Q,QXZF^4ON'CKC)N@CBP7*^_O,_\`2.4^
M5B9_%5&/#)G<J;7C+,\IYQ@;O<;C%X^MSMK4:Z!6QI=C9072[^2*NCC+)/':
M9H%)_9J4Y'^UQ<;TG`MQ-^8_J&\/]!7<?(YW.UN8XLI]-D-Y+@7%K'P_(%1N
M>7L@^GNRU><L9#3Q'3ZIX8;G-EN0L?W-./7<;:C:/[AQ>8YLMN'+'B;FXE=G
MN5^*^#]'S)"H\))XEH>4.9LSC-1@LQ/.G(C.0B?N(>0J:(:9'SQX,69.8TAF
MB:0K&G':=M;CV<LM?6V$\%?.MSPH,N6&JK/P_P!RLRQ@$,.OK_W&97U_YTU[
M$&+WR`!]CD\R,;W<C5NM+8GW/EH>;^A[OD/A'GOB.Y^:^**/FK:X;<T_&<W6
M7V`T@.074MCBG\?\I[C+6DN;/XPN(?X\NS@$'(`Q2>`2-+TU=Q.W3?4BW[XQ
M5EQWP-M\CPOSWN-!]#W?(>>Q7$N>I.-HO(]79\4?Y*SD(>L?J.4L[@*L6;D9
M62)SP7TM))'#_']K7*YK3CUZ;:LK1_R=<0TV3R^[I^)?H';XZW^?,/\`3^MO
MLKE\`T'%/$?(%OH:6DMM]"TW)F;M3VH)F1M5E0:$%X<0X!'-1_F!"M5X'Y=8
MUDJ7]SX2'S@3AA_%W-)*\'-U7\Y2>914F&=Q-'YDN.-Z_E*%D2$?R$SD=S79
MNUCC=.9G'5[9A$&I_%'$:U3B8G;IJZ^/_LKAWE'GFZX"PS=A>VE/0[JU#R/'
MS9&</Z*XXLTN0RG*6*R&Y++8/4ZKCBZWE2"X_"CEKHLF4^)^6Z;%F1H[0J0)
MUD[GOF`'`?$NUY?G8/><CU&!I9FDO\WQL#*2M8F>J8Y9U[<0HNSUN*I9,>CJ
MHY91Q_GMD/$)6A&4JM&YJ@$F-8BY8^Q,QQE$X?6FXIYDY@N^;,/K>2<GE>+J
MK!.O(6'P]-D+O37^@-R%R'Q_00!5X=W5A0`ITB68\GL,3F,(]K50LZV%XRY!
MS_+7&W'W*N26<N5Y,P^3Y!S*V<58-DN?V=#`T=,MA!4A5ASEKK(?M%Y.]9.[
M>Z]N_35I$&-84MOI\>:YOQW#&MX.YNRT'D3:V?'N!YBLX?&$OBC6:NMX^U/)
M:5\(U%RC<<A5S+#,XFU6.6PST,:GAN&]1^8U>U6-IUM'TU33IIITTTZ::=--
M.FFN>WWP=(_&)B.8PK4Y(XK:\"H[VR!N;IT)&B*T9.TZ0/NP*=D5Y5:QJ^3F
M]>B?E^O+N@`V/X:_?X?1N?D/'X#?IKQ;\XGX=@+1(_'8FWB1][(&Q\Q&R_$P
M!N1KB:D^+4@CZN2)IM!+:6/EYD0CRL@2V2+$!]T\`T.&=$_=5%#K56*WVRH?
MYHG(D-5?[AZ;6L<13&.-W!\1"D53M!XRS^;96],CS[?*?K58R+W&P3FM(J8&
M>+2P.1`D,.<)5Y-W3U5/W6]0QD.O%'ER;J+&CT%3'>:9.5\>'8_MBM95U@XI
MVCB--:6Y5*D:*Y"=R.\E=Z_-[(LU["P6@DY#F`-R.7U-(W\J[<F$;;=8!F[7
M52J-9E*JX52RS2%;C]"`':7<SQ4SOO,219@;>5R)H@21DR;#J'(7`8<\MS<M
MR?'DG,VE59U]0A7,S\K\1MLH0.0ABV4HZ/*Q#G56YK4KVW&*D7<9L4D<5]2X
M.K*6_G$\9.P"`0#Q76L7)M[WG"P'&YQ0X5B[^CC&ID=4G[LQSXJ98VNP+#D^
MVSN#Y&;Q%H<>3*_E4LF+0RJL=(P5T&+7X#+69HFZ>>T@)'=&T=]1&(.N-(3]
M+9&E;X((2/Y?/[;_`%C&N&7#H;`W+RDFUUFJ%,RBO!<#_P`O;>3'>]G[X/;6
M;C'M_*JQ:2G"+`%QZF(R)=8BVRLD5%O_`#H81Q6<:_3-30`ET=OCYLF1#VA*
MVY,9)4F6W0TYM_30HVAF34@08U%<%LXKQ7$<Q)#F38OL:YK7"<W:>V+LADLI
MS%`>CDL0!P85,2@$DNO$S60!*M!!,SHO?F-AK;3D]L9FJRBCDR3ZB'(1186X
MJ*W+@BY6+$.G($`J1<.$R3=#SCKLJ1@YL6=68L3*K,RXUD[02PQ[23'SM/:V
MEG%J@)*:U2',<KV0PA(1R>MA&EQL_+./V*G+'E96L\S@KP$J"[*JEC'0``%B
M0!N1&;VCMHS?=F3V\CG6]=`X5$-ZA`<BM'=@@GJS,2$`8GRA@U7Y5Y*@+I,S
MQ)`N*_2XW)P0FQ38P*^XAW=T:+&EVT6'#B5(W1JC)4P@QHXG"65/!(EE<K3F
M=WA[5VRS\-;W>Q&JS;F^]DE2JR0I)+;M8TDF>*D(!*J-9/N'OM)SZ/;=-J7]
MKQD!H@*XL<@%PJA-DI0*J@CG8K6,89CK6*P%)SSA7%19W)J>O@%E45I,N*^.
M:;N+[;TME95D^':I,JKF/7TODUL;LQLR.16M&GN(/KJ*RN1--RH+F:'4*2!4
ME3*K`K#*2W\V_$B2=@=<#>MF%&5C66G&1":W+J"V19>CLK*_)'"IL%V#J8`\
MS#5P[6O%:0)$ZAI;$,3\V\),C.6'#!4V<-@ZZ2"`D@#@%AR9U<R7!,\SD=#<
MZ.J(6.=6X^#8U5@KR'4OQ6#N2RG<$P9!`)5A'U>;HRSG=UH7(I:[#J<5\[.0
MV4(R^4A9$$%E#UMRW0E/J1XM*J[:"NCUWIG2IM0$,7/E:\7LLZL$JRG2,Q*<
M5S_*5!9)FLK48,;2QUDQU[(L8;\N[_A[#;*BMR2_^RQ"@./D87G),'BW^(C6
MX\9E"T0[6U`"LR)=`68U&?%9<50`"O--AZ:GHE\,LBQ]=O#L;">W_I]E0_B>
M907#DD\MY`L:QL!-&$H`%%('ZVJK4=("=%8G]:O\Y]]EFP\=3R_YBS?JNV/9
M*CXG8S\BN_2/;/RD%:=RS''$C\%2..X??,I(9AL0""('BRN".L]ZNO`=?86G
M333IIITTUKA]1M[<.\H&\451<+<U(CU>J>/E@YSNRM1456O]?ZKW14[?]O72
M^U?_`'UBK\<W&_\`:C7#?F"/_N8[@_P[5G?_`#.W]VN0_)>@X:E9_&$+G]#Q
MU82ZP4T6<I(Z:;.LH#@\;FZ%$FS*>\B#G3HDDSQ1RSK%\=GO7L!!]_8>V8_>
MDR+@+*\FL-'-CP?F#Y5D!E,`J`2%0'R_5.OFKOV;[7LP\5FINP;FK#"JL>K7
MZ9'G<!F2P!F#,0ILM*CGLG&:2?AS;:3CV!5<3BS/(7^54,.3MTK;.ASNV=06
M8;"OH*:JQW(S:Z6YL:(6!.DG0)P2VH*.-CT:52RKWK!QNXM;W;U<?TK"*I5W
MJYJ079K*>0W/-0)!7=B1M&._MCNN=V5,?VX,?-_$4@W\7KJO]-PRUHE.3Q;8
M&NQFAE<!4`,-RIM-P[R+Q_2VFTY+J+G/V$V"FCTX=::6:HP=93B"'3LBS*6K
M9!_/T@8S9)@A"4K`C8%BL4Y1LEN[SVWN%Z87;'2RM6X(:P`UK-NDAFF$GB"2
M!)),\03CXOMGO?9L6SNG?:K:;W3U;1<24QT0`6PR)QY6@<BH!(4!1'-E&-0U
M.@MQOTML\E"O^/7N5A1WR]-(RU5B(:+LJ*YTZ$AMK4NKJ0P[Y8)+D(,#B=FH
M]@A];-KL>D_AJAZGWBV$P@=K3]VZIORXJ(XD;$QX$G6B3&S,D'/R2:?N;*5$
MVFI*%^_K>WR\>;GD75MPO*`"%77NOY!;)N+RO,V8F!O13Z6RS?\`R8&RJPEA
M/M0VB_T,&/05\GW3_P"TK!1GM=&:YHXYD?2SM_&E+!Q_J%9#!]S#0%*_[A$+
MONWU$2PBM'>19DW4MR_H]P9&J\HE2S.'^5BF;-ME(-8(5&F1S>SI<FO`]^4<
M^5*R>$T$NE"ZAIZNMA:-<Q2!I)D]K'#EZV!527I)2/+<YQSB'Y(YGL:Z_)PK
MLO\`'XZ\0EV0@;SLS%.;<@/"LL-I7H"8WC46#W3%[<>SYC!VLQL.PH/31%6W
MTJQ6S=#<J'S<7/F8+,B08L#D,G(1[(MQ*G71PH>9._?)P($6V@54NVO9,WV7
M$-(;+29=20J\QDB(T3AR%\W0RM2EG;AVY5%(5%,`<025+!5`\IGB%!@#EO*[
M<QJM7>V[T[ME,]KB6;FP575"]A:76.;.5EFX0"K[FIAJ-CHK;4%5D-@^PO2!
MIXD*OLM';U`H>[K;QA+C15BQ7$`8EABJU%#/7R]KX@QG0;_6Q76YCFIGS,/C
M6"Y)5%::F7RHT[B+&W3P#$K(DQ)VRL9*5]L[F7N85!5:UT"Y"V>>Q(D$M0OE
ML\2@5PIXB9!_"W+5)L0)QAB-'MEE&9<4-IG\.-E8VCDY_P#QC,TNKMJNRCQF
MQJVOMG%LQRD=#6$57(X7F%4D'>^T7X9_JE]=``XNKV^;D'YNU:LI,L5A"OFY
M"(,-J`^U?<F)W,?T#$OR^1YUM70./IFOTJJ[G1@(57FT/Y/3),K*ZR'L^.,O
MDKZ)_P!0=)'S4W0"G>C'5\=NXOZXXY!XDNL;`S4N75%B+$B_D%.ZP&_\<@7&
M$,ODQNNPNY9690?Z=4;4K(^\)])"(!#2X#3)@#@=P0I(@ZW?=.QX';<Q?ZU>
MM%MP:*5'KV*02I3C42A6!R+>H#Q*EE#2!M5QA)XC6YXMK,M5W]K:_P#4'B:3
MG>0K29#BQ+NFC[2A$_\`&HXON$)Q%A2XBJ4YI@G5[@N=XB:B<GW1>\>CE6Y;
MUI5^'R`]*@DJQK?JQCXJVP"GF"-R=>A]@L]M_BNWT=OKNLR?QN&:LEV`%B"^
ML;5B0/I=-V+@UE284:Z\Y/\`]WX'_P`]_P#T;)Z\?S/^8;]7\!KZ6[=_R:?^
ME_XCJXNL;6;ITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.
MFFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG
M333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG334E95T*WKI]391V2ZZSA2JZ?$+Y>N3"F@?&E1R>"M=X
M&`5S5[*B]EZ::YMQOCKG\WRSJODJ\Y?XPL<5BZWC*G^:-G_T^U*;"JI>&]Y2
M;+CVFYNBIMQ5&M;!J\=34LR72K4'F!%(E]AG*UC&K^0F?'4"W^0?H+0\+\\9
M;3;#YOUFZ^FN9Y'(G,.<ON,N2EX<F8TG$.)XCAY'*+7<HPN2<QJ*IW'-1H8N
MB%9+)B6PGMC!!V"<+3D)G>!J-OOF?[/T/'_QGGHG.G"&PW'S?H\QR'R+R!R=
MQSO3SN4N0,MD-/B8<J+#RN^J655?.I]C+--*=TB3)G!$7^AKR#Z:2LGK!UE&
MD^%.)3?2_*WT]R%51=QN=?R7QYR)@&2;/91J?`R^/N'./^-*TALG_E1,)H+^
M'=9&5:P;0]2DV$Z8-K"><81$:IR,0-;I6B6;JRQ;2/@"N5@3$J"6@I!ZP=FL
M<B0'V(8AH\HT!DKP4S1$81P^Z-<U>RHU;KC(+^,'=67'_P!0TMH_Y3R-O]#S
M?F.;88/C;BKD:!PAJ7<`<O:+E34AY;S]QR1,T6IC<SP=(_.W`H<N$%*D#/)A
MW/(U6I.>XZ[:N7C7^/CG;A+,<16?$FZ^=,SON+.=N>N5:O"#XRY#B?/V?S'.
MF,=DY^'PV>@<C#UE`*EEB_=6O66^/(G3IBJ`?FUW35"P/6=430?QL\\1.+Z/
MB7`\T<0CH=)\5\5?'/,-QLN-=I-N/P>.]'OKZ7NN,04?(=9!KY=JWDJ<P4&V
M_-8%T.,YQ7HXS5:KS$R1XSK-\_XRYKE_0TG6"Y-XM'P-.^OJ#[$D41,-K'\N
MLUE%PC1\3)B@:)NT9C/\=DS*$<U93JQ9+0D<+P5Z(3IJG(1\XC5O?%GP+RY\
MR\R3-WR+SO1<OX:AXFM^)^&<9#RFIR:</U-INJ_0:&9319>YTU#8V?*M9FJ2
M3J)"QH_>WJ1N@CCA-+20T9@1`UNM]0\?<C\M<!\I<6\5WF'S6KY(Q][A/WWD
M*FOK_.UE'KJR7G]#,6KS=U06<BT!3V!G0_\`F6"22C%(CF=T5JT0#OK1"K^*
M_KW.8[@JQ@<]<-:[F+BJC^E\/;S.0,'R58<=EX_Y]L\5)I*''0:[DB+JZ1O&
M=1Q[7U\(4B;)CECE*B-%X"[-7<E^&VNBO`_&C^%^#N&>'2W#="7B?BGCOC0E
M^R$M:R\?A,A3Y=]PRN63,6`VR=5>Y`J8JB1_CYN[>2M6DR9UI!Q%\0:_COZ[
MWOT'HJ[YHW5?K>4N2>0J;D"XX]W$KZ6R%7ML^ZFJ<A1[JRV=ADX%9G8G_LUB
MQJT"+3$)'8UBO>YS5Q8$1OKIKTU9ITTTZ::=--.FFG336A?VQ8T5-E*>YT]4
MEYG:SE3C8MQ3K,G5_P"Y1)E)NZI([)=8BSQF;(L&/&@OZB$8UG9?+Q7O_9%=
M]V6].*_#(;$NXM`/$AJFF&VZ"#/0&=>/_FK?B8O;JLK/K]7"K[CBETY,O(-7
MD)$IY@98$1N2`-YC7(?DD/$9]F`K+K19>UFQH`;2GM,W'T=9DEDM:.FR$6PR
M4@=H9D:I;&B(D&HD"BD`02O>\94Z]@[8W=QA$%*[:@2597*-9'U6$6#CNW)O
M-8"P(,`$:^:>^I[;?N@86WX^0ZJ'1ZA:M,[)2&I(<PG!/NZ6"%64DE6U<.A^
M>>:;,-6#C+,TO)F0S%H*Z*_C[1Y`MK<ZBM;5.GS+FIMT_P`AJ!RZV=+B5PSP
M/;%C"<3R8:4OECX_N/LE19NZ6OBYEJ<?ODLXJC<H"LOD:"%9R&AF(&ZIK-S?
M97NJ]:T[#15G]LQ[`Y_#64EWM7AR+H_WJ`JSI4&KE%!,AK-\?W&3N>,*:/2Z
MRGN)<4)/V[VZR/:CM;&YM@-L,?2UQ`U,5H*BKL0-;^5#5&M"KY+NZMCL=L*<
MNCNEQOQ'16(G[LKQ"J8L8^8RS`_2WC"^+'6FR>VY78,48O<JK&K!XS<'#L[C
ME2BP@A$81S3H)L/1`:7%J!9Z!9:NS9`>VU/#N]93#L;6QJ#6$R@U5-+SN6DR
M0L@&C%T-<I?8,A#*UJ^:JP@U65[CDNN)5RE`5K:%#!0];![`#(/!H@@#X;@Z
MQTQ5PJK.XW\"+&%ER<G9"S5VH:ZB1Q(]19D$M'78KJS)FZ-9T.DH[F-%F1)=
MU36M-'.YK"Y.XBW=>.0M35L'_9CSX`4#9/7T(=T81>Q$`UQ<U,!:LBJ^DD.$
M96(_\Q2ICDWQ!,H-XY$;<B!J[>[OD8=^)E*K5M:CH#L:7#K/!/`,HXVGR\BJ
MMY@H+7;?:R5G+[E-V2GR(=_HZC(4,32PB%IPU^;E1;A-#71,[`\0FM="B,B&
M(]W9(_8;'(LI>L3'Q$R<?$&6H./6]C%#YB7!7@2YWXI]0`\=S].MCE]Q?!S.
MX'MKLN;?536+5E`M15_445KL7LV1B3]/E!!LU8,RUM-%@P1(UA,9/BQ"+[`6
M$2))H=!+E96-'ETL=%"XLE]!7A&(<:2OM`]@VM0H2(F>E-6-GEV4>F3X@D.@
M%A(8[[<R225V,D[,-:BW(R,[M`KK=A<J^#`&NPM4`U8VW]-5`"MNI"@<E;52
MR=Q2:QT?/6,%D2PJS0#,K),R-8L98B_'KL_I:F`Q2/LFI,<66*+'15($QHXW
M-[H]L>73?B3D5M-;@^8`C;<NC'^7:%+'H0&(\-3=NRL3N)7"O0+=65(4L&\P
MA:[47?GYI<(O569`1((K.-XAYVF69`4N#TMKBHT5:;3:0=77Y?%W8A6-GH["
MYC6]]*KLHI9&@G%2L,]XB.,C_8C4.5PH<WO'84JY7Y%29Q/)$Y&RQ3"H%*H#
M9L@',"1$1/$`Y7:_;7N^W(*8N'D6=J5>%MH1:J+(9K6</85IDV,?28D$M,P'
M8K<U1DN,,-N)-'N>1JXDJ!8OD_N&)K)=W$@"(Q9,:==SO=3U-`!\J6(,8\,T
M]O@SR'[E:CGXMV7W7/P1?@XS!&6(M8*3X$*(9G,`E@P3?8QX9^-VWL':>[MB
M=VSD-B63RH1K`HB0UC2B5B2`K(;!`D<HD]"?EM^4M=YL**DPUGB;:MPHI.A+
M=WX+.WOI43E7%O'.FP:RNA45/X2ZJ0C&06*$[7^:K^J.7SOW4,NKM].1?>M]
M+9$)Q0JJ@T6;`L2S;,/J,B(U[3^7I[=D]YR</%Q+,3)3$!L+V!GL(RZ(9E15
MK3S(T"L<6F?GKL3UXUKZ<TZ::=--.FFM=/J-?_U+\JM1RH]W#',WAV[^2*F"
MLOZF^*M7NU51?T5%_P!W72>U?_?>(?#\;C?^U77$?F"?_N6[B/'^EYO_`,SM
MK\^/-A2IO;84B;3?MT:+Q]F7S77LJKI4)#R>19`@V&M@C_=ZK?F'^2<%?%(&
M--A$0AU>BN:[Z'[&`<!&57]0FYXXAFWLLDBL^5JAY078%E80L>'Q?[J9OZQ8
MKO5Z"KCU<O4*)Y::>*M<HYID'S,M:%5=#R<GH<H_1Q'5><%7#;'DQF[$`K,I
M8<:8L<&4IITNCD:9DF,[_#!-;+0T>?$;8G<@1N\%5W?K5>VQZN2;#(;T3Q@D
M2;&`8)!^\.T%&X#<[[:Z#WPQQ\$4+Q:O\4`Y*@P*48UFT$?<#>5L3U&\JF-]
M7+B?I?E+'\3Y.L39S]C$;92ILH&EFR9UJX=4>M-4P(5Q+ER)Q:N4A7'&8YB)
M9!<!SQQV/?%3%SO;':LSNUUOH+2_$`%``OF!#$J`!R'0@`<#R@L0&UG=I]^>
MX.V>W,?'_%/E5BPL1:Q9X0J457)+%#/(,S'U04)5`37JV]K],W&T4\6YXII+
M*BN#@?9V)Y=A$TTQ+:<^;7QTOJ"/2`<&GC-<U)$B+*5'M$Y6^:.>_)PO;%.#
M#T9;KD(#Q4`%!Q$$\'+&6/@&7Q$QL,'NOOS)[KRKRNW568=K`LQ+"T\VY*/4
MK%8A!/F9'W"F)!)J6%X1QO*=/8V\%^[QL0$61)21KJ>*[C*`)U!*LXD>QY.`
M:F!#ST=80`F4M3+<*3%8K_-5:WJ//[YF]JN6FP8]SD@16Q]<^<*2*"&ES)(B
MQ95C$==3]H]J=K]PXSY-)S,6L*3-R#\*H],L`V4"@6L<5!Y4O#()G8:LK.\=
MZ3DR+P5FJZSN:1D+BO5:C\C5I+NZA:>GS.79+/D:+.TMM=S$*Z4X?XD*(8[P
M.:J=V(]CLW)[CC=L?/R;%1RV76D5PK<F=X%C.RJ.D\F8`'YP1JL+LN=WY.T8
M%%EM03M]ULW38G!*JN1IKK1[&F2.%:%BI'A(,A89_'<?Z6Z_=[;1[FWSTV.V
M8,L%V-J3FA%;$>%DZQ-::B:V=7R6G%[P199`H1'.:YQ/9)7DYO<<9/12NBFQ
M3&_J,)WF`%001!@LH,&-A$-V%VSLV?;^)MOR\FEQR!7T$)4\8Y,6M;DIY#DJ
M.1R!();EE2M^G\U%A5E]F^+J>ETO[P,L*%74T([E,&.T$R:ZWG&O]:;]Q%*"
M,WK+#&V$!P7KYD5O6JM]KY+.V/DY3OC<-R6(\9`X@)6(@D2&/(AAL-=#1[_P
M*ZJ\S![?55G^J"JJBG<"&;FQLN/(%0T%`*U*DRT:L+G'Z9YGV5@V*;86E'EG
M`K-9#I:";;1,W%DRA$MD6=$RSXFDO0UTF&?UQXSYSG,(CY8?6@W]9_8O;'9<
M.ODM*V9<M66<*7('EV-DHI((DMQW$(TR-:?W9[]]T]TN]-\JRK`A+E2MG6H$
MCGYEJBVP*5:%0V$@S8O'B=3/-5:-,I$LZJN<ZLC7]3:1H0C5]+#/7;2ODS)4
M:YM[0)!P,]*1XV$JV-9)E`:C">!7,5+>R6G\6:K6^]-;*3NQ!K(`*JO5QO#_
M`$J=Q(G4GNJA?Z<N1CI_PZW(X4%44K>I8AW<0M9V!J$,ZB&AHUE3YUM)DW_H
M263-FR&Q/H7(4U1/8(E=73Z65+S,_P#;H>=G&':Y6F@3(IG0JZ0XSO0C#M$@
M7@*#5>XZD3\>$503VZQF'4A@'$EP.-C$$<G$;RI,A@W0^R<BVW^D&QW8+WNE
M$:.*LA-3<5K8AZ45@QKK;D>,.%XE&3O'D_\`W?@?_/?_`-&R>O`\S_F&_5_`
M:^P.W?\`)I_Z7_B.KBZQM9NG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG337)CZ+WGW!F>2^;K[B>
M!R)>X#`Y#F^SI<31X&IM3;2(_ACY<!CW\=6<NE?)M=[C>1--J;JH@-.9M\Z!
M:5;AD(D?\9J\!8WZZH9MY],,J=7(D:'ZE9S$FAO(/)N5SG$5;:\8<>\*1^7,
M_50MKQ+-M<$V)I^24X+(:UHX]3,T5C:W19K9U<YT5D2(T@>$1JR=?=_;UVFS
M)P5?\X7_`!GB<3SQJ^(-;OQ2..M[LIN?SO`LS)@OJ2XX!T=KR1*A;BSV$/-T
MMK!S9=)71U]LTHAAG/:KY?'KJ]S,^XX59?<D7^WY&I>+[OF#;YK;5E!7LV/+
M=5Q&_P"@IU7GN0..>,6<.P;#C8>>XMJ?08<*?M)EA46ZV@6#EP@O>U3RZL>S
MOOO"TE7%YQ]<\RSN.\'6+:<>:#75_P#B.RU^._ZUS:T5YIN,Y7!]Q(Y2U8<%
M#DM!3SI>0FS:2/`FF>.78DD,:KY?UZNJ+=_;7)6ZLQ;!OT)Q1D-1SCQ_K^,3
M9*#B(+(/`6OUUEB=1C]4D'+:2913LQD<Q0Z0C+Q8M[#G:FT&Y?QX;&!:IY0-
MNNK7I-]]'/I].W<[+Z5I9(_H05)L)F5Q_)]WH\]P\SE_?UP;'/YLOR]`ST",
M3-PZ,;I6=L]6\L`SC/<)CW2.FJ[>$=-;-P^6.><1@OGG9\A1>6)U!*MN>J7>
M28W$]E>\@6.>\]8+YLON1./\-E)V@S6ITF?K:LMBR-6P@1KR;^/*#%4C0,:I
M"R8UJ59<C_R19G!6T.Y@<KW5KJ`;696WM!QO2SM#QK=8;X=LK"=EYT:ISDN+
M<4>YYQ-$M,]8"CR7+J(4VI5Y`2($96JPOZ?;JX]!O_I`/(.;K:;9?1MC\Z)?
M;X>5W.KQ7)F*W^A]%'P`<,+3.QGR[O=B6JJM%=:L=$2YH:(5F,4M'3C"A0R%
M:0(\)_3YZSYP(#ZUG<PS@\J7/($#B_D2K^M0QI9[<%E,I)>8YQJ,_P`,20TA
M^(,B/AZ;_P!,+*5)J$9=Z4-^$2R#-8X#'O:M,1MUUC)DC[MQ.$G?X%9[WD/0
MV'$_VY;V9.:GDCSZ328GE'-9GYZ_P],EQ1+;8:RRPX)$RKK)0`@NVF-)<]_9
M/%JOEGY;:R7\QZWG>ZV?.8^2K?DXNB@KS$F1H]%6[^NIXU=7[V?#P9:VEL^!
M<GQL,[\P*"^&6MV5^>6`RD('R>?\=H8\.FK*OOHKZBT/'_RU8<2X'F71V>'S
MN-W_`-?'G<6S,)=7$:GJL?1[OCFOJ.4<QF)>@T-S&T6ANXX<F`T_]USL*.%?
M1+>,E-(&\_JUCRFV_P#(C).2ONY'*5'#D9OD^$FIA\0TND-06OROA-3QI8ZE
MF:'409&E+]6<NZBFV&;K4*-UE2T9AP$8PCF.KJL+K+>=WOT!*^:R2Y$OFR#$
MB?06>SFSW\"DN]ER.#@2979V=J]?Q17Z?A;CKDBWJXE_8$KI!['(GNZJ.VS+
M"?-%"@S'M4VG]6H7![?K7><TT9K;2<I+P)CXTBPS%UOI4GBK3;K)#Y8WD7/6
M6NS7_1J<;7:.9EJ:(`D&?)R\PM'^#..Q)5@9Z-#`'SU6]?6_6.2YCWEAQKJ>
M4-E6%Y]X=ILMF>1C1V<4-XXUN/E:7D@C+?/<;V5_!HJ'1)^&V<U9CH2H.,YS
M4<YZ--HW^&L?<.[KZNLOHW+U7.4WD:BIGB9Z:BGKN2:_`R[1.9_HJND`C3*?
MYRN<[HZ5,C4Y=@SZ#198W[8L:0H^\CS,T/&-NNJEL+[Z5NN8_HS)5.J^@6UK
M\?RS:8F?C<O*R];A)F/K*"RXRIP0=5Q%:Y#0/U%K"DCK;?/:RVF7P)I@651%
M>%?P6FT#IK$^@N_O%(6]I89OI>/A0<(W=)QEN85;A).ZF?0O'V&A\BK?6\!F
M.DZE]!O]/?:7,>$RJ%3';F*-D)S33R/.U7R_+KK:3B6=R[3_`%_OL%L-?R_=
MX',V=?5<=&U;MRM+HLX/@CCRSEVUA*J/GT'%M^4N]G7CGSC;>'-2>%8Z0NXA
MB(U;_+.M<-%M/LVSK)-?BKWGLW,=[+TM7SAE[C!&S?&7%KEYHQ=%AC</;9>,
M+6$L(V2G2A`G5+],Z9FG2[FP%^;$$J#\M7>6?"-;)\U+RY@,Q\WYV]WG/])`
M-9\C-Y4UG!M5:<Y[-]P+(W5IA*V3:Q.$9LRRJ3:`C!1W2<Y71C%&&/(<K/\`
MO6K1!GIK52@Y6^TX3N5;CDHO+=9R/0U_&]C`R68R'(5SG(\)<CP)/Y&3-9*G
MX`N./="&-,L-4[V0]O96:26%#'AD<)K&-70OATUFKFSFGZVV')Q[CYYQ_*L/
M@@/'%UAH=_(X_C4<N?S/>9J\WN:V;\=O*"!RFM#0:3,YS)/.D!E,HM3<$D+[
M8("A:H`(WZZP_)Y+_DAU--HJ/-9CE:DUNYI*S5<=V4S$XFD#AHOT1;@Y6K\O
M>6&QJ(^4#H/D_!<8W6.FBLGH219ZFO21^1)(!4:K"_JU&VV_^_M#$V7,62SW
M*N(K[?\`(J:OC[P+9VV4D2?AV-JRT];Q#-X8E/G1JOZ?4D$>I;J3E6>W\9L"
M1'_M$:>7I^G770SX_M]-=<5R)>ONMA=WK=)*#)D[,G(9IPVMJ:9[10R<E\)\
M#7Z0E>]S_!E,6,PKGHV41WF,35C==M;5=-4TZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::T4^S*
MY;C/YFG>$)H5KS5PS`LT,Y6=J\[].AO2[Q>U"F>C1]U:]&M>KO!ZHC'=[[+L
M]'(MN!(=,')*_:.'^O\`5U'4>1?FC1^*PJ,4@&JSNN"KS_A)MF/F=AT,3,'H
M>%.?_)TO+]9/(2C_`"['7Z/118\J\/#_`"+88['0'%D215$38U,JRDO::-*(
MC(4PS@":Q/-7^\9''&[.U8]3@M*(2%!A=D'J3_EL%&Q42RCD9VCY%PO4S_<U
M=S&GU;,FVP`V%9<<K"*2(]="Q(*N8K=BB@;DW'S-<:.LT.*G4LBRH)U+22)-
M+JXBMIP&T=WJ'AD/SFLJ'`M1VQX$`45*YB@8_P!:C_(8BO5,;LM.-;CWUW!;
M*WL`:L^8\%3;G6TKQ!);F9B9XG;6=[HRLZC-Q;<1K*;JJB:[E\@-MEL'TKDA
M^950GICB#''F-]9;L?IC>UC,C&WEU9Z=L3*"9)-!GI67\J1H8L0EH^:2PJ)$
M&PN8YR(K0SH\@;31V![E>)"OT]?MC`M-S8")46NV!')`$)XQ#`A3\5(,$G8&
M!T=_OSO&.,:OO%MF0%QQ)5N-A-@7GR+(59P3LKJPY*%\Q7D<3Z_F,&SB2(^I
MP52E-!$@#2:FS_Q'13)(XS4-?3FG\Z!=/-EV3I#QNJWRD8-6=E_5K=OA]F.$
MX;$R']9C,,OJ(!/T"//P`6`>?&3.N=[G[G3NE;)W##K_``J""4?T;&,;V-/W
M?JL6+$&HM`C?H(&BX2I6<5)ROG;W7TM(LC-PUSW(67%E?WP4#15%)(9Q[>AG
M3H6SMVS1N(V.M="4\-!E$YGI8UMV-WR\]V_I.372]\.>=+^IP)1F'K*0#6L;
M3S:&D$&239G>U,4>W?\`J+!NR:L7E4OIY-0I]0+8B'\/8&9;WY`D+Z2<DXLI
M'$`7<;B.9R1NN4;"+<R:2IRV>QZVR7]->WVE]4V'JBH%V7QU+86,B(6*`HOW
M`Y84$/DT)"(LCP7#7O"=LP,6MT#W6V6<>#*B;&O?G8P`,D'@`S'J!Y9ULF]M
MV]][OW"^NUJ<;'IIY^HEEEL,MICTJ$9B"`1ZC&NL2%)'.-8/@Z#!<;6)[B%F
M+O<34!9!$/93X=!32PQ!1K4`Y.;H)\VT0D>(1QG,-:H93JY2M<[S:3>V8_<.
MYUBE[:Z$E3]V"["25,.X"[G:17$=(VCDZ<WM'8KSE4X]N7;#`"YEK0@`.`:J
MV9]AN0UW+E)8$R&S=QU]&U&3T,&-Q_A(=<C;&R==M?34M=4-99O95Q\PUU<4
M^IDQJ&B%$2*:?8&]DUY2>KL1B)HNY>V[LO'9NX9#-Y5X^9F;R^8OO%8+MRY!
M$$+`G8ZZOLGOC&[=FHG9L-4\[<Y1%3S^05>4FXBNL)P-EAERQX^8:L/8\E\I
M<F<G4]1R/M9FG$NC=A&P)EG(?1UZ2Y,^J:&JS^6D5D&*%DE!';,+$6&TWBV,
M=&,[=;#"[9VKMG:WN[;0M1]/U9"CD8`;S/8&)VD<0W*-V63K4=S[][@[][@J
MQ>^939"^O^'XLY]-9+)"5U%5`F&YE.$P*W@:IG)5?841<U9G_*B335AS$)Z:
M^3#C2*1_[M!E5&7B=K726-6.2D=LV,1?PBM<]A%8G8<O;+*[Q;4(-88#J02&
M\I#.?*@:)XL/,-B)ZX_?:;L1J+WY+::R284J#7YU*5#SVL@/$.A\C`D,1]/1
MOXZ/8QM>>SF!,ZULOGO!MG#G6A+1[EA<HT>.'*_<G%]DXA*JF$\A?6C22VD_
MK<Y7M9YM[R6M\,5(1Z2]QMB%X]:&LCCX>9C`G98VZ$^X?EB]]7<SD6@G(L[+
MC\@S\_IRZZ)Y3+2B`DQ!<-N3(':KKQ+7U3ITTTZ::=--:Y_4B(O"W*W=7=O^
MB_,Z*Q'=D<BX&S[_`*>+OU1/]%[+V[_Z+UTGM3_WWB?_`&[C?^U77$?F#_\`
M>KW&>G]+S?\`YG;7#'DOCW:ZZMRVYQF?T]PRWR5-F;&3G*+]Y-47U+25\657
M>F!6V40MA>U\&$<MM:0W,B"0C(A1O:K$]W[9W'!P[+<'-LJ0I:S@.W$,K,2#
M)*D!26`K1O,8+@@SKY&[]V7NO<J,?NW:Z<BT68R5,:J^92Q*U!6%5E+6*M;&
MZU"$'(5LI$:RIR)DLAH,5F1\V[ZDXLLYIL_LH%9#K[/DG=?O,>5,S5M.I\_E
MNQ9$N[(8['3730N!Z1J6.)&KUJ>W9F9CYMI['CV9=2AZRQ*TU<2`ZAG?H%@>
M7B9DPQUT7>^W=MS>U8Z^Z\RKM^0YKO5%5LK(Y@FIV2NK<ER6',NI6%Y(H!U>
M^1-\S9OB<TSC/,:GDV1-;/GU>HW<BJS%E/T4>?"]E;(9,@2ZRA3<SF"![30"
MRB`3\M2.1HWLP<Q?<^3W<)W.VK%58#)4&=0A!\P@AG](28#!0?)`D@[;MC>P
M\'VZ;>PX^1GNX9DMR"E3-:&65,J5K_$-"R:RY7[SD0`1CF\YTK^2ZBSB4--D
M<LC9NB"712TBZ6ZSUY41A6>OBV%QIHI(T6L!.5([%@QF)%@L:=BE$)PDV5'8
M;.V7*^0]UOE0\!**ZL>-9"H9+$;GDQY,2I@F=:/+]W4]^QK*\2K&Q_/8#8T6
MO78@#W!GM!`4-Y1Z:@)6`XY*I4:HV]GK+U9=2\V@T$Z%(FQ6Q+P]I^="DQQO
MALJ8)9I3/ASDFHX+VM"CO%?%B/5CGR.LIJQ*.-H%==;`&5"P0=^1B)$;]?MB
M0%\[R;^Y9?+&)NNM4L.-A?DI'EX+R)XMRE2`O383!+UN:A:FKX!GT]C`;:?X
M?9FD1<J>6&^H&OS-`J,LYII,ET2<1CW-&6,YK0F<ON11H]O4"1=;W"NY6]'U
ME`-@'!_._P!(`$CXANH^G>-9=O+&Q^S6XMB?B/PK$BDL+*_NJ]F8DPQW@J0%
M8^;RR-71F-UOKRP@P[V8O(6?K8:6%K'WL>1KI=?^V@/.6133[E&6-<:7(#^,
M`+K`#2>/@3P<*24&+E8';Z*V>A?P^0QA3416#R($,%V(`\Q/`QU$RH;/P.[]
MXS+DJS&_&X5:\G&0#<5X@M*,_F4DCBJFQ9B&@J[)L&?3<,:&76XT?&4BIM)#
MJVSMD@MH+2DS-!7UTFYAWUB*PL@:6HD:L$G\1CQS)"G.X0T$;U+Y\ZN+WK'1
MLTY0>H<E6>:L[DA2@A2C"LCD940),K.W:-G^ULVQ.UK@-7D-Q9^/IO756JEU
ML;DPM0W`\`0[<FXKQ;CO0^2N&^`-39QYO'G.^4XROKFIIAMS_*3I-$:NS9WB
MK"SJ37U(I%KF9D1([!)X/$&>A^QY16IV3([9WKW!B5%.XX%V5CH[>>B&#.):
M&K:%<&9WDI'E0'6)WWVQ[-[AD+;V7N^-@9EM:#T\N:RM1A"R7("]3"`-B!9R
M\]C#;5(YPQET'.T42'EZ[3T4J\)<R-701:G<<?NS^<D$H:@<NZIILJOK;9UA
M,)&?9.9.DQRQ_(@6^MZI-V+-I.38[VM5D*G$5N6JNYN.;0K`%E@!@GE4@P&W
M&L;W9VO+7!IKKQTR,1KBYNK"7X_IU$UH"Z,55^1*FV+&4K)008O'A:NGYC1<
M"TIED#MM#SGA=;IVS&./HG1#65#59]FLL22UD6=HZ+3L*^44(5,$D961PI[&
MLPN]V5Y6-W"\0::\"VM(V28=G],1"K+$<03!#2S;3L_:U-W;\[L^(W(9-_=\
M>ZWEO9!:M*_68F7>$!+E5E360B[@=W<G_P"[\#_Y[_\`HV3UX+F?\PWZOX#7
MU]V[_DT_]+_Q'5Q=8VLW3IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333I
MIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIIT
MTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ
M::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=
M--.FFG333IIITTTZ::=--.FFG333IIITTUSZ^[[.?3X&#:5GBDVOY;X@G1GO
M]?K&>$NGEQGD1XC*K&R0,_X6^7?M^K4[N3T/V%57=W!JK?H;#R`?L/`']Q.O
M&/S?ONQ>SID4?YJ=RPF'2)7U2)D'Q`Z#]@WUQOLL5N*GE8^JR><N])3-O5V%
M5)JJV"*IN:B3^0LJF!;/C.S6?'2PW_M\I$6)*//B'][&HC57V>K-P;NU#$R[
M4KO]/TV#,>2L(ABL\WY'SK]2A67B>NOF#([7W;']Q'N/;:+K\7UO60HJA'0S
M-8>/2K"+]V_T.UB/S`V.LA;C"<1NTU19\S<Q0<!+H(UH$N7XUJ+';[=^:F_B
MWH8EG;UJ!R^>B09=EV0LF18,DNG()R/>CG)KL'/[N,9ZNRX;9"6%3SN9:JN8
ME)53+N2%Z`)QXSL(UNN[=H]M'/JR/='<TP[*5<&K%1K[_2:+`'=8JK"ENK-8
M&]3B9,G66-#J^,L;BZ.[XCP-\6?GZIS(-AJ[BOSVADYAU<6>^]ER8\2TEC_P
M"&]YV1:^+$42.0']/X[5=J,?$[IFYME'>,BL5V-N*U+H'F.(!*C[T[<G9I^K
M^;71YO<>P]K[75E^V\.XW45^5KG6NPU<2WJ$@.1^'66"5HD3PVX"=?-5L_\`
M)L'#E82MS5"^JA5)4)EU&V^UL*Q%9MHU+:W4R9J9-[#IX;")($9BGF%)YHQ5
M51=#B87X;/9,]K;`[-]?T5D<>7E4!`I8Q!!A0(GQXON'=/Q_:%L[1712:T0S
M5_F7*P?TY=V:XV*B@\@PY.6F#].LUC7WEX\E]:S9EP6.6HDRBSYLZ1**6/,K
M(\62.5+/^5&8>!V)(5Q&>MBM<5K7(9'=17910/P]2J@(8"``-PQ(@"#!V&QD
M[#PC@[Z,O+)S,AVM92A)9F+$AD`(),B5W;<0-V`/*<U[>9H\5RWI)%%?#SEC
M(QF;!^XY#4$(2,&PDW;R@_?@&D6#&#C1E4[?(@QJ-")W<QHC:3!3&SNSUKD5
MFVL7.8L3J0%WX&!U.W0F8Z$E>J[M;G=J]QWOB7"B]L6H<J;22`QL)'J`EH`$
MMU`CEU`5YFEVU[>S;2VY*S]3R311)%75RK2^HS2;R<6YN:L*5HM0%U+HA1PD
M"P,QTF9)<-Q%$ON1KG+9?@T4(E/;+'QKR&8*C0HXJWFX'DA/4K"K,3Y=AJ3%
M[KEY=MF1WVBK/Q%*(7LK)L8NZ#CZH].P`$!7Y.T25/*"3E2ET7$&ZO02=%DK
M>FHZ6:0QY@H^=N(C[:3/C2+C&YN\K)D*_JA4%HXY2MFOM2!B=E:=%8`?6JOQ
MN\8%!7&N1[W782ZGB`0MCJP*-S6`.(K!;JN['70XF;[:[OF"S-QK:L2IR2P%
M3CF6!>BJQ66Q!6_(GF;B$B'D(NJ9"X8X)9MG:3C_`.B<@1];H9-K;Y#D@TWC
M+5@OVP9\V!10M`6'7Y6QCF<[\P[9Y(S(PP*Q(XW,=VDL[UWXX/X;N';KH:L*
MME,7UE)`+%)-BD?2.`8L3/(R-8]7M?VB.ZG/[-WO&)2\N].26Q;A9Q9EK6PJ
MM+`_6PL*A`I'!2#K'_,V(V=5HZ>K-C-,UD.%&@Y^974=;,)-F33_`+G)E9O;
M4<R='"9T,[>\:,L8,HJHT96M5B];'LN=A6XSW"ZJ68EP680`.(#U,`>H^H\B
MHW()G6F]T=J[ICYU6.V+>`JA:V6M269CS)JOK9@#Q(\J\5<[!@"-;Y_$?XL7
ME;<9Z(2&8>,X4RV/,>K&X-0>TIMMGET1ZI@WO@DKRZ25+<$T=2",%6=B.1J-
M;P/OGD_::,EPP-^<]D-]05JGX!O&>`608(,[;[^P_E/Z=?N/+PJRA7%[5522
M@A"Z7U^H4CRE3:7*LL@B(8Q`[7]>(:^JM.FFG333IIK5_P"JC-9QCR`-4,YS
M^#.>RM:CT;%<@,(JN;(:O;R>OFB,7NB(GE_OZZGVFI/=,<[1^/Q/MWM\/[?U
M:X#\PV`[!FKO)[1W`_+;'\?G\/UZY#<@<Y;7:9N44%T,$.EJJI)^;I9G[#2S
M:1C(Y)M]6U0'1*HBTT8XOR@/$([XR,*%&O#):+V'M_8<'"R0&0EW=H=AS8-O
M",QEAR(/$@D!I!V99^:>\^[>Z]TP6*6@555IRJK/IHU>Q:Q4$(>`(YJ0&*PR
MP5L"XZ"R)OZVUR6@O(T61)#-DYJT5;*8W"Z*?73*AVA?^"X$AM/>-D(*P]9F
ME=!\3=V$BL[[)B_;[4R\>LE00'7RCU4#!N&\CDL2DB.7EW#G6D05]YHL[;FW
M*KL&-3^9OP]K*4]3RP>%DQ9#3Z</(:L:Q[FMM:<6;W3TE\P`*[]VL(F]K[#9
MVK)L*JP8XD*GNZF#?FCNDFB29*?W`D6%*$]",_)0[%9L<K!J[KV^J_'DV\`:
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MC(Y+`!0,JU':646,-@=8HR-I7N/\W0K&9,NZN\X^M\U<5!*.OKC"':T>/KPR
MZ^>M:XKY,.2K3!.XKGK,CB5SD0KANVV959Q[F]86NU,A75N1/TM88(Y="-B(
M^DF.DCG.VY%)?L=5[-;CW83U.AK52`]=*@JW&94PRL23S59/F(-P\EXFNXS.
M.F'32K^K`:@N(-S59R1>R]X^;-M\_$'75[K%D-(;(%L.-80C!:2%WEJ8A"R/
MTQ^V9UG<P;RXKM(=2K.$%4!7,GC,RLHP,-Y(`"ZSN_=JH["PQ5J:['!K=;$J
M-AR.3/6`J\N/'BX6Q&4%/O.3%GVH#*Z3Q[ES6-Q4`U.@(DL&IG5-#4UDW:W-
M!.;)SM-5MD+ZW56?H!(-JM\Q.:,SF$]JM;UD&U>X98JI<U8^Q0,S,*E80[-'
M\SOOX'=01&^L,46=E[>;LFH9&:9%K)6B->];36B3_)76($2(#$-R@:QK14DG
M=7F@N=+<WD:@),H+G7ND65%'L8]'M\C:R&9"ABUT.7(AV(;BI'%JXQ98_2P2
MRNY`1OUV5]Z8%%=&*E9R(=:X#$%JK%'J.20""K%G(4S/#9FUHL/$L[OEW96?
M;<N&6K>Z6K#"N^ESZ-84$JP=`E2EQQ`]261-[NM=-=76JJV59YU9HY$F+G,Y
M69N7*@S'0CC--H(0Y=5/#+JPUK(\MZM1I>X'ED%>-SWD?B58M%.(QM"MC`%W
M9P")&SF&!#<I4>&\*`0`!LLC/RLON-8H+UYI85UK42K<3+5J&1@4"PY\?*6=
MBI))W`X\YBTVCUO$^.MCT^JD-Y:XG%8[UE.%NCL_VG4U2RBAT$5Q#S,G^4Z/
M'`LHA7R'/0JD=[F,9QW<>S8N-B9>;2'J7\'D<:N1X+RK:/(=A9$D\0`(B!Q)
M/IG9/<^?G=R[=VO(-60_]2PPV1P'JMPM22+!)-,\57F26GER/(`=E\DBIGJ]
M%7R7_FN[E1$[K^;)_7LB(B=^O%LS_F6_5_`:^H>V_P#))_Z7_B.KCZQM9VG3
M33IIKRY[&JB.<UJJCE1'.1%5&IW<J=U_5&I^J_[NJP3TU0D#KKXI!I_J]B?J
MY/U<B?JU'*Y/]?\`5J,=W_W=E_W=(.DCXC7Q2B:OBI1HY>R>*O:B]W/0:)V5
M>_ZD5&I_VKV_UZ0>L&-4Y*#!(G]!I[@IV[E&G?MV_K;^ODHT3M^O^U2M[?\`
MRR?[TZ<3\#IR7XC]/]8_;KRDB.[_`(3A7]._Z%8OZ>*O[_H[_3P:J_\`D3OU
M7BPZ@Z<T/0C]NO2E$G=5(-$;W\E5[?Z?%7H[O^OZ=E&[O_\`*K_N7JD'X'5>
M2_$:\ND`9V5QPM1SF,;Y$8GD\CQL&Q.[D[N>\S$1/]55Z(G^J=.+'H#^G^HZ
MH70=2/V_&(_B/VC7I"B7_0@U_P!OZ/:OZ>*/[_Z_^@Y%_P#(O?I!^&J\E/0C
M1Q1-_P"(@V_ZI_4]J?Z(1R_ZK_L:)R_^1J_[EZ03T&J%E'4C]/\`4?V:^H0:
M]^SV+V=XKV<U>SO+P\5[+^CO/].W^_\`3I!U7DIZ$:\^X*?JI1=OT_7V-_\`
M.]?;_;_M]K>W_P`LG^].G%O@=4YK\1^D?WC]HT><(VN>0PF,:U7N>\C&M:UK
M7/<YSG*B(U&,557_`$[(J_[.@5B8`,Z%U`DD`:^^X7_]4?\`Q*W_`(V_\35(
MCF_Z_P#$U1.[I_L\5_W+T@_`Z<E^(_3_`%']FOBG`G^IA)W<UGZD9_QN4;6L
M_P!?^)RE:B)_JJN3_>G3BWP.G-/B/V_9_>/VC1#!7OV*)?'_`(NQ&KX_T-)^
MOZ_I_;>CO_E51?\`1>G%O@=.:_$?IOKP27%#^A9,<2_U?]X8;/\`@&4K_P#B
M<G_`*.1R_P"YK'+_`*(O:H1FZ`G]/](_;JC65K]3*/M(^9_@"?U'X:]^\/?Q
M]PN_EX]O8SOY>2M\>W?OY>2*G;_>G5.+?`ZKS3I(G[=?6F$Y$5I1N1?'LK7M
M5%\D8K>W9?U\D*WM_O\`)/\`>G3B1U!T#*>A'Z?ZQ^W7SWA[-7W"[.3NU?8S
MLY/%S^[5[_JG@Q5_\B*O^SIQ;X'3FGQ'[=%.!'*Q3"1R=E5JD8CD1?;V[HJ]
MT[^A_P#]@[_<O3BW6#'Z?WC3FDQ(G[?M_N/[#\->D(->W8C%[]NW9S5[]_#M
MV_7]>_L;_P#)3_?T@_#5>0^(U#;*BN1KFR0.:YK7M<TPU1S'-&]KFJCNRM<T
MK51?]%1R?[TZKP<=0?V:M%E9$AEC[1\O[Q^T:^.EQ6.\'R8['KW[-<8;7?HP
MY%_I5R+^@XQ'?^0;E_T:O8$<B0#'V?9_>/VC0V5@P64'[1\S_8?V'X:BH42O
M4:$8I$:CU&CVJ]&JYS$<K>_DC5>Q4[_Z=T5.J08GPU=R6>,CEKZCV+_HYJ_Z
M)^CD7]51JI_M_P!J/3M_Y4Z0=)&H8Y,<K$((X2#<QI&O&5CV*-S5>UZ.:Y45
MCF-547_143OU4JP,$$'5HL1AR5@1$]=?4.!6N<AA*UBO1SD(Q6M4;B,(CE1>
MR*-X7H[_`'*Q47_1>J<6Z09_3^_5>:$2"('S^$S_``/[#KY^1'\O#WA\_P#T
M?:SR_P"-@O\`A\N__>$:W_Y9R)_JJ=5XM$P8TYI,2)^W]7\=M?&R8SFHYL@#
MFN1'-<THU:K7-$]KD5'=E1S3,5%_VH]O^].A5AL09_3^XZH+$(D,(^W[/[Q^
MT:^CD1RHCA'"1J]^SAE8]%[*]%[*URHO91._^Q7_`'+T*L-B"#JJNC"5((^1
M_3X']FOJG`CO!3"1R?JK5(Q'=N[V_P"BKW_U&Y/_`"M7_=U3BT3!C3F@,$B?
MM_3X:\++BM5J.DQVJY6M:BF&BN<]\<;$:BN_57DEB:G^]2,3_P`Y.]>#_`_L
M^W^X_L/PU0V5CJR_M'R_O'[1\1KTD@#D8YIPN:]JN8Y",5'M1ODKF*CNSFHU
M._=/]G5.+=(.JAT(!!$'YZ^?E1OZO^8!_3Y>7]X?]/@IFN\OZOT\71B(O^Y1
MN_\`17M7@WP/Z1_>/VC5/4K_`,0_:/G_`'']A^&OJ28[G>*2`J[R5OBA6*[R
M1S&*WLCN_DCR-3M_O<B?[>G%NL'3U$)@,)^W]/CJ&Z="8G=\R*U.[4[ND!:G
M=_X_@G=7HG=_Y0NW^_V,_P#23O45V'HI_9]O]Q_8=4-U(W++'VCY?WC]H^(T
M6?!1BD69%0;6D>YZR`HQK!(5Q7*[S\4:-H7JY?\`1$8[O_HO3T[)CB9^S]/C
MIZU,<N2\=_$>$S^R#/V'7O\`*C=T;^0#NKGL1/:/NKQJ]I&(GEW5PW#<BI_J
MBM7O_HO5.+?`ZKZE<QR$_:/#_4=?$EQ%<C$E1U>[]48AAJY4[QT[HU'=U_66
M+_\`*L_]).[@\3!C[/M_N/[#\-!;63`99^T?+^\?M'Q&O+IT%C6O?,BM8YBE
M:YT@+6N&C&E4C7*]$5B">CE7_3Q5%_TZJ*["8"F?L.J&ZH"2RP1/4=.L_LWU
M[=*C,[^<@#.WEW\BC;V\$,Y_?NY.W@V,15_W(-W_`**]J!&/0'](_O'[1JIL
MK'5@/UCY_P!Q_8?AKZDB.Y51IPN5'(Q40K%5'*YK4:J([]'*YZ)V_P!ZI_OZ
M<6'4'50Z'H1^W1),=>W8X5[]NW8K%[]T$Y.W]7Z]T.Q?_(]O^].G%O@?T_U'
M5/4K_P`0_;]G]X_:/CKX25%"CW%D@$T;7.>I##8C&M84KG/5SD1K6C`]RJO^
MC6.7_1%Z!&/0$_I_I&C65J)9E`'Q(^9_@"?U'X:^K(CHJ(IPHJN\$12L15>K
MB-\$3R_5WD)Z=O\`7NU?]R].+?`ZKS3XC]OV_P!Q_8=?$DQG?\,@#OU:W]"C
M7]7>GQ3]'?ZN_('V_P!_FW_>G=Q8>!_3_4?V:H+$/1A^W[/[Q^T?'7EDR(1>
MPY48BJB.1&'$Y5:HF'1>S7+^BA>U_P#\JJ+_`*+T*..H(_5^K^.J"VIME92?
MM'PG^&_V:]?E1OT_Y@'ZJYJ?WA_JK?=Y(G]7ZJW\8G?_`'>MW_HKV<&^!_2/
M[Q^T:KZE?^(?M'S_`+C^P_#7U9,=.R*<**YR,3N5B=WJ]!HU.[OU<KU\>W^O
M?].G%O@=/40=6'[=?!RHQ6(04@!&+Z^SQF&]B^U@B"[.:Y47V,.QS?\`>CVJ
MG^J="C@P00?L_3X']F@LK82K`C[1XQ'[9'[1I^5%[>7Y(/%45R.]P^WBB$<K
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MO_:)_P#Z+NPUV#JI_9]G]X_:/CJHNJ/1E/ZQ\_\`\T_L/P.OKIL-KF-=+C-<
M0OH&UQQ(YYO-1^EB*[NXOL:K?%/U\D[?Z]4X.1(!@">GAH;:@0"RR3'4=>D?
M;.O7Y47NU/R0=W(BM3W#[N1?3V5J>7ZHOY(__P`HW_TD[N#_``/[/M_N/[#J
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M:IZM7'GR7C\9$?IN/VZ\K/@I_K,B)_WG^L@*?]U^1[?]7_\`VK\0OE_Z/J?W
M_P"%>U?3L_PG]A\8_O'[1\=/6I_QKX^(\)G]D&?L/P.OK)T(CW#9,BO(U7-<
MQD@3GM<TSHSFN:CU<BMD-4:I_L>BM_U_3H4<"2#'V?*?X;_9H+:F/%64D?,?
M&/X[?;MKVZ5%;X*Z2!J/1JL5QAIYHYP6-5G=W]2.?(&B=O\`52-3_P`Y.].#
MGH#^S[?[C^PZJ;*QU9=_F/E_>/VCXZA%L*\`_<:=#"+P4GM+)",?K:Q2N?YO
M>C?!!M5RKW[>*=_].JBNQCQ56+?8=6M?2B\F=0L3)(CX_P`-]1/S(GB]WY4?
MQ&I&O=[Q>+'"<9A6O7R[-43XY$<B_P#"HW(O_"O:G!^D&?L^S^\?M&KO5K@G
MDL#YCPF?V0?V'X:\,GP2.5@YL1[T\N[&2`N<G@X+'=VM>J_TOD#1?]RO:G_G
M)WJ:[`)*F/L^W^X_L.J"ZDF`ZD_:/E_>/VCXZ]#FPS=D%+C%5S4<WUG$_P`F
MJ()T<GB]>[5#(&_O_P"B]J_Z*G>A1QU!'ZOM'\01^HZ+;4WTLI^PCX`_P(/V
M$?'4-UG6L54?80FJB>2HZ6!JHU`GD*Y44B=D2/&(3O\`^@-SO]&JJ5%5AZ*W
M[#\0/XD#[2-4-]`ZNG[1\"?X`G[`3X'7HD^")/(LV(-ODYGD22%B>;/:CV]W
M/1/)B@?W3_5/!W^Y>@KL/16/ZC^GB-5-U*B6=0/M'S_N/[#\->F38;T:K)<9
MZ/1BL5AQ.1Z%]'J5JH]4<A/RA>/;_7V-[?\`$G<4<=0?V?;_`'']A^&@MJ.X
M92#\QXQ'[9'[1\1KRRP@$5[1S8CU'X^Q&20N5GD%LEOFC7JK?*.]")W_`-6*
MCO\`1>_0UV#JI_8?C'\=OMT%U+$@.I(^8^$_PW^S?7PEC7B)ZBSH8R]^WJ)*
M`PG?PEO[>#GH[OX0#K_I_H$B_P#F.[!781(5B/L/R_O'[1\=4-]"MQ9T#?"1
M/C_^:W_Q)^!U$=+BL\?.3'9YD8)GD8;?,I'M&,3>[D\B/(]K4:GZJY41/U7J
M@1ST!Z?#5QLK'5E$F.HZG:/MG;4Q_KU;J_3IIITTTZ::T*^V=#893*5&AK14
MT@]7RAQ]))'T$*+8U18J9KD)DE\B#._Y28^()ZR!">CE*436,12.8G7?^Q\:
MO+RWQK2X5\6X2A*L#SIB"-Q/0GP!).TZ\>_-;-N[=VZK-H%3/7W#&)%BAD(]
M+)F5;9N(\P!ZD`#S$:Y"[?D>QU0A["TF2Y5+Y2HSZV7.)8PLU;(\MG75C:<<
ME\,`[H(1V$4S`N8Z.!['-&^.BE]AP>V58A.'4`+]CR`@NNREN42>)E&$S)!$
MAMOFGNW?+^X*.YY#LV))'%FY+4^[*G`'B`X`L1@L%5((4IYO@J!W*E%3$AST
M@[?)@`ROEQS'>W09JC..]DXD;JLU8\\D4TJ2*T;_`"5&N/&\2,,)4'(_I5[A
MUY8-Q,@QY'8<19YN4`C9R/\`9;8@ZHN&?<.'4U3\>[8P'$@G[RJL^H:/(4DA
MCRJ!G;G7#!EUC_B_:?M$"?EKFRK7Q["JII%7=+K2S+:'N-Z,US^SDC7<5+`8
M+6&!PVLE1S%'(8-$&+S*]NQ[K@^M8N70K<E=@R^G"FJJ%Y2IB5)GRD`@G<P`
M=-[?[K^&I?M^58A1ZT*/ZQ9UOR`7X$..0#@$`.K$,%\JRQ%R20W%)IIIXMDK
M<KK#WLVC.MO3%KN.M)&!99[/Y?\`(T##QI5/?FE&;%CM1KV'<K!(P@W.=BJ:
M;\559?\`BZ0H8<6Y7(2KN\)!#)`Y$]1N9!&LYTR<3/9ZWCMV2UC5GFA7&M`:
MNNJ;`04L)8(HW#&%`8$FZ^=\O4\4T11U['"N=U,;$VA62*B6N6%$U^1DQJ5\
MD4\Q#V6FB,#/N?0US%&>-&]3$<\:XG8,JWNUX-F]%"S7LPYS78"T0(5#*5SX
MAFDP#K9>[^WX_MW$(H!&5EM%YE#Z0%U)"2&)+VCC9?Q!$,B<1)&IFDJ:7?\`
M*')F,L;W.UT:^S>4NZ?4@KW5-9DM)7PM-+J[HS848,B+"]B/B6@43LP!6R4<
MA([>]E]U_;^U8N;778S5VV*U9/)K$)0,NY()_F0^)'&(8ZOQ<;%[SW_/[7==
M0B744V):%X+3:JVE+#Q`(7JEJ^"D6`\D&L;Z#-73;)^"@YNVHK`+KK)TA29U
MMP++H)<]?+KK681SBV48S*WS@F"(2S9)6_C(JO5'[3'RJ#5^/>Q+*SQL8<^/
M/ZT]-1_*1R\P)/%1YNFVCS<'+&0>SU464WCG36?3YBJ/3L]9SU8'C-94#FQ'
M"9@Q[0E9CAT[::BFE@VKJUE;'JR5E5)KI]_%BP]IJ!PY!VG(I+-ODA!D;VD1
M>SAO9#<CK:A;FE_7L4.G*2W)@0A)K20(Z>!'1NH+ZOR#C]K6H8M3&JPJ%"E4
M*M8`+[0I,F7WD'ZDW4BHS0,50!K`ET=Y86<A*X]A0U<*QMH=J[5;K.Z&RC#M
M)R0*\5;)I\]2S!?E@:5WNG>F(=K6CE]LC.R#:1C4*HY`.Q"E?3J=%/$29#.P
M/$QLLNI,IK"[5AKCJ<[+>QN!:M%9U?ULBJQ@';BH4I6C#FLGE9QK<`+9J-CK
M;5P]'*T.=U=[FKR5)6_NM5&M[J&*KKP'*L^TN!/MH8K`1PL:Y!26JL@Y1";Y
MO.$;[<RK$?'&/DU5VT`<%K*J>1(V5?*8@[2OT@$F`K$7]KR.XUYS9N%D749;
M-ZCVAW4(H)Y.XYJ&!$&&^IBJB2Z@],_DGDFQY&W^@/*BYUG[7Q6,,:VK<Y'K
M+NUB%W^,!&+L+&**"E[?OK*\)"%<)B`,<C&(Y&KW\P]W]MK[;V^M5-GGR]U9
MRRJ?2L)],&>"<B0!)D`$Z]Z_+;OM_?.]7/8M`]/MP`=:PEC@Y%`!N8<?4LX*
MI)('%F($@'77_KQW7TOITTTZ::=--:Q_580KQ/R3*(]J.C<&\\,0?FY#/&?!
M'<9PAHJ->@T`G=5_5JJG;_5>NH]ILW]7QD'0Y^+]FUHC^.N!_,-%/MS.L)W7
MM'</M@XYF!^K7![;1;:ME`U>;/#>%*N.>C(1C"L'`DQW799!_P`DS(,T%K4/
MF1E&,O>;$>80U3S_`%][P6IM0XF2&GF0WV@\8$;@JW$R1Y6"D]-?(/=:\BBP
M=QP2I7TP:R=X4CU),GBP=.:P#YT+*O75NAC$BFCZ*C+8$S5C-+1QX4A\LO\`
MC<A`AJ)U+.)%?*_"B0H,T1ZY\F0^1+J_616D>*0K<EG#J<>\*,E5Y$B/./J#
M"8DD@AX`"O(D`K."M;5LN;AES@NYK"DD^D8",C1/$*K!JRS%GJXF&*O&3-9E
M+/F#-,F0JRR38YZBCY\5/'937'[]AF6F>?(,6JMBDBS+3/AH"-$Q[^TB'YQT
M:\\</GK,3+J[/D\'9?P5EA?D>2\+>+QYEW"N7$D=&AI"LT;[N7;K_<V#ZM5=
MG]3II%80<']2CG7)*.8+UBL@`GS)*0719KOSC16W).JN,1IG*')9=-=NK75S
M@T=129C$2[*;32\O8D:297!IYM%!(6.9R#:UDW]?Z'H,>/[DOI[9B)G8N^9;
MZ=2UCDS/:`&#CHQ8,0"-]U^(DY?L;$R>^]PM[5G[=MQ_6R'N85I75069#4W5
M0C5J2K;;6?`A5K7)O+V<Y9;80,1828'&%96QH6/HK8$6A"L2D@PX(Y]$!X(X
M@4-=3S0/&)J$9!B2F(HR$&]A(>U]GR>T%;,Y0W=&8FQE)<RQ)AS)EV8&3MS9
M3N`01E]^]RX/N/G3VEV3L%:!::W`K$5J%Y5B`!6J,I`$BM&`XL00V*&1+1\#
MYM?`B;<TH.+LW.':/C&BM>?*Y&HCV&=E.0S*^`^58L8A&H^0B.'V:_S5';8O
M4+.YAS0$-Z_3(.UEC$./$P)CIUZ1KG!7D&GL1J7+-@Q6^N"-ZJ4#5MOQ66`D
M2WT[&8.[F-_;^<L<;%W=IFEYDQ:7NCHV0U4[:V'<5H:O9R8+JBW"V1HK+/E$
M.5%<IE8GJ.'R&0B]</F^IV+,&;0EO]%OXHT[<BK%JP>2F$5Y*MM.ZF"!KU?M
M?H^[>V'M6591_P!48OJ65\=^*NH2\KP<38U9`=#RCRNLAFUH+<K+Y+V^?BU.
M6IWQ:FXI(V*J[^AV<637Q(\V\S>TOM,,)H5(TTXU4DN2<SBQPP0HA6JUHS$]
M`HX=LP;&NM?DZ,;61ZR"2%>M$F6V#<5`@ECMN2H\=RO5[]W6FO&QZC77;6*$
MLKO!50UE5]EL%:Y8IS=FE5K4<A`5C<V@:')Y6-QU2_M[(61C5"#L20`4Y[^X
M#'IJ=;MR/C+^W0G.1`Q*_P!I&`KF(U$]A#/7%QR<O+/<K^7.XMM)8(LLW'KY
MCXL\`ES/0`:S\T)V[MR]DQ>`JQE3S%0AL<!$]3IY5_E2N2%K$?46.K9>D*/2
MRRV,;\&YT<9CIHVN_#G4V(MXIIX#AF1%2,AMEGJ-&1B!(.3%KY3^[E;/9XY0
MYM>!6>5-9V\0UJF"(.\5NTL""K.H\:SK`/I)BLUZ\,J]1R'1DH<%@0PVF^NN
M%*D,E;G>+A&>>"8DZ+N^))=G(AB/+Y[XPKG25D00_O%B27(OIT"L"Q2GGH,?
MB<GI5(H4B]T5%<Q":#OSUO@9B5!BH[?>8@^58"@L>@^`GS'E]L=?[1JMK[QV
MVW(90[=YQ5F5'-B38RH!);:&/'R+P^8Y=]<DJ+GZ]45%1?R^RHJ*B_\`.R?]
M%3]%Z^?LS_F6_5_`:^Q^W;X:$?/_`,1U<?6-K.TZ::=--8OWTQ165!#>!#QY
M22T)W<K'!)W$P14<I"![>#GM<QXD4HU>C?<U"1B[7MZ358X,,(_7U_7\/'8Q
M])AAS_>;.-]-1$HTS\ND'K'QD$;B0.0Y5MC>8:532W21O_(KI9QO;':TCO$Q
M$`@R@5QI)2SB',U55CG+)4C$1SI+Q.L]DBI>G$[6@=?V]>FT#Q^F#L%!%6BM
M:S%L]0&:&(V^>VXW)+21T)Y2-RY4W^K:)6R*]\Q'L$X7X[V2E(I/6(J`8(+F
MB.)!15_'%XM]@?'U"<TH5''DPE+V+8$@D&=OV_+KN?`]2"#+*]<FNAZ39(!$
M09F`8@;$0-A`E>BD,O%+*HZ!CWT%@Y?D]!O?ZY#8Q6^#5$HBQS_D1A"7NUY1
M'8X36.&,J/$/UR`P[9;'LE/ATGYS(@_809ZD03*L]P5,RGC9N`=C!^$$&0!X
MD,"((#`JO%UJ@UQ3Q9PJV1[R/8G=KR1WHJ]W/<V0LDK#2#,]LLS$>]KS$*[P
M(CCO>VTNL56K-JP!]O[HZ#H-I``W'E`]*VAGKM&.\EOL_?)DG<D206)V:7)&
M1*R32*B<1[48KY)4EODM$J]_:L=/$#!%0/J<1D=OFAD>JJ+N1'OA2S7JJW)&
M\`1'[>OC\?".NT!T$=C/C6D[2QF8^,=(,1].\S]/FDU6M&M8<>5$'=`5X3>'
MDYD5@3"(;U(`;B^7X@!((<9!D5Z@$@!]B>E@6OK+:G9']!H(^<].NW4^,B),
MG;D6(MNR:J[*AE)LWP$$3$;]`(`@SQ'$>;B%!QYH,8-Y#:=7%'(]18AW(UZ,
M>_L>._W!E1SJ\@U]['-,)2^*F"82HZ5&=8S&A^.Q69'[CX$?([&/I93LK"54
M3+KY[AX(/[QN"#N/,"")^I67>RLRE5[!VLJN8=TL:,<PB232'$>@$&QS8KG&
MDE>=LF0)CW(I".16*_V%(&1:7W0:A81Q/RCQ^.PV@&.@ZQ`!6J+'Y#(:D-R7
MQDG>/AN3,D`]3TF6*OD2"_E5<G]PB,4\!DLK7B3^AX"F"%K55SC1_P"E8HQ+
M&,\B!];1(I&B;$EPI/):OIOM9'[=S]OC/(`3,[$\T>+SX[^M5O2&.WP)`^8\
M(XDGC`7S!17955+$-:>M2P8&06*-%436HP#(HV(=#K(!*8(`(R#$6.5A0M&,
M?L:0;!,.*'%4UJV^F2`W[9Z1!&Y/0B#),$$DJ7GO6AZ/7`8UCIT``WF08`$`
MJ05``Y!E"AUJG1OC:*&\1O)CB$5SAI[%D!*-[Q$1&%&96E]I7(03V&<Y2N0C
M"*9XY]A#XS\AT_<?T'0[=!!$`URJU>;65;9B>F\@S'C/B3((:9(8,6*W4J.^
M3560Z]S_`&1R*BB<I'$(&-VC/3UN:\Y7-:A(ZL=Y.=_W35>J.B3"RL%MJ-G\
MP_CO]GS_`'F-G08Z%\:\4$RAZ;R0-OM/^&#U^D29KM:5E119V9%.'Q6*Y'*K
MI2#]0D'$4:J(3'11C#%C,5?/N-H`L1B^N*%KZFY6.2A4_7\OM^.^Y/AO)WW<
MQ='8BX5BLG^6?CT$"-@(```Z[!5$>6M0<:H6T9QXXYRA05DA6(1S'L:$JQ1S
M$5WN>%[U_H)(:B.&1R(\PRA>S\N.^.EN+&N9KC]>\?Z/$?RD$'@PGR4+H+B(
MOGP(@QR\8^;>!.[*RD>HA]Q3#TD513(Y&S(_ZH\;RA\I#W,1LP">4MPSC>9C
ME:KSO1Y$1KCM.,ME1P<5Y0^0_P`/@>FW7P`@;\>)%5:W7.JXV@^JOPD;[;CK
MN"1M+&3L7#JU\"H&&/8S*SW?VEBQPJWS6,JE"`3_``CH"0P+'LC>M[%&\;F!
M8+P>H61CQ+KB6K6V-Y)^.T^,B>LS(.\R.197LQ@M=[43Y>('6-P!T@@=((@@
MA0L'B*WKEY/MS<SO&;[810JXHB-0,,#/85"B_I8C&C%%CE\6O&QL9B$5!I'9
M)#7W+&2GFV<']9_0D=#YC&_(JUEC\L&SR;U$;CHHW,_N!Z@!1R\O`6+3&L?8
M\<6[BC,]R(JN"4#T:K'2#C,,P?2:1Y/))>GDC#G\R/5C3N)(!8TJ@$T.0!\9
M^0B.@\!X@0!)6%:NZ^2JY:`D_`CYF9$$]2?!FDF`Y9TOJ49\>_KF,1HT57"1
M4C*J$A&$X1X;O8*4XC7J%\=\<P2D:KG"(,I$=&D'B8-CV3_'Q'0^'V@@@'J"
M!YE6="F91&WATZJ1!7H9Z<2I4G<JRL9K=Y"G5K03:N:<3X,5RQ&`'WCF8-&O
M5Y5]!`,CP5`/NG@HP#0/<;@A8UE9)?)9;4!]0[SU'[YDS\9)G>29MBQB`CX]
MI'I+M'0QOOM$+`\(41Y2J@#'E%,7/RWQ9"_DQ2%<9JHQJFCHYLE@U4?X_BTB
MM8="!]?@]&E<T7=)D/J_BN0G)=G`CY'I\_L@S(VW^A]0\VPK#6_FK)GIN.L;
M1U^J1$&&(7:VK7NYAI`D1[6"A/;*,Q7+W<0!)$@K2>'<2O-WF%D(OBQ7D(5_
MF)7R"^-M2E_44U/$`?N`_L`\=@!!A1]S=E5"EUR*?J8_:))^6_F)Z"26,K+M
M&342#@WL5LIDD,60V,UC',E-_L^U0S6A=)&83C0S#")[2B.UJ((90D'ZX\B/
M&#9COQ@E9^'7J)B-CUV(\2&!EE:8K5EU^H&"N%^/28:)!$J8!D,!LK*5XHZ2
M\+USHL^GE2V/,TCQ-.B^:F:UDIJND"(P,9XD:TXE1&C"K1E\6`49@U]SS6RW
M(OEB?X=.I^!\3N-VE6LMIBZM\6QI>8GX]>H,#_$.@79H"0Z44^(^712WQR]G
MIYD4H7O*WR))<5D8HW**0:8X\IY?)C0O(0A'JYCI3Y`+&1PF0G(?J/V=?A$"
M-Y```@A`K5PU>KB6<&_6-^ID`C8EI,[<2229!L+I?6[(3X$@5E";V>5'#>)/
M8\/Y!OQWC*Q`']C4<11D(C7]C/\`4YI%,^,65!4?44U/T'\!/Q'V@;;;[<0P
M3+O5J7%]7U':/"3$'8SU@F#YCQ(8L4:R&5D#20/8WP!)BC?_`,*A>H$<Q/Z7
M/:6,$M;(9$1R=GB;X":Y'`4+'UU0;,:R#)4G]O\`$R)^!._\W(BRUA3GTR(%
MB_9M^\`J8^($`&4X`T2]8P%M$+7FD*1(K_$PW#03I</SDL\9`21AJ5C"-.(C
MB"3R=[QGCM=^5';=:6J<6`1/3Y';H9V\"(/^$JQ'%C'CJF16:6:>/41$KOU$
M"=^0)(_QJZ`^H@@N6;G9!8T5CY,.252C(44HY4D&[*UCO61[SRU,1$5[7/?)
M<1/)7RB-6WKY,A>3[.!\AL/[(^R`/!`?1M)MPG*5#E4QG<$F3_$R>NY8G>;&
M!R9BQEGJID>QCM%(@R`-:\;'M<C43\94>TZ&:UKFN02C*PK!*B#8YPT_%E!I
M6BVH:FD6`_W_`"^V1!/4@'SHU]]C8]JWI!I(Z?L\9^R""%^D$K]W8L8]?77L
M=)J_V4]3_-PPA4:D0;P%:=A0A1RL%&<,HR,$C`L<,C1H(@Z^U;+*&X=3]OZ]
MNOQD$$R8()D&RYZ:,NOU>@C>`(Z09D#P$$$```A@H4BB/71H]K5@;(17N"[U
M=VM(DF/)![Q&8Y\AAY:R%=),PK#B<]ZD*T@RN><4NVUFIM)7Q_81M\($;`B#
M`@$$0I22E$R*`'ZC;QD$2#UDSNP(8298,K$NMEO.-+HY1`#$UL0QR>CV*XCW
MA>:.H5')60,YD&0@.[U(CBN>-CC.>^'+FY(5+UY$^<#?]\[1`\?#:">,!T3!
M+6XEA50/3)V\=I$;R"=RN\R9`+$FJVV>M(Y:V5^YPU082N&YXQ_CA:H1!#V5
MODD8(O&-%;W(]6#];4:1PP"$>KCJ86KZ3[L/M^/ZYW)V$F>@+$K;->AHL_$5
M[*8Z0-@!]@&P&Y@0(8JBJ^/-R1U]M4$G'&T9QA.]WK<KECR6.E!*QXI47LU5
M5IQE"<#>PU*,PD:V1'9&ILJN"+])(_6-O@?L((/6"I^EC)8M.3C&YQ#@'IX'
M<="/]X%67IR5E@.@I5885B)E6;VM.XI7>`A$[/\`%&.12KWFG(1LDBJYQ5(]
M#G:A%D/.PEM-:IJ/JK'&/T^`Z?"!`VXA2*<>AEO48[R'D]`?W_4>IZF3R83S
M+@Y/B)'L::R9':$,D;Q*YK.XV!/'&D4J%B$61Y#>%1@\.QD5?6)BO4:0ID>K
MM7?7RD@S^L'?KMX[^'B3$\T:E:78MX0`,I'R@@<3*F>H\L>;P43'I6I.3P)3
MO_>8*C<`W@,L=P(XA@`R*416=R,C_C@`*,J-51L;':-[2HR,-[*RRMO6'HV?
M4/&3N9'VR3/QWD$2Q!MDN3\,?Q5,<3M$``""#UB``-MAQ`(:$4C'CG]-W7R#
M2$3M']A1L&TCCAD*Z1'DMD`)%G&`_P!SGJ1KQF7P(4;P/\SBG6KRHL"KX[?*
M-B(,B?E!&X!#"%*7OQRJ&9_Y=_&0=P9!#$&9F0VQ92AEUM^5102XZU<DC?.(
M18\<@UD>TO\`W?A*C$*:49"L(<#V(KG/&CA.84R$CR)E;@R-ZJCZA)Z?L,`;
M;$'X[R%AE1CLEJ?A[#NI@$3)Z;B23.ZD;R)4AF!1[98934,D$!QXG[:(HC(\
MKQ"<P"1V>WQ_'<!`1O2%'-8O80!B;V<V,QA*JXA<A38`?5((\>L_.9._VDGQ
M8D6QAFP[!267T`0=R!M&_2($"0.B@=0@#8WFQ@2:@Y9D=/R&%:4YBO8X:1?6
M4SG+[/2HVM>PIV*-PE];5-_:]*RXH:UNERA&V(Z?/I\_LWG?R[SP9J7TV8SF
MU/,#))^$$_+YL(C;S>7CZE:U#T-TM<DCLUEB-ZA=ZWJU3%8[V"$;^F8>.\AI
M+7M7L9Z$)_2LAI>]G'R_#6\?_+/[A\ND[#Y;#^4C[J;@,^CGTO&W7J1N`?J(
MDF?YC)VYAO\`B/E9,':HE?8"],Z$Q[&*-[HWM5HP=G#2*;TA.$:!)V&56HB!
M,`BC_'D#6H:OO*S-;?KCK\>HZC<?%6$\E*BU<C[FX1:@^R=AT@P"/*=C_A9&
MX\'63K6$J9083B15%/<]'C]:1B`8QIFL1CD;''Z'PQ$\41!,&T1%8Q@!%#57
M61<ALWE?US_'>2/C,B26(:V.@''<52O%_"(@"?LV@'X`08"HK+CP9=8>I(^;
M"]CFH7L?N,B>(W&(5/%&QWN.BOD/1Z-&5Z%>94$1Y)D2;<EJV^1_AM^D[=!X
M@1&X`1TLLQWQR;JIZ[['I,_`SU,[$R6\I+6UVUE):6E621'`-9`V(<371CF1
MKPR1'C$:4#WN,;LC'?\`+E.KE(-XWF\XQ9D/`U6\6/EZ=0.H@]>GCU`B""!#
M!,H6#(QRZ`<P)&Q/0@@R.IZ'REID%2THUDA$M0VC&5LX(FB,-W=&(Y7-8U&G
M`1"H\`FJ@&,>P@7,1K!M*-PQ#1U9(]1J/JUDR/\`4?CX[09W,&28MAJR%R%]
M"X#B1_I!G8=`""I&P#`JHG'^08X:NP?5R"L,&3#>R1'(GCZW%63XB_I$$;W&
M$.3YM4`VIXF1C&_\W%%2QFMK%JB"&V/V1]O^SXG^62?(Y4UKCWG'<@JR[CX3
M.W0#<!I'$#9H`^\K7Q.A+1F%-@K[&D,U2-*BF>YSY:N08F,0T@Q"FD(CD_NF
M*<RO8A9)",MKJW]<%'V@?9X?LZ#Y``084`TTNJ.(PMJW!/COU/AU)))WZL6:
M0&=B,B/(,EI1LGD0398GC<$L;LK48XT1\8;G-DHI&'9^.YBQY'];VA>`S52*
M<=JKZ5YK$\#UG[#/AX;]1_B#+]:F]V]?$%S0+0=B/M$>.\^6.+;D*5<'TW7S
M4$BV\%T.Q0#W-,_Q9[$&YXG@*O90H",#U>N.9/+Q&/\`M/=X`410UBX-2_.N
M8C^WXR3XCXG<"6D-;3&->35Z5T'?XQM!\(41`;X#8F$XLM'P2"I9\BM7L1D@
M:.8\SE_(,:2\[&#D(^.16N]ZG14:`WN*0JJQQW2(\RIF^L6^(_8`(Z;_``CQ
M$`#<*%9*+QQ+FHZAAX]23/78^/+^4R2VQ<NEL*PJ9%<<<^G0I?)SS/\`!C3H
MGB0!&(O8SY,AY2%&JM8XA#/5A6D60H33ZUVK8OIW0/W?']0Z'X`"01QY"NEV
M,]#B[&D^/Q\0?C)))&P)+&&!Y\6NG9P5N*J%-BB:$SG"*UJJTS/!K$:YR."\
M,8P/``WHKU"Q1#8J/C>`35]B-Z-K(QE?T^,F=STDR3LTE;)+4.5CI;6(?8_'
M^$`B`.L"`#*0K4PJ^S!8M_$EQAO(C#!;V"0Y$0WE%*XI)#0/5KU;)]B.$QSO
M65CPC>&5%#6RIJO.A,2#U^&_A/\`LQN>H()!5VI1D)>/2M4<H(Z3UV,S'^U.
MPF&!52ME:T^(]]1/D05\"CFN6-_HIG)(*5HE=V.XQGE=)E?U*1"+(*3Q<U\D
MO>WD<"ZL6="N_P`-A]D#H/E`&T*/N8*B<:YJCN&V^.Y,>,F9/C/(F"#8TY,S
M*JG5YAV$,P7%@^".$QSR$(Y@XY$>C4.J-\A_C/\`!#-8YGI<TS7MAS&6I<+%
M].P&&_T_+[=XVWVCFADLQS2XOJ(+)X?'8&>OPXF.0!'$A@158)ZS"ZWJAN_'
M:&9']9"17-:K&-*)R/5CRBC!)%=&$]40C1!4;7-(@$$]*V.HBFWK*'Q_23,_
M"3,$<I'JRY"G)QP>/&Q8D?:/F`"(!Z@+`(;AQ/H4Z"7]Z$6ILAD:]C2R6E8'
MN83D=)$YCXYXY3D=Y2"L(A@D4G<H#B4CI`9DCCT"+JNG3Y>!Z@QX"((C9E,<
M62&IOQ2G&O!D`F8W'4=""3U(/)3/F1UY%UMG:Q654^542!J@3M22&0<B.&1'
MO"S]$>4JR6E))$WV->20XKF(12/)'D6%ELVUBY3YAM`_7^SH=MA$Q`#+7+CQ
MCW-C./*=P3T/3YF9)`F2TQR+$H]TE8QATLH4NO%'48HZN,UQ6IZG#8%WN>CR
M``QOXC1(QZ&$/UB8CWC$./(K;ZV-Z\+"9)_OV\3UF1!,DP"2RVQ7UKBV"RD#
MB%WWZ1&_4#IQ@R!`$E5"/1,6PS3H]=/8%A#!&\<L`R_V!KXR4E1U9(`)\=[/
M6<9/(+58UQ!G%ZDE!C4I(K9JR?*3L8W\(.Q,^!&^^Q4SQ+7Y*M:B7`2P$$3M
MXR-P"#]0,J(\RNO'U%KBQ#QK^*2#,&X4P+G([Q&YCX[!N\/<#WK)*I6G)XD&
M]IB^9%8]I_;_`.T[75L=Q8AE#^_Y&(\.A$#:05C[JZMTS*S38(M'[H\1,F9V
M((8R8(;E]_$IY$$335/BKTC'(]DCN%\=0JR/("=IO-CFO8QP5:U7O>UK@/85
MPUBR74N6PQ=\1T\?$$?Q^7U`B>2ZKBO4H.-X*QWVB(!!G_XF-R8X$,1Z;FDE
M@2*">,\,*%B*C&N9XHP#0+V"C'$:P(HXVC"J-_0;0#8K51L0:I3RBQ<BLJY\
MW[Y_M_?),[N?OL=J7P[@]0FO]T=(\`.GR"@1M6/^&F+>%+CF?<,5WFOB\K1,
M*QHQ"4@G.*YX#F1Q7F*BHX;WB:IT>(C'3(A*4NC+Z)_0]?B/@/'?RP00CB[)
MJL1SDCZO&)Z"1OL3O)Z@D>:58&VMH[A0[R`.1[ACFL<I"JUSF%][2?\`+B(Y
M&2BL,0\L9&*-QGJ0S'#?(]S'V5LO185@E/W1X_`1`(,QL#(7B15>5JRZ0\@6
MC<_&?`>)DD@B"QE@5+\@;U4:#:04B20-_4,8;#-\7O(BJ(X9("1CHV,0:"&1
MI!&8-&#$81&B9'-&7"RI^:GQ.W[H,C?Q$$$R2")+*S':K(I]*P>`@_'H000=
MCL""&`@*RL%"/7(5QI=3/;6-]9@&.H1H7T-1K&.E(X2-;Z8T;S&$WD-&,&WP
M>YHVB'*B5LEBI;7ZO1@/[OM)\-]_`$DE7MBI:W&N_#B"A,"8'3EMX`;!I$`"
M"0H465T3,MA*6Q=,<ASQY9BA.T@E5QGD<94&UGKDED>*R'HYCAN>0KR*P9#O
MD1[*U"+ZN`@,!M^[[(Z=9@`"2%"M5?8#BW>H9*,2#(W,SMT)/4R""2284N72
M_P!7$=D^$MJP@6(-P'1G1U[J=A"1R1BM.`JR))22R"]/K.CO)1%`5Q5C&DTI
M8UOZ1GQF?#K.QV&TS(^(8`<E6N2BVU?B%(V(B/&8(,@R3R(XPTSQ9&+>F[^A
MOAZ6`L0K105BH%PB>8UC""HT;V(UJQ@.C*(/9O?U#<,:/&X*@[U8A\6SF):9
M^W^TSO\`,R8/+E]Z4U9U/IM"%8@^`$?J$0/]D0)!3A_P^S(VHP8V(JN1K&M1
M5<YRJC6HG=7/<]SE7M_JJJJ_[UZY<[DG7?*(4#Y:]]4U73IIITTUSK_D"D1(
MG&8#S(S)(V\K\0L#[7`8P,X_^41ZTKBR6O$+RL"B'W7]7*_Q3]7=>C_EZKOW
M,JA@_A,B>O0<"W3Y2?U3KQ+\YGKK["'M4,O]1PXF-F/JA3)V'F('SF/'7%"^
M_)Q%^%I8K+>AF++K;BC6N4*W5*PK+0WE)67[PN@@E-D5YGN\5D"$XG]L1&/]
MOQ^.=CD@E,@0RM,\6CCTB#)$.!X$QN01\J9GJ=JS`&468;\E>OC'.N>9WF1Q
M!Y5L=N04MY58'Z:-:9375]9!<I5.V)-H[:K',5DF*C9%+^4DJ&0<8=VR7!1)
M46-^3^/:!.'R[A[J5JLO#:VS:)#*T;'9H@[\8/E8Q*%3&^CUY';NY)CTF9AD
M=`T$;I,KL+)7SHO+C:KK/EU>&^IY&AB,Y2J8UI):-Z77(-.ZCS]HVNT`<M=0
M<YKJ\<P48@ZFTM2C%->(R/!:O1$\624\,+M]RX[GM5Q0$^6EN3KR3FI>LP3Y
ME62H(@UCQ*[[3O.,^;7_`-08RV,`>>0GIUOQL%3K5<O(`A'<@.096X^`?;./
M`B02Y76\D<ROFCPO#HZ:)?W]G`H'MU^QJV09M)5T5:Z-+&:\I[Y_Y`P(A?\`
MG`,<140Y2KHO<'J#+I[;V6#GYO(HBE_NZVD,S&1"LFQ.WE)`^D#76>SO1;MV
M3WWW07':.UA!98ZU_?7(%:M*UAIL2SS!=_.H)V=FUA#E[8SN1H%UKK/1O4C;
M2&:FJKJ09NGIJNRUU;9PZ^3$D*);*9:#KU<A2!\YAXSAHC!C5%WO9\.OMMB8
ME58C@0S*!P9EK9201](6>@/E#`[DZY3W+W.WO=-O<K[S/J`HCD^JB-<KJI!C
MDSA9DK+LI795U=M&^57<WZ_2PY%]-=79S.%A6-K!'$<,/KV+BI<5YD>.1``X
MBK)`U_I,%SW.$[Q]9<.\)9V*G%<5J&L>0IG?[OZ2.A/@8D&!/B-CB&RCW9DY
M]37.:Z*BK.H6!%\\U.Q43YE!XLI)*F.+;,:861W?%<SE+,6HKW5<255%0\L5
MU!`C$M_\<SEM*FX^JK(X+!!W-%464JRBQI)(JE:UB,*A'0T1W,8IS,#NR]JR
MD->)F.SXY<GCS=0+&8D>5F`1B`T;R(#Z[S/7MO=_;S>X<"P7=Q[;777EK6H+
M^E4Y:E%`:'K1C:BL4D`0TFH:T0'42>1=1-+;Q*>OCR(D^%H=%&Q^FF/S^"AZ
M?&:7(QZRJM9H:D;SQSMBPF>HKG25>A"(,4E1]Z;E[;BJ*2[,""B&Q!SM*6)8
M691RZCDQD>6($E9\@7&L[WW!VR5J2LJRV6BFTFO'6VBVD(CL$$@\$$$EID\5
M<K4=[=-O+J/!B5)6L#WBU58Y!_VQVUB6-`A(Y?QHUE<S+"PD2GN8WS/(,XOC
MYN7RBP*?0H+NXD[LW^Z))\2%``7Y``=!M/WC+&7E"FJLP-D3_?8A5\`SLS,Y
MC=F):))FEW%37Q8U9GXYB`9',,NFF,E*+][N($&Q,"EC><>>R969:+$9'(R+
M(6-,L2^]G]L<1634VV,SY#`$D>01]*DB6.XAK"9'(2J#B=R^H,K&IKKKPT)4
M*0;6F/4=58A!LTK4`%(1N+V'F/**XW[^%ZT4'E/3RB"B1["VX5]Q&N+%CV4J
M!7\JYV-&G-IHKE2'5EF%DL8Y6C[$&YO]?;NGG_ORQK.U5*"36F='B5!-#DCD
M>K1!/78SMKV/\HJ$I]PY%A"BZSM4]0&*KEU`-P'TH6+`;#<$;Z[A=>%Z^LM.
MFFG333IIK5CZK(0?'NW5G9W;@CZ$*@WHKA/>+"A<Q"L3OY,[_P"J?Z]E7KJ_
M:8![C1/_`-?XG_M3KSW\Q&*]DRX__P`1W'[-L<1.N(%[;U^+SU=E&/%*-`BS
MCRB1JT(X\JQ)766@)%I(+?S8M+2UDRR)'A"`<:Q83$&KT\%\O<Z*K,W(;+,@
M,0!+;@2J2QV+,P`+$@\F,QOKY.S,FGM>$G;@0S(K$D*`"Q5K"*U\PK1&<J@5
MAP0`2(WD(5U'SU8:GDQ#R;78Q*Q\X%ZL>7`SE"<]5`I[$4&W=JH#;[3#=(DB
MF-.T]1$:T*>M9)_&2RALBT7*0*J2T%9!=P&++*^F>*;`K$6-OOQ68:LI<+'.
M-8I;)RE3D+(9:JR45&"OZJ^I:.3!^7*E`%''U'C.&`W`\A21.2K'.B+35IY"
MTM=3,IZFPM]/:W'JILS46$&#5&A-CSI;)<DYG*V%7#\AN>96#?HNX8)S+V[9
M79%S`<BW)@J*OF=@2P,@%0!]3G>%DCK.S=V7MF(O?;Z`<5">"IP1GM=X2I&5
M4*PS!V9MDK$J2T`^OG`)^9,USKPL2#58^VW9<;NH^@IJO-P<[,V&/LQ0Q\:W
M,&IL[J!-J+R5FC&)"`-%'[2D<A'*7I[E9>S9.!WL,]U..+*BC,Y<5V+/K*65
M2&4.`&)W@#;;5?8R-[GP>[^UF2O%R,PT9`L1*EK:ZE@OX5U1W5DL-18UJ-I8
MF26UB$W&-AE$OX?(T]^6O$%[KZCEQDO3PCYW-1Z$<>56230*"5G34CK&2M+-
M-)!*8>,]L@;(BD'MU[I7E^F_;5]6B81@>(/-R\A@"X<-P7U%`*D,"I+P>:;L
M%W;A=7WQ_P`/EQ-E9'J%374*P"I*UFLIZC>A8S*X9"'`KY+8CJB+-?P7&K9%
M%E)3N-+\P;NHT+;,I+`V9RD<#KP4AMC'J4;*E$4XCPSM:Q7HT;GL&1,\7,GX
M]K19:GXI`59..P>PGC$%M@((8;QO!(UISC5VGM"4-3CV?@+"+$LY$L:J0/4!
MY!-R>09&$2`I(4ZSIP)Q5<7>U@["1;2<7AN)K^1MI6GH3N#)C_CEH"0N.N-F
M#4DR3^["AAKG.DE]!!0U[Q!?D#]VB]P=VIHP6PU07Y^76*@CC8SSFZ[P'&2^
MPD%OK/$\>N]G>WLG+[JG<WL;%[1VVXWFVLP1!KXXV+U8\P%KESQ(3>M>8Y,]
MR=GM/L.0+J+20<A)Y7M9EA3R(V<T5<RJ74:JR?4XNXG3E2IC1-;'Q`S/FA;%
M&&:4+GN2-(=TR.UY.+AX]#.URXB`,"Z-RX(O*Q0/,36;2.)Y$J&`')=,+O\`
MA9_<\W+KJ3&?N-C,A%5J\/5M;A0[-Y`+A0"74(!85)/!SJR+^YE5$T+YM#%E
M$!9U);F/;/TD5+0=9:GBRQ3_`,G3PA`?'DS&L];Q>OW#57->W^GK-QZ4N0BN
MP@%6"E>!X\E!$0AF0.H,P=B.NM3F95F/:#;2K,+$+A_5',(Y!#3:H$%@((CD
M)((VU94N8*/./(;9V5DFA':6,&38CK"R+:7>4\\4UES(KJN.Z'J(%O720RX<
M>:HH95:C/$9([G9RH6K"E54UE00.4*%81Q!8RA4J58K+"9W#1JK+52XOZEE@
MN#LI;@2Y=&#<RJ"+5=65T6R$,1`9"=BN%;&9,Y<XVENK*J9&E\@<55SY`$8(
M>5,#=U-JR;FSN/-%9`U4-P(=F@R+(:L"&]CUC(1B<YWNM$[/DIR=67'O,'_S
M)J98<0"IK,LDB/.X(Y0==O[5OMM]RX%AKK:MLW$61L*2,A'#5&6#"Y>*6P>7
MW=1!]/D-=X<2-XLO5#(C4>P<EKD81Y6HJ39/=&D(UI'I_P!JHB]>"9Q!RG(Z
M;?P&OK_M2E>WUJW4`_/^8^)WU=/6)K8:=--.FFL1<I`.G[19QBJ$M<DU_L\0
M-8P2M"8SW2#I'&,;&QT5['R&@(G_`'B"[-FP]QVIE\]3"0T?'YQL)^/4"1X3
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M?%OK>5:ZS/I;G[ZORM4%]S%#P)^/_'7S_P`A4I^-?H.VY)E:?;YW7_)L>HV5
MFR/A,2+.:K,T^H(L"7_[1*L6T*-A1L8$[;+;KGKFP1(;?83N!.X&TE@=XY$R
M)+*TV+C8E=Q6@S#H"(.VS&!#,)("$;3Q58,!&6^]%R+I<Y].6G)5WR_L=EC%
M^WH?#]5I^+?I8D2OPD6VT==Q=%^4N7?A;D&IH<Z7,U]F4Y)NISCK2\?'./2,
M>&&$J1*5.RVBMY(8@`K)/A!CXR0#$GQ$S+TOJ1\8V5PK5H6(<*!M/+S1TX@D
M<N*;%2!!%6=.6;>FY.^G>9\1SOSIO.$N-.(/GGC+D;BJKQ_,=MP)$NC:ZWY9
MK>9>:;B\I+FMMMS-XMDYRNK6UTY9E32LE//+KIA+'M,E953)-18K"`[&#\9G
M81L-YC8;K(*8];M9@KD+6+"UI!!3EX1Q(/(R0SR.(;<[/#"W5'CW=['E#Z%W
M=<3E+DOD[CZAR/QI(RFHO?MO9_$U@VGV?#&6U5QMIGSU1Y^LAW=UR%92QW$\
M)TCD--EK#;ZQJ)[X+6=K.<^6!.Y\1OT,"!)B%B/I'%@N91757CBLJ.7)P!Q#
M=&\LDB3OQ`/)R21YVY(SVE-W//-5NN1=G'U'.E1F(O\`)R_@F1S:OU.[_I/D
MN-++Z-S/%)N/"_*S[YE>6K+EI0J`!HX8<VKDSA6\<PAP5=#D86W#U>+_`%QU
M)ZM]A/4E=@=R"3)^\AK;&QF_#EZ2/0Y$%%62$WE@0)"JK@$K`4@#B/N;VY.S
M^GXAQ/\`)YMLI]`?29;SYUWN!Q/%,C9?1'*6YB92DT_"WSGL[P9HNJV4BKDW
M1;CDFZ,"=9#9+CCEO`-7`:6*VY7(K<>:9`ZF!(7H-YW`Z<NH,@\6U:]:M=28
MK`(+'R+)(-@@MY0-B=FX`P001SKU?O'D+G;>ZK[`Y.NI/+LW.<<\\_9M5E.0
MX_VAR759:AK^-X6C9C\U&^6(<%^0ET5#<&!#$J3O%"M;,7W.5HY<:.:[6*SZ
M8)\3MU'P`D`="!MN0L?=R65K=CU(_$7,JGZ1YIANLLT$L1*L=X`9I^^P=P1R
M-RKRQR4V-L=UOM%`J>$_@>R]Y/Y!-O\`+Z5QMU\W8+6;:Z@<;U('5O(USH="
M5ME.EDL'+/D':%3L:K##L,A^1)9"%WY="=S,3M!>)4&9$2&4S`IZ?#B$MY.`
M`GU*#Q6"T0017T=AQ(/(`JZY6QG)-YF/JVEU%WRQO-AD=I]H[3AR@UW&?T0Z
M50@_,O-IA<[\M\Q?#7(%/FHN*I,."J&PNES$>=9C+6LOGR!5AYK(4]C6&++/
M-R8[JQ,`Q&W@09#1+;ACU!LPZ4H7ECU#TRE8)5D42P&_G`$AEAD#!%@%!LK+
M3LOS!Q(.;_(!\_Q!\J_1-+GN1^+OHOD_7X&B^A^6,[B;#6\2:WYYK\>>!D:>
M\2%`IHP>2K<,NKAC'%EOGE_*CR'*04J1&Y.*BS<2#T)_V/\`:``$`^`.VZ[,
MD5J\,=\A43U$91NJD_\`FDF>+,22Q'BP,^5O,ENJ/&OTO].7'!OP1I.2Q5M5
MQMKOK"?5[7GLGT!^Z:_>X^E']'VJUNQPK<%0Q:RC8#+PRR%'HYZ1!5<8C4.O
MK>[&J>ZNQ3T3D1X]-Q!D=(!V,#J-H8+G9%6/=78JPUOI@@`+LWE,J0P\P)&Z
MR=PPGDC/@:G^@N:.3,!]:2^4M)]7<3UW*GR]S=]O?(]M)V.HX0K<9:<49O6,
MK.*^)IF7LZF7M>/Z_AFZXZUTF')8M>^[6TD_CH)J)7U>PM-O)@S2RR".A*F2
M#OU!@F9)F2?/2JA:RF.J5M76RH\$&9564\2OEW#"5'$!5B%`-7<W@'+1^->.
M,)6#ON0=6"_S]#HK&^Y+Y!U7)&JF6>BIX=C/?^^;.?86G[0.4Z0HH:HV,`9#
MH`#6_F0VYR)ZM'($EXG<D^`\=X\.AZQONCG3W6^AE\2JBHDKL`L[L9@0#'FF
M5W'*%VLJ&:+L:-?#M`^TTAJ*\$C\<DK\EZ%0@8QE![2L:K3N<)[6D/[']QJ4
MY?"TK0=C4T!?$3$?$_NW&P@;PHFJW+6"N0LEQT,3.\@&)/B8.[2?*6=HR/4D
M9+BNB$)*B-(K1D$>.]RA]A%CR!>7XY?ZD1K8J-<"0U4?ZR#*/PB2!%(IL8`&
M/@?UCQ_]+J.D@@RZE8IRJ%8LO*!!'2=B.A_W(*MUXLK+%;KXI")(`>CLXS$9
M$&B*%Z#:)PE]C6->UK(T=C48)_@YHQ`>T:JU@?5(CUU;QQ87U'<_I\S^\D3N
M6E6LIBGFIQ+U$*.AZ1O\@!T,;!3$@+Q=*)<<J-7VAX3Z][/<1H&&<Q&2'ADE
ME*I%$\!%,\TN2;P1S'N<XA1JQ9#I$>?<4>RH6!NF_P`I$?/:`!.XB`9XA6KL
M%E=&0U10B3`/C!)\"#,L6C8DDLL<RZ7>["$ZL=^\UAV"=[6N9XD4K3,,\/BQ
MK1G=^4LZ08+G-:17/51D81TAP#S*5N+?N;1(C]D?PC?P^((X\E2M]1QS^)H,
M&?MF8^!WY$C8'?RD,7*/;4+*"2VB@D#*T9A!8]T=J>V.C$8R2B!&_P##]CV^
M@;?U<`;AB144'J":MCK<5,5(E2>OC\/G\3\2"?YI8637TG(K#@PP$QU$==AY
M9.P'500/Y.*M1)TTTULR;#FHTK&@>Y\?UM1[U]L@;V$][0.<U7L,-[2`8G=I
M&$&)[)<4=]Z"HJZ;&>O[/A/R.Q/@02"C&/%M;)#56P1QZ?K(WF/]H&5'\P8*
M196M+H[(<4[H1XR.;)E.:Y9#"/D^TIO2X)T*D@JF63(5%\D>4AS*PGMD&8^X
MEOJ+KS4[@>'3IU$1M`^0`$B%!%./B7BM_2==F;QF9)B#,F9/C)+&#R=@<FHS
M*P-48)XJ2"?D&_J(1Z%%':1P",4KVF$[UHU@E:]3*C_4!5*US8DL426FY2KP
M('[>OR^W:/%MMW0S6T)CN'KY'D?'<"8Z[CY0>6\)Y@178M5N1>R(^8!H?,82
ML]$P0FB,`PT:_LPK(Z,.,`%4;7^D2-&Y'M$P;OVZ*EH;@9B>H\"/LG;X]3OM
M)(]3)REY5^JD2`=F`@@CY@;P-I@;&0H!]"3K93[>/*BV41A6Q?-$=W?^KA(:
M,:,8<OVR"D<]QD>A1N55>49A.?[A3+[%%+!ZC!/^@@B-OA$'P!4QQ*146')1
MJ[UD+/[I!!!DD]9D>+*ZD\UMD:B6RKDFKIHFB;**KQ&_KE*[V^EK6%.T\A3#
M]A0M5Z.*1#O8CR$<2-*GR7*;4%E9D@?9\?"!'C\!`,``,E<6-8,=S1:``QV/
M7K'4R9&XWDGD1)8M79=$M1!JB`L(:MAO:P3_`%$<X(C^L2!]J((P(:%C16,<
M_P`B"C_CB&CE$(8CUEM)-H-;^83^S?["=STV)DF))*VUR%7'(NJA2`-CL#M$
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M)8_ZY\/'S>&Y)!$\TU'C7>F/1=0@$?'<[1_,>GEGS&`%(;B:[!*SG+0V+)L1
MW>#-12DCG<X8'C"QRE8XCF!8,4<(WJQ7M8L80G(YK8@GI4WUQD5%&_S%\1UW
M_O\`'K)(@ER/6CM)P[Q;5_E/N0=A`&_P@`3$QQ`,@5J1C5"ZJAF&ZP[RC*YJ
MN?YE15!YC*QCV`6%)]C5*0B/:HG]O:='#(U\J)*CHM*GT]A^KK^N1\HW'18(
MA'2;+QPR^MYC^OIU$QQ,[DR(/5P5(-E=D:KFNNX!HY6-_*$B,89/]'%>P:@.
M!6$F/%(=[F/_`$*9R.(QXWG:2/(FTMK%%@8?2?#^(/3;;X#H00I#*E^/:<ND
MHW^8/'Y[01N8.X/4F2"I<,CVTBIFCKY+J<K`EAD(-$D":SNPC(X7L)W$^.-(
MS8X!=O![61Q"8X3TC,&2LFN0V+ZPD/'3]9^,[R3]I)!',D6XN-:M+G&:#63U
M'V"#M&T`=#"@`J?3`:B8L(D2LLX4A1'&AI9'->/Q_%&$<4PD`T98S4"Z,B&_
MH\5\8_O3U>E)42/96[VU%=MA^N9F>OCMO\>.\\7:^^NO'O6P@B6/3H!!$01M
M'FV\%YCCQ%E:5"XKPV#7S(9RK/#ZRA>$AGH3P-V1J/:D@K588_FTC$*092.7
MP,XY1V<=-AK/!P/3/6?T'PZ;`@=0%!JGR:4N!MJ8^L((@GX_K/4S(D@DF&+L
MN1#A2)5O","4B?E!09!/>Q`M60U`.$=WX\GP9X*X)6N8;MYH(H"/;^+(;6Q4
MI<,GT'K]F^VX^T=/B&`/)=6TO9E5%;!]X((\-]H.Q\/*9#=>+(Q'IN*;22#U
MYB0E`&.]1(@A2'BCLD.B"(OXXI#`AA,8Z.,CF+X"#Z0_T(,(R@J9;U6Q19)(
MGPDQ)ZQ)/6/B9.\L0UT&([TN:H4&-@8$\9V!@+T!(V"PNP"ADQO-K$!!MV%B
M=D4HUE*)Y'B$R0X\AK&L*T99`622E.BHX3O%Q#HUI%?,ARU+L],/X;?J@?J,
M;>/@NXA'1DUI5D\J^I$Q,"9/C!(DENH\7@&;:K)R=!;<A_>H[I3)'I;_`,HO
ML4@B!*P@W,>%Y9+E8XHR(H"&<Y[AE`\A"#)865V>BWH-'&>O^O;P(W`@2&``
M(KEMJ&4OXI.0?CT\009'23X@^4F3#(2S*UTU1D=/JW"<02QPC<$1`JX1%3Q8
M]AF*$P`L`^,C%8\+QC:C&.$X+&A=`MO`KMD`\B9_38[S,R">L\B2++\0F['X
MDC@!`C8_([$"(B((`@%2H"FFG0YKJ>0M<=GG"(7U,>2*@)"Q_`S&D_#9%$KU
M(-AF/:YC6N:PJM$U!S(D:1Z_67U%V<#XR)^V?LC[1),H[0U6G&?T'WJ)CI!C
M?>('7S`R`##0HXVUI+7$>/#G".".=S"&8Y2IYJU\DDA\D1XBQ4(9Y#'DN\$[
M$(\SR>MI#E>*XNI9G3BQ$@?NB(,[;`?(`1,*`:8\FM*K0Z*8)Z_,F01$F228
MZDL3Q!=BN37[6OC6D1+()"22MC#-")%>Q[""1P9+$&Z.01C,<[TO:HSH1KF!
M>$C7I&D]056-4_IM`$[S^SQZ>(W$;L&!')=9F12F15ZRDLW&5CQ&QV@@GP(A
MI!"E6!]-]?8A#6M&YL@P@.-')XRFI'>)@F/*)B%;Y@:OK%%5I'>,5/6U>R1_
M![*VCA:;Y4$@'IO/]OQV^K?_`!2#:J9LC$(<@$KUVB-QOTZ`;_3L/Y((HH--
M)DP[,5?(&Q%>KXSU_P!%>BFF+Y*4@?[S5.LAO9X4<][C(YB2/RXLK(O17K-J
M].O\/#PVCH=AQ@\>#IB8MEE5XI<">G[SXD;[\NJR26D!_4KLBV#755D*=!:4
M9'(C%200ST.I2`&PC%4QI!G2#$'YM4A'O*1CVJLDD<ME;6?5J-=D$?*-NOZA
M`F-A`!!\H855N!Q[Q;2"&Z;SO)&_4DR2)W))((/-D:^J3V!G5X;D1/[PHJOB
M/`HBQF,3Q+XM:\T,11.<$35\BA'V$-R.#Z@&@Q5DI8:#]).\]?X'?<^!.Y&\
MLMF1<$MI&4I\P7:((^/B5!&P\5&RD%>*/3Z"1;JF,PRL8Y4*(H!A[C];%(ST
M.9*"Q"HQ1$8]I!"1$:091"5D@,6A'H7`B8^,_OV/V$03X$$RK-56.5BD/`.X
M(C;;PW`GH09`CS*RK#K72*65*A22UTAK2>\A5<Q7R#O(=Y5CJ[S>Z01$0ZO:
M[^DA2%*K2(^2]5M9[T5U%B[1]@VZ_+PCX``;0H^ZQL6RRJPTOO)/Q,F8^?C,
M[$DF&FP_\1]F&6ALE+'01@RE<1XE?Y/&YKX_B]B,,)J%8Y\9S"(7L]?2CBH]
M8DQQ%_$5<6D,/]/_`.E(C;S0(YH%K?@\CDD%6\/V;]1O])!G?R@M/IVF;LXT
M&;";:A*T0A@=Y'11#B@1K(XG>T98\;N($>*\;V/4`T:-6D]+`]ZRRIK$?TB)
M)/3Q/7IN>I,CJ=Y$D_>RWUU6U#(0PH'78`=!O(&P`((/$;0W$+_P\6$U;FJ_
M',=S#(PH"L3Q=)<X)C@1Q5.)Y'L[O.(@9,=7N5Y6'$]5D@D6N?0MY`>7K\MP
M/A^H@@^`*D>5ENJ'XK'X,WG@@_'8D;R)_P`0(99,L'4DV(\&HL)89"U$E"2.
MRE'&<)[B':UA6(HW.(4D@B^R0-6/<0IF.(QKG%>6-)L[KJT9?63;X_#^[P/@
M!L8``9:K,:ZQ'_#62W6(Z]>FY)\1!))!(!+%JWOI,V.2DG+(`%CH_=YP&\WO
M&&,]C`+VD?D18ZB8)H/U(1@VH(+7D8$<6572UL+Z^+'S="/B?L@GX]!.[0"Q
M9+,>U&Q+N:@<-R#\!TZR!$<>I`$*"P45V47%>U\26"1+:YHY,>.KG>3F,8HD
M0['^;#!0'GZ6'&J.&T3V>QAF(-I@QL>BQT8(=T)_N^<]8/61L5,D,V;ETU6(
M;08L`^S;>=B(Z<AN`")##B&6N7@$6VISQ"/.V2)I`/0A9'D\@WL4;F.<V9(?
MZW$5KQ&&<BE>K2)(<5_[E=8/1N#B.)W\/]`^P@@0-N,#TK*6_$XIK8GF`1U,
M]?UG;H00QDPW,L?7DJ2581Y@JPS2N$_S1O=".(C0"$Y@@%;.5@F`(\/ZC,51
MJHD0KV.A3'R7I6R>J(G^_P".WCOU`G?8$.@BQ++DM%#`\3^W8#8'EM'EZ$QY
M88@U6F'(1:&V29^.UD)S7I[2(+Q(SU&4_K<\H&!]<>-^KNP6``)OEX1!JM07
M_B*>$_>?#^'QG<_,DGQ<_?4?_@\CU(^Z^.W2#,21&PZ^4*H$Q6/^&J=T.-^&
M"Q8KQ21$[M:/MY*<K92E:5I`2"B)']AU?XB>_P`5,QXGM=*C%BH+\S4=U/\`
M#;YCKMXC^4@B$83Y0K](7B18#^\S,[$B):8!,<@5(-E;1`,CW4$8''E'.-@C
M%*Q9#%;+,YB#[(TTI'&"I&$'V.<G<@W^1E,,MC1BU%G(`!>GAT'ZAL>AV`V(
MA8(KJ@3*I"$L7`!)WZG]9W$@CS,=P9;D&OEZ-DJ-[*F4!RQU:AF*STC)#'V&
MH7/='DM8,3DC"4;6E1`^(E$1`(`D"^\HWWRGS?Q^/4?,SMOO(Y<A99B"Q)QK
M%\G7P'$;1T,`;"(/EA>)X<&ID2R4SUH>.P8&Q"B8_LU!*\8T#*1/8CA#]8VM
M";R&\;6#&,BL8@1RHT"\+^(J#$GF#_:/[QO.Y(D\BC61,_X+(9`!Z9'RVZ]=
MMALT@@``-`"K8E,2^$,B1K9I7/.0D<'BP<APRR!$-V]9FB?)*U'D+X]FE,I"
M.];3.,:/9TQR1-40NY\.FWAT'A\!$25`5JJYBJ>.2#YI`Z&"03XP2?'P9I)X
MARSID5EX@7M?$E*XB.[,(US2LCO[J0+A&]P#D8J(1`E$0)5_J]1`F[K'.6$%
MJ+&7_3\=H(^T$$?$,/J4915,NE;-Y^V/A!D$^,$%6_PE6^AVE:A'SHQJZP&K
M15[1`>'Q`$3G!_4;E6/^,%C8[(K%:X7J"OK1[5"@VLJ[KHK865GS-OXG^,]9
M/63O'FF;8\8-:AIN$*D"-@-OL@;0(B%VD<`H&/1*R;(J)BP3"9V-(&$C?!AG
M,1)$L;WHK`A0WFK#M\?2U%1IE0#7MFP4GM1;DYJ3L/[!]OR\?AYB"CZQ*+7Q
MK34P&Y`^/B?D)_F$1_B\@(MJ$W8#2JLPR!J9P9<IDG_ES,[%<^2JF$2.UA7^
M19$IBL5JO4IB=VJ^41$M[*R;:BIB5$;CY;;_`&#Y0!O"C[F2Y?PUX=9*LT['
MK)W$;]21'7DQVFQHR9ZWK4D#9;Q%<\[!!.$`6")'>J/BRV$:UQP-?Y.8-ZHP
MH_:YH7L>Q[(LL,=-G$^B_P!))$^/B/@?F-P8\P((+H9LF@.HR:]V`!`$$=0T
M]1\CL1/D(8$5V*1"Z&K>Y`@CC[.&,?K11HYGDV0HU*..$H&A&1J#>,+>PU1Z
M`]9A5M=L>WJ2?TCXP9C>3UVY2#:\V;CDP%'0"/V^`!$3L0HV@\.++12Z>8&0
MI:N8,`(Y6'85'!(CS222B"4)UE(\SE><QQO88#WE,4HRC][CAGRW(R_>H26$
M?#I$[1\H(@@``$'B%:N#%L5YQ[0`A!G8[DDB#,G<\@0RDDEE8<RZW>HCXU+:
M-&P@Y_Y#Q*Y>RO4*/+%(SM)604J']QPD\VE>]?,"/(XYHTN;1@U]4D%8G^WP
MCI`(B(V:`%#(BLIBY$`A^1'SC<>,G>2ID$DRDL7:NRW:9OZM:O;MW1/T[*G;
M]/\`3LJ-5.W_`&HG7*'KKT(=-?>FJZ=--.FFN;'\B82S.,XM4-E/X7O*/'=)
M+6_C_EU2PI^7Y&88YXC"A=+D5W?\B*-SQL=,$-'+X>7?TS\N"$[H;3SFO%N8
M<##2'IV!W@'HQ@^4F-]>%?G:C6]A7'451=W#&K;U!R3BU63)(D25^I!(!<+.
MTZY,:O2CB1@8VN@6MG9/D+7*4D^1"FNF%B!J8Z5\WQ9/FNESI/I>/VQ'2'(Q
M%[N>JKZYAXQ=CFVLBU1,0"(DL9'00!,PT;^`U\X]QSUK0=LH2RR\MQGD5;D0
M$'%OJ:6/$B4+&/$ZF_R*Z!6@R!X]7>@JYTV9:W4QHI,BEO+*=&A3:.CLI\&Y
MKJ^@SU=G.TV5#>YEK8#66US1I')U9QLLM.8I:MF4!5$@,J@D,P!4EW+^56$U
MH>!!/(:DYT4T#MCK7<M;LS.T$I8S!6KK9E=5KK6KSNABVP>J"%"-K),B_;D.
M-"38L?\`?;[DS,:?,U5#.;61Z^17FIM'.M-%;?G6$.%.KX0*B5%C-.1D.19*
MB_TCBE<NL7'_`!G<PC'T\?%M1V8<B00R!46`2"2RLT`L$^)<#6]?-';.Q&VM
M?6S,_'MJ2MN(4J4M9['Y,JLJA'50Q"-;\!6QU=.#P^MYP^:X^.QD-1;7@;D#
M7Z*@SP#0"5_,V:VIIQ])>0`BFRF&V.?K]"5T.P&9C_<Y@@J,G;QQ<_/Q.Q>Y
MCFYK3A=PQZT=S,XSU0$4R!%;E!R0@[23(Z[#M':.Y>[?8B]L[6L=U[/FW65U
M`J5S:KRQML4!C-U:V$I8&!F%7BW36?18P>9X^MH]];,/:AG1&/JA`_=8K[:W
MW<2UGP[BTLS1H4G00M#<^EMO'"V=6Q@JQ&%')>Q.GQLTY7<4;'2*BI\T\3Q6
MHJ"JJ"0A19],GB[&9!4'7!YW:Q@=FL3,L!R`X\@',<WR`[*[N0IL6QX%R@65
M*L0RV$:K3JB1,WNP`&$`PXM/AYD@8I,:?&G-B6N@<:/.FP02X+"`*<4Z*R/'
MC3"R8`6)*$)Q5Z@%RIV^EBQ!+V@;$$2J;@$@[P5:2R@.QX$QK*.,]G>,E$0$
M+503!#!H>R0S*"NTBQ`JJY:M1ZBJ6UF+@6LM^(LIJOI+7NLK"AS.(T/'M102
M56;:\\VEC35\`X]+71QR(I\513ZV<;V*Z7(D/>Y&'<@'>.F[_;3WC+J]M8?%
M<BV]+F<;+BJ&8C@3!%C!E$>4``2OFWZ?V?1D^VNW9'OKN7-\.C$LQDK/F?N#
MLBJ1:H!!HK9;#,NS$F'/$QC_`([GUKLZN.%2'C[2FG$M1NC4UY35&AA9RGSM
M9=O>.1+_`![2SS)'2'1H3",BF@D(U&H01_;L.XUV_B?QK.#@NO'=E9D+L[+T
M$JK[<F@L&`W@K&F[)=0<+^F+45[I4Y<0EB)8M25I9L6AVJ/(J@(4UEA')7Y6
M3*EUM!>*EY-M.RLDULB=503$LLH8[9]7/TU6*3H3P8EO`D3&H%Z@>I(YBMCO
M')6,0><B69%'_#JL[,`Q'&P"&"-"`E2!OOL0"P*\@=3991AY?_&-9T*ED4\Z
M2>2-:@-A574L.)XF59@A6S@PLQQ'T98D"/:Q1?M$>&V(!OX]C7A8_.T9`2:R
MS%$IA6&=/!C+X3R$44F,X#F]D[M;F@"\-8R$\R9.X)\[2&66AP3NH$JW('6K
M+'$9:4L4>DJ\1LRC[NN"K`(&K*C:PF&7@1ML.B'PR:+_`-7^0%2"UTJRXO/=
MQK,"^'9A]OQM`N,P01S&(:+FY5?'_;Y`R?CDAR4;X_D,D%-YU[[#_P!'QQR\
MJY04J?\`U5Q5Y`$%P3S!$AA_A*A?;?RC:O\`ZFS3P^\?`+AQ\[\57J())(J*
MKZ;`\2C`1S#LW<;KPK7UGITTTZ::=--:;?:RO3A[D?UD4)%X'YX:PJ*J>M7Y
MBK9Y*K?U\41WZ_[TZ[3V1']9QI$C^H8O_C;7F'YJ2/;&=Q,'^C]PW_\`Z2:Y
M#750.)%G:?15L2>2'^*R-!B,ER(^GT\KPFSQJT)8K&4M20L-\CT.0KPB8/U_
MC22/'[!1<79<7&8J&F28!1!L/CYF\P$[`DF>2@'YIRL9:JWS\U%=EB%'(BVT
M^9AL1]VDH6X[E0!QX6,5QYGZUV@O)<NRNJFA7RNKO2[:UFFAN''@A-(GZBSD
M%1E6X:O))D%8)1O*<B#8G=S.^QR+1CT!*T>SZ52I1.Y(`11]7P`F8`D]#K28
M=!S,MK+[:Z?KLMO=BL!02UKD^2/J8@02Q@;D:M?6WLWDG0CQV2_9V5S8FTQ.
M!COH)VAC,-1Z/.:"9=:BPM/QLM72[E:9+.:40CJUR"CA*H@L:N7B4)VS'_&Y
MG/U9KMM/,(?,CH%0++D+RX*"1XLPECK7]RS+>^YH[7VWTA1QOHQQZ;6":[:K
M"]K-%2E^'JN0&CRHK<4`UL,6_3C3*YZ!BH4@%W,T4RZHK6#AZU\N+K-/&AS+
MCDV[@)($Z9GLY<UB.8U1`\&C'&<JO3W+SHQ_ZGE669S`T+6%=3:8-:$A:%,;
M.ZMON9DL-MM=LV9_0>WT4]J5AEM>SUNM"\A=:%9\JQ9'*NIUD;+$*AW\VLE_
M2DC-;_C*CYAKJFUB65H1:F_M`#?%E?GNKI)+R%=(,DFSJJVW;`6352!H[TM&
M4"(]P1)UJ_;2Y/;^Z6=FL=#4GF13N(D<2O1699XV`]9#;`G6]]]/@=Y[#3[F
MHKL6^P\+&`@\N)]17B717X\Z6$P`R02JC6M%(T&AO?F^J2P',@RL06M*,&96
M/*JDDCP8S`&YL&,W0'<G@0?DUQ'2.[AHPKAD3I[RV/1W*WB5<7\MWD-'J_,\
M!X'PCK(D:X3$"9N9V+'YAJ6Q"IBJ"DC'!'TCU#T(V)Y;J`Q#:VVYKV6<XMS6
M<XFICPZ3+0+)'[D1CW]C<979VYHL#*1F'H*R-7S:T.AF&_>S(IB]DBHGCZF"
M3D>R863W7)L[O>"^6R_=0$5;*UDV&'8D'@!Z8V'U]>1.O2/=7=,+V]@4>V\4
MK3V]+/OP38STWN0M(!K0*RBQCZY\Q_RP(XA=:?\`(63KZNX_S8<.F&"/JY-C
MR@Q\^^KOVR!E:*RA5-A"2L*L=<];NF*TRLBNB!D2$<YYW$:@^P[=EV6T_@27
M+&H"C9&Y%V!8'EOS6-O-R($`*`9\S[UVZFC*_JJK4%&06R_-8O%:JV5&7@8]
M-YAH4H&8$ERP`JE=9R.1<6^40L>PWN;PV9/I)<RYKMA+TU!;T(I`=%7V$8;)
M++6L&\`K,D@4<DR.X$CL]7252.VI>VYO$`KV^V]P@"FL(ZO'`@[<6W*`$A3R
M7:%U/1>_>^UFQB'[Q1B5&UBZW&VMZP18K#?FGE%I8*74H^\V'6-V&F$(&LN2
M!B0UL8S6SK:-+>*ETD@J,99D>Z.HGT\^:%T2T$%6D=72&.<17Q(Z-V7%`#;2
M"7XG92)9!_+U^H#S(3L'!`$.VM&&M8BC*(6KF/,X)"6D[.=HX,PX6A8)K8$L
M34D;-<`1'BY$XWBF86N=3\Q<9@?#?&<OE/C;"/!_:A>CWQXH($.:]Q3.<UI3
M1A^#GLD!4G+^X'![=DNL,'PKC,^!K)Y&8))(V'@&,@%6CO?9M;+WK`K<%#5W
M/%!6/YA<%X;2`%5C+$B2JP2'6>^&,8X>:K&.>\CFMDM5Y'H\CU2;)[N>]O9'
M.7_>G7@.<9RG(^7\!K[%[6"N!6I))$]=_P"8ZN?K$UGZ=--.FFL>;9['RJJ$
M^*\K9(I;W&&[LHO06(HVE:,HI*"(9Z(Q[._8RL:CF$>-";'!!".X,01M]L_J
M_P!$]0#&D[L0;*ZBI(8-N/""(G<&">A'C`D,5G%D=YZZ?^TR!C_;I97R(!&(
M-!1F!\3(..Y[@C<$`8H^[%5BQD&UPU;'8Q]7MF`LK]92?5`@_/PW^>YWWY20
M98D6\\C/3=^&<#T&,KT@1O`Z;``;;<8!$(`<>D:W*9>0VRLI532NFZ&O!0:&
M1+JH,LNIHXP[5@::_P#R*\RW59!BV5CX1Y0C1VAD2Q/C*$LZ,E,<EB:RH*$?
ML_3;QZP0P/%C=FJ$"WJY2Q3L9._7Y=0`Q^GH&5E*^H@\:7$9O6P()K/*9.[F
M!K)-&`MA0UD]R9^7*KB2ZN$V=!G%#36$RNAE-'&I1J\0E\93D:VRI4ZU.4:?
M3^!C]AZ#IM&P,;\8FI?79?4MB1ZX,R)!Z[$=3U,R.1$[<^1&1;U#QOQK)Y!D
M<F2N+..#<K18S8K>428+*LY&;';$!6"B#V[*M;\0&5!!B8U+!$2*X;0D='=&
M,&F134L6+$G]?Q_7UGPZS(!YJUV%E9#AJ')*C]7P^&W0@_5TXE6*FMU\ZWB_
MB[<7U1!Y!XWXYWX<_+!:Y<6_QF1U8L]:"BN1LRC=HJ28E+-''B.\%`R,Y&!<
MU%0`2BJ[G478XLL$D3ON3N1/B>IB3)W@_40;;*G.+F&JD\48#:0!L#`.PZ`-
M`($`,!"!EQZ9R-P=P[L=$';ZKB+BG8Z=P8@"7FMXSQ>GTPHM>1Y(/JM+S-6U
MR\$"1YO$U?82*9'.&)ZK)BS:4+4\I:JD_'_3('3;J`1&XA'KKE/D5$68]CA?
M%02(WDD"">LD[$@R0K$V5VW_`&>-R.@JB1&9?,S8%A<AO[&&2KKB1)%ZMA7:
M$6A-'8&1"G:`5V"'/%.7V2FRT%*$=TC\<\NVL^@2C;+N8C:=^H/ZYV\((`!"
M2W*,M1:F[[">1D"`=B">GEB">H*DDJUL*IS&9LZC0U-IGLW8UVA)&+IHLFGJ
M#QKXP8$"+$DW(WQV1[AT6MK(H@F,JC"&&%H'B`$"5EV0`+>:CS$S]IZ;]=_M
MDF=P23ZMF&S-1Z+'R*($&(!$[1$#Q$$*(\I50OH259"K<Z:WH25%?'J;V?:S
M+>$.KJ(X[*;>/F,M[BYB"ALB6,J]8,[YSCA<Z=V,][/))L,4SUK?7ZJ1SCY[
M]#'QZD09VD;F4<XM5UF-::+2WI3`F)'43'2"`9$`&&(41;4MD[S@7@'165-<
MZ+@_A^^M8L:KK:^ZL^*\5>V<*EI$@"HZFNESZ*?-BQJI0A;6``Y$CO8-H/(B
MM%9Q8Z`EI"D@>('S^/A$SX1UA1-61F6LG`*SJI:?*6Z$KX`[DF"O4EHCDYXY
M%V2N(>(96S?RW7<:\<"Y2L(;0,Y7A83,_P"<S@/@AB`',V\""'3R8RP`!"G_
M`#R>L:!1A&M;&..*K[JP\@`?$>/P,2-O&=M_,"#+*9[S^)I4*Y*1*D25)Z@G
MB1/A!G8\2K"*W%QAA,LG#+;P8`+^J!85%?>2ZRODV0H4T<<UA`BS2@B$B!E$
MJ8Y#I'='#+;#8YS`^AXJN5UJ2T75^81/4B)(^T[_``,P2/JE3;!79?;0V->>
M#`QN`0T`Q(\HD?$<00#`2'6BT(^6SC60\G<Y?*RJ&(8Y(>>L<_3S:"'+F,M8
M)CQ*V56%@QR3F6D]A',`TDA\F0Q[5D&G1;"6VJFRGDBCB/@(^W8?*/L$;\>#
MUP47Y-.3QM<\S\23O)`W.YWGPW,@CGZE=U?UN4RMB*EFV.3SEF6G%)@5<>UH
M:JV96UE]`#36]/719$:>"-`NJMXX<F/'>QDD+F#1Y7/C+,BH\P:EMZR#_;OO
M$;3X=)!`4,$GRYK*Y-<BX,#\3N1ML3.\=#/*"K%RC6ULL2#:5R/$($1\*"$$
M6&%`##!$U@2!8QK25X1P5%&&HT8^.QH@#<UX/2)]=1"U#\!])/[?X[B3X'<D
M0TD6+`F74;3M8%^(VZ'K*[&`1NNP4RG%31XI0(\=M4F."7%&K@K$(@^WJ>24
M*01S%B^I&O>,["H@U9[6%1PA.27&%=>T%+@"'.\_LCQGX$;S!&Y'!C;BH"MF
M,Q#5C:#'3<$](_Q`[1(:54^HBP&'=03B":L^1$-,1WK:TCNYCD*S^TKFR'R9
M2OD?U^*O)).Y$7SE$_\`:]Q49"2>(<+^X?L@;;=.(^"#[F,.<.TJ.;5ENF_4
MF-NLG??J68P9L;_B8]VYL'\*Q@B<XB*-1639#S*(:)':@5"^2UKPRFJ!4<IF
M,5[1=C#?^'*';1Y^55AV^$1\?EU&_ATG8CFIORR*N%]0WVAIF!MM$]#Y?Y@)
M"^8'TK%J$FO@7<`9F.$[S8KFRG=^S$1I&21%8]D8;!-8%S#">,348%6JT+0J
ME=&MEE%A4SUZ?P(Z[[R""=S/FY?>364TY=(<09'7^(/3;8A@0-EB%"_<0X,=
MT^":NLU:9\8SP#55<4CAC0@O,WFA5F,>1Y6N:4:N(USQF$][I`I-UC>G8+*M
M@1/^KX>'0[;%2!Q*TI0W4FC(@E3'S@;;]>4F09$D$AE)+K91(\^QJK&/`DD(
M<`RM&/\`K(KCB<0;`/#(4ASD09Y(_6CB$=["#8XCBOB2K&9JZKJS8L!H_P!<
MC8=`9@#8$@`!TKQ*[K\>]:;"2@,=3N-@"#N>I$;G<@%BQKLO]W)&UTL4RO!Z
M&EC.4\E6L8,C7>I/-CRO`$"I'AB\WH4+/4P7L<$3`2:Q0/54I89@[#])G<F-
MB9)CD2RVW93"FT6TCB"NY^/3XP!LHDR!`7D54+914YL))<<EE&&)D\:(=QU*
M@6-+'CF"9&_D@:(:C",C>QA^/BCQF8T;9,<,26<&%;D^F?#KU/R/QCH?@5))
M5FGMJ]5#?6`+AO,QN`0>H@;2/,(ZJP`#HBO:MS5%C31E60A7/8YWD-[RO[$&
M4)%_+.\BDDJA&E:8GD56/0ZD5;)9]S<&KCC'Z3T'AM$#:1QC[I3_`,5CFNT'
MG/V;]01U/CO,G<@\^7W]/J23XEHRO>I1QGL=ZA.*I?4%&B*#\<PI"JTP$*']
M1E5[.XD4CA_A2VR6BMZO4$%_T!G;Q@]1!WV!YIJ'&:ZO(%)D5D;"9@;$00>H
MD=#(\NY7TK!.2D!02QRV!:.%(:HB,&\8@A;'`5["$:5T8+Q"AQ7,14]3`"8G
MGX@$[]KL3ED(4)EQ^TR?U^)GQDG:6/WLMG##<6`141&Q``@'<S`@*"/`*!O"
M*?P\[:1!6,598WN"]D<GL>17,5!]GJ81Q$`5KCM12L_NC>B^91D$1"28\B.I
MS6W`[B?TC?ITZ'P!!$*RRY%:WU^J#!@S/PWD$0=_J&X/5@5(:Q'IM5X6=:-)
M:%GDC2T1/)\A7A4KA'CH)P#'.4S".&]JJ4K_``,SUG/[`GGRW35;Y(52ORW\
M#U@1U\!T,JL,M<&/%^./5ERK?/:8(B"23,'J3!'%WE&N\5QCT\QM:80WPRE(
M^$:.Q$8%BH!C7(K'IXQ&1V#_`*/8BQVM&K7MC-"6NK8%N3U03S`WG]?[YG>-
M]Y!:192EGQ;10P!J)/$@=.G_`-#$;3Y0`016%:CU;S953;(=C!#B&8-I6*,;
M1R4""0(C93TBH]J!$,O]+A^0V"([UJ)LR/$I2B75<3/,?ND@[;^.WCN2-Y*,
M[)MLQLCF(%9&XV@P"#.VT`'J)`#'CQ%B5S=C"#805LB*=)#1>UK@MDN=V:8B
M*00E&>4\JJ5RL7L=R/(Y$:93%'9V5N:[/2$<9^7^@?PZ#Z>(-4M]2W5>NT\X
MG:?CU`W,[[?49)`#<F&1YC"CW52-S7`=-]7A%*;^E0O;^+)#ZW09+'('R"$@
MC`.]$3UE$54_&.M6+47'KPG>/'J/$=>H((^((^I=6UJF5C`[>K$`GPZ$1Q(V
MV!4JQ_E96_RVU3Z>98QYR5QP#1@V"`HD&`8X;`"1K6)^.($7UMCB_P!C1L\6
M*]J#"PHJB2Y*VK]129.\[[S]LGK]OPW8@W0XMMR6^BX$"!$"!`^0`Z#Y"!(A
M0RXTL4\JKNW(@O0(\I>T7LA&.&8APO;Z2-5WB3N;Q3Q_XO;XL5Z384BX*EM$
MS)`Z_9'^C]V\<'6PO;CY6PA2W3KL9'3Y^;P_Q0)]6IZO/BU\N$>T`(BRS1V&
M`C7R"E:9QH[A$"L204CR^YS'B<$A7*]Z$%[2&82?#6UB.*F/E!WZ=(/Q'VS(
M&P@P`17D7UTVU'(0'U2`1U)F1$<23,P5(+;D,O)F!NC1I0;FH4#RA-),(;$8
M9PW>HC!!)'F=X)(C4&UH&'88)!-\6,<,@FL"2%1E--W(`A0?#]<C>?C!!!\0
M022'O2Q<K&X2"Y`ZQL8!#>6-M@P92!L"&4!&JD:3\X$PU7(17QQ@<3L1KVL$
MWN1I'-_M1A-$82E:J/",3D:]4&)&2X<.2_TV06KLQ/Z>)^7B3TW,H[PXGK)8
M<=]T`\?#X^`$$3U4`P?*L6U5>Y1"4<XLAZ_F`L9)!D"C"D*)2.:Y402,.JR'
MFDN;ZE:1QU>JM8224@K6B`7UA1Y64=?T\('7:(ZA0#5=8S8EI<^978@C>1/R
MWWDQ&Y:3`-C%<CW>/KYU6RR&B$*BB%$DB]CE3W$`0/8D:2/S"XS`D`1IT[$]
M+PE]BQ#NI0+$M-1V&\C]L]1]H(CIR#".:ZKEFF['%XW;8`CYP1N#TF"IY=>)
M1N7IN?E6R-=5OJF,`9T(?XXS.1B*@S!57>2C;!8HD:!J+XH$/]A%1H/2X=8M
M+4V<DD<MX^P_K^/S._5IFVF.J95$6@$J(!^T?^CMMX<5\LPG$BB(&22';K5D
M.96N]",*91HYR$;)$C3?DQ5<I'F>1C6^#VD>A&JQ2+*CR*,H>GU0!._3]72#
M\(\=A&\<&6Y;&JR?PY)@QN8\9&\CXR!L9/(1R]1'A68IE9)675N,Q'O:0XFQ
MWG&:0]ZE[HK5*9SY92HI481SRE(QPW.D."ZRNJ9+5X6QMTWC;_1X;0`#/E!%
M5N0ME#^KCR),D1()Z_,[D[P9)(()<J;XLIX;*H9;?B@]WK50-5S#M1O<*"5I
M!2(P3B8^.(@T]P1.]8GH\/B`T&U`:KO1D\9W\/C\08ZD'8G<B&EA9=85OQOQ
M/$<HVZ'X1N"`1L"/,H,*96$:F;BEA74-GY`@E*@'I)@/(PJ#%VD0S-:P@HRA
M$98I6.]@1J-&D&00_"1'BV.'I?R$@3L>GP/SF)'0F=B"95GDK:K*J'J`%HW7
MKMNIZ@0#!&X$>8,JPZ5T2L/+B61ZV<9CXJD>`P)4ATA'N(\D<:B(X9BR'E)(
M]9$<QSBE(K2-64][;:>U4>H6UCS]9`CY_*(B1&P`V/`#T<7'>RN]L>T@U]""
M9Z[;&#,DP=B23##U"1D^3CD9\R'A2#/KS%BO.,;7.?\`H0*M1QC/,-I"J@V#
M)[D4K'"12^S\282JE<A>+@>H`8_U#]9(C;?:.:`ZOA-RJ)-!(D#[1XF1)V`,
M[@KYN7IVM4[3\9]8EO&$$18R@DCD^3!(QC/&.42K_P`N%H4!&1KQF2.!!B1'
MK'8)75D57(6^BQ)!VC]_S/4[$29.W(F+9\C@:/Q-8`98,]/D1X"(&X;BL#?@
M%FCU$]=S!0,X;I+$E'&`IV-0_83S`.*6!.Y?/P(89F%"GDCB#*%SUD1RGFFR
M:S!@3'3P(@_L((/P(,<6"N,JKC<.0Y&"1OM((8=?$@@K_B5E)YHU.JPNC64N
MH-)>X)QD[L#YO>4KB#>Y[C(LB3W<AFJ]Z$*]RE&A7$,0,BUOM8-4+@/,#^FV
MP^S8#8P`H*U0XZ<+VQF8\2/#J3MX[GQ$F6.ZABS%7R(,\)<\93U[B`C&<U$1
M5CO$@F"CE8X3R21(OI;'8U'^8V-`P37E&)L65!NK9<A>-F[#[?G\OG\"9)(!
M/)++;E;"?G1*UD_*(@';<=(&\@<0H+*HKLIGK/O)@BL``0<B.(BN56L0<47_
M`#$95:,P!QPM:$9F.4H1HC!N:80QLD#AV5>6PUL?*3^T['PW^!V)Z@@DE2\N
M1YZ1>@AP#^H;CH1`VD;@;`AE50ZU3%<L>]CN_-"ULIA7#,Q$(CSO8JH9RC(I
MC.>I9#V/&]CR,]Q!N:52O2QMMY8[>0^6/]7R\)D0-@=H'IWTE,M/O1]X#!ZR
M?C\3U)!!!(Y%2&Y'UX5(X39,VO=("1J%<:.)J#>KRN_%*I!&:XCY!HHG`<UR
M%5[6$$K2$:L246M\E5L`/3?]_AX3OX>!V'G46XA7U&H)!$R!MUV.Q\2!QWF=
MU(9AZ=C4RPB$HS)+KO='@>:>T?L&)HF1FIV:WS0($@B!&[,([P$(#$811Q6-
M=42UN+UX60;(_C^TS)W'4DR)<D7075MB/ZE$BF=QTB/M@<0!L=@%$-QK`.-6
M;1ARP!V7_,1)$>.X[E1BD*C7_DL\7(2(1P2=BO4BNC*K&H5A1D:LJ,2"HJ+/
M3V*DQ_#Y[^$;[[$$>5AE9`=J1?NKJL_/Q^(,=3/EV'(,"/41O-<<.@CDCS&?
MWT_1KP*HC^;7@*AP((LE6G_)DL?XHXKD4K/ZY"'$:RK8#CL&3Z?G^O8]-H!'
MAT.R\2M5*'7,0I://\MCX;B"=Y(/CU&[\U>^F5,V/%,>L/*$:#Y-9',!",;V
M1@58L<P3C440<=@7L<AF^D31N$3\=(YX4MR,ZBU019X@_KZ[=9D=-S((Y<E?
M'QK4K<X[L#3X$2/AT(.R@<2/-L.)4\.#U?;"*M`5)L1/7&4ZL=%>X0@N&@S*
M40VN$SU1QBC&\/[:MCB81'#;&;(!!I6WX@>F_P!4==Y_UR1X[F()8JUE;JSA
MMZM>U<]-@(@S&P@`!HV\H!E16'2FI63)\D42TCN_%(@3(5A)#FJC)+"N&Y%>
M.<A'N(56^+1$,TQ']FG4A@6,=1K4FIMQ(\/A^S^($`?3"M7->+W5<A/*T&9/
MQG_>G<Q`!;D3`<LR7PH,\&A!^')\&S6(`X7HB(LM0+'D-.(H#D41?(H"+Z#*
MY/,10F(Q\:26ME;8[<U^C<?9,B-Q]HW'Q!4$.HMIO3-7TG_S1!'^U$&003!W
M4^5O%65R#78T*F(`I9=2U02*L#FD!W<B!8B)YL;%<S\40X[&QO,3.PQ#02.$
MX0A(RJK<&`%VXM/7X_KZ[[P>I,P9)FVF*59FQA#8X.WP_5T$;2!L!$J558QX
M4\<C/S`&A.>X$AQVOAN&]8ZN_O*4+FMC%5HU5YE4?I4@U0KFC>BS(C[JRN0A
M5XY"-_'^/V;S!VDCR.+;E?"M#53P:?+&WC(Z'_:VB1YB%/WM9GKQ)D9X+:*1
MS#*`<8B-8KR%>5ZJU%43I)C_`-<C]!^1R*4C7"4AG,;:1X_!IJ<>69_3H!TZ
M["!O"@FJ7+]6MAD5GS0!]L_9)/7IYC)!7DY`R/->H+R(]3N&4P1@<I44:O\`
M)P(I@&4L`T=J,_L"*)PB(U%1A`E8C8YHM;.5#^68)/\`$@C<'XD&1\00?,'I
M3PRZB7@L`-]O@"#Y2/@"(,=&5A"-7\K"0R@-26,445&&>-D,A?`9&F_+>@?!
M6A%ZVM"7U]F#"J#<B"$H9`*]:'#"^LD[=?LC?Q^(GJ=QN>2M8H:ID.)>H4`_
M3.QF=O`>!C8+L?*O!TID7"L*.R:*.Q3`FF]8?<UY?(A#.4C"C1CB*9Q#O\D\
M7J4A'N1KY+I`+2\&N^N6V91O'V?PV'V`#HH5JH2MV)D!4$HYVG?>=Y'6=S.Q
MDDF#873(^6@9U98,M8S/QO=*_I9&53L(\C@*YQ&")V<Z:\H>S4>OM*X:C)^0
MZ*>=6HUVU^D^\#QVC_5O]@F1QYK6R%MHN&0@XRWAON8ZP?YO+X[DB&YFM[IN
M>*ML:Q;5Y&"7UN5IE(OXZ?\`<]D1ZDC,=%&,0T_I)&&C1,<K@*`1*VRLVUV^
MB!/R\?[=^O@QW(AN1%LERT7T?B"8VZ^'A]FVP\5&P,IP5J(\8<:YIOQS-7W!
MCN"\KV>?J(Q)$=S2M/&$AVN5#M,,L9GEXF&8+59(CBM8M3=R7H3/V]#M!V\(
M()\""95C>BUY.+P;Z@(GX=1O($_S!@5'1E900Z+3ZDM@&S2#*4A`*A&.0SG*
M]W8R=BJ=7%E%?[9?9Z$]Q'O>@R(^0YK[>2U:VJYI]7Z?J\-H@")$*"*8,9KD
MO]&R2G3?[>L[D[G>>1),-+D')^J636VCFK*)%K_<Z0)2N5[%<?TH%[R`*%"M
M$X@5[N,B#8H?(B?\E-:`6VH0)LB/V3\>GCX;[[?6AKRLHR(+%:9D3\XC<$3$
MKU;8<9;_`"K1.7;(8(_[H%PPG22GB9B1O-Q`H1AB.*_P`C&QH2M?YM8%@0]B
M($(2?MME'-F])I*QTW_5\^I^9).W)F'JRY8J2OUT@/RZ[>$SOTV"P9A0J^;@
MBGT/DB/^_P`)944(H\UA'(GEX,))/'4\<P3,?'D'C&8AB,1#"*K5*41@$:^1
M'E55OP[\&)*']P,';<`^'0CH"&$*RTL3\93ZE8`M!_:1((.Q(.Y`D'JRLC`N
MEFR,=54`%5>ZJ$:JJ>'955C>ZIZ_[?\`K_Z/]/\`N_3KF6^H_;KNTW0$]8'Z
M;:C=6ZNTZ::=--<Z_O\``Z1QW!8C6/5O+7$SV@<#\E\S_E-DTT,8U1J,)(`Y
MS6O]C.W=>ZJG]#_1_P`O6X]Q8]/^$R-YB-ZX/ZC\C_:/$OSE0OV1!L8[EAF(
MGEM?*CX$C:9']AY$Z!Z9B,&PALGEVER"4[)``IY$VGKO.Q#.T[8R&$P,JQD&
MD"@"]9V>@+Y*J$OXBO\`8,<?BF-;\?P*$>H3`#-L0D[[``%S(,D+YASCYJS"
M,!!=5S/=+5/H@261?,&MB1!8EA6(8<5-DJWIDP^.L]101.T-Y+:?#4H7Q9,9
MY0U0K*7(KBQ:#-U\DSOSI5O;JQ/%$>C@B]Q/!1@(WJO<LB^P_AJ!&>YD&"T`
M$%W(&P5?WF!,L-4[)A8=2_C<MI[34"""0G(E2*ZE)\Q=_#?8<FB$(U9@I:\I
M<@`L)4K/0A386&T<V9#R-M>56<Q;<B:DMLMGK#0AC0HS_":V+7C9'9((0G<G
M=SCJN:4_I7;C6@L8JUJ`&Q59[/4#*[A))Z<G),`#;HNM6MA]P]Z%UC4(KICV
MLRTO8E5'HFMZJVL`4?4%K`4,2?-N7.MAHW(LSCC688&.I9M&_/QV!DUE/3PV
MTXL7FIUI!/CII8+VSX%QO::<YL8WF(KS._,0*+ZU3G6[<G<L2]LQU<6'9F8\
MO4<*18`=BM3#S""(\D]==K7WNWL?<<1.V5/4:%@JB+P%%3.IH8KYE?(1CQ,@
MECZO'Z3JH?77^/0*;,Z7/"1^=V106M=9>Z4E3/0NMHH:NL6(61+9IPJX@IK'
M-*XB1%,WP0Z/2/V?^)LOMQ<@_P#$T2I7;D/NW.W0<.A7<1RC?C&IOS*_!4XN
M/GX0G!RB'5I/!OOJU\PDGU1N'$$GAR$!Y%(P&<D[?G;35L@9#0C4>=0T#.1U
MH:ZQ2$/3264YGR*UHJZ`=G@:98F9Y1H+7O(KD3QZE[ADK@]@JM79Q8^[GF1/
M`<MF\Q&X5!U:`(ZZQNS8+]V]WWT.":C35*U#TU;B+3P,K"J1#/8PE:P2Q/35
MX[?EF/\`Y'0\?!D1;+&0(M97<>1DBZ6V!;SZ^JCVVPIS`/45,&NCNK'5HZUK
M82,.`!8Y1G4SW/P\'M#?AK.XL"N:Q8W&44J"Q6MI#,2>7,OYMB0P*\1&S[M[
MC3\=3V565^UHJKC"+7#LJ![D(*(JCAZ0J`2&561E<L2=4-#`-@Y,+1Y&R2NI
M@.:/+7`-+H*BY%OMAL:JVLH![-8TVK3UU]<KXZ3XXI$P"*Q1IXG:SK<>P9ZG
M&S%Y7GZU*(R^E76RJ0LANIWX$A3O/TD^=9M3=GL3.[;9Z>(-JG%MB.,BZ]'9
M2\,GTKY?44,Z[<=G`O?2?CZ*HDZFBJ@P6FL]%G[=Y)-=9P85O5._9R2:P\0A
M$CU6B=5$D5[T;XQ2C+&>G>(OLP,;EC7#%O<M"HZ[,I*MYH8&)9.0#_X@0P^O
M;;9_IYV,W<,2L(#9;6\E6573R$H5F$LX%JS'D(:L_P"7YK#B5CK1`5"`0DB$
M3\[*A6*\J7;VDF3;3)))$,8I(&SITL54TI0O#+(0">?YH_7L'M]*;IA6VL,_
M3T"V1X&`I>`05`;;@9TZ8YR`,8"70\J1$^I]3/3($$<F<525*N2F_JKQWG^#
M'B_ZEWTTDTC?_P!2MTQ`2G2&$CQ6\E\9+'DOF28<:($3Q(T"`:Y[@EC%5W9'
ML5W">_@W],K0*/\`GEW$;GT;Y$`DGXSM(81T.O7/R>*_UZZYG/\`[J?8R"!^
M*Q8/(J%`Z+Q!)4JT]1/=[KP37U[ITTTZ::=--:=?:"(O$G(".1RM7@[G%'(U
M.[E1<[4=T:G=.[E3_1/]_79^RO\`WOC_`/V_B_\`C;7F/YI[^VLT?_NG/_\`
M9IKG'S5R-PV:NQXKO):/+:.ZJY@2TN&M8DNFAYIB3/V\0**8K)-E:W$I[)U@
M"+(CS#QI`RN*J2&]_2>R=M[TMEQHNKMQD<'E:I#%]IEALJJ)5"P*A@1'EUX=
M[J[Y[8:G&7*QK\?.MK8%*'5D6KS<0*VW9W,66*C*[*P8MYQJU+?A*WVN$KJS
MBG99(&>T$?/3ME%VFE!QULY,B=&GI34/[?H*)L",*N.L"0`<:R7\N8UKBC=^
M.)'9=/?*<'/:WNU-QR*RXK-:&ZL`$<GE&DR.8)9/*L@$<C&NR?:F3W3LZ8_M
MW*QAA7+6UXOM&->2P;A7QLKX@*?390EOG<`L#P68=3P=R!P]F+[4[K*Z1UE+
MSQ;_`'HH9+;8)5BK;:-&N\Q0%JCE-YZ&-'&I8B,8*0^.-45&,>=];>^]O[SE
M5XN!;5Z0LX53QKY2I*N_(1Y"3#3(!/B0HIC^TN]>V<"[N'=\>_UVI-F0%+W<
M.+@655E"3]X`)2`&*KX`N<40J"2=+?9[J/$H+IU/-IIDIM5>$J\_B*&QAZO)
M9J9%G3:J)$GV@#H*2GL(^2YSO$:':CB;:S(1>&%@EK*.88#DO)[64UV."`Q(
M4B1L`OB>)@<Y5AV.+.Z=W5:<LU,C'A9PKHK9;J:F#,@#.##;DL9A>8!:UJSE
M*YKK^^),AQK')RZ.\H9F5.BLJ(>8,20>1$;%@M9"@6M=<.D29$P3O2L[W.7Q
M$Q5=E6]JILQZPC%<L6*XL'U%Q`!D[E2L`*=^/'Q.VOH]PY5&9<UJJ_;6JLK:
MD_0M1DE87RJZOR9G&WJ<CLHWKF1T#<-:<%:B.E^6='XDO2QK#2S0+79FU?1X
MQD?34L2$Z4ATHAM>:.TX5&(C1%<B^I52#,QSGU9^*WIA#F+(0&77G9*,3$<N
MA@R1('767VW-':<CM'<$]8W+VVR&M8<:G].@"U`LSZ8EEY+`/%C].KHS5\MV
M"[;-M+6%:1Y)SDE2;>VJ(QJ2IB:BTGTAXD<-K`::!:R$,1RN$\D?\E4*XH!-
M=BY./Z#5E$1JB`("JQY,44,">)@J('4`\=H8D9^!F?BDM%MEBY`8DDNZ`HBV
MNR$`.LJYDF02O/S%D4&>Q\4U2@N/)`[05:^$6DRPM-K*R\T>VI(C(][M\Q=5
MHZ@CENL;!(HPL7TAFU;VJ(J>A%6/,=;I[DO$V\N5G"MD2IC*5.IY?38=SU*N
M#(\VI^V5OCQV1Q8*"AKJ%MRV6WHH%E]3J$^NA3"CRJ]1'%O)J-6_.G-/^5,T
MO&^*T=M`%8DT-)IKR!CZBNSR:"KC9VLSE[+OATDHT#'9TIB3B+**DJ,5!=NY
M48E+?<G9/PGX;N5]:6%>#(IL8OP8NSJ$Y";'@(.(XD3X3J[']D^Z?ZB,[L6)
M?92'-B6V+2BU^H@J2JPV>F2M%18V'F>2GC_-`J&HI^.,W9`CWNCAD?<Q'7=/
ME\1'A;:XS\N"60&ZJX>OL;&MQ]A4T[8!#-G!.?T0RI[$?XN>2+%O[EDU%J*S
M"'BSVDUJX,<6-8#6!FD#B0)8;1T$W<,7L>#>$R[U)M7U$JH"WO65)#H+F9:6
M1.);U`S<4/FF).SN2UO'Q[GB+/Y?+W0G67)_$%QGMEH"._=;G/?YQ4O07[<&
M#6QJB!"*$L91D88@C,0(BO`@W.Y?,P^XK3F9&5:A"XN0KUI]*OZ3>,DL3(:1
M`(/(@-(UWW;>Y=E?*[;A=OQ[0;.X83UW6'SO7^(0QQ"J$52"L$,01Q5BD$]4
M>-`ECX7.`.-1&%#(P@G(J*Q[9<A%:J.:Q>Z+_P!B=>4]S(;/M93(+?V#7T-V
M%&3M%".(8*9'ZSJ^NL#6WTZ::=--8GY&*<%A1&B+V(U)`Y;7'[A+$,\8T8:&
MKC->U%5_]Q`J5J*J,][5+#D;?MH5J[%?IM&V\CX';]DQ\>)AUYOOC.E]+U]1
M(.^Q!CJN_P`]^,CPYCE4]F6R_F5BFB1/<<9F&]!6/_)$X4@)WE8$!B'.=I"C
M<GJ*\KO:UXWE*X#YN;3Y+8<PI$3X="/'8#KU$;$$`!@FKR?O:.5:RX(,'J((
M,P"23N#L2=P5+,4-L2+*@W5:X;@C5O8330O:UCP(K62(Y8QFE"WQ0(6%CG&\
M3/$;'->)HQD@T=+*+9!,^!CKX&>OQ((()W,@DD675VTY5'&!'BLQ'B"#MX`%
M6!`@`@J%5J8-1$DP)DVM-)%(B1QC/'&Y!L,Q"N./R4'K"@&>(3-,Q0H!SVO7
MP&GY<:/=<ZV(MH!#G8_N_;X1O,1N?(S6XU=E-KT,P-8`(^(Z^$".A##CQ)!,
M#[RM)><>526+I*H21#L2*U[>Q"$%*<]S6_CC1L@K9".*B*)4(LEQ%1C7R7N'
M:W(JWU\.CJ/W?/IM\]N,;PH!JCM>S$N]3=JW/S)!^74SOTWY$[`N2,B%?J.3
M7PI8FL-YMCJVP8CG.<,BA)&0189F-532&`()6&9XO]3AF&18<E*X\K8R';KM
M_'K\!(,CI(((YKJF;QLI2Q8.P\WVP1!4^)XD0P@\2K*WI/J:JWALZL7M:CY`
M@/B>]T<+T8QK'.[^*"CQ/0H(Z-<J,`US1+Y#`@W"K;+0U5ICZ29B3_I,R?GU
MV+2#;?CE+\<<H+@%9@=/V`1`WV68W"<2M'JOE,!8&BR&B`KW*T0P%(Z(&68A
M/RHCTD-(=LDTE2M12#<CR>T:L4JR025B<JPZR?MZD`;';:`(Z'I!F.++6FP)
M<:W@3L()@,29&^\DR-P9/)8Y>HEE-L'2(=HPL$DJ,609)+HR",^.5RJ-%.\8
MRF5_N4G8B-<]WM>-S7?D$CEL9*^+U19!`$3M(^7AT\/D"(XAEK@N+U9`:DL&
M8S$$@_.`3U\8),E2#S9&OC:)CW-#(8P`"ACH5R%6*X9&(L*0YL1Y'14>X#@"
M<[N\`U$(:^8&MC28%,8@$J9()^?S&_7K)^)DG9I9;+LU20KCB&"SO'^R?+,=
M($[J("F4`2RFL`(&TKE&]HY*_C>$J.87=CD*.0%PWI)C1T14:(S5:\;%8K",
M*QB-D@CPL#5;(VWV(_4?`GY>/P()E6;*0ID4PP#'CN"/B"(W`^!Z@1!#`0Z)
M2<X\0CV<+\@K^YG*V+)<Y2.<IG!D$\7(<Y9+I,CP,O\`65Q7_P!QA#E>^TER
M995>!TZC[)'P$0)'A`V(4`58V"5#V5%CUZ'[8/Q),F&ZF3Y@78G(EIL1U)*C
M2XKC%@NF,<?Q(-?Q_-(2``Y_M>G=PT'ZB.?V(GI_NH1(<OJ]&%Z%&@/QV^?6
M3_&1X>;:.::LMJ.)8MM<FKD)^7TP.OPB#._E\W+TK=36@+[X,6="<'T`;[&'
M1!A-&&H_-Z/0Z1&1HS0Q?ZVO0(F()4)Z1,5]7;CCC8:WGD?#X_LF3OM$DSMR
M)BV_,;E4MU4<!X[`@1XS$"!O,`1YN"B<>8JIB2XP(D__`)H4A)49'F&Y_=P^
M\8L&:V0U\A)':04:^T"O>YQ&$:I?R`2;+4X,7KV(@_VR(VC8'8P-B#'%EDQ[
M?5K%=WF4R-Q/R*M.\[D;K)\P(+<TLE(!X\>[F".,06R`,:'U]E`OL='(4G?V
MR2]I9C"5[FE<[W$'YH\A(\BQOL5FH#*9@_K\?LZ`&-N@,0`RUQ4LB9;JX`#+
MM'3>)/4G<D3O,E9DLCWPK4'[3+BS`%%!`3P$](OK"S_E@C:TY6K(CQA,6.$+
M5>US`-&-BO>P8X\FOK2WK(48%F^>_4G;H3U)^)DF`266RW)3\-8MJ$(I@;;=
M!U.X`V"[B%@"2`J64U:[26D57"((*A8CO-S&/>-C5>T_K*0/B,2!"17J02,[
M(]CQHS\D46*GAR@@D']!X_&.AGH09XE\G+%OIRI`('[/C!(V$`S(CJ"(]1:X
M=%.6RAGC37H0BD)'<,C'>11D<T9&*TBRC&=^1)5KFO:\R/+XN0SWJZRK?6*G
M#)L.OZ=`-A\A`D<0(JMQ+?7K-=N[3$1U!V/62=S!!!:3!Y$S?+T,F"P\^$C2
MQ2_D.(P$DSE\A1G`>)HFM>UK310N`KNQ%(YB@(PI&+$E/KD+855]B(Z@?&?X
M[^$3R!`/-1;AO4+'JW5IF"?`1$;]0./C)'`AB/3L,A,212RULHKALKYC_%\<
MK_2QH`A;V>9JBB,"`(@.5CE1J`$%4)XQ6+^T2)QN3TW_`,P#K\Y\.LDSO\2=
MI<_?06\\6WUZX%+'<';8#J=A``!C_"%AHK'_``U3T4>2V..;$(54C.]A',7S
M*QBH8;S^;XT@RL5'D1[O6_P_N(0!6OF1C1XS+R*.!O\`Z-NH^7B)VA@0C+D9
MJ6!!;63"]?CXB>A/QG8QYI1@;:V]1Y0[:IE&DB4XPJKT9%]K[!DD:",A?$)9
MA_R3D.TK?!QE>A&^#I*D":PHRFJX!3!/QZ1T\8$"(WCIN%@BNJV#(QV9Q*CX
M26G8SL6,DF=IF1!?DK74C-62(]T,R->(PFO8;VM\6-&T1A(-&'2.Z.X3AO:@
MWM8P;1O&3\=`%KYLJK;F-F!_3PF>O4=9!'+D+,;`O'+TVW4B9GX01XQ$01!`
M`XE6X!&IGBPWT]J`X2`C5IWD"^.]0C`,;8TIQ!M&88$]8Q1C+XH-K@-1[?#T
M_DQX=@<74E6DVCQWGJ/M^(\=]M^7%GE:HXN0'6%H;:-@!L9&X&P`/AY=Q''F
ME432C>,()H7.81IT&UP7F8\J&(Y[6O1K9!CG=).]6^#"2/(K^S#O(:/9VXI!
M8HW2/EM'[`!`'P&PW4!6JNSU(46ILW+PD3/[23),0"TD[.2R9$:%*_=:]Y9"
M,E20$"]K?QV]AG&@)`D1P#D1KS^L)4*(KFHA1."=_>+(?1U]*R%D*0?'PW'B
M/#<01X$,H\ZBZJS\11R>&<$>'B((Z$]84R#XJ5<_=N9:@DJ44NO_`!HHDBB8
M\`6-\H3&N>4PF.>\HQ-&%K6HQ&M$%P0=V*(8W#JKLA8(LDDD[_']#X]3)WDF
M;8\.SDK4\5'$2!X>)`Z@;>$`+Q7;B%*X_P`)'%56X%CN:)DMQTD`(-[`,>OY
M"N:(;AD_LN[G1!O&CF/<9&M7REQ3`QMI/+<K$'Q\/W]-P=QQGHC**#&R1PV#
M3((@>/00=OJV(D'E`,V5M&N&S6>NSJY3VD$,K%$+O[W"F*GN(P3$D%DO>LD7
M9&J4_D]A!.>=P_W*E)0S5:!!_LZ?".A^`Z@PL^E=E"T1D8[00#L.L-U,;D]1
M\6DAE)<CU_466EI3J51MDG$\!O4-1$]Q`C`6,<C0D&)1N8$;V/$4;7M&-XRB
M1`%B&3TKHZ+O^KK(W_6-P8D@@^8/6NP9&-RCDX@[1O`!!V('@"""`0%*LOD:
MN7I)44D(E;*$BM8P[I,=T=K(P8SG2%>]Z."$`XW9KT_40&(@C(H@^J3&@UO5
M@XL4[[09W)V^9,]/$]1N95GLQ+$:HT6"8F1&P&\^``'7P4;-*KQLKJE'C+76
MK!K(`R)*?^6-[$[D?[I!_4!S6C.7\@\B01&JUCU,\SG=GG>85I>"+*I@EQM^
MP#?PV``\=@!T4*:HBK49`'("IC(^.Y,#H3)),;&228+EER(F@A/1!6`'J4:J
M%!>II7.?['!D(YSP2A_^L2?21JL*U7O4+A$:=(DD],>P&:VV._\`=XCP$C<=
M)D<>:K=F5':]#(VB)^1\#XGB1!W/$JP?T['JLC\.XJ_>C!&=^.5C9'K$HXZ>
MII2*KG/@L_%1(K55J.`C?4WOZ$%WKHEYTV\22-^GQ_COO\^O\T_>9+^EE8W,
M`$\3OM`VG_9V\H\5B!/`+]Q)5-K&EA2ND`%'1R*!`C[*R0KW2P20R`R(K'C:
M\OO14()".=[A$$A$DQ7WW5,A]123X_9T(((/V=#'TD&.+B+&R*[%]!P%'2/C
MU!!!'QY=1,\U99YUF73QJ]`)B'>U9']Z5ZV/:QY9!?9V8K6F<B$DR&)^BE\S
M$8KG_D%&6UN_S<<F.FP_4/U>`/PV!VX@BJ,1CY@'(RVY^TF?GU)'QDD2>;*V
M1-WL(X##N*]_JDA<)%0:.>XO=@D[M1#CCL%Z`![L]H@E8P:^T2CB2X=E#JP-
M-FZ']/A/4GP)!G8RZ/+EU.CC)I,6".GZOF!$!=I`("GDO&NRKR1765*R0Z-'
M<JC>*4::V*Y@PC`<-@1KRQH;&>0H[F_W`L1OK<,@@-'('"J`*[RH)^0$]9!'
MB?$^!/4$%I4O0DWXH?BLQ!+1T`(8[A?`$;J(@JRH`ZU0L[)81DNNE=B>3G"-
M'D*4K">9#@.U1'"9SG'E&<POFCRN,1[2L(<A/W.N2I!%B[?`C]1'2.@&T;0!
M!"@>E;@NK!J+-YV(,GQ(.Q!ZDP9DEB0P9RWK^6AC0+7T,DD2.O>2U/?ZW$21
M^(BD;*#*>:04+S!\'->KU50N\U(L27(KR>RKE'FZ?LGP(V\?"/JVCFB@M=.1
MP#'AUZQ,QO(,DB5@@S])F?3L>9NJX$Z.ZPA>)'L"5%>(\9@7-`UK"^2O<".C
MAQXKF.9Y@&Y!-:YP6!&2KLHL:MO3?83\#._[3U,]"=S`)8BV_+H2U/7JW(!Z
M$1MUZP.@((E08`)4*K8\6*25-H@(KVO*Y[XA''<A"-\'2(;AF_)CN(LEY%(Q
MS31_:BN(PH5=^4%U&")>?AUV_4?`].G0QT(;Z&%U9LMPQO+3!G?XC>1,]1#+
M/4,L^HIDZFR_$F+5SG/1S)#T#+:1SD5R%\61Y#T<<SQ*>6U6O5Q"LDE8TCB%
M*$]K?=5S3U4^'3^T?.!\@0#``#+5%C7^G9^'NF0VQGY]#U,2VQDL&(#%F97R
M*:4P:R\62X;D\?8\;V&&$+GD2,GL<1#"8R,*,T/FOM8GBP#G/038<N'*%-M'
M&?TW^769\/%@!/-'@9EQ\LV1\8W`'AO,B`!QG<;!"2%%5M56NZPB$6QBM<$\
M9'/4B/``36`"7L9ZR!C`U?6$K?ZF-8X:.&5C0H4<"&BT$>FVZG[3U/3;?X>,
MS!!Y0;,C+QVGUJ]G4?$`;`[[@#H#U$1(8!0RTU0R&GU1'2.\4YX92'8/^KW#
M<V0C?/W19C_ZW$<YPU&=S2$>QS3.>4<Z)8KM`7=0VWRZ?`C]LC8`R(!KR6Y7
M8Y+^5RI)`\1O\0WQF(:"2"&)9;K?H+&4LED!SGD>J%&\4ESW)V:X)48(8RG(
MQPUD#<O8IE\7"5#/:^%,D9&14@4V"`/E^O[/@?`>/E!#HN%A7V%Q29)W$']1
MVW)$2"=SU7S$&JUX<)P*F]/'$+M'>QS`C:<(QB0<=I&(J/>`3`"CQNS&JX:B
MCC8J.2,)JU%7#6XX8GS#Y'X_KWD_.23_`#'[ZE17&S&11Y"-A(@0/U"`!L-H
M4"#P4?AI[201!"MC'1R2?R&/*9JM5S6-'('_`*$CO5K6J0O=5$1?%Y6$"\2R
MXJV8UA8^FWT1_:/G]GB.@(8'@^I<ZE57UT_S.6Y_41\/F?`]6#*5]2O4P0:V
ME0QB3&F4)5)(+'&0Y1$"HW_CB<QTB0A7MDHY'HXY".(U4=)4B+96@^E=/&)&
MT[?K/0>'38"#LL?=7L#D8P`:2#N0)((C8=3.\SYB9$&SD/7D:6003FTM@A%&
MY.\5%48VQV#%&E-:,@Y#%:P#1"<UHS=@(@W")Z$C2(E]R@_?5]?'Y]1\/'?J
M-]P1RY*\6([*1BW3QC;Y1!VW\(!`#>7RE6X<'K\"D!JKH@R0Q"$]6L`B^M&P
MQ?CG'_;1S`B#'9&"1KFH)/[`R>/8(I,>MJ5:VF0Q)\?GN/MWDCQZD>)5K;5=
M<?**E`$/3IL(/3H`(!!V^D-$*MB4>KF`=K664(;H;1M>TS6M]$E4=*.0!D0`
M3G*\AY3^[%`4PR%?_0=228MBHL6?2L,D]/$=!(W@=`/$`@#=81JZY5+@"^H<
M8Z^!ZD@[`G<D[<2P).S\K*[Z@(([2ICO_(,8SAJGM:I!N4Z>HT=K2`D22""0
MS@E&\1B*YWI>PSN\<YXF)JN(@!?[.AZ@;Q((('\P('F59U5<C&4\B6CKN-]B
M.A)`GB00QGR$,?([RU),,&>2LDO=[8['1Q,=XQQ/:)''<5S55@6D6,)'L:SU
M"4+/(:L"SM4WWHK5BU>AW^/R_CL>IDP98_?18EK+<:+#YE$#P'QGX=!(B!Q$
MJ0@C&HA2NJK4O@-`HJN`6$O_``*%72FM:48X[FD&Y6G<C4$KFN0Z()>TZ%U.
M!ZM0DSXS^SY_9X_X=_\`+?6*S''R#`CP*_+?J`-_YCTD>>%VNJU6[BKCJ!LR
M*QHFD.CRM_NA,^21[VQR1_%IR]WSY2E\6>9"&-YC4I2HEG!3:W+@VYC[=O&>
MG@(WV`$&`/NLO*QZ^'JI`!._4&2=B.I^HSM)+-(Y,T9$Z4#["F\&RVRRMCH5
M'#"-RD(UP30Y(F1YH5"][`#>-XSL7_@(%X_&*>/8&%=TD0)_O!&X,]2""#X@
M@RZM(R-=BP&Y-QGH-^A4B&$;`$$,/`J5BMTH]`=Y32*R4J2(OI>B#,@E`(8F
ME:GBUH0QVA<V._LWP"+L,BM:)HY,6MFR%"J+5V>?#K_:?$>).XDF5>W'PW+.
M<>SS5QXQ``GY`1L=H4;-`4"RNB2C)+K[MS#L#$D%*_Q"ODL8Q"F,HQ>:B,?T
M23G+XJHGO>9[T]:R7RH]E>W"RB5)*@=?$;#]4@`>,1&_$(U4-8LIRR&`5R>G
M@9)@3!,$DQL26)\O,V)?5-$D<8X4N.A1R9/](S0SM:B!(012M18AU,9TF1*$
MYKF&_4RC<,RG)%++BQN1+(T%!X$?J\1X`'J.D@KQ#A,G.X*%L218W0J?#8GH
M9,EA!!^KB5;F:VLG)$)EQ3QBL*AB"CHH9CWA&KU=ZED/,1BQ(RQ5#':YS&K'
M8WU-5JQ_2)]=8K^C>01`)Z;_`*OB9D_/K_-)%DCU#*Q58&6`V.P^$ST$0!(E
M1L(*<5-$.@(]X)];.$I6C\2/?(:\X7LD-*U1DC28PE<U7L*JKZ6H1?=[`C>V
M7&;7(4!EMK,?9MT^8/V>.WE@D<&-N&Q*O1<)`WWW&\]00/G_`"B?-*@^J@EJ
MN7(K[,D&>``"RSDD/E(,HU*IR/>-6.:A'^L\Z2G@YWFY"E5A/.25I+>ZU%LJ
MYUDD*(C[/[@/EL)$*"*;,>UZ<@TW`!F),])D[1UZL=CN9,&;&#9,OHF.BV@I
M37^+2B&K?3Y!(-B^@97MD?DB"U[D$%6/89C&]@K[!*V%-#=C$/45/4'Q_7X1
M/QZ@_P`VQET,><#7D"R=B!TVCH#O('@L$,!])E2*K5JUK%CRHOY+'G3\0"L]
MG<0B>'J>-2'?(8`?J?&`03FJ@A*BO]K1L&]M=#4S(W$QN?TB/&2#XGI$DCU,
MK(K2ROU`3Y1UZ>'C,;0"/`=>7$*11[IWOLJPX)37/*/\B"KS,4SG>#3A4;VR
MVE?)>)QRM>AQ>SS<]AF$>LADI<!5:&7IL=MOA\.G0=#$000.)1C$WT%;!+"5
MD[_$1YIF"2#R$R2&#'F+*%06GXKBUTM%:,SB)YN;_4T[WC:\<AI"G>\ICR@H
MCWE,1'D$CB&4L6793Y%7.+$ZC^'RZ=`#L`!L8`ATJQ,/(X$TV_29_;ML=SN2
M5W)8R5!+%J[+_C&#J;T0!F)&ANDM486%?V8P0QC$\B-4+?0..QJ-=W1&1F#7
MR2.R+)K!)NH+$2\=?TG>?VDG;D76TH&-EA`2M?+I/P$">FT1'P4+N$%=E%6T
M5>]C5LQ*C%B+[C.7R\T1GL&OZN`HAA8'VHY7A03!M*TPT#^2"-%C6`_='QV'
MZ3UF.AF8*GEQ9LC-I('XA-BNY_>/A`$3,B(#!EX\TK\'?(O*97D$)9CS,]:^
M+VN0@SJ,ZJA'2#QG$++>W_@DD5Q'M5DI2.99U4+1=`)X1_J^`.P'P&P,I`-5
M'+Y>-+`>K.WV@P>LD;DCHQW(BSD1?XS\Q)HWP9(@.''])0N1HF(-X61GC4:B
MD$8YZ,014<P[O%JC>,Q!/B2G,A#6>:DR>O[_`)?:.GQ!`(=13"M]4&JP+Q6"
M/E`$1!/R.S&/*0Q4UV'Y6CCUUW+AL4BB[!"&.%%0(D?W*-JL50C_`!XT,/\`
MHK!L8)CD9XQQ*.I6EK:`YB=R3^D[DGXDS$RQFY0$IRVJ$\=@`.@\1ML(`'B`
M``8A%C&V:;W\6]_]?%._?_7OV_[7.7_^*_\`EZY@]==Z.FO75-5TZ::=--:'
M?:-M'S^=S]W/H8.JK:_EWC`L_/6GE^W60#TNZA"#(0*LD.04Z2(K%:O=A1M<
MO=C7-7OO9-+9&39178U5K8=\.O52&J,B=N@(/R)'77C_`.:>2F%@TY=U*9%"
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M#B"`TL`2S$Q"JNLKO'M'O_>4]#VU;@YF`CEJZDO2FVVZOJSTV(C<R"R0K,%1
M5`,N[:MS3<?;OAG`,HI]#JYLITR+"0D^IO-$NLU%XU\K-U]]9*;]J'G\Y8C>
MR/)D/7\>*]6JT4E?Z<G%[C@=Z[C^(KLJ5.).S*GIHNSE!]7-QU4#=MY*]<'/
M[+W?VOV88=M.2]G(+YDLM]:VS>I;&G@*ZF!"LQ\J&(6P[8_AQ#XBIO-GI1?D
MW%E-#=:A)69L)-)LM/HZ"^HKD;XUV6O@QX]1:@\!HD-SP#:[NUWY0',V+N,Z
MVO"QC%*KQ2'`:M$='7=9)+*9/F@GX<6G355OVG&N[IGCEE.PLMFIC7?;;796
M^UA50$<0/)*B9!]12+'7DI9^4V%=HAR+2#HKBJLHL=QF3Q9C6Q[6E%"N\V%/
MQZR-%2I&^(UL;Q]S?!R>3DBH[._IGIY=-F-"65HP)Z<ZRK2KG=B>7F\W3<=.
M4:G^N^MV[*IS0;*K[48">0JN#H%LJ&R`<`4`6)$$217-W6U[;YW4<B5V>2T%
M<:;/Y`$W2V=BZON85686D@6%7`!+,2&-M].8)IC%*UQHX6@5J,<9ZX=-%.3B
MXUF3P]&JRPA%$J6\A#$C?R"8`&Q/+KQ&MED9>3A=PS:,+U!DY%-(:UVXNJ$6
MJR*"2OWC0&)/F50D06.JC+D"W6.MJV8^Q62D=H=$:)?W-;=QI$N5GHX=%30I
M\:4P2`@57L#$&2*T;7OA.$Q(Z/6-%.!F):@7C,H"BE2`')1B".I;=B&G9P3R
MC4]CKW?MEM%IL]3C%A%CK8"QK`M16!B%250%``345'"=73E6V>RHK2EL:X1;
ML+X5_*H*>4.^F!CQA5]%CMW3Q&C+"?/MY("/DQ_[!02&N&5%:9S5Q<KTL*]+
MZV(H,H'8<`29:RICUA00%.X(W&XUL.W"_NF)9BW(#ECC8:T(L8`!:Z<A!!7D
MY!++Y65I5MF(U"SGSKSOG9!YA\8>+C8<`>:LM=R#9X?#9/4Y3SM;JXM1V%DE
M781YES=6K35JC">1%,%IGC\_:Q:Y/N/L.2H1;P<UFYBNE;;;*[/*JK"\@0JK
M#R0&!*@Q!U;@^R?=^"YM;%*]K5!4UV2]%%-M,N[N&;@P9W?E5"LRE0Q6>0U$
MAU/$62O+FBU&]N-15U&C_,/89"A,T7[5(:9M=9V=S?$@2C*8\Y1L#45\A9/C
M_80ZN1$H]O>,RA+\3'2JUZX`L8?4.JJJ2!`$S8XX_P`W&-758WMKMN7;B=PS
M+<C'JOY%J:S'`SQ=GL*DR6@+36W+^3F3K=_Y\N*63RO<TT7CJ#E"Y[B3:Q9+
M(EZ[3V&PA%Y)X>_#OITY:ZIC.',*$R@444+)"*\JHKGN<O"^X:;U[2ESY+6B
MS,J(E.`K/HY$J!+':1,L2-AT&O6/9>3BO[BMQ:\%,=J.VW@Q9ZK7*<K"XV,W
M%!YB&XPBAMVB23KKQUX_KZ5TZ::=--.FFM-_M5ZCX@Y$(U%5P^"N='HC>WDJ
MLS=2Y$;W14[JJ?I^B]=G[)$]XQA_]GXO_C;7F'YJ'C[9SF'4=HS_`/V2:XB<
MY1XMARE8MERJ4-++O^/\\6;+B'3,S%#0YQ:NDO8505;.[WT."1LR)/(Y*A(,
MD0RN<97]_<NQ,]?:E*!S>*[7@$<Q+/R9"PXK43Y60?><E)'EC7R?[M2N[W`X
ML:H8K78]98J?2,5U<*[%0\[,A5/-+"?1X,H8EIUE;ZK%*CU%9#>DF)'3=WS[
M%9[Z>5%KH]%1-_8X]U7Q8[K:3%A!G%+&7,!=-&%4:]/:U4ZU/M0JUS.(+^@D
M1R!)=_.5)/$$P`WKGC/3;71_F&MB8U=1Y+7^,L+<N!"BNO[L.H',A0Q*_A5Y
MA=CYAJV\WS+R/@>/\7&BZNSL0BN;&4&GM36%VZ?,IS00T<8QWG]M3!C"C,(,
M<:8LL37(LM'24E>&3D]E[;W#N%[-2JDH!R4!8#26($>8F2"67B3]$+PG`P?=
M'?.S]FQ4KR+'46L0CEGY%"HK!,RB@`$!7Y@1ZDV>I$7<<Z<C:=L:FUN/QY*R
M6K)(*O5UEJV38>Z>DT+`7K(=7L70P,F)#@HXST>Q6(1?8Q.J8/8>VXLWX=UP
MM&Q:ME@;0966KDQR;;XQL=7=V]W=[SPN+W'%QCCM!"7*\M+<A%G%;^(Y<*Y8
MR(Y;@:J^=X5R5]@K/7N)J>')+JV0X5UKKNB3`$9'@S;&$41M#8Y[=NJWV4`4
M8;*T%O+84(5<U&";XPY'>\S'STP_NLU>0\M:MZNY`.R!ZN7$EB7-:D$QN=\G
M"]J]MS.SV=R)R.V/P,/=97^',*S*0;&KR.')0H%2W."JR(419W&./@<BZ7@V
MIK'Y_.2(/$.HNI+Z,EA;Z.YE5%/CD/`!11),9UOH+1I>\6$C@M(]3*BHX353
M,[IFV=NQL^ZWU+%;,11RA44,UD$L0>*+_,V\>7XG6K[!VRGO>=VG&H--#IVV
MUR:RSVN42F5%8(YV//E25!/*#*B,@V%?C.(-2>"[.Z>TL<Q.'8AD[)TS#L.^
M(8Y(K19BD.R>8<'\3P&U+)SW,(QKFJUC$37UV9O>,4.+*DKM6(KBV)`GSL(W
MG?R>!^)UNKZ>U^V>X-4:,BR['<,#?RHF"8BJL\B%B!][)!`(@#5[)];G@0`5
M&-S%/57OYL:TDR:6O;49J1-;-CG<,$:%"-9RY5HEI'))`2RE@5[$1WZ*[RP?
M^D%LL-V;:[T<2H#'DX$$;DGB`O$@$(I@[:VO_P`)#TTC&[7CU5YG,.36O"HM
MR!V"J7)?FI93:ZR-^IG!W/')O*&IT%<2]TES8!!7TVJH*`3I%A6UVCD5\/2S
MWYCCVKE04UIZAW_VF$>*^G`YI9:R%-['[WL';.U8N.PHJ16+-6[F`Q0$H.=S
M`^F&^+!O4,A./&!R?N_O_?\`N&:C9E]KH$2ZNL2RK:56UC5C(5]8I_AK9#2I
M#6<^<FM<P`"ZA#+(*O#%B;BL(0%[I"96G_\`OI@$GR(-_.$`UG;%:+T(V@.V
M0#^E0N8J(B.A[,Q_$%`6+&AMU3U&^[,`H)XKX_>B#_-.LKW,BG#%K!`BY:2+
M+?23[Y>16Q@"SF.,8[<EVXQMOEO@D"DD\+_FOL9$ZI^ALI!C2+H,FNTQ0S;/
M"V\QVGS"'2/AK!9)2&%2-60"'`-'(-@_:KTT_?FA<[AQ%;]NL)"P4V6U1P>)
MM$0#;L68,"3$:Z3VBA-G:O5+M;7WNE07!6TAGH=O5JF*&DEA1YE2MD90O*==
MO,$49LC2E#Z/40!W#_&<Y\?Q69)[>EST1SA]O]%5._7AO<`5S'!F9'7KT&OK
M#L[*W;:F6.)!Z=/J/35W]8>MGITTTZ::QMR`)Q&`4,5DB4D24H/>-J@=ZC13
MO`ICB6.-7^I'JGL:JH/R<C6L_(C;/MQ@F20DB8Z]")@;_N\8$D\6T7>E+`<5
M#6<3$]-B#$D0.D]1TDP!S3%M/8>LI*J<A0O>1SAF.]S5+^1[A*(S)('JA)1_
M:C?[2>PCC#()#))C'VMU<CU:X(CH/E\(/@(\=AQ(/'BR\]C70QQ[9!)V)\9D
M09'4F?#<\@R\O41ODN(D"UCS(QVUI2G<U7E>Z0DAQ2`1'.8R0\B!G2I`VO\`
M)RJIRL>TBR'A)9D?U*BC#D`/LCK\NH`,?($1Q#"I94*<A;:SP8GQWF2/GT8D
M3O\`4002Y5KZA<02#$R76=A2HKG/1HU[D(PK0M_H>D@(W-:(;50:E&(C&L5I
M1(.-(A1T.">%NZG_`$_(_M@D&=C+*\V52RJ+:-K%_:9CYCP`VD`@"&6*WJF(
M,P%U!.R1!3Q]*@E1BM3TE\FF:48O>`']A6B>G]8QJ/L09!C4<B/&M=&H<%6W
MF01_H)W_`%F=B"95FOIM3+J(=-H@@]#UD"0-MCU`C<,J\72N6IE&)940YGD:
M5RO$.8][BJ'VK#>PXI"R"D.669S7]V.(1[_[C'F(]+&^Z3#J.GP^/7:(VC]0
M`V(`'IV8I5>5;DD$[!NL3Q,@R9))!V)).X+,?7I-@KJVVBHR218CNQ'JXI>P
M/?(&Y[W."_LXBJ8*L)[7J]7![D:]84I\M<64DD>?^X?Z#(C;S;1S08U\T9*P
MQ]+[3M)'P\=U@R9E)8'TK#.6\=LN-^9!`V2*3V<CQN&!`/:P0G?D@]<5KF^B
M,YK_`&."T:C1K_2(2/J[*6*-PL,$?KG[#OXG:)F=N1,6RY*"Q/4I')6^$".@
MW$#:`09(B(/%5G'CUCB6E22+(>Y\ABEAJ5XU(83%4P">])@'/.Y%:9A6%#['
M?W!'"KUE`+;:!5<&7Z>OR^.T';P((,="K1P874%LC&-;GSB5F-P-P9Y#?^8$
M%9/F5U)]16\5<TH%_;+1OL1A%CADN0QV/5SE;_6\KI)_05Q4:USWD(Q[T8]Y
M7D">RK:BM]Y5\)CI_<)'R@$"0``RU4HM9#Z&0)@P#N1^^3!G:22"0"6+*]\E
M(&.KM:]SBGCA5[".6.YPX9?$;6!<WL=@F,8%@V%<UZM8%!N<K!LBRH-ZDVU,
M``3'CU_A]L;;F8DEULC=1CY"$DJO7;Z3MMXQT@&#L.))`%=E,[;UST]D]CPQ
MID8A)+I:H*.(H`QY+/U4C&-#(B1!D:OFU!%8,C2C:%"@AV4VC_+,E#M&Y,R/
MV@F/F"00>4,\F301-P(6U23.P!`!^/0@2-]B`0RA>253['R)E4]1^D4PL8C6
MQ_;XC(_N[R<1JBER!E,V3W<U[#N84GZM,]Q&V$<*EHF2D]?T@;1X1L/`1Z<P
M+VXYB!:5Z3L?W$R9\0T$[AB2+J)GYO:22+(>H"(QZ2`G[(AGC2-V>OG*(\9@
MC>!/`9B=V.$]I"L=#F%GR$\H==QX1^OY>._4#Q!`(=!B85L.:W,-!D'QB/F8
M(\NP)V*D,P-5K>K!S:>R#("$7XZ"(5R%\(H1HP0V'8DAHP!](8$=/#NHF"8Q
M$?XQQ*ZI5@W5%6)Y3]OV;;^)^<GIYC]]6\C%O#H!PB=X`$#??80%&W0`#>$6
M<::OP@EUZ28K!O;%*K3.&GDL5&>P)VD`V.9&O$UY6%\@D1HU*T@",=*C$MQV
M9+.+]2/V^(WD?(C<;P0P(1A)F*ME/J5@0IW^74':#TW!E3MR#(P-B-+T[C6=
M6:'(>Z0K'JR&1JE67'>K/-J/E><X@5(XS$$]7G+V,B>4E"`/9W7<:K0Z[?'X
M']6WZ^@VZ+#+59C%K\<U.>6\+UD?K\Q'4098^8;V2CW^:J6:GD,J[%44/@T<
M20Q>XA,1(Y&@!X.&Q8P^[%<UI&I'1!JQR1T`:"M5;E]6OKXC]NY^?7PWWD<N
M2O3'L?%<8]_TQL?`=-ATVZ2)\OE(/`(U7FU>.LO(LD@?`"`:TCVC",17`CR1
M+[6,&)B+&CL(CNXAN8!I/Z%`R4"$J!MH*@^:?UB2/XF/$R8WY%6>F0RX^6MC
M#R1N8$&`1OL.@F=@0O+;@+$JJEI6I;,2;$<T<I@AO`5WF-YRL,;Q0IO`YFN8
MXQ&B(HS*CS/[M-[3!L8JK?1/!]TG?Y=/L^4B1L!NL*U>1D4?B1ZM9BP#8])(
M)ZG<^)@P=V.S<F6^%4M%9U+($I/8\3&*G@4WM"Y'B+%D,E,D2'`DM<\+QJ(Y
M$:BB<(KVK&D$K<35=S78'[/L(B!(ZS('C('F46XP7(QQ59N0/B9'0@S)@_21
M#'^4JQ'!VAU-L;\U];-<-KPC44=.P8[7($*/&-K&(**\[XD?OV1P@J(*N&K1
M,>VKK;2O#U4Z'KU/4_MB3\S)@R2#;3&R6]4T6Q($#H.@_4)@?$+"RL*",>GJ
M9U;=-04>9'`\R1SQ50;0/))_('ZHX'!>IHSE:]S45BO:J'1H_+\Z$^7CZM&Y
M4L!(/CM'4SU_7'T[_0XA+FC*\JLJS!'AO.P$;CKX2//"SZM1JEU">4!)<$2_
ME">`A6,'YRPH`KS,<%HFR9GM_)D(1$$YY5(3V,4Q7L2RAH<!@CGR']F^V_0=
M!&^T"#Q`/I3Y=19#;2/O`1/Q$&=HEIDSL29/(<V(]>%&<^ZHRC:0*F5XW"[D
M0GJ[>F1&/Y`,+O\`VQC>)X##3L,9!%$C8Y8ES?<7@F8_U@C<?:#(/4@@^8/2
MLG*PR`1RG;>8Z$'8CP@@JPZ`JR@(U<K2&=[R5,X(DC/1Y`QRM0H1E1I'N8(K
MXX0^+AC,[^H8Q.]9%8P2#E1(%UZ^7UJR>7B?T/V>).XDF4>R+%?SG&N`],B0
M#N)WZ2`/`]0`8,!>-E=,0[5J+QQ5"$4&2T@U<P4I_P#7((0Q(Y`^$ESY1YCR
M>(E8]"/*]&(IWG#9T7[ZB`2;!\QX=#X;`1OM$"?*%:JYQ^&RN4`4L".A\23$
M;[EI@09),#F73(C:",*6&--BE"G8:N9*$1W<@R$CE"P+X9E.9Q990N:K">32
M*)XS(58ICTQV9"4<'[/VSU$=)'3I(*QR5;LU%L1;:R.G4'J)!$<3)DE2(,SQ
M*OR]-W]$A):U4$Q9P%*@G*MDQ@VM47AZQMD-$2&U6(@FM+_W`VH)7HD;UC=6
M4#^C:P"F)Z?W=?CMU.\>:2+:FK\1CHS..4?5\O"8X_#S?2-IA.*FB#23C-(M
M3/812JXI7DD^3V$&[\@7@]),7N3WE]B(YXAH1?:QXFF27%==>@CUJXX[=/U?
M`^&WB8V(,<'%N+:W+\-<#RZR=QXB-QXF=R!/F!4-ZE9]-D,KKDL4JK#;*E-F
MC,-9'K(0_<2B,Q?<A$ERY#7>8O)5EE:CE><@W6M"IMI#KYB!$;>'PZ=`.A_E
M!B%!%0.*,HUMY0S<@=XD[0>LR2#(_G(F793D0KF"SU.MX;W>UZ]^X5$$+FD>
M!KG*@I(O8^0T86^*'$TB,$[VB<.+*B74V&?1?I_K^7AOX&).Q!='IE4CC^)J
MGE\H`W(^!$SY1'(3"GDI%=E=3](;BM#&>0*G_%1"_DC&\B">,H7O(%PH2MCN
M='=YL>$+50+V/&)&&'!AY&FTL`>,[0?U]=]]]B">H()E2\_%<K'%9(Y\=YB8
M@C<0NVVX*@>4@JL,M5/I)LA[WU4MS2N$\Z$*92D0HFE)%(TOY`R'E=Y+WC17
M#]GL(YIFO.I!V4M]:@>JFTQT_;X;#:#UB!*PL&N#$ML)./9N03N=Y$P9D$G>
M1N)DD,"Y9;Y#VRJNU]RH5\$\PB>LAG?TL)(")#*Y'-&A5<42->KG(]7":I5*
MZ',E20EM4?\`F!?[#M_';PW,1S18@UF/D<MS26.Q/Q($_"=QOXRH+<C5;9.V
MT8(5?=`E>IC%&<1Q,%W1R,1CD3^J/%9%8R.U2N)ZA^L;6O<(81%JXZ6)^X(G
MP@_H3.^T29)@$L1;+DUJO_%HT`000!_H`&PDF!``)555L>H6,")9P#%!']TF
M0B.&US6#D,-XDCE$8<@"M;V$\HBC.)P_!Q!D'X?D1DLKL>JP*QA1^SX^!^P@
M@ST(,\6U-=37D4LRK-C=/`SN"#(^$@A@1$JRQS35/STN0;WP)OM*Y!/07O4C
MS!]*N"6.0,E\D[R(Z2B?\1C^3T0BF>01[6_)11%B0-_#^,B!X?(;;0`5JAPK
M'::;9)C:9)$;$$&3._\`M-OOR+*^13X1Y%)8_P#-.'^/(<U"&[.%%0`TCL;*
M&QCV#C^#&@1'H3Q$-!=R*#\*9&D=5OJ\GU#]L[[?/QVC<SMRYHT%3V8E_P!Y
M'!O'H($;CX?RP9V''S</2MKG;X<)4BR`G6"8RN0GB-J1_P`6.QX3R)8U$$0B
M0HPG-<UXVHH&$&43`B,VNLQR\E6')1\]Y/0#KU/SZD$$DKZDV8M4*Z'@QZ[;
M0-B3L`"H!D$?2&5E"JPHJ98R6L1\=K&I*&YKD<9"-81SNX51$>.6=%*,CFN1
MPS/57N&49?:<,Z(-Z+\C]'R_0#]X\""(5JYVK_$5<!_F#XS]GB"=]YD$[E6#
M<G2Z'GVJ-]C&[^3&2WL:CW]R$([U$;W&BJ5Y'"4;^ZD<56N$J/*BQ94JN1N%
M;QC]/[1TCKL/.BTPO*7K_EY>/4^/3KT@]9W7=ON[+*.Y4I+$C6M7]H3_`(F.
M5700!8,*JJN3U"$&$SP1CE5B`$QO?QC#&^HFWOKG_P`[]YZ_O/C\3\6)%V*?
M^$O,?\M_]"!`_4`NT';B`.E8!QIW11/:)9P8HC!4#ED*1JL?&1CI+2%,QPR,
M.PHR'`5'@?X-]K2">)9<9+,9X/IDD&=OGTV'P\"((\""#P;4N=5R7U44%8WG
MJ(F21&\@LIE3`Y!E*FRO578R-<5L8?\`WB_VFD436"DQ97J\7$$Q73E8=KY*
M*B->92(5.SC*5%L83RIM)\/W$?NVV^`B.BQ]WD@5Y5"KU.TQ`(,=1]6^_P`6
MD'JW(&^E4JGC_D5D\W]B.H!14&1?>!QF@(%C$C&(P`VB>(C$4J(!&C<,JA;&
M/'EOXM%M8\QF?A\^HWWD';?>1R+*V/BET#46GR+`$=1,1T)@1!'F\L`JW`5N
ME/&V1GYPHD@BO@?T^@[5]00QQJ0A%<%K!``P(0E4H?6,;&#>]K&QAGCU<AXY
M"%U'WGB/G]O4[D09),@$EBK6PJ'PKA6Y^Y\#T``Z[;`0`96```2`*U=,>LZ`
M`&!!-")_Y('J^.X#2^ISG.<B/(T8#O<9CCD5BH,AE\RM41E?(C3H<=F)*,?*
M>L_ZQML)W`Z&5A6KR<U$""U0?4'2)C[3`)G<QL3NPXO+UW3)10;>*@1$&\GK
M`\$ABL1Y58HY`7@.)Q3M:IB#*T@G>?\`<&\;WJ\!Y-H-E+21MO(^'@9'3XB#
M\""!#*LC+3DU\%(+0(/B8W$$2>L$$&=P5)E'LH-*)TBNL:LKHK!L:'TM(P)/
M21P%*!XOQY,1J-&.*)0H)PA,8%'`($0QI5SWGC8MHF=YZ_'Y@_$S,DDPP))]
M7$Q5+T/CMQ"[1,&-I$01T@1!``6495"C'E6K)H91WB&[P:-1OCROT5XD)):C
MGB$(G8!6L.Y5]"(QRF\1)XS83+R%R$`;K/4?J_>-O'_#)^AS&/4P["5&P$0?
MA)\`#L?,?IV/*%VMJ%1OO>,\2PBM>TA6.[JU[CJ13O=_0J"24<I"^]/T;[7^
M;_[*F,3UVT>/Q*FMN@/V=/V#P^6PWA1-4V9S5UOKD$C[>OV223/S,GREG/'(
MC`5E[6J93@?*8QK'(P0O<-6?CS(CQFC'&]&O00CC)'.C7(@R`*SM'.&UIHMB
M#PG]7B#L1]H((^(8'S*;TC,HYD@O'P$^#"""/@&!5O@480CK!HOQ30Y%=..`
M\=SA^N(5R#:C9`C%_I5XX;$:1HW^+6#$%K@$5K`(,L>MNOY!Q;6"&^/V']?\
M2=Q):0UMF'P:HT7$%#_*?F"?]GX&``%!4D!(9**6=)%':%8,DIPE*GBB(0?Y
M`CD.18YFM`<KO;(*1%]8WO*52JT;Y#I42QE7C?4"8F/V1&XW'01U(@1N%"/7
MCN'Q,@@%N,_,2#.QV)W)/0$D\H4N;*[ZS>-+*##M(0B.>X"]RC([V>ISPD$Q
MKXDISSHIGC(-&%<Y[E&X1%,Z,^9#1"%JK"(G^_XC;:09&V\B.03*RP]BKD5`
MS'Q\-HZ&3O!$$R>)5N1K-M2"E?=0F.>@9#G`>`;R_P!M%1K4>TPG"?$_L=X[
M"(1BA1/2UR*%!#=7Q'U*7VD;S_H\=]R(,]2/-)%DZ>CE528)B)/\=HVV!D<?
MI!\H5311J0P9,.963B-,\BF'XRF?DL7\A3Q7N5DD(VO&0C"M5/4-'.89KPB(
MDN,.>\,KK;7L!'3;I!\#]GB?`@D<&.+B,ME346F29&^_61X@=3/@)(8%5(LK
M%/='F4UA'(3\@J/E>)O7_4.2205B*QC2.DD)^4>0G92(\I3._1SY;^]S(&2^
ML@0(&WRC]G0#PV`^"#[F'A;BWJ6Y$%M_@9/SF9)\9);I-A_XJJW`CQ9,:XAJ
M@U&H6JD9%>CGR/1_0-PCL$5I',&O_>B"7L%4(QZ1)8H:2KJ:7\9Z_*?E]O@2
M/-L1S0Y&4KUV+E5;$1T^<?`@&=O$*?)Y@?2L69(:';U$QRM&KAQSI[7A`-J(
M@T0B=I(X87`:@?!R.:(:(!4>@/405?:%>FX#>)'Q_LDSO/B=]N4@V2,U63C,
M3&RG>!\-^H41M!F!Y2"$XLM$C0NC312*V:%IB,))*QTQON,CI'Y$&0U03!$,
MKU]A1E[A5RO<5AQ*9YQS;\@.A%J&!`Z;#:"-P8^!&_2"I@*4BPREJM1:)()/
MFW.\J=B)\2#M,E@Z\BZVRJK*HIKP--[8\IS&M]SFG155\1%<Y'R#/_ND,%GG
M[O85'C1[W&?$E3[O)>G(B&'ZOC\OMVB!!@<0ZUQ?>8EO$&4;X[_#YGK*B9DR
MLDN:[+JA?DDUI8\F`KHX6B[R5$K6PV.$K&@(1G>+#8K1C1/)3#%ZV,1ZA$P,
MFLLQPEH*V;F=OC\_B?W$R3'(EEMGS&>AQ93(4#>/IVZ$]%\.L@0!/%0ME'VP
M6MM*I9)E-W"DD2.((?L4@PR!G4P2Q48T3&M*.0PH&M1C3",)K6R0"5^K5;Q$
M;Q_$1X_800>O$J?I8KO0R,?U&F1(Z;[`@R".G4,"O0,KJ`+$6%7"CV5>E=(:
MKIRO5WM(CW6#"!.\3RHID-*5T5)/J5"K((KC*PGY+C*MI6TM59ZB_P"7^[<3
M]F\3M`VD<>/W5M`3(I]"S_.GK_-L8G>3MRC?D9:#ZA?_`(B5@%L8-H&N0K2Q
MXYB(U%/ZA+%$P!7O"=Q$<GX\=PGHWS<K4]34)ZUA31W6"NRHV1#$?#QW_B9'
M3X[3S0QTM?5D"@$%%)\8$"#L9\!!B=O*)CTK1[LARJ>P27',C@$<5?67R4,5
MO@ODO9WI"..`*]T7N-@F,5I$'%8JU"HK=7Q8>;^/\3,_;,R)<_?5O6S&N]2L
MRAG;P'\!`'V!0""!6/\`AI^YAPGQEE-#ZS@&].X'*)[.S#.:5T?\60CWC0A&
MD\@$48BF&01&NDQCQ4NX;@3*D^/]\CY1N)(4@CRLLV554:_4`AP/#;X[Q!Z2
M9\I@%@RD&RM_G:/:U/K"Q73H\>(0,AP#M(20%'."Z*81IDY3#]RJU1E.]JG8
M]JR/<)]E7S572?H).TCH>L[`1MX@#8CRP14A,C&A1-R@08,R.D&6:=]H+'S`
MCGR4WRE+,*UPZB5'7L(J(YAD9X#9&8*0``6",(8_5ZA/8@GJQ&-80;TCH`L"
M^Y!'K*>H_CL3T^T&1,R".7(618EK`C&L7H?'PB"`((`B`1!B(93P"-33ZTQZ
M^R2,=&C$1KA+',Y@XPP*IS(UH"BCQFA:T)E8GJ"Q&L*K6#$R7#KY+0ME7)=R
M/'QG8==SXCQ)W$DDH]D-#/3D<'V4B(/2-ST(`C9HV40&("J+*Z9^_AQ@(&9$
M<1CY3@>`XS.[._N.=7M($9Y#W%-)>YK6M,]2N(K&&(4\:TCQW=I1^@GK]@'R
M'0#X"(DJ`K539E:+%M1(+1L/M)\`3N28`!,S`8LZ9%3GQ0V(84N$]RE\/(,T
M+2O:83$`8#"/B2Q%6+**(3PN&5%1RC*(S7K&D&BK<ULR/T\1^V>HZ@3,CX@K
M')5R+JUN1+*B>4;,)W`@B8:8)`((;KQ96!X.VQK%56-5R=G*UJJB>79%5$[I
M_4C7?Z_[T1>N;/77<#H)ZZ]=4U73IIITTUI)];@;)K,M'*P:A-S7PD$[R-"]
MK8IYFB!.<GN&00E;">]/-_@-J.[N>UJ*Y.X]H,5MM8=1@Y,?:`A'3YQL-_D>
MFO*/S)468^.C`<#W7!!F.A:T-U!`\L[F!\2!)UPWRK8NKYJSZVUC0_@W&KV.
MBJV-8YM99WP8\K12K+CV."1`%2O?:/5DM]R5%=-<1\=K!.1@_=LKGB=DL]%;
M/42FM&_Q*A(0"XD'EY=U%8^F`Q)$GY*[=Z?<?=5)R7I]&W(NL3_`]@!L+8P!
M4)+F'-Q^OD4`4POKFU]A&OL0V#:J@:_)BLJ_0#\1"'=6FDL4FEJR0"QMC"O'
MNK!C<?\`)CT[R=_:\8NW:G8Q6^/?S3S-<5*?[*H(Y3-97S$QQ-@'0$ZN]UFZ
MO,Q!39Y4QPRV#8!WM;D4*D7+9Y0"W):2?J*KK)\CF/E&DO\`(@::SV<?_"(T
M/\:79WRWE@+0U<=TO\&^K'1;-;U9\AOK>Q9D1I8XU"QPF1^M4O9NU7X]S$+0
MWKDR%3@.#&)1I7C`W!XL03R();6^?W/[@Q,S&4&S*K_"!89K/486*.7&Q8?U
M.1$$<T!5>(*A-8_U?*NNY"NGQMOQ54WPXE?,D'$"O;G;T9IE=``526E&&LGD
MT-B68>8V1.AR!*I'%1A&H1>MCB]IP^W4<L'+>LE@!)YK`)/TMR'``!85@=@)
M!C6F[C[B[EWK**=V[=7<JHQ("^E9+*H,O6$;U&+,_*Q&&Y:".6HF_P"*<H/C
M,W(M:FPXXG#L*&8/#\JSLD%--WM:BFEU>:'4RZG5R)*-(^01\FA'6OCO(19/
M=C')3M_=LL]T';K?1R:RK#U:!9Y/*S!GY!JP.@`%I<$`<=S-W>?;O;E[">]T
M?B<&X/611EM2/5\Z(4J",EQ.Y8EL<5%26-D@$9#P?#D;E'=\A6#+(]<#.Y3"
MK+SN&IEY+OYC[N/JA2)\3,)8UJ!AUKZYS9,HAC!C/E,'^HWO:76Y_>F[5@8]
M94,UEML/:WHH.)K@%X.[3Y5`!/$GJ!&Z[/[8K]P=WS;A8R)1C8\U8Z?BK&]0
M7`L*N2PJE8=RS*I8+NI(:S*O<Y7C/23BQL?93+%C+B'+%R1*ELEU#&MIR^^9
MCJU:FI`XOX#/)\H]@)KU9['$>J]LZW`R^Z8RAKE6KRD>B!#?5L+#R8]3](0Q
M,0-:O'[OV[L.<[5XSM=YU(RB>2?09:E>"">(DNU@F.18DZR=3?4][5V;8F,I
MUH@0"#BO!+;"+3GD7(8C9H:W(TU=5TK:RKKX(84,DI9<A&-4RD4KGM?JK_:F
M/;5SS7]1FWD3R`4F"UC%FY,268+Q&\1`$;_%_,+,Q\CT^UU>BB$"#Q*$N!R"
MTHJ5\4551"_-H'+ER)!Q#)V6STG+M)-T^EN=S,@W@ZB;/N?S=6L2CT$JPHRB
MBUZ'!,H<D>*,2_O+7$BRWM1T:('NC$W*X6%C=G=,6I*$:OD`L5RR`-N8(>P&
M?N]F4;,[==<T_=.Z9WN6JW/OMR[4M",S\KHKL+5D!9#5TD`??B4<B:ZUZ:E>
M0Q3HT_(V4(L=DV]K+-U5^V3Y5Q8$)!FLFA?QSA2,_;]M<_\`.-8V41C#17O4
MHG#<SS2_MQ1J[JG!*5LO+D`HW$'UK>M:[3Q&S#8@S&H^]K;7=C7U%1;=6_#B
MQ=I5N0_#8Y\M[^8`.0&0DLI4B1O)\PR59LXUG!C1(R_^%4T:-^V6LK0"0-!R
MYB<U`BNN9K4D6$JNK:<`"*\7DCV*GFYOBUG">Z5!PC4Y8_\`SV!/)0GUX]KD
M\1L`68D0>G@/'UKV!81W1<BI54_]/$#BYL$5YE%2CFV[%515,B9'4B`.VG7A
M^OJW3IIITTTZ::U3^Q8<4_!7+D@XF$)&X1Y:8)Q'$:QHY=35!DL>@WM[L*+^
MER_ZHG^BHO76>S7=>_8:J=CG8\_J9B->=?F=76_M'N3N`2O:<P"?@40']H_T
M:X_\E<:;_;G@\B8VAT,P):2'F+2Q9+-1S\VZMA``M-67EG"8"CR.@_"99S9$
MH<UTM\@P0-_M%>_V/MG<^WX*MV[-LK!%A=5CD'Y$GDRJ9:Q)X*%*\8!;J`/F
MCOO8>\]V=.]]KIO934M3M)K:KBH'!+'6*Z;.(ML9Q9S+,J#RL3?VYJ>+KW,Y
M1>9-T6@EW1*[15U5QQC6[FU%<)&L:;5)2W4BNEXVEB3D$<T@X)/[A&\P'?ZW
M/8CM?@W=UHR;?Z-0+$0,C-=9Z2E95J^2AA8Q&P`*\&AE$@&-QW?']OYF!CGW
M/EFFRTK8J8U'XAP\,EW!RII0-#%F5O464<\21.0<YK.%Z[B]D'A#C&UNX\EA
MI]+.Y&MI<&X#IP2X,>J@:*6:DLK.B@;)H&F<X#`..'^\96E*XB:[)Q.]V=T]
M3OF4E;#9A2H*\""6*`,%8US&\P=AL`-;K![C[6I[!Z/M/`LM1@61LERKBT,H
M1;"49ZUO@,2H7DOF;S,6&&[+GFRVU?I8],F>Q%2I+R/)N4B6M1;!U-"?VWX;
M;2:*LE7I*N79RGD4B6,-`1&JK%4@PBZW578*L&RIKO4ON\I"RK+P<>0JB,$Y
M!1$<&ENNQ8ZY>_W??W6F],7T,3'FP%^+HXMK,V![;%-A1G),^JG%)CS!5UJY
M94=SIYE@LE9QKIC#(<TYC9MLA!FD0IM8,L>;'D6-A'G`:$I8\CU$&[V)XC?$
M(/JJ[Z,5%X\11M`&R]`0VX(`(,@$2#MN0X/G]^)E=PM<V<SE"9+>9YDJR@A@
M68,`I*M!!Y"%-96I$<R17_/=?7R7G)$X]NI9"FIA5'<TBGRAF5I+`M>9;(<4
MP6HIE51MCHXC7$_4!8A*V=QLL$`Y"CZN6P:P<HD1(/3K.QCZA.2'I[+32Q)7
M"L,E`FY2D\2Q4\H(^KH%D@MNC9IP.TV99$NMDSRV&7A1)D^ZK[]\.RK)[ZZC
MLIT.-%@WOYL*N)9NJI`H4>4086#:<AU(V"=TC2=PP<$*+54+E,0%*2&$LH))
M2"W'D"Q4$SQ"QZB\>I[-W3NC.U#N7[>BEG6R&1N-;,H"V<E4MP85JY"@<V?D
M*G+YF9S!@[NXCXN;A*9]+4#BNUXZC4U$&GR^;DA/;8TLC*336,6'>;%7)'(V
MOFCE-:UKU>-H1,;I3V;/HI.:E[^NY/I\D8L[CRV18`"5KZCFI7P@DDZZ@>YN
MSY>2O:[<.HXE0'K<+45*JB"]!-+%@++OI/IN'``,J%4"S>1,O\N[BW_"_P"I
M>@XDM;6ESTZVS.PH++58UV2C'K(0&!M,[*%?TDNN_-2'$(LR3$C,DH1\?P(B
M]9O;<KW5@T^I^%KS*D=PKUNM=GJ$,3*N.#`QR8<0S<8#2-:SO?;_`,O^[9'H
MG/N[;D655L]5U;6T^B"J@!ZB+*RO+@AYLBA@2D'7KF["WUC5YJUQL$6YK;>Q
M+I3Z[&NC:JN?$IWV6>S]-)KT@2-/#KSRXIPNL@5$*2U&(\1G$$KDIV//QZK;
M:LUC18B\!79-9EH=V!D(2`00AL8;[K!U7W9VC,OQZ,CM:#+HM<VFZB+5A.5=
M:%>)M520RFU:4;:58LLZO'B?+VF8MN",W-J;*!80N;\-I+F')&5DBH-;6M)'
MAU-S:RK69*T,^%3PXWMF%-(E%+ZQ&\G#\8^'W;*JRJ<_)1U:ML&U%(Z-Q5B6
M50H"`L3"@!0)*[&6V?MSM]^!D]HP;:W2Y>[8]KJ9E"[H%1W+L;&5%67)9B>*
MM)6$[(<4HB<>95$7R1*]W9W94[_\U(_7LO94Z\8[M_[QM_WO[!KZ?]N_^Y<?
M_<_M.LA=:[6ZTZ::=--8JY"EGA6>=*AE9#(L@4I'.&P(N\B"T1W$&U)@5][Q
MM1RKZ5?X-\PF<%[MMVY%LJM6//M'[#M\#M/SB3#+R`YWO5CU9%#3%9D'I`W6
M#/U#>-^DP)5BI./KEXPOB3&M9,B0SO.Z0KT(V`U2N0XR%80`4A^4=&HUSA@"
M@41_I`-"5>QI!8%#LQ$1\?X[[_,F=I8Q;I,DA"MHAJU,S,\=]Y.PX[="0J\1
M/%%#8]4D`BWE8K%5[FN56-<YOE(`=%/'(R4`D8G<C4(5AP%`YKD<49!+WDQW
M1*SX]L^/[B-CL9^P@@_`@_2VLETKR\>#/]H.XW!'7<AE*^+!E^M#+43)[&2H
MLISB*%S1,E",4D@:_P!'I"CB$EF5R^YI!*KB&1ST1SCE>,]E=>:R0R>/AX?;
MX#Y'H/\`=`*U688N`:NPR08D$DCX#Q/C(ZM)W+L0]]'"%U-8&/,:YH2/>^+8
MC,YX8OFT+&2#HIQB_&*%!,<YQ44*""OL]0XDF',3ZU85/J'41N>NPVZ]3TWD
M[275\95_"WE[?H.X:=ATW.\01`DGRPOFXK7954KUDALN(Z,V2LA0*J(!$2(K
MAH5?[A)`PQQNC.:K511,1XU(U[$"V0R#%CE>!#1QGQZ_N)._VG>(/(J;)LL.
M+%-?+G'ATVGJ2`!'3H)$@@('%,<14LX#U<"-)L?%S"1S.>UDLC2*UZ/8UDB4
M)CTFO8K7C*\:G>U[2N(4<^A'IV=2*_C\/X#P!D$`P""(!KO5AD4DE5:_X'Q^
MW8D?41!!(Y$$,2PN@T!A#C%CE.\,KWR6?CM(X9QH%8KF>EJ/<9AQM*%S.QBO
M5'">PQ/*+*/=D`E@RB4@;^&\]?".O@!U!4>=%LPW5:RC&+.1VF"(CIXSNI'F
M)W4AF^[L>E!_)I)TU[`H.$HFG<TK_5&>$36(K/R%[1XZQ0M_H1ZC08Q,3S9$
M8BU$K<;ZUD^>8^)W^74R>O623L7/WV.O/$N<A8JB=]A`\)Z"!TF(`&XK`_#3
M]Y'DL,&T!$;)&/\`68"2-7JYB(8*-,-&%5T;P<9K_P"RYXE<3S&]BRXJQT,A
M!J8P?`C]1V^?2-]]H(/!]39:.&&0B\E'U`[_`!&XWV^J=I$M*D&RO53<6+;0
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MW$L%;R<>3O'03!Z"`-C*[`"3Q"!ZZ*A??\M*'-4#D(\;H[9`6$>4I%>]K1%_
MMG*LD*R#O9_:*9WD1K6$(^1'GQX_F0H#M,P?[.FQ@3N!T)(`5JYLSR6"T@\H
MB1U)GH=B9$L1L6W8`,2Z73QGCMH#@H5K2^(3!.JM=YF8,)_>!(THDAKFN>Q6
M$$7S[J-XRO\`*/(D1@&FSE&W2/VB#(CXR"/B"!YE69BN325!`>`0?GL9$$GX
M009^DJQE'>D9LT4*2:Y1DC'5P7M][8[6/&V.Q1C:QC8H1(V/'\AM_H$L=J>I
M1!"C*N;*5VBP;K\I^/Z_$[^,]99IMQL%JU#4$%7VZQN(&W@!L)`V'$>7BBQC
MPG0YE;8>^$US`EENB$@N<@F/0KSKV5JA4*1R?W55J-5X54O]I&K,A+<'2VOB
M_P!0$S^SYS/3Y';?Z'U::K:+^=0A2T%>G6?E$'?PE?-Y?\VHU2^%9*D6=$,I
M?Q7M,Z(T3C_WN[E26!K4E23._O\`9[44IN[FO&I2N1MI%CFK>MQ$[3TV^!Z`
M=/D.H,`35/F+?"W5F>)F(G?XCJ3UWZMN"O)B!D>8TH%U3R'$;^0HQM<08%&:
M<U6>B5&+'>$\8?L>(8B`*$S&.<T9!$:UL<T<RM1<`-I/CL/$&9GY@@@GJ"#+
M!B6)E8S$^8@=!NW@1$$#H`5*D#8%6`",DMFYT8,=83O-CVN<1$+XHU`N$=W9
MHO1'&,"!C$7L@@A\&%11A:*1&K[\FMF?GX?V[?,^)'B3N-VE6LCP;45/2Z&9
MW^$'P@"(!\`L!O*@5ZZ94X2U5NV7%8S\:60(?:55])#2B%*]&M4:HO<IB.5J
M-(KGE(HT<<DB/9W*PMIX/]0!/SV_U#X;`3Y0K51NIQ\GU*P/38@2>DDD_#XD
M[;[EHERZ7QM!!ER"QY\17':K&^D@D\2(PA(QHZ">`[9#U1Y!D&K"J_NK""*A
MDC2)5N/8J@UOL9W_`'@]1'Q!D1U!''DJ7YE-CLMU>XC:.L;$1!GX$09Z%6#<
M'LJ#RP[BN(_TCDE;"[C&QX2H-A7>(_6Y#1FM\DAM<UW<"=@M5%"@6NKK(>FR
M)('+^'ZC\?GU_FY?>3%JLJDF`S<-NAZ_#<?#KY?I'T\0:*=03Q,:L`D9(YY#
MGM645513E=^6UPY#9`0F>1".,B-<(?DJG8\3"MEQ4DR*R?O`94>'PZ=(V^'B
M?Y2"04?4&'<H^Y*PS>)\3YNL@'KRZ@?S@J&%E>O"PGUUT&2I!#$20%KWJ,P1
M.-*\GHB.<V>[^[/*GZ>9"%.5'(Y9#_.V<Q925@D@'Y[#]G0#X``#IQ$4T](T
M90LD!2PG8@2?_BNK'XDEC,\S.3'O1H-X+!GL<9J-\F!>OXJ@]H7,*WL4;6F>
MST^7<HPJK!.0K%9#E1Z4&0:S$?/K/]W7P)ZB#+HU^6((N$\OETB1OUZ_3.X&
MRGD"*K$@2YG[S4.8,;%.$KBR(S&(]C!D;,"U%:=8PU"YS",3V":-/4]A1QD&
M8=;<B>A=)/E/0_L/A._0[&=P06E39999^*QH4#F#)'R,CQ@1U&X`V(9:X<43
M-%*;.B2*Z8T(TCJT;&N0B'<IGGCG0XI82N.99A2->A&/*XIB#,)Y7&9.LR%*
M.+$DD_LV@B(.PB(B!`!!`XFN3$L%U3460..WC.Y(,@@R>1(,@M+%64L6%WN,
M-]39*A#1QAG'?(<BE40F#&@&L*+PD/(0RFD@_N(KO)SQJXCRK'DRS$6U;`DJ
M(^/Q^738[?(P`.2I5`<:_<@*YGK`\-QO),E=_FLL6*662ETA(]@IE5YX4L`V
MR0^+$&Z,$@E($<CR''`YB@'XO8X"#8-/-PPC%(JKJ(:N.E@.Q^9\8ZGJ=MYG
M8%B5MBR@4OY]:F`D?($2`=@.@W'&`-RJJKX]3DJ.RJWFCQF354<B,C)+6->+
MLTP3!ELEQT1I!-0XBL*%.SO8T@>R2@MB2:K0&/'<';Q\1$'["(/P@_2QR+.-
M^.60!]B-_#J""&'4>8$%>O(,L>HH\T4P#X[*PXR`FB[^T)5,KY*J9%<?R<\\
MAY'2)#6E8]YC-,5$<XSS-)95O1@WJJ04/[OEX#H-CL('10(JIB6H4%#`BT=0
M9WWZ^)F3!!+-)W+E@;Y6-X5%O+4QVQ8<T9)`R&(UB>(G1U0@W(1@U:+R#XD0
MC7-&P7=RC2')#>TW4CB)==MOU_Z=HZD^/-3'7&+DMR;C4P)!.W2.F\;>7>00
M`NY`JL6GVL"5$E)/;[9'JD#<A/-BL[+[6(QSG-$T;T:$B/:K&`$)JL>QL9I&
M55]-BNOI])'Z?']6Y).X)8@VPY%-E=GK"3##>1\_L@[&=@H&Q`K!&/7+=YYM
M,]6#"95:JRT[R%>)[?8CT;'_`!Y9'N(I2-<PHC>/L?YB/Y'!,AI"UW;DCX=-
M_P!<CY=".@@KY63,R2]N+(`)\>NW7P@GQ,@ANIE7ETMAU5I'L8:0C^L<L8D8
MT;7()AU%^,HR`\#2U81CS@<Y$(9/(@R#(9I(\F8MJ:I_46>$_LZ]=A\#X#H0
M0L,J68V0E]7I/`M`Z=)B((W.XE2=VZJP+`H]LA3!#5V90*11C)$<Q/:Q(S$)
M$$%2M"Y5#$0`HX&/8K7C5D88_%R1QB6KDO)MJ#1N#]O7]IF3OU\Q/\Q/JPXJ
MI1D%"84KX[=`)CH(``(W$*%@\`OX>2MX4BN/^:PY6#DO*TWZN<\;&>XA?ZS1
MU8X3D0ZN:X79C4,C@K'69$#?2ZVKP(!(_3P/V>/^&&Y<',>34]#^J"0&F?EU
MGJ.GU;1L.4KP-M2UF68]K2_E16H20YOIFH-3C,-6D1[V^EBS3*Y3$1RM19#E
M]J.;^4K_`!LX4`JNX-LO4=/X[#I]G3^6/NLFUWR<3U*]WZ-$@]?@.1ZF?YCO
M(]0F+_&<.,L0T22P(TC%`C&IZ@JJM$$PW->&7Y-(,00O9X$\&L03PG47XIQ5
MR5(<.LF0?C\_E\R.G60RSS4TP75JVK>!Q(^`\`?`^`"D08`XE6X^FZRD!64U
MA*;+1L>*KBJU$"T4<7BURKY.*@A)'B06._I7P:T0R*Q&`&0%7?9-]8X;O]LD
M_P"DG[=R)EB&MCIXXMS"S:O?P@#]L"`OAL``T`(K)C_+BM*V:*3"$0YRF"0+
MQ/<Y7JJRGN>]WH,;VO,4JHJ,?X(\J((JDEPYRFT%"MAA0/[OF!TCQ'AN(1ZZ
M9-#"T65`ER01'Z_D3,SX&);RMRLJMJLQTJ7"@M:]L>1,8O\`S2#5P4F/5CA1
MWO!(E$`^44C/$PR$_NJQ["N>L8DR%`J.WBJGI\OCN!,#P(&T@@#D$R;3994@
M!XN_C&T[0-B2))$,"=X(8DUM;!H[$;5!7RE]$V.)@&!_'$`2B&-%&$7H>**Q
M6Q`C+_;]02!&CV*P(VK777UDS8NZ$SUG]>^_4D;R03!DG[RS$O7:BSRVJ(B`
M!`&P$0/I`.T*5$@A5!HD(#8<*^D1S"=$<G<81$3P"\KUD*QB#43`M'X)(]+7
M"0?C[VHUO:9$!)9S?'#`S\_V?K^$[_X3OY':&D559C(PX_`>$[_*(^KB"(CF
M('WM21+BI(*2RU@^R6\IU,4(_:]SR.(\S"1G1TDR7-5YE5Z-\R^;U>-2',\=
MM2FT%?2>``(G]V\P/#[($&%4&F[)QB'&13+$F2!/69D1)\=XDR97D[%<FIVC
M"650CXCOZFACR5B1"@D=E8@CB01(L@:E4:L&HW!D#548-X2M<V+(9'4?3NA_
MB1)D?+Q!^<R#X@B"ZF?(!OQIJ.\`P"#T@B(._A$,.BE6!%;BFU$H9@.K;!?!
M'A0+@/",#GC<(A&^2^J(U&+!CD<CD&%OBQZM:!HRQZR2Y2&]6OXS/7^_Q(\3
MU'U2&MAQK%=#1=XB(B-H)^`_E!,PH@&`@5DQY>C8V-;$\D*K#.+'&:4-Z/5W
ME)<(+WO`YSI)/,OFC@_\;C(YC3/F1YMUYY4B(D;P/U;]>G3Q^&_$(R1X@%>0
M9F"2)(^V!N.IWF1U+2`QM2V+;1OQS1+6&YLIK5$8!4>,Z.13C,+P:PA33BDD
M2!$:[W/>1ZC<(BG<`LZE+<@:GV^/AX1]@V!'2`)D<>02[)3@RY%7F&Q!Z^((
M\26,D&9))@JW,HUTU;Q)%E"B$AD9((@FO,P2A1"B\!/&_P`D)!0;A)%143RC
MB7UIXNC^$>1764NM3D/L)VF=OX_'YG?HTLMDF36]U2M49:-XC<0(_P`,1'Q5
M=A!2$>CS363_`!+6SFD>[NY&'>UQ5(BM()1.`:./LK'#)V<X(AO1I4((3V2X
MH:W5"?43I\/](/V>).X@D%':F+<8-%H)/QZSX1!`Z0=X`,-*J196LK4EC0+8
M[9T<\.3*[K%>;W*JMDG5Z-*GB]ZOERCHB.\2._*(YKVOD&5UM=<&LI!0@J.L
M?(?V`?+R@$0J_<QX[UTY!%JE;&Z3/B?'_>)^9YD@@NTY/N_:0<J+<07M3TC:
M]"H]I1^;)(48Y@T(P+6$)Z5_20UA7()6D&1L.6RF/!0TV>/]W^OPVWD$<T-<
MP%;%RJ3T'7J-B.GAN>/\T'RPRL*K!4K&,RPK/^5,%WI&CV`C>M@4<-Y&E'ZB
M*(2^KT/9ZBH$2(-R.]#6+^VQU,:[?,#OXG]/F-Q)W$<B?O<B]!=1]V1L.@B/
MGML-H(@\1L9X`'T)?-V"O8ZM,-WM$UY&,42HY44AW%]["A][S$DD,CWE%Y(1
M7C,Q3ND"EUR:X/J*=C_HZ08Z1L#T@@\0I2S`ND>@P/(?+YF9D3,EI)$S(8<R
MZV4^JERH$TRRXKP?FR4*26X1?Z'&*A/!'L>?Q<60K/U:][_<K$<\I'Q95E+:
MB6(.!!XCI(\!^KPGX;3``#)5!CV64VDV*1S,DP?$_KZF/$F8DLQKLOBZ**,*
MQYXA@8(AD,>41[4-[.P7-8X;W!CCBMC`&JJKF":V./R>!HH\FMMQG+362>0$
M`>'C^N9)^)W,!B66V[-K5"MJA0I,DGK.WAL`(`\0!Q$E0J645&Z8RSKB($B*
MX*$<2,Y1N]P1_DQR(0!$<T:.>T@W(8*M5$*,PFL_)#'CH)JL\PV/C^P]?V'8
M_`@D\6:;*5;Z3P.XZC;<"09!^<C=8^I64#U%23J;(YX\J#(]BDAA>X9'L.Z6
MQH^X9`3,(D^84@SG5._B>0BO5A&E>1'6M]U2JPL7HQ^4?*.@&WV#:00!%4>-
M>S(U+SR4=3/+;8@_4Q()^#-N0P8M.1+54G]ML9/YK`A:4+RLDHC`)ZQ_BN7U
M,8?MY&[QG.\3*\?B%?8\?X<OJZU?4J'IR2#TZ_'K]GF\(/FV!YIJS'L_#WMZ
MH`D3/3;;IOX^68:1Y?,1Z5NH]\V+'DU\UI/Q.Y#(<X_056B`)/>5X2M$$;HX
M@.&155HVA$Y"L&`3UJZ8Y=E9(Y;"!OX]/VS(\9.Q+$>K?F"NNQ+0>.YDB#L!
MN8,#8"#T`4'D%12<>;NH;+6"&0%[B&"AV(+NK_89R&%(CF82-*5I1JX['*H2
M*[R*,@B,)*C2+*']*PJWTF/V;0>H^7B/`@@A&63*J&12'4RPG;XG>09!W^H'
MRGJRLK`V(_BB++)$EPI#6MD#1WX[)(R,<C7,"US'^)Y4@BHXS/\`SRE;[!JA
M9"DCR9Z\('%B_2>L?K^0'[@-CLL,M=N&UC5M4X\XZ2/L^9)ZCQ)W'F?DEETG
M32G5?M!."^&R2YY0/>,,021P"8TSV&$<(T2,"()&M:7P$)HWC*R,P):^2Y/5
MAJS)'7J=STVCQ)/A),@@N2+(\:PX\I:"H;<3`$#KN"!L%$08``(85JK4^K8;
MH]X&693CCF&-RE"P(VJL9DACAO*Y!L_M!8_V^T;5]7N:K'`27'B4I/*@H(+#
M^V/XGI!ZQORX,]<E?3RQ8W((1X1X`^/R$S(Z<A!3U$K^W5628-D^(,YG/097
M.+)(8C1N:K6M:Q?S#$\"E<O]#"N\CO<B'<4X+13:$/IO`'V?ZA^V!L/I`5JF
M5CM8HNJ!)._4G;_Z(]2>@)EB0'+.F14X,DKZ<?X87E+'"R&>,B*`@G,&)&.C
ML$<S7.8A`D11E>PC5&X)%58IB16*!:>9@$R#U_;M]HW`C?D/K43U6,<8>D"6
M4<2.D;#I!/Q4[$@CB4;_`"V:E9NT`-`5K@!$]$(@I#'1V#<+T>UB,[)'CM:D
M:*JHC'#"X`D<-!!"YE5-DU,9MDGY;_']9ZGQDR8,L9MQ\'(18H*@'P(@"(GY
M#H/"%*@%0JJ1C2WI!4Z`2=GN`Y6(B#8-6(LM)K6L<,P?%J#\SKX(/R7^^C&_
MK-AONEKL<_XO[H^!^S>?\,GZ'%G%,;-'^#Y`>/+P(_WMH_QP/\VHQ[N"=DL5
MK7H\Z&>AVH!#R6^WLTZG8HG22M4SR(]/!SWN(]'B<Z21J6]M%BE#59M&W@/E
M'ATZ;^&QA1]S=ETN+!D4R9,[2?G(B3O,[29,J2Y'XF<L7.L:-AP>N3(<V&TG
MAX&(Y$<$HUBDBD``CT(@GM>$H6+XL<$PE;&D1K*P*[^+;+O_`&]9D_'J">LJ
M996EOF[$#I#/Y>FY\"(@@=8((*C8%76*W3U!-&M:U*Z1[FO&%C2!;Z1(HP>T
M?J_JCQ@.`<(2,_N!$WL(J.&!0G!7TL5J;?46(GK]OZR9!(.Q/406Y*UE:7KR
M*/0>9`W&PZ2(Z`00"-P.C`A.+I32Z1K8T^>(KGB(BL8Q'*U\CN2Q5C%1YT84
MAB2Y3O+^T1[S/(A!?D$D#LIKSRK4C<?NZ?+P@?$"`(/$*:L?$`2YU:0W[_J^
M>\DD^!)8M*\V=;]IF?HQB?\`UK?]W^Y/]R(G_P`A$3KE#UUZ$.@^S7KJFJZ=
M--.FFM!?N*RD4^'AV<3S27`Y3XJGQ2HH4#'DU\?63XYYBF>)$BL+%3R\7(Y7
M*B=T[KUZ![%J6[.:IXX-BW@_,$U@@?/?7CGYM7OC=I2^N?43N&(P.T`J+F!:
M8VD?'K&N3E[QYLHG(9]KBJ2<_/6U_&TM/=VMK!S-'>QFSWCG9F^N;$(JR0W'
MM<.IB0!Q6S'+%]AY!!.!Y>MT=QPF[<,+-=?Q"5E&55+LIC9T4>8>IO8SEN/F
MA5!#:^<LOLO=*^]MW3M53_@K+A:ECNM5=@Y0U5CL`I]':E*PG/R<G=E*3>')
M.?\`G^OOZ4O,&XUEY.HJNSCR<KPYBY$BR+G",@6((%AO;*'`C`K32)S?QY%,
M25&G$*4/]3`O?UA]MR/<-F.X[-13778ZD69%@`Y[@D5*22P`W%@5E`!ZD#6S
M[[A>S:<RH^YLO)MMIK8&K"H)8U'BP5LAE4!26\K4%EL)9=PI.LGW>^R&4QM*
M?BGC-@F92NE1:FTFZF]@Z:QP:U:FT\:5:U%;%M).DR4%2.CQV3H2-E(X`VL4
M(@]:NCM^9EYKKW;*DVL"RBM2@MY0A"LQ4)88D\6\OF),DZW^7WCMO;NUU/[=
MP`!CH0CM;8MK8_";0710YMI62JBQ(:44#BJZP':<B6FEQH"9<]-FX#*ZI'`@
MY6$[)2KZ#=5TY@:^4(T:!)L)U?3>+899$R<4I$,QP$8P[NN@J[=5C9I&4'ML
MY-)<^H%*D21!(`+?4`J@#B0TE1KCLCO61G]K!P#512$0*M*^B;%=6A2"%+,J
M?06>QB>0*0'.M=;:DGV]5:SQ-)+2#^%'L2"CR&$;"_?:EA)AV'*VQ`T(OT8U
M[R#$5JA<CB"[FZ.F^NFU*VVY25W'7BVPCRGYQ!(/(0#Y>)R<2[)Q[+EEN'$,
M0#/'U$EB">0`'0$D`C@99?/E3063V<@:J7!FCE`CY'&18UL"O/20D,"QOC.G
M38_[>LR21(I>Z>)'&D%*SLQY6A\-3CU@]OJ2Q88W6$J2&,%4V!F!O\H`!W`+
M3T.9>1WG)LJ8,HQJ`'"FM9#6'DPX\B8/Q+,2-BP2+^X^UE]+%^9J'MW5!$L(
MKAXW:!B:]91)UK4UT\0+"]1JQ`9K\[W2VQ)0!M*QPXXU:YGLU_<<3'0\,7[C
M(93]Y637$*S"0O7G$+R4F""QF8W'9NXYEB^KW`_B\-7$47A;I+.BL`UGTBKE
MR?@Z@$%46")RZ#DWB[7VJRKCC\MK0T9[(4N97:R!I(D_;LEQV:;+T4.<>)8T
MD6F4`IY7`L'0D0CQC0KW(9=0W:^ZX=7"G(X9%@6`:RA%4'@[$`ABTE!*<M@3
M`''73)W[V_W+(]3*PS9ATLP)6Y;0UX(]6JL,0R!(%AXV%-RJAB0VK-FY#Y?A
M\@UMAF.;IV/M\W=V]O,R?)%'>R(5?M6T=E;QB5G)65@S85.4[WK-*ZPBV3I+
MP$8,SE:U4S$S/=+]N:O*P5NIM15%E+*":^2J>5-A!:/I'!DB02!)UJK>V^P*
MN\UW]O[L^+DT6N[4Y-=A5;_39QQRJE94G_,)L2WD58*Q@:M/DKB'E0FRB4D'
M*V6B`D.LIH:X\T6YA:.TMY!I,I5T.6:&VR4F&"8P/JD3:N&IVM9*;ZWN:N9V
MSO':1A&^RU:VY,Q]0%2BJ`!Y+)6P$B9"NT24W&M=WWVU[A/=%Q*<>RY.*(OH
MD.MC.23]Y5#TE0P$,]2<H%@XDC6U?RK,<+FG04228UH+)<!2Z`,YE3%JX-D2
M)R)QBME8`K:]K0`B6MV^5+$UBHBLD([Q;Y=W\G[L0'LE=\%&N[@'CD6*S3?`
M).\JO%3\QUVV]$_+NPCW5=A\EL7&[.:PW`*K$9.+R8*NP5[.;@#P:8$[]J.O
M$M?5&G333IIITTUJ[]?.>/@7F$@WM&0?"O*)!O>B*QCV5]4YCWHYKVJUKD15
M16N14_U1?].NI]G`'W!A`[C\;1_%M>?_`)EDCV?W,C8CM67_`.%-<G-QOM+R
M4ZWEVUNEA=5L9D1:YQI$`EW1CBM),L8D?W`AQ;&L6$1YXT4+E<`:D<!J`D/?
MZW@=OQNV<%J3C0QF=CQ:=@3N2&D06/4QR\R@?.7=N\9_?3;;DV<\I%`XR5-E
M8'F91(`9>)+*H^D<B@X.3CFBBT>[K+3`:PD"H#I66*UVGMX%?H)]#>28!(L"
MQBNG$BN!6SJFW6(9HW-9*B/<B*I@B<+9WO?@6KW#$#.U42BDH'4&2IB9(9>0
MG=6`_E8SH\2O$[O19V;N)2I+^7&UU6QJ["I"L.1$*R/P8"`Z$_S*I7'M/I#<
M,[G0,T(*JLJOS=;<;Z`6-IZFV6JS=A$S_'UW2DF&L,U8?X_*EA-!,-PXLR)(
M1T<+E,KDV-V,.]8-9QR[7<:UJ,HR\G!>Y6@!QS`(8&65A#$<8UI<;.;VOW:\
M9JUIC\KGR%(M1^%3+7C6(6+5-Z9*M6P(1T:44\YUEO:0BT5FWD*IE'DC-7XJ
MEW1(6F:*JN\#5R(VRLN3:T"@,8UYFXT)CRM*PIW17JI6M]3ANT^"XOJ_IUP`
M(:UJI266U@:Q03(`5R=H('(;$S(Z3NM+8>1_6L9BRE*$R.-L)9CH1>V4H@DV
M5!02"&8J?,!Q*G)>DRD?*<0R>1)4<TW8ZJFF1LQ:B<48!XFZHI4R9H8<NK@Q
M1I<7N:G?A1W*@Y`:B,AGL=X-(FLQLMLOO`[<I"X=3@NOCZJL`$(8GRJXY'J#
M8>((F-;W.[<G;O;3=[=2_=,BIA4XD`4/66:P%%`YV5-P7HPI3D08##`7&%I'
M@ZGYOKYE%-LZ^YP-EFK.ODZM3P+JKOZK#P9H(@P20GI"!$OM`@W,>.4(".5J
M,<O70=SJ:S%[G8EBK8F0K@BN"K(UI!,B&GH9V*ENLC7'>W\A*>X=CIMI>RBW
M#:IE-TK8EB4*P`!!K(&ZQ!#A`8`.LT\V<<)@35])05%KJ*:6:!)SL:%%S:65
MS?DN+JGOY4<%M,:V$;,4%D*-9B"V2^%'@/:]4%((1-)V/N7]0#7WNE5R@AR2
M\*G%60$J-P[@E">/(L(W4#75>ZNQ_P!'9,7#JLR,5BIK"BKD]A=TL(#MY356
MP6T*&*+60?*Y.K6_!L.-\@8TZ8+7Z2%!T\2#<V]IG<Q8<D[:ADMNXLN5-*<4
MEE'1U05$B/[JT36A,-CI2.3+]2ON>8!6#3C,R$JJNXIJ<<2`.G)F,[>,D$A=
M:_T;NQ]L+6L,G.1+55W>NILJ^L\P2Q(/IUH(WZ`!6`-@.L,8FH#N94_2::8^
MWQ='80-!>1I6ZO[M]M8<@8T$Z=BJ@="ROIX8;"W$URM"^>.)#&XS6A>0*+NL
MZXX"KC8R\,VQ2BD5(O$56$"QN<L87X\"S$`\@&URW:L9>[V/G9[>KVJEULL!
MR++.;9%(9J$%?%%#.`?*;`B`L`I*ZO&WM])?Z&,]@`2)D^0CH@@3B5/9`PIB
MP8T)SU,M7GZ:NAMF#7R4<&'&<U%1$\UPJ:<;'QR"2$4;R.74B2?\3L3Q/BS$
M?9K9Y.5G9F:I"AK7;R@-PZ*W$+UX5HJ\QX5HI'A.MM.->4M)=S.)\-(GS+K.
MQ^;^,9H)]PH#Z"4D;3TSW6:GFR%L(%4MA(C#%%;[R-`K/8UA5D.!R7<^U8U"
M9>>JJF2<&\$+(02C>6`(+0"2VPF8)''EZ/V+W#G9=O;NTN[6X2]VQ6#/!L,6
MIYI8\E3D5`3S'C$@-S*=9.*6JWCS*M<BM<E<Y%145%1?RI'Z*B_JG7D?=O\`
MWC;_`+W]@U]'>W01V7'!Z\/[3K(76NUNM.FFG336.M^%YXX&#:$I%#)082M<
MY/8_P"UZIXRA_P!0BO8GE')W\E3L5JOC'V7;R%8DR!(W_?\`+Y>(_489=)WE
M2Z`+!,'8_'I\QT)'TGK_`#":WQI13@2@)6F:H)@F."H?)[726B<`BG:B2#E2
M3WD!<1B'*J^8B#*5I(TJ5M+T9&]1=T/C\.NW0;;&#`Z$$`AD70X=J6)Z+[6`
M1'QB#/4F=P2.1ZJ59@:[+(,.`*KMHXH\E@8TMA7+#4PQJU8H6N`)H6N"%X6Q
M1=Q*CQ^`!JSLT`A+55>PVU$L"6'C]IW,]>O7K),_43ZME5*X^2JHP",#Y9CH
M-A&PB!MN(41LBK^']6T29627W$#R(R03PG`)W7N@VG:1JHZ.Y[@*A#>3E$XD
M95)_;42RXK5+I:OHV=0-C^SY]>GC#;;SP;5<BNW'?\35)#'S`_K^73KU$KYO
M+Q]2L5`GHN((7A$<R>35:%7JD@,A[D&U7%(Z4QQ1&D(YSVN.]Z/[M]SRI^XQ
MCE2Y#$#^!'[NH'38?[H'W<S<,JD%03\O$'[=]P3N98F=N18>O*U3@OA1ZVP;
M_=_H>&,[LY&CCK$*!P21B^L3@*@2,]9_$;4&X1&B9&,"ZT,+#;7T\3]LSU^.
MX,C?>0265H\<H:EQ[_J\!]D$008$;$0T`<2K!0C+(/,E+8K^X#CMB%0+!R80
M&PV"%&8?U$,$:!&]`1(SF2!*-K6@$]Z-:%AP5MX'KU_=D\QX$SUCQWZDR#/4
M@3R*M;$6&+?]^%%1B"HB`)B0(&P!#"`.()`"AUHAVM5(2R_-C#?^,JAE#>)[
MS?WE*3W>MB-><3D<8I%[,+^I"*C7N++B6%U5J^EP;ZMQ\/#;Y>`'AT&XA'KL
MR,=_Q'JH#PV(C?>=X\1U)Z'JVQ+65WUEPS6U4&4(KF35`J@DM:HAR/-1>3U&
M"5)<@2D4;V/$8CVO]11$>KHYI,`(IM*,/).X^'[0/F((`B00/,JY1#9..+%,
M6QL>@/3X,=CL00Q,\64F4:SW`LAE\($OO'FL&QJC+X*K_1'`0C7O:.)#0BB&
MBHC5&-XA^;?6,:+7TLJ(^\3=)_B3]IZ_:03!DG[RZF\/%-GEN`^7@`=^B]/A
M`($CB%'H4:&*-4W)P#,3V.8T16$C-`SN<DE1!8+THUXRHI?%$`C$>T[&M:GY
MD1L[EKJ0Q&WVSTC?K]D[].)_P.<2I:\;***3/0R(ZD[1'0[QY8D.`!][6/=E
M6RZV8EI6N5SU([W#)Y$1ZE*JO9ZF^^09A''52-:A"*1ZE&KY!',MJ56I:GI6
M](V_4/U#PV.PC8PHFFZ^BVBW\11UG<=>IZ1N3UWZF3R$NQ&35ICR3J=4CQ/`
MI8PI(XZ^!'@<)T4P7`]$@+"/:Y@GA>PXE5K1O&5O:,<4*`)=YCL"1/QZC>1]
MH((/B"/J4Y-I-V+Y%ABH('PB"(@@?`J0PVXD,(1U5UC%F@6'(:(4AJO`:&YR
MD;XC&3N_W.&$)0E;&*K2>(FJT3VJP:!,*O65NC<UW7J#_H^.XVWZC<\E-E*+
MZ[4-3P'W!7]1\8`(,'>`(#`A>++31HP/VFU)'D.]U>=)2#(42N>0SW$:5AV(
M,KGRO9),-W<3_>1Y$1GO?*!/G9O6JY+M8(_3[-@>H@1OQ"M7BUI^'R.%AFDS
MN1U.\SL=]V'0\B3`YFQ+O5W',TD>S"])`543A%8I7E5KD8>.C2@>1WBPS@J'
MP(KGO<)PR+(6.>:H80:FV;X?N/[IF1L)D<>2I=EHTKD*94Q!\?B-Q\^/&#))
M4AN?![9XS7W52U6.#V>URCD1U0HVA8&,;Q<KT@H]7>A&N0*B:B#:J$CH-CZZ
M-8HN\?L/ZQ\_CXSUZ-)%DK@Y>-(C[1OM`/CQ^$;0-AYDX@T>:202$Y:F<Q0'
M0YD$AGJXA_)LIY.[/QD`T;D$;^M6,855*CQ->DN,->H<>M7NL#IX=/G/P\3&
MT&.#&F*YJ_X>[9I,3U/6?"(V;>`#Y@5!]2L2CWBJKXKT"H?R0N8)[T*HW'D2
M?8\CV@0YWOE2S)XM13*207MV_(,W]UO`-M`WF#^X#YP-@/E`'^$?=1L5Q\PF
M(Y#;KU)F=I.Y/^U+&/K;_B(=U5K(<MI6/4ON:ABJ%S4"02L`3V"(&3'8CFMB
MA<[Q.SV>(7-*,C(<L-:;>(]*W:/C^OX@_$^!CS;$%T:W*Q_4/XC'WG<QT(VW
MD$?!9AA,*0RL*K%JP&Q[*H'$\8W@@0?DQ!>/K;':U_F-B.CQ`KW&!Z)W")C$
M8YKF!1A&0(FY57%]YDP3\?VD^(\3\9:0;,E.%^,*O+'$2!\-]N@'0'^4`000
MD,*:90V2J4U?)`8OFIF(]6/DD(YA9*2QSWOCODE/Y%*U5>-SE>I!$$LAQA3Y
M<BO86*0/W?"(WCX=#T@@\0#7CX=Y+&FP$S(^,[F>6TD[D;@F>2LO,LMT$8BT
MEP2409%BG-X-D.(G=WY3P/1&E&9[GN(8HU:Y7JI'H/R<IG1I4ZI(OIX`CD!T
M^R?E\`?#;>!')$M"MB9)L()K)Z_;'B#\2(WW/&3R-=EL>ZK(BQ6V,)@4&/Q*
M=PWB&PL<;!H]?:]X(D=HHT,;?ZGB"K!,17"00#UEM%K\O2LF3T^W]Y.Y/0$[
MG8RRVWY6/7P]>H"!N8C<1\=@("CJ0(`W4*CT1W#_`'FE$'VL/($GBK3=GF>Y
MHY8)$0CID0#6G\&G"1)`.SO$K#A:BR0#MGT;R8A3\.G4$'8G;H1!^!4_2QO(
M_$XH20U@^/4]01Y@-_J4\E\&#J/O$$*EF&*=U5.CE(UR.=&22V20BB"XHB-(
MTR',;N<JM<1RE(I2^!/:4C"6MUZ!5]6L@'QB/E]@&WAL($B`"*K,6UV?\/:I
M(/29Z"1T,D[GKN9,'DS!LB&&:.GMI/Y$5(D:2QGXQ1N>P9$"0`FR4<0K6(U[
M6A\R,(/U^(7*11?ARF5*&ZD<3R8=1^W;^,"#/F$3S0T2U<;);FO%&&Q'0Q`G
MKX^62"(A3/'TK!YO(X7-CV%=_0K'%,0O]@(T1L=4<KV211V#_&BQ'#?[&L`,
M(U&9@PC(E8H9@37;]GB?'Y3U)D1)),J2Q'JTRT4A;J?`DD[`=/F!$!2#("A1
M#!5!]"=G"705P5`BDD#>5_@1K8[5.K9`3QGBD@DF$9"/>)6O$7_O7L*(J$D1
MY5E9_#V'ELO[?A!V($=#L1T!!$*R2W*<V@%-W$]=M]P1!!(,R((/4AE;DZ6?
M*,_XGE4RF*^6PZE8Y/[C'L?^,-I!G:604BB4PV+W*4S'$$U"E\XTF:O7G]\O
MT1_?X;?`^`!@F!#*C$;TC^'L$V!I^/P$@R3X@=2P)4<FFNRV'&L(]5(DPYC&
MQ`J5Q6F"J>AH"M%ZRF,QXG`;$C!$U?ZV,$%C2->V.,9:ZK5M<H=#R,=/&?L\
M9)/AN2006)%E*[DQW:JT<5F9'2#&Y.T0`/$`*`P(0*U$KH(:N)^>$K/%6+X,
M<K6$1[6G"][T/&_4*"9(8_V@5J,4C'C<!9<4-^.^WID?IM\#]D0?@00W!FBS
M:I;UE.T;?O!.XZ1R!E8CD"I0V5I,S8_[Q!@OA.D25&H@%&]3&EQ3$(#VE(SW
MR7.E-_(7OY*<KD*JL]ZD>.TL1O1L8/`\?D1O\AMM\AMOQ@&J2U/Q-2-5+1`/
M4D$Q).YWW_VCOMSY$9"BD^07UY@D:V"1S'$]3&##Y,"D4C7B*YT0K$:)6N:9
M[6M43Q&42PY+%Z[^H#NP_P!?VCKX?$$3S4L.R5]%@80]8Z=(.QV/2(8P.)5B
MOI.)>MG-IS/@2HJ10F,0;4"-$2.UOM1K?)JM8X8HP_\`@1!L'&$I&H(`BAJK
M[*_67U$,L!^W]#X[DDP98@VV46C&<TV+Q0GP'3K^X`=-@%'(!45EQYFTJ@*:
M*4)%8)3H,SHHV>X#F+*[E81[7L7UL,5OK43G]W%1PR^V7%F656MQ(8;QX^/3
M^X;S'T[B$=+\C'3FK*87EO'41._ZI.T$[M*MRMKMG;>&MI$#(BN<^2%S7#<U
MST4RH4+T1RC*YQ&))5CV/&]SVO<P@B$<X3YUE+^DY5_I/[NO]FQ!$=00!(KF
MR:OQ%0>OZQ^_<?`[[P0020892Q*FZ%3RIIHDV)(8HID0;?2\HP^EOD!OH561
MS148K?0Q_P#008E&C'B((31+7W7+6KJZ[H3OU^._4'XQN">H()GU+<:RUZGJ
M<18HVD".FW0B.@.Q`B"I50OHTZE*E7,D0K)BQI1!M&SNYCAN8-9B('P''8WS
M(@S>E'!&-PF&1HA=I<2-)>/5K#U;J/\`1\_LG<F8W/D=H,1ACVM7?Y;#_P#I
M;;#QAHD`$!H5?O*TBW,1!GCV$-Q%"`S@RP!&5#-(.7_=(Q6HZ5(D$E2E16_W
M9"D>KA>TA""M;:7)4UO$D2">G3]@$#Y"-C``-5V55#+=7/$&"`#.QW(\29/3
M=I,KR8LN1'L(H;X89%=(B*L4;6^2/*GJ81@)8"#=$(TJC_ICE"K"IY?VBB*U
M[(LCJE;MCDK:&W_T@S/ZP9'Q!!!9=77UKEJ'H9?*/GL#!!$&8^DB#_A96!%;
MZ]9LAFPBP7C4/XPRJGM3Q8/V>:-8UB.BC''&,2]T&,`/!JHC0-84%93)`]06
M=9/Z?'?[23\V)#6UP2XJ-)$<0>OS_9L`/`*L3`0!DQZ97SC4D@T:8.1^(IG`
M>KAM<K#><EQ7M1H'O4IO<17"5CGE<I447Y"RHLJ2RL7J&0CE$_JV^?A`WZ#;
M?CQ9(*+FQ7*6@^E,?KWD].IDR()/F''F;*[/=\/_`)J)8>O\F&1XC-E15(A7
M>\D<D03"C.1Y"K)<PP%&]Q"$>Q1D_(=')8L<^0U]'$['Y3.T=(D&=@)D<0PJ
MKEK]XMT<JC!D3.Y$"03O,%8,DD0W,HU];G18MW#!(B$`1XV(^-+17(C0/&Q[
MD3TOC^8'>@3O!'B1JB8YA`^H!X,%;-0Y5P0#U'Z3ON?CU((,LMF7;77EUAZB
M"1T;Y1\B-M@8D=`0R\4>FG5DYS@2:BR,)LEOL@,"7UE]O8$X#P(C61`D[MC%
M9Y*T32N85CQ">V5&CR6H`PNJ'EZS^L&?'X@^,2#)!1F@HME&QKR.?TP8,[,(
MZ`>!'@##`JI%E=<E!=,JK`466+NTW:+[2*Y5012D*Y?-HI!9)CR)'BCR>UY'
MD5J^4I[DMI'"6UET/3?].D0!X1$3L@^YBI-N/>$M&QVD_`F>L$DDGJ9))(WL
M)_$U&R:\-A66@?R0L8-CI"B(/TC:18RB&QWO8U'2G/$B]GN&]4"Y'M>D.2D=
M1!J>IH)G;]_R\-_"1YMB.:ZGO!6Y,A.0$;P=MX@=?';H8/E((/I6:G+!HK.L
ME-KG"D.[*_\`3U?U-3NXH6H9L:.O=D51JQZA&C1.8JA8-W[='7-5H]21^G7Q
M/C,[G>?,3]Y+<%OQV%$,?U?K&\#PB#`V(E0I]"D4C!RH5K7J1?>89&&KS>M[
M7$<^4&3(&V5"*KF'.\K#C>%WB7VH4*%?*%)FO)1TL\!T(_5`V/@(((/2(:`A
M7&Q0ME5E,^8@RICKN"=U/4R&!4P>7).1L5_-8IZ0Q72/R6Q9)P,8Y6$>]\G^
MDJJC6OFG]Y"E&Q'J5Q2%>Q'.(=X9-C6T+>H"QR`/[/W".IZ0`#T4,M=*.>*Y
M+\O38C]NQ_VC,D"9))(!)<I9?'G-_;Y0K>$(*UQHS&3#(O\`2B.4/B92O*%L
M<WA%"K3-,(:>D:%<,;(\FOMK^\0TN3Z@.P_;^WJ=H)W,`DLMEUP]"P9-0'H%
M1)_9O,B#LOFD#RJ&*J$>F?L8H=!":^.82B&Y_@I(J>QBH.4";%=^0P#!N5$>
M,H2A0?\`;*,HFM0X8T=;MCO#`R?G]D':?M!!G<$'Z6:>^M<RJ4(XC_9WZ$,-
MX`\0RD1LRLH'-*Y"F])8$FIER&C.4YVHP:%<9[#&1A7O0OY/Y+R2B.15,PI%
M<7L5)!#.=:272+!:@V`'V;?LC;X$#;;B%'I08O%J6Q[&AR3TF=SN=YF3_B!,
MF&#LQ.1*PS'HISHTLJ_AN_H$\2B<%SO^6,-S7.D.*UCW$`WVJ=5&BC1Q'(L.
M8M[JM]?)!Y_W^(^$?':-]]OK34=3/AV^G8?NO"(CP(\9\5$\MO*"2/2MU]MA
M3:^6ZP&-(\</^L@?XY!M:87D4SG&]#8XV-BH-SG((;0B[/\`7%9_[(I2:[$]
M,[L?#?P_;/6?$R=I<_?5R%MIM-P'%!XB/$;G>(B(DP`HWBL?\-7)2UUK'<_^
MR7TJA):&CJXK!";,#)"016(]I&^\XB,<-_92$843D?(CG@7U*6C<3TW\3!'3
M[`1N.@((A67+L-&0AZ&-S(W`'($$'QW8$0>K!E,NCT^I.&76O@MEH6<2,9P@
M?WT.%.Z"5@BJLLQ3-;($JN:2214.-WL/[0GL)+E*6>I$(#UV@_PVV/@!L=EA
MEK@QG2R@TAIM*F!O(\-CYB3N.A8^93+\E>ZEPAS::4)#17CCO.%`E&[P16,&
M[UA#X2!B]"!`U%[.08F#&[V-C-C2*V:PI<A@^:#/]_3KO]ID[%BRVP5+;BVC
MDI"$B"/LZ#>(@#Q@`+Y@@K>B;NH\V/-6R8-[(@$:[S81/,2*PZGD%8\+4$T2
M>X;_`"&C1C1S2-_'_*CP[*61D],_6?\`1`Z_81ON8CS<6>3+2U+O7`(J'P.X
MZR3MM&X.T`2".'J)5-V)!6E6Z1V<1XHZ%<%PS))`=SR-0RD<R7(<1%.YCVH&
M2\CC._I/[7CL;*P:K>/@3^H_+P'A/4`1U6`:Y+F7(Q^?4A9B#(,G?Q,[D$0Q
M,G9^16^6J'`F5J0'R`A(U55$(Y_O1@4B'"X1@3$4+1J43QH.2_\`H]1!'<Q8
MTA]UW)+/4`)'[MY!V(W\09`WD%0>2BS&*64>D6`;]^T$00VW4$0QVXE7(]-S
M+Q5/GY[0D7_DU1XU>WP''?$&WN(I`>(A1AQ`C7^EOK8(8U\$'%8]M1<W'(KY
M#Z_WS_;)^TDG>7(]:ROEA7<6_P`KI/00.A(V```\(``V`K!&,MFEJ[0<U&E:
M"2J^;V=WN*]&G<0!44#_``,UQ#+ZU$]Z-<;Q81'381E,6U<-N0_T;C?IT\?A
MN/(X9`;'R!:)X']_78[==VV@G=H!FVIJM9H*X@NF0>\DP&N&K0D,XPRN01D[
M)'<8YR>PXB,<QQ'.0C2#<9Q!K80U32_%]E/Q_P!,`="#TZ$'B`?3R;^.35ZM
M7F<?"9!Z^$DF2"(DF0REBRF^#6_AV-$.O"\+BC"UKFN[*L9C"`D`,%X9`A#"
MC&A(!X#A$C&L<!XF"`2)=;SJO-C`P3^WJ#,CKU!!!,SR!)8/91Z=^(*4(Y`?
MLZ$$00(^DJ58"`"A4*C5R]1,/63%IY0ABCL0J(I&,$]O;W*QR]A!C*-XA&16
M^L8B-816,8T<J)!NN06IZR'S?I^OX>)(VDF4>RS&L?'M_#6`!!/R^/R`C9O`
M`PT``65TRQCR:BS,3U2'A+))_<]?;\Q#N,5D5C6`E*\;C3GJJM$0I2/)XL))
M><%G<JI=4!(D#]D>/4>`^,`1)"A6JC9WQKRT,5+']<R8Z'Q8GH226@%RZ9$[
M<5@Y+1V4+L_P"IGL$YY'G\'1RC-$4<AIC>)G!)W857/<HB!+[5CGDV4VE?NG
MVWC?PZ]=H^(W'Q!$<E67*H6P"^K?:=O'H01O)W@[&2>+*W+@]GN8Z%;5I?P4
M'**$86J)G9'JKHXU&]HD_!"0:Q8:*SL^.-%#_P`8$`TE;1/4IM'J;`_W_K\3
MOL3OT;D1;6TU9-!]&&8`;?JV_P`((A=MU'EZIP#4?::9.:4E7-'W,(!'?WO!
M_P#4A90V^Y7B;YJY6O9_6%B/1I4>(;VRXJ+DKCU4/E)\/U=/W="8V@D%&U7%
MMM#''M'F`\8^)&^WVC=1,,"H(LKU*P9AJR>2NGN:J%,1?8][G(0KCJX*M()3
MG\I,J6B>3T*1YBH,GG((PEO?8BVUBROX?NC]0V`\($"1"@BF.FUJ+C3=T)Z_
M.=MQ)W+=3)+-Q,NP;)]6,`5=.BV3"H!AI:>TA58\;?;^.="]@JQ!C9Z0(CO-
M6/1H'*1BCB3`4KL:Q#41)`_O']_V>;8RZ-6ZI:+5O!@%MYZ;P9VZ=%WF#"'D
M.-=J+JN%.&,U9%&9[C/68J-#Y/:H",[E;+&,:`],<@G>34%XB]11C$-_[8HL
M*&+3`C;]OA'C)!^.\@DD>JRJ%N4-0H)GS=/@>LQM`(W$0.+`*I_#[-!_[H7_
M`/;9_M[_`/FI_M\R]_\`[)W_`)5_UZY=OJ/VZ[Y?I'V?I\=1.J:KITTTZ::T
M3^T=+:8['!TU/+'$G4W)'%\D9BQ8,I$"2-KHTL<>-90YL&9-E1#/$$3Q/1QG
M,3LBJCD[WV3C59F8<6X36^->.I'C61)4@@`@$D$;3KR'\T\[([9VP9^*P6ZK
M.Q""0IV(N!`#*RLQ!(4$'S$:Y&;R]L=)82=CH;A3D*R%5WH?S+6UE!ER+*1*
MS[:<MI((;]OLA)[1?U/]?K+!*J%2*KO7\#'JQJQAXZ0!+)LJB`H#\N(ZCH>D
MR+!MSU\V=XS+\^]NYYMLL>*6#D[D$L37P+&>+#<=8AJF\WIS."H*?E6H;F9,
MJ$';99:^5B"FK&3)L]E-8K-E8A_ND1B.BVTLKID`1'.6+8,0;&,;))VL.1=V
MF[\2H8X-LBV&@#D(%O0[J/*Y'U(9)/$:E7#Q?<.+^`=D7NV/Q-!*`LP1N1HW
M(V<DO6#]%@@`"QM8SXGW4/)ME8;5FKZ.GM8><A58DD:FOMZ/DG8A?>%EGBWO
MY,B)$MXH71949)!SA,@U(HFC*WK:=VP'RR,_$#67HSEMJRK4U^6`4@$J3R4P
M`1,22#K0^W.[U=N#=H[B4JQ;%J5!-JO7E7#U)(LD@.`4=>3,ICEQ"L-7U=U<
M_%WZWL:4^#G-Q8:&3I(4C1E?'RFYL`ER>1960FP#QST^EG3"B9'0/J61W&JM
M8T:.U]%M>;C^@PY9-"H$(3>RI?O+.1D$,@`,S,;[DG6WRL>[M>9^+1BF#EO8
M;5-IBG(8&FG@O$@I:S$!>,<I78`3<_T)GQ<>\>RJ:J@.%=:FTA%W-Q%.=K11
M:?74#ZW-1)"Q(P%>2P>&7;2(S_02T,T+V-:!WCB^W<ANX]Q%UK`TU(?24@=6
MK?DY$D])6L$2$!8$\AK/]Z82]E[*V+CH1E9%BG(<$[!+J^-0,`;MQ>YE/$VL
M%(`0PXW!0Z3F3=<?ZLUK44.KR-"KI8I\:TFY^562-E94VCJU=(8KY%6$+@2$
M8U_E'4ST7R1C>G<FOQNRT=QQ`CY%5S[05#AA6&1MNC=1,;\1TG3L28>=[GR^
MS=Q-E6'D8U?F#!VK*F]DL3?J@'%HGR\CU@:<DXF_J=!78.NK?VH[JNT@U>HA
M'HK.3@,O:1JBXB[*9,E25D7=19FKR"JY!`1D//>O@JF&URNV9V/;CMGV-S7F
MI9#R46NI936`!"LH(+@$PG7RF-.^]IS,;,3L]*>FYK=4M4UL<>IPCBYB3-B,
M5(J8JO*P[>90=4;47@<%207T0X;)A(V8D?LQ-'2Y8M)EKO\`'S^HU<M\Y?&=
M<WME-)ZR.<1RF>4PGL4;!K/BT-GWM^(G@"XY<&LY6++I6(Z*H`D;;0I!DG6+
MW#+3LV*AQ`HM*U'AZJ5&NIXKMN/+ZGL9C!W\Q9E(*A=6IB:)<[6QMCH3PK.3
M!FVN0PP+'27&AL27V+TMP#_-;%3L@Q#Q***8H(SA@<LFP8T2&-'@D8N7G7_B
M;3A8P9595LM(147A8BGTA$D%R`6D[(2>*M8#K7=IQ#A4+W/-*66(STT!K7L;
MU*+7'KM/$$5@E5(7S6`+R=*6!E:V9:CNQ6<"P-`C1FKI)]W&"^-8U`A/]L^\
M?)@$+.FVZGEPQ,`A1.ES9,9BKV>I1W6I4:#58H9CY`IW#?!8.P6`Q)@\55CX
M0;*+<@98R*7*5K]ZU@$,@F6LE269Y*`+(YNU8.Q++O=\]\B:;D'5:$.D/$*/
M.<+ZFNI6,=7V%K`JC<B<2M%%O+H;_P!XNYZ.@KY&.A!>QI&B<UC4;UP7N+MN
M+V[$K.,&!LS:RW4*6%.1NJ_2HWZ"#$2)WUZ[[+[WG]Z[A>N<RD4=KM5/I9U0
MY.'`L<>>QO+U:1/(*0!&NSW7BNOJ73IIITTTZ::U:^PBB#P'S(0R*H1\)<JE
M*B(Y>XA5E6\J=V_Z*K$7M^J?]G75>S@3[@P@O7\=1_XFUY[^9K*OL[N;/]([
M5ED_8$2?W:XB:JYF,G#F4LYBV-@8=C33:J9^[PI_Y8(UO738\:ND#CE'*)%&
MXP#27CEAD$8Y$:56N]SQ*4-?"Y?NU$,&'$B"5()83M)@@`J0#U&WRAW#)M%P
MMQ'^_<AD9&YJT@.K`*0#)`+*6(=68'9H,@L-L&:W;5C'!STF<R`2MB3!,_8K
MZ.X=H"DDK6U*PP,/43R&K(S5(KJ_P5Y/,,M4OYFQ/P-N^0%F2#YD/E+#DTF&
M`#MMYY@0R:A-0IM_JN.(PF?CQ5A]W8/.*SQ3B)1BU2[_`'<296R+]OLA-Y0H
M`0*E^H/R!0UD:NC0P6T2J#MLG6Z?]^N\A-22V?6VEQ40H!253Y"$>01'PQN5
MRB:+`Q\Q.UY!LM](=OL8DDJ6-5C)Q6P1#*K$@61$$!SM).XR^VV^X,,4XYR#
MWFFL*%#A!?2MOJ64M/)7=%4FHM)()K4SQ"U_Y;D2=K)OX^ED,!Q5C'7&_P!;
MK-#;9YT?-4NST<P[^/HI:Q#1UAZ"OA1W#&QI'O?.(K/)YG/'C>ZE7!6ML83W
M:[C576BO+M6@'JGEO*$F28$()@+!S/R^=^ZV7)GL![=Q>>1==8]<55WVL?PP
M*R.-BJL`22;&B2Q(IW+')=+RJVUG5LIV?RL:AFV-%2:E)_\`RE,&/#:[2C$,
MC9=76#S]W&2,XCZV/"#ZA!<5HO>&7M/;+^TE$M'J99L"LR1NQ)\GP9N:F8YE
MC),$\3#[C[[B^X19;0QI[<M+-6EO+9`!]Z`/,B"NQ>))J5%XJI8+S7$N;KH]
MC<<#?MQ\F4T3C.;(ECKBI0S(4PE/B:]2W%FXD1\F8LN2KF=CB1"M<J^3'.`3
M;Y-C5TY_JBX*V4`.7G!'*T^5=X$#X':/$<AS>#2EV3V<4'&+K@,2%/ILK<*%
MEWD2TF1YAO)W!*-T(Q6ESW-%*O'5_=5-AR]0P;N_H+.;!9<.FT,FFK:[31,P
M6?"#(-<7F<G14D$@ND@F1W@<,\@C3]_.\W&R>R7_`-2QT=>SV,J.H/&'#$H7
M@P%5PT!^)4A@54<=>T]JS\+W3B_T3,MK?W+2CV5LRA^5915M6HLH)>RIDY&O
MDKJ4*NY#ZT&("[Y$W%%';51A0Z.TA2:V/=X"K]6(SE8':YWD29>W4FRL*P2Q
MI=5'G2Y@Q&DG9+8QC3J00V^@!J.W8-C<SSL0@E;6^]=C6](50H;<,5520HXD
MGC!)\<9,OO?=J4%:BJJQ2H?'2**D%]>2UCEF4045W<!F8.``\JHN&PF0(]!5
M8?-CE?XYFJ><.GES"P4-,/(CPJ69<7=%$="CP+BXM4]RMC^H<8?I`+N,8V)C
MUI8V0^=DD?B;7'("=@"6"JYDE57:3)8RQW).LVZVE,.OM."&_`T5,$)*RQ(6
MMGLK'$*[OYH6`@XHOE4#5*E`!5#)!BQWR;*WAC2V@G]K1)E'QARZC//_`#&S
M(I)6CH\_&+.&I02X?D*,BL<>2Q959KB+',5HWE(Z^I,,^T&$=V"F"K;MOQ4Z
MQK%3&!IK4M?:OG4S_DP"E>_($VUUJ;!*NDJDCFXUG;BVO'&Y`X6E2YZ0YTOF
M+C(`:@JD;.E3@6<*TT"OB";*C`A!FVCRF.XS$_*4(?U(1K5T/=;"W;LY$647
M"O);P`*E4WV))"P!'T\CT!UU_M^A:^]=JLL<+:W<\4!#/(L&5[-A("AG)9I'
MGXKN6`/:_BXIC<?Y<DASWF=7?UN?^CE[2#M;W_1/]&HG7B'=0!W"T+TY?V#7
MU7[?9F[-CL^[</[3J_NM?K<Z=--.FFL9<@60X,FG$?P:"2*Q0A".>-C$&,3W
MI['!_':Q`(\A>YFN:$;GJQ1,(:-M.WU&Q'*_4"/T^/6`-NI`F2%;0=ZO6JRI
M7C@P:29'0#QB.DD[@A021Q#,F*):K6W$2;*&^1"(GBR0%G]XB%64X;)(T"53
MRP/.9?!6.*9'%\$<1\J)-VZ?>4E%,./`]-HZ;[`P-^@VG8(Z<[9]SDK;8":C
MXCJ9F)$&2);:"6EH!)LKMKUK7I910GB.:XXW1SP3B(]6%;YA(-2D:8A"M0A!
MD&1A'&&]S'L>][A$F8]5OI.0_P!)D$?M_P!(((@B00!(3,R*1?6'K^H05(/7
MI$F9/4$$$D$@@DE6M@P33K"O?'.5D:?&7Q*][$;W8P;5`22P)(PD&]HV*JB>
M(11#1XW`8T;H%;%2NSDHFL_H8F?GU!()@AB3ZEE36W4\&,7+U_9M,0/`;@@$
M"04`4TRU1)-#.E=:-%'>.,@!JK!()5]TSL`Q6L$%"/&TWAY1QM,Q"(HQJV5$
M#?<H=?4JW!/]VX\?AXF#&YE':S&=JG]#(A2!`Z1U;8F`)B8E1(Y2JQ96GN:Q
MT*X%8#$=XB@.CO/W'&V5W8J+%`%\B4I3$.B^M6&5Y7N5GD<CFVMM9#TFLD2"
M/@-OF=AM'61L-X4?=5M!JR1<`2I!^)$_("3)GI!DDQ+L1D09*MO:XDNK7S(Y
M0)(BD)YNCO8L:2*1#<&4T32N8P!&%`=GM$@7B.QS8LEER_<6!+>F\'X]1!D?
M:""#!D%2"RFRR,RDVX_U;2#X1!!6#$QQ(*L)'$JX(K<3E8QIH!:^0YKUBJ^/
M-@N03?[2)(:J-(W\0:A-Z7?W$8$*-"]OK`QA!5]EI*V"Q?'<']GV]/AN=P98
MD&R7'`:DT/OQV9=NF_CL(,'>%7RD<4`9:(<`QZLC(4YCF1SE,",=SAE$LKWG
M0D8KF`10R"H9ZHCQ*\[WD1PW&><$NZP+:/4KW8"2/E`WZ].GCL(WXA62E+/C
MMZ5PA"2`=HF3L=MB9/42Q+2I8NEDG(::GG-EN"V?">1&]W*IIPFJ\!F-1ZF*
MOY0SF&03O)SY"E8BO4[HYK"Y2MR<)XO^P?PZ1(/P@[<>2UQ.&QKO5CG5/VL-
MP?B=Y((ZEI&_,HUU3L8$&[@BD1RA5$![(DIG;UH!&C=X>+2QV-C(V.Q7,1X4
M9ZF.:0/I":!'7991858'KN/G^_??KO,F0TLMD]U-674'0B(\I'2/VC;82)6(
M!#+Q5J?+T%:T[A',J#0#1J<:N55F-$8)8[VS01F2V>7N"41@HUZ>QA&-5)(`
M!-5LJ-YZ?+K.Q,>!!!^!!^EF-&1C<7/EX]?G!!'F`G^92&6#Y@0(L1):!+DP
M)0:ZQ3R(UK&"FN>92$=)>WN)SG/.^0U)LCQ8<BE*Y[U8_P!AS-6UNL1;%-E?
M3X;>'[(V&X$#Q$*OW4=-CTV"B_K`AMY,^'B3YC`8R23!EV!R)1$_:KH\V6@@
MB<PSXIFN"Q3/(RN:I1#!)0SV/)^/W<A?Z7>MSGN[0Y?5_P#FT!$DGQ&^W7XC
M[?#XB/K340_X?*-ED!2#!VW^G<09Z\?';RDDQ5;J;N8([.N2;#]788R2%4K&
M1U,)0>,EBDE-BC&P46.K%$7U`\!.8]`L'WK;*7-5G!Y^'Q\=ND^)ZB3N".1/
MWLN54N11ZM4;`G?:1&^Y@"`(@PL`@\0OW$*&1MO`4`$4,D)7+85I_>2-9L>X
M@937)*$60U2O0J*UPU>*0XHSA>I)`9-S@TV<FW4C9A$KXCIM\/&"(*D0K+;6
MPR:>";6`^93,/X'J"=]^HD-R#J>3K9]J1RJ@[Q'1R#G*TP6>TQ2?D(C%:GBP
MTES2O(<'>1[2N5[F-4ABJ&5/I<5N65ZKMT\/W?`[0/'91R2MCBS%?B_TON-R
M3/[3O)7S2QD@%F8K9=\GFET]DZP5C),<X6C1BF:Q(\8/K*]@S/>`+&>J.PB%
M1PQC\!H1[`M!(K:UJEU?IC9@?VD_M^,1N3)@%BRV+GLQ;_6(#(1'7H!!V.PZ
M`&9`$+)"!'HJ<YE?:U<B3[/["1I"N>Y&,42QQS&ECRH\P8XXU"[W,,(XF-[-
M(P@VM;(`&*LV56A?YI'[XW!&_P`""#\"#)5FGN%&1CFR?+Q/ZH!D$,`!'F#!
M@!]08`!T62K#1Y=6RKDR""DJPK2.8?S.U6G0B%0K_P`@KWM-):CV%_(>I">)
M%D/,JV=]JLEOJJ`5V\-NGZO`;1&PD<0OW45#)90,=V(L@]#OUZSN>I$@\C)A
MBY:;X<`MA5S?QIR-_!1Y%%.3UH)!E]4@;_R4,TK(Z>L;D[$5P7H)OL5BQ):5
ML%=J<J_\SX?NZ?'KX;B=IYIJVEKL>[T[H]+P;:-X(WF8Z'K(/$<H]*S4E9Q;
M,,Q]D@AA\'B>,C'11^*>APE1/'P&I71XRM*Y[&A:,2H]6QF._:)*FJ9/2DG]
MOQ_O.T&9.TL1ZT>0F0MIO@""-]AX1]DP(,@"!O%8/X:M2R"NH#EC#":0$CRL
M#+9X/1PWR8TEKT*,CXI">PPWM((G9SWL*$GG(CR8$#46>8D*=MOU$=.O@=B/
M`@B%9<JPKE4^0`V`S#;>)!Z@Q/F!E3U(93+I9+1)S;2$^J]AHUBHW,=Y^]"N
M5KP$*Y%;)D26$860/NB%*Y'/$]'E::.:?<]9J?UMC7/R^?R`\#X#H1`AA797
M<,BK\-)6^(\9\)\29DCQ)W4RP9&NIM0`M58L$4B?BE<@?(!!,8IA1AD$CQB.
MQGHCQPM1RL>Q@FA9V=^,*.2LEN9;JR0/./C]N_AU)^(WD[<BPMQ\5&Q[PK'[
MLF-HZP(V!Z``3!``4;^FJ-1&L&SJN;^[A(Z0-6-9,%,5B(P3TDM43VN"UPP^
ML15<J`;^,OL\A^E)4:+;64M3T6$'P(_5\^O3QWV@\N+-=>+<>W\2IY+'F!^!
MG;IL(!_E''S>7AZB5Q[@@KBL27$88Y`2'>P8D(XXG(AD>AV>B493#4RN7P:8
MO8J]FR?<X5I2@&FW@\`$?J_B/A\AMU7C-5^45RL?U*Y+`[@3(Z]=B9WG8,=S
M`?F5R)NJD!GU*Q`(\;XT88G(+NQ6.5@7!5A0R'L&]W]I['".O=GI*(OBL61U
M9:IKNYF()_O^7V]1UD$?6NI<=TNQO320RJ!M^J-P=O`B&Z<65H-;ZDZZ.V@G
MDCG>QT>5'$T!$$J(Y`KZFC1@A@C,:P`GJX7B)H0A<K/7&$X55?8WXBL,L\@=
M_P!-S^O>21,L0;HJ$&'<4<C@R[&/AMX0-@#(@!54QQ12N/*V,:QK)IK`7LD!
M(U5*?V+YF]A9#G#*Q`E)W$\A$5$`16(\CF"<KID23=6U5J"MMF'0?#I_H\1T
M$D0CK'?7?CVFY9*'J9ZR3L1!Z&?Y3$L0I)MK>9EN)<5(Y8QL),<6.(RIV"HR
MB,UPW^:$D2D(I9@WL0$@KG*1I`E.YX76%J13:4,\(/\`#]0\"-P.A!"@$5WV
M<LG&%B@&V0#X00>O4F98$<6,R"K.2IOCQS0IL(<$?X]=-&P$5@WA`XPUBAB2
M!(/T?C!8%6QAO$\)&-0`FE$\31"-!M86(Y<RR&3U,;R/&=]R#(.Y((,D67HU
M5M0J7BEH@00)$`$1$"-@05(\H#*5"JU,K4%6HE'KYS7B1R.>$2(UXT:\AA.1
MPF,&,#5'%,K4<%K"#87Q&)&RXD2^X>L@LK_3I^WJ/'8D23Y'>/&;\-8:;I`/
M0>'B.FT;`]5`(#0J@65UP94"?5'?-!^5(>Y_<LEQ'E7T+))[(Y(X6DERRN(=
M'=T:XBO>][6$DE,*UJME=J\&@".GSCK)V'3[.@D*`:K;*;<=C:G)C.YF=I.Q
M`DDR?F9)(#.S+D3UJC[6*.3`$Z5%5@SL4)6M*[U2`G(2&(3VODG<U0E$0,GN
MJ(QPBH1(DAUE/W+E;##]-_L(W^`Z@@CX@B.:B;)!R*Q92.5778[[$&5`ZGZ2
M"&^!5@WIN8_Y-?=5SHC#^EY!M:J(T2(YXQ>36_UMAQS#*".Y/T]*(P3T10H!
MW[;;QLHMYD2/T^TC<_/<CZN7WMW.C*H-0,$CY?#_`-$$$#_9V!^C@?0@4[UB
MRS5L\KDDM5S&#[&>]1]R.[G.H_6K'^)F(JA1'N]K2#0KY48UUPYH+:QY?U?N
M'[#UVV(,!6%F*?3L-%Q^\&T;]-^IB/B/IW\P*\C8C2J,F9R6DPJ$F191&A,Y
M'E/(0A2L<-`&>\LE\E"&9X*Y[G2WO1/)\EXBVMTIDIP$*XZ=`.GB.D;'_='P
M4$51\;<*SU3+5L8/4G<B(.YF2(DGF3U-A5LB9OU"<%?9,$"5#"@S*5KAC<L0
MJ!(U/:XT88A.4`'"1ST'[&#7S"@X\J%;CRK-620Y_CO\C\Y\8)V:61Y,THZ)
M>`&J$&>FQCQD0-EC>)`W2$LJG/R8MX`XD\40*&>BD#YO$/PE@9^1#((8GC_M
ME8\)&M;_`&RC((?KD1XEG%J&!^/S^P[']D$?$$$RK/+ZE>6A7P$]1TZC=8B-
MB"I$;,I58=*Z;3RAUII\*S*]I33%:GFI#L>5_EY]U:V2Y7R2R%;_`*.(XY?`
MC"22O_=)+E-JJ]0$!?L_NZ1]D"00H'I8^-8*&>J\^8M\SO\`OZDQXDL8(9V/
MXB5.TM7;#L8PB$@D5DA/QB(UQ0D;&>KVO0RHOL1P?%?-J%>T:*]'_AS"WK%M
M7IL?.-M_`[_+[?#;?:.:"-@^/D"ZL$U'?8]1M\_':-]SQWGTK6F[,$NQ2'8P
M$<0;4::,!K!=T8UJ*Y51Z1XHO)L=%\">MO9BM)Z1C8^ILJ9*^5=G7Q_3<^/4
M3\1))%TN0EEP6^G=>H&W^@#IT,#:&XJH.-/Q;`-K%+`E]ARG`*"5&>B.&12/
MD`\?"7'<]['N:5CFE%YL>I1E'[%.`L;UM4XL3=)D']A\#]AV/P(,<6$U=R9%
M9IMV?B01X&9'1A]HW$@\E8<N:-3Z&;$A.F1RR2AEOG(U1%:9P7$0S!^X34<4
M[9)#'&PBN<XWM(%7/.0HI%G+>COQ8`%./RGIT\!&QCP@-`4`K5!AVU5<D9B+
M"_0S'4"1U,DD`R2TE22[,KY$L:!(IK`$N&-Q89I#$&)I>Y&->@?6Q7^8E\4$
M$3F/5R#:@Q,(1!CBRH%RV+=64?9P/[_],CKN2!)=++&I?%N%M0FHG83OX1OM
MX`09@0H)`6NRFHWHI3FMGB*U8T-CSB;Y(`L9R->TY2/($361G`81CF/8,3&M
M*A6()3BA18Y6?3(\S;?&?@-CUF.A).T&>)>?+6R/64C@HD>!'Q)D#:)!!```
M8,`I=:O,&S'90S5T\SPR7>0W(-AG$]*(YQ2>3VRG.\2/>QS3-*]I">LS3/*Y
M+.ME1J<65B5_3[/W1L)!4#[JE60+ZFHM)%GZYCQ^/S!!D@F&#ECZ\GG)(HIW
MQ"L1BF<IQR$,Y6/5K8RM1B-D%:X2#)'5RM.5[7>AWN(Q8<LM^2A=>:]!M'[?
ME]O@!]6P/-!%@V)6YK;:=P9^SYG:./1B9X'DP]*UOIZXE--;)`I$KWK&;)D=
MVB9#8Y[/:O\`:5JMB-!%[([Q8P(F(QWC&$QU0%@NKXM'J;P/C_ID_,D[CS$^
MM5Z&Q;?42?1,2>G'I/3P@1.P4"#"*#C3UY%E3V1#1'->^.9P^S9*,5I7M*QS
M?"1%(J'<12C7S&Y41Q&E`1CYD4EE#I62K>(^']QZ=#U\`0P(1Q+F5V7!6K,E
M3\?'?XCK,C<>+!D(-M9\Q9H;H,@"B"RZ1CGH,_M8.2<?J\"L1'S2(\1CC\V(
MIW,(5A$]Z&$6RHZ-0P:3Z'R\!^[X'?;8$>7B152NU<I&2`,J/&=SMO\`S="1
M(\Q!(/GY*U\*@EQ8`WUDE/PIC"M(]RJ)6&:@H[FM<X9$$%8L80>[4*C$`P1`
ME:!D<T2[(1[#ZB^9/])_;)GPF9!'(LKVX5M=*FBP<+`9\-]A\#`@`>,<0I5@
M@1JX$P#JFP_-5KHT(Y5$5SE$C0#9[FN<V/X*C@QXL<RKY,11#]BJ-H&2(\"Y
M&]:OAU<#]O3Q^))'VF-RQ5K+;$.-?ZI'&HF#TV&_A\``>HV$^4('2F9O(I;$
M;9T-SS)[6N:JO]?J\7D`Y_\`?$4S5]QGJJ^!GN4KU\#^P\:RLQW%1X/L8_T^
M']XZ#=85JK\JMKP+:MQ/V1U'B">I/@3N=GETO]P9HK2(D-[BOF1XXRL$SSCN
M*=&A[N]PY4EG]LDB.5OK,Y4:X)1$>U\6058AJ?F(X$Q\=OL@?`C<?X@0(=16
MFU<BOTC)L"S'23MXR?$J1#'8JRL0:W:4I)$>"0M?(CC@G&17(TA&C_447P5'
M%8R-%:$4(3G"8B,!^.+R%Z@A1E7=>K./44EE_P!/ZS,]>IDP99IMCQ'2EC2Z
MA'G[.@^.P@*#`V7B)7BBQCP9L.56V3YW]`(#Y(U]C>YB>KM+:02`<,DE2#&D
MA58T:HSS(J#[.F0GW(Z6U\.MD?W>/3X>.\#?Z'%MM5E%YMZ4ENO7;>1&YD#E
MM&TMM!MJ-0O(1)+6SH3BR'(J2QG%)*=/`J1T8H6,+(?Y/>\;Q*!'E\W^QKBF
M>G[I'0X7R/`'2(`^/V?.9V@00`/NILNHNOJU2Q^H$$GK'3K\B.,F3R!9C_Q$
M*!9ML*TL)HG&E`$,P6-<-(YVL<`HE$04@<=J1A-"5C1F&-XF"(`C6-`6)<]1
MKM#S"$_K'7Y3ON#()!D,">0>VF\78YJ`)L`D?`]"(((&WE(@@$!60@!&KEZ<
M_P""CJN>$8/:K7#":*G8[T>5&HKO6%C.P`D4;?QQ#]87^(A(.3%KZW+ZGWM9
MF/GT_CXQ.Y,D23*O9'C/Z0]"X`3X$=?W`#8&/*!"F%7C973ZDUPZNVB2&R/$
M4DY/Z'A=(]KE(]5`]O@9SBRCRBIV5KG.,1[FH\QI`+,MAMI*QN!]GZ_U`#]0
M$PH5JKGH7'R5<-"L3U$S\O'J2?#ZB2)9G3(G;FJ)8.'80#-*1BC3LCE<GBU\
M8P'QBCD)_P!R11$5&E5W?UE$7W)'.>RBT5_=V"!_KF1'CN.GQ!''DJRY6,UQ
M%U)EA_H(@@^!XG8S]+*W(([^1$-9U$F*P:O.@6H<<I`._K:(*B,A5_;@KW;'
M0HG#6.)HAHC71T&G[8(%5P<F%GPGY[>)\8,R9.X:?O:*S7XS5@>>-YCX"#/E
M'A((XB`(*1_P\"IDL@-F4U@)4>TZM1OFO:0AUE"(/P<%B.88C#-\O6UI5<5A
M`M(DN+U=<ALXW5G:/V1'S\-O';8@D<&U9CN*0V+>-Y_;,@CIXGEO$&6!4-ZE
M>I/Q'5W05244T,CA2&D5RF>1Y">0&/>U#^UWY$EO@YJE<4SV.172BL?;WR;:
M"(`?<?#[?AX#?I`GH@(ICA<?+!Y$UD@SUZ])ZSN1!WEB#O8P.3[N8IG&%<13
MB6,H8Q@O(1O]CQ=$];7(^2P/AY)'>U6F&BJP:^P3APYD6E#KQ-+@\I/Z^ORG
MX^!\=C+H]<JMBPR:R.$`B?#Z8\8_PD>83"[J5JMKG9@CV5.#T1A2Y3FJ.01Z
M!;Z7!BE:<2K*'7A,]1B<)6O")K7#<PC`(PO[;8A6JX\C"^'7>3MTF/CL3UD%
MI'JRVJ]^*."AK/$[;0#(W"@[`C<``@A@D-Z$[$L8%F#\(C&^U&$"6)($1'/=
M_?`]58<9W(A#.,,PS,(]I'$&5CGO,"5&]=E3>H#M\1^H^$?(@@@1!!`"LDM=
MU.0GI,/-$$$'YCQ!ZGD"&!()(8$EDLH=0BP;AT63(5IF$>".^.I9"D(8@/!6
M%\Y)O%3$`JJYY"(5XO8\A'QI=AD7?>4\E'E(DSMTGPV\)\`(F``&2O$QAZ63
MZ;F&!@1)ZD>.YZE>I)DK)9C79=ZGULFKD):1G^(8WD9Q'&8UXAM08^ZF,Z-$
M5A8H!^*J]HO!C6O<P`HTBJI7:MJ^DXW/Z=-SU)\)ZD2Q9;:W4/CO^(K,*N\S
MT&PZF!N`(W`@`$A%1\>K6P&S*\4]D<)O!R2GLF,,%J1T9(::,04@8OQF/%[F
M&]H48J-(PHD'^2`,5+<+/3)(\-M]]H.W7P(@_`@SQ9LC)06TBX*#&\,"-MY$
M$"-I#2(V8,H7FB>'28UY#?#8Y26;6*003#.,HI#WN$3L]XY1/<%YW,*OB=6N
MD=G,/[D;9N#4/S.U7Q'P_=L8D=.G5>/W5#97EU&L;W@;`@@@]#\3(F#LT%MP
M_.,B3IFK%?852S!-D,.+TJ(;W!.[QAN8K3"D^QJM&D=53V(00E$YAU&V))2^
M[SA;8/&-_B.OR^WP@F05GFNHL6:R^.6'.1$=#T\0?]WQD#B0Y45V:V=9W1C$
M7]%\6]T_5?U[)_Z2-=_\E$7KESUUWXZ#7KJFJZ=--.FFN=G\@$M(/&\24^5$
MAA9RUQ"(QY\HD*$Q9C=5!BNDR1?J%@I\D3VN<K1M>UJO5&(Y>O1_R]3U.Y%`
M&+?@\CH).WIDP/'8$?'X;Z\2_.6STNQK8654'<L,$L2J^;UE$D=(8@ST!`),
M3KCI*O"TMP5S0S=`*RE71;;/?B-EPRTE>V/9LK%"(D>"!6M=,)&<Y)"P#M9(
M7^D+6I[*M`OI`E:RH7B\P0QE>7B?\(;IS$KXDZ^8[,ML7))`>Y79R]?'DIK6
M&"P(4?SE2>7IL`_10-5`]?.J;FMCP#LD4]FTMWG=$O@-DB/'M64,SNV-#K(I
M+F@(6-%FL$GJCS@N[.0*C(Z-;*[J69Q%RPKI\"5YCJ6/%_,RD[E2-N4@3/1=
MC92)20V-9-E=GQ`?TST507KE4L`V6Q3!X\6-;Y*RUOHJ:1RA1!TZR*",E_RK
M"L;*N@)/6/1W%)3[.%4W0R5(),64HH<]C%:]\EB37J@RG\8.V95.->.UWFKC
M8>%!"DQ+JS5EE\Q!$LI^'D&X765WWM^3G8I[_B#(YTKZF6K,J\HK=$O5+)0$
M&$L`@EAZI(5GC,_`5G5T?'EYRMRA8.+C..?VS%4=A/LX4V\Y.Y"JJQQXT&EK
M6^\4L^9N)9G"[(A8OJ&=WK2,1%TON"JV_N-?:>UK_P`;D\K6`4A:*6;<LVT!
MU`GP:2HGD-=3[.OQ\3LEWN+O[D]KP>%%;,RM9E9*+(6M=^1J=F(\4A7/'@VL
M(<PZJ-R%3V6@F60ZXU394L.5F;\=@>QI'2=36SHF?E3/'T.DS#Q)`U$>21\D
M@)3G1D>TB&WG9L1NW7+CHI975B'2(:*V!<#K`D&0!Q!4<H(CD_<W<:^]8MF;
M:X1JW1358&+5S:K"LMTEB&$,Q+%;"4!!Y5S/LG5G,&SU-!>9V'(JJ''/9;TD
MF/34T":65JY`H,44E*ITV(P`FJ5J>YQ6=V^LC_%[(,@I;V:C$R*[&5[+/*P+
M,1%8DQR@STZ1UD"0<O"%N/[ERNXX=M"O731YZR$16)N(4`\.2P-QYI&W%C!&
MV]O>XSDKB[4;^@>;6\E\1TM:WD2D!5Q!76HSU):2K6A'2?FBC6SLK3Z-\Y$_
M(&GXPY)'*C$;'>[D*:,WMG=:NWY$4]LS';T6+'BCLH5^42OJ,G'H?,5`W\PU
MZ3DYG:^^^W\CO.&3D]^[;4OXFL(`]M:.7K]/D`_HI:;/J'E#,=H0G1JESTO?
MWMC<WMG);5)"G1M5?DX]S-19!S\RYRVLQ>2I+*UESX4:PM89RBAH(3([$B&D
M/]+(B>?=WY"=OH6FA1ZL@UIZSLO,+9798RJ`2%(!:22>2J.1?;R3%PK.\Y;Y
M678WX?@PNL.-4C"MGJNHIK9RRAG4D)`"C@SGB*][EUYY=\:**+`G&!82AU<"
MLA1_W$%<V;..V!^#^),CF>$:$,YICN]ZN<UY?)7N*N+AJF."690RCD6)XDP!
M,R#OTV&W4"(C6?W-[,QU6M'*NP154<@O)CQXP08$L0S>;H6F2VJ1*:4PEHFO
M#:!A*&7:/KTDR@3;TT>7;"9'28<9"4^=?)B0ZM\60X%@!Y93V$0HD',D`^ON
MI;99@0DA=X'U/#-8&64("@B#.*_)E_"`BQ4@OQDAK""XB3/"J42HHQ6Q2UA#
M!EX[6_+031>2=06:\3BN^=[-S((CRDD,KTY2XZ'%G&8X+!P8]M,'*+&1%]A6
M-<145'(]W)^ZBK]LJ"3']27>!$^A=(^94<0?`;#Y#T7\OD:OON0UT%CV1O*"
M9X_B\8!CM"AVYE?$B6/4$]TNO!]?7.G333IIITTUJI]D6*57`7+TQKT887#W
M(;8R^H<A629"9^%%,Z*1S6R``ERAN(U?T<SNG^U$7K/9E7J^X,-/Y3F4SX;#
MF3OX$@&->=_F??\`A_9W<K08<=LR8VG<^FH,>(#$2/AKBG:CJ<Q3K4L7]V'G
MI%U(MQS(87K.F!BS[V58I5UG[6M"`]O.+^,Z,]H`-()@V(P2(GMU)NRKO6/D
M-@4+!.PD*!R;ES(4#ER$F"29.OE7(&-@8OX8?>+07+R!YF`:PMP3AZ8+LW$J
M0JRH40HU!J;23DH4O'QO42\O9B5>E:>SC6L:BJSCBT])F:X-TVV<ZZL!`/-L
MWO[2*TP61A&1&RVNK=4N6ZYC2**UY)"E2S"69SQX^42%0#9P2Q&Z$6XV19VZ
MINV)!S+GX6RP<5H0$KJ4/S\[`,]I/FJ916K0+0<V9_:U7']&[>RHM14&JM!#
M@4,!MA39Z5I[JQM:N)_S<L!8CBT]`FB%*G.?V4K1^D1%-*&SK29&#;W"_P#I
MZ%W#UDN89PBA6.P,^9^!58Z3)'%"==7A]UQ^S8G]8L6JMJ[E6M>25FUV=!N0
M1*5^H'LGK'!6+6*-/FB?:<N9+EGB2]MA4$G7:'.[:@Y$HCY$T"+R_C[*/3`S
MQJNLA@B60K*;E1$-&6,H!-,GH];G";T]SI5VC,Q.[XZ&Q::WJ>EQ9)Q[%+%P
MS$D0+"`9DQYI@ZI[#NR/<G;>Y>V\RP4V9-U5]>36:2HS:6""LHB@,&:D%EX\
M0&\D$J-8CD<70./YVOI^0+:;2ZBO2=9W,>I-#LC"MZG,1ZI+N-^[SWUS9I,Q
M&GH$$G]VK3+8D=ZAJ(7AN%[K9W&NF[MR*^*T*I:5'%G+<3Q$QS*21Z;C@-S)
MGG']OT]FNR<;O-CU=P3DSA"K$.E03U!S;CR-0LXJWK5'U2>*\5C'X`+=FX*J
MY.AMX)8O%M\E?=+12:D%)*D9_)QH[*:SJPR;16"4WXQI`VE?)BD<!CFI(0B9
MY;T!GW)6C`Y:2O,,6`>PGDK0OS"F.+#D0>,:TJ)^+;M&/9?:C+V^SB_IE!63
M72!P=`6VGBS"2R$H".?+6R'!G#<Z;K1\BZV4M9QMQW?V7(\.RJ1R'S;O4I,K
MIT+'<8*$D:KR<"-9>N`=C2*9HX<5AT8XH_#F^^]ZK3#_`*;B#EW/)K6DAHA4
M@@V7]6L)$L-HEG*R`9[GVE[8NM[D.]]R;T^Q85S9*LD\K+I5EIQ(A:5#16P!
MY0E8<`LL4G+<E$UNFW-MI,M%S1^4KJ%+BVU5F,W1-I+/3ZS53:ZBU4@-Q*FL
MS\[/9:.><6>-BQYYA3#(Y4>T<V7VP8>+13C6FU<5""K.[<E2NL%JQQ`YAW(4
M(=T!01L3C=O[Z>Y9^7DYV.M#=PM4ATJJK]-[;K66NTARWIM72K6&P#C85M:=
MP*!<:&=57`ITBO@^^GGPG28U[2CD!;(H]`-TX,H,6O?,:T$*2V3YBDJHI`O8
MUB/1'K/3C5VTFM6;BZF"K089-B),;D<8*[@P3&VL/*S;L?*%SHG.IUD6(")K
ML'($!>6RGE(;9AR`F#JPK::6NLP7,*?)9&NDG$`:W(T4N:9E5.J)];<H-33+
MK0TUU'8ZPDCA^FP?-!);X#,CNMA2@LJ-+J.21/'H!R#!E\%1E)X*6E`K*9*Z
MT^3:U%XRJG85V\B"Y@L>#(ROU9[$L`-C!(L-B.(#SK8SA=+FRY(P-Z`U=*CW
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M99&M!WU2:U90#8H)'QV*GXCIU&X,Q!5N+"Q`RH5U7R8P1,=VCA]X'*-@E7P5
M@U[O;$5T9C(:HA/`#6M$YB>GTD96YY1Z+`Q/B8/Z3OOTD]9WD&S3I95E4LB`
M?2)&P'R^&VW6%@`CR\2*):D:>&:1"*HI#0H5W<)&E,XA9IH\AL@;G+XD$=#J
M7N%[W>PGL8A5D@E77E74.)!,=?D)$?JB-P.D&.++'B!JG-30P$]#)DL09'R/
M*=B3)Y+R-B60Y[I=/9/L!M0L:<X`7%7VF*)_D)?!'*\Q!G,11>'B5R2'D8C5
M=(>`MA6L)=5Z9V99/A^D#>=MH,^4,*[;39BW^NNZ.0)W)!V^TR3$;GD2(ERC
M7K6,R5%#.$P*![@E.E^UL7_EU%&0CD52QP]CB8Q[5[":C0C<A`H.-(@*F*,:
MS/+<1UWW^T[;CQZD0TLME<E!96+ECAL9F-H$^(&X@^&R@\EXH],^-\>TBN&V
M29BL<6."8:*,1N[V$["<.4`:&[,&49AN$QKT$9A1,\9$>/&0U3R0/`D`_P!Q
M^P@SM(()\K-,&3(K@,01(#$0?':"!.P(80)A@RB'1):O<^M,R+-\_8209&%C
MO+(:^9(*_P#Y8Z((A/,[B(X:JQSW'*K7^V01_P"YWV?>KS3H`.NVP\1]GC\A
MM"@>E'230XKMF2QW$GS$]#M._4;26:#R=C^(\R8\V#)_<8GKD!:%TEK!$8`W
MBJQ2R59WD*^0K_[9FHPS6.1!K[/-(LM:JR.GIO(,Q\1XQX;>(Z?':.2:I8EM
M+^M7#+$[;'P)\=_!A#1TWGT[-)D8\\'Y$*(QKID5S)H)*B;'(P*L01!@D"%%
M;)]`7*Q[_1V$+UE:)C%_:Z(RUMQ<[`[$3/[1O'RWW,@DG[VMJ/<O.I1++#`Q
M&WB`0!,`P3QV'%@H'_#U&'81[098Q4C_`)+$5L^,01G@,%'GCR7!9*`,Q!*1
M"C=YB5PB>QA!*Y3@/&];5$,L\?`[3.Q'0]>AV.X@@_2RS57)D*:VX^H/J!!@
MB2#$B2)D&1(/(,I/-'H-0\<&QD1"'5PY#SM4)/*2,_\`<9ZI2R'/*9'D(8;7
MN5Q7/4HG$>4I(\FRGN!LK#@;B/E'RCIX'X=#``#+5AXQ%-[5D^5IV.X/SG<[
MD@'J3*DEF9++SHDRA.R2`(SU9R!$:*QZF8-K%%^(YRJYC!/$(0_QRL<T8VB&
M-Q&A9&DU[FF0O%C%P$@]/M_MD=3)($EEL&NW#?U$`..2`1UCI'V0`.)!@`*I
M(4(]-9NT[1QR?2(GXSWE_P"9$)%BC6/(9)8Y2B:P"O"A6N1XU8CD<CQM&V2*
M-#0?-QD[_#QW$?;O'0_82>);*R_H%D`\3.X&P@SU&VT]1$S*A0ZU_"%B7L-X
MG!*PGL?X>X2N/%*UA/-[D<R0HI"LD/8J/83S>56N893.98@'QWD$1\NA_AMM
M\HCJL369J\RHJ009\1N#^^#N1N#),$-R(OH].049TBGE%(5\T@6Q9$-2O:X7
MH`H)`)`Y17L8QOXZL5'*X/D!WN>-8DIT]P9@+E$<1N#'Q,@B/M^WS>4'F@Q,
M9E0MC6$DN1!$]($$$'_=CQ7R'D1Z=A^CC+FI#SE5IHQ`/:L@CHX&L04=Q$>@
M%(`:`:"-V<J>IH1#[)ZXHT2IH7_$KQ79YZ;GQ^/QD_.2?%C]]<M9P7YMNA'4
MP.@^&VT#?H%`\*UC&J]C`D6(`F4Q(I8WL-XM*J(XCD=V(Q2,*(:M8I>R/&Y/
M-Y1$81KY0#PUV+4Q$`@[?I^[H>D$$0C+DW4O<@:2K+)Z^/QWD#QZ@[EE8$&Q
M'@UMI^[1TB.(@;$344HE&_US!H\33(UBF.5'D20/V-:4KV$,-["&]H#V%UE7
MI-S&]9_=\/#Y&-@"`00L,M=E&1^)3TR8N`W$;$;3XD^(D`D@LI#/R1[O,$T"
MJE'JT*9KE</\<;'M+'$$@`E:,2B>+U?BC8QR>3F^$=!*U[`B"6$L6RU1;`CQ
M^/C_`!W\-S.Q8L'I2]./8:),[1X@"`8$1TV.YV7C!"*K54FYK945ZRHXG-@Q
MO%[1.>Q!1A*TOM:HS":R.%OI>QS%#X,;[&O&L?\`)C0YJ;5<<6/WA_?^SJ=P
M9F3L0>7%GQ\JAZV]1!]ROV0!O.Q&PV((XP!R!7AZB55F;&DWM?&*$KV'5I/,
M"^8$?(?[&&'(0K)A6D<8GA_PF=YD=W0_M**RA1EQ["&`X_'KMX1T'3[.G\L`
MU9-M;Y=*LI(>.G3<]9F3UVZ-N3]?)EO\U=C"F"'7DCD8^*D9&#<%'H!0-CE:
M=3".4`E`3T*US2^'BX!!D<Q\:0JVIT8V`B#/ZYG;I)G>=O\`$")#+ICWU6J*
M"""L;1TB-Y!($'C!!C="K$&MS2:R6.GDO@'5SX<E$8`XU"Q!A:,@T*@PN`(`
M6BC.5S$1B!"+R'ZXP7CJ);4-ZBQ?K'4?/]_QZ[R3!EF!NQJ+%QG-+;U-T(C8
M;[P(`$`[;<5$KQK4C&FK>N-%*ZS0PFO`]JHZ0]ROE$:LEW@=JQWD4S'/.U/[
M1W^;B-<%S'S(DBVFT./2(,'X>'3IO]GB!$&00CK)DT-6QO!`(^/B=^NQ,_4.
MC&9!4@VUO-R(QK8$2:%Y!RQQP28YR(C8ICE*W^GQ8:2Y/:Y[2(49#$81XWC>
M1Q&.L;584LR'="2#\8_8/L@@"`00`"*Y'K;(1;4D6``@GH23]IZ['D"Q!*E2
MQ(-_J)*CV335$T!0D$WS<-Q%3P>/TO:T,H3PL$6*U@BL<P@V^+1$"1!C$:%1
MT:HBY""#_IZC?8[C<'Q!$DAZUV)>#C6@@CPGX1T(B"-B""!]+*W$*U4K4J"H
MFRJ\[$`^45K8[E5B>06,.P87^0@,"C6,D*B*U!/:TR,&)HY,6%?=RN06+O`W
M_=OXSX?/I),JSQXY3&M:EQ!8[?9O`Z"/YMH@PT*H6RNJ#:0WU)V6E:1C?:3Q
M/%1QG.D,.57O1HV(8I@%DG=Y#8TAD,9SV(4QC`M*U.+E]*T=!L=MH'ZHV'78
M0(,*`U5N14<=_P`101!.XWWD_`22"29`!;DQ(#.S)D19\5+X4>97.$LD96H7
MR]P50:OCE$89A&:XHVN_'*U[#*KVH$H#->D602E;_AR4LGC^WX_Z1T^(98Y*
M+KJ_QBK;1','?J-MB""#O_*00VXXLC`^F[353*?,BNKSQF@0041KFC$Z,P`N
MR-<]Z-C1&]VA[,0;0B4+/)B!&)XZNRY0C^HIF3^N?WGQ\9,G>20;9,:PVU^B
MRP`/@(@?L7PV@*.(D<0I7'@1YPZ4SZR:U7/[O./U-*9[W3"%50R`J+LLEYFG
M[>,=6E52M]?L63&+<R&]?53IT^'3Q&_2(\=MC,<6%B6KBL<>WKN1$GZB=B(Z
MSRZ+OYAQY>HC4NZ"6+9"F-E(4YR"(-$8[R1KBA\/#P(5Q/\`FC-1O@YSG$()
M6/=+(-UM+2P>HH1"@?W_`-@WGP!D!`13CY2-7>+`TL2#^\?,SN1$$F2I!-C*
M<B:L*\EJH;6L(TBN$%7JA%];48&(1KH[_*(A&M&,3D<)XF$:(:M>%XHDJ%97
M8*IIM$;_`-_7K\^LD2=F!='DNI;)C(H,F!X[;`';I.P!D$`PL%2M=E5:KYPK
M0!XKHBM".-Z3$>WRA/(@RA.!/8.,]6C]9/\`B&/LUA6/8)128\.&RLU,'!\Q
M.WQ^(/C\O$^!!,JSY5-RY"&LKY0L$_R^((W`Z0?`;!@0O%TJIM98.KS+2VH$
M$5"/]!D;W89\N05/!SE$Y[TEFDN1A7->4A2/&5'R'N;92VUBQ?7J,K&X^$#^
MP#<=``"(435#CW&EOPN0L-.Q^/(GY3YB3!,DDE6!<D7RKZZ/2V\.3^;XQW2$
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MU(,R)_Q`@KL>2LNUB&2KK$,7RJK`?FYZO8TXV&.XSU<P*.*Z2^3)*Z422WP5
M?:1I#,:YQ2'`:TDLK+_?5]/AL(\?"!M&_00"0`%8514WK7_P]PD[[B3/AO,D
MS.W4@L`2S.C9$.0J4$X9V.1(<QKWK&8]!,<$8HK!D&J$C,C+'%ZO$JF:C6-$
MCWL&R+*A57_B*^)^L>/SW^V9WVCK,`DNCT<_@[@X_P`IO#IL`-^H`@1!Y"!Q
MDA1795'MZL,YAI$,2&7^\I3*<"B56,E#.`R26LCA0#!%&0;QL&@F*,C6B:44
M"VFTUD*Y@;;1]D';<SL0029,@DD&R[)QTN!>H3UDR(\009V$0P((`@<6`4,M
M,6O]]M3.C%5QRC))#[%,1DD11>:1?!Y0SCF>\Y'L(V4QY7(][2,D.>5MC2SC
M5=R&P(!Z;?/Q`&W3B0-A!4`>G?3SR,7@TE@2.ID$=.H8G>00P),D,')87RT"
MQ%!'^U6KB*0<ACFD:]S_``3QB2(J"/&DD.QXCO!V59!'B<0/8SVOB2Y%SUFP
M^K5$1_>#L1&XGP$PWE$.BQTWK2/PV1/('K\.A$$$G8E?YB02OF(-=CP)S8U7
M;-LWJXD4XB2&":*.WUN:#Q0:O,D2,(8APVJY5]?H")/9XQPM?47)RMI](?4#
M'C\?UDS/SDG:68BZR[T\?(%[;UD$Q`VV^<``!1/3B!YH10<:H3JME@$UE7R$
M9)[/1R/4;&O0+3A/$D(6.\4:1&5##_N">U%4PRC<Q\F*L:6FMA58/+_?$$;R
M0=CU'\I!!"OJ:W'%RF^EH?\`5X2"#(@$>8;@_P`P92#968L*Q-=0GHKO18!7
MQ>J>8QRBO4;A*(GG,?'(<QF>;?\`F"->1%8IT*,EE:]8I>>M9_=_"8$_`0-^
M/$BJZJ]LNJ)BX?JD[1'U022)^H@D$%^2M?(55B6(<4"7YLD>1!N\D:5IB'])
M6R#N:92C0(QA:UHR^"#]1&$2.V-(B26UAU-B?3_"/`;>._4=9!'+DKQ8]S5N
M*;=G_;,P9.\[0H@&(XD'@$>O[)A!J[*-9.<1U<US_P`A'L3O"4D:0Q[AL<R-
MXPV"]GEV8-8XVD:K$CC,&N+8UM1KV]3P^>X^W>8^,F#/(JUBRI,>];R3Z'C_
M`+.Q^SRQ/@.(Y".`9:(EE")8QFRZZ1[!B*YR^Q6B<$X72A.&-&0CG:7W2'-<
MJH1?,CE]9U-(CV-*G%3<+!!(^W8Q\P.@^6P&ZPK5UOJ-]8LI:0#]D$2(^DF9
M)!Z[DGB_)TOB!>M]4J$,A4.)S#JB,)V"YJ#?"$TT0B_UN7TE8\)GN_K"41B(
MZ,>10C\/=)'E.WV_'8_K$$#H00/,JW(3EXW%&\XW\=NG$2/_`$2"K$[JRL9K
M=Y6H,M2JU]BB-C&8)\/Q&TC6HK6IZQ+%]80C"%GDYB*-@A#\Q**,/M4WW+ZW
MWE?U#K^AZ[]#N23!EC]]'C,<?[B_Z#$;?PB``!N1L`!*\46,;Z9645PLDX5/
M&E#(%3>?F5KT60PJ>CU*WRC^LS2"<%%1KS^`_P#UN'U1?OZ>*F&'^CQ^>T&?
M!9/T/JK1AY7-A*,")\?'PCPA@1QZ%X'^97J)91H\]B6\8QE>-H7H55<1_N'(
M5[6=AM/+4I'2&.`YBE<XA&."A2'7]TI4S5GT6`@S_#]0C8S,;`\H"_=5OK2X
M?B4)Y"-^NX/REIW!6),D%>3/_P`1&'[;^E&UQE;.$YA$(-7`&JL4*!+(])Q!
M>,@/45'QS-;_`$C*`H_&,>/0QCWR!]V?U_'IM/61!'Q#`RRM>O+,Q0"?O1XC
M8>$$P0((@RK>"LC+%;I*U5BE:Y*2PBO0K9`A-8U@R#;[&O\`'N)P8X?`3`/7
MN,0PN"(CFB&T4F/776U^H/7K.T']/$^/B29(!))5K(L:[T#^$N7S`@>!^/A`
M&T'H`L`D*H6Q*/3VS*RTG3R1O^7-)5",:)QY/J]YE1P1*L@KO)YBJYGB]SG$
M(K1J=TF-8APMJ6L'S`?8)@=>GP&^W0;\0K5U(MQ\A[F7[LMOXF)/0;GQ.T'J
MT+S+I?,3(46SC$M@G4!/1^0$R(Y[7$(L4PVI(AR7F/W<@O4X!7.1[PD$]Q5#
M(D6I8U3>DPD3!_?X$;>,R.@8$1R5;[:J[ZSDJ8:)!^>Q&ZF3X05)W*,I+<'?
MV,@KNG,$+QDEH,+S(KQHP:N3^T14]D49@BC`[L>B@&B"16.CJ)KJRA!HN#&>
M'A^F_B>FYWW#3][56&7BE4(-D">GZO$`@`;'RC;8IQ!HI=7*DULMM)-C@>`Y
MGA,-7C<YA3/D,1_<HF!>QSV'1S'!9[?[O]II6RX74MJK:GKH3R`_A'Z_AO.V
MV\%'U!CV/18,6U058P1MU,_$1X-(@3YO*&%M6ID_Y%+;+,>P7XDE'+ZX;3*Y
M#G,U7#:'V$,26>6;R;W]ON(;^E'27M6VM7C?5P$\Q\?@/[`!\H`_P@^C>_/$
MR?5,>FW@)ZD](W)8D[=>1.TV$?B5V.',@#MH9&F<+\;LYIO:Q1/=&*)R/0[&
M*/\`M!<W^^%B^`GL,(@XLF/2@NEAJ<0#/]O[^O@?$%2"ZLREJMI&3402(\9V
MV(\>FRD>91LI#J16Z>A-%H(,>*\O>1%&3\F02.!B,`I7A]?B@8[7B(&*]JM<
M(`W-`1"""HBBKA)Q["X'E)V$GK^T[[CQ)W$%I!LJH7-I6LGSJ#)@=)CX#8A2
M-PH/$\E7BRT1*9)%9,?!L$\72/)H2(19#?8ARM])'N$\[222'>K7/&Y3/>Y"
M,60\[+"EY6VOU*_#KX>'[-H'0[`"#Q"FNN+SQ[33?U;IX[R=ND[DF)!Y$F5+
MEQ=\?*/461Y$MB**:9Y0F`\CO%Z-9ZQL$(KE>L@I0>#VN[N,\:.>XCHLF94*
MMU05.JCH?T\!,CX3M`=4&Q\:\O8/*QD$3\O`'Q)6"#U*R2QK>V!<QQVD6/95
M[AO%&"]7M5S%8YBN"[L)A4C":QK0*KE>4`/$"-50((1ZNM+&IC59]1/]_P!O
MQ^!._P#-)6VW)09"+?3!51_=TF!X>)5?+!X<5?'AK%!=QO,#6@D!9(CEC2FL
M1QW]Y,?^EAXK`>+U)(&]"QT<QZG`8/\`ZQ''7FU#0VZF""/#H?`S\"(/^%E;
MZ6-OIIEI*;.)!!\>H\1'^(&5V/-'3ZT6=I9SG^59(&\IX_M<P:I(<XBQB-\G
MN>8QY+WNEG5'HJ&.A2HA%*\C"6EEU<?>K'$Q\/']0'0?(0-H`(JEQ+B?N'!+
MK,=?`_,D]3O]32=^18'(EQSW4L@HI,94A$<Z6&4!6E:9'-CK$*,KGB_7LT2(
M]3=Q$47<B#6))2XUB]05/GZ$']<_V^&XG:>:ZL%QQ7*V+]T=P1O/2#.WRWY;
M'CYN/IV:D;BL2.Y;(32.AN(PIG$]*,`!P6#>DAI8X!1@L8!XWH5B"$)GK*T<
M82_M%]-O+[HQS_B?EN9Z@[;D[@EC]]#E8_`^NL^D3)F-A'C(``V(,B`!Q8"M
M?^&K%C!6W<&RKBN:02D<3R]P9*G%YC9':UT4RMDHYYQN<\3W-<\C'C*PLJ+)
MBJ?T0:K1L?UC[>HVZ'8CH"""$=<J^G\21?2?,/M!G<1T._U#<&"6!5@UE;S$
M&2&WCR(10F#)$CAH-[BH<?B2.YJH="22J<,@P5<U7$57/&YKCH4$B?98K4L'
M!!4_L\?#;8@'?;H=EAEKNI=<E#4P(L&T;R-QX[F02L[G<J07Y(]TG73RU9PU
M<H?:(`3(X)(FN:Q'=VF:5[4/Z`QV1FC\FL(,<<8V/8YL=HS5U]E8M4VH?.3)
M'[OA,S/@222""TBR.FYJ'&/8/NP(!'[9ZP!$3!`4`$$(%:B&<:5U@EF62HH1
MR."0@VM[/`(1!H)8CH@O_5_09Q.[4]8QE_MH)),:+<I]6OT@)<"?UGYR>LB/
MB2-YXL]KJ*+_`%V:*F,'[`"(B!TAIVV`;;CZB5^[2,8Q!7%6U[D8UCCL1DIA
M3,20=W=C0"+,DL=(*[OXH4R.,KAH5Q3!M*5,`#3;U\.FVP^.PV^P;08@-57(
MK9F&5C[_`!ZR=S\`6.Y/3DTF5Y%F7(V6$O<8U[(G=C%[)_HG]*?HG]+/T3_R
M)_Y$ZY@]3KO5^D?9KWU35=.FFG337/#[XC%LN-+*J28*O!/V_&L"3,/`#8L'
M7VE=N(%NT$([C1IDXE80C8Z21?C!D.&5_FUKFIZ-^7["ON:V\2S+1<0`8W4U
M%9(W`Y1/$\B)`B=>)_G&C7]BLQPP17R\52Q4-"NN0KPID,W`D+R'$,0QD`C7
M(S:2VN=7Y2GHPEDS)\2DJ`-.69)E7HA#J1`6UKI$:WAG(ENUY%,\[GN1%>C.
MSG-]?PE(#9=UA"A2S'8`(?-/%@5(\L"(CPG7S;W6T$IV[%I!=G%:"2Q-@'`#
MFI#J?.">18DQ,02*Z75U\:3'Q4)L>RKH)SVFA,]]=;1KFWF2X86AKI-A&EM/
MG<W2TXQ5\F*9AK)G:05'>04%`,2QE.<\K8P"H/,I50"9(!'G=F)<,(0^4>,Y
M;=QIK<=JJXO0C%[#Y7#NQ40I8&:JD0"MD8&T>=IE>.0-9N*W!<>]XBUD'5[*
MGT,.LSTF=G:4=2$U)>RBZNTIWN!&<2R6B+#B(X+VH0Q9#Q?CA8U^OQ,&WN'<
M//R;$I="S@.W(\E'IJVYVY!FWZ`*#R8QN>X]VH[/V7[KTT[CE5V*E9:M.`*6
M$VNFPEO3*)Y2)9G*\$`-?XES6D^@_G>%GJ8X:?<</ZG9WO&K'28S*_E/#[$L
MJ;MHTB+^3$8"<&OO2_CV/F&6XKT1#-1CRIC=WR<;V][C;(N!?!S*JUNV,T6U
MP*B#!D2HE-UCP,@:S?;>!G>\_9*X6*PJ[MVS(OLQ1(XY=%Q+7@B1#!;#QMD.
M28Y""VM6=#EJ"DX^NA6]G:BO:2?'_;*Z%&20ZKEVNU@6=O`=-M7M_=8\O47*
MS'O)%2T`)(XV2F]W#/U>-EY%_<4:E4-#J>1)CD%J(4POTD(O$0W`GD2AZKY[
MF]OP\3LUJY-E@RZG'!5$\6>]7=>3_6#:_,DH+5'`"P20]VFHR7?)>R>>V+^3
M74&+=#+?4LR,6UKA6-[8S*FTBA1ZS(!6,)(!'D*.*V?%#(<5117IUAB\4=LI
M"H.+663P8'B>*@,I/0]`2);BS*!+C6R;$;+[[E%[#S2FCB;$8%U#6,R.!]2G
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M[#<S=N/9K:JU[I7:[UL%5*[/3KI5U<(7!L#2:>2SQ1ZQ`52U"K="5]DJSX=D
MYA12L\8\.K#$MXU=,%+S3K&I*VJ"E'-`RW08B.>5I(R&`YS&'<YN1;C@516R
MR(?=B5)$/#>;S`\9(@0T,`2H!Q*,UO7^^5X(-9*H%<*P-7)#P'IL.<`DF5Y(
M2`Y(L;\V=2V$"&8U:",VL=/@63R.)7V5:E#"=FKB!3'6RN*^GLGTQ$`U6"<%
MP"!(J&&]&YW"N^MG4,7Y01XJ>9YJ6\JEEY">LR"-B)U/JW8EZ5,4%?I\E:?*
MR^FOI.J'DZHW`\=AQ*LI\RF-S?EL<K_->1R27"<&TXNT%TZ9(18E@RSE['AV
MMLX_X0$(V51N!21#P3E\)`$,2,C5`(#UXKW44_!8P697+18&XXBO(93)Z-+,
M&`V,!IY%AKU'\OEL_JN<7CC9V^Q^1V;D;L)6'$3-<5HU;&&7D:XX*AUW!Z\,
MU]9:=--.FFG336G7W*UK_G/F)C.S9;^(=NR,7U$>\:.M,:U_BHFN)V4JC56M
M_J>K4[(JIUV?L0Q[DPB?H_&53_\`$V?Z=>8?FW!]D=S`_P`P]MO@P?\`%3\/
MG&PW/AKCU8VCE-,U,Z%'LWQI!?\`&HB5K+")(L8<I'SK"2R0!7QZ"AMXT=L;
MS4/LF!1W]0@RA)[)75L,5&*@CSGE!"D;`0=W=29B84QU*'7S-=D$L_<+D%A5
MCZ0X\E+*?,QD;5UN%"S$NH.ZK8NJ)050Y$N;;W]M)A4525U_L-1<H^Z!!IXX
MS(^WNHYOS3FO+F78D>(2%>25*EA'^CB>Q)LBTJBTXZ!KW'"M%\I+'^52(`50
M!)B%56/01K$P\</8V3F6,F)6?4NM?SA4`/G<'D38Y8D"27=U78MRU8^GD7G,
M6PB5]#6R<^>RK=GD:64N##-I<C69345-I'L)]WHRO-#8>E%^3/DCCL%,L)/D
M-ZJH5;GXJT=FPS9D,+%5J[&'JPUC6(RD!4ZPVR`DE46"/JUJ>X/E^Y^YK3AU
MM2]B7TH?PX:NE*;4<,UEIE90<K&"@/8TJ?IC.UM<AP5/0Y_C23:P3>\1:69&
M7*>[,PM'"C?O_,6CIY0G?DM@7T-KX@Y*M5\Q!!17-CHG6@JI.?=9D=S",L>8
M'U(<H3PQT8=)0PQ'19.Q;77Y&4O9\:G"["UB-(*,/1FI;5'J9MJ$;\;`"@>)
M?BNX0#66OHN5'U_"PN4\GF!_N2`*V[.0HFB:5U'+_/GW21+1D.QR5_<UKW0U
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MDC5>Y0IZ^(]O85G<7M[C<1^+LWJ)94E$')PXWAK5XA!/E`/@=_5_>?=*.RU8
M_9L96_IU(XY"K79;QMM8)6U32H*46<S88\[,/YEVU;Y;PL6/(=RC&@9N(.ML
MK?2[SOG;4Q)T?,9RPH,9K:R54F(Z-53C63`_T/<USB-(`3V/(Y.J[1GNR_TM
MFM8LJI5YUV+N'LK8,-V`4G?X$,00->?>Y.T5H_\`U`B4**W>W(^[<EA54U=%
MRE"81BP&QW)!52"3JF8^X@;7)0<_+6JFZ+%4.7BM`&UM23]553,7%E6"EJK.
M-$OS7&9A.60J2DE%DU8QG5R/`;RES*+,'+;(3FN-?8YGBL5L+"!YE)3BYV\O
M$*Y*Q#+$';<JGNO;4PK/3?.Q::A`=RUR-0"THX6PO4OF\_,M4%>04>:/76$$
M1IK9\F96P+5KC^(F,2347T%JEC:`((#QSCBK+-HUEQ%E,%*@2)"+YD&+PFLK
ML8+Z8#6)M\F4]4D[#DL\6XRK!>@)G%HNJ1G%S,E-F^W5+%W%@"^8A&CFG(!Z
MV?JRK&UW!=40&TQ"S@E@RJ[DWC".I`J"<VU4.RA!`V/+5.XZB#%G)X%1/^;`
M\)6*B/<C.2[]:&PK_3(9&Q;SXCC-9F1_B)&X_E/('H)]%]HXY3NN(;04L3/Q
M1(AN<7J!#>"*&V/\ZE6&Q,=H./TAIC,ZE>BI$2N'Z45_FO\`QO\`9_5Y.[_W
M?+_;UXKW'G^-M]3Z^6OJ3LOI?TJCT?\`+X;?I]NKQZPM;33IIITTUC7<2XRS
MZRJ.UR_FQI#T5KT<URH<`FA.$;RG:V0KU8UR@<PBN42*]S_Q9.TP$;TVM7P(
M_@=QX;=>NW7:.2Z'NUJ>M7CN/J4_Q`@C<[])XD'Z=R?3LQ:YL2JO(;R^X37!
M:[\Q"%&!3G>)O=7(9Z_B*BA\G-,1/;Z'.>CEARG[4<[:&`@[]/&!_;U\!MR`
M$<T'/D5XV6I:1M]4D"3'S.WTS#'?@29]*PSUO5$>Y+&L:X,T;D<4+$`UDIHA
M]D*U"**(PZ1HWBBN]8C`8C'^H8VOK(Z;@!Z=N]?Z]O[8D_,@[B22+9<G&8GU
M\>1:#N-MX'7>!,#QA2H@\0`<>(9IKVI3MWC&=[%-'];7*96+,`Z.YDP'<"F,
MA$<,X7=O[HC!>CI4<E%XT7?%?C\.F^QWC;<'X$,/(PN8/EXVWE;Q$=?J$>8;
M29V8?XE93-B-`@6!G/6#(8*?,,I'JP/L:YAV$8&4,S9#C$_H4K2.>UY7^1V-
M1QB%`:RNLK4#U%E4'Q^'41$?9T'0F``RU64VMR]%P'M/PGKT,S)\9F298"69
MD:_[W#23_P"V*40=@URL$`HR->4+6$`HV*6*%B#"P(V/8]OK&P2N(P+(YX;>
M]-R`5^/SZ^!/Q,1N9@$EE=*XEWE#%7\`0=QTVD#I`!!V`66"JCU135*GDFE`
M,,8RA?'*$JIV16$.&2TSD&YJA033(K%&-S?`@WHT32QX5JW<5"L-P9G]D1\Y
MC>3X$289[GQB[FQ"`I$$']8,_*.6T#H5("ADJCQA)9P?28Z%4)B`]L=SE."9
M&,YC"!>J2#^2N*[^@J%>1I%1Z&<4K)]KMZ3RH@$3OT(/QZ#]8B(V@`&N^M?7
MJX.9@Q(Z@@]1U/B=C),D'D6874V#93*U/QK(15$A&?C3'*X;$80\=!/0CY!2
MJ-[WL<BJ5RA?ZO[[FDBS"2O6EOFJ(GQ'ZC\O[-Q/E!#H(*K[:/N[P>,[-T\1
M&\DQ,'KL>/G,UVM`(=:6YF%D>L<:8-SVG(1Q&-$QOFYR^2QPH@AB_K:OK],<
M'=%;%'_[(N"B^E0L\E\/TD_9UDGQ8_?6,YQ<IF>!6XF9G8?L&P&_3BJ^%:_\
M--7-3[U_<`/8DH+&G(CE42&&Q9*-:1ZB,C7(QYF(1XW(U%*P@WC?*B$LINX_
M=M]!V_A_H,3\"""%<2Y6-S/K(1ZHW/A(WZ['_:$D'^8%2ILK:=EC-:5?=7,%
M,5$E`4)"D>Y['B.%["1UE20G>\XU\A*8C2O;V<9Q&.L+$(JM^*=#/[#U@1UZ
MP(!^F#Z<E@;(QYV%O402?@1TD@R1TY$$C=B0;I"KO2$D"KYX"I.]KA/>UH&,
M1PP@*PQ`C(-$,K!#5SAD]?AZBC>@$$>');0`ILK(]./G\3M/[8D3,@CE*O#C
MY;%Q3>I]:8\(Z`R0"-]A)!B.+*>'%ZO""%1V1B-:$$(S'-0#"-08P-$=_P#>
M$0#7*QOI*,8D8UHF,)_2T+#1X-9-]0!DN/'Y[?/["3.Y(W)*M90*N'>6$"HC
MI\!!ZB/D0!&P#;!0Z53%C$+[/W6M5A",?YR!%:0CD<)#B)_4T<J0K5]Y!^+&
M%*PAR.8TKRG!8V5N(]*S8>'[OL'@#N0"``2`%:N^^MI_$402#O._20?`GQ(@
M`D%B0&+.E\Q)&V^K1I'>T!A(Q51[S*X!A^@P$_Y>81S/)4`X1AF<Y&J(HB*Y
M8QS44G'M\VZG]XW!ZC[9!'Q!'U*)+%&90.!`8?&=CL1T;;^4@@].+*TE':2J
MI!ZZ4&E,C"QT'X0W@8,0/3ZB2'$>A%C#%X`$C7!:@AC&/R&C`,5E3?:JVJ;U
MV;QGK/3Y_MW))WEC-L.,[4V#%:"D>6(`B)GP`@#<;``2H"+&,+.E5%DJ2F-D
M5DXCFC,(*>8R]SC(BL<%7>\35(PH'L7V":]6L5R2XK@K2ZKR[6K\?U?N.T&=
MC$F.#ZJUMF-?%F^.YZ@>._RZC<%2-Q)`GU*S&M8\*TC?N(W$9(C($@I('*XA
MFN((P!*4!)!'%]\ICPN8\IQE(US%*XS5L;:6>IO3,<3X'P\#UCP!!F`0#,!3
MZ=V0E5]?KK(=8@CJ=P0)$[R94@E@2".18>OX2-_D-5&.15!)8/RASD5GK(B.
M"Y/-T20$;P$6,%_F$HT:K`F"07A&-%KR_#6E1NOB/V_$==SU!ZLK`RRO3A^-
MQE=MK`-F^/3_``D`C93((Z*RLL5M7!HSGB&)52!,;^*1!%=[`#:QIA2%8STE
MC1D*U7",G=HQ`<QI%08VLD18%;U5QZJGK]OA'S/R\2>FYE7LMQ'>MSCN!Y3!
MW`Z@QL0)Z-X!2`WE4!ZZ9<T6VJ#/F#]!FE*12Q0@,8J@4A3':5K8A"/:ACD:
M3Q&\SG$<]HWG(<%I>'JN'`R('4D#?H/'Y"-XV@D*%:J-J\C&8VK!DF0`28W)
MG;XD@[$[D@%RZ9$:=&B3X"V%;'3\EA126I'\BF.OE'D-5K02$>89C>HS""-[
M".09@E<1T8Y;:V>NST[3Y8C?8#J/$;>(@B!NK`#DHOMKJNI]:A?."#MN3T/@
M=Y,,"&D^5E8L:W:HCE1K^I-V8QCU%X/"YC3C`7P3U&%V?"$6*C1(X96N`@V#
M_50(%?VZ(JV/<`3M/V2/AX[_`!&\S_-/WDRV5YF,=ARCIU@QL1]((VV,K`'\
MG'[B0@QI%-)'`F%">#/=($K#C*C!&:,I7#:0L7U.(=Y#,(-PFM([V.]:/67%
M))8RW*;$!#K'3Q_8?#:#.VPF.#"*E'QK!3:0U+R(/@=SXB-_,""H!/(P#ZE;
M0S"L*.6Z4$Q)<*9(8Y?)%>9"&*U!M<OD1[Y+CRFHU&JY\GV)XJZ4]K[6JFN]
M.!`#J/U?ZH'ZHWA`15:ZW8EAL0EJF/ZY)V^.\GYEI$380<CY:DBVL$<B/$(5
M8I(Z#.$K'/=%(P9WL&8<@:*+O'"X:J1C%>T+PG$YD>3#K4'JL*L0)G8_'I\/
MF9V)Z@J997ID&O(I#UJ3Q(W!\#!ZR-MA&X$A2KJ0CU37MA7T=\`S4B/"QJ,0
MJ#\FM>R6!@W`,@4>%PH[T>T@VL[,(QS!.$8,&R'H86#<'X3\O'X[B(,[@@D%
M6LEY59B>BWE(^,?,=#$B`9!$;,"%*LE,Q3ADUQR5\HJO4B_DA5KE?Y.\G_EH
M1I@ED/<23+<BF<USC$<J/8\Q#-L;;BMB^H@^1_LZ&.@Z>`Z$*%-=V,KT.:;#
M,[C^V9!/5OJ@DGJ"[.+Z/8/G4TATJ*5KQ3FC4CT0QQI((X*M.-_Y?G^01?2C
M'C/_`'/(2>Q"NB29$U8KN7@^S+^K;?;ITZ]1MOM'-5QKC=BOZE1E7&_4[[;_
M`%=3Y8(;?RCER-5CS5JUMM71[",-I?QWHY&(T*C43QC<:.PKTB,]0TBM16/4
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M-"<5ZM0951HO8@_0KGOE-1J>@8W,<I_%BL&UQT&D27%E^[R/*-G_`$GP^,SM
MON0L\T:#[_"/-A-4^!Z?#Q^$0>4"`"X45V5U2U!^XQ8TX'X_XX1NE$8=4C*]
M!,?[HSFR@1PC5T<!6/0[!":T3V%&T;2LKX:F]-S6T\CMMO\`KV)/4@B).X()
M,&S)R$]>I;4C@!)G;IU&X`&P(/(`""&4`,*8@),'0`E1WC+'*]7C>YR*AU(0
MA&N<-AAR'$<AC/881!D7S>\;QD]A!SC*^.P8$$?N_L^`(((\""(!2JO3FHR$
M%6.WSDGX$&=R0P(.Y*E6Y%;I2O,=OY%`64TAV1D2(=A3C,(JH`B#$=DF1*=Z
M?R`/;XD>4*/&OF1'Q9,JZP*8R`(6=Q`(\?"`/`CI!WV$,J14LX#8;-+A=C)!
M!VV!DG:5(@DK*[M-=EE/1TO,%12E%*B*,C6,80(!H-C4(-SFO<$01LBQD=_2
M\08[6)W<R(-CZB2%RAY00\_,_P!\[GYDSXN2+H0;.WMYB&KCX@"!T^``@>!`
M4#J*U!QIV[3\<M?;BCQRM:Q6G"09!O5PA247W,4)&L&(+SC)_:]@VH5KQO'^
M7&;91YE:DD@SL?V?/XP1O!V@@\&,V7Y&3)4*8ZB(Z3UV/0<@=I`Y`@KZB"8:
MZ/J([FJTX),4J(USE?V5Y5&1Q!(PLK_FD>5$[JIBM<5%13-D-=9VD-BM.Q4C
M]/AM^P;?R\?NKP4STC<6*?GXQN-SOO\`[1D_SAP<B#3HQ(T^G)(5I1&)'`@O
M.-Y#8.-X$8@"CDQD_K"1%]K>S/4X)_2R*8%;IY+<!L1)\?C\=CXCIUF5Y%E:
MS&"^F^,Q\P)`C;:!\""/Y3UZ<2K<16R4GREY:2]BM0T5WEXN\11XTH(@/\AE
M[QQC`^,`+O)J-8,#!O5K&162`5<WDREGH_[2-_MWD_K)(DERK6X\V]O>.M?Z
M@"`.AV@0`=H`4`P!6'3'J=S7'5P[F"/]$8AY`W>Q\EJ/:5WL5!AF.<C7R3-=
MX,,5CS$5&E0DF+/BHM7>FP_(?#^SX#J0"`.D*]<^50TC*I'S(\?'?8-\3T#$
M%FV;E97=40/@Z&,YKVR$(Q[5[.D>!12E&$PR"=&.5S2@(81!D8Y_?S$\92>P
M$B3&PLQWVB/L\-_B!U@@@_,$"&59D-6:A!Y2/G!!V((@G<$@@@GJI5FE'LD:
MV1"():(@&O1&+%,\0A0V/2.CT`5J1SB&-S(L,;VO$HF-8QKQJ,046MOL5PWX
M@'Y_'KUZCXD]9ZD&2?O8Z'J9?P;"1$&`%Z=.A$0%!E8``!!"K]Q3QQRYVQ`X
MSE+%+^4-".8Q@T1C9"$0C%%X..T;3(X?I8[Q4JC%V=,A,D+#)J(79A']G[NF
M\_"3]#F!4;"O!?>LR/EXS(CK]6T`QRA=[:A-W`I'Y4>Q56>IOJ?%,@S2"R'B
M\2"`=\9QSN.<\I_I<QQ2.<3^WY'?X6]M)7B:_'QZ"/F)@0`-^@VWA1-,F4K^
MH+MN.T&"9C<`Q)DDF(),G:6,9,=)L;10EC-,D68J-+&7R:]IGB%$EJC$BR$[
MC\4"]CPG:]6-$<)6HV/(!;P;'LY1*>/[QXCKUF1UE6&[*UYMKSJN$\;>H^<`
M'P/3Z2"K`P%=&$(Z2E:>-+5U/9Q^Y/Z1>U7M`*1%CADM``C1#C1_T$,J,[-$
M%XV/5K0H`T>LOM5D^^J.W[8)(D^)ZQ\2#$D\E:V.ADM/X7(7S?'H"`#`,`#H
M#&P4@$@+P9*/1*\M%,`2)(<])9&1"*=B$,Y3R3>(W(YGB0ABE-Y-<QSU*XCV
ML(4DJ-8!8+T(<=!.W3I_9MT/2!(`1JQI;$M!K:>1XF1ON3M]IEI!$SR(!9K$
MNJ-LRR0C+.`YSGQD1%A/84SVO8_R?)8,1%<1WDH_T0KW%:HWA(I5C%F14FHC
MTK.A\>GZOX^&VX81R"3Y(OY#(IF5_EW/ZX_9XDGRE3RX-;`:<&CK9'AXAD#$
MUWB-K3H-K&(<*#1"1!O";T-\'L()%&-KF/`HFOK;BK8U@G=9^SY?/???8[DR
M&F+;>:9U!C9P/MCQ'B!!C8@KL`0R%0:)2E/`.`U1-$,PV(]ZO(CG#+YI(!(C
MF$2,+P\%8<:]PL:1R':\+"-EQ1WWK8K"ZLP?]1!!G[#U_P`)!(X,8L5Z7K.-
M<`1U^1Z@@@@?[0^D`^<%0PLK6(P4C/V#2*YTF#.D-"YS?)Q!',5JHPQB*<R2
M5-*54[J1TMY._P#7**JV]I*Y%<=+%'[A\!TB!\N,>"#[FH5\._E]5+F/F"3X
MG<S)^9<GQL;_`(F:D1)#I'[J"4.P@%8%4%[4&9(A"#-Y0)(7,8(D1?20+F%:
MYR(/^XCAQ)8[5=0OI,.-@G[)^8/QW!D?':"Z&1ZW+_B$8/28VG>)!\I'2/*5
M((G;>5KL6%YAO(#P!')%^/'_`"`.8\#X[S=BL<$K2CBA>T80/8HBM`%6^UKD
M"H#,K;H-%G(P9,'K/V^)\>HD]".7(&V@9<NDHH80LCI$[[&0!T!$'BL<@>/%
MA1XJIX8Z?L<R,L8Q$>GF=SWBD2Y13HK2(>,\K/RWF=XN()[WG>5A6*=Y0S5M
M9;[]#*_+P``^!\(\"(`!!X@,E,:Y4_X2U>+GX]"23\1.Y.T@DL6#`N66V`R$
M2BL(TEQ6H"1(:+S]Y5)_=>)ZK[%=((]SRE"B/>1?8YXU4CI#H\J;<7%]94#S
M`?#_`%?/:-M]@H9$L%38ERV$^0M'4SO'CN>I7<G<E?,7*66KBL*`YKJ/*"@Q
MI'E=O4(7ZM:`9'>Q/17JWU11/[O>$;AC:CWC&*-(K%%H910P,[CQ^?VGQ/23
M)V!)9;63CLC'*1A`@]`/A.^R]`#N0"`)*A:WQYXYQW]8?U1D_(%[1/')8B"8
MU%DA/XMD,8)JE$P[%&</9CFE$<+4;)`.-5./:.1\I^'ZB.GPVW!^!4GRL978
M9N.W%?.)&_3Q!Z[;CD(8;$,KJ(=%\U,]DGQIYL56F1I&KV&YXW*A.SE*A5D'
M>XYY:M5'H<ON*K2*8AVNM*W5E?OD;;]/L&P'A`@2.(4BIC7*_P#PUJ^;?P_C
M,G<GQY'D8;DS@Y$`$9*"Q1S#M*&1',<49CV^Y$&L5&L`\LD;7D1/Q_`J&3^V
MT?D3LR))'5F_$5;B&!$GP\>NWVR(ZS`W=38B##OD,"I4D#QVCI)Z_3!Y=(D[
M5V++6M<>$=EI`(I!^1RE+[6M='>-IFN<]YT%&0+0">S^I&"&P;AD8R*-4JKZ
M;%=?2L&^WZ_V;]8^),@@EC]['D4/4XR*3(DDF>G7XP(@$>``!4@5@_AZFQC;
M^O(]([8\ECI$5R%1_I]Q3/;-<L8@3JP[FD,U6'"1[2$*,HB>1PRXB?P]@$RF
MQ^?RWV^6X(V`((A2F0`,RDL%"ON-^DD^;8@[]=F!,EE96EULA5$Q#!?4D1P3
M`0Z^T3T'[?!(Y6JQOMDRWF>LAA')YF(-[Q.1YO9&D3KKD*MZHW4Q^KJ/D/"/
M`&"(6&6NW&LYJ<=MF$[CQZ';<F=P3NQ!*F6Y(]TI#+'IK`D8Q`#C,C(1AG*,
M+A()H>S5*[UC'%='CM>K&O"T0&,5KDCC"2LNL#75AA/*>G7K/[Y/SDSMR)%L
M53)BW%'("!9GI$1X[`"!,2L*!!X*IH@W,*5$E/LAJIPN<IGO5G=PV!:<1G.<
M^,YH(S!O*PGF-&M12HX*QORXL:M#HZ^D=CT_A\]ST(W^&_+@[6Y55E=AO7=9
MF?D)!\-A$@R('FE?3]2M*E/%*N88),-CW%5/$S"M(QQ2R/`:J-JOFM[,>8C'
M/\3D:\KE:DGVE%:1UE*7*OT\/U?L^`,;"`/I@&J>Y;,JL/4#R\9\28'^U\2"
M?,028%G)ER)FMGQY?E7N')AR0-4(HQ2,:]O@`+WO$X17JPL=2"5J^PG]*@*(
MKVNC2GVV5LGWFQ4[S^O^W?P'\P('F47T7);-!#*XV`)^0Z0>HD>)_D96(-=A
MIU45D0AJ"=V<CVMCB0;V":T3X[O[3%"Z*.+X1@J[P9ZF-&-SQJ(0G"J9+07`
MR$^W]_ZYW/SW,&29NAQV%;'#MZ'81MM'01`&PZ"``"1Q52N-!-#G4<ADE'K(
MB^:J9.Q%[M]I5<DIBC0DF0A2R/-OI5452N02^<R&6Y7KO7C$/X?Z/@.D;_`3
MLCBQJK<1^?U5SOU^)Z[23):?+/U'CO;4TY=H25#@6$1CF!1[ICPN]KG/*8T8
M@E58T@[I12RGL\?4I3$<1KPD*1P_W..B$=JW^KI/ZC\0(@3U@""&``/I2Y7*
MRI+ZAY?J(WW)((Z$R28Z2QD%68E?Q'H4L>BAMC-;V(%(I'D*9C6$[@$_\@3X
M)A#:@G#$43V.$Q6-$0)1^`3PA0XS\O`SX?NW_6"-S,A@997JM@SJN`^H09)&
M^PW'$CIL000("LK+"O5*0!>23*5)CF>C^T.6GJ&`#"^\;A-B%9'"_P!I`D$1
MJ`8(C4.UK`HR3'A7V'Z;R.OAXGIX[GQ!&\CRF6E6>.E=FQ0WT[3M`F1'$P/`
M@CB`1S`"Q8E6SHD5!#151RH-B*K45&JJ-3NJ(I"JB*O_`-<[_P`J_P"O7+-U
M/VZ[Y=E`^7Z?'^)U$ZIJ[3IIITTUSX^\H[C\>@>UXVK#Y/XOF*.0JI#E,%!V
M+209JM>)61IHWJ)2*YK0.<A7JC&.Z]$]@MQ[B1OYL6\;=1O7N/F.L>/0;G7B
M_P"<"%^RJ01Y>X8C0?I,+=*MTV8;3,+(8[`ZY'V1I%-5PV16`D['21BP(AEK
MT!98_.GBRY+K6.Y2MFP;?1NL"!"9DMRLI6*]Z!=-"K?7J@M]I+2,.HR1,K8X
M('$^!5(!(*_YNPY<&GYLO9\7'45A6[G>I4'C#4U$$\QOR5[>1`8.8H$D*;5C
MS@XU%FH0M5;!@1JVJ>^(M&\4VSBVNFDAF)1Y$"JDB:^P/'JS'*1CW)'A(IE1
MSV-&]GMD9+G$I+&U]^6RE4!'*P]!`+``'JVVP)(=G3#P:AW')"+16>/ID,P>
MTAN%(ZMR(1F)!/&OS;D!3C^OB67)^TE:.Y=85M=Z^/-IK;,&"BQ:]]0[-#IK
MBD@V-G++=@(60[\>##<@B`BM[N:J!5O6QL>OM>",:CBUDW5UJ;23RY\E8A0%
M.V[-N"WCO.M-37?W_NC9V7SKHC&ON88X"\/2X/6K.38"3Y:T,%5&X\I&L[3N
M2G9+:XF5FV284;)28P+5*R5E_P#$JC.YRPEM;QY;54<<("_YAG;,S">TA"B$
MBG\6$(3PT*=L&9A7IDPS7`E>0?U&=P/OE8R?NW41``)\NX`GKK>^GMO=<2S!
MY)7C,`_`U>BE5;'_`(9T`4??5NP/(DA?/`9FBH?8TBKBDS][G\Z&'!UZ1Q^8
M9+R-.0VEJ(Y:<O\`[4,,6OIXIV!?(0"-.`@#*+U^Q.H_9BVL+*,BPEZ9\.GD
M8\OIWK8B0)V(83,:G_,Y\>LTY>'0%IR8&QZS:@*'SD"Y`0"W'S*4;CQD:IO&
M^4;K/HJSJ;.HFN:2BSTV)'L;N0%S1U<S4RO1-MH$.<L7.UX1^V45!J<88?DT
MJ/1KFR=RRSB>W$NJ=9%C@E5!^H()"DB7)V43!+01'7'[%VX=Q][68V14Y!IK
M8!K"/H:TPSJK16H$N8Y`)(:8(R5ON0H@N3Z7.U'Y"XELA^=Q,@5#>H"+:P(D
M:]T!M)(MC#KGUVE`"NKH0%;'C0VPW`8Q@W>::WM_;G/:WR;H_'1SM'-9*DE4
MX!1/)"7=CN6Y!B21&M]WGO58[_5A8T_TKD:J"*[(#J!98;2Y"\;0*JZU\JH$
M*@!3.M5N1,DS$+_D51`K::HD5<>K@._8M35W%!R/K-C3ZJ?$_<,X5+A@I\6M
M4T1A/<HWB<,I$]*^75]NS/QW_#7,SW!RQ\Z,KTUUM6##^78M#1$S('FUYYWO
MMP[5_P`;C)75C&L(OW=J/7DW7):PY5'GY@O)`>4$%6;RF<AOFT^_H;#5Q4K9
M-S6_O%5KXU9+D+&BO99SZ>OV%=6-='C1*Z]GP5(2(K&L@68C1GJK5CN=K0EW
M;\A<1^0I;BU98"3Y0QK+;DE08#3+H58?S`;LVXO><-^XU\&RDYI<%)@>9D6Y
M4V`6QEDI`%=H>L[%":;05Y+"HAP@@'%E):/L:3Q-&A0@2#G--L*&P/#='>ZG
MT$]#?BN*XZ12F8@T1DN65)<BP5W%V)*<(;8DD``!P#/F01RB.0!G=$&L?#I:
M_&6I5"V>H6KW"J"26:MB(\EC<N!/+@2($66-K;CY5K6#T^SL3U<^K([B;1UK
MZ@@F,$,,;D/C!XC$L7/(]EH43V,/'5KO6X7L5W<R-3D/=EI.+16K*X_%HW+Y
MFF_P_P`/B#XS'A.O2?R[QPN?E7O6]9_IMJ\(`$#)Q8/+<\R(#+O!'(GS1KMW
MUX;KZPTZ::=--.FFM0/M][6?._+O9&/D)Q3L"!$K$(0C16^.5[6A\7O*-2.8
MCFHB]U<B=E[HG78^Q@3[CP_\/XNN?_B;/].O,_S8('LGN70O_3KB!U)AZ?#Q
M\)_5KF#ROR9CS`J";#`UQMG:013[K_IS)!20XM,YD,M11OJK`>C@P=(2(P,Q
M8YPUL(T>Q1`J\GL:WU'M/:\P,XPLAAA*T+ZP+$MOR;D.!*3*\@78%/-`@Z\!
M]Q]^[8Z5'N>&A[I8@9_PQ%:A/*4KX-ZJK;QXOQ9:JV6P<9/("5Y%XAA:C'TT
M?"\OY'$U4\E7`O\`-\J6-[@;^[W-]468H%0;:U;I>0DV%+$9ZX$$1@N0[)1'
MD:]P?7?VWO#XN8[9V'=?:H8H]`6U%J1EEO2:+`&.[,0=N(`(Y3'WOVU5W#ME
M2=H[GC8F.Y1;*LMK,>RR^Q'"H;T+4EJQM76&4\A8Q8$KQKM+\W<C\(Y.1HC8
M23I[E\6)H]@'CT?^4RK6WA'@5J9/+B)?$DMAW+&M*=&"4)>Z$5AA!1O4%_N7
MMO?,L8PO%5$E*_6\@52"WJ.>$2O029'203.LO%]C=\]J=N;-;#;(RN(MN&,/
M5+NI5?1J!L)XOL6@<3]1#*L:Q''P][DWVVMY)@$KMC`A-?8VY<W#K&Q:>MM(
MMAA\G%CV#K.8=GX4E!]P@]9W#5BO5!-,_;MG49@3$[8W+#9O*O,M+,I%MA*\
M1U$[F1,QN5'-IVG,[<;.Y=]0IW1$\SFI5A%<-12`W-CY3'E6&(B?*&-JQ.09
MI[G3::T?%D5]]47L:321WJM1"S[Y#S&@QH+))7E8,[VM$<C6?D6J$EL1S'1G
M&RW[<BTU8U4BRMU(8_47B`28^'4"8KA#OR"Z^OO5KY61GY!5J;JK`:Q]"US)
M4+.\&(8QRMY6#8UEI7(:E,G/X>NH+,\^WB\17]7';G&6-?8TY3Y_'1EN9;_6
M.)8W<=)!2)W0S0&8XP^Q&`3J_,Q?Q=>;0_J>B<Q&\\$-#V'B/%5,`>$@@'8M
MJ/MG<?Z==VS*J%/XE>VV(/2Y*R$UTCF>BM8))_FXL"R^8)J^<IHW[$5IG;-@
M!V@DD-@SC0K>TG65;6U=W+/BFK5SZ^WEF_<YCI40"1YBDCLD"BIYR(SGX&7C
M#"*9-4^D8D2JA2S*!;Y@5'E'%C*P>)?96`VW;LX]S6S"O"C($\6*N[,JHY-'
MD97)YMS1>+RH=:]WK)K7$5;;U_HP46BD2*RK$2GR8(#MUH+^0V"%+WDK*:&2
M&LG4\<45QC)`>5S72QD_&$Y7HT:0]XMILGN#V`6L>5A/I(@GR4V("P8S`Y@?
M21R(C?65[:HR:8[/72QHK'"D+^(LL/$>IE4V$*R`"3Z9)','TU,P-7`[Y7YD
MCZ6/ILVXF:S;+B=:T&GY"Y$AP#4=[H0UM6RMKH&CS]E*F)A8CI00`"CRSY*O
MCD8GD1>L<>Z^RMC'&R8MR>`5TII)Y(A+22CJ!ZIXDDP$$,#L-9I_+WW0N>N?
M@S1@BUGKMR<E5-=E@5.*K;6Q;\..:JJR;&E&&[:@:FGXRQ%R*YM[FUOI%R(T
MRQA94YJW`U+JR8&/=?C[C5U;OV^@K8#7G>LRK`5[B*P"R?Z%=7%N[IG4FFE$
MK5"`#8`UK<@2LU5MNY.PXN1M+<=XL[AC=A[1E#*R;;+GM!9EJ)7'3BP#Q?<G
MEK598\ZE8DPG/:=H<IMJB38\093*8L=+06/(_$]]16<A)\O2BK&[6.LFMLIL
MR7W"#V0Y;B!BA!#\D]C1M8]B.Y;+P;EKS,O+OYY"XV0C*("<O3,,H`Z[K!8E
MO"9!CT#MO=<9[^V=N[=BBK#?.P[*V/)K>/KB59F.P\KR$"IXA0")Z>X`4@.,
MSHY0Q".VN'[!@1B";W<]S/%&*K?U8J*O;_:O7EO<"K9MA2>/+QU[]V577M="
MV`!^'ATU>'6'K9Z=--.FFL3\GM`)M9/*.25\1)2B])O2(2+ZWR'F(1A`C`^,
M-[#=_P"E0.>I6N`TI`;?M98\JU(`,>$_9'C,[CYQ'F(#<YW\(HKN8,2LQ!@#
MXDD[1`(;_9GD"@9DM0P8>@@M>CB^#BN>B/8OY,:0WV",%6%89PC^92,>US"M
M(I2(YAO:44[+4OCV>$_N(^/AMT(Z1`@B`4US+5F52)B?U@[@C<&#N0=C,L"&
MY,MTEGCS'L/$,5A1!\?QY()0S%$AF19`1A<.1*<YC62`O&JF(X;G#1I2HL24
M>_)5`0ZB">H(^T&=A\"#L)WD#SJL6$]I!J8@J.A!!(F"(@GXJ09)!XPS`UV/
M+CD%H2MA6)R2*^0)R`DL&T#0*K7^Q0^LP6H!@(['$1JB2,B>;%'&'WJKBHR!
MSK`%@.XZS_IDF.O+H98_>QJYPV%-S$TL-CTCK,01M`!/3CU'%%G'F-#'&T<(
M['2`GCRO-C0L<Y'=_,<AY%]*N9(&)I4\O6]RL0["!>/\R,ZW'8RRF"I'C^[]
M73Q'\I#`\&U?FH`J,.08-X#]1G;J!/@3',,A'JH9DT1]Q'89S5#,1!NB2&KY
ML?['H81P$&Z49I7D.U?)JE(PSD1KBJ5'6-H<4L0-T\1_8>@\/D(^$?=2-6<I
M`Q$6^!\-]P1$F=Q\2#T+<IO\41!#0D$1R&2(UODCV,9Z_P"W#7P:X;_%`]F,
M>+L?P]3A*(B"9&-&KD!C#D03_I_T@[=9D265K<1E$TJ2>/R^0_=T*^:(X\3Q
M",DFO:CEB$`+4A'5P2-[!"OFT4IS&>!6""V&(3"KX(T2"$-W]#0#,*!?_GH2
MQ\XW\?E^_IOO)(W+%39'_P`I:%0?='8]!O!^(`XC?:!`!V"*ZTS<N*Y7I:M%
M)*QPD.6`?\C\D9_-SAHYB#F&]*22N]X4&5ZO<_Q:]Q#AGV(^WHD@&8D1$?N$
MQT,@1'0!6KDMK,_B(8@B2IF0?#P8Q)/)8)DF`2SK=-M_#N8;D>([NZL<Y/)4
ME1I*O"8;HT@9W?W@D<)XBB,YKD43F%?Y1Y![#SI?8C^PCIN(Z=001\00(95E
M'I9=6X)_B#(.QGJ-B"&/\I#&4=Z/22""8^O0@I-<-Y(0"1E0!A,5J^N2,;'1
MQAKW@"JJX;F""@D42C`Q&U4UZ@GU-Q8=S.X^SQDR?&29WEC-N+B.R@TR&H!X
M@C8CX$=`%@=00%@<>*",?P-9.?G"@&:2763#JD=5:BD"=[S#=V8\:?WU52_D
M!436D_NO8+NDN)U4\,A#8L"U1O\`9M^[I!G;8$_0^J*7P[14\MCN=OD=Q\.O
M7DL0?,0L^I7JIW0XXS1+`W])8L@7BYK'%)+/[%<"(1/&4Y7^T_D)R^T_N*B#
M]A2HEE%06(:M?I(/ZAXGP^&_00-X`^ZR,H(&6]_J5A\R3X+X^)VZM)\O)F'K
M^9:1K:`Z2A`QO$83Q)S'#.-0HD8X_(@BA5H7&8-6(,S'M5@2C*Q4C2`53E39
MQ@G<@CI\1\_">H^((/F5K;!7DT\Y"[`ANNVQ'0C:8B&!V5E816Z4NM/^XAE5
M*%.\:#>P-@(30L?%:U[%?+`\<<+7(,3AN8K!,<-I$1H?5(C5TMJ^FPN@3/3Y
M_([GY]29C=I5K(*']=&QI)$0&`C;<;C8=`01`$!A"\72B/ZOVJ8)!#:(DU[X
MCHZJ1'N(XIG#(DT@I+VCF23$\FD:\GM>7^@AR'!86SZJ&3(7>?V>&W0`=($1
MN%"M7?Q_#6#B`&<\8WZR8/(@[,2=B"9+;,[.ETQ;BDM+%G59&MFC&:0L4#6O
M+*%[(I#&:T9D/-$CY(U>QKW/>KQ/$1"K&-)MI*$&NW_+)B?AU@?`=#X#H01'
M)5OR5<,MV.?O@"8'4C8D[&6&XD`DF5*MR]-G]#6/>0G.]*1T(]C)@7=WC[A`
MAFO$4;HHO0OI$YIF*/N(3$\@>IKJT>5#Q,_#]>WSWW.QG<GZI/JU'#+JF.,G
MS#PV$['81L/,(V`W3B#1!HVQ6`EUZRQRA>TSR1I;%1PA/_(:BK&+'1B.4HSM
MDL];489A4>)C_P`N.E;^?(61!CJ/U>,_9!GI$$C@VK,05A&HY!ED['P!GP(^
M/(,(V8,"H/J)J15DJKL7/B.=+C$DO,\+$\GC>KXY#/8Q3G>2<0IT5Z-\R$5[
M7*KY1&K;2`I;7Y]FCK^WY=-OD!!Z(#Z,1%F/?-<LA:8_6)\3YI._4F0=[&'X
MFL3!F[CLHS8CA-&-1I&8ULUXY2QG2&AF-,P2N\Q`>)6D&B]F*A&HV-(!"A7_
M`"GF?GTVF)$3\0=CX[&65LFU6VO3CQ`$1]6\3!F/!2((\/,(K=*A"DI+BB(-
MK'"?'1ON0WFC?$11'$3S!$(T@'@>TC7""C6M>CF#:PP843IP8@]9_P!(\3UD
M1N?M)(9YZG]2L,(XD=9^1!!V4R((((7H9``9:K=KI8H,V753AD]9'.C#-(&A
M'2U*>2,8I)/`BN60\YFM5S2.*8A&$:LAY16&38ALK%M9WZP/#8=/L@?"``0>
M(!KP:;%IM;'M'E.P)$\I)@$[]98;@RQ8,"Y9;CX*4MA&-%F._P";DHU@7N<0
MZL*4#R%1XU(Y[1/(!%>I?[SG@52J98\F4%GKUE67H/U>/^GPVAMHY*HT_A;E
M9&^IMAX[D29$]/+O/F)0\N7"RRI7<1WK98QRD&>$OM$K5$K6#:-'>(D>6-#$
M)S0-\D>X87#8U?(3!"+6Q4/OZ;`<6_3YGQ^9GP))%L^76>(O0D,FXZ=(\.B@
M;"9(4@#=0JM1!BV#;Z-,CR8/I$,#F2'O3W!]STF1R"_%DQ1J]&JTJ*,HOT5#
M#*)CF28O5SU_AV#*TDG;P,;'J#]FX/\`A()!5]6UW#,1DL2%"[GJ)\P(@@3_
M`#;%?\2LH(>O4G3'6NEDK#1W-/Y.(\J2BR/R#/.-BE'YD*0CS$DL\G=RF]SN
MQ%(8S36M]R^H@M4^7[(@1_H/P$=(`*U18K^C8:''GZS,R2>O4DS(^)Y'S$NP
M;(E9@G9^6.1&(KQ'57N80P'O>,*1#*89"26*U1H@$$_V-8K6!1QFHV)+C7H1
MD*58;C[?&=NGVSM\8!ET:.U?P=@>LRI^8F!!D$D=/+!D"`LL(KLKG[N*0S!6
M@IBA!%52"(YK$_$$\;TDD*XC(HXX`LCN:K7-07BA&$:,32-KHZ&`)J*RQ_?\
M/C)W^WH1)CU)\JMF`R`T(NX^0@R=X``@C?:`0P"@BB=K2MMJYXI(6E-'(>(7
MW"4XGD5#"?ZDD#(1ZO:<C',,-Q6O>]I&%<XHYL=H]&R5,`B=MOA\/L!D&.A!
M`@I+0PR:"KB64D;B1.X,2#\2(()DD,&)86R=/*)7&'22(I7'<XA6&"Y#-)[5
M`89%<PI#^M6%%W<XQC#(X7<K_9$DRY+D%B^NI''^[;^_H`")V$.J0XUAI88C
MJ>>YD;S,&>I/B-Y8@E98\J[+9:=)=3V/O:8302U.XK2.818[&-8]3^".BQ1B
M;&&SUO\`,;1"$GFK(XV%JKD7UJX(\PC]?R\3UF1!DG:6)%MEMAQ;^<@(TS\O
MGX"(`@R``-X0!L>+<UAY!F60G$`5K0O5S0C;Z&-=*&IC/*G;S"!Q$=Y@5&HI
MF%&X2RHP[:;55?3;<?QZ;#]<>/P(,\&-V50[L+UD-MX#:)$F?$"9E?\`$&!4
MV5B=B%)?0V?EQO&2-"*USFO:T\A7."XHA%241A'O/V7]3N:4JM1QU(UUE8X&
M._D/E/\`#KOT'A\MA_+$52ULV74/47SC]YZ2`9,[_P"T021+\@;Y:EM6/8&L
MD-8"3%:C6JA`L"0(AQG-:%HS$&AA@>)W@,RL\4$015$L>0.^^D@FU=U/\=_W
M3.Y$]01/)3'BY*LHQW@.OS`$`#I!B0(,!H^EE;CP=9!`"I;(;(\M',<X$>1"
M8T0&H)L8I!J8;4BC;':&.JM1HVM8,16*UL890UDG(WUDL-X)!Z^/Z]]_CN2#
M)8@VPA%Q;P$;:0"NPV@D3T$0-H$`!A`K5EQYZXA'BR?WL#/:9BM65'D(Z0QW
M?VQ5"C'`/(5KVG*UW81"B>4OBPBDE19L=+JR^@QA?`C;YSU`^'B`0!N(1DFR
M:GK?\6N[#J#O\1'0GQ,[$@EH#<K*[9MXRWE6]2B?%D(]"1QJI5\2"(Q0E:@3
M+(8=7/9XD&4G]:C((I?,!I=DBBV`05\?[>NT==B!X@@0RI(0V7CRP*O,@;]0
M=CL9GI!#'?B59I1K)2DF,F--6$`QT6,(*,1/7^.,8D$HO!X5!'&-$`QP_%PQ
MHP;'"<T34=67WH4BT'SDG[=_VGQWZF209)^]CQ+1:#0RCTU`^$"(CI`C81!`
M@`J0H^XIPVCIKE!*YYPR$4+VQ!>E1-<62X#21V"]9O3X&0@E$WLULCP&C$F0
MQ2$F^F>A&^_ZIWG:=H,_X9,\',`"XN5P,E3ML(C<QM$&/-(C_'``]6I:A<0Y
MWYA;,:-?ZVC:'P:=)#B-.QK!D17'.]XI17.:K6&(KC=V->5[VVL=+U\!4?'K
MTCI^H=/L&V\``TSY55OJ'(7PZ=9F?UF028@$RVP+$C(C*%US4QI358PP1(8"
MHU)#7J'\>0%S6PY'8GL<(+FN"?OV0)0E8J13LIR%-Q7^4F#X=9!ZC[>H^((/
MG4W<3E8RV`@,!(\>D$=#O,+NK?X65A]VXEZ:0TT-]>6&%!#0[4'[FL`C%4K3
ML$@0L8,;%&1&JQ@0-&)W9@&B,"LNN4AQ8&,GY;_+J?LZR9/5B5:VS%<-5Z+*
M($[3MXS$#;QZ!5`!@(%9*)-TAM-<'#'$0BN<X;([E+'$XDEQ412J1DI\CSDN
M+Y(@7]RN.C1N.Z5%G7A3?2&8@?/KT_9&T>(VXR>/%ZXBXQ<ID0$SM&X$F>LR
M3O/@=RX`+FRNZ;LZDHY'[G`(*.0KD*:.KC-:OFHCE)WBD(0GG)>/S8-ZN*0@
MR#>LAX2SK*K@5]*P$@=#_K^4]1L`01Q!%<E^,RO^(I(4DR1O\B3L9.\2`9)*
MLIYE6MFRA=;UD<S&@CD<TA_T:*<16#0)2>HH7Q@-=^1%8K4:\2(-C%8^/ZQ$
MKK`WHVD;D=/A\?C)Z$_'<F0TD62LIR:`XA6()\&^!ZB!U`Z$;`04A6IID2X_
M)$.FE1TE1RC)#,9Z`>1`N64!ONCDC#`5P/25CVN"QSD89%$T@I<,,KT\3ZZ&
M&!D#?Y>,SO(C?X;D%'./7D\P,6P<D(XD[3&XW$`&((((!V:5#+94L".U*:^1
M@U)-`YTIG9'F-+:UQ'>]7B!^6:1*'*>J+Y-(\Y7JJHLHJ_O%S'U\>3`;;Y#Y
M=8@1]D#_`&!]S:@&+E\5ET,_$GY["23)^!+$_P#QQO\`BH\^M48V6\8A6=G^
MQK)/]#Q#<L7U(CQG:0W91!>SL=OL8@7L,Q[(DQME=LGT6`_5^N?#[9VV/($$
M%T-UU'%?Q-9(\=_#I'0[]%(\PD<"&!6NT3+D+;48QR2BC":BF*5!L>!(H`E&
MUDEJK``K^X7(YKA!%ZF.[CC(Q[:V@BF^5!)Z?.3\.I_>3/BT@VRGEDX@5R%4
M;DQM`!&_TCP,B%$`RJ011XIK`LWO4V;"%>HW(,KQD*5?!TACH]C[@/-Y]D,/
M^^+R(BE$<:E4X9B^L5_?50!_JW7>/@=CML5,<62S%N:W_A[P28V,2?'9I$_X
MAYA)\RNO(NMI2@I[E["#<Q)J1R,/[G^/L=("0I6]E,]7RI!`I[&D7R,X?DJE
M+&/85AKJ)!^F=OU?JZ"=HZ3&P9:Z\EQ<H@CZH,R?B)/B=SQW!W8B3R9'N\V\
M)\1S[V',''(KQ'\5]+$5RL&I/!RNAQU:(447='N$T@AM]A!-#&D5BEP_W#J2
M(CQ_TGQ/28)V!)9;:9-1K)RZV`,@^`\!_NCH!U@$`2RA4>BHJ+]_K`>SSB%8
M]S3-3UD&PS&2`N>41XXE(U&L*UP#!:J-<41@-1)``1S^'M,;C_4?C]FX/P*M
M]+-/Q_&4+,JWCT.^XW!`^?E8#;DK(/.B*^P)^0E*8"R3B\QR9'L5XR.><CY#
MD9ZI!GC1TGLB/4IE*16O5Y2M6T65CCZZF%/0?JV^'P\($"1`!])1<W/\*PY.
M.IG8R3/@3&_C)DP99A^(I[K%M1;2?)6O%+,I?Z7M&V.BOA]E5[&C&U&C]3VN
M&1O;R`KR>*Q):7BHW4CX@?MZ_P"GJ/\`%`^M-0>N,;):=U8S]FZ_J^!!!\4E
MH-5@@WE-#`(T]I5$)P_)([Q!1K&_CJU6$:=L8(XPP1E1WM1@VA:YA/6`*)5W
M47.Q%9$F>OZ_E.\GPDS!$LWWMN7BU(IN!A8Z0/AXS```&\P.,AN*)_P]0DBC
MW<-3%<01X0W_`*J,HV.[#(R0]H909;OT,\['(\3W+Y%$89$)(!)C4M0\+!5O
MT&X(^7B/`J1"LLSJN75R:0Z@^!'@9V(/CR!D$[LK*P+I9!IK(TIQ:R4Z3)<9
M)(TFA5'L&CE&K$&G>0_P<^0Q6O5YW->0*>9D+%E6%U]86+4@`1M^D?#IMT;8
M0ZUVXM[V3CV<F)GS#P^$=?B(,L02N[<J[+H$)[L]+=$<(;@S58]A$?ZPB%&$
MQ>S2>T4=1AC,'Y.1S?0P0^SFQA@+6U<#(3G)E?[?W]9^TD[<BPLLJ)PK/3('
M!O'H``/C($`1\.(`W%81J*G;C#'&>P]A([RH%A?4BB9*"-ZN1LL2"8YZQQ1R
M(]2C];1>UI!>MDB.".DLQ%?4#X^'V;^,B(,S$&2K-D9*J@-TE6,3&TCYB/``
MS(B.0*\0Z)!EPOWH(R1W'`6)(<PA"L*QY#H]4*YHD;)*DA)$DB*YR$*TCU[H
M?VD'9U1_0)#058?I\-H`^`C_``P#59;5^+0%)#*V\S)/CMN9DGK)!/\`/R9<
MB/1$(\'XA1HJQU8C".>K4>%B@_'='"Q[T"C!H-R(AW(J^IPS.8L63U;D`<N:
MGK_'>9/CX^'QD`\EU?B,Q3TV&Z_PVB!O'@?J/\I5B#6^J=%*2BLBQ9#4)%F>
M?XSF?V@B8U2*CE0BB"P`8T9R$:J-:(0E</PBC(.IE<#(J#+LZ]?C_?))V^),
M&6(-T%;'#O-;[UMT\`.OV"`!N-H`E8K4KC0KN/\`@R&6\8R*0[WL,"4-ZD<]
M_P"2)6H$D4I$&Y'R$5'">4;G&["(CY<236AO47T6&PZ$?J^8_P!GQ`/EW$(Z
MTRT])QDUG<G<'K.XZ$$_XNH)!Y>5ILJLCRH:7H@V\(A&G\6M<)S5*=3,+']2
MH]DAZ(UBD0B*%QN[R,*!Y7D8^QM5_0)I<;?N\?E^K>-@0P`!%5UE7XM1DU$\
M_AU,@B.A^<[%MR&0L6!OG:*7*(-T"3$07X+/4CW-:)KE!ZW,\FL*T#?`;!*O
MJ<P'@T;QO:+TN@67H@/J(9Y?V_O^/7>9!!/(638=MC`TV+'`1\.D?./AT(6`
MI4A>)II@+1:N4:#)8%T2,XHXZ^OT!`U/R>_]IHE"QC8XC^QOJ3R&,BH-B#EQ
MH,C5>JH=9YGKXD]/G\8\>I&YE&LQTR/P]II<#TUF-H`Z^$1T#2(W`;8!;:Z?
M-M#%`DQ)?Y1WN,=JG8HU?/<XDJ0494>-AB.)YG*WQ\7F<97>MIBE/'M*TN;%
M*0(`V^'0?9\!\!$20`K54R:EI=;>1DMOM+=29VD^)'B2TP&9G3(J%I6AD166
M,'M[A]Y8WC:BDD(0H9+7>8)#'F]A5"1'-/[D<HBB+[?QSGCJM96-;_3T^SJ/
MA]HZ1U!$<E6?(H5ZQ?3]0W$>,D'P,G?B9Y3]+*W+@[Q89I5I52X\YK0O4)0-
MD$"/TN<(;_(BM$6$/_EAA;W<-8X_!B.:H$8K*NCJE5H9-]YCQ_MZSXR9/\TS
M;6I[,C'9+=F@B2-MOL*C8`;CB(`(*`1CTN#<DDM_:)L4<IK_`"AD>YS2C436
MRQ%20AXBH=&/`5B^04<YC3->)#,E1%E>D*?60D>/\.D';J#UV\I!XE'UCU91
ML'X:U0P^GX["1O(WZ$;KN`X*\A97HT0:*T1Z39!U/[7^L,=QI#_(P2(`I/9)
M.4TB5(<U51#/(4@U5SI9VDM7)KZHX@1\]NGZA``^0`!Z(L4@J8>1/-C,]!)Z
MC8]222?]HDE3)L<-D_)\!(BCM8KTCO\`R8Q"#>T3TCN5L8[44KY`([_)PXWB
M[S&PC&!<IQJ.+,BUKLY_=/N(/Z^H^!/^+XD2WE,NCTNI].,BLP>0GIMT/Q`\
M%@R`0%)<%:[:]H6=_!O?OW\6]^_?OW[)_KW_`%[]<J>NO01T&O75-5TZ::=-
M-:-_8UZ7-YRHN`5E1=FB<I<:*.DO8*6=7;^55M4)`DP'M>*3[0^2M1Z>#'-1
MZJGCW3N_9E`R<EZ69T!Q+O,IXLOFJW!\/U;^'CKR7\SLQL'!JR5KKM9>X8OW
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M2W)MB0=2]U]I7=URJ\?V[W3`:LDBC%R+'QKGL7B7,&*[>7(\@MA`3TZSR`(U
M3=%PGR1Q-F&92IXRNM`899=?7%J0NU1)5GHH\>8VVT:QIY),>GS5FJ.:.6'O
M^(YH6.<XGLZDQN^=M[OE?B[LI*U@$\ONX5"1Q21!9U\5/U2Q$"-8^;[4[Y[<
MP/Z=C8%MS@E5*#UB7M`;G;#$A*G\'7Z"%!),ZL,F.)QG5S[+653;.TN)@SWD
M&WJPP6[35SXVBH=&8E9[?SX<'/V\<9%`]T1Z,!''W4LLS&;`9@[G:M>(_&I%
MA2K$^G6"CH.70EU)$CD)+'H@)TY[8>PX[W]QK]2^UIL5T"^O<PLKM)6>2K6X
M!XG@85!]5C`6!8[&>[&ZL5P$=@NF96S;.-*\Y*TUR2ZK25-W"(JA6M>^+*>I
M!"5Q5A26IV1QA>K85X58S:302OI<@I&W)>+<E/7EN!!.W)?@#RT]_<[3VO(7
M*`<Y`5F!D\']12CKTX&"9`D\&'BR\;P+KC9F[Y2B5PZYLC14.(AR;.J>]OHI
MX\K2F/5`>\8G5\>Q<,:2BHKBO:)OFCA,/VPQAKE48CV\N-=EI"MXL0@#'K)&
M_$=-S$$KK9'N;8&7W"N@)SOIH4NAZ(#:2@V'$-`YG<D`3*A]3E08_)6:TU&^
MN4DDD1L&_KO.>"YT]9H-+01"WX;&JE#'6_XZE:]2*6'VBR4,R0481C9U'<J]
MLR:KPT*#*-L51D1SP(8;\^6T-YEXE06).IL9G[[@7XA3[PKQL7S![4LMK4V!
MD/E]/B9E/(W(.RJJC68N-6:W5QK3-SJ:XN;"/'BGEKF@:Q(<W'@)'I<#9R[$
ML$X(.TK+`"2I05?[!>+9!&D&]W;3=S.'B,F36Z)620.9KD6&6M4"036P/%3$
M'Z000-=-V(=R[C79@W56VW``MZ0NXM2"$QW+%2%O5AS=9D0'(928E*CYIYBP
M]Z&XOM#E<EG`5DVOJIW*>_CAN-CD8CIMU8D/10\K?;*Q!I;F<U#LCC.Z&!K"
MM(UPF^5]WN?LV=0::*[KLDL"PHJ/&NPPH\QL2L%%&Q)'(R(,[1XWL3W/VG+&
M3F78^-@A&5&R\@![J5Y.Q-:U67L+7;S!0Q188,"HF3)-X6Q^G-!MA[?=5+9-
M&]\BLAAR=?8"E-8[/!K)-U&NYUM>3#E2''AQA0I!W*B'#'[D<.\5][S,4/2:
M,>Z&V8^H1'U\@I4*H^HLQ8#^5FV!C:WVMVSN!JR1EY>-RKW112K`_P"6$+BQ
MGL8G@J($9OYU26(W,XQU<JTVFNS$K+9R@%F^)],:JFYN--<RVI;/9<-K5R+B
MYM)<VTN;`L",(XG&>WUQSM:C455ZXONF(M6%3E+;98;,M.0<CRLM>3R"JH"J
M))!CJ1UUZAV#N-F1W3)[?9CT4K1VZTHU0;SH]^%P+NY9W8J`P+'96`CKKK-U
MY'KZ.TZ::=--.FFM(/NY._"/*#57Q1W!/*B*O]/Z(N@XN17?U?T?HB_[?T_W
M_IUW7L+_`-^8O_V_1_X+]>3_`)O;^U.X#_\`<^7_`.TQ-<6.=*V-8<QVY+!3
M$AS='GZP!3Y:;8R?P:F)4"'!-D"1Q/FQ($1X_3LS#E"CHY8@F(@NR>V=BM:O
MLR"N.:UNQBP`2Q;<63L29G&!4GZR=]?*_NZBN[W/8;I-37UH":F8\4"`*:2!
MR"K$9K!PL^FH\NKGY]D28<*A+)D'+'M==J'/BR2(U9+T@`B`C-JGI!E\NLCM
MF2&LB1YL$PE]@F]T&KUQ?;ZJ]EBJ`&2E-QX;DD\MQCS`EF5@=B>L:S_>3V5U
M4M86-=F3;L?'R@`</*V9')@$5ZV&ZCZ9U$RW)NXRN(Q4+%3[)01IUV']G4TR
MTB3K*OMQ10Q5H2CBP([*D42,)@XX8SH`U<!ZD.%#%MR^V8.5G7OFJO(JOFV4
MA2LSSW)Y2QDEN9\PA3Q%W;^_]V[?VK%J[4[\%>P<)9PS*X`'IF%'`!0`H4UB
M4,NO-KPV',O/-Y?0\7I<I3GABCA;(QUYDY-['>#\U/8$!)CK&YBS0R6^+V!E
MB>!BK[N_]35P\/LO8*,<YN+<X>3%B6!3,>,<5((\2I!/T^&MGW/W1[PR\M>U
M9^-4:PHFFRDV".6X'+DX8'8@."H^OQ&KAI,%A;+CVWO=S1U'"EB&!I8T2Q@[
MPEQ*6VCU!K&'"E<:6<.VW5JKYZ#"C13H3(CT$9K7*,7;'N[AGU]Q3'P;'SJB
MR$@U<1Q+`$BY2M2[2=U8L)7Q.LW%[/VB_LMN9W:JKM5P2T!ER.9YA"RJ<5E?
M(?S0(%B!#Q8`PL8KP&<C\@V?"%/J+^^IH,3B712LXDB!2U<JVF5U!@71,QE1
MVM[G<U(MI!'/*LZREQ`D$C2(ON1CNMKW#);MU6==B5UNYRT#P68*"]LO9Q5W
M"C8<45B#M],ZY[LV"G>K^TXW<+KJJ5[;::I5$+E:\?C53SLKJ+DR?4M=`1!^
MJ#JZMS$@\4:.1^V\1W38M;)CQ:.UY&D_O+Y<ATF.P=G4P\K"K\L2J5CBH-HI
M$EH2A:Q%1&>#<7`>SNV,/5S$YL"66D<8$'RL;"7Y=)D+(,^,ZV'=ZZO;N<PH
M[;;Z=;`5ODGG)D0R+2JTE.L`,P!6/"!<4KZZY:E4\6%'SR9CRL0G-:_@EIZH
MIJR6DUO[?4PHU1G/<DV4KGO(^4<Q!@1G?U^/6,GM#M"W&QK/5\I`6>3>81NQ
M+/$#P"@`M/76=9^9/N2S%6E*!C^<$OQ*)*'EY44)5/([DEV8A(^F-8.YGU.F
MTFJ#?6M]87%L*FI-#%K))X5C80K5D"'=3S9"BNV+CXTYIA>Q#V0(3(\<HQ59
M"$4@1[WLN)BXV(:*:U2GFR%@"H*R5'J,OWA$;0A:2";0!#'DO=.?GYW<!F9-
MSVY(J2P*2K,KA5=C378/1#2)Y6K6%4JN.Q;DBY&YZ=%9G8MRLFBA'A\ET%A4
MMLTFE'365S52R2X]?%#(9>6FN;+$-C%(A*@1FJBJ@D>J:WL'(Y)HBQE.,X;C
M'F56$$DCBM<2=HL(^<:WGO#@,%<KE2KIGULG/D0C.A)"@'U&ND`"9I!Z^6=9
MB^7OQA&X?CR7`>>DY];%6+/;$?KZ:VMHF8DV$?82:_\`.K++4%L+@QY,F&Z)
M$5EDB-5QOR`]:;W3R(S&2>-G;YD3Z;*I<`U@PRUPH"JW)O)O"\6UT_L`UJW;
M$>"]7>8AH]9'<5%A<5Y*UI9V9F3@GWNQ+<UUVRQ)0GR=`4#GO$ZN!X.>Y7N7
MQ[M=W<YSU7LY%_V_Z=>(9P*Y=@;KRU]5]I97[;2R?3P&KIZQ-;'3IIITTUCG
M<.AFD0*V0]6%EQ9;A(BDCD(P)8SWK%EL_'<DB,1&$[,.CF*C7_VG(PX]E@AP
MK6+T4CY]9ZC?8[CI\1ONIT?=S4[I0^S,ICJ"8(F#MN-CLTC8^4@.,75SVUMD
MZD21YQO0WLV2T8G!*@C.>&.@VQXP128X"/02L$-C1O1B-&(X*S:V`VU>O'FG
MPW_6>IV)`F23(F25:WGZ#Z%_X0&:^/CM!@["(`!`)B```8`572CY91#TTI+2
MM[H-[E9+A/\`8YCGN<='-]?J/),%SRE<\2"(41'D<QA'DDQ9ZIUN3TK>HZ']
MGV#X;R`1`)`"M72^I\6S\11])^I3/S^1)&YD02"20"6LKNJ,QY)\"#.`]R-8
MX<]!B:PQRD5H_P`=0**1+&[^X5CT<,A".[C<,CGK'+*C0"NQJV^SY?.=A^\`
M=00!R"3V%KJ4M0F-FVW)/A$$^)!D$GZ2K$E&L@54W]W&8!V-&$0&>P37^'BT
MK6H#L4;X[6@9%`CF/:HQ.:UKVN&T;?VVZVOT2&7=B?\`7\=Y/3<^$$G[VS&M
M_$@HXA`-Q]O3<1M`V.P,`@@`>A+QE96'E51VJ^M4+R'9)<-[F>_\H3V"BMCI
MX#,@C>P2B\%3W*K6*R7%9<TVJ+5_S9VCY1XSX;09^&YE'-B$4.V.X^XC>?G(
MV$>,-(B/J,"+*Q%M(;1`?/KRN!(.X:^45[D%(:8Y"*CB#:66591YB/3P>4OO
M)Y#:8I5;9VU.2WIV"5'Q\('[-@(\!`WX@?=79%05#=2>+D^'0R9Z[D\BT[$G
MD?*&9HR(IXY;NMC/60P/N&DB*2(9315<OI+&=*+&,%7,031=R!,U&$091D'X
M1)`BL*+2(F#!G8^,P#^O8C<2"#+J;W1LNA3RB1(*F1X$3!'A&ZL(/%E98K=?
M%-:/<_\`;+-KF3XZD:TI$8K"M1AD<TI$&&,I%`$OB[UB`80G]F"04B/7+J@/
MO:O\L_Z.G4]2/$D$C<RK66XN02?P]_\`G+._QZ]>@F`=X"D`[+Q=*($2>D>X
ML(DL:,EE*04(TAQ485CB/'%A$_\`6FB$\GL:-4&_R*\HWC][C@FW/7RI5T,H
M!N!^\^'RG?H`0>(5DLKNX93UV"+"2%)\=X"GK`F0-C)+*5YETM^SJPL)[KFM
M(@)2*UY0M5KQ$>4T=SE\E.YY%D%>Q2M87R*1XR#(IE">91+18/0MW7X_J/R\
M-XVV$@B)5%U#5'\508L\1X;D?/>3$@'<E6!Y<7MF[.`^7'66%5)*!&1S8P6Q
MWQBF8D:2-[$.L1A$"&.SLB$",C!C_J$T02UUM5@1N!^@GKO(&X^?4GX$@D]9
M8629%)L3U$WL5>@B"=CXP-@!XJ"`NZA5:CS6V,>WB2(DL03$<%[)$1S55#C5
MAQ$81DJ.'R17",-5()BL>PHRB&X<F.-;6U+AT)`G8_#I\#]AV)F003*L5%Z9
M-9JL`+1NOQ$$;R!\&&X$$,K*I%B+2Z<AXTH@!!EDJI,B3W9/CE_*4B(U3>[S
M?(7\H4@_@550CSD>OFCY)$=;S7A63D2HM`'0B/E'3:!(Z0!M"B*<?&9DL*J&
M..Q/U`S/C/7<$P>I8G>7(.3/6`(]8QEF!J2&JXXWJ[UO;_SI(KT*LH9PO]C2
MA#XJZ0T:^(O[K52-(%'6S6GTVVZ?NGPC[?">NWU*9;D2@?B$\PW^'\Q&\@@]
M0L>8#Z?,(K=?MY%&:,&6)LHBN48GN`UG]3%$00G21/0#!A\6.8_L-@_!%0B!
M$-ZUJARK%#`^W^SKOXC<F>DDCU:Y=:L@L4,9@&/LVD&('@=@(ZA5!-$"N/*E
M--66;##)$&B!FJA"R!E(A6,0KC#(8Y'>941'B(XJ.((XW$4PIU;%18MJ@@]1
MT'[MAX="(V*D#B4LH>RP''O!#*-FW)!,C>1)/7J"3YE=2W-;5;-/5R_VJQ:Q
MK"N0D>6(9T&YSG`"QRD<4I71RE>+Q+YD(,I!M<0CB194]8BVIZM?4=1M\_WQ
M.T`$`P!#)6HM?'L_#7QQ/0@&/`#Q)@F-Y)!*@L2U=ET*X!%KBBL8+AUTJ.B^
M#'JQD:2-@1A><*L.`+'Q0"'YH\@0E`)BO<(80R*RZEGL4U6>9#^T>,="=S,;
M$@DQ)8K;;E)70PNJA+%^R"(`D;@;`"9(4J!)555Z)Z=3$L!`E^3`V047V^E&
M*,RM:<7@J'`UB'&QI&?W!(US/:$PO#\@`8Z[Q62G6H_'PZ?`].AV/P(,\6::
M[&-RBR0+QUB(/4>(B>HW$1R5ECFB_*&<^;[X!Q/&0`6N[&*=THKDD.'((0<C
MW'*59,IJ/;W,9"$5'H5Q&DM&16*XL4R"?"(Z;=-N@VZ"!M$153#M-LTN""!X
MDR=X.QDDR=_J,G?D2#D4B-/DT\QD9@`,`I>YT"O;W(U(K0'4ZR$9&,&/^*OD
MIU1B>I7%\'Q)@YFK6Y.1)Y1M/ZY$1N">7A\8$AT.,EUF-:*PH"3O'CT@S,`@
M</YMO++0:[14[R+$BPORV#<5H9*RFJKQIZVN\5-["'C]F04C`(CFE1D<8T5'
MM$`3VUT5#N[\"=R(_NZ'K)'3S$])8CU,C+KJKJ]11(#3]GQDD?3`/6%`ZA44
MBBIE&"VC/=(<]O\`2IF%0;5)6G09A$5/>$[UD.]ID*-XRHY'D8]CU><,N)2U
M+@+]G^\/U$;=(,CP((A2D[!,BN7/SF-U.X\0=]VD$&98$&76R0A?N4CWU,[R
M\6C:04\7O<XS%.!1EBE?(*4KBD>U[%]A""(YB*XWG&D3I7]-8MK_`&;;;'8[
M;?#H`1/2&5(:?7><:[I$AA.^XW!)),F"-R0>.[2CVTP!Y-%.;'E.1T'S51R4
M5GX_I(P:L(BL]38PP"8QQ/%S6@:QG9S(K0DJY"J9"<E_S/AXS_;/A\=^KDBV
M!7LP[>%G^3/7:(_=``B8CB`-Q6%;'G='$9ZDM1M)[8ID:9&*-HG!8DD!"G5!
MHYG@UI6.>HG>(W%&8/J_*CBLQG,^D8@C;[=CM^[:>L%3/!C+G5#C^(4'DIW^
M$;B3MMXB8Z<@R\?418PQ`TT41)#WB,$KAKZ'N]CC*BM<X@7?E*R0KS^3&JIB
M(I53N=#K^YT);&<A=U(\?T&VV_0;?R\?NKPJY]89Y#@QMUGYC>#)D?4=S]7/
M_B%0X@CSZI9#&M"L=L8R>M3O\A`>]H_`_K8W\=H5$/S1X6>IS".8D60Q=!5;
M8ZS(\.I^7QF3XF9`/-33'Y*SX\](@^/0=-XZ<8$RHXD,1Z;BG/DMSTEXXJ,/
M!<(:F81C`LB-$QH7*X@A!!^)^)%=X(]HV@&-RHUD8165<@4Y"@MM9.WC,_M,
MR?"9)&Y8@VPFP83E:X-,"9V`C;J`!'$;3`4`["M6&/ZM&H5X+F$-#/:9JRPF
M0S$<@S&$GO:\*F*-L@I1N[C>5CR&[#,U\F+,I48!H<QML1'P\-XZ0>L$`;J0
MKHR`&(RJA)G<&1T)&^TD22.A();9@;*[:VH8%_$"=&O&YZ!=Y#5B3!*US2A8
MAPE.YSAED-($@RO1SWL>PA%((LR";,=BOAO]GSV,?"""!T(($$)F<*<VH.)!
M,=.H\1N">A(*D$R2"">2M;*U#4]4^ID'"](STB":!GX2I&%'$@S,0+HRQ&>I
M@U&K',$U!HX+V#8)U?=<=UN4&3OOOO/ZY\9G?>""219%BQQ?'<@\=A'EV`&^
MT<=HB(&P*D*%--!!9S*.02"9WY$=')XC/W_M(]#-<]&MCM5!D``Z.8@4&O@5
M[!(C)D./D-4EZBP;-\O]?Q(WF>@)W1VPTOMQ'-3>9/GX=?ET(#2.,;,0H`MJ
M2HW+VQI]=8QHKBO\E[O\"G5S^Y6C%Z6-DD(YA"O<Q$1Y7$([U*0Q'BMHZ06K
M:MC`_9_=_=`$P`#3/E$)<ER*2?UGXP(W.TDCJ9)X\F8KD3L^!!M8BS8S_P#F
M%:.;'EQG^7FQZQ7#8A12@H\#O0$@W,.PC'-$814>D:3U97994_!OIZ$']?R.
M^Y!V(.ZD1R74M]-615ZJ?7LP(_5&X(VV4@A@00K*T\+-0H`Y$^K-7SE8'N-S
M0R.XRH]J*3NLIC?Q0#431*BM:D<:B9Y-;':QXJRMA6NT6)O\1T_9U/C\S)_F
MD&VVD678YHN@;&#U^/7H-H_V1`D!`"M$.+-_:);JR6]3$>D=!&1$*1RE/($X
M$I'A&_WM<\Z(JC?[GJ5',<9TB-)N=/63U5V&^WZAN-^G3QV$0>/%EI7;^&L-
M%FY,0>O4D0=AO]7@>1Y`@L72SY;-943@644#3%E.*QPE&][1E<6,41HZ!.XJ
M'?+,-W;N]3&>Q6/=(*!]BJFZLUN84?Z=C/A`/P@`R.(85TR0N-:M]:RS$^'0
MR""(,SR(/CR8@@EV0WS9(@[R)'G(Y@7H`S@/`]GX[O8@4:CCC-&(^,$<4:N[
M/"US1C>Q0^H!H%@<T.:^HD3/7]F^YD^!ZD&9862FM<NI;1`,&(Z;QXR-@`)W
M4;*1QXHU/N-_[9BRX5B@V_C'<`HPO\F/8Q)`%8=2C41Q)Z3L=W:C5:A&$"-6
M28T>C_<.+*YW$_P.WP\/W$$RK,KG)K:JZ/*2#'ZQO(@C9@=NG(,JPZ)2Q324
M4U:_P4\)\I2>1$,D]4FG<QK_`.KW)(D)+(Y%<K7DDO*K5\Y1/&VE9!>GJ='C
M]6W\!'ZEB=D'W,"VMAV^A$U%I\>7F/ZY,D[[ER8WL,9,*;(_8K5YX@XY&2FH
MKD[]Y#>[8;G*CVR?Z'O(Z,1'H5/:JA\GHKH<IUR+Z]4/,C]GC\O]X1&V\#ZT
M%MK_`(/(-E84AA^O^7Y]9XF9W\LD358:Y(AP;FN61_::X\5?$[$1XAHQBJ0;
MAE_$9Z$_&[%&Y`=F!1'>IH52NQU>RFSCOL>GZ3OOL=^NTD_>9;UTY5'/82O7
MP'QV,;;;CR[#?B%^Y@UYA6]>2OD$]CDCM"12^;I!%:XP9##1Y07G,,)_,16G
M8Y[U4K#"\G2`'NL4TV>HO29^7@1!!C<01!@;%3'%ELI9<FDTN9/&#/7Q!D$2
M8,@\@2?,&62Z/)-EFII42M\FS1'\&H5%?^2B&>Q/`+W&D.,]LR8-6/<0BO<5
MB/(\Y0'L;RBW*;?I(_9M\>D;`R($08`4,M<8L;%L6CZU;Q\=_AN9\S""29)`
M)+LCWP;0!Z@\NQAHP<?TQ&=VA1HFHY@FJ7WL*&,U6MAB7S4L=G@T2.(,;(LF
MNNJ9;E%;_5)\?[-SXGP)F8!)=;++T?&=KZMD@>&WAO,@?RC>5$!9(45V43\J
M$"RC?NA/.#-!'*AGC5K6H\$<Z.1!RF!$Q&M]@R(83/[7M"8;6L.&-&KM4_I#
MS(3M^LCX?J(@G>"IW5FFLJ2^O\0WDM"F?U`^!@?$&0/+R5E`#)7\AF%>PG0)
M*.;)&KG'\&N3RD^URHL=[_>17J0[V%&]AWHXCFD0RE5+(X.._J+])Z?9\^GP
MV,@0)'&/NE3+F5>B_P#F#K]ORZF=R&!#&20>7(^O*UXY%/8L`)RFB32`:3R>
M3^P1K0^+G,$4J^QS4%ZB,*Y?#TM<54_$EK?85NKY'9UG]?[?UR(_Q;?6FHZ%
M?%O"+O4Y'QV.WS._2"#TXRQ^[LTL_P`FDENGQRM+&E-:^2#R8!H1QD8KW/1G
MHC-BJ,*=C/\`!!-8K2*R,Q75-*N-Z>FPAAT/69_:9WZ;R3M+&+F1ZF+9ZR&:
MV&XZ1'7X"('U&(`@Q6)QHLM8EI4$E/\`8Q['&1[%80G@7N4,B*P1P%2,\KWE
M:490/7LXS"A(UTF.>B<JKN(B#^@.QW\((/\`A(8>5ENM]+(QBYGD)^)WW!$$
M&)D@@J>K!E(+H\Q4OBW%6D0P7L_')Z!K^0XLCV(C"B/&,II,MLI&2F=_ZRN<
MI&JTAT*$]A;<'IMY@S(GIM\""(`C;Y=.BP5KOQC7DX_IL(XF!O)GJ"#),[CQ
M/407#*]TF$YZ*?'JU<U:TJM*,C@M1@V/8/S0)0F;VB@](W)_6W\=C6?U-CM#
M(K[V5;ZS;_YH^?Z;G?PW,_S%ELB1WQ+EQR?N#N#'A\B#T$#Q'$`;A`CTQ9T6
M1`F2I<,J$65ZCR!F:YCU49C#6&&4K/`(I`D+^A!-:)@BHYK0-/'ATK=;$"/X
M;"/LZQ\MNAWD1+%6>ZZNRFUK*C):"9^T^4'P!$]1L`P("!TJ^&%'MZU9QD%^
M4#VO>,#Y:L)+0AD<$K%!+D-.1Y7>+6LDO1TA[?&1[GLLREJ;?3$\#\8Z?'J!
M'[!L/I@&HRIDT>LP'J"9B>N^T03)GI#&6(A^1%\U42@V<<:*`8Y$4:@9X.5&
M^IOX1A,11&,-OL11.;X'*GB@C"(YKXLE]ERM4Q,DJ3/\1XQ\^H'B"`0RB_&L
M7(0"`+%$#[/*1T)^40QVXLK$&MS3:YJ5$L,9I@HR6U0$&%BD2.8(N[0-\/QH
M1`QXS$7LWU(`(G(UHXXG,J9;/OD+09&_VCX^)W/VR3XL9N@H_P"&M%8(AMC'
M@1X>"P!\(XJ#`"+&-[L8<BGD$LXYBD_5K"QRL=Z"C0Q6.B%:@WE1B>PB^*!<
MX;_<J"<CY40]*W6Y?28`?/Q^WX?#QW''?9'6ZZI\9S>A)^(/0B3MTGX_RF#S
M\IFRIXLV8"PI/R@C&]PI,?V#5ZNEB-^0`K%8X9CR$E&?)8Y%"0YC>]CPOD/(
M%UC1$:N_B3U!^R(/R`@1X@`000H!%=;;$OQ/40`D,-O$&1'0DR201Q+,>0*E
MRRF^)%G1=`#\4@U$)J`+X@,T;4<QHB1VB)&*O<#&((@RL()K6B$49&M:$T.C
MUMCMR!WWZ_OZ^/4$$'J00265[J[J\Q/380H@[&/@1!!Z=""".BLK`!6J^5H9
M\.RFPI,E\@9AO(V495]SE\CN>]R%:)K6N\#M*UPV#=XD5B#8DJ-!6M6]2NH@
M@]!T\/\`1&Y/29/!K%"W57O58W)2)D]?'XQ_M2(`V:.(%E=4G81R4)PS(ZFF
M_DJHR+-]A7/EL*50>10C+**1SY#_`"$HR/>5SWM:604H+2^MAD*4:%CX?#Q^
M7@-Y`B`2%`:J.]#AN+$E^6QY2?-)CH"29)V@DL20&=F3(]VA$M*B):CBI[T*
MU6$:I/-@O>`HV">"0OY/F9H'A(*1_4[UOCR/8^&8BH>E<:B?+']A'B-O$$$?
M$,L!P&0WXC&7(5?//[I!V@[[\2"&W\I1^1J9IVO.&\A/=-8/SCC>Q#*K/!H5
M$WR,BM;#"CD9'[H1B"$U@FJGH]2MK([%-#CAT)_?\/$^/0R9)^J9MEI=<NHF
MT"0.OR^/\H\.H@``'R<8HBP7QX93U#">UP&.7VN(@RE]Q"#]!D(!L=AG25*%
M?[:HY_N:YGG^4!U+.3@7$=?[/'K/2#U^!!C@VKZBE3G&!DCQG<R2(,B)F5Z=
M>0(GU$--G2'4LD?H=Y/.K"'A/$4SO(DCR!)!(12GD2%E%1I/[A'GD%8K5?(*
M);26M?70\N@\?U;@CP$=-@``9A0?2Q[7.+9Y.IW*P3U.Q!W),G?<EF(B793D
M1[*$RQB1;.N%'(=6CFJ,3D(PPU;'<KP$$:(`[Q.!'?XJ4?D@!.80#F1I$:VJ
MPU.:K"0O3^/78D=3X'J9#`LK7WU"^M;Z`I?9MO$;=""`>BGJ)XJ0R$(Z3?\`
MRFC@O9)C^(O[K&F];5`GK3QDA[E$%BQU8%S2-<P3?!CVN8+TF#`L\^-9*GS?
M#Q^1^W?;<]09/)39)]WFU$6+Y=]XV^8W`VV@@@;`@A>++3+PRJ]\V@F/<7P1
MPAF:-7JJ$]GL26I1ROR7DD'(WS(TCC/<]A1N,\PYUSB`N0@Z[Q_=TC:.D0((
M(4`UV5M);"M,QL#'QF9D&9)(D@R20REBRW4]5)G9J>)%E5DE_K4)7*XW=[H[
MBO&Y#&>\PS&"C2^QWY"O$QQ'&=%E3)!&2GPM'[/']VQVC:"0./)4@/+"MV/*
MAO`]?"8W.X)&\GE*@DL:[+9^S_Y(@+L*)X`$,CHY$]`'BDB1B^IS&PAQ7Q@!
M1[B%<(7@UGL<$8Q&J[*OO%-#=2>O4[']<R=H$F9CD21;-D?=,,I>@`V.P((\
M/I`@`$DD"(Y%556Q_4J*W01AE"]L<PG=W.>%!H_N(D:4P@I$=QQ*!5,QS2A1
MKFH4)@^/Y,=E$?\`#M!W4_/]8Z&/@=C\&#?2QK96,U`RPK#Y1X$$$$2(\P@K
M!\RLL>H@BP3_`+O$)#*4WY0#*A"1T*!RO$=%9Z".4DD+WR"I_0[V%:KT1WO4
MJ/M*6+Z+AP!P(\=_#Q\.GV#;;C$574O^)K-;$^H#N1(Z'PZD;GIN=]^?*<C8
MH7?U#\D1KO!GDU%14:OBG=$5&L141?\`ZU/_`")US9ZF.FNX7Z1/6->^J:KI
MTTTZ::T<^O8\8T/#DFF8*/&YWX5+W>Q%:ON;K8+F.=YH5%<V6JM]*>YSD1K/
MZE14[KV>S![P@EC@9(_]F?[/';Q.VO)?S+1&JQ&M("+W?!/[?67[?':/-X#<
MSKACF%'<\RTLZ>]H)DK0:FY?/FT)Q%ES60)4N+9"A^"1^(ILV6K4=[FDDSY+
MOS7.7S&B^[Y4T=E=*]T%=:P'&PD`K/7(`'PA47R>!U\D8!7*]T56W$+:UUK\
MFK,EN)(8+TPV9NL@M8_WI.ZZ\<MU+ET%=5I*D3`'RPK:"W^R7\EA]9<S#2?\
M)`,-HR(%T$?NOE(<(QM0KP$:]&I7M%H_#M:0`PMXGPC[M0!ZIE9,F*H!)V#"
M-4]R8TYB8X8LAQPZ]#,W.2?0$/`XCED2R@`,48$`94S_`"7RG`D8^LRUG9[T
MS,A1U];0SDLKH<@UI7!%:CIR5DD=C!BR76$LB2!$8_R'[A(C/!&:G([7VJQ;
MK<I$QU]9BSCBL!2>/+D()$*((/7B=YGH<+OWN"FS%Q^WV69C#&K5:VY/)=0'
MX<2&4'DYY`@[<E@1$KK^4N7-]-GTNIRU/O4K?R3Q\X3'S;EU1`]$:`.)'NZT
M<.^KHTYAED^ULUPS$?Y">YCW+U=A]J[1V]%NQ;7QRT`OZ@7D9)DJ91B(XQQD
M#J)&HNY^X/<O>+7Q>X8]69PDBHTL_!8"P'7C8H8'E(>&)E202=3W(>#P\7AJ
M\TTN$[C'<Q(]))I<4+?U>R)>RF:6KKX\2=EZJN)J,J^3!>24^1;3R#\7D"03
ME(]%L[=W#.;O5>*C?BL$E@UOI-7P'!B2'9N#P84"M`=@P.PU/WKM'::_:]V?
M8AP.[*M92@9"7FP^JB@-4B^K5*RY:ZPB"RE3R.JMB\!$Y4Y3Y)=J+2\DWT'+
M89U505X<U7::TBFM]$K)M:787-+11:>I:`*$9%9)L72#,0('C:[SBS>X/VGM
M6,,5*QCM;;R<\RBGBFS>FK,6:3!:$@'DP,1D=K[-5[A]P9Q[A9<V8F/C\*U%
M2VN"]GF4W.E81(60@:WDPX(5!FRH^\)Q'I&'J>)9V9OW?F0ZVRY'@RMEI(,6
M.(=C8E;7OJ::I1L):Y&L&&,0+FF:X95\1IUFM@#N^,5NS%MQ]BRTD5H2=AOR
M9MYW)8'8R.NM6G=V]MYP?&[:^/F>95;)4WVJ``S'CP1/+Q@`(5AAQ;9=9+B_
M4_*024?L?.SDF+*).'^YCFNF6%1:=HT]*2HFQ(>?J*X`6BK@@KXB.'W1"O1S
MWO75M[4[4P>.-BD1Y8@,NXY,"78DRY+MOX"`!K>U_F%[@5J2W.BQ6+#F&Y,C
M[-Z:,%K10(J5:TD?S&23K#M=8V=ES?`G6MS:WT\.]6&:Q<8=C<1,_.M9='*-
M,D:0Y655"V+)7\A*TX-!*?['20>+6E=NK:JJNQLE2)76<>0(XJ7"AA`0>9Y&
MW,&E=N+3(US%%]]_NM+LBVRZX9G$M(9Q6SFLEC:3PK@^;TF7(<R72`&-4Y4A
M/!H<3/C2AEN+ZLU$.K2AFR&:ZRI89D*:JP\NV(^AK5E#.YY6W8D>Z,1?ZG%=
MXOB[4_+&OK<136U9;D!Z:L1LUH7SM$;>D8Y#X;C(]PU%,W$N1@<JZNU4]-CZ
MS(IDI0SGTUD&2+Q/$]2Q@[F?,LR',MH4B(.C+`_\+<V&"1G1'CUI@4O+^/HH
MP(83FF$C!APJT(O%3,\E9YM'ZU84G%>Z$=*BKFP6?U4$AX+`MCV,28B9+$]#
MU@F9`]1]A6U6Y"O6*33_`-/L`:@0I"9E%8"@EB`JJHZB8D+!#-VRZ\0U]6:=
M--.FFG336D/W:B+PER>U?U1>">4T5.SW=T70<6HJ>(U0CN_^YJHY?]GZ]=U[
M"_\`?F+_`/;]'_@OUY/^;W_WJ=P__@^7_P"TQ/AO^S7++ECA#=:N+3[ZNJUJ
M!:*II*G1/V>F;DY([&GKX(ZR6ZTMIE):P<1;P(D:1*CU4AWY=E((,P$>-CNO
M5.T=]P,1G[?8_-JW9D]-/4$,3R'%0RFU22%-@\J`%6@G7SW[B]I]W[C75WBB
MOTEOJK2SU[?1/)%7@W-VK=:'4*SK4WGM9@R`J#JZ]TG$!,UGP<RR=3JI5R*B
MM8%;Q:E+354JRK*VRK]"(NRT:PW18+J$95LX#*XI1MDA5IU*1A%Q<#^L#)L;
MLHJJ1"REK^3,`S`I]VDR><<'+@&&\L`C6Q[O_P!--@4I[H;(R;+16ZKB<*T+
M*K+8#?;QA?3GU:Q42`RD,68-K*>2Y=PMAQZ:LX5XRH,..1$K8%?7;-)NIDY[
M6/)#9G1:.156L?1.K[&K$Y\D/Y`HPXXFB\$=[`KJ<SL^?7W$6][RK+R"Q)KB
ML/7OSX!E*2&^DP6)),Q#:Z#MON7M%_93C^U<"G$!555;^5IKN\OIBTHXLXL@
M)9>2J%`6)Y+K&<GEO8<CY[0U,R?>8R')+9QG5D+)S<PL+1TTR%%E'93YTI9U
MH#1VGOD.22TK9P3>`T$5'%'M%[1A=MR*[D5+W`4\C8'E&!(')Q"E%@>6.)$F
M1L="_N3N??,.[&M>W%J8N."TM5QM1E!/"HEG%K\F\P(L5H'%I9=>8V?NKN_O
M\C^`1+2-'L@S(*-#,D-:")8*62:<L5K"QJ]GM*XLH)!2ZLWN=W'((P71-D44
M8]>9R'I$K!Z#<C8">IV$*05<0-U!/%)AY67F7=MX'\0JL&&S'8-)+1N%$F64
MAZFYGRNP6F"B.L(?""U]=41B1^,[8EF:@NIUI)<T5/AD8;2QE4K*X+)#6%*G
MBB.?_99V,T/:0OZ;YWJ,Y!RE@.H4?5;LA_FVV'[3Y2=0K6;J^T^BE2LN`Y<U
MNSG9*-[1OQ$P3\3Y1#!=7QQ7IM7!L9ER_4+24,81K"62XF0*FIN'BJ+VUBU+
MDEIZ;>=:`K)#F"9#.R*"-(((+W)&0N#W7%Q+*UI%7.\D`<069?,JEMMU"EAN
M6!8E02/-&U]O9_<:KVRCD>EAJ"S<V5$>$L<)OL[.$:`$8(JNRJ3Z?+8:G^B0
MZFZ+B"XS"6=763**9R#/B1K"B/255O&DVF%IXPJO.?X[>SRW=@2/(8^&KVC?
M(5SO)@WLYV[VX<2@9POR%M96%()#AF4A;6/)^:CB`1YHD+X$@]KC>]U[AE'M
M+8N'9CUM6V2P#5E$<%\=`$J].QC8Q5@4D`OO(4BW^69?R%K+^,"\J^0N++Z7
M`H[74BRV83?\<?A!/$:7-Z"@L`L@FG1_:-T=XH[Y%;#3R`,2=W)D=H3WCB8Y
M:A\;+QU9EKYOZ5TD'SHX,P=Y!,.WU$ZP_<=GY:=QS%3+KS>WYC)6]HJJ_$8W
M$$3596PXEA(*D*6J3=%42=2/*F5T.G!E"\?6XM%2VAK+5SK)ITSNP)#LSOSM
M/2S<'IF9S56>1=$$[RA?E1OR(A?(1'-4?LD[5F8^*UH[BAKN4+6!'.N5'-F%
MJ<ZULG^;B88;@&8A]P]NS<],=NRVB_$L+7,T^G=Q<^DB-CV^E:],`_=\UY(9
M5B./+*7%&+L<3K_GG&6M9?U9<UR/0SI8?Q`Q,Y6VUNUY64%18BHH(K"GIJD4
M6)'`%[O%PW^R0;UJX^J[MG5YV'W'-J:MA;C.`9EV5?YV',D,S<F)(\1"B?+T
M/MWM=_:NY=D[7D5W5M1G5L1`%2N^_IHPK4,B($154GH>3MQE^P.!"2/C<Z$H
MT"]E<+R&UZ$1ODY[D[/1$1W='=__`(^O'.X,&S;"#(Y:^F.S(R=KH5A!"#YZ
MN_K#UL].FFG336(N2BACS\])(&610D*[RC>#V*SW`8HW@[F*4[B%;Z40*O<[
MN,3WE(D.9N.V!FKL4$;_`!^P^.VWQWCQ(`'-.:[ZRUW46,&,$]/M'AN29(X^
M62=E)8BJVVI4<,P0;6ND#9)&-LB%8"?Y@>%4`56%09D:>&=K`JK4*U6JT3V%
M:K8TEF4C%&-5@\O0CQ_AL1OX?$$'S*<"Q%M49%+`6`2K#<1L8.^ZG;Q'12&$
M(XE8$F3;5L@<H8&.(U_H*-@#1W#8YZ,0@2-"!GXRQE;W<@6N$-5\0>!0UMUB
MK3:"DQX]9_OWGY[GJT@V1TV69..RV``GH1!$?,&!M$>`@=$AEH@5<XL2:ZHL
M&(&1V\6/5I'^U[U-X,:]P/UCN<X[6/>)SBD<1A&>Y9`9=UJ!Z_6KW7^'3Y]>
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M*(;FRHHKKE%;@K(,#?Y_J_5XGP@D<&-N,YNJ9;`"LD<?EN/$?$$'8?S<E4BR
MM92L+*KI;X+A/_%7VR&L5"&G%<4S/[SG?W)!3>PSE5WK(0Y2*UR/D/\`*VNM
M"6IZD^;I\OL^$;?$``>"C[F+':RBTTD?=[GQ+&3U^),GX$L3!ES.1ZN'"KY0
M;4(CHY"-1Q1'5HE-XA:G]K\@;/!XO4O=IFB(1H.Q6+^+*8I!L4U,1^S_`$?;
MX2!RV/G0URB*+1D*#,]0=IV\)^$?S02$\P/IV"I6D*OM*_WF<T`T![02RB5B
M1Q.$ODT\<S(S$BO$Q4,)[1,\!KW031*E?%4]E5G%=S.X^/V$3O\``[[GQ)^\
MGR*J,BGF^PB0Q'0?,&-H'F!`$#^4+]SXJD675OB2CAEO\#1"HX;Y"L15D1G@
MF-E`5TD[#>Y'-('V*BN:4;R.DCDUMA;>:@@2#\/@9$'8=.ACH00.)6F-][CF
MJPAC!!VGXB&D;F>4@K/4,"38MDK4$LX;_P!JEB(1/-GX%D)"2!_U>,AJ/<TQ
MI!P2/)JB)[7F$5S6N(5[XTFPON%3CUD,?%>GR^0!'B(`(W``#+7'C-?4?P]H
M)W\K#<?'XDD':#)8&`2Q-;W2]H,,.XCSQJ&O14\BRB*GXY4>%C23$:`L<;/Q
M@!%[51[!N&,:O5@QQY%==46>DUF6^7CUZ;SU,QL2"3$DLMEF0%JRA<(3XD]#
MMNVQ'0`3N`0%F%"/1%NX8CQGVK"NB2([FN*1_;U&%'9(9W:TPFL&@F>Y$4@4
M8YB&&87J20$%*'*MZ1')3^Z8^'QVZ&>A4SQ9KLJI6K.0#P=>I\"!/Q$;#EU6
M(Y*R\>:)&A>5A%/7S5:Z0UC7,&`KU0['-=X&&4B32$4YY7<B/]ID>56D:9Q%
M_<[7^[<65_3\_#Y>'0#;H($@@#[J^J;JS3;]?A!Z_.3R)DG>9:3#!B?OY:JE
M3`V3(RB>..9&,&/]%+%2-&`]C7"!-<T3%<0"H9KW.[('L]6.B2TNM1&KY3YA
M^^2?B-_':/CM/--1X]EB7BN"$/0>(@"-@VPW7<$GZ=R#58(L][JF8&Q"<0ZZ
M0Y1SV(UCF^`V/0AC)Y1A^F.&/^A41B!:-R$1D=COVNVL"Y#6P/J#I_<.O4GI
MO,[2Q'JW7$XUHO4@4MLWZO$]!``Z[<8/*$!_#_+&/!L*Y\H2IZQN?^4YHWO?
M'4:RTF"=&='D%0J&D&:\;Q$;V(5""(U\J-)K4SUV!3U\/GT@S(V@""".@@B%
M95R574>HOTCKMN(GD(@F9+`@@]6E6!L2S[4QQ6=*L4Y?R%%)*T2HXBR(!&O&
M^*K"^9933M4["#<I#N<TK.Q3^83SES&J_FHB1^H_'Y>!!V'0[+!6MCHM^)Z;
MGD0VWQ4[1ON9W!!EB9'F>5>Z%7NG5D]M8YW>J"U'BD%]2#'&;'5_]IR&AA!'
M4@&N1K51`-&Q&.2.@2UU;`EM?J_^:?#YS]AD[_KDSYN0LMI]:B[\//\`PXZ'
M;81X;@`2/_1`$'AQ:CU8B2/8'F&$4+WN$V*8+T>.2C0G:J&!ZPO_`"87I,CF
M/$YKHZD:YJ#25&C*SRK"*00.ORZ=#OL9&\]8WG@S+U].XVL""8@CH=CU$#=8
M;8B"O($<?4K2?LJU9T=LA%:MBU@?6_NY&RG(]Z#$JHR642FDRG.:YJ&(PI7-
M[&<0C+&.JWTVX_\`E[_J_AT`^0(`^F`:YKZ/63F/\_:/GU@>)$D[?402?J+,
M+_57*_<H;&R$>PZ]T(\:>E#D&D?R,UP#/"I$=ZGHHSO8[L(@RJU8LA:6KZ3R
MOT_MCK\=_B-P#U!$\EU6BS\15#[/\MI(C?8Q/0[,0?*RM'IOJA162*VU#!BF
M!X*!D=[7*$8W`&Q_K<2,%H8P2L`!ZL3Q$UC!JU$;&&1E3D,5MI-C@S,^/7[3
M)ZD3UW/BQ!NQ*P]&2*JR(B/"('Q`@`P#&P@"-JPRXU3N!3X<E+6&4Q_'^U(A
M%]CPJ'N5IF.#^.0GI(]2*15&\H2*1WK)Y2HLJ*DUNGI.`/@?G^W[(W@B-Q".
MN1DK=4_XFLDGH5,Q&\B(.QWF02IY&#-E=D:<X$^K640$U47QD1VB<UTLI%1I
M`."6,LLZH&3(:\;QN>4CO!S'&<0!)]M?*NW@"OP/P^>Q@=!N#`&\\0&%=;BE
MV/ZC!_B(ZD^$$2=B000228(+%D-U,S;F38!($A1ECQVA(!HWM5@QN:PXB,*"
M0,,<8VM$X",<,3$$QX'C&P3J^7)!KL%BR&,S_#Q$GQF9)DA@23ZD&"1;2:7@
MUJ`1OT'4008`&Q6"`(!4A0II^H%M)*8)A/(<TBB-),H6J%@V&1S4$H8XU5C0
MG]@G-:C6H5K`M$V5&CN7KI)ZKT`\?X_$0?LDDE&9P&)9Q!\K&"3&T3X0!X-(
M(_Q0H465I%OT,`D6QAC4IWC<(LH8Y#WN'W:YOB\/Y)?(CCD1J(PIT4S_`%^X
MI'@M*8_%@:W,+/3;^V/E\!L)X@!JKLSDK+=4)<C<P?[).\F-BWF/'FQ*9$TT
MK;2N'/0+ED>M5`YB,"UJJHW,_P"9;*<TL9JJ$S3!-^J^H@"]UC2.K2#58:Y\
MOCX_NCKU$$?$,/J74H;\10+H/J1MX?OG<?2P93_A9&GTWU*TY8_X;:N8T$4P
M"D`@4`P36^C^\UBD>P,+NH`+X>#1#]0'*C0,$\59=<&Y^JDE2)Z_';[>I\9,
MGJQ(-L>,R>D,>V%<&(@#IOUV7H-H@0I@(%*X\J(C(%RZ%#E@8,[R>32->H_>
M1YV_A_UB(P99!T.Q447BAE*GBKW2XDJ\@V4\W!D?PVW_`%"/'I'AP=8E(IRO
M2J8<3\>DF?+T.Y/(=(Y<MI-E=DK:H:ML%D@<Y9<I5<H?`KG*A2!<A!NC%<5[
MGRC,;V8Y5>=[%8YTEX26EU/&VOB?I'C^WXCX#QZ`&80,*K,@/1=ZB'[QO#?Q
MC?8SU(&QW8@@FPHV17K"*VWJ!R&#&^5^.PD<HG-<K1]P&>UCQNC(8:,`-[6M
M>#LHQ/8\"CCGA8];&FXK_)._[_MCJ1T/4@AI97R[JQDXP<`&R-B/AL?E/0'8
MKT4@I"/5]JY`;>"0,KP*J"<`PW#_`*6!(,X""_Y@`GE1HQ$&1SQ#[*PC""$K
M),:*M4TV2FV\C[=CX'["()\""95GKCNN325>"8@[=`9$;@3L""2!T(*K%B5T
M2L>^#>/KP'<Z,0[D*IT4Q"$]I%<UKG!D%<4THRC(Y6O<4KW.?WDD>EM/:`^.
M+&'F`\-O[MH$CI``CR@>CB4$U99I1IK)WG<DS]AW),$P223/G)&3/2AGH2)+
MB/DS8\J2U9$9[E.J%<X18A6F:57#D,?Z6C?[/[Z>I/=[/Q93XT*Y`X/"L!L>
MGR.WPZR(VW\L<T$MBOB-ZM99JV;<==^H,SL>@!GS>7S3Z=A]Z`;35'OD1Q*\
M7@\!AM:)@`&'YF89LC\8;(Z!!V(A4"!6C1RK&8/RK*8YXW<5)@]1\2.D1.^^
MT2=X\Q,6W9JAL;FZB1N#T@$;S,"(&\\5V!/`+./[J[%;!AH-@/\`1L=SW$5?
M%5`)[Q2H\L4ACY#41WL:Y2"[JBE&832)(CFI;7Z9%E9\?]1$;?#H?@08XLM<
M>_UP:KAT7K\AU#`[_&9'^)64-S1I:K<$$^;!$=ZQ2,0Z)[BE?++[!M>4)"D*
MK_)3L]A6O>4KR#5SB$(`]G?:&:M7(\XV^$?;^PP(``!Z`,M5F.52YZE/W9$]
M29,B8))^(DR225DEF1\B6L@OH3"?5O<P9W*9W@T9%"QBQ4:UG=X8[0L$P+!N
M]C&J-@VN*(;(TJ!=4PR%(MZC_3]I^,['<D@$EDLCO4X;`T&`=_`Q$?8(CB!N
M!`4%E4)934K=OOC!D/AOB%5[_-[GQO9!:WS04P\8@$88+XL8C'M>P:,'YL,-
M@V210XJ3Q8J&D?KW^4SMN1$3)@@DE2\^3YJPY4JWQVE?@Q!&X@$$$"!(90H=
M:H\,C+J$BV`V-DE*81!C'V,JC\PD[C(R5*'YODD:]A&N>KBN&Y#*1[;&C@TO
M]W](`_O^0\!$?`$1`-<E3#*J^^'WA)&PWVV/63XF003N5/(L1?+59WQYTV"D
MGSB1"**(`YVO>HV>HZC`53->5P/>%S55ZO1CA*A'(Z'*-=:H9!9'G(W('ZM]
MMI@^$==AYT6+'<I:U7*:E,`$_88!G>)7QF./F,U6-2+.,ZE)(DQ$<*-(_P!%
M<\"-`P;5=X?W'!:^$T,/NJN]0AA&UCW#BC:^GFJ;UP%?ZA]N_P#ID_,DDD2Y
MB['R*SBLUE>U9^S;]L>6!XP`H`)%:@XU;M`*Z%'G$4XW1@.>]\3S4L4CFN&A
MQ!D1BKZ1.]WM\AJOBXS2,(QTN,2"IO.:Q!D^/C^P_9&_P((/!AE9"34MK2"%
MG;J#\0"#L/-,CQ8,&!L1O=19/N(TD$IZI(4;T*X#',7P(@F^0OZY;GF<0S2*
MWR*Y'&&K7'4H#V-+JA0P91Y9\?[>FVT>'0[+#+77&O.2C)8?/&\?..GU;R9Z
MG<B"_)'OIV?,,<F5`8YPF-=ZPM(]$<,#0L?ZHKAG"(3FM8)[51_9`L"HB*!L
M4T*7(4E18=SX_;/CL?F/MY2.7)7@PF57:D;`=/D(Z""`/`]>@3BW$5M5YE0%
MI90)<,8R-:B#0<E&(TG818Y(X^P`@CN6.TR-1!,0`V$:K&QVR`026>NA1YGY
M?:#/B3O'B9)&_(JUAZ?PE@MJ`/A!\=B"!L`-N7@.(#"`@=*IZZB$=%#+\QPY
MPVD]CA>]62'N4BH%R_CRB*5[SD\'*,Q4,1S/"0XIP6-E#CD4W:L_9M\^H^4[
M@0`96%:N7*J8UBV0MPF8G?KMT.^Y@PQY$B'+.E\*NF&N8LV)-&OY`&QW^3`^
MER/'^.4!&/"<B#DH51%:C3*J*\1`E*PD622MJ+2RNGTF?&?C/4=.HZ>!!`(=
M1;1:^56]=H\X`.PCI!!V)WF"(/BI5F!KL;Q2.C09TZO:-0!3\11,DLCM(THP
M*UK6N&D82"<&/YA%X#8R./NQPP"4=56_E96MDRV_2?\`3O)W,DDG>6,VTQ#7
M5<]($+M$Q,@?*!$"5$"%&Q5%C&E[4?[)8BE5K1,1S%'(@*/LQ4(69Y"<STO(
MHS*XZ(U0J0*H5&C>W\R&2ZH^O64MGY']GS\-O&#M)!X.(\A?PEXMH`&T%8^)
M.W0F#YOY97S0I'JU&=FCEGB!L!J1TJ/Z44#57UI(8Y6$5H>\Z21_L./OX%.1
M7JUXGF(]JV=E917-9C@9W^7[AX'J`/`@`?=36BQZQ<)]18V\)^SS$[D="QF"
MI8D>O%JIK;2,Z)*7WN'%80Y!,\'")_;>$@SQS^E)"C:(HWB*QJ>(WB>QB`+$
MMM3TGYIL"=O]1'3J""#X@@GD'NQK1D5^G9N0LDC:#X$$&)Z$$$#H5(`1JJ;7
M34KI1J@@F%K1D<QWDK'/C^2$:CE$HQQ_5VC%0HF"8)B#*K6L8&5%KY;$]11<
M#%I_?_;.X@DDF1N24:S'HM]&PXS`&@&/L_5`$;&0``(8@`+972L(_P"UE=+C
MRCB201#C"UBJ(KBRC+(`X`FEF-<5QU5$8-[GG(]6L(4AH]G2MO57@P!@1/ZA
M!GIX>)&P$D`*U2Y/PY]1&(DS'@9)D0);>?`&6)@%F=+ZA<0GGCQK$$E"2`L$
MYAAL*@B-<X4EI0A"<KD0I%$3Q:1Q'$]#A%]GXYSV4N%8UL/*?#Q^&Y/ZQTB.
M0(CDJSY519%O5I<`;B8/0R`">I@[$F>!5N7!W^5LU]S"**9&0\7TKY>+&L0W
MJ:KVM#(0L8*%$(8G-*B@8GK1S?2UCFU:U!0X*&'G]GVC<]9VWZQYB9MI1:<J
MHK:LUQ\.L?`R!(`&_E&TCB`1CTRED10S"U9O20)B.&(I1^#R$4DON"2XH6_W
ME*AA*-0M&\B':\32I+B.EN5B@M$R/A^K<?N,S('$@D<'U!BO6MIQV@J3XCJ9
M.QD=9Y".(!/,%0WJ5F;F0OVN6*9$.4,DTH01N,]5"]ISHI!RFM<<QOS)$A'=
M_)Q'G>CVJ^25KK6Q+/50HX!4"=NNP\.@V`^R!!A013);4<>P65DARP`GIN=P
M>I/(GXR6((EV!R)JWA&5X;*"\R3_`!1K6`]<A/$(A']8$_(C,5C4C#\FM(-I
M4:)R$&K(LJ+;2X@U/'I_/;K(WV/Q/@8W$&75I,JIY%]1/K?+?H`8&XVV&P(!
MA2"I%=E?J"X=S$*Z3""@5&^/Z7-1B*QC3#5&^YHAD%ZA.:Y7B"UG@]KAC]4B
M/"I9-+#BQY=9_3^\]1!,JSW5%<JLET'"(CY;CQC:`>H6((*KQ=*I:F,CG3*=
MS@FCC))'X%[NEF&>08)T,,@S)((R0\C2JHGE>\ST,Q3.,RPNN6.-VX:!]@@"
M/LVB-X``XGC!KBQ7EFQ3!K!/7J0209D&2#(.Q)+'D"Y874^9&956D2-#(5H9
M*#.Y#%E&:\GN8@2.>(CBG<TI0(BL,_S>H'.*AWQ)4F1&-M19XY#Y`>'SZ>/A
MMYMN(=%AM08V0J5$\6WW).\[';<[E>A,G@2W,UV652WK`%9(M(W=DE@F/1PG
M,"-'#"Q7O\7NBQ%\HH&M<JD"-PQ,17":$1:R*FU@14WT3_;^L]?D3).QY$6Y
M&3CJP;(KVL`\-N@^<#H/BH(`$J%5J(XT;=4_>9&(PK/:%S3,>QB_UD&;U-/$
M<1X7A0P2,,!'KV.(PT7\L"4/W%WD.WR_T'KT((,?25/T-J]1^*Q?O%(82-_V
M&)&X(E2&6?K5E_S$U+55@O\`776*Q/$161X[T<<ON\U<%ZHYZS"F821(;V(1
M[R*21XJXY",):UNKZ65\I(D]-OX>`Z`1`GR@$51X]_6B_C`,#J9\/'D2"2-R
M29:"7+!LB7/)%23@MAE:T1B_WXOCV`P2>@;#CD(0062`#2.B.1[FJU1*\S6_
MB2PWJIOK)<;CQ\?LCK'7P^,+]:-8[KB7`5&%)W'@!L)F0)'EWF(XRP'IV+.3
MZH=:TUE`>Z.Z.A)!Q/,T<5XQL<YK7N+^.QGI8)Z-\E$+T,<)_K`)65UE=IM(
MJLWG8;;_`-O7]9DR)8S9+=CB@&^G8KN1.VWVQT@]8'$%3Q18HB'27:4KWD&U
MDEXE8HU$9B^PA/`_<1H\@P&JCS-<PP"KW<1I!%[G!,HO&JZ`?+/R_5XB?#H1
MX01Y62K^KD8I+"+".D'X[[$$CQ$%3U8,K2Z6RL"R2[4E5.:WS5B>!HCR`*\H
M'A)^4#Q,=['^90$1&$(YKR#5'&::-)G7/5Z$6IT^!WZSL=A\QN!(!Z%66NRF
M_P#%SCW#>-B-C(@R-S\5.Q.Y4RP:NRV7@,#66ZPH\@BM(!.P/$`Q,D^@"B&B
M-(@WMC0A,<S^X+U1T8B*@!A?5W6$VT^HPWGKOTD_Q,^!DS_,2+;*0N/D^DC&
M".FT`P('6-E`(W$+$>15./$FQ5H9P9]>B^DYT;(AD:Y8K!I[V%&K?Q2$02(I
MO'^RKXR(5OI<'\F*"B/^(K-=G4#8^/A\_L\=]C/+B[5NK.'<+J?H)W4](WGP
M.W6/+*^8<2OJ5ILTBHJ(J=E14145.RHJ+_N5/T5.N7UWHZ:^]-5TZ::=--:!
M?<YYD?!Q25L>=*LV\I<4FKHU;$/.G'EQ`:N<,<>-'>,Q'N;%7_1>R)^J]T14
M7T'V(J-GD6E15^%ODL0``?3&Y.WCKQK\W'M3LZM0':\=PQ"H4%F+*+F``&_A
M^@URCY'XKWD#9Q]?41(U%^]7J[@3]G<_LLJ++&4<ZVI]I`63$TU\ZIE36P:F
M(&+8UP(49A@/>DA6]>L]M[M@68)P[B;.%?I?=KR!'16K,%%Y`<K&+(Y9BK`<
M=?.O?/;W>*>Z+W+&5:?5N]<>N_`@R&=+UD6V<"WITHJ65K6H9"><:O7D$WSY
M0W&<'R96\I\LVU1"_=Z_.XU:+(9.QH[)L*?!8^VL[$NGU=3)OB-'%="B5QF$
M:=Z,1!.8N%V]?<613:>UOBXE3MQ+V<[+`PD'RJ.%;!-VY,X(XB=P=;;O+>R\
M3*H'?J^X=RR:EYK71Z=-+5MQ907=C;<AL("<$K((<QY2-9@T6ZKIF$@GX@XU
MR57759;!]%`A4<C463J``%F;?.D-77<,TW4QY2D!$_=73D/-<1!H5"M4>FQ\
M"Q,]E[QE7/8P'(E@B\R8J>"I`K(@MZ?&%B8@STN=W>FWM"/[9P<:NBLMZ:K6
M;6],#E?7*NI:T&53UC9RLY<>7(<<&:;6[+F#%UT4MD:KK0C%-S^892V.=J75
M\R'?6PJ.[AY[]PKH;Z6EBI&"V2P;XQAN=[/T9[=]C8F%V?-9PH>TF'?DKM(*
M+R4O!/)C)B>0/3K')9_<NZ>YNU)6UAKH`#5U<&K3BRV.*[%KY*O!!Q7D`58$
MSTY:\%SKK;*:Z6^H>5F?%`DF_*1K&U38U[6)*E3"BBD%"'*89D<S%:P@IR>`
M%1J@<SHAD^CETH'`-A($?S2K0!OO$2/`INW\P/%-A')[=DVFLD4A29_DBQ)+
M$`A09"L(!%FR;<"+FUPGR.0==/K8%94TT2@R<(C:F?/NZ:'-835$#8.GN(\+
MY*@4@Q1_Z%>A?)JHSV$'BX9"]NIKM9GN-EA\P"L1]W(CX3!)^7Q@'.[DK/WG
M)NQTKKQ5II7R,UB*P-L-RF"8D!=IF1`Y%<C<3;/28VT;?R])*BTT=L8=1EK4
M\-`6%G.L:BK)91ZV6*U//@P8-A[3&!7,25,*!'*'V]AZWN^%C9M7X=*@UQGE
M8H,A0&;B6'$`DB`"_E4-]4;[SVYW3.[9D_C++V7%4#A4Y6&9F1.05@Y955I9
MEK'-RD\.6V:LMS?`V$YY)_&N1T.4S=]85]C85X[1(6DY'KG0#ZV(E3*H9]/'
MHH=*+\I\F&(".FJ-HV*)[UZTF5V.S"2*\FZO+MK!`/&4I,BL\@X8N6\L,3Y9
M),@:ZKM_NRGN=W*[!QKNW47,K,H?C;DKQ-R\#6R"M:QS+(%EX"CB3JT-`_XS
M7DN/<U5_R?C-#0ZH=A'K9F4G<@8>]V,ZM*>IMZ(L=":"#-!//W*>M\B3;!@T
M(0JN8C\W''O0=L--M>+=CV502+!3:M8:&5Y\A!`V#[*A,`08UN:?RN/?AE8]
MV?BYM.0&"M2V319<RDH]9'WBL&.[52;+`H8M(FW^5.(.2-1JX>9RT"EVT(,"
MHH9U;4:N$6+;2),G]_FEW^2FK5:&ND5S))&.D%9-?$>%$+'>[VIUD=I[SVS%
MQ&RLMGHL+,X+5F5`'`>E8.2,&@&`5Y`[,!&L+W#[:[YW#N*8';TJRZ@B5LJ7
M*0Y)]1CD4MPL4K)'(ARA'F0GEK:CA"OL8/(FMI9T"]8+,<&7&4B75W"96GO&
M4^\XK4UH9JU54U\FXDE?._J&)49)1?7_`%HO7*=\LKL[=3?6U<VYZV%5/+CR
MJOA?J;91"]3]/7;7H7M.F^GO>3BVI<%Q^T/2KV+Q-G#(Q)<^1-W)-G0;-TWU
MV/Z\8U]/Z=--.FFG336DGW2=8O"W)<IK_6Z+P;RA):3Q\_6Z/HN+#-?X?IY^
M"L[]O]O;KN?8:\^]XR?'/H'[4O&O*?S<<U^UL^P&"O:,LS]EN(=<IK_3Z/7I
M+)-GS"[.#^19ROW@S9<S4T42'*6?$ER$#(E_Y93O"I5(U7*2.-[BO11L:;UC
M'Q<;#@5JHPFA1Q$"MR1!`D#TVF(\"1`W)7YUS<_.[GR:QV/=$ESS/)K:PIY`
MF"?62)D=5!+$<0&H%7*S.PKK/)WI9,VEUS(T%]B)8,F3533LD/J-/2?N:38)
MI0(DQXY`G":(D9\B,K7*X?CD6KE8=B9=`"WTR8W`8".2-Q@P2`09D-Q:1!G#
MQ[,#N=%G;<LL^+DPI8<248SPM3GR4D!B&!`!4NA!D1C$LZUX5W=P749H`\Z$
MFHT>FJ!9+M!V&>E6-1182T@6]$4L"04$*1'G5LH@DED$5RN]7N+VV@2KO>`@
MQ+2<D\$1O4WK<!FM4J^XD@JZ@\01&\#6A:W)]J]WM;N%`&$#;;:@I\MU99*\
M=U>LE20I6RIR.9!,\>3:S-K<W&KRUG(^/2F_-#"SS]%)9'O2MT/$..KV:*^2
M#2/;.`FNS1(K%1H7NEA:%XW%&8?@NEQ,EK`W;<SGP+/P$IY,BP\$EMCZ;SXC
MB9!@J9UT_<L!*6K[YVSTO5"5^H8L/J8="^I9QK/(>M40/I)=>)4LK"-9;Y(S
M_P#@'`$O5/C_`)FTUN-5RWS(=A[4QU["DW*TBLO#OG?Y/=1;=Q+%K%,L6E:(
M86-85PUT_;<C^H>X!B`\<*F[Z9'^8I"\O*(X*5A.G*R222)UTO?,+^C>S6[B
M5Y=UR<7_`#`K3Z-BE_3^\/+U7#DV`<N%'%5`#%=:W9/6RJ33_,I_PH5E7RL?
M.HCP_P!I6ABVM9<U&/K;ZHFSFMC)HT=`0K?=[2.8K4.B(X:/ZZ7+Q$OQ>Z+R
M9;!<&!Y<RK*UC*P&_#>-H'^'H8UPO;NY68N?V%^"64-C-65X>F'5TI6Q&;;U
M?+(Y28CGL5G6QG.F//Q7(R2\:QYQX^HF.DY:KM;FOS=C=6E;:SRZB);VUE!_
M=EFY*KLQ/FN=()&?`K`*@4"]SEYSL.8O=5N'<RH:H18RJ7"JRC@54'C%C*>.
MP(9VWY#7<>[NV-[?LQOZ$'*9#32CNM3.ZNQM5W9>?*E&!L/(J:ZD(7@2=8FF
MV47AO%Q@)<QKRY*;646<EZS9H)VNV,%S--(T%Q(J%;-(M.$@6,&9RR!.<"/V
M<PA'=;=*G[UFEN!2D"MG%=?^76?($4-MYC,D;'S-L0!KF[<BOVOVI4]5;<HF
MZNHW7QZUR_>FQRGF/`%0`?,/(FX9CK#W%.7J-'/L^2+^OIK/)U,Z#=OKB5M]
M=QM[L-=C6$N:$,F]F1XTFFBV1A3K)T6+Z&0C#$]&DDL[;CNV5=C5KVW'9URW
M4K/)%-5==GE>$!(8J"J<FDL"1LIUS/MWM^+G76=\S$JL[;6ZV<2ME@R+KJ)>
ML&Q@"@8BRTHG$(RJ8+C63?\`++O5:LSCE7\J;Y2[6VG.AOKH%;)&>>>;/?7M
M9%AU<*MB/DN8XPW>`VQQN:_LQVL_"48N(.(\B[*HGD2(``G<L20.AW)8@C<;
M[^HY?<>XGF?O&W=VX\54@L6;CLJ*JEB"PV`12#L=J.&]Q?S=MQ=F(MW:RLFW
MEG'H*HE31D8O[;&.(UY.!)BDE_O!YXPI+$QX6Q7E:%B>$<BFY/O.!CI@Y>4]
M:#+_``EGF`_Q$>4$&.($\20>4%CNPX^A^U^[9EO=>W]OKML;MO\`4:80M/T@
M@V,"">9;CS4%>!(4;(>?8G)_^[5)_P#2Z-_\S3KQK+_YE_\`>.OISMO_`"%7
M^X-7#UCZS=.FFG336/=Q$!+=#')8,PG1I@U$5ODQ6D1B&\D>CQ^)!(J/_1%4
M:.\D>+V>&QP'9`2L@R/]'Z?&(@Q.D[M6EA46`%>+"#TWZ_+<=?E,RLQC6`$(
MW2Z<QVRB->0OX;P.9[FF(XKG$<U)#ICEE2'L.KD*]RE1"H4I'_N6SL8D"X"!
M\9Z1^R-A(Z#;:`!Z6BH55+8SGD9F(ZSO\YW)#=29'+DS'UY"0-V;+&F@\SQ"
M.:.0'WN?_4J!01@/4R>F0P30(PJF<TW]IJE1WXLI9%/XD%&@/X&/W'XCK(C;
M?;ZTU"ZG!9;4DU'8B?L@C?8@<8/*&\HY3Z=FIRX>5HZZP!XJ$+FN_(?'8(D8
M4AGZOD*1(ZPX:B$U'IX#&QHU0B!$U7U=E(!+5M]1\)F8^'63OMU)G:28MDRB
MX5+T^A?&(@'X](6`)V``'FXJ"<>)&+'N(YHLY/R7"(=S^[&M(H_R9`7C]+0*
M4@'*XH2->!5>BE&43G_D`D48-2P:O8&/X`_'KT(WVV(,<66ZLUY2&N[S$$_;
M$D=(F.JD%=_,K*3S1_=<0463+@$,WP$=CX#'J1YO!7#8YRR$)(=)*PQQ=R(]
MYD><:*\A"!+8+`SJM@&Y&_P_9M'0[1$`[``BNZEEKL:DG8'R]9_;O)DC>2TL
MLDL5:ZE6"/ISQID%D=H'!<J#$YHU,]@0?\R7N:.T8F1@@1BM,,:L&Q'/$-`2
M:^6N+U*63RG^_;H?$F=B9)@$\ELQKP<5UMI`X1T'B8&YW&T!8\P$``E5"V4S
M5Q729'X4V(C06/9KGHP@X_L,R*=41&2A#:IFA"4;4>/LHT((PO2D@46RFQ%Y
M(^]?[?$?#PD@]>L%3/$O)DT6/PMJA;_U#>#\0-X!`D=.2LO'FM<_66`K,21I
MC&_F>!&GC2!N\I#5(X,AS`&0Y^RFD*PHG(4C'D5KD(\B_N$=M9J/)/HG8CP^
M&^PZ#8["!X`?=S8]ZWKZ=H^]@R".O@=C)ZF"-R"8/(M]_*4<R.V1*K6>YI1'
M,@E,9[VNCQ_QDCA`BO:3N$3Q+X^:O\%"1A7M=%DOOR$8J+3$$#]IF2?W^$3R
M!`(=1'B6IZC4">08Q)\!$`>.PCQF.+!B#7892;$DTLADRM:KJXI&),C(_LT?
M?LUJD=XM:D9H@]AE5&L`P?@]&1F)^TWHZ7J4M_S0-C_=\]]QXS(EC]]'979B
MV"VC_))W']_R`&QZ*!!BL?\`#U&Y!,`K)4(:$0*.:0+GG:H>Q57LT#`O:X1"
M(5"^07D:YST<-Z.E131TLC>5SU\=OX_LC<#IN/(ZS926I%E0D#PWVW^$="9F
M5)DF5(]2MI@4R+:PD:UZD.\;_8%RN%)%)$T3R>ST/EE8KBR!JCAN/[/<-S'%
M<419]A1ZGGHL]?"#/Q@>!ZQ$$$""*[UMKR:H!ER.G0@B)Z21N1T+3R!!8LK7
M4"EG,C`?7V)6#CC;[0N(0(F0`L",S48<<A@@-&(8WC8PO8+&L>(C([0$@Y-U
M99O4J$MX]3)Z=(W\021N9!!8L'P\6X5H:;R`@$CH.(@'8S`V@@`[""K!`C53
MKH7[3-!Z$]->='`>HVQ_()2#,(:#&6.UA6-8$J*-!,03?8GK]+9`(<?/U4/+
M>P;^.XV/Q^8WG?;>2K/*:OPUHX;4G;:-B9`@$;]#M`@<MN(=*O=]#<\P3@<0
M5DXCQC.C3M8Y&M.]D<A/5+=^0U[R>IR,*=#$?_05Q#`LF.\*5;>J/E\M^HVZ
M3N!`&X@-5=F5$L'21>21._SV)AM^L;%N1.S$LE_NLG-N(A`G_ORXZ-*INSQ1
MGE=ZWQ#-)'*1`E3^P5%&5_Z/$4)7M=%DNI:GH.&79#X>/SZ]?$;CXA@"&45Q
M[OQ511][%\>@G:#()@_2=B>JLK$&NPPJ"4-C#5D@(X9`E:@8BH%HVC0"$1C6
MHR,-&-#&5S%_I"X`D5GI&)1UE<A"8M4DJ1UW^/Z_COU,G>29MLP[%`-#@*P.
MPV^$_+P&W\I4;<54KCP94#]ILVS8LAD.+(>HYL=?[CO`BRO,88CQ.*="G4Z-
M%ZG.$9Q.S'(^9$-5+/6JX.)<=#^SQ\-HWG<1OLCK;95^'R/5K8+6Q\PZ]9V`
MB3)Y0()!)V,VUM,W5=W>Z?$*9M@OC_P.D%<]J=NZ(T:R3^"KV<B,5Y4,Y'#]
MABM6RMHLV]-P/3_5_H'[8$;&%'W4F71)]:LD7?K,_P`3\]I/(@KR9AZ_VK."
MWKEAR'>Y[1#0_FH0J$C!@?'(%890HQ&^@1AG&0;/T&\1&-:$D):K4V\UV$[>
M,]9Z_K!!!\0026#L=TR:?2<R8$]!'2"((CH&#`@="K`!35(U\Y:QJBD.1U<W
MV-<UR#(^-X$E-+)8T4=HRB(X1&F8K&-;ZRJ@QM9)B0K[*_5W7_,_CTVW,_"#
M\QN25=XJ+O0'&S_(W^&T<I.PW!@R(`V:%`%E=4]9!'#,VQ;)D-0\B*!@`O\`
M8QWL\AJT+7M(]%(\RN1C?83VJY6M(4Q165E3%U],@2`3/]_[/D(B2``:IKT6
MMO7Y-N0`!\]MNIWF8$F9@,S,M\:PJ8TECY2=@E9WDA/'>X:F1[@R/6_T*A%:
M<GI>CV%<5I?409//\>22E5S*0AW'2#X>'C\-QN(B01')1==C5V`V=&&X(VGH
M8VWW/$R#,\65IX.T.GL26$,PCO>A@!&,IO`;$[$:1C%<HOQFJK@@_5[&`"@V
M?IZ4&]E8NK%;@K'$G]/CXGYF3_-(-MN->UU15SY@`)V_LCP'4!1`_D"D8\*$
M:;!.V!9E(\<D8X\5TM@W!]PUDC6,]_H0B29`_-B(82(94(CA^S\J*2YU1U]2
MH01N8ZQMOUZ#Y';:#'!A;4]M3^C>20P`$Q$B1'3J1(\PWWD<O4K:8E!!%L(4
MUC_QC'E-C$5B$[-_(\"*([AK*3O(E&8J=W+W,1KF.>8S'V-JLSULAW`$_L^'
M3H)_4#("@BN^Q5KN2T'BS-!_7O!Z]6(\?J(@EF!N\SZ>%,:Z0(:./Z6.4(Y+
M?#]6QD&;V,D,0;!!B,=W$0:/](GL(Q11I,-7<Z>4GRSUC[=NGS/4&)((,LKT
MNQJK1S4>>.@/V;R#X!1T(GBI##C795YJ(YR`FQ+0B2Q*@E092,<B#<R6`K2L
M6/&<)S71B-<U[&,11O7U!1LF/$K<RAE>K9O]1^)GJ/$]1NTJSTQD<HU60>2[
M>/A!!D0(Z$&0!L?*L.E=/AF)133099#'CR/,[6*AY!$<YZHCD[C,<LDQ2N8O
MB,BR3/[.1THA&6DCJ,A`Z`!AM\/[M@!\1`&T(`:H:G;$N-5A)0[^)_O)))(Z
M'DQ@@V,PR(UFT,.;#N8KD]!/ZR.'W)'>4_I='.+U%1!/E%4*N7W(PK_4K2H5
M8L@EM19T:A_J_?M,C?X;^&PG:.:B[("U6KE5_0=]MQ)B"(/B8GS03Q(;D:W:
M=GPH]I!'+BC`0J"\P.148UK5%XF8C>\(:.:,">3'J%G8#450M$U];96[56%7
M)B?T^/QZB3O_`#21;-=4F12+:P.4;?V_X1T&X/$>4?2%!H@Q8$FQKS0K4A%-
M$*6-[&N$<R=AG"YA'FBN&=',<1CT(-7&8XK)`?)94=]7L6NP/3])$_#X'P.W
MA$'8P5/TL+*Z7OI-.23R4D3L3T(\1OX@R/,.0=9-B&EQ;2;!.M7+>B,]GIC%
M/[#M];I36M8XSG$/(:0LAHT(KB%4I6,<]YB`/:S/4EB^JG6),;>'PZ#83&P@
M$P`&6J"N^VIOP]AVF`3)\?CU.YB9)D@$EF1\B+/;&K+N*9@WUX?!BNEM4;8B
MJYH&H\:#>(0Q,"`+"O0C6H-@GN5K&1)4.VLO;0P)#-\/'Q_M)(VZD@22Z/6T
M)1EJZ@HL==N/ATB!$!03(V"DP!7954K2%'6.LV&+\24(C#,EH)1.8UB/CJ]Z
MJ!$1B1VO8K""0;@L>P@QB88<*.JQN7!S*D1'[_C\=Y!F8())4OD9%2</5J'&
MP$&8CY?#X2((CB"&55#+5Z![;2K+')(\[%2F5Q!.<(C)`)A41C'(!SWO`]ZL
M5A!G5'$5A6G<0K)]#%5O(#[N!^PC[?'X@CI(X@`UDY9&.49IOD]-C(8_+P.T
M$-UA@Y+"Z!439OYTFLM#"DD:TAPD5S5<15>`A$&J$>XS&H<;D1IG$%YL[/(U
M\26>ZY$],6U`@=#^_P#N/A!@[`AT6W&MM]5L>\ACN1\^A/QGJ.C$B1NP-=CT
MZR:VIGMGQ?6"-W4)FL>`9&L$$17/\"L"(41(T7Q0K?`+0@1I%'&&TE1)63=7
MZ;[MU\?C'S,R>ADR9$L2+H+P,>[UJX"=#$`["?&`%@1(@<5ABM:@XT_90(]E
M&#.BJT*@_(:9K48]&*GY`"!,&1'402Q?(['J\2HQOM$\)&.DQG1U6-6QK?>8
MC]QV(,F=NAZP00>+":^E+T%U>T3/[Q!!$`CS`R-AR4J0;*S[AA9=5[?.6\LL
M1G*\PAN`@))7H]HV,:LA[BA>9KQ/53%[F;V(=3(2Q.319L(0C[9'[NL0>@VZ
M+QBNM:C*I$L3:#U`B"?V[B9!\Q\P@OR!OE*^5(K9*5TX[2#$]"1'.;W4P7*%
M6-`HS)XHQS1/:QQ49'1&N81`-CR(=UBK8OJ5B">O^G;[=XWW!'+DKQ46/19Z
M%QE1N/F-ND'["!,+L0W`(]4L6:&ENCL:)@(:-1LA@4:Y'B_%.5C3)("!&#$C
M2JJ(C&#")_9/0&2"MO"-?0#,OX?M`\"?E]I(_F96ML:U<7+(``J\8^$$[R!T
MW^`"@P."V)15[>LCSXO[F%Q8TH3%E>Q5,]Y6HI7N&]$'+*AF$,1!O:,JH\A&
MJ,R&/'L(:;6K?TF@H=O#_1MTD2-@#*PK5Y.30EU?KK*V`3.\GKM_,9W,$`[E
MAQ8,Z739((;:!&*5XCR7Q`/%-"Y6(YY/QI#3!?$E%\7..@GC>,I%&]6.8]RJ
M`TBP6-380)"R=C^L>(^$@@@2)D?4JR&E<FE68@OQ$,/G!D<2?&"""8,$$RC/
M;-18V$:<"N,5!!CD4#HCPA[(GK;Y-:H4"-C6`C^UBC<P*,&KF>,9JI3Y-U=;
M(;`))WG?^V?C!F3)@RQ^^P,:^^NU:&,*#$0/A\HZ`2(A8$B*Q_POU)TFIM)4
M:.'L$QT1L<T8@47R0_@((U"][1F#[6^*C5$\2J@D5DV$E>"W5!F/F`Z@_9N?
ML,>/PWW1]5%KXV0R*/(3T((^.P$=")\/\7EVMJU<%M"'&`:?%%Z9@U5_F)A2
M$4D@XT?XC81[R$]LIRM5J&.A3*HT*4R)8XU+EF",90_V#^&WR$#>`/N\W)I"
M(;JQ%H^$D[GX3),F=N32WE#,WW_TW_M"GCR`%*<@A`EC)'()"&48QK[6MBF8
M`KB,8QX_60:(Y!/$1GC&D`+]W<58``R-_P#2)^V0?$$&65C??8RNA)8`,(C>
M`-]C!G8B"/Y2K"*W2CT;BD<>DGBCFA-BJY\=[!N8+LI&JU58&.`;50!.Z*((
M^XGN:T*,D1:Z:\`1?7(>>OZ2?$>).X!F5:W%Q"S<L6X`U!>D#;K\@/`^"C8D
M!0KUT&R)%#9RDD))F09<A6.*X;WR/<1Q'._XF&(64CCD1X_%[I+G$[,=)<<%
MB*K?4.,+8!^J/W"-A!_EVWXA6K<WP[V#\GI8]?&3^TD[F1!Y&?*;"Z7S5TV"
M:+$M!(KO60+XTX/<CCI[HRQ@#_O.<9D@J">`C2JY"J)X2N*^,:39075C4?&9
M'PV,GIM&\B.D@B`P67*%35KD+X$0PWG<0!OO)@J9Z\2K%BC63HPQ;N"(DMB&
M&Q'/%(CO];2"1K%<-"+^*U&HD=O^T34](R(H4$QU=:2]#D+L?@?T/Q^?4CS2
M?4E5:\ND&P2!T(\1MM.WP'P&P/DX@T4NL+.CV9J@R^$=BD?ZY3&D5@G*=@^[
M5&@U_*1I?/R9X$<I>[&D;,B)):$:H7+]6W3]/#;QVVW(X/K&QS<F0<9]D$['
M?;?Y1OYIV@GE(!%M>H4V1855F0Z*=0$D"11M$9['*1W]M!(CCJ\IS'<C6(KG
MD*7LQ'2GM6XN1*[J^.W(#]/AT_<!OY0?1I:]V/D<Q/`L/`^/2.NY)^TD[381
M^)]V:0BPAVU>!Q992A5)$=#>A?)@E>3L,P8Q(\CU@<BM*%I7-"Y##<D:0"E7
M,/Z5AA`#L>O[P3(W\#'F$$<E:M_I-4,FD382-Q,>&^Q`(,+X@$A#R!%;I5P?
MM5L!0F497(P23`*1`^:(PX$4PD9%:X7:,5GB\0VL]+VN&-!%%!A;U:6Y+('@
M>OP.QW^(.Q/4$$R#9DI^'R4XO!,#D.GQ&X\NVQ&X$<2"%XLM-/K"26R957,*
MDD#6N'^)($TQ3#>8J$4KBA0LDA2RR"*\@WN(]7H0:F4P["2T+Q%J"&^(,>'[
MN@(@B-H/&#7#CEQ8U%IY)$01).YZR))))!)!),RO,LMT)JR:&<%!E<M7.(T[
MVF[.DQR'?'\?=(84RK)0KA-&9"O0JD8CB*9T:5,K"9"';[U1&W0Q/0?")D0(
M@P.(94L!LP[0%)_#N9WZ@F.ID[S`#29D2W(UV6S&BBPP!_<?Q/81D@#C%$\3
M`C&-&N>XZ/>.&(1Q`8U[G(P*H(2N(`8A'K;<9G9O2Y;08_T>,B3\]S`8DK;?
MG5U(OK<?,&$G:`!\?Y0"``3L-EED"J]$\4,6Y@)[!>".1_<;A+[D<BG$1KHY
M6]V@(KS#*$X>RM4K"B1$DQVV*S46;']_V'K\>A!!^!!^EC.RUY5/F$;=(W\1
MT/ANP*LO3D&79T$K4!F>R373'N>V%ZEB2&(]QFE.1[T*"2J2B'(UYE1'*\IW
MJ7P*AB/0EI=<4@6)U;J/D/B-H_8!M(@"*HL9;9:BTDA(@CK)^!W).Y\2QF&Y
M$\LBC#/+H)AVD5S8T@G<!GF<5CQ`1C@E$CI4?^E%<!%(I6(-&C:IO5^),#,5
M3(01]8&^WQ_4?GM!G?:>:'&#V8=I#?Y;'8S.PZ$;C_9WD1Y1RX^E:D?2/&$\
M*;$1P#JUYGS&HT86M"UXE5_L&..,@0B>TWDUC/0-6E&V.(W[73%!961]UZ1X
M[_OW,1U,G8EB/5NSBJ.EM<JW7ET&VWP`D`&9@<1#`(K?AZP^/'OHC3O&OYC6
MJ)O=\D2B)[BH1?4\1E'((CS,5A`D?_=*,C"(0X9D(9L=^(/D_5_?TZ'8@;`@
MB%9,HHF95S(^\&WB/$^$&"?,(*D[LI#<G6U4D*?\R!+(]"`(K8[`O()[(BK%
M<-!%CG4JJQQ`JWN]3-4@U:4OG&DS5P"\;$Z'K]N_61'Q^6QD"&5&,S/RIL)Y
M`[1(@;1!!G;R^/+<$,W)++:$^9*I;%8[3OCU;?:R.A/$L0`/4,J>#G."T,>&
MUC']D>Q``:B^38R#-4SA%OKY1-OC\2?[S^N3\6E;L,VV8M_"2N/O$[@#8_*`
MNQZCBH&XK"MC1+4;:8L8U?%5@#`,^2TC"_B>M'&<2/ZC,(",,#%,[Q4+5`Q"
M=QN"R6&-2HFX$6'S`B/CX;_$SMX[[;R49KLA1BLK4K"$&9F(WD0=@!YMN/E'
M+RE18M=P%A5]L!"N4OF5KGC*C_"2%_D]R*Q$;(_N"-*7]?$JO4SD=[7&>VQQ
MU>RIN/@/V'^'@/E$#IQ!KS&JIR4Y&9(D'Q!_?N"?G,GZBY%]%II2RX!89B^Y
MZO&&`C')'58R)!*JQ"PY;2HP+4"9O@;LUJB>*0\:Q9/4]R\+`ZB!U/COOUD?
M:.GQ!4'FNL7%L]2DUL9,@+&VWE/E*F=O*PANG$JY!KLU"B/E5-@E85Z,@2'$
M8)S6C08QK'<]6B;_`,J%B!$'NX:>+(XQN4;61V$'45<)=7ZH_P`P?W_K/CUZ
MDD3+$&ZVLV8]_P"'8Q29CIMM_P"B!`'3HH!X@(&&-\L$%4W`7BBDCQFL<(I@
M#<9[GG;*1[/1(CD'[0>9U:/TN?\`U'[,>Y9D.16N;:2"9;J`=ND>(/CMO/\`
MAW'D=5W'&R054K7$$C?K/@01(\VW$G=X!/JU/5;.(E@$<^"CY!U5I6F9)/X^
M*('UD$HB'*5$*1A&>E7/5Y$(-Y"D&ZQAJ?TV-=FR_"!\_L^8,[;00`#Z>1D5
MBY!=3)?K,GY1$23O!'&3)Y`LS*;P&,O*H2E,,L@1$<PG9C`,<WTN`\K1201S
M`4(@E]C##8G@QXR!1@"0C$T6F`0I_;XSX$@S(B">H(:6#D`R\<%B"X/7P\(F
M"`1`4R&`V!4J`C5;&IW[)W[*O9.ZI_HJ]O\`9W55[=<UKN!TU]Z:KITTTZ::
MT2^T[VYS.0A7N>N)-'=P.3.-&UDZ&Q[Y/Y<^MV56.,!!C(Y#2_SE&QRJUC'N
M1SW(Q'=^]]DT4Y68U&0@LH;%OY`](!K:3\A$GJ2.F\:\A_-3,RL#MB9F%:U6
M6F?B\&7K++>D#;J>4#H`=R8G7'ZWGRKBN/KHZ1I%]%BUX]='@2']T'++^1"N
MG%&I1BJWI)<$C4:@X]HU`C<5LH:#]CIK6FP8;2,<D^F2/AL5\/-M(\37N0.!
MGYFRKK,J@]S3B<Q57U@I_P`1E7G<<#)4[0MOE4L+%XU&KS^>Y-J#9.P*.'<4
MQ$F\=7'HB%CI:B+'GQL],=<CDL?G]:3Q5B^QBQY?K.PK6H;RBMR,CM=PRZQR
MI?:Y9,\8(+CC'GK^S=94@^74]&%A=^QF[=<0N55YL9X!',$,*VYS]W=X;CB_
M%PP'.<<<;7IN/+;_``+8!'3ULX^/R\:!.QDNKE8K?7S7V]G>J6G<^"!L.=&6
M/;#BR1()R=R/*D=C'[+N=`[C5^/PSSM46.2+`PMJ3RJOFW,@S66!GP`Y$C1]
MBRV[+D_T?N8%5#M34%:@H:,BSSO9*>4<6'&X*PC^8MP`.7+7+3,7MBZO+)!B
M5FSOY<75UT=VJD3(^PV<Z1C\1J<N.)%CI"A6@9Q5.9KF1$:=SA^YB#\=13E)
MFX(Q,KD;:*P:R?3`-=8%EJ623)4@0/JV`,&9Z7([?;VONI[CV[@M&5<1<H]8
ML+KV--%M4`<5<,>3"$AB5Y"(N_ZVR9.'\@+/U+(<>9I[6NF;:QBR)MD>RF5M
M_1NI:V"ZQ$2PFYS-/\E0Q6,?(LED^PRMCMZP_:&6.\YAR+N12I"*@0%"AD;D
MQC8._P`!("<8'F.ME^9';F]L]M&'C<5LR+%-[`LQ9ELKX*O(%FJJ,^8@%K><
MMY!JV^.+B%>?0>^RMW2I<YS>X6@KKR/25A:F9&'6GTLJNO*"H4WA'N:TX$E"
M(BH->Q(RHGY"-=D]RI>CV[CY5#\,G'O<J6;D#R"`H[>*L#Q(Z]&_EVP>Q9-6
M7[TS.WY=7JX.9AUK8*TX$!3:5LK2=G4CF#TZU_SP:ORMC;NIUB\>TJRJ^%=T
MZFCSJ*[J,])H^/;>N9#A;:N&X`K.W?=VU<Z-&$<AI'Y[RH\J*,;6P]IS:+L3
M^HW0SH^X96<-<IDU-OQ7BIEB`!P`@;F<GW%VO+Q^X_T7$Y)5;5(:NQ*S7C.O
M%;UV#/ZCJ54,2WJ%I8$*!B;:[7,83',SM"M/&M+"IS15J;?12HK*/)5!3T=Q
M93QP8KD2]TMC8J4;Q1_6;Q<9[O-X%ZV^#A96?F')OYFI7<<E0'E8T,JB3]*`
M003(Z#8-KG.Z]UP.T=L&#A^DN0]=1X/81Z=*$UNS!1_F6LT@A8;=B9*:H7%^
M:AY*DC<GVD*`D^&E[G..*.P@6IRUX*>]N94C9GF7%B^1(6H"^3$JS*WTNL5.
M<*HD474_=,I\N\]KJ9O3;B]S`J)+(H%8"K`Y'BU@Z\.*GZSK#[!@5=MQ%[_D
M*GK)ZE6-6RN2H2QR;RSM)X`LE3?3ZG-UVK75PYZ^F6TK]R+8SJ:KS3(=K:67
MXT:1-*HC-/!@QBA8Z-97]L%`,"UJ/<DF0TAQ/CQY*LQ\C'2E/3"J]MLJJR0/
M@20=U13)/38$*0S+.;@YEN39Z[.]6/0%=V@%C!E5!&S6..(`$^9@SJ41XW@X
M!WFNVFGOX^BG3Y5?0<*:F/2PS6,6;7U$67R5Q8T$&M07LD&"&)7C"Z0\CO<:
M.1?_`*Y>%]PX&'A8M;8RJ++,ZLL0I!8BF^2WA)))@#8$:]9]F]W[EW7/N3-=
MVII[5:$4L&5`<K$A5C<@!0I8D\F5C\SV;Z\6U]1Z=--.FFG336D7W8Y&<)\G
M/<QY6LX*Y3>X8QN*0C6:#BUSAC$U%<5[T3LC4_5RKV3_`%Z[GV$)[YB@;'\?
M1_X+]>3_`)ND#VKGD@D#M&7L-R?O<38#Q/R\=<A-@$)OPM=G[[RCV/[7(H[.
M+-4,!CI(EMJN<[^R_P!\K\BF`5P6Q6>)7^HO=&.:[V'#9EY8>17YEY!E(D[>
M5AUV$,1/([;CKKYI[FJMP[EA7>1^)K8-"[^=&Z;F44\>`@GBVP(,&XC#),!J
M:PD.'7ELV+<5ST$$>:LXL9NC$",6XG5\Z/"N*F;-G0'QH[!1VB+"83_ED\JT
ML0AQ;038%\IW/-2>$GB""58*K<B29#D>;:W)16M7N&.52DV>==@*F`]4`%V5
M@KHSV5E5`6&J!^[$Y%9QLO,U%4TD$D>;R?EY"5=+9#U5U'%.H(^JJ[Z7E94R
MM<\X@R!1RGB^UC_5-*0"^`SJ\6N/<_Z+>]]@*]KM')AZ:F'-;(+`&VD2`T=5
M`;<K!W8[%_U1B5XE)#]_QVX(PN<!JQ<EAI++N`0&9)!BPE-E<E:Y\IF(`FLO
M.0]-%!Q#Q\=NVT=V;1W-X>-M=SH&R:[!P&+55I2FLJL,`25[6%(OO\&C8\A'
M$@]V`,*J.W5$]XR!Z2*$50:JD@VGS-LK<SSD#:9(``S/R\9E.3E][O5?;6$?
M7M<VO81?D62N.OD4DL@K'I@$^:``68M:'+O+E'S$?57DU)V)@!I99@T5I$9*
M'6UQ*-ED:7>%]YFP[2TJ+8,AXYS66<OS,@T;'CN;UF=G[1?V9:J$XWV%P.2F
M)/*(782JLI$KY%A9EFG6K]R>Y<3W,^1EV\\2D5$BMQ(5?3Y$V&3#NCJQ%@%K
MR_$!$(UBK,YR;.G<$PK:R6"!O'VGF@)=:^"L0RES&0AK&KZV#.#+11,.AC"(
MC7+%$KG-&@'$9M<K)2NO/>I>3?B$!XUF?KL,DD1X0"/YC&_(`\[@8-MMW:*L
MBS@GX*UASN6#-5*PJJP;:>3`[\!)"\"PWSXGW>(WV?J>$-#HOW+6SXQ;7C[:
M3$`!-!*!`KWERN6MKNK%"L)=I26L8"2@,&DP4A`$1A`B;UP/=L#.[?D/WW&K
MX8BGC;4)/`$G[RQ58D!64GB9XD<A(8Z]A]N]W[3WG"K]IYM_J=R=2^/>8'J$
M*LTU.Z!6+HZKS4#F&X&&51K19E3L>3N3R09L>;52:>=`)HZY08&X!QCF,/.T
MF;O6OD`_/O%$6$5D@H?QHLJ3,E"$+Q4WJ;WAMP^U]K]1"KHZG@TVJ;WM".NQ
MA>L@&6554D])UY&,;N??^_FJT/794Z^JL8[C%JH:VJS<<K(*D,5XH[NZJL<N
M(N_7*]D.ASN6B6$6GH,\[.Y4%HZPD7?Z%!3-2QMZZN!`M;RR$\4J2<@RO<8K
M!HJ-8U&X>'!>S)RRINLLYN5@+XMY58DJJ[JH!`@$^)G9=R)%5.#VY77%II]*
MH/R+]0GF=5"O8PXNS$$\B%Z``6DRNN:.MD4+#1I]K+)[MS.&JD0(`"?,;@G)
M1E+;$K*8&882YCR4:QMP-D?R5L-[R9ALHOL&1!6D;5#YG;U?-Y>3%R*RN_ID
MM_.`-<*,K$H;#!5\AC.0PW@`%OP_W9+E$%0-ZM`%P"3%1+;+<#S(-=R;PE53
M73B7ECN\U(BQPQBR_P`>%X2IQ;2[EB*./6ULDD[T@(1BNFS'L:U'."]X^8[^
MEEG:\ZU./H+0X))B3L.*CJQ$20/I4$[2`>[]GVTT=^[5CW<SEOF5$``F%W8N
MY!`526A21+N0`"5)';[)_P#NU2?_`$NC?_,TZ\,R_P#F7_WCKZQ[;_R%7^X-
M7#UCZS=.FFG336)>0'^%]FU>0H1H&8J$$G@ODAXKW->51A<X"J-OFUA^S/T>
M1H5:.9&V_;A./;`!,CK]A_?\)&_0$[HW-]Z,9E$D@0W3[1U.VWQAMNI"PMJ6
M9;U:N5EI$1`6$=6N(C58T9V-:4*J]Y`B$(P8[2-]CQL$H6D&9C1-,*'G4V_^
M2^]9_=X_Q@P"3,$$F"^KRL>?^(K\MR]?@=B/$``@2)(`CDK`*&6KCY<_0'UM
MR-!C,S]KR9)S5-RM]RTFV-\QX3@39<]U,+BCZ+M>-.!R6'$G-3)Y]%PV+,4]
MM$N9V?@V=[87C8X2N5)$A9N$U@JL(Y,%#$;<28#0".@/$0?#H-P`"FU2GUJ`
M2B&QJT(Y\PI)62#]1!<DJ-V`Y'9B2+<D<P\W\K7O\?)OI_AWZ-/F]9E>`I'*
M(=!B^+<N'+<GW8*:!&ECML'S3D-AI\/#K[Q%,^J$^/:UYE2-(D'8R+))/DJP
MQEM4RWBP`@_./@8(ZCQV!#H,/!:ML]L6Q2$)("$GDH^$CJ5!4SN8XF6!KL:I
M3^:N9?GWZ:U/!DV!SO\`5F;J/EW%\I1;/,X?Y_I[6HO]%ROS3G;*=J5!9<*4
M$:LB9?)5T:L'#%('^-6&4S!=D)%J+;'!5P7(`W'U<B3!._\`,8!$?49DL3Z@
MX]"`65%:@68<6)X%%"R!L8X"6!)C@((55'H:I<,_2WU=S_;YF4_8?3$R+_X9
MOB7?7,OYPX6^4[S+Q==S)QS=;#DBUY%F<J@E7U>MG;02#%&IHY8D*":0UH"*
M\@'P4VV\Q2Q8`@$0`=V@;2!TD-U_E7<;,,S+Q\5:6R5%;%782S,-D+'JI/6&
M3Z?YVD$<D.Z'V1R[REG^6_F3C;CO8\W4^>Y,IOH:VV*_/?$7'G+?)Q9_'<3B
M5^9>VKY(S6LKZO.0C;:::1+`T9BK)BM\S-(TTN[(>S&=8\ICY08_2"(ZB/+!
M5(L*NG-H<L>8Y`"205)GX=3,$'E,$$<Y#6Z5<:?6_P!6\MVG">7JM+]&-C6_
M"G/VTMX/SYP=\SV'+!9W'WU5;<,XF5R_D>:R-HN.-)4XNNC1K^FHT%$BZ$!4
M"1(X0+'BO>U0KN99@9,1)!/Q!$F#,$^8M(ZALC&HQF]2NH`(C)`))XAE!(!4
MAN*D@K(`XJD/'%DVD/M^?^0MK]*K6_2,SY^K?DNKX[R,(FNXWX<M(>KUDG@#
M'<W;#E3ZI;-I):UF)FQ]>M7+JLB;*,KX-79RHTI_K<RMR*U>VEP+("_'X0#/
M[2(@D3&\LI;"O:K&R*F:CDUDS!/664*(Z&%,\E#<9\O%+!7:^JY7Y]WW$WU_
M]99SGZ#QM`^7=!S)383BBFP6*N.)]36_.^6KM-:VG+NHU5!+Y+ER.:YCY<NA
ME5EO3-J:"YA$$.=(-*2SA3(O"LR,O%3])@SL9!C>"`)@B(4[!04R;,+%:RNN
MU&]6Q?K')2"2.)6?+*DD#D#R+.LDNRV8.U?V=].EN.:MK1:;G"!#R7T_PSQK
MBL?)X`XVF_+-'C>0Z;YOE&H>:>8Q4!.6,W<1YO*\Q;&SKK9[ZZ6V&\#3#:-#
M1V6LEY5950P&\&)\#($CJ-XZF1U`R:<6JW%4V<7L-;,>/(%N)B1#&"?*WEY"
M0(8RK'-^=YY^D,WFHW/%[S7;:^EF??FE^8)G`5YQSQ5"STGCRR^Q-#\U4`L/
ML*#+8_=1>0L9GF0;CSFV%A%LH]7*8X#!]S5<UBN(O0@U%R(^(Y<1$2?G,G<D
M'ZASPZ;*2QPW0C(%*MRF8;AS/*>*P1M`"^4`J?(?1S-R-]$\D<9?77*/&N=X
MBY;Y4Q.<^7^,N3(M1Q/F./K$V8V.CY`^@:*[LM!.W>VPKI%/?5>*A,KXT=TU
M(LB/+:^.-3RH\B9\AC-;^8%1QZ;&>I,S.PGP(`(/TN,:O#K`%]<5L+&#`\H(
M@&`.)6)+1T*LQ4KO96=>OG+E/ZD^R..KZ^KOI0G`E_Q3P%\Q7)RYSB[C#1DV
MG+7-?SMD.=-'RORE6[++V3Q<6$L=>VHKZ7.$HBE6MLR_G&DD`UT6.]EEJ\S"
MP-MMX$GK(C]@$=0H^[R<ZJC&I<5J&M+-O+2OFXB(@\I@="22-F=OOMB/@/Z3
MY,^L:7D32<@!JX,%O'?R;LL_24M(>#6YR?RQ\^T/(>Q=46!F0;:;2S=-(2;6
MFD2RG!!?'\3!:T!04KN^]Y`0NT"0>O@>LS)&XWGH98-3)Q>-(K9@S^8%H(GB
M=B!Y>)``/E;8@$%81DU%Q?TE]<87YZ^5^>M7SRG*"_4'%_(K[?":GB3C+/AP
MNJC_`#'S!SSEMUQQ:\?9RDLBT>'L^+4@7%?>"NHDVHGN+[0'C%CB6;4K=REV
MZ]-C$GX3X>,B1\5:R^I0V79BE`M=?2.7F7EQW^J"-QTXF"#$.E4C)^A?K+$_
M&VL^@[;4_7%?K)O$WS]:UMCRGP%\FUE`30\J\C<7T^FG<0U7&M-966MU;*V^
MM?VNJT,;\60EP/R$^9YBDT2QK:&\Y-@_W2!N-^H\('P'$>$,E;::\?-0&M%H
M8GQ>3`)@R"/J!/26]0QYB4MVO^7N8.3=OS']`<=;W1<Q:*AXNQ'!NGRY.?>'
M</PYSDZ[Y'L^3DM0P:3C2OSN>U7%-G'Q=<*HM#1XT\6B!-CL,]PXQ72X3W>J
MU;CR?`^'4'PC:#.W3D&'$,!B=VJQ?PZ9-9'J=`5)((\I7^:=Y6/-UXE&Y%&;
M%V1Y@^B9_P`Z_.GVKJ.;7:2!SIRCP107OS,G'O',#CVCPOT%S#GN*ZW"8/0A
MHJ3E1W,7%L+4Q95A8S;N1'L["FFB_;X0$"M3"F0Z.+D(X%OI&X@[0")((GQY
M3/FGE#Y=N'58CXEJGU%0@6'KR4$R0>"E6`B!Q@`%".(-5S_QV<G_`$9S94YW
M?<N[+Z0N*^WH=C/E)IN)OF?*?.]X4>NM<]61,%I\4&5S)+)60H)"Q5L/6DL:
MR73&/=[8RU6PN0QD#?X=01OL`=Y$#Y"#]+:I;2*N58"&"!L6)@@R#R)$@AI(
MF9:5^M-=)I3WU5S*>$J1TDE`43&QWM&5YBC<]K^ZR"D821)5'*%[G$DF9_K)
M(QUML5`NI`83`/C\/V>`\1LH/\H/HZ.PG&RF*GCR(($=9/ZY!)WXDRQ'\[`Y
M-2L5C#8.2.*CWRT&0L<+#(9ZE;%&DN(8;HK`R`N;&497%&QR-%XO%_R\F-'7
MR)*D[#Q/Z]CUD'S2()Z['S*T]_!0+%62W4"9WCS`B((\D&0-E@KY+*ZD#U2X
M1P%CM1%`YI81$802(C#-:\/FR,U\<OI>K>Z"1O@]'-$C#AAQ-R1PP/CU_9]N
M^_SZC<RK/D)QLI9&'ANIW'CTZ;&#'2(((6'6J@U,F66<2.&0DR&]HUD1IKR-
MGC:A31C/<&4(Y_RHYE<.2-4*]RO7R:LA3,LI[E0(&(XOX$=/`^$""-P=AMMY
M>)JP\9[&N**W.H]0WU#<@[$$R#LPW.^X+EA?[>:3663I36JZM/.8%SOT"T3B
M(#Q<KQF=ZR.D.&HBJ]/=_;\B*]T.5)!5MJXG_,"_W_+X3(\-]H#HM2UE%YL'
M^07`^$=/GMO$&?-M))-5EE8M&1I-80CPI+"@2&$C'#"/UH%SF*]2FB`8-@`H
MO=SA#9ZVN10C&CJ^"HLMH`,&8^/C^L]?M._\Q,69.0$LQRS#DL2/`1'C)`Z#
MX@"`950#13:H@;8*0K&,Q21&M(T!F2$,03V'C/,99(F$.$_E(&1""57JI1F"
MCDDQG2V@TMSK.Q\1$?&!'2-B(/P*F.+"''*Y*^E>NZB8(,QN),B2#Y@9&_F5
MUGU*S!J/R8=A/CDF"\GO$JH]Q2M_)><0Q(%/8Z2\KCS&-[HYQ%<1BN0ABC/:
MW7<7K5@IC?Y;?PZ`_+8Q"@K59C>I7<Z,XDD?$[R`(WF9('4G<3R9E?(]7B)!
ME`E5Y"AG'<IG1P-9ZY+`LC*Z2U?8,".8$`6O:TC&$8H5]HD;%E1*4?>*4L@H
M-I/A,[?'J3X$C?8RRO7+BJP64DBT[P.AB-^L=`H,$`CCYEBNRN=DH^QJDDG@
M@,YH3(Z$3L(3FJ,@SHA)#`,:)`"+XH80F(K%:08FL,*%8L5V\58@3U_ATGQC
MH3\B25+RO-V/S9`3!\IV'0SN8V@&.0`VAE4!UJ4STG5K(LQJ2"B(<+PS$_(>
M432$"1'(]I)!E[2GB?[6/-YO<TC3$>5L]<.%G--@8,C;_1X`[&-A'$`&MBGU
MJ!7;YF!((;>1T/Q)ZD&06DD$,Q872%818=O*@".UD1A'%$)YO)[FB<!SG(9K
ME4A!*03U)[5*K5%W>]SX<N1?:.=(L8>>/A]OA^T1$==A#HL..QJR6J5HK!D"
M?A'CXQ(,S,<9))JL>6MH\FKFDL(1R-C/>R1-=[6#9'>B*]$*1ZAC>A(H.S'+
MX-&!B,(HX[!%J;Z62U/3<#ET&W7[/&9/SDF1+$BZ/)2S'M-U1/I]6WZ?;T$0
M-CL`H@\4"MC5J\CMEU*G)&80HQL-XF&]J#8]IARV>!`E]/L`\PWH4!&=E(TP
M5;^5'Z@H8I=Q!@3X?JCQ$[P1!!Z$&>+:R\M!9C<V4%@)WGQF>H,2.0,J1]09
M8]1-1X1(UM":C.Y1JA&*K_!\N')?_2L;P<V2]3,9*3Q>KC*9"(OD9Q6OL:.&
MJ??8_N(^/AMM\HCPB*[ZFKR:MMUW^U3\(WWWV,M,]6+`WT2A-(#+=#=8"?%C
MN)&C1QN1_DB,"<7I3W-<(`A>I[/`JHUB,5A%`D23&FR`I3F%/([D_NWVZ]9V
MZS(Y<U;$PV=;/2+@UK(`_81&^P`@B#L(AN`KLKASQR:RW`>/'0XS(16@1BM"
MK!-,-1D,X:,$R-%\D[>(V@&-W<;8S#BK+JRMM)#&"/'Q\/XG[9)&_(J;;;EL
MHR0Z+(,[1MM(W/A`^0"@'85AUHJNC:U(;#_B.>?\D)5<K"-E"47Y'=RN8(TA
MI/(KQO[,*14(1JB,YQH\Z'&/GXSY8/V>'V#X$;@;#=?*U>1G1Z7/CY^0/S$3
M\B9W(.S'=AQ<EDM\19`+V,OFCFR@(!IRHJ@\G?VC-_JCGDJCVF>(C$:8B?W1
M$$4GL`>35U:AMOH,QX_+Q`\)'0=""!#*M*W3,3?_`#!$GI\#X$^)!$$]596;
MDCV4[,?VRRX_N;ZD`/\`M,1!L&WQ9Z$:\;QQFA2(QJB\'#$@VIZGM`,:54F5
MN`T;SU_C\YGKU,]06)]6'M^S,D^6.G2/AT@1'2"!'TD(J_A_,R.^EL>\`J`;
M+&95A^IR1V-0A6*!R/$7Q\VH?P:\'83T,C1*/\R(A&%]?W@GB>OC]O7[)@[B
M-YX/JEJ'%O\`N3`8'R^'4[=#_M0"NQY0L>K7JHW4<Q@"LHD7V2>T>07S&IY3
M&">T@VL='?*,1S"RG*[U..7R(KA>XA/&TCH8!C4Y\NX^`_?'P\8&V\`35-E(
MS*+ZUFR`3XG;?PD]29CDVY*\F:,B<BH.XJA$F#\O<+R1HU]/AZGM?%DQR1Y'
MZ$8UHB",$WAW:,@GL:D<XK')IM(0]#]OV@R/M!!$]00?,IEJXY..&L'4?9TZ
M$0?]TA@8^DJ0.#K3\^L;L>,.4\L<2O\`QHKE1@61B([L7TO%':)A&Q2*Q/`8
MF(PJ(,`VECUTN1SV8B&/4_/]_P`1\3N-V)#60X7I[UAB4'0>$'QB!$P8V`$-
ML@#)129#)='/1`E>HCG7N)[55Q$*<GF+TC9[R.(^05',8)5<5[W-80[I,6QE
M4I?7N-P.OZOCT\!N3TC<*%>O&<6X=T*3Q)Z?:3M`WWD[`;DD@,Y>N^L6[3`F
M09T9'H:*1SCD&U7D)%,4"C&UZ%>A6N>]J-%W5[RO8X1%*Z,:9#3Q*-6WTD;?
M:`?TGX3(@,$RLD,EJ7)/-3N1U()$>._R'4D@JW(UM;6E?&GP?:)HI(#PW/$]
MC4()S$8UZ#&YA(JHHU`W^EKP^*#;V<-C&$@P@-6\&0P;]/C\?GUZ$DBS*FNZ
MDLL,I7;^[P^`VE8@;J`#3;5%+C302J^Q<AG3)!U=#*TSQ^MS3J=A$-&&P0WO
M8=BM>P:>0C,>`1$EQ1Y-Z.C"RO;B!OM\HB#]AZGJ"&(X.<#$L2U&IN,EF.QF
M(WF9`@;,(('1@45A;6OD*2ZVY$%B&4$@R&=#C&*YA2R/[+Y/F9'>YSCRO)W;
MS4I7)_Q22(MP/"RDL8Y`1)'PWC;IL/E`_P!D?<T0649003P8S`)ZG:=^NYD]
M22?&P_\`$S-^]L!85E!<(4EI"M:\0QN:]IDCJ\JD%("U[5(,']*F03E]2M*-
MR1)0K<<>I-5DE8\?U[=/M\)Z[$<T,F8125OJ@62?#XQOL1/\NW*#Y893Z=BU
M!"Q;F"3LQ4$C6HY`L9W(_P`7*4+&G!'086I&<-WDT2-1CVN0*!*ROC(:FSY_
M/_03\9\>H(Y<@;)N295)@;1X>/Q&X&VQ!V$00>/%A33\R@#P)4(WD12%E),A
M2F$>CVD<X)D:(['O<CBD*R0UX/;[WD0HW&=)',DRN2V!QML((_T?JC>(B"%"
ME(<`(]+5-N23R4_L.QD]20TK/(GDI8V"V"6-85MDUD&4`,6:0)_4TR-\'H6+
M'\O60Y2'D/?($[S&1SY"O8OFIUC2)M0U=M4N"641/[3\-AL=B-H.W'DJ6LE^
M/?%3`5L08GQE1T)))W&X,M(WY\'M]WZ&;%CR5:U610N<RR!X,+'<1&M8`KU-
M$CK",$3%(_S"%JA:O>,Q`GK*8Y4N5\2?I/C\^A,]8V)W_F,K;7,YA%L_E4?4
M.H^1W4<2`),J-@?NQQ>BHUCQVE/Z)(U*WUO#($15?[E1\H;V%::.#S1RB*Q[
M#":3NA6F$UR28[([)JNY*8\1\NGS/R(@QT*D^5C/05R,;A8)V@@^/4;R!\""
M&`/U!E'WB"5J9(/;/K)*B8YLM2-"UY4<YSS]RM<K?9[?&2=C7]_,[C&[%0I"
MH^TON5H6U9Z=?U?W`QT$#:`(JCQK%Y/CO`/*8W^._P`9W(!ZL6;S!F:<BCGC
M-IKB.D68R*QR#-Y_ZJ$:+&<K%<A'(L?P''[O4Z*X?I5Q&^,*:&96-U)YJ2?X
M]?W]?#K,`^=#BN@Q<E?38*-C/P&WSZ;+ORZ<9815:M9O(2C8RRC*R*6O1AGO
M[L&QXT8]I%\W>H,9@@#?YJ1!@()BL*@Q#=^W0X[R?3;<-M^GB=_A)!,B2?O,
MO+JX@7UPK)O\/MWV`@3,PI`(:%!]"<:=EC7$?+@_EO"AU43P%<`Y^\J-X!82
M*\[V%4IAO:\+W-\BM(Q[E.&5&5-=@"-$QX[@;'XQ\#U'@00.)20.+Z";$Y$3
MM!@G<;2)WE@05)^H$$EULIU!8"*!E4\"_F">5OK,KR-)V<,BO54)*,YP7&$C
MVN*8B.(%S"F]L:3.ER*R#ZP/D(_3X#P,;`;&0(94@P[E9!CD?>B=CO/C\SM(
MD2QW4AFY5V6RL0@(5M%CUY6,C.>8$B(_Q9Z/0`/K=X_V&JU(@&/`09/%`(QK
M?$`Q&K+W#/46L!Y;$'XR3]OB2"".L]6)%L=;)3D+720$D@CX0!'P\`"I!CC`
M$(%:B;O@F@D2?%>\3G,1DIHQ>/:/'0C'J9RQ'""$`T(GDX*JQ%,A!J)),8$>
M.RN/3<2/#[3^O?P\=]H,\6:7,5J6]:N0?&!X#X[0`!.Y7;S!E*^HB3ZJ&U@D
MD)&<9X72%C-F.*7V$\G]OZF,E/\`<5Q5&YR,.3N1S4][B+^XV;U6!9@&)C]!
M]O4#8?3'W<WDR*B_&2)CE)W_`&$R9B88[D><L?7E*)PK""6)(CA_Y$D835$C
M/%JB8`L8HGLE$*(XO$3F.:7P3^T\)G,6+(2[(FNSFI/F!_T^'3KX?$,L\UU%
MAE;JC4ZCR$#;Y001N2"-B-X^DHY!K?4J()(%H^%!D,'#&,:2`*^,$05D,*08
MA",J-0(XT549W:)@1C<U&MCL(.JO+"RKG8"7/0[GI]GS._621_,0;8U5J<CT
MJF`J`W&P`G<``^$#;8!0"("!ACRU^DJ%,=+C/*`<Q%1IQ$*1)#W(]7A>U8AE
M89I'F>Q'C._^HGB,G>7"EWX_!TX-!*^'P_>-N@V('3<>1TLS?4JM]1"0&\1.
M_P`NAWGD1(8_5"M]Y597&M?;U$>1($(LEP$.,A&G8U3,<(PY`619$LK7E/ZU
M:\13*Y7M<-Y?8`DW',4W%5)"S'ATZ1N!X3U`Z00(8)E@')Q@[@&R)DR-]C(X
MDG<Q!!;J""THUOBDG#+''6&&@),,`QJ-K!!&C1,&K&-0#Q1@O$(8U1&/&-PV
M,>-1C8-\&M]9#>JIE6/V_P`=_CUDS(,DD/;B6AD&.XAU`$0!TCX0!`CH0(`(
MX@*:J!!(\=XZ*"8@HJO*@0^3@A,)/>\<)C2#08/)L<R(U6L&B#,U&-8V;"@Y
M#@&CFRR_QZD';?Y]1\3NNY/!WPZ6(RS6C17)@=`1O"]('1O@-F$`"VJJ:M(4
MNNG_`)]8,K&O4R%$",9[41[R$DIZFLDF?YEED<Y/!Y/<1[A,(9YP6MM3I97Z
M=L3MU(_5\!X#Q`@"2%"M5)D56T7>M0"`9F`?F3MN>I/@3R)*@L73)K-HKI50
MXZ0GI(<(!QL*T;Y`""-&,)S'1Y;7O,PBC>)0'\E51N&17+%.^"D!;N/+RR1\
MCL?B.G69'Q!$<U&5D$V8O,)YR`=^H(((Z'KT(*M/TE6GTW,"LF1[BJ>.4HI)
M!B4)AN5C7J-[$:`[GC;#"UA4C_H8:`&B![]@-$YE9=:C4VRD@3M_:/$^/0R=
M_P":9MLHM3)QRMD,0((^7@=H'A]0XCR_R!2*)'/E,*;*@%G(2/%[M:+^UXN-
M[3Q"(BO"UW9QE,QZ()?89">P;"_FQBR9"@H+`OF/V](!^/PB-]A$$C@PBPV9
M;6I9Y1?#;KN/A\>0.V[<I4-ZM;02?FU5L-@%(YA58]')[B]O:4A'->Y6J0CR
MR#(Y7-(YQ2.;W>Z4\9;:H].VDEHD?9^FP'PV'AP!%-C>KCY`"3!CXGJ2?M,D
MSL9)(W-A5LG:!G_`S_9_2W].W;M^B?[/%G;_`.0G_D3KECUUZ`.@UZZIJNG3
M33IIKGI]\VD&GXT6?8S&5\,?)G%8RSBL*X$)#BU04F22!&9T2+#5_M+(5KF1
MQL4KD\6+UZ+^7]5EW<_3K7D_X6_;:3'IF!/4GH!XDQXZ\6_.+(IQ>P^M>W"H
M9^("QF%D7#D8!@+U+1"@%CL-<B]%%;07[+6H>\\J!9V$1PS,](+V#((M@:C+
M6ABE0]5:1DG!:Y2]QO*CV(PK!.Z]?QG_`!&/Z5VRL@.VY0C;ERG9E/$]-P(,
M@D:^:\VL8>:,C&)-B6,-Q`L4GD:RH!E''J`'EL3(A@IU(.ARZBW0M-9LA9K1
M26F@6$L=='/!_!LOV"VH+,LZP;9_N=.EU':649`I,:\4P;%!(&C9`Z74Q<G+
M)K&X$D&1S5U@<>+<3"B>.Z$\E.H359C9/+&L"8-[2K'B"O%O3>MBS<N2<U!9
MN/,%;5'!Q%_<@Y$^YJ;+E/*06-TF:IK"7N+B'K+>L!=4];F)U.R]FRJ]LP#K
MW,R?QA3@+&<,\,8)SG%*(R.U_;LQ<"U>TY;?\-:X%2FM6*LSAN(!@\7'(J>4
MABU<`$:W'>NV/W?&L]P]N0#.HJ8WNMSH+$6ID%C%>0]2H\18O$AD"7$LRM.6
MN!M,O''%UQRER$MA94F)>'C3A6#"T-E877)]]45\V#;0J_\`'CQY$N-F93YJ
M2I:#<,0V.5%(Z.-G6H[_`(O]2[JG:NW<5OO!NR244+0C$%29)`+CCQ69)/@&
M)UTGL_._H?M^WW#WKF^+B$8N"JV,SY5B*RNJP`2*CSYO$``]2BC6K?*>I!O:
M#6Z">3\"Y+H:Z`^LFM$9*Z<_8A8#/9ZS8*9`ELA3X)P>H!VNC$`CY!%5\=6]
M5VK%;M^13CU^:@5L>0VD>GN[KL1((,D>8&%&S:\^]P]P3O&'DYEQX91N5>#0
M>+>L(KK>&5N+*R\5:5*R[;I%U`BR$Y6WUO(T9:$]9D,<O[IH-4!]C%"RQU$=
M)T0\%YPF;&FA`",1S4'^29@FN1QF=8A9?Z3CTK6+%:ZSRI68)XH8(,=026'6
M`3T4ZV")9_U#F9+WFEZ\:CSV7`L!RM'(%9!A@JJ8CDP4&7&MR:_69KEOCBX;
M3!+9\V<)T2:`%/:CK0V/(N?CR[`DXM/^\"2Q'1@L(IS%1KBQ@L-^0%7,E=NN
M,LQ,KL_<D]:%['G6<"RR12Y`CEQVY$$`=&,<6W77J%/<<#W)V*T8H-GNOM5/
MJ!'"ALFL%BQ3F.0K#!F.Y50>:R+-:#<?8*ZY3N+G::23<R,`!]S_`)+90;',
MMN9@M,'.W5+CXUG&646/(L7R'0PR4<U`10',1%8R,]WH'<<^GM5*86,$'<#Q
MX*0_$<"ZM85,2!'(KXL54;E@/'.R]GRO<&5;W3.:UNS+S]5E:KFPM%;I2'$D
M%IX*T^5%=VV"$W1KB7VIN"U-8!J'O8@H='71X,B(*)4!E#@H&$-T-E>R+3UU
M9(>UR.]`X8B%>1%\R=8F(*,6D76GRUF6)(,L1,G>99F'S+$`#H-;#N1S.X91
MQL<>:Y0*U"E0$!"POEXPBHQGZ0@+%NIU1XX;$Q8--0QG2LOG)E;++;1)#PQM
M;=S&NM`7@C06?C'C#-)%!H7RP!<*K[/(UA)AO"=C6`UUYC*L##B1O6H\I7?<
M&`6M"DR^PD()QD6YF3$PUY=OH927!@7.WG%@*[$217CEU!%4%@#:T;G_`"LZ
M`?D+8Q1>]ME4<$6]9<)^&Q:N&1>0^.#P8<VS>Q(A-&^*GN-&3^H0C#)XL0S/
M+BO=8L';J':/2?/5EW\Q^YNDA>O"=@WB01)@QZE^7AJ;O656L^O5V=U?R^13
M^)QBJLWTFV/,R>`*M`Y">X/7A>OK+3IIITTTZ::TK^WWR1\0<A$A&=&FCX5Y
M*?"DM$,SHTQFGXJ=%D,";^R9P#HUR,?_`$.5.R_HJ]=O[%"'O&.+!-?XVF1T
MD<+Y$^$C7E?YLFP>V<TU'C:.U97$P#!]7#@P=C!W@['H=<E=)8LS5<2CCQW?
MA4W[Y"1]HL^187,ZPBV-S*G7!Z_TMF6]WI)S"B11.8IY;E:C50:]>N8M9R;/
M78_>/Q/E@!0"%`4&854$'?HHF=]?.&=>,&@XB+]U5ZB^?D6=F#.6<K$N]K`C
M:.3DB/+J#"N#8]TK+T+B5LV8.)7;FSH`ACLK112Q<[!Q4.76&I#PQU(X,PUR
M`Z*%]J)BM7PBC<^YZ%S`,J^&126J5]^4RYM(8,#RE161N*R9W<@6593=L+=O
MP_N[6`7(>L`<8(K6A60UE0G%VN5O*;E$;5J3D.3R1$X]SD'5Z&PA-N9,YT'C
MBCT%\:14'E3KRI@6.N$Y4-:/S^3-<A<J^DB39;$C-(B+*>W7+VU^XY+8F,K>
MB%FYD2&`"L17_AYV!3XCBIY1]`.ZL[Y5V7"3N.:Z_BF?CC5V6$H2UB*UPZOZ
M=)<'Z3ZC@5AA]X15OF!\KFG(\E<;\AWI2Y397%+=4&R'J)SM)3\]9>PA9[\^
M%(EU%/-FL<6!6GDM?YC>TS41K?<WO#[I"=DS,;N?;JP,NE&5Z^`X-B."\$!F
M`ZN%B"(ZF#K)]@&SW3VW.[%WJXGMV5:CUW"UO53N%3+7R4E$9MUJ9@9!#`0.
M0UCK0\35/&1;_/:1C[32TT.QM9D#+SQ4D=EV.@;2UM[6V46-;R2::=G*P419
ME4*,)'6,D90O*88W;+&[O=W,5Y.-Y<9R%!<<CQ+\F1E)4<`[%N-A8^12"`I(
MTF;[<QNPM=A9TV9U2L[+4PK'J"O@MBL`Y-K5($YTA!]XX92S*IQ26%G+MW#<
M+O0Q02N,[:#;OQP9"6H2&JL7%!:VRR35\T$X4^2U1CKY<4DDR*%'N$8@R;8/
MDT#-?[PL,I2OJ$<=FM)58!!$#<NK`#S0"`1SK58.6>UU?<JC8#J_H@\P2E`#
MO)5@P8["MT+-Y9*L5.SW!O$0I5G/Y=Y!5A./,MHW[2F!`:Q\C?<DBMZVQA05
ME2`!AT--#N!_W4C"<9`BC#=*,P#VBY;OO>"E2]G[?MW&VOTV)Z54\2"8&[L5
MZ<C$EB$4L)[[VE[:6S(?W+WJ#V7'O]=`O7(R@ZLJR0!6BOUX@M`0&QPA"X[R
M7.$R\W.]C[U)M=*Y-U-*^W)&N<@"?A[W5:+3SJ]20:X;;:56PZ#/Q8\Z$4DL
MS(I?8QKB`=VV67V)*,#';`XLF+4W&5L(M6M$!W/E#%W8JP"@L()AAK2]M]V6
MY?=LQ.\<Z[,_(KYD/2&HLNLM9?*OG95KK1;$)<A#R`+(=0=IK-#B]+(.81!G
MRT[UQB2:C-(&985ME".23[S0)SFO)7S%=Y(UODQ6D`5C_4HZX6)CYV,%!!6U
M=X9Y`92(@$>(_L8$3-G=.Y9O:LYG<$-COL2E4,RLIF2K;E6F?A!1@>,8N)90
MQV%1HJIG[;"O2R8$(AYDFP-46803J*VI9H;"4R--2GDV<-PIDUC"V<62DCMW
M<1H]J*W-;XUOF=`"=@`RR&5@0)'(*TJLA&7C\">?-]2W59N..%-Q*J22Q1P&
MK=&#&&X%T*NX!M5N?4L%V?X2DOL^9.*M."P:Y-)R#@(FCC-DI8P;FQJ1:21G
M+>N+!'&C5EG6@F6@I0G^<>0*2WUM]X'O7E^^**NRY>*R_P"5CVE#'$J&X!U8
M&2RL0A4C<%3)XL!KO_:EAO\`<_;NX(_^?FXXM$\E=D%IJ=2H`5U#6AP95E80
M.:$Z[AY/_P!VJ3_Z71O_`)FG7A67_P`R_P#O'7UGVW_D*O\`<&KAZQ]9NG33
M3IIK'FZBBFK#C$>YJD&91N&K$D!<A`C]\9S54[#=S(QKO!R>3T:WNYZ`D;'`
M<IR8>!_4>NQ\/#^WH.2Z3N]:V\48Q(/3J.FX\9WCH>L#<\'QO51ADA2JX\QL
MP(GL&UH59'=$$HP%CNCOCR!OCC<T8C`\2-:+LSUE1C(Q8^SM8BP6J.)/ZYZS
M,C?Q!VWWD26#:+'16J:EVY*-MMH&Q$$$1T4K!VVXM`K9-8-3\C?.-X:MB:;B
MZ!$9&O>1+^LO,5I]WQWJH-GRSHW;/D]G^2\?:/*7Q:3>:43["ZJ2R/VV1(CK
M)_&8P1@UU&IKR%YK/J*2=_&>N\SN2(WZD`R>+67)E9&%9Z3D>BX"B`-@O3:.
M.P!G8;!FV4.E.5M-P_Q,_BZ-PW(P&<3AJ3EA<;RN.:V(6NSY<0R(L2%FX\"N
M:TKJV,)CFM8/_FOZB>/M,4X;"E"<ZVH\`)`/3Y^(CP^6PD@!6KKE6M5<F7)Y
MEH)!/(S,>!F#/@6W8`,69+KJ_P`'Q5MJKGD6)3U_^=:#)4>%M]4-9CI=GC<_
M<WFASN>DH.<X+Z^!;ZN9+CE"J&]LU'LD/18IBV\?1>6'A'S\9\/M!!$=00/,
MJWE_Q57&MM@01UB=H/7Q\I!!GZ2K'R.^LD;XB^29TZ(4_$G[)9T&6Q&#K"T7
M(')N/`W(<95Y8G'^?D1L;O,W#M(F/K1N2`^4A/&(JM89@$>VOK=C+LZ#RD1Y
M9&W3Y_&/C/4$G[UC9]IY56'SAB9?B=R0WR_P\AT6/I*J(HV!O,+E`<@X_D>1
MG!R]/BZK84F6N",DOEYVLVJ4X=C6UZ?J!86@=FX2F$>.\HG1'*)G;\R(29..
M15Q;CZ@B#X^'SZ[#>=]I/T.,2TMAW\JN7HM/)?#:?ETW.Q$CS0I'J5G!^\^*
MOF[26%?=SN)XX9M0[</A3*#<\J92S1W*>NG\A\@P&'Q.TI["96Z3?7)[:1%]
MAQ-L)7MC,]_@RSBJJH>%<;[](`&\SX#P\=MB#"_Y63D9.=5+U-Y3!,RQ)XE8
M`\QV!B!)D@B7C\14]!\:?*/*,FGT.PXBJ]!85^3Q^%EK(T^V]6CR&)5DS$YK
MDF/5Z^/6<OTF;*7\BO34)<,&TRJA$&1I11V4^DX6-EF.N_4&0>OB"".L[26#
M34Y9R*BX/F<"8B0=B""O3P(92-H/(`(R1K;Y,^8N3-:?=[3BFEO]<6;16&F9
M(MM+7YG:6&1(),G<<A\?4UW5\;<CRLT.F`.!)O:B9^*R$@6L`*,^-7W96./5
M]4CZHZ?+X^,[^,F(()E6LLP,QQCC&1C]WRZQ(DF8V@`P>@42&!50'2F[+K@K
MBV7!Y'REKQW0V>.Y>V0-UR72HR>(>OV;CY08M/<`CRQF6]!*Q53V>)6$>2$)
M[6.D>\%E,%KMJCI9U_6!\?A`'2`(ZA>+5XK/?1D`_54-NG@2?#Q,DS,EB3L6
M+)?:,+X]^<L=R.O,E%Q14LW0=IH.1(UG(N]??"K-OM[>YM=7MLSE[_26N.S^
MNNIVIG&?,KHL:6KK!WI.CB"++BI2DF(`<SN>@)$'[)C<Q_BD065,C)NR@HEV
M-2\1`ZD!I&_C$^4<CU6"2*WLS0N,P<[17_(@J*O!M-1AJ?`W&Q]#FS;?%9BQ
MTMS0YB84<B-'?55-CKK(XV-4"HLLCFO&P375M0C5V[B22`1/^OXG>#UWF8LH
M;EOQP%,``D-`^`^SP`VE1M(*\0:->]#\4_)NVK,CE-+Q+3K'Q?'%1Q'0`IM'
MM\V$_%M"V7%H^*=O&SNBIF<B8:B8"0(%3I16<#L24-0->:?&<:A>7K*@X;`C
MH"!!'0]-QX[2#)'%M5KS;2OX5[#ZNY#&&(8R#]0,'RD$D"880&]1!7S_`"'\
M^DY<A<K&XX;#Y`>S&N6[RVLY`R%>5_&\,=-@XTW*9'6U.7GP\S3J.)&%)KY@
M5C,$!Z%>H_W(Z56UEP`"/X;'[/#Y0)Z*"*E5F1CW"KD2C28@$29'S;?E)/FD
MQ)+D&^BYOX>^7>+2NL>-^$,Y3GD9/3X!H#V6LU`ZK$;6+^/K,GDXNDUEO#QE
M!I:]S!3(E*^OCS(S1C4HV#AR(],>NF#7;NL>/A'VC;]DB.A\ZM7,OS#QMI)#
M!I@`;D^)XD`_&)@SLR_=V)#S/QA\KY_)7%#E.*/343J/.Y^=E[;D+E;2T;*3
M,Z'.:?-P*VIU^ULZNL!4W>&KC1GACPW"_;E"50!;,##+CK1:%;>L_K&V_3?H
M3X3U!'*5-BS.MRL<M68N`\-CN.)@P-B%(W"C9@W"'%.P6=S6+=J[C<CHHD3D
M+0YNEQ.EN5;,_.O\OF;C5V]%4RP'4HCQJF]V-P7N^,LP<J?(8;V.(0,N^^MJ
M[/67X#S#PB"!L8V\(VB""``4BQ<A;<<8K[`$RA&QF0Q@@G<R&D%N4A@6++;A
M>@^0?GG(<OUO)V?XKI@Z2)?W6WHT?<:R5F,UM[Q)K[[>97CF5IIG'6>Y`M27
MAW'O:VK%925G/5TA3G%*FV-7CV5FTJ!;RD_`D[=.@F#(@;@GIS5)1D9M5R8Z
MN6QN$`'J%&X'+ZC!(@\CL5$SZ;V97SV%RO%>9I,SQW0UN;X^H`'AU-!5C<&M
MH(DHIY4D,9ISM:P$B1)*5#O(UC'+V(\06"/5ST<"GH'9QT^>\_,_JZ[R`6)6
MW$RS8+#ER&K8^8P!&T;]!T&S;`0`Q50KX]_'2!:U*/\`)Q5`-_I,=J.D1C(T
M\8WY39$3LGA_>'*&:/X+XF:079),=L:^I3='23N!T(V(B#]A4@S])!^EM3.*
M<G'GJ5&Q/4'<&9'^\'!6/J#+]:":JK,$Y2`$I44"L&QI4*TY58@T,Y$<22<C
MQR)"([NKR^96JJ/>5CK*RVID\S1O^@^`Z#Y#;P`(JDQ\A+95)V^,R>D^))W.
M_4R1U+`WT+TMK;>"27-*UKA$>P@R$:!7(\:L1$]RH"`-GH1W@9S6L:%SR(C8
M<F//R]6E@BCK^O\`AN>O4?$`;NK8A48^2AL8P1UDQX?/9?IZ,8'$D[56).VM
M2YYOW0#APYD96.>H_P!6R&L$HE*YJCC#8<8QN&B*QHR@&X94:-KAUUE5H"^D
MTLA_=O\`KV\?B"9$D@V2Y&,2WXA"%M7X>.T?*"`".@!4$,`H(HB(>=:U<T"A
M8"Q1J",(PGI'D(5I$<UCSAE>+CJXJ.8417A,YXRA(JF%-IQKJM4S-?A'4?L(
M^70@$001Y2EW.[(QW2.-_0@C8S]H/7?8@D&0RL2RV^:.S][5@S'^$P#%\AD<
MC_R&JH#.(UZ2)#D(%)`?,2'*]BD&]I2H^+)EKZN/WB?0?W=1\!U@[P.A!`AU
M2F)?S'HVF+0.A\>A^)W$K(Y$B5(9IKLL]NCPXUF!0>M2_HJ":=HUCHV,)H0,
M$+T#09(85<BJX:*(#$16!"Q]:Y.U1Y=/LZ[]?'Q/SW)ZLQ%M2E27KQCE\)B-
MA`@0(('RV4#9%!HB64=94<LB.UH_6A#/[?\`*R#G!YA1IC*#Q0*#&8;T,+Q[
M-(T@_#\D"6U-P8*WCM\0`?@)Z]"(/P(,\6U7(3U$+I`B3\"2)&YCI$@R(V(*
MQZB#S7N)9UK&R&O,Y3^LCA.41HQ'.5W8/93F5X5.QJM5Q2/4JIYR'/:ZRK8!
M5:>.PC[9_@/C\.G18(JI26OHAY)F)&Q'V=3M(\23)W<D&^6@RDJB/J94C^AK
MN\$O<;PABJ.*5C6.:?S;&$BL7L\C?QV(-S2>E(\D%[IZH]9!OX_,[_+KUZ#<
MS(GDK656#';\-8=I\I\`(!^/0;=3Y1Q(;B$=(-@2NJKJ)(,%HP.B^+G":T08
MOI$4`S$$U@0%&&$`K7)XA4<=CU5OI"9E;6L674,JF6G]L[QXG<D1UDD;\B#;
M9<:,?*5V$)Q\-@(!`,;`@*"#LL*#MP5A1.6=6RY`*7'<YDYC4<Q?ZA+)>U#,
M0)O:&2\1VD*1K".&5R*0@WC*A9$>;95::&*/_E_P_AMTD2.@((A62;(QQDH+
M4VN_9/78R#O),&"=V!#<G2WY%&2VJQB,CH\L!F,<YP6C>IH[F.0:-]DHT9W<
MS%:\12.1[AD$8OF`\LS"FV5W0C]Q_8#X[$#Q!`AE2E:MD8X5MK01X>(_62.H
MW!)!AE9I1[)6DLFQB&K)GD.0$JC%W8$06@%'1[6HB/`T:,"!KT:CD$H4:03A
M@&BUE]]18"U-U(_>3^O[/C.QEC]['B7BLG'MD.#ML`(`_5&PGK$05*HLT0R>
MFLT(QL"](TH8A-"WQ1@3/20)HP@<$;$&WU&11E$U6L0Z-3Q;,BBJ)MQY)\P/
M7XC;QG[-P?\`#.Y1S0A<?-"@'TV`$?`[B`(`C8[$=.<;"VM9ZYB._%?,BPFO
MD)X$<BL/^9&<(WL8>*V.DB0\[)!E[HWVD13.<UIRD5EG'0_GX.T+^J#/@9@=
M/L&P'E`FJ7*J/IFVM`7Z^/(09D1)F3X2?,2`[&+Y@4ETZG&0"N]Q88CL:%PW
M/[-<%XE&^+*43O9ZQ*-PSM1[?6]A&HD8X[2H2XAOI!C?]?Q'VS(VW!'U*;U<
MVXH*?45G:/E$08W@00PD00P\CK3J:;&5TJN0AB!"J/80R17A[!]WY)6_VQ""
M`OXKGHU6-%V:1&H)HC`K);D:!88#'X3._3YSO'6>DR2&M@QKDEJ))4?&(VF3
MX``Q/2-FCB%9*#?"OOI+I+&BCRAOC@>P$E6%,]_L;"*QWN['0CS(QBA(TA"$
M:UB&)*!,;V8X"[L#)W'3X_9TWD0`-X",@<:,MBXBMA`@'<]>)Z[_`%0(,DL`
M.1L2WSI*\KT!/A>:E&KAO''&7W$\RI+]XC1"/.YS3JUZ_P!U2>QPWA*IW`).
MKC6`379T^?3X1!VZ?*(D$<>01G4,8NJ^KQ`F?C((WZP>LR5*L7*&VI.ABLJ^
M,CW">Q\8;U*OCZG(H&*QC#1WPE8R,0#']T]36^#7M42#"2!%S:JPQ,S_`&_`
MSUDCQZD&22+)S4M]*S!'&9\.G@1QV!`/AT!!4!6IEZ.3Z!GK9Q&"EQI3A^!B
M-0AFF62UJHA!M$5K_0=ODT3&.[%8\+'-E1@W7KR(M3="/#PB/V=1XD]"&(X,
MUF(_!31:0+%:-^IF?E!Z-N`!]0*@BRM?`9[(%O-@R!K#9*D,D1R(PJM(0KV,
M1KD<Z4K?S)!'(QX_-5D&5CVND%3]T-6;*EL4R0(/ZOV=!\?`2(4?=6I>M.2U
M+CB&:0=^I_;]1)@B?,Q!!=O^(A7<16C':U;A#<CEDR#,<-HS#>D5S7H])@1O
M0BH)SAM(U#=AO:9CVQ)3+J'DFJV2.@_?\OMWC;<$$%U-N57Y?Q&/`/4G:"-O
M'D.NQ@'S;$,"*[!,6L!;."(PA"(_\17JSQ8UY44/9X6K)9#&U%8#_A(T(W-$
MK7M$UG_LVVJSTG*DF)_MZ[3\?"3OM,_>R9%/KTAU`)X_MVW&_$>'0@`\8(4#
M[B7J[13C6LL@R#$<(K"BD!>Y5B+[6+^4L@*F)W84@U]HE*KT*PK%,I@2[K:N
M)]6H@"?#X_*-O@=C'0@\>+)9CW\Q^'O#%B#((\-^LB3U(W$SR##D62R%5S%K
MITBOEC9$24?W1R!]KF*0KHL<#T(II#R>PKQ_W45Y$.1GL(1Y8TFQK:GJ(+$\
MT"#/ZR?`?/;I`,``,M=N/::+6HL''DT@B?&`/$^,;[GD1)8LCWS]H#T.#9#:
M@G`5%*K"#'Y*_P!8W=WB,`#?(;6N54<P+FB:JO$P8)%='4W*:CO/Z?`G^W?H
M266R7(3A%XV(Z[@?`>!`Z?8-@25"H]"TCAEUR3`,(Z0$?>,]K?Q2@7L83F&;
M("C8S1!4K#L,)K/!I6E8QB2`@5,4MX-'$]?&>G2#OO!$&>A!)XLS(1;:/46>
M8&W@1U&\C:!(8,`(Y!@!S5*9235D-D5<B.Z21@2H-BJ0CG$:JQS"*DA9<I22
M"R%:]RH4B*16%0I"H^UEO3C%JF!/^GP@;1\AXB`(J@Q+>?+'L'(@&!N?D09D
M[DP>IW(;DS3D>J4AZV66'9-8!IPLF1B.(C1]V.C]E`K9#Q/\/8).[#J4*H)$
M(1BPY72\+:G.K<@P?W]=OMZB#OL#S75<4M18:KX`(Y#?;PZ;Q\.C2/+YB/2L
MU,7+`QYL*P0PH@F=B'*B$'Y-$]@CD7P".(SM#8J/>Y&-2.%R/:P`G+5VT%F1
MJX))Z?V>,]>@^)V)8CU;\H*EJ7R%7J3N.G7PCZ>IV\JF0$4_AYVUA+9@8>"3
MQDB>]6.;V:\A54@%&1SHIRC*-"&:BN&Y.[BL((C22HTB.IQ4W&P>4C_3\1\O
M'X$$0C++D5&].=)BP']_2.A(/4;CQ8,K!K*WD\V=3!DP9+I"R!N5JBD-+W>-
M7C;V:Y2R#.>,A&(YBE*7N1B^P_LCR9]^2O%@ZQQ^7Z`?'>`-CLL,M<6"W)33
M9RYCP,])'S)V,;23N/,\I9=)Q9PJ^SE@<5T8?8+%1Y!^EK6C#(4I/$B1P)$C
MHQ6^+F-8!&.0B1Q`+77NALJ5@)/^L?:9,_'>1'(L+(J[5IO9">(V'7;H#/6!
M`CH0`L&>"HU$Q?K$:(<YL19*D?[O8C5C-$R.,@3O,18K'*UX!D$]"B5&A]J/
M$@FR@@MQ^<^F3$;?'KN(W^,$0>L09*LTF7Z87UN/*3/P@`$&=OA(,C8<I7B+
M%2MGKX5I$:QX51#L$HC,_JEC(Q'L`YAU24\Q1NDO:GE[D*I7M5"N*]MA"MCU
M/(/3P\/G\(Z?*('2`:\IJ:LBJ"-B!!\?EOO)$D?S3)!Y%B+J3G32#`EP#O>H
MXJ#$$@D\%&,K6=FA,,Q!C0;/2\;/:Y6=QN&9XUB2.I<D*&%BC<_IN(^V=A.\
MJ#S76/@L[(U+$PNP(\`?@03$>4@28\I#%?2?4E52#4\_]JE/<^'V(*$YZ-`P
M0V>:^8PN4$84;TQ7*YB(,8QB<X7A&&0=3?<HNK]9?K\?']^YF3UW))WEB#=%
MC.^-=^'L_P`K^7P@;^&P`@=-@`"5BM67&G[04>"2!)'&>K6$(A'`:@AKYJ9@
MW%8@'>UXRG(B-:/VJQQD49$65&DV5%K`RD_M_P!?R'C$\=QY&67(5*62P+L"
M9C;K,2(WB3M$P6V/WE=D6QABLX:2X91#E!_OBEQW/>I41J21]W1$D25>9\EA
M1/$YYF$,PC'%>1CI]M;FI^#@\3M!_9XP-H(,P"`00`"*[[JER*_4J(#C<$>/
MB.DG<D$$$L"P(+%@;H5$29(@2HAE-%?'=Z4,Y6-<U',"16L\""0?8;&N5["-
M&C5&\)!C:!T"[("+8'6"#O\`Q_3<3U#`GD++,-K7I:IY4@Q/[#\1&T;@Q'$J
MRJ$--(J2R:R>6+*9^.YS%`(!G(V/_:;)<V(PGH9'1'B:16(HAL5C2KX":V7#
MARW!;:PZ;CK/CX;_`!^$[D]-SY'?&QV>BXUV"#$`'IM.W0#I,>4".1A0+*JJ
MC<$2OL*RP$!WJ*UP#NCC<]3=RH\<?Q:LA3N]IGN8-1O*\A'^M2'(\-I'2/4K
M:LG<;B?LZ^$=.LP`!,*`U61DL*;Z[E!XG8P.N^P\9W)@0223QY.Q7(F+2"EL
M(<N,1RHZ.T@BJJH'L)XBQC#<*0*2HWJ5A1O&7_8$HRM>D60^VJST6*,/'_6.
MD?(R/\0(CDHNR*1DJ+4/\NQ\-B""((/B""#_`(65@?3<^*J(Z11$A2%:U2>U
MS6G01F"&C^XE4"H`0H[/Q>Z>*1V-8Q58V,QGA6KG"Y'->@^&W[]]]_F=]RQ,
MVTQZR^&:GZF>L&/AML`-O#B($@5@11#I9*@<>JEI_<&YWL8145'J9TEIB(TH
M$<1A7^Y'*X*(J^QA`H9948M;UY`7)T/]D?/[/'X$-QX,*8MA0G'LZ@[S\YGJ
M.A\WA_B#+R]1&DI:OJKULE@W'9,]BHD?R"=&SBM1K>P'F<Y_Y9D<Q5\U.5_]
M+G22#=;R)%M'&8*_'<;?;\AOT@#>%!%,-DX^6'`D-/38^8_*?$[=>1.Q-C*<
MFNVE;&L8Q7B>C)`1J\1HR>2]VH,RB<R.8+R"-Z1KV89CFJ,3QE&HXTB+!5:U
M;0?I)Z'_`$_K\#U((,LK9>10E]9*F'`V(_;&Q&Q@=&$0I5AQK>N3:,MKGV>+
MBN*D<R]AF&A"R1,,)X3/.&)',U6,,PS"C`WLCV$&%&&'!OE:LCPB1X>&QD1)
M'A!!/@06E39'Q;(PMIY<3T.Y(D09"@[2""%'4$)#+33:6Q,"6^NL2'<IGHC/
M<Z05SI"$4(Q^14(5BF*KV.5['N*1SAE8Z0\K+.2^I63U*P-A\NG7^X^$""#Q
M`-4&)>Z6&F\F3\9._0#>3N9&X,DD,"Y87^V2?Q-$1'M0`Y"O8IWL>HBN>]G8
M[/017!$::4".<TCD\E$KGN>2',EBO/&$;D>']F_6!/A\8``=$J']/-,[*WCX
M'Y['8%BO0_X9))JMLG;R"D<:6<+P!+"<16O&,;7+W&UA'(K'1XJ,_&BC1WL4
M<=0`1'/",8S5<=#\CZ5FZ$?I\3U)Z29.P8DK;+EU!!Z]7EL#`[#Y0?@.@$S"
M\5W*JJOCQ+&,>XJ(9`M1937-*@WC5%\W-D`D!=^7#:0#E12L<TD9S%_NC,!S
M%E`2E;K3<P/T?ZB.AW\#LWP*M/!M77UODXRLO^9UB/'<$;KMXB"I'U*R$>HF
MMBPHJ!$B]E5!L151&HBJC4[]D:Y[43O_`+E5/^U>N;;ZC]NNW790/EJ)U35V
MG333IIK0'[JBBG\=OKY-M.HX=AR%QO!L;"MCQ9$YM3*KM@*XAQEFB-&BFM*I
MQHK9#FN6,XR%:BO8U%]"]AN:^X^HJ*[KC7$!B0.0-?$F()XM#1_-$'8Z\:_-
MVM;NR&E['JJ?-QE9E`+<"MX=1R!`+IR0-'E+<A)`&N56ML?W(M/Q]6UU4X,Q
M!QJ2O(*3*BWK@BBYR"D,*P9U>=E>R08AS2A/:R/'>KG^MBL3U;#K](/W&UGY
M#=CL"LRYDR")@`!3N2($F=?/'<K_`%VJ[-0E95X%:P2+(`J7B.+*>,DLS@@*
MI,\1`E:S:2:<0,GEY'?-"((EI94XY-;%UEM:326,W1'93SHOY^>6NK`QZ@9X
MS)$2N>WLQ#$*WJ^W"6XG+RQ_Q)^E6AC6JB`@Y`P\L6L()#..L`:CQ^ZV8JCM
MW;V_X`$<V25%SNW)K3P8<J^*JM(90R5$;<F8:O?8<F4N&Q[:BMLZAO(VPSV@
M17R]'+),H,],SMW:1S!>E396R6^E93+&$THT.*&8TG^LA(R/PL+M=^?F>M8K
M_P!-IL3H@AW#JI!\P7BG+D8,%@%V`:-MW/OV+VCMGX:AZOZYDT6=;3RKK:NQ
M@1Y&?G;PXB1R",UFY*3??&.+;SYP?%X[/<T]3I<%>W6T^>-*.Q?#B:/`:"0\
MVVS^G%8U=4$E%HH-I-BL2;'?['>TA%*P+VKK^Z9Q[!WUNY*COBY%:UY:<9*6
MH(J=(9CR0JK'B=M@(+"-QV#M0]X^TU[(]M5>?AW/?VVT,5%N-89OKM#(@].U
M7=!S4R>1/(*0=9=)D,QG\;KZ?L9^KHQS*F46%,+44=>8>TAR;T44"P[.T/12
M[F3)LY,65(="(K`$:H4CN>WJ,;,RLC-INV_"6$,)')B/3(23*J&"A45E'(>8
M>;D!K@L[MF!A]KR<;?\`J-09"58I6I%ZFP`<7<ULY:UD9N!A""H0D!5E4+D7
M=3%OZRL/64F,MJN32ODV52DRLFWD]@2/]E=+EAE11'&]A'2H8/)IRQ7OCL<T
M;+3VVA/39@[V*P:%:&""?$"#!D!6.ZAP&.J+CXZ][R[/6KK>NFAT*2R2C6-'
M56((#`@ET60[5DH",]\,9&7\_P"`G\YF&&PT%;F[FG^?L<U!V4N:ZSI@AF[6
MYNIXHZ2U;4U"%BQ1LCPU>0JO9_?"\G/]ZS$]P]P7L0E<=K5;+LW4#BTBI5$Q
MYFAF,M`$'RL!V/M;MMGLSLS^[6`?-KH=.W4_46YH`U[V,!/D240!4DM(\Z%L
M<<,;W]WBKQ&CARK@MQ/+F+05UF2MMKVJJ<W7W&>T(*<<)UJZ[F'*L,AF.<R6
M)\57"#)CH/9=[[?Z+?U?I2$'->+^5&9RKIRGCQ`'(`[J0^[*TZ/VMWC\37_T
MWLV4;6-3AZCSL1*E>NP(%Y\V)X%@8<&LE5=`+!DZ1<;86JR*B86%*:@+>@D1
MV9]\NN<$]#9#K;4T29:1#/5P2`D#,,;##<)W]AYPEV"XWXVM.+J'&ZN#SAI#
MCDH(4^((()@R/,%8:=\X]LNLYU,:FV>LCTY6#6W%R&<$[%6#`!@5/D+HTO76
MY*F<18$LEE56X@7,>T+&'&#<PSP"Q`VI(YI9VTUA!GT4T)(#7+(CRT*)W=S?
M);K*A=6/4'&U"5*S)4@SQD`<@0RD/T*P>AU'1DG'M)I8V8]@#AR``ZE2`Y!)
MX,K5NIK^I7Y*=Q)W?^8!_CZSD<U5;D-G;CCC3Z`%1/&;]V@:"9M.((MU;1);
M/".3/7\2%"*`3T?(`9A6^:B4;6\-[I/+$QA<D9*9*(6$<2@KR"JD=>:$L"=@
M01M,D^L>P!P[CG-CV$X-N#;8$8'FMAOPP[@]/3L"H5!EE8,)X\0.W'7AVOJ_
M3IIITTTZ::TJ^X@*?AKD<:J88R\*<E1WG`C/:)9&EXL8CA.*Y@4.B=U8CW-:
MJM_543NO7;^Q&X]ZQCL2,ZDP?DE_ZX^.O*OS:3G[7SEW"GM.4)'43;B=)VGX
M3KD]?RI5..9H+42#OWK+9G@3X:ECQWML&/FZ-P9@'H^#`EB"E:Q1O571'2&&
M8Z,-AO6\=4N*X])_X?;F0=SMLD@]2)Y[_P`W$J0Q(^<\RRS%5LS($9AY>F&6
M0#R\UL,/I5@OI"#NA<.#6`V.<97PFQ[6UO+(X<CG@`NM!9PA2+QT:HK4CUM?
M^",,646;HM%-D*((&N*-TN2Y2=Q-,YNQS;'+)5CJ#F6$JBF%EFEC,D0B`23L
M>*[;Q.D[714$LR,MRO;:%#V,H-D(L*O&`2UMC&%7<%W/+RAB*-<LVO+>Q_:H
MP='0220]AFK"?$;49"KQ./RNAKKNJ(0\A9EN11UWI"$GGVGR9"D*%CSM<V>@
MX/:,+U6-5BAJW`/*QK;+$96V$+]4DC^0+`8A2#BY0[K[D[G^'K%]+E+JF9>%
M*44TV+8DDRYA>*J9^\9BS*"X(S;=:B/1UD+%9*;9UQ)+:NR`VLVE?4Z+C[CW
M75\<%[OO9"`1QM8_0E&.*@QR&_F%>X30A:,:Z.C%:^ULW+56`Y`\JRR775DE
M:MSM7P!+21Y0)Y$DZZO*[@F+CIVKMKV(S!&'"]4LQ\:Y0+,CR@S=ZA`2`PYD
ME0JA5.>.=[.BY)X,3;5,&O)M\K%2?H6P15EI+KHTFIGUTNXD*Z&V'85>DF1?
M">=7N:&P&@T1GY'CUH>PU7]M[[^!N9OP-IA)Y*&(8$*-Y#(#Y!&Z&=^.NP]W
M7XG??:7]6QT0]VQUY6<0KLH*,I<[<62UA%C2>-@B!SC6IM30R]3I/F>@8S06
M0R9!(TD!,T&DFQXLE<'%`RMLHPD_=G%<5K!%(OK&BL0JHUSO+K+<A<7&[ID'
MTU/K2#SY`D>J3*D^7XD#<[QTV\YQL2SN&=V'#'K6*<:"#4*V`/X<#BP'GF8!
M.PVY;$SM/]'[=F:BYN@S-8DS+9P%=7:^GS%%63X&IM=*<U+3:;.6%O839S:+
M`RFS)`T8J_G&EG<_R1CR-Y7VW@G*:W(RGXY5I)K9V8&M4')D<*`.5HX@S](5
M8Z@:]!]\=V&!71AX%?/M]`5;DJK1EN>TFM+:F=F;T\<\V$?67<F8+#5_EW')
M(K7<E9]AE/53[;1ZU09*KO4U5165Y:'+:6L,+Q:>7'?(4;_3(26<3E>@P,&9
M5ZGL^;QM_IF1$.JI7-C)Z;,>;HT]`8D2.(.TL2NN`]R=KYT?UW"!YUN]MT4I
M9ZR(IKJM4CJPF#Q;FRF>*!6.J;Q[>+M,E3\;3R4X--C8-%$Q;?VRVSEOI*Y^
M6@6-_FXX;`TCM;9>O8Z0)D4Y6/AL($B->%C5D[C1^"S'[G7S.+<S&SS*ZH>9
M".2L>5SL>0$-!$AB=0=ER_ZIVVKL5QJ&?BI6*/*]3V+Z2M94`Q/GJ7S`(Q!0
M,K05`U2:^K_;+-U?=?ES8%XA1V4-'$G6-=9-]L>#J:X+HI(LB962I2R6/=[G
M'9[XXV]Y'L;-9;ZM7J4PME?TGH"O4H3,@,!Q\(\K$^6#C4T>AD&C*Y/3=(=?
MJ96W"VJ(@E">0)DL.:`2_(;0\&UKX7*G$@9T%8LF-RMGI$(E2D<N>FQYG[@,
MML*6-&N-'EF4I(;/%BM261KD\PD[<MWVT/VK,-;2IQ'!Y3S!$>6/B!'(_P"R
M/`C7H'M*@U>X>VK:G%U[C65*0:V!Y`N&\03)00/K(.ZMKN#D_P#W:I/_`*71
MO_F:=>%Y?_,O_O'7UEVW_D*O]P:N'K'UFZ=--.FFJ9-IX-@<,B6PA7`$0+&>
M\S0*PKQ/)YQVD0#W/:/P5RM55$][%_I<J+*EUE:E4@`F>@G]O7Y_:`>HUCVX
MU-[A[`20".IC>)VZ?+["1T.J,F)H&R1RVQSMD,<5RO26?L7VHY7(9BO5A?[J
M^U%5._M5[N_<QO9/^.R.)21Q^P?I\OL@>"QBCM6$+!:%/,3XG>?C\=]_MD]6
M?E,&R5%(8K#1'O9YC(C5E2D\"!_4)!JTJ*,@'-&YCD[.:\`GHOD-CDM7,R%,
MJ=X^`_7^W?\`:1T)U(W;<-Q#*2)!ZGJ.AZ]1M!ZRJGJH(^_XG0^G\9(+6QNR
MM_'8\C`(Q7*[UM$UR,8-&JK4:B(C6=FIV:QB-I^+R)Y%O-\?']/[=_$R_IV'
MQX!(3X;Q]D?#P^S;H!$(&.H8Y'F9%(XQ!C$0I)!GO(P2)V0GD_Q(CGJ1SD5%
M172#_P"PQ4=5LW(8<21Q^$#]/A^Q?\(BU.UX=;%PIYD`$DG>/C\?$_:S_P"-
MIAR\3G)KQED0B.(%.PR-F2QE;V>THW>P9FD4@3C&5CU57L*-KT5']U6J9V2@
M(5A!^0_N\1(/Q!CIJVSM.#:0SJ>0Z'D0?CUGP,$'J&`(WDF/+R-#-8@S1"-8
MG^K02Y4?NWQ>SP5P3,>C$&]J(B*GAZ@JWLX(591,S(0R")^8!_L_23_B,WV=
MMP[1Q93'R)'\#\/V0L054B(S+4S/!$CO<C$5/%YB$1_=6J[V>;E5Z/\`ZT<G
M^CFE>U4\7=NJ'+N/C^[]/T`/751V_%$>4[?,_O\`W_J)'0QJ3CXC.1B(<4,B
M'[E<IG2Y3WN>=S"&(]'%5CR%D,]KE5%53/(__B,927MG9+#B6'';P'AT_=M]
M@`Z*L1IVG!K;DJ'GOO)\=R>L23O]I8]6:?J8C--F+8#@.#*5RN]H)<L/]3A>
MI[O$9VM\B(P3G+_YQ8X2+_6)CFOQV5P],M*?,`_V?;^HL.A.G])P!;ZRH19\
M06'A!\?'8GYJK=5!$V?*4$D1`'KA%`5CAE`YQ%$1J_IV<SS\?Z6+XM[=O%B-
M:G9&,1MBY>0IY*Q##Q_3])^TS*_;L-U*N@*$;CP/Z=!\!`Z`1Z7+T3F&$2O&
M4)_9[@E>4@2H95<=I!O>K",.YY/-'(J.0Q47]"D1U/Q>0""&@CQ^SI^S:/L'
MP&G]/PRI4H"IF09(,]9'C.\_'DW^(S3XN%S<-7K'AF;YM:U?.;,-_4B-[F[F
M.1RR".$-[R*JO(432.57JYSI&S\E_J(_8!^K8=.H`\`8Z1$-?:,"N>"G<?XF
M/Z]R=S`)/4D`G>2?C,)F&&8=L!R/%YH)&R9`VB8]OK];&B*-$8T+1L:GZ]F@
M!_M`%1CGY17CRV/R'Z=9/ZV_Q-(=GP`P8)N.FY$>$"#\('V*GBB1-R,CGY;6
MLE5[9#6/5[6D*;Q_J&\1!JUI&HX)A&(QXU[L<PKVJGBO;JU<S(0RK1^G\1M!
MZR`>NI'[9A6"+$Y`'Q)^$']1!((Z$$B(VU&9F*4;1L;%>K1-8UB$DR2N[,8C
M$5Y"E>0CW+W<YSE5SWO(JJJE)YVG*O))G<_(?I_J'P$7C`Q0``NP'Q)_B9/S
M)ZDL3]33+!QN>`0Y`PWC=(\/;X2Y;456-\&O9V.BC)XL%W>WLY5CA5551,5+
MCFY+``M,?(?W?;^T_$ZC7M>$A+*I!;KYF\/U['IN-_*IZJ->'XG,NECFI6-$
M<:,1BA/)"Q$&UXFM00S-$C?QR*%41$10M8Q?Z1"1E1G903ARE3\0#^F^_P!L
MGJ3-#VG`-@M%<./@2!\.@,=/+_N@#HJQ&/D,])0*2(#3>ESGL\S'[>PBHI7N
M:A$:YQT<1I.Z=GLD'8Y%:8J/HN9D+/%HG[/U?LVCX$*>JB+G[9A61S28^9_7
MX^.X/Q#.#L[`Q69>E&+TLBN0?K]:(L@[U1.R?U>3R.<XBN:CE<Y557IYKW<K
ME6AR[R>1.\_`?I_HVZ1JX=OQ%7B%\L1U/]_7QGX[]228,;'YV&\KXU?Z5.UC
M2HR3+\7>MKV#?V4Z^)!B5C&N3LYK``:B]@!\*MFY+@!FF/D/[OU_:6_Q--M?
M;,*HDUI$]=SX=/'J!`!^"H/Y%B43!99'H]:U'(BO7U.D2'`[$\D>/T*7T^E1
M&*/U]O!`G()$0;O%+_ZAEQ'+]PG]OQV!GK(!Z[ZB_HW;IGT_U28^R)B()$=.
M+%8XF-3<G'T$L"`/#>]&O8895E2O>$XT9X'$7W>3"]VJKE3]'J4ODBH8WG8N
M;D(W)6_<(CX?IT@1]*Q+9VS"L3@Z3O(,F01X@SL?XRTSR:8\;,TL08AAB.\`
MK_:0DB056-\D<QB.(5SE:+P9X=U7Q]0U_P!6-5+7RKG)+'<_(?I\?VGXZOKP
M,6M0JKL.DDG^WPVC[!X@:^IF:1JE<V"UBF)[">!"M1R]E;X=D?XH)!+ZT:B=
MD&UC4[(,:-?BK]I;H/T_O^V3XF7X#$W(2"3)W/Z1&T?``?RB)`F(S1#LDN@*
MAV-1KGLD2&>Y4-[VOD-:5&'>A7E_5R+W;(.Q>[#E:^09V4%X<O+]@V\-OAX?
ML4]5$0GM.`7%G#S#YG?>=]]]Y_4SCH[`Q#XO-R%<XU?YD>X9%-[Y#3H83F/#
M(0[2H7\@1!-<UZJKD>BN[^3GJZBYN2NP;;X0(CX1\/E\-O`1<_:L%]V3S&#,
MF9'0S,R"`0>L[]29B!R%!'5?1#<)JL8/UCDR6B1@_)!HT:%\&*,7@-JHB*T8
M0M1>P1>%#F9#?4T_J'Z?/[2W^(S5>V8:?0L"(B3&W3:?`0!\E4?R+`&0S\<I
MS"@=GR%[D1QY+QJSR([TM$XJC;'13D1!HG@UA7,1$8OCT;,R&`4ML/D/V_;L
M-_D#UT3MF$C%E3=NNY^>T3TW.W0`D#;;7R1C\W+<CY-6(Q$]:H0A9"O5PB,*
MQ[G>[N]_FURJJ]U<AC(O=#F1Y<W)00KD#]7Z?ZE_PB#]LP;3-E8)VWD^!GX_
M;]O)O\;2_P`0S_XZ1/P50#1L$)C)$D;@-$WQ"L<HS,,`@$:SUO:Y'L<(;D5'
M,:J/QF1RY\O-/P&_V_&=Y^TCH=/Z9A>GZ7#R1`W(B.D$&01M!!D0IZ@'7N/D
M\_$8@HU<P`6H]&@&4Z!:U[B.];!J56C"-I58QC>S&"1C&HC!C1E&S,AS+-)^
M.WZ?,GJ3)ZDS5.VX5:\:T`3X28\=NO3>`.@$`"%4"&''9T!RR65Z.,8KBO<2
M1)*GD]ZE>U&$,YB#>4A7*WMXJLDZ=NQBHZK9N2RA2WE`^`^S^[]B_P"$1:O:
M\%'+A/,3.Y)^?B?C.W^T_P#C:?)<9G3F20:"XIVC:)AG2I:%8UI&&8K2-,U_
ML8<32->JJYI$5Z*CG/5U5S<E5XJT+/P'V?#X;?9MT`@W:\)WYLA+Q$R9^/Q^
M(!GK._4DF)+R&>G,1DFO\FM:]K5')E@>UKV.'XM>`XWM\$\%9V5%&\`7-[.`
M)643,R:S*M^X'^(^V?C+`_49K9VS!N$.FWVD?P(^4?`JA&Z*1]%DJ$(4`.$K
M1?W.[$DR>SO<1Y#>2>[Q[%4KVJB(B>!',1$:O;JAR\AFY%M_L'AT\/L_6)ZZ
MJO;<-%X*GEW\3X[GQ\9/ZB1TVU!CXO.Q/_5X+QJKU(Y?RY9%>56M1Q2*8Y/8
M1Q/,KE7NKC&,]>[CF4ES9V2_U-/ZA_8/U?8%'15BQ.U8-?T(1O/4]?CN>LR?
MF6<G=WY>RX[.G<)Y8'=X?9ZWLDRA/1"N1ZHKPG&YW@48R,5556%",B*CQM<E
M!FY*@@-L?D#_`!'VC["1T)&KF[9A.063<3XD=?L/Q`(^!52-P#KW*R&=FM4<
MFL$42M*U1>PS1JA6O&Y/%A&]NPW(UO;MX(,?CV]0O"BYF2AE6(/ZOT_UGXF5
MG;,&T196"N^V\;[?'X;?*%CZ5CX+(9T,<L5*YCXYU*IPF*<PS*=561[1D*YC
MFR5>12-[>+_>7NB^TGE4YF26#\O,.AVVCI^S:/A`^`@O;,%4-8K!0S())!GK
M,GQWGP/)O\33ZBY*@A-<R+!42/<Q[U_+F$<XK!A&AE>:01ZG=^.U[G]_)Y5<
M1RJ][W.HV9D.99I_4/V=.F\1X"`-@(K7VW"J$5I$_-COMON>NP)/4F2=R2?C
M\CGBE$<E<QYH_GZ"*:2C@M<G;P'X&:C1L\1JU/\`1K@`<G9P`JRHS,D`J&V/
M78;_`*;_`+6'1C-&[9A,P=DEEZ&3M\AOTZ1\U0]44CU*RF>FM:R56`,QOFB,
M=YJQ6D]C2,5GGXJ,@C/&YO;Q43O#MX]D2BY>0FZL0?T_U_;OJMG;<*T196"!
M_;,_J()$=(VZ:B?XS1J)0.@#>%S58\92'*TC7=E>AD*5_N]KO)7^?DKU*57=
M_:7SI^*OGER\WZOW?#^R!\!%W]/Q./`H"L1!D_MD[SO,]9:?J:84;)T4,;11
MXA&L:P;&>4V:5S&B:UHO%Y9#WM>-!L5'(OEY#8[OY-14JV7>YEB)^P?W?;^T
MCH=6U]MPZAQ12!`'U,>G3J?"!OUD`]0->78_-NEI._:@-E)V5"L)(&J*@2Q^
M_B,S6=_QR(-?T_5@@M7]`!0=1F9(3T^9X?J^W^._VD_XFFG],P/4]7TP+/B"
M1X$?'X&/L"C^18F#YFADIV/61RIYJ16O1ZM<KO9Y(YOGV>-[3$:YB]VN81[5
M16O<BVKE9"_2Y'Z?Z!^L`]0-7O@8=FSUJ1/Z?Q(CI!(Z$ZETR&=0+HZ5Z>MR
M@<O>3,<_SCI']9$*Z0I4(JQ6J]W?N1RO<_R4A%?=^,R>7+EOOX#QGY?/;X;1
MT$6?TS"X<.'EV\6\(@S,SL)^)DF2S3\AX[.0$(V)7(%"HQ'HV3,5.PVN&+Q[
MR%\%"+P8Q4[*UH`(B_V`^!\W)LCFTQ\A_=X[_M;_`!&57:\&D$5I`/S;PZ>/
M@(`^`5/\"Q&;EJ%AB';7L:0R*A50A_$B*KNZ/9[?!R>#U8GZ?H+LQ.S&M:E/
MQ>00%+;#[/T^?V[]=7#M^&&+!!R/7<[_`+_U?9MT`&O,G)Y^8\))->A7`+[A
M(LB4C6F\QD4G@TZ-<]SF.[JJ+Y-,=J]VG,A"Y>0@(5HD1T']WZ0O^%8I9VW"
MM(:Q)(,C<]?CU^W[>3@[.T^"Y#/&BMAD@=P#07J3\F6A1.!X*`HI"'_(&<+Q
M,>TB.1Z/&UW?R3OT&9D*W,-YOL'CUVB(Z[=()&J-VS":OTF3R"(W,B.A!F01
M`(,S(!F=`Y'/QPI&!`]49OL1@!R9;!B:7V(HQ(TZ*$0V/1@V-5&#&,36HC0B
M1E6S,AFY,TM\8']WZR>I))/4R3MN$B\$2$WV!,"?`;[`=`!L`%`@*L>W9//N
M,DAU<-Q_$37E4IT<9`O>\?Y'8J)(5/<1J^:+W&8K%[L(]KJ?B\@+Q#>7]6WV
M?#P_6`>H&J_T["+\R@YP-Y.\=)WWZD;^#,.C$&')Q^=F/$617H4@4_H>Z3+\
MN_<;D>]4/_<*T@D>CW=W(]SU[]RD\ZKFY*`A6@'Y#^[]-O@(H_;,&Q@SI+#Y
MGY?/K(F>LR?YFF(/*4`8XXH8#0@$C&B8,TAOK8)/$3!N]JN&T*-9X>*IX*(2
MM[*(:MH<O(+%F:6/R'Z;[S\9/Q,W#MV&J"M4A!T@G:.D;^&T?"%CZ5B%%QN<
MA.58M:P#7,4;AL+(]+AJ4Q4'ZE*HT$/\@C&,1$:P3U&U$8C6I5LW)?ZVG]GZ
M>`_6)ZZMK[7@U'[NL`1$28B28B8C<@#H`8&T`/\`#L]^2LO\%WY#D:US_P`N
M9V>QCQ%:-[/R/!XT,-S_`!5.RN.?NG_,']C\;D\>'+R_8/[OTA?\*P_IF%ZG
MJ\/.?FWR,=>DB?M9_P#&_*)(R6>EL<.17,(CO4OG[I#3-<!S2`>R0TK3L*$K
M&D8]'(YI&->B^2=^J+F9"&5:/V1OUVZ;C;[#'357[;A6#BZ`]/$SMTWF9!@@
MS((!Z[Z\+C\XZ(2"ZM8Z(3V=XZFDH,;7N>Y&`1#(L=@/-$"C%;Z4&)&>*!%X
M5_&9(<6!O./&!^_XSXSUDS/(S0]LP36:C6/3/A)C]6^T>$?3"Q'%8^1L=FXG
MEZ*UC4<CVO:XTD@WM(5YR,<)YG"5A"E(KF]O%4,5O;Q(]'&S<I_J;]P^SX?9
M^P?`:I7VO!K^BL?M)'63M,;DF?\`>8=&,Q@Y6A!()*'`3WE5'$(^1**JJBA<
MY40IGHWV$`CWHG9'D<]Z]W$(KZ'+R&4*6\H^0_N^<#Y0.@$7KV[#1S8J><_,
MGX?$^,2?B9)W9IARLAG9K$')KD(UK5:SM(EB<Q%;XM5A!'8]CPJT;QN1?(1`
M!(Q4>$3F53,R4,JT'[!_=]L_$%@=F,VV=LP;1QL21]I'\#X;$?`JI$%%(C+E
MZ!0_CK6@4'I?']7<B,]1$(CFHUKT1O\`2543MV[-[(GZ-:B6_B\CERY'E,_I
M^G\3J_\`I^'PX>F.$1'RW_O_`(#P$>096@C,5@:]C4<YSR>19!%*][O8]YG$
M*]2N(17N?Y=_-3&5>_N+YU;+R&,EOX?I\/V#_"(HG;L-!"H(\=R9^V3O.\SU
MY-/U-/T.6H`$<85<-A7JCG$0LE7JY&@3S5RF5?8YT9CU=_Q.(WS55>JN6AR\
MAA!8Q^KY_+YG]6W31>WX:-R5`&^,GY?/KL#]N_7?7F3D\[+;XGJP/;X$'XM>
M8:>!1O$]O]HK/Z?!S41/]&^H2IV4(E95<O)0RKF?U?I_K/\`B,T?MN#8(>L$
M1'B.HCP/P_@O^%8BGS-%*&\,BN$4)&JP@7O,H2,<XJO&07M]9!O0[VN:J*US
M'N8J*U53JBY60IY*Q#?':?TV'ZQ/75SX&'8I5T!4]1O!Z]1.XW(CX$CH=>8N
M6H8:*D>N&SR<U[E<605SGM]2J]SBF>Y7D>+S>O\`J0A"O=W<8JO-EY#_`%-_
M#^[]0^```V`BE?;\.KZ*P/UD_#XGXB3\26)DLQ,O%QN;A*YT6N03GHB*]),Q
M7]VC&)"(]TAST-X`%_7W\U<`3E7R$Q6W/FY-GUM(^P?W=-SMTW/Q.K*^UX-6
M]:03\V^$?'KL-^OE4]5$>I./S4QS'2:F,7P]J(U?8C%0PG@(CF->C7M='?Z_
M%45OK:QO;Q&-&T7,R4$*Y'^C?^._VR?$S5^V8%AEZU/7X^(@_NV^P`=%6(LG
M+4$Q/&56B.Q2^U6/>96.=Y=W->Q"HT@BHY[7L=W809BL<BL*1KJ+EY";JQ!B
M/#]/A!Z@@$;@1=9V["M$65@B9\?[^AW!'0AF!D,P/F/E,_%&P0:X:#8X;O$A
M3G\W#8%C7F<<I'G?VCL57/5RN<WR55<KE6K9>0YEF,_J'QZ1TZGIHG;L*L!5
M00/B2>D=9)GH.O4B3O.OL/*9Z`B-B58`M1HV(Q'G<Q&!:HPM1CRN8C1#1C&_
MI_2P(6I^@1(P^7DV?6Y/[/T_UG_$95=NPJ=JJP!M\8VZ;3X"`/DJCHJQ</6-
MK-TZ::=--.FFM"ON".DK`J%7C&O_`%$XS,U3#]T=[HT362D#*"B*\L21Z?65
M&HK_`%N56HJ]D7O_`&*W#N'+?_EKNG7<UB0?B)D?/7CWYLIZG9N,@'\=BG<2
M-A<8(\08@QO!,:Y+6T"=FZD$8#'IJ+^N19,ET8879',R#S9`:(TUQ'0H=Y>C
MLGRI:#:$L"`6/&7V?DR/5ZY38F3:6/\`RM;;"?\`,<``N!U*KQ"K,AW#-MQ6
M?G#)IMP,85H#_4+DW,`>C42Q%9:>*V6!B[P%-=91/-ZC\9K(PJ+*U*[_`$@@
M3H)):5E53O>26"ZTLRDM29BK,D%"!C4]6`(YDZ2K/2Z,/T=V.(%RVYCWY=O]
M/QB5L`Y,W0J@9>;"=RS$E4'63RW`(U)VVK$[?C_UG.`>DMP1-R'M:M_20\9`
M1``]C1Q*CAL64ZQEF6:+D72R[B^L=C&J&PL%R%H[($?/9.)<V$BDDY^?EUBU
MK;"0%VAL"*%8Q):BC1&.4?AZP#?M,HXW;<44T+2;N5M**2]A4!@X>6@>0;\@
MLLQ$S+$:#MXS>^9[9.6^4N,$Q\BU@*Z0[&LUM5"\B/48\>)>%0'C'%`<U6/)
MES3<D9YM-<`K4PTT;-3*C:T,>LK9V&4TRFXSE0/7WDTMY0J\,MIAH\57Y#>9
MS_8BZ.OME-W;;#>A;UU\@-<LPMV:X'P97W6#!?<*!&NJN[]E8O?:!BVBO\(P
M%I%P"*V/+)BE8W2RN5?D)%4J7)Y#5?\`K$51;4E-R)F(\,%:=BUFA%7@BF-E
M+*?=9U*W.ZROBB"R3+K0F5U?,"-II=>OBKR()6N@]I&ZF]^W918VCS))/WBA
M7Y/63,!NCJ3"OX"=9GYC+C9&+5WOMZJ*".-@4`FEF>OC7<H`DJ#-;J`7KVEN
M,&A<=9NOV?TM;'G2H-C&BY_&W=BMG0$S="B0FZPL@N@C,D1',H*H:CF2_%S6
MR@C5@_,BM3J?N639A>V$6L,K&RQ5XOS;?TXX&#YVW5?\),F!K$['@T]T]]VO
M<R65K318W*OTJ_+ZQ)L$B*T$.\&'40LF-9#Y3W];&Y-B6,2/:P^.A$@9R(,-
M)55L7!Z#/PQ:8NLNYTR=(/$K]?*DPX+45Z.A-BL57"5C1+KNU=OM;MAK<H>Y
M$%S+,QM1SP]-0``36`S=/-R/62=;KW#WFBOOZWU+8O9`5J`%:*,>RM1:;K&9
MB0MQ*5C<&O@-U@+K5CE_(RZZ,#84T)\7/V=13T4RK3%U-DE?L-3=0;B7;.=4
M&C3(=+<!J_U?&D^(Y4=5(57()B]7V?,2QCAWM.0KLP;U&6:ZU*A?,""RENA&
MZG81)UY][E[;916.YXJ\<.RI*V3T$;C=:ZN7\A#+6X3JK0&7=IXC5Z2;HW,L
M&VTTXE<#<5T:W;JVQ)%Y`EVV:!;SL_4Z^..Y;'D-BRK4(P6(HZE&DKP.WNV2
MBMP5H'9;$Q4#'!8KZ<A"%<J':L\9$A9*$P>,J=UWVCY3>YZ;,^TH.[(K^M!L
M4O4':M+AS@P7`6Q5D<X<;6;6G@P=P!H+60DPDF8231M,*.\&>O"F!:O"I"?E
MB'073:^,V83NQKE49_-@0G0F7GMYCD5"`!#=9=0"L^'G66XC[5@EEC7=G0%!
MAY)Y,S$US$5V$AXWD"M^*ASL#L\A5?EM[\H38?\`G7(%;*AV<2ZB<-7JS*^0
M]L8-;7MY#XQ!"@+&?W(^PBR4*(DA!,"4`!>"J[S\>/\`=J/^`Q[$*F@YJ01N
M2?1O),_`B"!)(),^$^E_EU;5_5\VBQ;%RE[79R4F`J_B<4*L?X@9!:`"JK&\
MQW4Z\'U]<Z=--.FFG336EWVW*+!XCWTT"]C0N&>1IH?[33]C1-5Q1($OH<BL
M/V(-/Z%14=_HO^O7;>QD%G=\>MOI;-I!\-C7>.OAKRS\U[&J]MYEJ?6G:LEA
MM.XNPR-O'<=/'7-?FWZ`IZN;52-9@,WJ-$>'$-N[ZIGLR=A41K^)"/0YZ46*
M=M%6W\G/"B3&OG`$DC\E6`\'AD*OIG8_;]UJ.N)D6U8P8BI&'J!BA(9Q(YL@
M?DOE)CC+2"NO"O=?O/&HMK?N.'1D9Q4'(L1O19!8JFNLP?36PUA'!L4<N4)!
M5]?>1^,./M/@LO'?RZ+AG/O6M@V68Y#SLZS%/TVBJKV&D'0ZO(6<ACY46J>)
M(Z2*H0*\02$0RF,\J.V]T[CBY]K##.;D#D0]+A81&4RE=BC8M,Q82Y($<5`T
M[YV#LN?V?'0]R':\(\5:K)J9PUMB6+QLNI8[A"./*D+6%9N1=BPNZA^8=1QC
MBH^HS,;-<H3Y98NJNY/']AG3P.2=K5D'6U5+G27%I'AK'GB*CBD:I7*AGO1W
ML:T#<._W1B]TSCBY1MQ:P#6HN#@TU-NS/Q4F1X#;H!$>;6SP_8.?V#M0[A@+
M1W"YB+;#C-45RKT\J)67<+#`R3N?,3/(!!@NRX]U."C6=YRK&LP7#Q65E=6R
M0\Q26QUB2JNZQ^6K&QX,^8>JJB/($#F=AJ@T4GB%W<>]K[CB]P9:.TE33*JJ
MR[*)#+8[20`S;$SOOM+=>1O[+W#L]=F7[A6P9)#,[Q4CGB4>FI(5F*(952-M
MO-"GRXRSO).F=?S]E*E).O[8-A$+&DP;"SKSULX3HZT+Z^8$;9<-S1AC1!@"
MKWD[R$<X\@+![3([9BC'7"0<<=""""%(8;\I!V/5F),`>6`JL3H,'ON?^,?N
M=C<\VP,""K,I5A'I\6'F78*@59)\\EW4+>\*\ML8O#MN&'IHDV7P[>UM=/L+
MM+0\.#+I\&.=)S4*N8PM9/?5J8?]UJR'B*@Q]S.8G6"]%6:,VEFJ9!FHQ`7B
M"0UL!RVS#E!VV!$GRSK:U9>1VO\`IF2BY"VMVRQ59GYE5*8X8U*HE6X<AOYB
M"%'F(U0\OHB7;I6>.SV$FS7/@2(\"%:'N)8:N\)%I@SO;%9*@V$RP5T!`N:`
M\E/607:5_1/E8PHC)78*NX)*A0666(W@@#SSN%W!\F^+V_-.66PG$L[^4A5<
MN0ED(&D`JS-]W$*S>5E^\VO_`(JXYT,*VAY:LRJEQS)7_P![SZO,:.U#F'44
MI+34Y;0Z&;-@U8*O57;2_M7L\@I*(Z.0?=SO'7]V[ECV4G*MMC-CS\G12_(<
M:[$0`L6K6/4C?B.0.PUN/;W9,VK)7M]&//;`WW92JUQ5Z9YVU66,RH$NLGT9
ME>9*$;F(FP^0]CG=93:.-R-QWPU1Z"]C6$`VOY"F`T<33:N3'+*ILC45,V:Z
MS!7+#'#JAA$G<@E[JC$>YU,/WAA9.(^,V-DYM]=9!%=(*%*P8:QF`XDR6L)/
M0_&`+^Y_EKW/![C5G5YV#VO#ON#*;LEA:+;B"4I1&;F%XA*@HZ@^`),MR'=9
M/CNXJ92Y2TVDNVA"_>[0@5PN<=>T[W$MZFOK0"O-HPIPA85*U6Q9)?R'HSU^
M0VBN[=1E]QI=/66A$;RK_FOQ;Z6+$I7MTY^91`F=YB[WE=N[)DUV'&LRK+$'
MJ-'X>KU$^M%4>I?)`!]+R,>1B)`78CC3D2PO^0."J>NC4E5Q_;\J9*^SE+##
M6OG4TT$;11[+/3K@4ZUG6EU2V@YPYC5DJU/%'H)O]?JYWN?;J\?M^?=87?N"
M8EB.Q+0P)0JX6%"JR\2OE^4G:>V[#WJ[,[SVC&H6JOLUG<:;*JP%Y(P%H:MG
M#.SNC\PXY1X\1OQ[&Y/_`-VJ3_Z71O\`YFG7C&7_`,R_^\=?3W;?^0J_W!JX
M>L?6;ITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG336
MJ_,'U9E^(N7,!PU,STBXU&_STS45Y2;3C3'1&U<#156;/'K0;S8YNUUE]^5:
MM(VOJ(\V4X3/^'R>-KFJ@2)TSGUQQ[I]?PKC(%)KQ6/.F!X_Y$RLB5"JQPJZ
MFY&P_*^]IHUZ]EN0\:QB5/$%B.2P(SL9(/':U[VN(\;2#JE:?[+X_P`I54%O
M89/D"1'V>NY4XSP8Z^JJI1MER[Q?R;:<7CXJJ4;<M%'UV^L:2=8T7Y3P0C5-
M?+D23Q?QB-1JO$ZM[F'[PXIX.Y>-Q/NJJXBK69_%:/1:4%]@4;3UNZE:V-7S
MXV*F:Z'R1IJ:C3&RSW4^JJ)D6IAHL@[D"*0\+0*2)&J7!^^L1HZ7C"7BN+N4
M=+I^5ZVF/180[<-FM!3WLW3[K'W^-U<J_P!G#S]-I\1H>.+>):";,,!LB-ZP
ME,YR=-.)U>^M^U.(\1PKBN<]'!V,#-[/=,X\?1$JJU-7E=!5Z"_HN1G:F`MT
ME;'K>(!8V]L-%)B2Y@A5U)*-$67_`&6E:<23&K`O/Y#>**@V]J@8ODFPU6"Y
M-W?%DC+?@Y>LL+VXQEDVFA:&BE6VIAUI\1LKIDF%6V93!&DROFADM`2*1J-.
M)U>.C^UL'B./I>\W>'Y(RYLYS=G>!^0\F^MH+K0<>Z:_BTEV327),_HK.EM<
M'2XG11-'+L*R5-(.D(XOH4XBQF-.)F/EJBM^Z\-,E:2;2<><B7N$XZTR9?ES
MD:!_AO\`CO',F7R%>\>UD^1%-K!WFIK'NI&W<PM1&F+`STZ+*>CBO?'&TXZN
M/@K[8XCY[-G8E#%TN2L;_.VMV2KWH:.AL::?6ZR#E8^7M(X;V?WOM".VAVM2
MT"G#94TV/*"1S2M;TT*D:QO8?R.\.I@Q[[/YK8W56_EG5\3][.=@<-6)+S5$
MW8U>D+KMQLZ'$P*7DW$2X-KD!S+&+,O@V48;0A(IFA:<#,:B:O\`D/XWR5CR
MI!GXC5#3BV=GZJP=9ZCBG,3RS]%O,%QY`E75!J=_3:##Y*=<\APY$&_N(T2D
MGU\>3(%)5&@;(:!=7!!^Z,7*UW'6.)B+UUAR#F(^JB2:?:<2Z2&>OGW&NIX0
M\*^CWTQ_,\N$_'&-;AQ[;H],&7%60-%*]HFG$ZM^G_D9X>E\;T7)UYG-514>
MAY1R7&40,:XXXU<JM?JJQFAG:34?XGN;8>3@<<9IIYNM@3U!<T38I&OAE5P%
M,TXF8\=5*B_D"XLNN4+[BO\`QC4`N:CD>;QK'E1+KCF]0]I5\]5'SO83[JDH
MMM8:C%0%V]V&3#;<089K&J:61'8]PG"Z:<3$ZR;D_JC+[+Z%W?SU4T?KO..[
M4E-?VL[><7QIY)@\/E=TLJLXZ_S,G*,VC6!L8<=)_P"SMB_D>S^KUM\U:I&T
MZQ95_P`A_#+[FT@:ROMN/:>MY1C\5'TFPT/'<`%/>22;^-')O*`>S-K^,G3)
M7'DE8D:^KX,B=&F1#1VD1YVQVJ\3KZ+^1?@22"EDPHVPGQ=#PORMSA3SX4*B
MD5<[/<72MKZJ(-B/0J`FGY"I.--+;9\3/*+*K*&84QXZM&PC3B=8_B?RA<33
MPU(8F1D.MK722\TU3\P_.@,4.7%Q5)N_4+E1>7'\<SKA:701D)4AL7VP'O1Q
M8S`O$8C5>!UL1A?KC$;3D?E;CP]#<Y9_$4#3V.HM[VYQ2GAQ,9,APKR=:8NN
MT\WD*@I+#\S\JCLY=2.MOJX3Y,4[F*%#-4*D"=8>TG\B6/QF?SM[M>(^0\0G
M($'%Z/BX6TT7$F8@;3$[>UBU,+3S=):\B@S6&+1GLZ]UI7W<J'-BI:PVL84I
M"C`TXZS9H?IM:R5A:/,\2[ODG8:OC5>8+G+8*XXZM"Y/CP<FL@+:.OYNTK<Q
MJ[.UL+/TU,.FF376GXQWB>T;&O(TC6&=W_(E@N.L;=<G:#B7E\G%RIN@<>;2
MIA8VP_ZJ6G&]M*J]/3YK.)L!:.IG3`U5A.IDMH\%EM`K)!&*-ZQAR&G$G[=5
MW_ZH7P6G.1>$%B:]KQ:J7DG<EK!I5XR6;"X8C<UGL&W:7RV2TW[/(6H21^%V
M6^&Z)V[=B*TXF)U0N/\`^1/!<CXJBY4I.)N7(/$9YF"H]QO[Z-BJP/&.NY+)
M0#S.6U&<_P`Q/IY\V%_E],MP>KBSHM4EL'V$?ZIOXE)T*QMXZOSB[[CXNY:X
M]ON0\UE>361\MP96\Z:+)2<Q%-O*N%.E;J'(X_)F*RVGR9'(T$^!D*D,3WQ9
M89<,T628$EA.JZ%2#'SU:T'[LKK.AX^U-5P]I[O,[K8:;%/U.<Y,X%TF5H;'
M(X;0<G7MA)OJ/E"=&M*>OP64LI1WPT-(CS(9()0,D^+7-..IF/\`=%68^-HS
M\&\N5^XY@JJ;1\`XF>7CT5GR]E[B/)L3W$:P%MCTV)+DJ*.VRO8=X>%+KX4@
M'@R1)>Z,QIQ^>VKJROV=B-3S)6_.[<3O:7G,M35Z?1<:W+,F.YQ.)DQ3/M]U
MI)4+4SJK_%:6U2/6L/#/+)9S9P/P1R`?D'CM..T^&ISF[[(XYX$Y+I^.-K1:
MHC[#C76\ISM)`7,!JZ_-Y"+;2YX:VNNM)4:3;6[&4I4DQ*&%9GKFGB$EL"&2
MPJ-`I/37JS^P,?58T6BD\?<FDU+=_KN-;3BJ+"QDC>T^GP.-NN1M@.45NU3$
M2X55@*$MJ(T2YD-G"-'!']DH[`=-..^K0A?R`\+6%071P:#DV?F9LS)_X7?U
MN5AVD#D'.:OEAG"B;C/BK[N385.0SV_>T5E)NPU)`0BAEC&4)Q*YIQ.JSS5]
MN<9<$<N0.*=K5VC7/SW'^GN='&O\#'2HI^2-?K,946$/&VVNK>0M?74$W'2Y
ME](I:J>.EJD_+/\`VV%\&@4D2-8?O_Y0N%*+(<=;8^1VD>LW>/Y$V<NHT%]Q
M-C==FH_%VSK\)K,J_-:ODBJDZWD45[8M;%H:)]E/F(K$$UQ#@81JO`S&MB=Y
M]:\:\;:K0Y'6P--5V6;N,\":<\*O#!?D;KC/;<K3N21&/9B(F*S&;XQTHK`K
MV-E,G4A@#`12`4K5H!.K>P_VOQGO,+;[RMS>^K8F?X'N.>;^BO*NFAZ*CK\S
MHMUD=7@;2%'OID0'(.7U/'=G`FQFG?#9($B-DO15<C52I&WSU;/*WWKQOQ9I
M:'(3,U;S+O11<O-A&NM=Q;QSG!Q]7C='MH0Y&JY)W.6I!SQ5N:,)T9"N,0SD
M]37L:1[&@4G5>Y;^U<)PWRCB.*])EM!.N=CG\!H%?3W_`!V6=$!R1N)7'M%%
MH\I/V5?LN0Y<"^AO)9-SD"T6%`[2%\D<UKF@4D3K#D'^3?C"PP&1Y$#D&BI=
MWI*K.9Y9G-_S5!!#-9X#6<DJNVN)7+XJ#CZQC9[)%:M=;2HU@245HAB=ZS.&
MTX'68-7]M8#.9GY\U@,CL9U5]%YB#LLBMK+Q&'=!I9T;)RH]1*F;G74%+:\B
M3P[*,^OS=;+F6=J*-+?#:9(_]QIQ._RU;R?R*?.\BIT4ZGL;32W66PW*^SN\
M3G#9JTVL*;Q9R9E^(AX612-T0EA[GD+=ZZ'!ST220`I97JTQHZIVZ:<3JC3O
MY(.%XVXQV1ATU]:P]OFN'=-2VT/0\:"MYT3G&!+L<9^S<<SMU$Y*U,>%&B.?
M;R:NJF1ZL3#%*Y11I+Q-.!UG3Y@^E\[]1X9W(&5I14]&4-%)A,3?<8;B8\-_
M2QKV."V%QIL=@',V\2'-$AX-@0$ICG_\"HBKTU0B-M8+T/\`(?A<MEJW<Z#B
M_D.CQ>ZK(=YPMJ;VUXTHZ7E:AE;_``?'_P"\CFVNZBAX]KW$Y'K+H+]*M7[L
M^XLK^DP#16-5X$F-;H\;;47(V%S6X!`#6Q]-7-LXT2-HLQK8S(I2E;&+&TF+
MM[[+7$>4!C2L-"F'$K7HGEY(J(U0B#&KXZ:IITTTZ::=--.FFG333IIITTTZ
M::=--.FFG333IIITTTZ::=--.FFG336DGV%H[?&Y>LTM&H4MH7)O&O[<DJ`"
M>`T@L'71ECI%F")%DO,,ZM1%3^A7(O=O9')W/LW&IS<IL6^?1;%NY02"!-9F
M1N(C]?SUY1^9N=D]K[?7GXD?B$S\7C*A@25N$0P(,S'R^777,;><LT,GD*NS
MQ^.JJQE'N3YNWO<IHAY4^HU<FU2'J'TJ3'6F9F2,Y=L,!U>UKIT=P&D<Q!'0
M;?4,#M&0O;FR%R750@=5L3U`E864Y1Q<!U@\_H,D`RLZ\#[Q[CP[.])A/@UO
M8;34]E-@I-MQ?C;PY<JB:K.2FL?>+Q#$!7@3'*'$.+W5_0#JOH/)82=-!)7"
M9#E/,6U!6QW4,^!9,LXFCJ+Z3G[*P-=H9DN;.!7/,V0,;!M&!H4L[5WC-P<>
MPV]NNR*U(]6RAU=CS!'$HR!U'&.*J7B"298MJ_O_`+:[7W?,I&/WK&P[G!_#
MTY=3UJ/396Y"U+#6S&SD'>Q:BP95`"H%U6=/\^[#C"AJ\QA\HZ^ARF3@9(6>
MM,S*8T^H"*3<[XU6MA[94+&S0BD/:!CF%*]H$4@$>3J+%]PX?=,A\K.N]-Q!
MLYJXV0PM0:-C8"1ON`"VS0-96?[,[GV##KP.TXWK5,&%(K>HB;0"^04Y;K0P
M#'B(8D))26UAJ?76/$U'7FT@IX-G$+'EJ&Q+1U1+[<&@:"AU%]>*.N2S4K&B
M#*4SC^IQ611C)W$]SMS7;5W>]EQBIPB")`9N%4HR(OFX_%8B8YDC<:Y>ZC(]
MN8B-G!QW52&AC6GJ7E;*[;+/+RG97GE$BL*WE).&SZ>8;-;N&CI%HS2!JW6S
M5E62DL%=?PSQ[QS#M=)#8UX62B%5[&QXK"JPK6N26]FZ7%1<G'<PIJ+<=EV\
MA!7;8J?*!&[$2-N`/,/GVM@Y=0Y6"\)SW:6^\4BS?<,HYDR.*`PP!]0C).AU
M%YGK[D2ACP+*M_R/.X:/8S+J3YW(ZP$O52:ZO9<-:&&#*)8%<22GK\WJ)IO^
M$*#ZUF-BT9./C9#,K>E9:0%'EY$5@GCU-D;#>-R/YIUO,W/R\++S<1$LK]>G
M'#%SYPH-I5>>RBGD9;:3`;H@75-RRQN1JR?G;^O;<VL&M<&=&M*D#3:*BF6M
M5%F?G68K$%R:17LBO9,>CY$H1%-)"KE]7E)E<NVVKDX[<*F:058PC!6(A8*P
M9'$0%(XJ8WB'M_I][H?"S$]7(2N&#H)LK+H&Y.&#DK!#F68'E8L^6;VXUR'(
MFQC3,^W"VEK6Q(9UBVC:*SI*6VQLP$6-F:!NBGV,>%.NJ*N:DDIG.*@6MCR&
M.1_];\+N>9VW"9<@WHEK,)7DK,M@)+OP`)"L?*`(GS*1&PVO8NV][[G6^%^#
MLLH53#^FU:/0P`JK]1F"L]:^8DSQ`1P0=S4A_,^JXHOJ]-1S+Q[QX&'72_\`
M&\WI-+;ZC=WN2@0YII<&QP=+)EEGR;.39D_<&-=$"X"^"/51A>.(^Y\3NV.Q
MQ<+(R"6'-T14J6PD`$6L!`4*.'U&=XW(,Z^P^X^W<Q!W#NF%A*J'TJK;7MR+
M*55BRMCH26+ESZ@\BE=@=E*VW9:/!\?[F;&=D]#IZF;9!NZY]I8BS,&THC`%
M#@NSM'G4D6,\-98F<BNM;4`(Z`1QSM3NU<FK&S^X8"MZU=5JJ5/$<RK3)YL\
M`%@/_+0DSY5.L&_-[/V;NS(<:[(QGL%B\V])7K("KZ==<LP1CUNN55XR[@;:
MVYX.U^LT7*NUJ;V5FIM%G^!KIV)E9>NCPJ^5F;GD+B.963&R'>VVG-F5XP%:
MLH\IPFO\&E<B?IR'?</$QNTT74"U;[.X+ZH=B2'6K(#"/I$&1Y0LQ,:])]I=
MS[CF^XLO&S&H;$I[._H&I0JFI\G#96G=VY*%(YLY$P&(UVHZ\2U]4:=--.FF
MG336EGW0(B\$<J&$9HGCX5Y&$SR&B^)#7W'#AF4R.0@VA<'NK6_\7?OW16IU
MV_L,C^O8BD2#G4_^"[:/GKRS\W%/_2'<74P1VK)'3Q-F-!GJ(CIX_JUQ9YBC
MS?\`K!-4@[^:3]TIP11QZZO-KAX\`*QUDM306%.&FA<81W(CW:'U.L8LKR$U
MJ#$B)[9V9J_Z.L>FHX,3)/I^H2W'DX8L;ST]&>#+!.YU\K^YDM_ZF?D+G;U$
M``53=Z("<N%;($7%'4Y,&Q'E0.*ZN_ZBL56#F`A*Z%%F;;;^$H)'/D63$JAU
M<>OHFH:'4;%I6.,UT?0.CQVO:\3%\$7RPO:U?WEK'S,M%6QZ#S<B6ZM7X&:I
M,03OTV?Y@7GTL=4/&MLN_<'=O)P"U[A+I\P*Y'%005&PWL[)6.ZJ\GG:_C1N
M@%"FR[L,V'!0L^OF64>;&CO"6"0/K,UK!Q#]B161AO\`8"$1(@F/?FYE>!;E
MVV=S],V*%()V(4@GK.W5ALQ8B&<<R0-7VV_N^/VZBGL/K"IVL#*LLK,&`@J1
M!_D;=`H/)*F]-03D&7<_4;23JG1-M:R(*8=TG,0J2'>U$8DJR?/L/SJ`CM%6
M5PVRPOCE0H&MBE_I[(U[FIKDI]JPMN-P9RHARQ5C`@0_D8[$$0?,/LUNK,K\
MP9?&SA976&,U+6MB`EN3<JSZBJ)!4ROD.T`$@7;#JN*2Y&RL.278#)7CZ^RE
M,7C^ZM#[\/C0VDF/^+QY5&V&#-(DW#R!7WR*P<44AZHG=4:_$>WNPS%K[9^(
MNHY`?>JOI'SJ#-S>G;`6#L'+$#]6RJQ_;K=MLN[Z</&RRC'_`(>QSD#[MR(Q
MD-V.27E?,U00,=O`V3C\W@M1:</TV\L\E1U\?B:]MHJ4UN^!)T&H!7<<-KJV
M_P!#<U]E08TLT;^RS)(#1VO&5O9?:WOFYF3W#%JS+L!;K+#F*IY+(1"UTE$4
MJ]D?X00=P?`ZU/:\'L^?D=LQ>\68U-*]NL<<'*FRT+C<5LL=6KH+#^=E900P
M_F&IC:`T/%]W8W7'O&U=,SD&VK9-5KF20\P1QHMC(:)Y;.&*9D61Y2RE,>3^
M)"(-[D)W<\CNUN$V/W6A:>XY++DLC!JX..>@_E,62(@+R8'IT`U)W1,WL&4^
M5V7!1L%+$*72,T#S&)90:8,\F;@A!/*22=>;[G?Z&M*&#.EP[D%;/LXDX>I%
M3W`I[G.(*1!!#D&<^MK6Q4(?T/BLCO(8"/<YJ,:)*X_8?;M5[5HR&Q5(X<EC
MX$D#S&=IY3`,>,ZMS/=_O6_#2VU;10]BL+0CANH*A2?*D2W$H%)99)$!=:^\
M[V1I^VL;:593Y>QE4.9NK2[EVYX<O]QL:>GGQWOTD]65^8&>:WVD+-]PICW(
M&"T3&*]>A[#4M>"M**HPA8ZJH4$0&8'R#=X&P"P5&]A),:XSW?>UW=7R+'=N
MYM34[V%RK<F1&'WK>6H%MR;.0<^6H*`2=D?HMBIQ_03WR8I;8/(E*VG(+,&L
MY\)MS06<B_F1(:$]E/8J4`/R+_O_`$.:A`.0@N_7->W#/<;*P"*3C-R\X4'B
MZA`3_,NYBK]3;'7=>]Q_\YJ;BRG)&;7P(J+LO.MS8P6?(TA>61X?4AY+.KT^
M:(Z.F_-)54(FP/H>WAQ(;9!+!L>.?-U,QXH^H\`BWSV%F>UUP+V`FK)*]/U8
MUZX7N=H3N8$GEVY23$20[#=-_2Z1Z9@KQ`\2-;3V'7][V%C`"=[=562T`U(T
M"W89$%I-PE7Y,>H!UW9R?_NU2?\`TNC?_,TZ\%R_^9?_`'CKZ\[;_P`A5_N#
M5P]8^LW3IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFK.-@LK(V_\`U%/5H76_X?(P2V)),IX7967;AO)%8^O<9:]Z%L@->I%$I>R>
M/EXJJ=-/EK6Z%\-<$U<2K#3NY0IY^<F9U^-T-;S%R5'T^%H<AG=QE,KA\;?_
M`.2/L:+"4&>Y)O(H*L;UCJRP>I$(Y@7#:NY'5[YGY<XLRMD*PADW=F*%R)+Y
M7IZ;1<C;309_/;^RLM=<7&BH*6UN9,&JD75KNK21+&-J`.24JJSLQB-:IR.K
MGV/`'$V_-OSZ_)@NUY2I,;F=\*3-L4C:7-86RM+2DSL^,*6,*T4@EU+#816H
MT-I$DDCRVF"Y6=-)(UBZ5\0?.:$(;.9&UX]D-T(]15FXQU^IX]_QFY2;864D
M^2C9:VK868CV5C<3I$N/"$$$D\^21[%>8CG-5Y'5R7?R'\X:C)8W!ZOBG.:W
M&8*AV-!F,UKDFZFJACWPPBUMY*#?RK%]KLKAC3*2]EN-<(^=,>V2CYDEQ6J<
MCUU:M[\,?-FBBT0K+&W/[CF:WD&JI--%W6WA:V&#D_2U6SUYGZ6-?CMITZ5K
M:6/91CR"&+`F>PD9PE.?V-.1UDBD^<>)Z//U6='26EI'K.11<MFM-'J-+H]'
M?\C#C/A?Y5JM%<VLRWTLQU>K8OJF%+&9#"&,P38X1#8TDZQ;G?@WYHR$;/U6
M4R&@SN7HB5CY.*J^0MZ+%ZUF>VEQR#DXV[S9-$6OV43(ZN]D&KQ3VF8R,HX1
M$+!`",-JO(GKJYJ_XV^<:NS2ZA\<0VW+>+<QP\*U/:7<R='QN)E64W'%BFF6
M)_Q-=ESVQOP;\2,NX[/6QLI&!"T;5.1U02_"OS5&KIM1C\3/XLJ[:GJ<[>5W
M$.KT_&-;H:&KI9F:)5Z*LQUK55UZ.ZSTML.P-*$65,%$B*\JDAQGB:KR.O=E
M\0<"6A_:6#O(XJX<=N*A0>4N08<'BTH=3D-L:5Q5'%H43`GFZK!5$POX"C8C
MX:,8U@B&81IR.JW9?(O$E_*HI.JE\F;`5+^T%DUNKY9Y!O*?3V.;MI]WE+O6
MU<S0/A7M]E+&Q>^#,(Q#L:*.Q[B,BQFB:IR.K8?\%?,%I^\$V^"E\KSKVCML
MY86O,&ITW)]LZHM*JNH1#C3]E:6QX=G245:V'760E9:0@GD^N2CY4AQ6J\CK
M[(^%>`I?M))%R8>6&ZG:/-6!>8N323L#?7'(-/RIH+CC^0_3N7)V.EWU!$L;
M`T5&DE$%ZWKZ7D&YIR.LE8/YUQ7'.RL=OG-%RFZTNS!G:&NNN5-Q?YK278<G
M1XK_`"2]S=O<2ZBQT):'-PF$EN%['F`AE_NJYRM4F=4+/?)'"^=VU9R$*OUM
MSJ,]9`GY&;J>0-KIV8N)&30J'.Y2/=W<T=3E1EU,Q[:]/*.U7":UJ#CQV":<
MC$:MN9\(_*T\-BDWBBLDV=E/GS7Z@UE=OV<$%K3W]!:4=/LEL?\`):;*V5/K
M+8!ZJ+*%7E2UF.<%7R"N<U7D=7)I_DOA_2::-M(PMKC-=%'$`+1\=<A[+"6C
MHT//Q\NV*8N<N((SQSTD*,(S7L=[5BA<[NX;51JDG5P9WYOXOSF[L>0QQM-=
MWLVMV%1"BZ[9ZC79_.5O(MG57?(D++Y[0VEA54<7<7-)$DV`@C03GA1HFB$K
MAN:2>FK4Q_QSP7BK*AMJZGU5I-Q\G,?X*35<@[C5MP5)C"3S9?'XP=]?3FT6
M.J36+W)`'_;D>N.TZE;$BM"TY'5Y\J_//&G,EG5W.PC:6/:UU)<9*5/R.TU6
M)E:+#:(\&5H<%J3Y6VJB:#'W4JL`0T20KO!S%]3AH4R$:`D:L+_P6?/K[.5-
MD9J^FUBV5K<4>-G;C8RL#B;70Z>%L=188/%ENES^1D:;0P6FE_A@&WUFD1Q(
M*-+E!,U7D=4%O\?WR<RF'GTXO7]H'"%7LBKKMJYWXXM)$UC>\M="LUQENH0W
M.(I/-P$4"JH'.&K3DTSJN@^*^`(=I&FP<_HX%4RUJ-!:XJ%O=I&X^U6ESEG^
M\9?3;#$CO$SVFOLS8,`2'(E`(YOX4)'^Q($)([3D=7'G?E#@?)NVA,YC#4Q^
M0N*./>%MA*KM-JX<VWP7%=-=9["1OSHUV*9`T%'2WQHS;F*\%N48HZ$DO6+&
M435.1U/97YHXGRHH*MK+O26<7>VO)LW0[74W^MO]#MKGC.?PU-N=-87,^2MZ
MB\7V#J5D<[7161!C5!^UB$Z:2=8_A?#O`E?!'%BQ.0&3JF/GJ[!Z,W*W(<O5
M<34F2+-)FL]Q/HIFBD6>$H:QMB<+XT,C63HCTBS?R8PQ!8U7D=5P'QYP=71X
MQ**ET-#I*ZP@WE1NZ[:ZQV\J]+!S6GR?^2BU,VXEVDVXLZ;9VC+)\I\AEH2:
M0DMIG^+FM4Y'4SRE\E<-\U7V9O>4(6HUXLW0/SY,W8[+0CR&C8V-,C5]SI<U
M#G1JR=IJ?]SE$BV(F`E,+(\G/?ZH_I:`D=-2,OXZX8L,K_BDY.0)07WLW42+
MXG)^[;KIFFN8&EH]-H)>I%>#N#6^LRFNG4MD;VHLBH<**GB.+%]+5>1F=3--
M\><`4(=+#K<?+#5:4E$B4:Z72/I,U`S^[;R?#I,16.M/QL=02.0T=;R8=>@`
M293O$C5"P0F-4Y'60MGP;QCR"7?FUF<2T)RAA:+C3<O_`'&SBNO,)GINNFP\
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M*9[3D=;#0N.,C!V1.065Q)&R-C*/`&OYTV9-FES&=L+VUK8C_P`DQ!))2?I9
MI#2&M0YU-V(]R-:C6J3M&L3\?_*O%''0L3%JEW5[7\:&"3CJJW/(NSV]7APQ
M\;><?AK\Y!TMQ8`A5@\AH9$-`*CQ^"#=V\Q,<UH6)U#T7R9PUIL=A^/ID#60
M<5@L:SCB!F:3?[.FI[[CEH*R,_"[2'`NPBU^=*"GCL5LY#'8QKV,*QACM*TD
MZB7'R/\`/NAK\53:#CZ'>T6`-H#9_/W-C;V>?(W3[>EY)MXM[2S9YJW35Y=S
MFZ^R'&L!R0!D0@JQC48B=-.1U+TWQ]\\9ZCL\W1\?1:NBM+S(W_[5"M+D$*J
ME8/66&SQ\+.@9/1F;HL_=6ATC5\%`0A0W)%021FM$C5>1U<?%_S_`)KB&)FJ
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M<6BLF`>ZX/\`XK#^P]#L=MX/37$[(FE'YKKSSYMY)L9=S<2;@YZ^#(*MD6KD
M.IG[Z).B/?Q]9EM^[(*5S/.P@*T[WJ4CE)[AF!5[(PK6L5A%"@$C;D.7I$'[
MY>.[<S"-*@0-OE3MKV/[J1[FM:]K7+DJI/(H>!R`P_X9B^U?IB;*X<GD?-3_
M`**$%=;AF#,&1$G<:LKX,-7?E6`GLU6E6;-6CNX[Z0<$S1,`M@(LJS8@4.%B
MG<B+)[<+?@[R00ZY,D]!_EI`Y*>4]3P(5#/$GB-0^]E3^HX@!!J?!XJ.K#[Z
MWDWIV#TPI@+Z@+6CB'4<R!J]X<[DW\/&T/'1;:]A+D*24&K6,&XS\IDB*]UA
M%GQK!I(L6(\2S%.62^(9[E<^0U#.(G6`]?:_4NO[D$K?UF!:2KB#L01N3],!
M0P&P4\0-;6J[OWI8N'V0V75?AJR$@/69'F#!I`!'/D6*$F2XY$C4H6XYWNH!
M!Z4T[5T=36K$CP+V@K]/BJNM-5`6F>";:&D5CZR?7QG$81DEA3.?W>5GK:G5
MXI[#38#BA:KW:25<I:S<CRD*`W($P01`C8&3J)LKW?E5%<\ODXM=?$+96MM"
MJ4'"&8E>+*"00P)G=AQ&JIMXG'#.*+.1:P<=DMXD.L2KIL#K-!L$F>C2YT$4
M5_GC"O\`,96AF!DB--<"]+8,,Y@V1O%R,6+!?N1[LJU-==@<FY-;6E<2CD\'
M'!['$$+-02));QUD=VK[&/;MCY"8N-WCBO"O'NLNF+:P!9619536P(+E<@V!
MH`K@QJ^,UB>.M5R+R#-U=G30)%1B..`TF3H.0H&3JK@%E(US[.:G(.KAV]="
ML62(@!MJ^XY+V':09$(!KVX.3F]RQ.VXZ8BNRO?=RL>DV,I45\1Z-94D02?4
MW78@B&@[?`[5V3N/>\VWN-E2/5B8PKIKR5I1PQNY-^)N5U5I"CTMF(8,IY("
M,36USR-Q#.D7&?Q=7QM,#5R_VBZCT)=V>*[\%8CEI-U+2^IC282.8X1H/J>1
M3/[#7]&-VU-/;>\5BG(O?)0N.2EQ4#O/FJ'!@#XAI`@;^)YS)RN^>VKFR<+%
MKP;16>#BLY!'EC[O(/J(2NT-7!/(^4[`7/$Y8YV'8Y699Q+#CMMA;ND1]+^+
M-A?Y"ZSGM#<O_>[MQ)(VV*B9&6.*0U@Q#$-S7%&B]8K]H[":[4J*Y/%(*2#P
MXCR^5=O+]4D;DDR`=9]?N+W>MV/;D*^$'LD6PR^IS:'/.S<<H"\58``*I!8:
MQ8]JQ.?HC(\F20:\IP\VUSB"CR;.(VVDT989Y4Z*L71,@1))&_L`P,NF,572
M3O(JKUM@>?M\E@`?PI?XA3Q#2`#*20/O2?3/\J@:Y\CTO>2A&8K_`%`5=0"X
MYFLJ2PBWBI/_``X47@?6Y;?5T\]QZ^))PDV.V'(F3<YJ*ZP",%C32IE+76LJ
M93Q!:EKI#N+ZJ41[U_#5_P#S7D^.YO9>R8GM]K'6]&D(MB,#(8!BH#'T]O78
M;>:/+LP.L_WBE-=F':G%K7HM5@`R%D5RR`6[_A4)GR3Y]T(C6W7RM*61MFR)
M,H=@A_DCS-$%2_X\X!`\S4$$(A4#O6E:R/'CB8K&J@VJQ$:B=E:WD/=:\<'B
MH*QWC8EN<SC.?K_FDDF>N^_Q/I7Y>6%^Z\[&#AO;>X">G!&;6H'I[<8``CIM
ML/`=QNO"M?6FG333IIITTUIY]N(V1P)RI6M4;I4_B;9M`%PWF<5$OL''=V"-
MA'F&A)@T<QK7.=Y(B(J_IUV7L:5[_B6[\%RZY/3^2T_V'7F7YK^?V?W&@1ZC
M]MO@1,_>8XZ"9W8;=3.VN5_+?`>CGQ_WVP-1Y&5:U%%%V%-OK=:FPDW5'`KX
MU/?RH+$/I+>KB4]=$<Z'5BKB?NBD?)<YGK:WU;M'N#&K;T*Q9<JNQK:I>0"L
M260'9%8L6\SEQP@)O)U\\^X_9^=<GXNXTXUEE58N3(?@Q>M5"6%=[7145)2H
M5GU>1L)'$"I;.=Q)GLGEI/+<'1<F)>@@SO30:&NXXQLN;1QY9IHKG2V%S'U[
MQCH`/+,A&@-#)&5J->_Q>4<>%7W?(R[5[0U>+Z9(\Z-=8`Q`'%`IK^LPK!Y4
M@[;@&?NEWMO"[;CV>Y$OS_6"M%=BXU!:L,6#VLXNVK!+HU<,"()@L,@9?GX-
MQQ_.IN)\-@^)F#+%J++,PX5;J&8[4VXH[<?.LA#T`(U]5DJ&O,=%1PRJUH6(
MJ#=[-?E>WS3W%;^[WY&68+!R2GJ5K/J!?(2C<H`\1N3UVW7;_>29797Q?;F)
MA]M`(1JE5;?1N<#T6<"P"Q.$LW4&`HV4S@<_*NUW%9(SNV+H@1O9*"*@KZZ.
M9(JUIJ^'GKVIRM)=!B0JO0R1_D`5]?+_`#RD_'<BH9S^M\O:<+!M&1@BLMMY
MR2)Y275G99+(-CYUX`<A],:X]_<7=>[4-@]V-ZI)`K508XE5JL2JMPJI8?,L
MUOZA/`[.3K$8\+HSVUGFY@Y`IXX%BP$"*3VM]0H\J;.]KR!.P577PW?N(3RA
M!<D+^^9J.6:PFX.?C+4N2A!KY+)/V@".GF)\A"D^;RK_`"$<V.T9SY-F#:&%
MP1H4&=@"S3(,*J_>*S@'AYW$^J&K=A&L[6JXJ_`/!N5J.(K:QGQJ[-2JZ>"N
M+%X]"PEJ^+Z5OX4684;D?YJ)Z,13N&XGF+'K:JJ[+]0,G/,4`EPP)F[Z9^@D
M3M$B?+,0<NZN_(Q^W>BR6^EVUV8+458*1CB7B/44,1O,&/.03*RO'_[G6Z--
M#)TESF8<20\L.5^5+:MS=1Z.PMX-%.DYL:/:R6:$^1.&%7*"(Q1"8CYD=@[^
MX>E9C?AUJ2UV&X@>52P4L`_P!`4GJQDF$8F/LWXBC._&O?;14ID&3Y[!6SK6
MQJ'B5+6!9XH.*B;4"[&5'..EV6\/`?F,],!G)(&;B[D4=V.YGOO1/DXO&4FA
MK$A$LBT=E*,Z:DD'X@XOM`HW.)YNYR[L6+A=O%GJV*U@/I*&7B..UEC(T\>2
M@<>)Y%H:0!`[;&]VY_=.[M2<>ADH8>NYKLYMZ@FBBNQ>/(UL6Y\EX!.2<26D
MT+F[E+Y@T.CS\_DGAC=0-(Q8F@TNNXOL*&#7J=E@$USG+S-:@'[!9!",+"S5
M"*-*8%7#0_L&]73]C[5[HQ\>Q.V9M#8VZ)7>')Z0KJZ'FIWA9)6=^,$:Q/=?
MN'V#FYM-O?>U9B9PXV6W8C5JL\@7JLJM'IL``"_$*X65Y\@2;<YTSQ-VW+0\
M%K*]T92V>FM(6P=)PFAHIV@EBB5=?9UDBQDY`P!0'H[\"58S/`<CQ((:/:WK
M)[#DC`-K]PI;E`137%J,$!+%6`%@,_SJB[B03$ZPO=V$W=QCU=GR4].7M=;I
MQ[*VL8!%="QI("_^6]CP&AE$@:S]QMQ?L>/]]\TT%M132T>-Y.JAOU(YA[3,
M+>Z!-,Z779RU$UL!\6*[SB`B(C&Q@`5S!A0C6OY[N7=</N';^YY%5BB^[%;R
M1Q?@G""Z]9.S%M^1.Y,&.R[%[?[IV7O/8L+(I8XF+W!/O0Q>KU+/5Y+4X\L#
M=%38*JDA5D`]F<G_`.[5)_\`2Z-_\S3KQ;+_`.9?_>.OJ+MO_(5?[@U</6/K
M-TZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ
M::=--.FFG333IIITTU2+^ZAYNAN]%8^W]OH:BRNIWH&I3_AU<,TZ5Z1)V4I?
M0!WBU/\`B7].FFOR0?\`U0C[0LOG7@;^2GD+^3+YT^4J?Z=W^DT/SU\3<N\)
M!F?/MUP/CM^.ENLMR)S;D<CK^:H_)C\/VLY%M#1@`S9`XP8[6*[TTU-Q$E`"
M8\==&?FS^4N=5<^?2G%OTW97=EE)?W)]?<1\#<D5]#CZG`\?8'YK^;N+?H`G
M'FKLH9:6[L+JVR%K?VE5-/&F'FC@G&8PU&-O35I38$?`:N0/\W?'^BK<78<5
M_&GVIS9(D\'<5?1_-='Q3QWCM/HOG3B7F\$RWXID[NE9O(\S3[K98Z'^_1\W
MFFV]HVH>A7,1Z.&E=/3/B1UU=VZ_F@X1P_*NKSK^"OI2\^?>+^;,C\W<T_8U
M9BL^#@CB/G/9R<S6Q<3J(UOJJ[DHT;,WFSJZW06,:B+%I;&6T!E5R+U2=/3,
M?..FN+2_S!_>F;D_RL<<7O(]!9\D1N7['C3^-Z2[C["!?06]?]I7'REI,^2%
M#SPHF\D9$.@I;0CK5L]_X\=2/54(_P`FK^"^4^'C^R=;4?.O\R6IXXX'XY^@
MOJ_><K<NEJ_XQ^$?I7DWC7CCA[B&MJM)K>4/L2Y^>X_(V6TL6\R^@?LI9942
M*;,MB1:,==&_)`5\TK@JG5&3>!MO_9K99_\`/CQ_2:G<9CD+X9^X.-7<*\G\
M7<??2=QJ<;Q@^G^>:SG>SH*O@_8[T]-RA9GGP^0RZ2,5L&I'/G00>;S,_P"[
M0B=6^F?`C5^WG\[GR=3?3,[YX%FMO95<3GX_R<'ET&GX8AYJP^DVR"5,/`P\
M#9\H0^9TRD_7L;GV[$N<%EAW3T$28V.CI*5T]-HGY3K5GY2_E:YHY"S'Q=M_
MJ6XV_!$;??1/W_E=H:+QUPE;<;\K<<_-V:YGU;@Z:XK]W<[3BR)PC2X5D.=.
MK(9)=]H:HR#&6MD-E.IJK(`2!OL-;;9?^;#BV9Q7R1S[R/\`)?VKPS\_Y?@&
M\^F^..9-SQ'4R<=S5Q'33Z6OBR\U)R^NO5Q>LU3M)7RJ>HU*TIY]=)_+1S`C
M*YE=4],S`(F=;L?$WV+$^T./+WD&!Q'L>*85+>Q*>*FAVW"W)%#JHUA25]_%
MM\AMN#.2^3<G;18\.R&&:$DF/*A3FO`07DQ5Z:M9>)UI[]N?;W)GR_\`?ORO
MB67<HGSM:_(?WI]`\TX*JSV8G7^PE_-^&R>QS*TE]<@!954^$`\U@@BG1(LD
MAFI(56M16M7*H92?&1JS,/\`SO\`SE99W=['F'@SZ;^;LIG_`)4S_P!F\>V7
M*^-R!9O-_!NCTN<PU99<;TN*W.IL'Z6VW>OJZVOJ[%L&1._<`2$\`/\`-&AK
M/A!WC6\WR']D7OT_/Y!SFU^3/J+Y0V?'T?*6YJ#Z&Q%-65NGS6WCV,K/6N2V
M^+T6OQ-O9`95E9;5'YS+6F.K&20-\VNZ:M98\01K$OV#S1L9/V)\(?&>0NM!
MF*CFN5S=SWRY;Y2S+0Z:_P"./F#.YJXJ.*Z:^%(B&JXG)')FUI6W)`F`4U'7
MRH:D:&:54:JH\I;7''._S!?<4[-_+NSO^'N1SGUO\IGTO\RZ/C?"Y+A"XUG-
MW&F)J^>!9#A[(A7:V$3/;+C'0Y"HA:._DSJ:%(+$D2H\V1`]I%IJ_@-]_#6^
MM]_/5\VU'$W#VP!Q-RVO+O+VSYTP+?G;5WO"O%NTX_TGS/H&9;FT'(.YY2Y2
MR'$=+&S5^<$.`H[TY[N5)$*&)[T,@:ZM],S&T:W=Q_U'9_;OP1*^D_X^[F@E
M;/E?C33R>#I'*H_V2MSW(]=+LLU(I.08\2%K0U=AD=75RHDQ&1[2*DB-Y,;*
MCN:I&K8XM#:YN<T\[_R66//GRO\`QX1^6^-?GSG'Z5TGU?S7N?H/&9FBY<+Q
M]\I<.6]4#C/)<;Y_89'*Y>3RCJ8FDB1;2190)[8!(Y)0WD0R#"U<`L%NH'\=
M9Z%](?47\<?'5]0_<6S)]QZ;D7Z"RW#GPE_T-PN=S'TM]!&UV3D7I,AR=A1#
MQ'#^7N\=)I+$IKR-8!KR5$9\F4@2^L96D!CY=A&^K<L?YR>(X6<P42+\K_6E
M[SWL?H'DGY5N/EBCR?'\OFG"\^\<<=1.3C9#1`/R)$R!Z'292RC38%]"M)-4
ML`KI1BB$$RL:>F?B(B9U.1OYN>+P\EW&7U/RM]58WB?&?5`/C#D_Z6N*#C>5
MPQQM]`6=Q19NCS6@ET_(UCJSTTO1Z.'"EVD>L)#KCR@(9R>UO33TS'43$QJ[
M,3_,SPKM>8<=D!<%_1E'P#RGSOI_E[A[[,N\ME8_SWR;SYE+#1TLC%TIP;"1
MO:ZHOM#D+.MIKN=31ZVSGPWC8]K44B-4-9`ZB8Z:LC%?S;9#D?YXC_2^/^,?
MK%G&FBUM-B./-+NV\&\78O;7#_\`/&[:Y?R1O>8J3!8O!<?2\(2#)N[N?!BV
M5I-!$K6RR^WUM5-<&"1K"6<_F3W'T1]#_$*?.G%/(POFWZ(X)^Q+_D0MK7\-
M2]9GN0>`-CF,+=7%99EY--6V.?X4L?RIEBM>:7&TT.ZKWU:S/7)8&FJ^G`,]
M01JI\3?S8YR@^<^!YX>*OK?[@W@/D7%?67TGO^.N)^',;>\7\.:J1H@UG(7)
MV+KN1ZO&UVMOXF6L9T?+Y>1:270()#L1&>/E70U[^`$ZR9RC_/)\]X"[W4G+
M<!?3',?#W$^)^:>6.6/H3C7-865Q9@.'OJC+5&IXVWUFZ_WM%K)JK%NALDU<
M:L)8C0$@GK]8'.5JGIGQ(G6S0>"?N;D/E+F,6_\`JE:OYEY"IN<X?&M'QU59
M[*\H<=?Y.;BQ>`=#0[O/92DT+;OC@U+J)Y%DSY()@;*#'F#FJP_K?PU25`Z;
MZOW^,;Z9VGUY\.<$\Z<E1Z\/)=W5ZO'\D'J(B0*6WWW%&\U/%6NTM+"8B!A5
M&JO<8>RC@'W'''*0355&=-4<`-`Z:WTZ:MTZ::=--.FFG333IIITTTZ::=--
M.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::T<^R(=
MU/R4:+GHDZ?=/Y(XT?7PZV,^9..8$+7'<V/$8URR',$)SU:OBGBU55S$3S;W
M7LQZ*\LMDE5H_#726,`2:QN?#]-CTUY+^9]65=VU:\)7?*_'8O%5')B0MQV'
MCL)_M'4<IN2^(KZEUH=?9SLMA9,N\D[BNJ]-=EEWU'<3I"SM&$F:JDF;"QL9
MEI*("(4SOV^)7>A`QVF4R#]9[9WC'OQ#AUK;>HK%19%`1E`A/.T5@!0"P'G9
M^7)BO&?G;OWMK,Q>XCN60^/B6-:;U2VPM96['E:#4G*YF9R50L?32KAP0-RX
MW7R#L.!JTU5`U^$U_,)HT8^HIZZ=MJ_C3!6C+TL3]O%'AEO%O=JLW6/0(A62
M0C`*,_<8_(8BXG;\/O\`8'LP[Z<)20C$5&ZU>,S)X\:HKW)3D""NYW(V/>>Y
M^S\=ZZ>YXF3W-U4VHK7KBX[^H1QA39ZE_*[R@6\&4AY42JM<UKSQ.V>+AQ..
MZW"43ZQ+2)6TN8I(6HKH:@`"7K,H&LLK']F_-L&>42+8FB3%&8R%5SFR"$7%
MJ[`F%G,W<6R+`W$EG8H3)(KL+`<H'U,@99`C^4#6?D>[[>Z]J6OLM>'2:^:J
ME2+:JP`UU(1FX<FW1+&1X9N4D.S:PM9Z70\GY\/^0R[]EI`F'G4]'9"L[:/2
MSK&+=V&CRMP"AGV`<TE93H&,P/[<)(@([I#7#<@FINZL;'[7D'\,*_290&9>
M*E@"H1U+@<^32Q/,\B>,$3KELC/SN_X0_&M<,A&+)6P=PC,+&MI<5LPJX)Q4
M#TQP52X*GB!AF1GYTZNOSQ'-,2F/4V4YIWPXAZDX+VOBK)M&]Y$3]P#((D/U
MQ4::1*5J"$UD@*!W2Y%:65JX@.&`B3R!4F%Z&(\TML%F3*MRY=\*VVBYZS+5
M%&:>(*$6*);JO($\(2&9H"J`Z\;WVU!:W6AWUVY17$.+0\?MGS:>D%31:N78
M3M=,B`GPCQXT:/9V(F."&08'@)QG*TJC:5A,'!R*J,;'IW1S9=`9BQ8`5@D$
M$DJ.I`.\"1,$;7NN%DY>;F91BVI:<?DR5A`A9KF`92``S"0K,L`L2&XA@U?X
MVL+#)63]'&OS4ME*-XT><;,G)5SY4:[H8<R;/6,UCK&NB"LQLC..$C9DGUJ9
MJM&94Q^Y55Y=7X9JP]0'F>!R`*N0!/0GB>4$<5GCN1K-[%=?VW(.<EQJO8_=
MU<FX,0]:LS1]2@.`O)3S:"^P8ZR_QSR_9W=K/NI>-Q$_,P[^73L8_+VM-*TG
M)$,M<FKTDU@Y4BHDT:5+`/$<\42S)+/8B-49.^G[EV>JBI:4NO7*:L-]:L$I
M,^F@V#!N4@@,>*F/$:Z7L?N:_+R'RK<7$?`6YD_RG0VY0*^M:P!*&OAQ(9D'
M-QR$0VK/T&V^59/*L>V%QARCAKRLLIT2FTG'<RFTV1U\^SCVD&CN6X?0SJNX
M(X4Y[HT5]7*A*V8C?(+$>Y$S,?!]UKVHTG*Q;Z'4%DN#)96%*EE]5`R]-V#J
MWEG<QK69O=?R\?W$N2.W]PQ,NNQ@EN,R6TW,X=:W]"QD?9O*AJ>OSQ*B2-6+
MO^+K38\CQL_D-KA=+5U(Z_/MDS]"*B>.+(86SN)VFH-))94SW17O)&9(K4L9
M8_6UX"$>-%ZS^W]UJPNVG(S*+ZK7)>`G/<0JA'0<A.S$/P4S#``ZU'>?;^1W
M/OBX7;,O$OQZPM<M8*X!EW:VNT\&C=0U7J.(!1F*SK<KA6FU-/R[L(U]E=-G
MZ>%\ZRJ3(3M&R<\EY1TN\XDACL$LI/>/:6,]B#FS"#>=S33/%Y5=_0/B^]WX
MMW9Z7Q[:K+F[D&L"1Y6:K(,0-U4;JH(&R[#Q/J'M7%[AB^Y<JO,Q[Z<5.R&N
MEK>1]2M,C#4-R.SLVSN06AG@L3L.TO7B>OJ?3IIITTTZ::TU^X@L'P)RK:+(
M+%)`X>W@V2`H1SX[)%[@)#Y0QA5AGFC.KVN9X/:[NGZ+W5%3M/8I)[_B50"&
MS*MOC"VB/AO/CKR_\V5`]G]QR.15D[7D"1X39CDF!O(X@B"#KDAI-1J]..5'
MDS/=IP$=)!,3S-;VE;#$L&=4S+!'DD2["%^&_P`3F<?W,;ZGN(\D1B>O8V+B
M8I#(L8I$$=%4G<,!T`,C81'40`YU\VYV?W'/5DL:<\&0W5V51Q9&;<EEXF&)
M;D/*2Q:I=6GG-&'5KH,Q8R$OJ;55D2IEDJ9?C;QRV#RSJF\KI8"O!%L8\(3G
MB'W\'E&1KE<(SDZS,G&.)Z>56/3OJ8L.0\IC9E(.Y!.Q/P(B"-:[!SE[B;^W
MWMZV+D5A#P;S@M+)8K`P&"B0.A(8$E6.K2+)TW$VQNKMX+*9`KXNMV=Q7UU+
M1Z6#KLQ?V]/39.*N@I'0+.,PPI@9,/L,AQN&HI1$>!XTRPN+W?#2@%18QKK4
MLSH:W16:P\&E3T(;<`S*"&!UK6?/]N=TMRB'>E%NO=52NU;JK'1*1ZE?%P""
MK)L6!'&P@H1K*UWF`265>TH*^M--@5]/#L.V;GV=KH..<KZ]-I<0Z/7FBJNN
MA7=<($-PB">R3YQVO<1K5ZU-&4RE\'(9A6S,1YPJI=9Y$MD@_=E22T@@K#1$
MZZ+*P$L6ONF&E9M1$5ONF9[,:G[VVB%(^^6Q0J000TH"2!K.O(N7SW''`<:V
ME`AGVVRQ<L<*49@Z^_H:'0H;13<%*J23S6C9UL.]*:Q[A&@8R_AL:UZL8NA[
M=E9'<O<!I0L,&F\2!NCND(+0T!87B`FYEO.3$G77][[?A=C]G+DV!3W7*Q2%
M)A;*Z[)M;'9.1?DXL+6^4!4^Z`!@:UNQ]G=4&C^9I4M+J>AL;.@K'V06.RCZ
M:;78$4@,488Y@DIYM-[12V/\Q)%<G_$[LU>ES*J,C&[HB<%BX&:S]YR!M@G?
MZ@T%3L>7RWUPO:\C*P\[L-EGJO.*RQ>/N>#+C@@``C@R2'!D<2.IVUGSG[C6
MRP5GFA\=QG5U+LVR!9&CO+2>R%%/2V]O?\@V6@.2"9X)6:IM`:;$DH^-^:"/
M#<Q2>'B[0>W^YU=PJM/<CROICU&51)#*J5!!.X=D"L(/$EYB9'8^\NPY'9\B
M@=D7ABY4BFNQVX@H[V9#6'B8-26,Z-*\U6HCE$'6_=2A<'9FGR.36*>>06[J
MLE&N/WC53[F5`..]CZP@`1%_(F6$AS"PB/>CHR`4@)+A`()W28"GON4^9ER*
MQZ36%>-84$<37).P`D-\9AEE@1PW=[%]IX%7;>W<3<1D)2'YW,Y4BP70!N6,
M&LDRO&4<JA4V[QQC(U75CY6MX4`T);.COLB"9E!QH.SU>JQ%<NC/,MK$LN3(
MIL_/EAE3U-^,LB3Z8I4*U)7;)[EFM;:>TTLPLXLEA%DFNNNUN`"B`&<`JL<H
M66$'AK"['VNO'QQ[BR40U>I792&IA;[KJ%]0EV))2MB'LGCR;C6W(>IJ8B0+
M[0[:PD.O9JP1#72VE]-FRRP:>C.TLJ?=6`X@FQ9$AXB->C'N:V5-<&*CT4[5
MZM>S'Q\%5%:\R>"H`)9AL%$[@>&WTKR:/*=7UTYF;W5W-S>D!ZKV,S%4K,EG
M8`03$&"1SLXUSYQK;?A;2S++D+B"E6QF5T"!S;1E@9258S7C2!$B6D-\DP&_
MD5MEHASI;7SY7FQQ3.*@W.%'&UW(=[QDJ[=F7\5:QL%IL`'4E3`.S!('E7P$
M2)8D>D>UL^V_O7;,4NU=*=VK*TEFCBJNLD;JUO(S8\B6Y02J*#VNR?\`[M4G
M_P!+HW_S-.O$,O\`YE_]XZ^J^V_\A5_N#5P]8^LW3IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG337@HA
M'$0)AL,$S'B*(K&D$41&JP@R#>BM>Q[55%145%1>FFOSW\B?P(KIN+.2OE;C
M[^0'Z9XE^%.0+S0::#\F4V8XGTE+A+#1Z$FRF9?(\FZ;,S.0(/$X]B5T]N:4
MZA<J^MYW-5_FU(+-Y@<M6G]W_P`/V\Y&X7V/S]P(RTVK_JS^0BK^K^3^9=-O
M\]QT7Y;H9V,QW&')'^+4E;42+_DN'K^(ZV[HQ0(Y`R5-<.=((L=O9&JJ\&3X
M"-;E<S_Q0,U7,M]RW\U_7_T1\2BY1XTXKX?Y^R7`2XIL/D["<*P"T/&I\]>:
MBAMKWB7>YC(R2TP+ZD*V2RN5K&L:]JD<U:'V@@'5F;S^&#';7DOD!P?J7GR@
M^4N:^>,C]/<]?'$46(L,)RIS?D[#+7LC03.1+.@D<ET.;W6GQ-7:Z2HB34%:
M3X[B(4*/\6M5]3;H.0\=2[?X/^!I',?#G-5SR9N[C1\,_5_UW]7T\(]/EP5U
MU??6-G&TDC$W*!A(8N7XMV%?%M:5S%;(?(#_`'G*CU7IIZAB/D/W:LA?X%N(
M'</57#R_0'*G[;5?''!OQP.Z2@QG[B;,\&_58/JRIVI`K!6*FBOM$!*F4%$_
M%'`7V#:AOZNJ1IZAF?GK8;FG^)[CSFB7]YR[/E_?4)/O/>?)>]UR5E3FC)Q[
M-^2WY!^;@Y19<5ZSXVN7("_/=-]CP^YWI5O9O:NJ!XCY3^_5M9G^(C.<>_4-
M_P`W\8?1N_P?$FSY^G?3FV^<HW%7`&DK+GEB[GLNM5'J^8-AQM?<LY;C38Z`
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MZ]CDG3ZU(-I-L59*/-0`'12TC52X;J/#;6T_UO\`QV8GZWYDQ/,FDY(U^/M,
M3\T_5_S3$I:"NHIE=.HOJ_$U^)T6GDFLXY93+K(Q*]#P!,<D<Q7*AD<W].JZ
MM5N(CYC]VL#<C?PP\#<N9_#Y'D3D7D>VS6)_CPH?X]XT:L2BI+4E#E=GQQO\
MMS3`NH\$YJ?DS.ZKC"OEQ6#&2M0GDCPO9_2K5?4(W'QG65>%_A/Z.XS:EMMO
MY,OJKF79RN2^']'<7&MI.**[+3>+>)EM4E\/5W'-5DTRV>'RH*U[:O2Q&,T%
MFZ.!S#A4?ZM"P/@(UGGZ1^89'+O)7S1SYA+^NR/-_P`N<@75YCKBYA2+#/Z;
MC?DRD;B>;>+=-&AD'+97;'(N%*@3`^1:V_JJ^3X%",X#-4!@$'H=:3<7_P`/
MM-QOREC-J7Z;Y.U.(XL^Z>4?NGB;B^TQ^"B0,3K.9L_RG5<B8(NIKZ\.@T.7
MN;?E$UB(TE4DQ20QC'V80ROI&JEY\/"-67JOX/N/I<:BTW'?T-N^.^<,?]!?
M5?-^/Y9F\9<.\GU\2E^OMD+:<F\2Z;BSDO*:'";'(0+.'&)4R9(1V,&1'0S3
M>3R-=75?4/B-H'[M=7_G7AEGS[PQ@^(?\WT7)4G'51(ECO\`75>-IM+K[27-
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M/R'S?MOY/>1_L6D^0<I(XSM^-N9Z^@UN2VO"F^UNOBU=AO\`,0[*^I`FNLRV
M8%DMU1%<5@']WO:N+B``-XB=;'8?^&7'8SE3!RB_3W.&C^4.'?HC2_6'"GQ;
M;5^";QKQWSKI+;2Z0=JFYB9X/(VCPV4U>QL[2ESTN9^+"F2>[R&:BM<U3U)\
M!,1.I#4?PKX:R^6OB;YTR_T#M,_=?"NVU>UXOY&TO&?$W*E7I)>V_P`P!>CW
MO#W(F=N^,]#*APMB5*F42(I:J4%D@7=ZN16GJ>8D^.J5QC_"A5<-M^5C\>?6
M_+E;<?-&G^L9%C=V>%XPM97,''OV-L:K;<K\?:Z$RE@T]&YUK4L2):5,:*>.
MQR^L3'-8K*1H;)G;K'[M6U&_@JIL5@,%AN"/M7Z%X&>/Y2R7Q?\`05YC,[Q;
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M`7AKJ0MHV#,F70U#!:X92HU4F=S]4ZZ"=-6Z=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--:0_85
MI84V7AV-382*NS%R3QF*!-AD>"6.5,A:Z$)L:2Q6I$(59'C[G*@PM57O[M:J
M+W/LVJN_*-=RAZCC7R#N(!K.X\>G3J>@W.O)_P`S<B[%[>M^,[5Y`SL4*RF"
M"RW*(/@3,<CLO4["-<@=/J;"<DC0RE'*M*^*]MY:(=U<Z6*08C8U]X"3T#EH
M8"@E@5HW,FC&0;7`D&<+V+%Q:ZXQDD5,?*L3$=5^,094[RI()Y*L_-&?W"^T
M-FV0V0B_>//&028LVV!D<778BP*R@H[%9;*/A;:ALLU;:%P'0K%++*:**58(
M:NZA.`6`LV6D(D-F?U(9`ARF&5%:]HY"^1`]G798?!R%RJJY#+QL0[EE,S`F
M>:$$K'S7HVH^W&KNN&^!DW<2K\JK0>(2Q8*\CQ*^G:"`X/0A7W*[X\QEE>8:
MTGYV]K-(*IMEQ>`OZ-,EGY`:_9623+VQT?[E4`+4M/43X7::-(@8S@D56H7Q
M$3K99M=&=4N3CM4;4]2U&]1P36(4)#'E#`^4\B9'AN-:3M=^7VG(?"S*[QC6
M&C'LK]&LA;VFQK>2#A*,OW@X!2IV#0K:S9/R1P:4EWF:Q9HM;:K+VHZ7,W5I
M<6UKH9)LMQYK<Z>%+"5L:I/+61/DL5P3Q'.*HU09%;HZ\M6Q11E-Q-*15R=5
M550>I=6X((E@(1>H:!.XUU=W;73..7V^ODN39-X2JQW=[":L:ZLJ080GE8PD
M,A+1Y6B^?IREJ>/,(N,S(H@;>[M:-=C+">,A;R56W]!`KYD.J=<6"PZ.@F-8
M,$I44A[%3G>Y_9/+`]KWW=QS_P`;E$FE$;TQ!\H9')!;B)9Q)*]`G%0!K;^_
M<7&[+VC^EX`49-ME?K$$385LK56"<VXUUM`5^K6\W),;R''L$LKZ!VF3UL2Z
MNJG4<?96'H_W\3_W?]+3:EA#IK/\*1'K+`%G!8>!)5CR&F,8%K58=W4G<;`O
MMZC+Q"B759%A3A]/TU3R606!4D.-@%EB94:@[+2S^\\KMW<EMMQLC"I6WU!Y
M_KO*\&XD*P90U;02S@(!#G5*Y7XKMR\E.XO..,/+W=)77-O>DF6]0ZCXWTHP
MTU5*SX%CC&S06]MGEKDC/57#D-E>0_U5S)NT]VI';/ZJLG+1RJK"MRN3S,',
M_0JOSY>(X;^!Q_<7M[);OO\`0'"CM]M2N]G)TX8UL(AK$1ZCO7Z7$[AO4D;D
MC'W*.RA9:A@X_/SLR&ZD4F0MY=#(BZ.[D5V-`:-FY=1#+75H#1KW0N(D>:]S
M!F_'<K)#%0SS-V':L)\O(;,R5M-`>Q0X**#807#&291.J]1.ZGR@'3>X.Z5=
MOPT[9A/0,IJJ7-9%MA6@$5%%*J"++)XN2`W$PX\Y84O+9.'Q92.TT^H_!TU@
MFKS>0HXN=CUCJ[$56EO)#=85A76ED6XNZM3AKO69&BBN+,[,(>,3J7+RW[K?
M^%K?EBKZ;V,7+3:R*/3'TKQ5H+R-VA)(5AK'[?VZKV]B?C[J^&>_K54UBL+Q
MH2VP^L9YL7=.2UP8"<K8#.C:LG$5TF6:\N](^,[.U)F+9&D>$*RFVDV.^349
MBJ=($"`R99Q6M'XO>I0Q'O*C'^AP'YV=8BBNC&!_$N/+&ZA089VB3"G?X%@!
M(Y<AJNU4/8]V7G%3A5GS$^5V=A*5)("RPV@F0A+0>!0[X_,M_:W6\TL&QLY4
M\M/P)H`Q*HGYJ0*V),Y.XP:%N?@F18PZ5%A.CB42->YT5SB(KG=^N!]SX]5&
M!4]:A0_<$);:211?/,C?EO)G_%`Z:]?]AYF1E=WOIOL9VJ[/8`GFXJ#E8L>F
MIV">7B(@RA+;G7<'KPS7UEITTTZ::=--::?<,I[.".4X3(SY*R.'=[*0,?\`
MN3#OAWW'HV1(L9?%#EE+-\6IY-_K\4_\[NG:^Q5![]B/,1FU#?H)2[<GPB/X
MZ\N_-FPCVAW&H*6+=KR#`W)*V8P``\2>4=>L#QUQ4UQ8MM(68*W:B2'AOJFY
M9"_M5Q9@3?MZN!+4<BJN8DFL`CQ/%[*Z:%R*U[F+V]MPU>E>!3IY&6>L==QL
MRD,=P8=2-Q.OE;N;5Y+^JMH\Q%B/QV4L#QV,%'!59!$UN#L2-48@'MM)>TI(
M@@P;$K96I+$0LC]JE)^%-@:CRB2_RSY^:&P,S\D@6QH-L3\1?$*Q$ZF#`U#"
MN)+J(KG;D-P4W$!Q`\H/)JQSW;GK%*,,ANZ8J@4N9M(D\#Y66W8R:V#,.94+
M7<?3V7T]9<%QR#DBMC8Q]3$9>5#RQZ'573SP@&6%HXUI-R-TZHF!GQ,UIY%2
M'TO&5K8MH-AC"]+I+GZ@]R;MMIS0[>@^[UK!B4*BQ>0@N@8S(\R$J#RX@=*O
M9$[[0O:VK49=9(KM>5!XVAVI?@P856E%XD$!+0&9>)<F\OEW-.SYMYK>3(IJ
MCC/&SX>JTGG&V<S1GY0VFF;/H\K51KJ)#F%G%HSUHSAC#\?`S5,YHT5'X7NG
M)_$+CXG;"'[G<I1-ZP@HK2&L8J2(#!R"Q\-A/39_E_@'#;,[EWY35V'%<76[
M7M8<N^WE72@<*Q8UFH,J"(8<B!UQ?R;S([F&VV=WL:E*8\BJD5U)G8[I%S"K
MXCJ<VA!53XK7.>S5VU.>0<@(3IY)LF)(<\8V*Z.7:=K[-_1JJ*,)^:AP6<PI
M)Y!"P/\`\;5@`"W`*K*`2?,-!W[W0?<V1E9?<Z_2=JRM=8EU5>!L",/_`(\Z
M%F*IZA=D<D*)1K<IJN+*_P"AB7$P5..5QYJ2T]E9SY.AK+0RU&&9+#5UXDLC
M1;.+$63*/'8'W""'S145K2"R;KG7\?Z(+D9%?)5`1E\UL<CL"I/%09@DQXP<
M'%QZ[/Z1^*85!L*THS,;$<\*)"*.1#`<G90O(*LS(#+N5PERYA-I3P^"M1/E
MQYM\$_\`@F\G3%H@:;1U@:W\;CI9?FXM<AZV]!&&^9Z+#V$)'03/6'KC.^=H
MS\*X]^Q5!2LCU:@.91&F;H\892Q"RD`-)EM>H>U/<O:.ZXR^T<]V%MP/X?(9
MO3%MJA8QN7596Q5!?C9)*<1Q76GE=F]]R)RAK![&7J<JZ@MJB1O/3J9,")DZ
M;,GT>/M*>D"ZLKI'G:AD5RPHCGB0IS^TA$:(Q"=E9D]O[=VNHX0JM%B,*ONP
M38SA+%9CR(\L/R:#`$`;@#S*G![QWOO^2.YMD8QIL0Y$6E12E1LI=*QP4RX-
M?!)$LW)B`K,;MV`;(8XU#ET'5YZ%7P,[EZ&%:Q;!\*HEGJZ*AB1XELH&V]C/
M++(:3)5"EE/[D>YCG=UP\,UDG(RI?(9B[L5(E@&=R2L\0(`5=@O03K8]S6Y0
MN'V^*\)$6JJM7#%48I76`'CFS22S;ESYB03JRYN4E5DD.7JB.E"=;#G;&T@2
MDKUT&C;+DDAYYKAP3Q(^?R%=5%B2?3(+&F3COD,<X38BMS4RTM4Y5H@\(K4B
M>"0)?J"7L+!A(#*H"G<OK66]NLQW&!CGDOJ<KG4\?4MDE:]E(%=*H4>&*O8Q
M<$J*XV4X?C`K.9>&JQ(\V7<+R3CK.]+&B^,"D#(@WHHUA=F[BBPI-[:/DQ(@
M!,]QRQ9+W(@P*YW,]Y9K>RYMLJ*?PUBI)W8@K(4=2%7BS$F`&4#=H'<^V:TH
M]T=KHXNV5^.H>P@>5`5L`:P[!38_-$4"6*.3LDGM_D__`':I/_I=&_\`F:=>
M&9?_`#+_`.\=?67;?^0J_P!P:N'K'UFZ=--.FFJ-8Z*@J+'/T]K=U5;;:R?,
MJ\O63["+$GZ*SKZBPT$ZOI(ARL/:38=%42IA1!:]XXL8I7(C&.<C359Z::=-
M-6);<FX:CY!QW%5E?##R#O:75Z3*YD,*SFS)^>P[J4>IO))H,*3"IZBIDZ.O
M`Z1-+&$65-"`;GF(UBM5@Q/AJ^^FJ:M;1[;*9&PQM5I+R%46/(6H7%8N)*4B
M&T6J;F]'L'4E>@QO1TQ,SD;*:J.5K4##(O?NB(K37BMW61N-AJL!67T&;LL1
M69:ZUF>"XBV%%5[9;Y,I-G-4;1M#>+F)_H\7.5?Q7]T3].[3YZNSIIITTU1K
MS14&9C1)FCNZJBB6%S1YV#*MY\6NCS+_`$UM#H<Y2132RB&>UOKNP!#AQVJI
M9,DS!#:Y[FHK35+PV\R')>8@[/!W\'3Y>SDV\2!=5KB/ARI-#<V&>N`B<48G
MJ^!=54B,3NU/[@G=NZ=EZ:=-5^SLH--6V%Q:21PJRJ@R[*QF&54#$@P0$E2Y
M)5:CE08(XG/=V15[)TTU3LIJ<_N,OF]KDK6+>Y784%/J<S>05>Z%<Y_05T:V
MIK6&XC!D=%L:Z6,PU<UJJQZ=T3IITU7^FFK8R.TRV\JY=UC[N%?U4'1:S)2Y
MT!SW!!I,+IK;&:ZH>I&#=^70ZBBF0CIV[(:.Y$54[*K2(U<_335B;CDO$<<%
MQ8-G>CIY/(NYJ.-L1$2#9V4W1[:\A6EG`HZ^'4PI\IQ$J:.=-D&>QL:'!AGD
MR""`$A&M5`G4GNN7^+^,T)_GN[S>7,*%663X5G9!'9?MMSK*+"5EDVK&I;$E
M=*V.GKJU#M$H6RY@AN<BO3II!.LC]-4U8G)G)W'_``WB+SD?E#65&)Q&;%&+
M<:&[D*"''?.FQJRLA`&-A95A:W%K-!#A0XPRRYLPX@`&0Q&,<U4`G8:MCAWG
M[B/GVMOK/BK7CT7^)W#,_K:>=3:+):W)71H,:TBUNLQ.SJ,]L<S*GU4P,N*V
M=!C_`)44K#!\QN1RM"".NLQ=-4TZ::=--6/H>2<)E9Y:F]T]7#N@1\W--1"*
M^??AKM?JH^(SEJ6BKAR[<=/9ZJ2V$V8H4BL*UZO(UHR.:TC5\=--2LZ;&K84
MRQFD44.!%D3994&4RBC10O.<B"`PABJP0U7Q8USG=NR(J_ITTU*45U6Z2DI]
M%32'2Z>_JJ^ZJ93X\J&^36VL0,Z#(=$FAC38KC13L<HS#&5BKXO:UR*B--57
MIIITTTZ::=--.FFG335I/W>0'NXW&3[^"W>S,E.W<;+JXG[F;(5MQ7Y^=?L9
MZ_5^#&N;6/'<OGY>PK?T[=U1I&T^&KMZ::M+7[O(8(%!)V-_!SX-1K<YA,^6
M>XC6VNOUU@RJS5!&48R=YUQ8D:$*+V:KU_54Z:`3TTU^\Q^!!02=C?P,^#4Z
MW.8//EGN(QMKL-?8,JLU01?6,BNGW%B1H0HO9JO7]53IIUU=O333IIJQ]QR7
MQ_QK`)9;[8Y_)Q&4VHT#775E'AGDTV)H9>IUT^!#>_\`,L0YW.0#39:`&1P8
MPW/<G9.FD:NBIM:^]JJR[J)0IU5<5\.UK)P?+TS*^PC#EPI0O)K7>J1&,U[>
MZ(O9?].FFJ?J=11XNAGZ;23'U]+6)'6;+'"GV#PI+EQX(.T.LBS)QO.5*8W^
M@;O%%[KV:BJC35P=--6[K]9G,%D]1NMC;Q,_D<7G;K6:F^GN>V#29S.5LFXO
M+>:X;"$;$K:R&4Q%:URHQB]D5?TZ:==M5F',C6$2+/A&9(ASHP)D20/NHSQI
M(FF`9BJB*K"B>CD_[%Z::MFUY`PM'92J:ZV.8J;>"N);-K+&\K85A$7DK2S<
M9QVDB)(DC.%=UKZZ15U'DU/W&P`2.#V%8YJ-(.KOZ::=--.FFG333IIITTTZ
M::=--0O2SW+([D]BB:%4]Q?5X->YZ*@//T(3R<O=Z-\U3LBKV1$ZKR/'CX3/
MZ'KJWB.?/?E$=3'[.GZXG47JFKM.FFK6S^VRFJM=I1YZ\A6MMQUI(V0V\"*I
M%/F]-+RV;VT:GL6O&Q&2SY/7UDYJ-5S5!-&O?NJHC2-73TTU;^MU><PF5TVX
MV%Q"SV2QN?N=7J;^R)Z:ZCSF=KI-O=W$\W9WJA5E9#*8KNR^(V*O335*C<BX
MF1F,CLBZ&%4YW>.RP<G-TC9&5/<3=M^(W*5`ZS2@J;:-?7IIPA`KS@%-4[T$
MHD)W:C58/34?";S'\FY.GW6!OX.HR.@%(/2WU8XCX-B&+,DU\@D=Q1B(K138
MA!KW:G]3%_V=-4Z:NU51$555$1$5555[(B)^JJJK^B(B=--:R<8?97S+S+MF
M<><:<LTFGU$R+?S\^$5;HZVFW-?E9@X&FLN,M7<TM=E.4ZW/22L2;(SDVT#&
M:]KR.:Q4<K52I`D]-;.=-4U@[6_2G!N(H[73:+D6F#GZ6#83K"XK`6FBKVNJ
M^08W%$ZJBR<Y7VH['2BY+ECHDJ8REM"6BK'9'<1'-1JH!.LI9K3TFOJUN<_*
M+,KFV=Y3N,:#85Q&V6;NK#/7,9T2TBPIC?P[BK.'S4?@5&>8W.&YKE:IJ)HM
M+G<A3R]#J[VHS=#`=%9-NKVQB557$?.F1ZZ$V3/G%!%"Z7/EB`-'.3S*1K$[
MN<B*TU6^FFG333IIITTTZ::=--.FFG333IIKGU]]%;!XL/82F%'!#R+Q@23+
M;&?)9#A,9IAV-D03%\UBU,0KI!WM1[@A&XB-<K43KT/\OP;.ZBM(]0XU\"8D
M^2!]K'8#Q)B=]>+_`)QL*?;QNL!%0SL0DQ/%?O>3$?!`2S$254%H,:XZ363(
M5B:R&Z+6RH!+>Q%.G.:6N>JQ#6BB;)4KXDFKL0LFQ"-`P)),:P(%CW*Y%3V5
M"CUBHRRMQ$#KU"].H8>5A)(4H"0(U\QW"VJ\W@K78A=@S;KT+Q,P48<T(4`L
MMC*"9U%CBF1F16O/(_Q@A$!^6\TF=941Q2#0WYVP],U\`9$B7D;\)YU1+.K&
MR2U'O4S148HQ,`?BHF(`#`@'F)$]5;E'T.2I@03<B6UJH+-^`)CE)9JR"5-3
M0W$;6+Z9;_-J`<2>06\;CCXVQK#78?VL6HSE39W0@`6PB7F^B5.*NZVJ_'BY
MLTA9=]F32WBB.\9*S*Y"`&Q3#C*_#I[B,.T4'D<2QU63!2HM:K-)>(1P);Z>
M+PQ/$M&TRNS-W.@Y:>F.X45O8`.2V9`2BQ4@5$S9420AAN=8*`%UKG,G#!H7
M!O&MKREM8J75+EY5QQKP5G8@=(MKN9]%2W0]C,<6V?7S`YF%9.M'OF'8R,Q7
M%1J^UPGMTW>E?OO<T[5A-POM"W93GAQJ#,OICRR.9'#R@ENGA(UTWM9JO:/8
MK/<'=5]7%QV?%[?4HMYWM6CBYI?B14K>J2[`*/-'F*D:E[34@V-5IK*V`K]5
M-L(IV1H4-)D`0*[91ZPD&LFA,1M569ZY@LBN<".^+!C%`[\E%<-P>MPL1L*Z
MJJD_\(JD23!DUEI8?S,ZDL)(9F##CU!\Y[KW!.Z8]]^2)[@S@PHY+"WA"J,#
MY$K=0A*J4K4H?4DJ5R(@057)6[L),N-GYD;,8&4"N2QG:FT8(=[I@B+')#_.
M?^V%G2`0T,KQO84S6J0;2%0NNY-;VS'K4&Q#;:">(K7Z4.\QO`+1!D`[$@1N
M@B8_?<NZQEIL7'QR%Y-:\>I:`05Y>4L529!!8`LH9N6U^;Y1@<O<?7N:R\.0
MSF?C;+SM7C:J:3\%>8XP0/D2;NL=&?/#*_;9,84M\$;CH<+_`":CGGDJWDLG
MM5G9^X5Y641_1<FT5V,-_P`.28"M,1R!*\C$';8*L^BX/N"GW+V:[![>K#W3
M@8[74HWE_&@"38D<@>)`<U@MR!D27>-2./<[.Y!/9:_<S;^[QE9.L/S!V&S,
M,VJN]%_B>PIL4"-7UM982!54Y9PY9DD.-#A(X8F.+(8WKK^XY*=O5</`%=>:
MRB(K$5JGJ5M:268#D.)41#-!)`4Z\X[+A6]Z>SN7=WNM[76[<@UQ!NLL]&Y*
M`%5&(1O4#MR+(DJH+.!J%KH>SY"T,)@2PQ3+.7VF$%+C/BPZR3"G2[2:.JG+
M&/7TM1GJ^0=X`":P4=CU'Y(UHVUPWPNW8[%@2B+ML9+`@*.0D%F<@23N2)B9
MU9W*KNO>LU0I46V-O!$*A5B[!&@JB5JS%5``4'C,!1:<ALC0S\^"@D2Z_/Y4
MOK`%BEK2:H\B=(NYE_/A/$<2`T,C\5*X$ACSUT48HS$\Q'0F6I7'KL;("MD6
MC<]?3``4(#MN@Y<R##L2QV*QKG#YMU*8;,F'CF`-U]8EC8;&6"(L/#TE8%JD
M"UC=7G</Y840N3=Y#`*:9]5\_P`R#,M!B,&E!:+R-QK+F9V&XHA^RVJH\B/(
MF(SL@TFB541SU:WC?=<GM>.[%0'[B"%V+%?1N`<_[+$$+\>)\!OZ;^7O%>_9
ME2!R:^S%6>"$#_B<4M6L@2Z`JSQTYKXF!W<Z\%U]>Z=--.FFG336FWV['&[@
MWD^5^5+B2`<0;L`30%%^8`<G0\=O-+AL*GBZ=$?%&X*JJ,0G;R[]_P!.T]C,
M?Z[BI"E3F52#T,)=L?D9,_+7E_YL(I]I=PLY,KCMF0`5CD`;,:66?YE@%?">
MNN-.RT@<Z>355%<\\2')L`U42SEDNKF2:Y\(\1ULZ>.0"XNKG2SAOE+W]CY<
M\CG^".5$]HPL9LE1;<T.P'(J.*@+N>,0554!"^`5!$Z^7NZ9RX3MCXR$U*S!
M`S%W)?8<^4A['M8%_$O8Q,2=4!99JH\C-M.`!2&C?Y<:,R3!'-D1",K8U%`:
MT!ZZ'5YX%9,%)='D.B7$QBR?%1LA]LC@MJC)()`!].8,`^8L=P2SEE*R.5:G
MC,E]89L?'=L$$!B1ZQ$J&(/$5KL55*PCABK%+G'J1`JC)U%R-_TVS4?2&FQY
MFQD25M<?7S*J[GH6*M[14]GLGPJB!9%%542:%X@-=ZXY;%B(1K@B(G6KO[;_
M`%+*.*JE<(#C80RC?BS+7+%?,W`$]2$Z02-;_$[W_0L!<YW5NYLW.E62QI'J
M5H]_%%8\*_4*J#"FP>8%5;5Y?.';2U^\XNY<)9KQ[R!8P:$$NPC[.+J(/,>+
MM(M17ZND;HC3I$)L.L@UAR2NXVF0S4/Y#0CAX7N7_AK,?NO9^']1QU+$`UE#
MC6*6-;<``98N`N\0>,&`=I[&C.IS/;_N0V?T7-=:P6%XM7-H8(MR>H6*\46I
MB^W+D.<CD5Q_O./,UQ6[3T&F4&RDU%-<G/:0[!V?IY[*:@BUT<\B1&=7LGW?
M[53`KTDM?$M`O+*:T[VO>=NQP.XY7=15D8TTJ[J`I'-AR<D@`S"\F+\89#"2
MH("G2]X[+@>WCD8>?&4]53DNK>FC<*PH)(X\K."+7R!2U2;`'()<8YCU-5(7
MBV!H8$&-5S.);!++_';)E@RR;.@8..AKZ#-DEJ&284THY*#>S\5LQ&J9%$)Z
M-V+77+^+LQF8W#+''FL<8-IA"!R@B5GZN,\=R-:1,7&<]OJS41<=NVMR]-N7
M+DN.)L5B4E6(:".`>.?E4QLUPWQ964)=#]![0H+;)4EN[08W,+,'#G\C\DFF
MS)$:[THY!2GD9^GT8I90Q@)$C]W.\!>$5Z%YCO7=;<@5^W<*4S+$X6/$BFF`
M"J1`#LG$$GD>DF7$=Y[8]OX^&U_O3NI%G;:K?4HJY<6RLHLQ%ELDDUI:'(5>
M"[F%BL\L'X[Z$T=1KMF_E&UKVMY$TU>+;1;&Y/(M,-NK]VFO:W30<](J(T$\
M>II`0XSX\:2WV5;7HW^I@RDWN9[=QK<.D=J1O^'J/I$*`MM2<%*%PQ(+,6:6
M&SQ\2!R?;/>F=C=RRF]P6)&;>HO#.2]&19ZMBVK64"D)6$4JK;U3&X#&O\@:
MO;86[AFB:*5,M8QFSORZW3W\K/+3,"2QKPQ;$]R:MET=U7G)%$GBL>3#.SQ:
MJ$17X_;\3!SZ&5ZP*B(AD0/RF"2`H8,I`8^*L#OMMF=Z[CW7M&4KU7LV0IY2
MMMAKX1R4!BY5JW4E!_*R,($-OBJ99+`G@U.:KH-3`M)L>D?(KV,27FIOA,J;
M"O616@F%C4@(LN.>D)*F%DRH;/)WF84GMM4J]2LXF4S/8BEH/1QLP,,1+2"+
M0JA5;X*5USUM_HW#N&`B54V.*Y7K4WF1EE02$`*M07<LZ"3+K9&U/!?O+RMQ
M#</M9S)MQR-B(^DKY$7^S=287^2GH))1R?*56V6:8M@!#M>YIX\A8[FM8('7
M*=^XCM.92$7@F-:4(.Z@\`XVV8/Y#$;$<IDMKT/VCS;W%VS)-CBVW.H%JD;.
M5]4UD@[JU0]1>0/F5N!`"IKN'CGJ3+4!%8\:DJH;U&1.SV*X355CT_V.;W[+
M_P!O7A>:(R[!,PYU]9=K/+MU+1$UK_#5R=8VL_3IIITTUH#]K?/^JY>W7REN
M<=@X^RM.'.0N7)\FP;>5%):XN-R#\Y\JX&CU<!US;5`9L:MY!MJ-\H<9QIPQ
M-0P0E09&]-7*8G7."U^*OJC%)\V0L'Q)=29_$>%^++Z=LZ?D[/:;5S.0<ARO
M5[/Z^CW^YY4YDC6M!HM=2)+CJ_/4\D6VCR5B6=N*($,835X9=Y\9_P!&KZG?
M"//=-AWGI,WN%V7(/'?V!1\[R<ASC5PMELY6P^MN,.1>`J^-/W-Q;XNZ?2<0
MPM%&KJZ:V+4@K),B@D2ZV-8/*-X:IR$_L_AK&UK\$_5^CQ%5?TW'='QYR+F.
M$.<^,LK+IM5!SFK7`ZCZLX#Y(B\=/I(_+V_RN`T/)W"M)N:I*VFTYLC3+9"C
M#E5H3>J)35>2S\I_LUE;!?%7T-%KL193,AHW5?'])]J;7BKBS:<IP,#28?DO
M95GSZGSG1VF>X3WE]19NA_R_%:BWB1JZXT0,J:Q=)#(!)(`$6NJ<A_#6"LK\
M4?2T)];#W7S-L^0>&Z;G3YXYAE\.MY#X;P1;:)F_GGZ1XLY?94YJMYRU=`Z]
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MA8TPW@!J_D!X[ZVQYJ^>^3.4OC/Y9PNYQ?\`U5Y:XJW?P]R+R3G[+44S[:UO
M.(-[QG<<PSX>FM[FLH+C0-IJ^Z(PAIPQ3WJY&$4A!]VK`8:?#?6C\G^/OZ;Q
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ML\/KJ;Y-4'T%7Q'_`,?&PM.?>4=GC+S761]J$VQ_Q+B[39&*Z?G?\HEC#D"Y
M\0S5LEDB2U3D/[_GJL3?B_ZSJ1?2\/0@U_)^9YIO.9+KCB#AN0./</H.!Z6Q
M^W;KENSP^:SFDGMX[WE)](<;W\;06C+=T:5,-62LO:V$"NE02PFG(;1^FVMR
M.+.'OI6)_'WR/PT"/4\-<X6>4YVSW$3ZFZG5A<M'TEEJR<7V%H^NW7+5?QI?
M+$L8[RP<[?7%1F7.:.K<T$<4835I(Y3X:UJXY^+-M9\R\,<@)\[R>&.'>-/I
M?C[DC,\,[/E"@W%WQW)SOS)]!8ODKE6KDY[;["CC"Y`Y.U>*CLKX5C*EV!J$
MES-``LN2CFJDB(\?].KO^_?B[>_0'-;-GBN-(VFCZ3YM@\.VNRC;.JR=K0%K
M/JO@KE*?3G+)OZ:\C@N>/J"_=#F5C"E!+`K'O`0D=[J'16@1\]8"YS^%_I59
M%ME<!DM#;_/-1S']%VN!X;R.PQL\E/$Y&XTX`%Q-O*>OY'Y0PU#FZG'<@4>^
M]:MGEM<W.OOW*OK3^?<-=5##QZZZ"?0?"/,^AX"^7_V(*<N\M?-/)_S[S!IL
MMH--50IG-5AQC4'H]I7IKK>)19QFREONI%]43)X:^O-H*^(IG0AO4P&K01)^
M!UA3F#"?0W/LZHY`V_R:@>(:[ES.GUOS7&VW&=7SWS?QS2\2\ATU;>\KZ.KY
M*!Q#=P,7RUK:ZQI,B?4.`R%7FFGD.FNCU[*:J"!M._QUIUS1\P<[<:_+_.W)
MG+H-?=[C,_(/S]QAQ<ZHYQU4FVSM[*YYYEF[S`UFCA7@C#UU9QEM\?EI>Y/&
M6=8,@N..4YC#*ZNK@02`.DZRI.^3N872YUO/^7-QIOFB?R)RS<9#XCB\[XW/
MZ/C^ZTG%/#&9Q7*4FZ!RB+CT$!G(>/V=@VL@:267/$UH[J(`EDAP1FJ<A\=_
MCJ1M/B?ZCC9;57&]SDOG+DW1:/Y(QVOT9>0R:Q]YQ7QY\V<757,MMDN.MIRM
MQ7QWH#WWT7BUDV-=HY5?'O(S76,J//?'B0BTTY#]6^K,XI^(?J^C+QCIM-QK
M;!Y-I^+.(>++?D"1RIC)5[2YGB'^2.OYDDYF78U>M&6?G-!\T'&VO!#"0/X]
M:6JDCBN<`)ZZJ6!^S_1JK2OBGZINJ"VS,?!Z[)ZN;1NSWT;RFSGV.$7UWJ)W
MUAPANZ[D;++2[E=+E`YGB/*ZPS2V<;/6=5&O&YZN#(BM\A-4Y#]/#;71W@O@
M;=<2\5_6'&-95DS^<T'*O+-E\YYZ-JG3X5#Q_K>.,@VF@49CV<LV0KR<DNNY
M`X+R!2&0[B,8,3V)TU:3)!UI?Q5\3_0><T7%O*.DJKAW+F0YP^.R2]/(Y>F6
MLFNX,Q7QGQ#Q5]`T<4#M/(J#5EYRI3WO[C!:%Q;Z0T=@Y#.2,9C5W)?U0?XZ
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MC<=T4_AO5\3\4Q]-\HLYZX]O.>H6G=R[LN.7\KGYUYF+99O>W,BZSNSBWM-`
MG?GFAWFU$G>UJQ,B#0K0L/M.MV*3@+GVC_CYY*^?\G:RLAR]Z/HK/\5D?NIS
MY%3B+;F/D:RX>S-?OX\NWMLR)W#\VIJ8,UA22\^-PNR(6)XHU;(Y2>FM;^/O
MC3D70<I\<3;+AS3<.?+M/]&.Y(!\[77+U=/-D*VA^9-+E27UU"P'(.ESMA0[
M3G@]58#S<.SLX7Y5;^\3`CD3)(V-7%MCOO']NKO^^_F3E'E[FRNW&,X/N.5X
M_P#X3.6^(L)J*+E?/\<R>'^>=;NL1>\<<EV(+769BU)69%U(2?\`N]6RRMJ=
M\;_DH4@LES6M44@#?XZB_(N)Y!G?7_-=)<;J1N^'?E.VV(L5I(6FL;*%?\Y_
M4L3';[FK*W<04I]>&PX'O*.W'!@$<9M7`WPXK6!?%]8VA(X_,_V:M/GCY/YJ
MW7U1&V8>([C;'_\`%SP!R]D?H-_+%#3YSC7YZP>$R])J>(CX&=JXVDD3ZKD"
MMM[H5?"ICUMB6Y99.F)8QDCMIH&`'ZM8\QGS-]@;%_SS7<F<4W6:S_#'&G\?
MO&FS)KN8,1IA[/1?/?+&LM.=>1*B+0ZZ\(ZILLI*BR8$Z<Z+?VPC*,T6.82,
M<U4E=X^>MDOXQ<_O;;/<@\E;G6R-M094M?\`)7`FL#HI.BI>1."/F+0;'/4/
M-@)RRCP[/0\M7U],6RL&^UTYE-&(TYA>MZUU1_@/MUIAJ?DW[DO=OSU?4O&E
MIE+3DSC/[!S%C84')&-I\]I]GH.5^/\`D+YXL$U\GE?3\GZV/)QN2LJR%9W4
M2E9DI=NE;$JX-2IBC:NY*/W:O#FKY,^E?H#<[;F2X^?+"HMK_D/Z23C3-:WE
M'CJSU?'&.Y0_CIPW`^4NK!:G:V>.IHUAS=DY;)];5S;$L7\YDSL8;Y!6-4!`
M$3^DZN`OPYRGQU*JZ.AX?N^0?FN%_P"%[0\G?.U#R]!C2^8-'F.&N><1RG,8
MNUWM)16UK3\B7.#OK.-;6M?`U/[(TKBR),9HS-.0_7OJ5A_#OU!,PFUM+\-Z
M;E*!\V\&\?\`![B\XW%F[CJP%](<^;/=XI;8VCCPK?38G@?59'-3-3+$23="
MK7BCRBL4JD:<A/RG5M['Y&^DMU8?5VZSW`VPX6Y!Y)WF1K:2FS_(7%DS`;#Y
MGQ//V;UV^R,>-6\U`?=\X?2V=CS[:XE7T:BJ!5R1LRLZ(!DN7/IH&`@3MJQ^
M1OA;Z9O>!-#B;7AO<<Q0]5P5]48+A#C6?S!QUQW(^8>3.3=38S\!K+:/3\@L
MQM3FY.6F,BQP45IK).5BQEJ8_P"1`G2/6U4,)G[-=,_LCB;E7D3A[@[!8_C\
M.^K*W>Y<W+%+'-G;"QAYJIX]UD"++KL;LN1^,.-M['#NI%8R3$O;&7!AQU6Q
M#7SI<.,-M=6J1).N9^>_C^YQM<C@[?F'YS+R)R;4<-_QQ4^RM[CDO`76AOM+
M\@_9NRU7+&=)=S=S`B6UCI^#+:LF4<TZAAS(\-T:26#-1L=U-7<A.W3?]XU>
M%S\8_6MME>3<[38O79?DB\XOYUR7,G,P>=($07U;M-QS+A]!Q1K<@M9MW:3%
M'P^)J[8X)=I$STO+BEI1U228;G%'73DOZOX:SU>?#7(-#S-H.1.*L]+SI\O]
M.?,IN$KMG)EJ6/C/FO*<'X'"<OU=;GK#4$BAJ;+0AN?W6J.%96A<UARH=[8Q
M&4U3D(W^&M(:W@WZB^2N#]/SCO2Z>KY=XCKOGO0Y_.W_`"%C*VE^L_JG);2X
MA:ZNHQXO9[S0[N[^@,=JKC-1+;0)375D:_AM/2L=5!>!JL@F/#^&NK.Y^>.8
M<[_']5\)X>UN-[SCG*WC'5W=B_9/I+CD/?T7*^4Y<Y8#7:RZGQ8U47>6L.X!
M`9,DQZ\+9@HY2!BHYS:ZL!'*3TUSAY5XRYTV//<.%RI\Q\E[].9I_P!Z\E\?
M\'1OH+)TLK(U!\9\$8?BS;:NUK^1JW!09V9U=7:%;%@VL^;G#6!K"L',./V/
M:O!$;'X?VZRP/Y'^O(NPAOOJC0;;FJ-?9>RE?8`^5ZN'FK/ARH^8*O`ZW@QV
M*F:B'K&3];RO$GO;$=1-HWRK-NF+/'9A_'8U25_5\-;:_#OS#N_G'1%%95$V
MDRV@^3/DRFV`Y6^G;,E[].XI.6H/-VJM%L[RZES--:5%EG!3;M%1MRV,'N0K
MHW=K5&(/[=:5WWRG]?QMS](76(XVTCAZR^M=VM[IN4L?$V&ZL<Y]:<6<Q9'$
M<>[_`#')-9&V&;ON,LW=5]>SD#(YN;BP$BT<>VE5IIA7-5Y#:=9`B?*OTGRK
MR?H^3.2^/]-E*21JOM;D3`8:WYIKYQ<SI]U@_E#/_-\G0UF,V,S+2[.#;<<Z
MB8.&AK&LS\YZE0CB$#)(TD`;==O[=8AG?`GT]GK[YUK<W$VCJ;+\*_,==7WU
M)O,G=VG"_/\`G=S:ZWZ;Y#U&SY&Y$=J767(_Y\)\FYH:C72M#&KBU,D$>&\3
MBTWU7D#U^.KTM_A/Z-J\G^Z8BHMX6_W&<^Q8_/""YIL8%ARE1Z?[`XWY4X;X
MR/H7Z:4E0FEX%J]+G*:;%4(LD"X)%4L012=-4Y#^'\-89U'PO]+3P:Z7C>!]
M?@.$-3S_`,P[JK^9H7('$^NUU:S3_./S'QQQ)OK!;CF2AXZI@8W5\:ZT((<3
M1V$K)+;QYE9&E>IOH:KR7QZQKJ+\B_-V^XQY.YFY.YDDW>IW=_1<%X;*[F^Y
M`G;`]IF,E\Y\)9OD8\>K::#24<O1\S8ZTFV$D=36R;8[&27L03@M;75C&=AT
MUH1S%\1?1')L?Z#RSN*+"9LMUG_NJ-N>;KSF"IDX_P"EL/RYE>18WRKP["QQ
M-<>VSI^-+N\R2(EM55%5E_\`$#?@2I0[,SC4U<&`C]7^G6_OU9\WRN0^%/F[
M%93C2OV+.#_H/Y6Y";BAW%95/K<IQ7ML^W2FH9M]<5=7(FY[*)*(()Y;721"
M<,2O.X;'UU:I@S\M<XQ_QZ?3V&X3J<]Q%5R,3N-3P1O:?GI*?D]CY'(^K=]=
M\.\E5V/0DS60J<MGH^!(VXHZF9[X%=6Q[9U::5"BF1PJ:OY+._QUT`^7_G/D
MBB^2.9.&-E+UG'<CE"SYAAX&HN960);<19#?9H.?J(5/2<>:+5Y''PX-VLVZ
MBTU=?7`*]\Y6,E,14C1VK"1,ZPG#QOVYJ_FO)?-F5^?LE\^;OB/YAW/&4#GK
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M[DYZY6E\B7<L&H%H#1=9P9K\<Z+^QP;VQ2+GG9J5%B0I!%?75)$;&/\`5K5R
M_P#ACZ_WM;SO6[+@J1,J^5>'K0VNQ?\`G_'\;(;;G#)?4''O+>>="M;+F/8Z
M_;&M,%#NH5%JM7)K)0U+^')A4L3ULZ:J&7;6Y?SK\O?2N/\`MB^Y8W4?7P\\
M_D#Z%OK+;-T."_Q7;<0;N9,=P/Q-)'#VNEY$OW<5T9ZF*RKFT5'5T$O/E+!L
M)PI;DEM4+#C`UV1Z:CTZ::=--.FFG333IIITTTZ::T%^YVQS<?@A2'W+8MCR
M1QW!LEII$2!+_;2U.T?.BMLI)F.@Q;6$(D2082))&(Z^G^YXN;Z![$+#N!=>
M')<:XKR!(Y<JX,#J5,,`=B1YMIUXY^;@1NS"I_5]-\[&5N!"GB4OY#D3Y0Z@
MHS#S`,>/F@CD!K=%+M9HZ"H2J%*DSY%-&JV@&&((S:ROS\G\L,T3H5-79BI9
M*E--%,X`PQ2*U/Z&MZ]CQ,9*D_$7<R@4,6G>.1<01NQ=N*PPDEA\=?,_<<ZS
M(M&'C>F+&<H$@!0>*UGD&'%%J3FX9&XA4:.@&J"70&<M;7Y^)()1PUDO_P"0
M_)K)=W/*=\^QTDD=E&>H@SZN'%9$@%4Q:^*1@&>/][O.N./-9D$"]HZPP41`
M0<3U#%BSB`[`L?#6&V8Q-=.$K'$2?IE38Q/)K2&&P950)6>1K4A!'FG)VAV-
MGA:N?G\K8I_F6NHHU;*FQZ*_DVF(I['&WMW1!C/SC8Y*[4:M:YGH>0T58]:4
M3A*A3-5NKQ\.K/M7(RU_X*FPL`60+:PL56GG/)*^1F`TN"#LIG?YO<[^T8[X
M7;W_`/GIDTA2PKL+T(U%CU@>G'&V[B.))3C45*^9A&8>%\H/GGB&3QAN+,=+
M9.N+?DOY^T<@E[%NLU575<^YT]1;,NVR);,[>O-8#_'(4KD:$YF(Y$"QVG[U
MEGL'>!W3!4O7P6G+0<"KLIXHR\8'-80R`.JJ?YB.F]K=N7WA[:;L'=K!5?ZK
MY7;K2;`]2.O.U']23Z5A-@XDG97<`^4'5_;U53F,WHZ1U0:PNH%I70Y%V^R'
M`KIEA9ZBE$.PK8U:6%''66]C=3)LJ/%*^'/]@_R`N]`VLZG!NNRLFN\.%H9"
M0O&2`J-L2TGDH554L`R0>)\QG@.ZX^-@8-^(:B^4EBJ;.052S6H`RA2`%=G=
MW524LE>:G@`*W,S]&WE?7EG1ZJIN8]%AK"G!F;&-?1*^2"7H)#)$.5/-+!73
M9(WFAN]!?8)DA4`S\EP'=8Z9%_\`2*167>DV6ABX*$@A!!`@D#9MQ!(\QX\A
MK+LP\0>XLEK177E"G'9!4PL"D&PRK,2%8^9#Q,@-Y!ZA0ZS_`,>8>;\]\4KR
M@2..XY;LL]:TGSYC(A0`@8N%8TM'4EU=B)4GSY>VD4U?`:V0?V*SVC&J.<9&
MMY_N6<GN+NW]+!*=G6Q6R[#)-A5F;TUZ`5!BVPCH3L%G79=D[3;[+]N_]0%1
M;[D>AT[=0"`M"LE:&YAYF-Y1:P&:8Y*-RT##O"W*$>3`@<3WM[72V+H=(7"[
M&;HS2GQ+C-BRV4-##*G0ZR9`SVBO)$B0LE4\8]@X:]_^:(@MSWOM3+8W=L>M
M@?33U:P@$JYLLD@%@710!Q\4G_")YGVK[@2RI/;F7<C#U[3CWM:3Q>KTJ2H+
M*K+7;86;ET6PJ?\`S&XX]T&ROLS8-"Y;*Z99M-0ZZFL;:\)`G4KK"P#:UIB2
M)<>4W\-DAD@2C0/X\L3"J]5"B,V./A8^57/EK*^>M@JR&@<6V!&\$&9E21&^
M^DS>Z9F!=P/.T6`UW(SV<63DP=220?+(81'%P&GRB+89)?F["N;FK1C*Z_K(
M)*:2P#0V&IJOQ)=;-2Y6IAK6ET=3,HG1Y\0I'^B2]_9Q0."[K**C)K;\2GWE
M;'D)VK:0PX\CRX,'E&`W4#8,&&L`6'!OK&!8!1=6I0Q#6I!5N?`<3:AKXV(2
M>+$[LA4ZW7^3D"SE7D`<`T@E?*X(N;1*^0(,B''N9_)_'`[F;`,-J3X_[O\`
MC1SR8:HX#):$./LZ05J<1[MY'M.,;`!8,]5D;$J*+N((Z'C)"MU*PIV4:]5_
M+D*ON'-6DDTMV=VXD`@.V5C!V4CS#G"LR?2'EUW=AKO%UX'KZ_TZ::=--.FF
MM-?M\92<&<GL49BPB</[P,ED<@@F>8NAX[9'$$Q&/4)RC]J,=V5C7?JY%[)U
MVGL8@=]Q3(#_`(RJ)_W+ID>(Z3^[7E_YL*S>TNX"":CVS(!B`9-F-`!/0D3!
MZ3UUQEVS+_(6OYEE#F%URNLY.868UKVUH5,6NLM&:`\(0Q33X\UWX(W1R,9&
M8I?2A&PRO]IP3CYE7"IE&'Y0\?S;2J`[D@$>8R/-M,<P/ESNPS.V9'JWJQ[E
MYS5R_E$E6M*P`"P8^F.)`4<N(85L;7S$1(4&YNK5TH-/E8[K8[(#&Q;FUC(,
M<#/U$$,P\6ME6MHD=XD08_".Q2S'M\0D;UE93EW2BJ#=:>(G=5/5V)`)"K(.
MYD[(#Y@=8';Z_3JMR\CD,;'7F>.SN(XUHH8A2[01L(4<K2(5AJ@QTON4MC;4
M,ITUT"2W69O4'K=G`K(N<S$2[I[C."J::B=_SQA@&&)`CE.R4[R_O)W(9_60
MWX?M6$F0O'U!Z;H&K)+N597Y,_03+,0"O^'HHUAH,SW#W2S#LY>BWK57%;U4
M55+8CU!$K^H@!4K4L'/\P\S'69MKIHK(<+"9^PK*JTDT%=8.K37&MESZ3BG2
MP9E-H;:LLA@8*3OM)/G.='4'];R$-(7^IXG]:7!Q6+MGY"L]0L(Y!:P&O0AD
M5E)D5(!O.T!5Z`C74=USZQ4G:,-ZZ\AJ5;B7N9J\2U2ECJP$'(M9O+QW)+/U
M*G60^3M7+Y.X/L:H@8C]]A:R+*D53A21VI:6!`GY1VH<\\#]\G2A-KW!N(TC
MV">5\>2\9!JYW6N[7B)VOOJV@G^GWL0&D<>1(LX;'B!O-;"#')00=;KOW<;>
M_P#M.S'8*>\8E8)2"'**K4^KNOJ,1QXW*TB2EA#"3K#N&S[];LOG6M'7Y)T>
MQRWN*RE,-DV7'5G'YI$;3,K2NG5H!-BD<<CE%^.BE-W\6?IN<[(&)A=RM+7<
MEMCS#8'[X`IRV8[B!O.P\=<SVC"/<NZ=DH6O&X/CSY#YF'_#DBW@>2@0>1,<
M?,W0;;"<^\AVJSZ^OXYCMNJ3.PAP+>'GK7/0,SK0[$CZH_(*5TDB'A2LY"S!
MY%2-2.]4=)*N<(#D:O.^W^W5>FUG<CPOL:5+JY>OT_,*I&Q#EP+#&YX[%AKM
M/>/>\CUDI[&/5Q*$"NM;UK5<+SP.3Q)E34M3-2),+SDJAC6`^1Z\U_51>2\E
M,G3BP*Z^U01U4_/6\/D.I=5SZ&KG"KWQSQI\[-$*YCV&$)6B:\12*0+&+T';
M;%Q[3VS,"J&9$/(.II;D'83((#Q.Q.\$""3KCN^4MFXR]^[<SNR)9:.#5NN2
MG!JT8*00S5200P$"59BR@:D,/;II:"!Q;?L)%NJ6OHX&%EGIQ5KK&)#R,6UT
MF2E3HB2L_8/:>5(?6(Q\9D0RGA!5ZK&7J3.I_#9#=UQX-#LYM`;E!-A5+`##
MC8`/(8L.+F/-J'M&3^/PT]OYH*Y525KCL4"\@M(>VDL)K;<L:H*!#SJ4F:]6
MS7@LZ:?*#:19,Z@L(C:_0459)0)E29%#!%<5\5(RPJ^S@M:.4*05C3/G1U9[
M!A,;SR;&JNK#5$+D*91V$C8D\29DJ=U(&W$S!8+&!0F1BW,N0K/ANO&RM3!\
MP"AU$<59=F#$<C8L<E5FG;3@?.651R5Q@LZ..;!C<JXQ])>Q)/:'-C6BVYG6
M7X[VG*JV;6*HQ*5OXQ721O\`)S&=^1[_`)-=W;,KTR5<XEG)2-P5XCC.WT^)
MCS#B1U.O1_9^#?C=^[?ZP#U+W&CA8#Y6#<SRC<^?P$C@?4!D@:[=Y)%3,T:*
MJN5*V*BN7MW54&GZKXHB=U_[$1.O#LO_`)JS_>.OK#MO_(4_^K&KAZQM9NG3
M33IIK3WZ8YSY6XYY`^?.)^'<YQC:Z[GJXY/K`W?*^GO<_F<P#C?CJPY`));#
MSE596^CE6;:Y8WXP7`<`+WRU<YD=XWM7``@D^&M*\S_);S!R+$A76,X6XYIJ
M#40?D/)Y*1L.0M`Z0#EWZ^I<Y=T*:5]5D6P`<8X6'+G.2>$JS]/(+71HD>*Z
M2I6M7<`.OS_=J#=_R/\`.T(O)-97\5<(/MOG+BOG_D[G,]IR=I853J1_-G*4
MG`ZVDX8(+*R))TUU:!#1YMHB"H+E?VJ:R0__`)A&G$?MU+VG\I7(T:RYNTE;
M\_'D<5<?5?US792;=!W.8O3;'Y.PFWUDXNLT5QEP8(U/N[?CZ?7-KJ65/N*1
MI8DF2PS"260VG`;;[[?OU%9]U\L<'<L<GZ/Z6%E8W%]6'@6-OH>3O;*TR_!S
M^0N&.==]GIN5L[+-4]GJF;;7XFDS,M\]D/V7%K&?&&P;E'TTX@C;6UG-7U?R
M1PI\K\.\LZ3B=C>:^7[OA#C_`/Z:0$U.EI\-R/S)(KHLJ#<?XU1S]?H:_$%D
MR!O!`@I,M9D<<8/H60A1M6A9:!TUJ39_R5?04;/:*]!P-QY6-X;X:V',O-4/
M8:W:YFVM:SCOGO<\-75-QS02<@2UHY^KJ,26Y@IHFQI%/)>E;/CN(CY(VKN(
M^.K=YG_D(YPQ6ZPG+!*#&0.!JW0_>U5"XZIMK(C\C;:7\J5>LP,8'*P[C,DK
M<M26>[H5NB2ZUY4S5<H/S4EN*J,:!1T\=M9W-]J_1%5RG1?.UKQQP7,Y?9S-
M!PFPUE?R#KH/$E?A;#YVU/T?_D=86=EY&B9L:ZAR$FK-33/2'O*@V3I88LKU
M":IQ$3O&L01/Y1.6DRU=57/#.?JN;>0=YQ'G<'QV"GYHNY>5SG+.6Y?V`M3I
M:ZHP,I.7\I50.%;6'4:+`6-M2:RP?XB)7#`0CFG`=?#5I<P?R$?2&WX+V=YQ
MYBLAPM;<;9#@&ZY:LM)K+*/M`7'+7TSIN%D9Q'76&7=72:4`.,["1VO1QK":
MZT'5^B'81CNZ:J%`.^NQ7+N.7DGC^XHZ[D/?<?/$59Z:KBG15]!JHYZ(I2FK
M0VTZHOX@HT@X%#*$Z.YRHBM_I5%Z:L&QUQ:XJY6^K\5QE_'KKL-R_=\RZ[Z)
M^5^5N?\`EJ']([!I,G)N,SP]PAJE2C7"82-;UL(5Q?3&P8,=K11W69#E>9L=
MD<K5Y`D_`'60)W\DO)@<_I.0L!Q@RTI;2SR>^T'^9:#6;FNXNX]G?&?R_P`]
MG&N/XDPEWR7594]MS(^!8Z*+4WE3GY073Y[498Q8;&G$>/Z;G6W_`-7<I:&X
MH_D#*8+DZ7Q;C/JSG',X34\RXF;3FMZK%6O#?)G*M'28/27E=+JZB\Y:T6+K
M,[7VRQ72!BM'_AM'/+$>-JT#K\AK77;?4.M^7;Z/\[\2<BZ7ZXW6BY?VN:K)
M7).<VN[NN"86*X:Q?*F@XRVVCXARMIK>6+Z6FJAS:XY(C)U/5W+OW*3)_;F,
MDM5"SN=AJS>1/OWZFVW%W)NRX;P/%7$\;!T'P_;NL>0M);;#3LTOU+<\.6]Q
MCCT--FW9O]FS.>V4ZO+:LF%+,>81HP`J-7*U4*/'YZQWJ?JOGQG-<N>[5VT7
MBS'1N5:!V-J=U*B:"SVB_P`K47Y4313K9V&-"G9VHRU6@:JL*%SX-4<L12DD
MO_.2AT@1\_\`1K8V)_()RO+XUA\K&RO`E7G^8OV[_P`.N5=OM[I>7U).YDKN
M*QU^YXEQV&N]9K[X];/?9+$S3%'!MHSZ28</=+1*ZIQ$QOK!$[^3[G>H;"Y;
MLL%E'\?4_P`\<[FT7$D2/I(^JMN>N,?MW/\`R%1WL:P-GYVASV)G6ED*9,K2
M1Y=C6Q)$H;Q2I482D:KP'3QG^R==%OG?Z:U>_P").9-MS)CJ_C>[X,T^IH]-
M-F"T^,S%W34&"S?(P]>E/OZJ!ML%7,IM,V/,C6\5Q@%A%DB<>(:.1[5I$&!K
M27'?R4<Z[(C<5%X;XY3D31;[Y5H,G-O)7*^%Q+,U]34_--E`N)E9N,+5;^\#
M@W\,22"FLKJZ/IP2QJ`5>J.5&KN(_CJPN:OY"_I+5_//+]IQSG>+^+]7PYQG
M#N.6M0?>6RV2Z*?]/<O_`#4DK@@-IDE@6=;!MN";2R5;Q@R2%M8-6UC)/MDM
M:!1.MIOY'>>>>^&'\>0>']-F\S0:GB/[/O=K+FP/RM<RQXK^:=;R!A+'&RI$
M&97P9]'I:QDMWO[#,X;&$1XU>WIJU0#UUAHO\A?T-@X&<XFV'%.)T?.^GN.!
M*;*W.(+RAR#D1T_+O"'+G,,FSU>;R^)7>7NGSL'@NXBO!51PQK(LZ-):Z&$4
MEC*:NXJ=_#6X*?5?(-E\1U?TS1</-?RA<T]''A\/S])&$CM?:;Z'QW*AUM@9
MD"?H6#G'+/K:H007MVQH:X$<=G)8!M=6\?-!Z:Y^V?\`(3]$MT^FY4S$+C31
MY#AOY.Y-Y&YSXNL9G)N(C1=-PWSW=971UV<H-GQO2\C9#E:\Q]?ZR5^ACMA4
MDE!A<Z>(K9RM7<1T^>LM[_\`DVVV%Y`Y@K0<89;6X++\;_:>JXYO:B3R)4Q;
MG1_&5"6?H*:SW.EQE3C-3_D5W`F5EB/-I/'EIT?\<TJ:7V()JG#;Y[?OU/Q/
MY!^=J[F^'Q9J."LJ>-C-7P-AN:;C'RN1K2GK;?Z*!4WE!9Y#D*UQM1@X>?XX
MSFPJ'6"7TBOFZ"6.Q'`#'<",R6TXB)UL#\7_`%QM_HFVVV:Y1QF9XTV=-E</
MR-3X>`_<+?1\3O)NJKH$Q]KH<Q`PW)F7%-R[QP-ECKBVH+Q[BH,<10-_(:HR
M@=-:Q:W^1CZ%KBT\#/\`!V$G67(G*7UOE^+V5TKEGD!Z8?XXY'M.-=G>;RJP
M6!G6M/HN0+Y]<M:"(R3`IX#I<N9**X+(9*:NXCX_#]^KLQ_\AW*NMT5=HW\2
M<>T7$4GF/A+@R;1RN09UGSC"UO.WSAQASK47#J&KI29(M+B[/D1:ZP$.:0DZ
MK@RK6.5@XWXYVJ<1^O6)T_E!^AH]!Q5;S/G7(V-GJ?F_BGZ[V5!BK/D[81('
M$_-%U85>.Q%3M(V#@YJCY!@0<S:2[&TOE@9X<A8<(1"(4TV/75>`^/C&KQVW
M\G/(/'5AS%&U'$.>'*@7EAG.`\Q&+R3+MN02"^CL%\Y5FMCZZAPNDXXY*QWY
MO)=3=7@\I9R;[+J9M1+KB32H9C5.$ZE9W\BGTF[.70JG@OC>#L^-N+_K'ECD
MA=[?<B8:KNL]\LSN%3_C8G+3LE*VM#9<DTO+Z":&_%'+03H!'$9/CN"X[5>(
M^.VK9?\`R%_1>?VF^Q5?AL?NK??_`$GL<WP9'K,GR1=Q\-Q9COE[@WG:WK-S
M3\99>]U.EUME8<K1QC/'%Z@NDSY13.BP8\<[3B/W:J>A^\>>N5O^CFAPN7Q_
M#O'DCZ?^#^*>1JJ\W*3>99%ES[5\0\LZBFIZP5`?(6V#+E^2!9]""D-GV2`L
M+".\`XK!%:<0/V'65OKWZ<Y]X#^B==;\>Q\AJN+.*_A_6?0O(N"VM[8T0K%F
M)Y0$"R=CI%+GK>4W;7F6%)B19$TK:R(\0_:$GM5XFJ*`1\YUC^^_D[Y%H]!S
MO-JN`&2^*>*P_7^9REA,9MLY/D['Y#P^ZTDV5?::TRT?CZ3FM[;\<SZX$"ED
MSK>G":'*D,*,LED.FJ\!\=]OWZKU?_(1SU&YLK.*-'P1G)(LIJ/G[&<RV.*-
MR5>5D"X^E'U=EFYV*W4[%U>(%4\=9O75#I[;LT&;I)H[`%<`#PQF2ZZIQ$3K
M$G`/\B/.^*X:^9[?Z!J>+-G1;OA+ASF#7<L9_?SY-UEN*+?D7!<*\A\@\IQU
MS4#/P[VGT?)E1H#.@J*M'6PKX#O!]6TTAJI4$F-;]?\`BNT8?BK_`,5MQC:#
M+6NDIQ:+`8[16VF="G5&_P!V/-\&!N29G):;6GTFXH=!12"5-943)Q+6P_;H
MK"$5A%:MCS1K4C*?R4\OWIJ:FD<,90=ME]=]50^99DZ?M\K-CXGY3SW#6YT%
MI@^.KC/2]2S;[+-<M,@PZ.XDQOPK('L-)>+^VYJO$:V+^'OL'DGZ</>Q^1>)
MF<?#-QEQ1S-C+2!#VU;73<KRU_E21<M*!R#G<Q;WEKEW9A'+H*V.ZANQR^\7
MU/CF'TU1E`Z:UVH/Y!.0L[:X2)8X^J%Q5)Y/Y`SO(G*FZO\`8:Y*)\_[3YB^
M>\[0V-SQSA+.-Q.R-78R/,HIFO@0:&Z<=E*"R8>'*GI35Q4?K_T:J_'G\D'(
M]QHZ/,\A\6XW':+9\L\#YS/8]UMN(]Y`XVYJY!TF#9M(FDL,I_TUY=H8)*F$
M6OT>/NK"GLY$]8SQQ%&$DJNJ%1U&K/U7\J/((]%:5/'O!L'91./W\L:;?RH!
M]K=P;S"X/ZOYG^;**)D-1G,S.R67O[>OX6GW$NRT<N+2Q99X\!'N:0LN.T"?
MI^K60L;]7<Z<I?6'S)"<+'8G@CDG;?<62K,K4Z*7.Y&O5^:IDGCP9N3J.THH
M\6"8^GJ)%J(=5)3]G]H(<Q9!2H1K2``?CMJ_>5?NC6<?_5V6X5J<3G-/QW.Y
MCXKX$U5_`'R$:\SN[Y7Q!-O7FM=2[)Q>+*6?25L^L.N:2RL+F=6S4G.=#8X`
MS-`LK.L#XW^1SGS29_BL6BX9X:K-K]'\:_+G)O!K86]UMIC\:SZ-VTS$,A<O
M6<S*5U@61F"1QRHQ*<34M)DL54U0$5DTK3B/U#6?_GGZ'Y>_\)GTQS)R`#.\
MB<E\4\U_9=/59>MW%)38ZR?Q)RON\YC\#1\@:"#05U5GW-HH\"-,M!#/$8]&
MRE<4;U<T('(`=-M:L3?N?ZDU>XX\!B*[B^OVF&QGU_-YHXNV,;F+C:G:G&.+
M^9>2\6;68[<\;U_)F6VJT7(YXU>`))M.>%9_NPYLP+A0VM5XJ!^S5\6'\E.S
MU6MQ]-DL131<!RG!#B8.BK6;NPT7'G).A^-;WZKC)=[6;D*[B6;>YL=:E8?-
M0)5A8M`\=F8X&N=`:TX;?/\`TQK+7PCS1RCRAPQS?HM]MK33W6;I>!)%'93`
M5J2*LVI_C^^6>5=`6..#"B"(^TY"V]K;/1[7)^1.>UOB)&#:U:P`.WZ;G6JG
M'O\`)+]!<?<"_/U?RAA<3R?ROS/P+\@[#C76X&VV>XB39O.QTQME9<Q4^7QZ
M7,C0CGT\FVCBS<5\>_EO/6Q4C?C+,)2=7E`28Z2=;9\C?3O*VF_C1^COH"#1
M3>(>9\'Q=]$Q(88JGC_MFYXDF[',0=)3`U50VVI8-U89P<\,*YKVV%6AUC3`
M..`B.KJT`<P/#6,-U_()S]@M?.X%LN'\-<\_?]:#\>P+#"@Y=Y#XV'F!_/E#
M]"_NAJ#*XR7R78Z$,"_'2J`,8<9_J-:J001.@]-`H._AJUN*?N;GWD3D^;19
M3-Y>%?\`-UUQ%;XO'\Q:D\+#<+4`/C?$<Y\DY=-#C:&9::;07EY:F2`J,]:@
M_+L7)Z8:PR-"HC]/CK,_%?U!S#6?QE?./T(VH%S#S3R!QOPB29&GVD,YKN_Y
M%G4-??7\*#0!K9W(4NA@64FQ!34(&VF@2(D>`)#&9V:$#F1X:M./_)=:-XXY
M+U\C(8&PM.,.#N.^0+84#0[;/P)7(&E^F>7_`)NT^$F4_(6'R&WR<_/W?%S/
M;`LJT=E#MI9*TK".`TYW\-.&\?/6!Q?<'T+B>&M#_P!1$SVOK=?H?M8/&.WQ
M.]/5<KU#?G+ZPLL,R'O&NQD_,4M.7(W$6NCFA!DEJS1(T27[SS_;':KQ$[?+
M^&K_`+/^5/?4TSD_22N`"FXRK++GG(\:6<YVVR)G[#A'F:%P9&E;[8Z7)@Q1
MLAL]5(-+G2<\ZS/D(($2<.2][W!I.G#Y[ZV"PO/7U%:?7G$7"^[F?.P,PO'_
M`-0GY5K^*]+=Z^1::7C:=\RR\/90GVE5%M^/KRKKN:/1.S]D1Y'!,28I"C-7
M*VNJ0.,[_I.K,T_U;]*9WZIYMX/HP</WL2]Y>X$XB^?6:Z5?9ZHQ$[7?.O)?
M.N]N>2+*GJI%GH_W&OXQE1Z>NB/:>392@"0H`(5[::<1$ZSC#^P9LKXJLOJ"
M3F\I3ZBM+IL@[-2M+H+C$6')6;Y=M."A1,YH\KCKW6:O,ZW?UC5S_P"WT9K.
MYC3(@A1FR#HUM=4X^:-<T^4_O_G_`&&9N)E7,F</ZGCF@^N,/JXE'5SJB)H-
M;Q;R'\)/R>U9E]_4%U>/EQ,KS?90W5<]Q"@+*.I'/[A4=)U>%'Z?KUU7^D.=
M>3<!NN*N).'<_P`93]YR7E^7>0/WSF367.1P55E.%HV*)H*MLK/U-O:S=1?R
MM_!2/XL:"!71IT\R&;%2.:NK``=STU@3X.YYY0^D^5/I/E326JP^,+C*_*%Q
MPWQLZRF')Q[2<E?.F/YCMH5O$;6PZR7?S;3D)4E6(BF=*:%C&(R.(**U5@``
M!UUHWB_NW[5HA7?*FMD\2\@T_&WS9]$<P\F9%+"YR-!8T/#_`-C<G<<0!X=E
M=EIDT>^L,!DGUPI<]S:T2P@OD"*628HJ:N*KT^?]FMX^%/O'?\M_3,GC%W#1
MZKB*TY.^@^'\WLRPMK`NZ_2_.UIH*6YT%Y;7V=J\#H*C96F0LA1JVCFR[.H:
MZ&^4A&GD?AUU:5`$^/\`?KIUTU9ITTTZ::PO,^A.)(')H>'Y>EG"WQYXJH=:
MF1VA*C]S-5U5R.O)L!9U^,#-_`O8+E$^P:]I)@!.1"E&QS58,3K-'35-.FFG
M336*KCFSC.AW43CBTT)P:J7)I8*B%G]-,HZZSTJD;FJ:^U\*FD9#-WFD</M7
MP;"=&ES5>-`C>I1>;58,3X:U<^XV2'X%J1&><MO)/%YXO?VN8V3%CZN7'<<(
M`G/*B^T"(8(V.>42N:U%541?0/8I4=PE_H_#7@_836#!,`'?8G8&->.?FT';
MLT5B;?QV(1UZ@7$2`"2)'F`$D2!OKBKN#`HBS*&2TZ6%Q"'&T3Y4LM?(HLZ0
MGNHLV$RB(+]P-82/S;08E:\)R"B^:^F6-?;<$->!D)'IHTI`!#/T9_L@<4)V
M(!:/,AU\K=V9,1FQ+)]>U(MDE377,UU`P1R+'G:!NK%:Y\MBFO8B7!S4$6VM
M:P\@<XR45%`##<2GG:P+BO(^7'*Z-6O#EX2@DS53N!Z^B*BM?)\FX^<EF38<
M&I@"HY,9\PK/P.[><R%\1YFW"QK,[395@TCNN2A8.?3K4+*-<)F086*EXL_\
MI\E8@O(L_,1;79SF:?22+NYB-?E=;/NG[>)/=<:NM6PC660DUF3#%I88IIWO
ME61&/,!H1HG=CE$G6;E/5A5G%Q@B/]Y6%](CC68*V!K"6,"%0;&3XB=:O`JR
M>Z6CN&<UMM<U7-8;PW.U>0:DI2`BAC+VD%EXCP)76:YG)5@FA_"R)HI)N%L#
M6.HE4ZZ<6DBZ&AL5UG'V.IFI&<"=502#<EL!HV`D1Q?B(C6=N^C3ME?X?GF`
M^G>L5AN'`HZ^G=8V\AC_`.69D$\]SKJ[>^W_`(WTNVLIMQ'+6E/5%HMK;UL:
ME-H9%/\`G+`5E'I[#K,?1FA)R%E(FL@DJ(Q:2SA5FOIXZ12&SY#;&@L(%3-&
M*"&2_++#"2?"*]YC"3WQE((D9%2WVWCCMV6<2P.18I:MC/G^[<%AO'J20C"`
M#Y6@AM7^]\UN]=N7N-1J5JK%2Y!QFLFZME1H4$U<0;*R2S#SIR5J]KEXIHH-
MESQJK6P-CHE/0468EV%A31V%SE=^*75G';GA_P#*CERX#)C71XJN(*8]!@4;
MG.>U^-W:^ROL%558N-UEC@!CYS(K'$'>`8W;8J):1M&?[=Q*;_=^1D7'%7&I
MIJ+,@!J6#<>978%E#>5-PYA.))(/KESE4P^40Z1B7%;QVD>'GK8:Z&B!!X\/
ME&AD0K\8H3YC@&U%G=-BW#%3P:<;2%7NWPZIVCM0/:CC'@W<9+KY&)N%D@IO
M$\`O*OY$@=9U7W)[A=?<"YP]5.R<5K<>I6%QC3!6P!>4&UWX7#H&`+;B-8#Y
M*R,Y(S-!3@N'U=I74.8L\XQ,OI&4A[RTJ-+8;%:J7''!BP;`HWA,1Z`&*0OC
M':]"C]?0=LS*^7X>XIZJ,[J_G3D%5D6OD#)($$#<D?41!GCN^]MMX?C<46G'
ML2NIZONK?3-CI:UW!@%"L00Q/$!MD!Y+%=G3P<E9B<Z0B!W=4S1G,T]4&EDW
MV1B6\JAI-$8LI3CD74:OAA9.0"N(9GHF-8B2#*W'KK;MF4H7?`?@-FY!;"H=
MDVB%))*SL#R2?*NLNZY.^]O8OMW>L6DR@0V4JYK2PDR"X55%G&2PX6QYVBP\
M_!+[B1+<4MM;:3/R8%O#*(Z9S00"C`V9*&L,A`U-@M>-LL(BB8U@6.1'FBB"
M[89#B`U)'JHL%3MS0[P-]V63Q)!.Y&P8L-/A4MR->2&_#V-*NI!]*Q2!)\I(
M1N(#J"!"@[M6JG=7Y.@6,#D+D']UJY]=8Q^%M%5H8D8D*`^-!Y-XRD#BUS?P
MQ?E_B2+`KW27&<XHS"[,:U/,G$>[;*[.W8WI,K5'.1HF3)HN$G?:0!Y8V(._
M@/5/RYINI[UF_B*W2]>U6))!587*Q3"[">)8GE)D,L`#=N\'7@FOK_3IIITT
MTZ::U%^U9,B'P)RE+B%<"7$XPU,N*5CAH\,J+?X<T8[&D[-5P3,1R*JHQ%_X
MO]?T[#V0JOW_`!4<2ARJP?L*6@C]8UYK^:ECU>S^X6UF+%[?:0=MB+*"#O\`
M`_J^.N0W.W-.C\@+IJ_":VW"ZNT&JNM-028MD^SL*6NF9;+_`)=!(S5V2*E&
M^*P<R.ZS)^7(*$R,$`7L]@[#V3&@_A6R*:3*(J.".(9A8\.'6>7*58(.*@B2
MQCYJ]W>Z<Z1^/3#R<D%;+GMK(;FR*U-4UFJPCT^`#J;3S9E:%1>57V?'?"&E
MR]!"T^AVO%<6F/"';!IZ&HYBRG[W>U=LZ^/9>(JG6#2'5=XI;$[31*^'":-J
MHUYO;%A=R[YBY5CXM=&6[@\2SMCV<59>`7=J]V\P00SLQ/4+&3W3LGM//[?3
M5GW9?;JZBH<)6F;3SL1_4+0$N'%/(;&#)6B`#8MRR;G>#,_F,&FMXTVV'Y8*
M-:.3&TL>^@9&-O\`=PY81XJMLUA5TNMK(+PF:)/>@58XR.3L0K2=:O)[[D96
M?^$[G1?B`\@4*&PU5$'U2LL"QD3M,Q\!&M]A>T<+M_9_ZCV'+Q.XL/3(M%BT
MC(R%8"A6XJ558('FB"P/U,&UA[2<);;$UMQ<:4=CH\]92+RUL+!FG+*B6-W8
ML#8QZ_.Z'/0*ZO+4YB:`PQ>Z6T=<QKGH+S8X3MSC=\PLZU*<4K5DJ%4#A!55
M\I+HY)Y.""867.TP01S.=[4[KVK'MRL\/?A6-8[-ZI(:QH8+596JJ4J8$#DX
M%8D\9!4Z_5.FNH=M8W\R7[=+6CMWAFJ-88!0)-6K98!B5T6$.'.B>,44>29B
MCB#;Y.8YLMX^ANQ:'I7'18QF*R.ID-L?$R#YB5&['Q!0'C,;/RJLE\RUISZP
MY#1Q`4IY@!LO%A"A6(A`)((L*W;9;'49ZIXC#!G4WG.XFO,Y!&RE?46,"IEU
M.&6RC,L[.%#$0UG%KEC_`)`SD4HB/\U:,CU;AU86+D79C6*\+EJY\W(%@UL'
MBI.REI@@00(W`UL<CNG<,+'[:M+U2_;;*U'#@RH4Q^0YNJ@EPO'D&,@F8#&/
M?'^MM11V9FZ]B*65(MLX.&*-'.E^^AN*V#4NAW0%BC_.-8>;1J=C`38J,,OB
M,P^G<,.DM^*H\`%>9(X<E8M*F=HB8)*M*]5.KNS=QR%08&7.[%ZN(`/J&MT5
M.+B!R+3'(!72'V5UUL!Q=PCR3%V`**)F31<+92!_XZTE5GL_68FVIGM(6OB#
MNY5;;6\/D6^_J&,*$,`GBYS?!5+USW=>^=L?#.0]H.>H\_F=VL5O$\0RJ:4Z
MDP"/&=M=E[?]I]]K[F,.O'*]IL/W4I76M#IU4>H5=UR;-P%EE.Y$2VK?Y-^4
ML+DM9#F:OF_C;BJ->7T<I<5`B6>JW$?::$\$N@-30J"P@%K&3I01!KSSY`$@
MH,1$)XL8I,CMGNS/R\1DQ,')RWKK/WI*I4:T!"!BX(:!)<(#RDB-S&'W[\NN
MT=M[BMO<>[8/;J[K@30H>V\7V%3846ME*\B`M;6,OIPK<H`Y5KEKD:OX\D9V
M9698.S+HHSPRM;M6I"%HM34/44X%=Q_16\*1(U-E#1K00@V$R,,Q2/<X?<G:
M#M';;.XK8EMIH%9VKKWX(VX)M92`BGJQ16(``!VUE^X^]T=E>FW'QQE-<L&Z
M_P`HLM39@N/6ZDVNL!46QU#%B2LMK+'&7*\O5[GYXK:ZSJ(V*T/)E)<P,;3-
MJ/P*+0UK[^)<UR3ZNKK26\[/R8RQF'*BF?":Q2N>Y>_6I[IVE,3`[C98KG.K
MQ64V-RED/`J89FXAP9(&P:8`&NB[![BM[CW;LE%%E:]JNSZW6A.'&NQ?4#KR
M1%+M61Q#-N:XY$G78/"')*QF7DF"Z.:11UQR@>B(\)"QF$>)R(YZ(X;G=E_5
M?U3_`%7KQO/4)FVHID!R)^.^OIKM#M9VO'L80S4J2/@2.GZM79UB:V.G333I
MIK13[/QGQM=VW".Q^Q]5QS6YS`7/(,G%X[E0^3-D=S<:'$GIKP1J'2P)LJ]G
MYO/N+-&D!6&CC:4A?("$3IJY>6X751U_)O\`'O'J>0<1L-=\N/I;KC[$:?DG
M*S9G'DRONN-@PLK6<76V@J`^\-KGS0K^FCY=SF$:?WQAUWF[P1&D-\]8G@</
M?QN;769#FROD_/.ER7$/$^"QN(RH(W&=EQAQ[3<B<LS[CC[5TE2E81:'2;;D
MJMDU\0C"L2PM(I`^I\T+E:U66Z;SJN5^\^`+Z_E;>VROS="YXYXX@N[>^SED
M?AFTY#Y#PMME;*3;YNZU5=8V.;TD/4Y/,G:9'V9HME65SGO>6)#<X35/-\X&
MI3DVQ^+OHC_&>,-5R?Q;C+[:P^&.=>4.+:VWXEG:3D[$<4UL/FC`8G>W#(VB
M9.S&=#6Q;SM4S6R2T<(I8ITK#F*]JHY#?65-;]/?"'+G$^U)L^8_GSDOAX$_
M/YO:1;C0Y77Y25/OP+HLE$-6%?8!MGVT:L?8U9@",TS()9,=ZI%(035(8':9
MU6;V#\2\4<,0M?=U7SSD."+W"TN"J;K]IQ`<#I^/-1.E:#/XZF)#BDK=1G=-
M9W<B?%@1DDBG'EED,81Y'O5IYB?GK#N!UGPYRG];<B9+CWB7A3:<E%^?LMSG
MN^<:?.\9W`M3B^:37^*JJR/>1V2]#JPZS)44@MM*8U]:6N/#"<IG':,;3S!9
M\-8GX!^Q/XQVV''./XMJN(>)LQ8U]AR5Q3>66:PO'U!+UFIY#Y!^<M*#-B<4
M%C#V$N;C#5TR6HAB+564&,LA4.R.C52KZV(QO'O\=FCM^5?F7!X;Y;M+@DZ/
M><L\.9O,<?E,6QRUB%L>9>9N#!099>%N+4341C%?0S);&JD8IVH]JGGZ[ZP-
MJ-7\W:;;#@9_^/)W-/$?R[MHG`<CF++<6\07=1Q9HZJUH67=%Q=QC,FCY)U.
M-XET5G&_>Y5%4N#4SXDMT$4LT"2HFJ[@==SK<"I^A?D''EY3QM-RUP=EDXOE
M:G7\O4L/39.D@9*9?:LTC?:76M9(BU\8Y=SHG_O\LJJH+><K9SF2#=G-6PWS
MUK03[6^"*MMS5Y47'MW1?-.6'FR2J"KP\&EP_&.Q^?=-S2.%Q>*PF5JZ#-Z'
MCWBUL(M50#*1_I&X@/P8AY`&KN+?MU:=#RS_`!P<J\'93DGF_B_YIXRX^+/X
MVL<U6<I?]#KF)$N]!P-QUH**(P-%.NH]98YSA[]IK9H)#0(&AJ1N5'5`HQW-
M(8&!.MAN<OH[X9F8;F#CGE[9<,\B9KCCC>]W_(_$LW_&=MY9#`T$+<3DC9,_
MY,"SM:*H=!L`Q@]Y,-#1)'837A+TU0!IVU:>67^-;D?*<7?-5-G_`)CLZ#84
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MWD@:$_<JCG'_`*VGG'QU%K]/_%Y74W'9*Z1\?5U!RFWDC*\=Q0UG&D*JT<?>
M7=5F.7,W`K/PQ18M?JM7`@UFAAF$$$JX8"++8Z6K!JT\_P`]793\[_Q[<`Y;
M2\69[DGYJXRR.4TN@QVLP%#;8NHK(&U(V\?K,O<YRL5&R]>L?/V!;.$019_H
MBE+(9ZVJ[II#'??4EC:W^.#C?D3`8;`5GRAD^2]M59+5\<4V3K^.86@TE6UE
M]?<=7F=-5!0D]I(L^TD9PHR*\D5TI:_R"TO9IYR)WC5H7&Y_BJY*F<>-NK?X
MUWAWZ315O&Y9D;C'311:/6Z>#=Z7]EDNC38,0F@WVICGD'5S!2-%,9W>M@Y$
MZ:0X^.JN3ZA^)?HD%C8['_I=J<+Q).^@'VVRY7_P$59A+_A[8@^?N2?QZC63
MW:(4+0!W98;+.)$=`EUMBR+(*PL\$8S2&'34?D'E3^-'58VID\FZ[Y1N<7R[
M`HTK'ZV1@)$#75W%EX;+4YGML6>W\7BK17I8#BF0;<W*E/$5T9Y'-5H`_A.M
MK-;A.%8O$-OA-OD>,X/`]'D71+O)Z.DS,'BNCPV;B,F>J?3V$<.5J<SGH5<T
MS?,8XT-D=")X(-%1JF\SXZU1J^2?XTLKQ&MW5WORSG^'9L6WX0E$9"Q%;G3U
M]@A=QH^.[BO+#"1U9.CV[[^QBRQ>@L66MG([A*LAS58:?&=71RIB?X_>*E?S
M#R[B_FC)%Y*LK]/\[TV6PPYFYG;C(W$+8?C6+Z\LO0BU6(F6!+KU>T,RN=(D
M3/(2$(C0<CL)U0N0>7/XV:?ES.;3D?;_`"@+FW&9VKDY/47L_CN9OJ//R\VW
M6Y9E#;N_(MQ-L\K?/GT(0$4TN)+,2O:]I#*K0!XVF-7-QCL/@;ABZR5#P]=_
M-7&]U](Q*+6X^#QZ3"YT_*M;=&F!R%M7+0-CLM:JZGR)(*3NY(\J8\X82/.I
M6=-#R/6=M6AH.0_XSN7<5L,WIM)\E<@\?\33['E374UN7CF_S.0M=1I[:/>;
M8L22P\`5GH]K=3H5A*`CC3+:<:'(5\F0\+VD.#XSK!?#/('\:D+>\J?3QKGB
M*BU>^^@M9QWEN2^3%XPCRS3>/>*N*N(+VMX>T,0:V-=Q97YNGA@D.DE8ZLD6
M4R/)=&#):!6JD-$?+69MML_@6ZY^^>_F^?A^#>2>7LIIK/`<=9:OSO'E_9<`
M_P"!\6WG*P@?MTEJ3,E2U5/@(0A1*\3U@6!JQQ`A[A*QJGF@G>-9)Y1P_P`*
M\%1-SN>6<-\[<=QN<C6&6WUQI\AC(!.52W'Y.DOJ2Z"6L=(UO[E^VGMK,*C,
MA?Q23I2+Z7F:T'([#PU1\WJ/X]<O>Y/@#(VWRY5WVAR=IC,CQG0/X\0]QC.8
MZFLWUIG(%5`:\4RDY?J846W?'7R'I6`;(1)2B5S6GFZ[ZQUGM+_'I].\M[O@
M?,\<<$<U&3'9WF3?:&JR_'6NQTF?B[.3PUEDMY@$E3)FFIJ*M+7P)GI?'?1C
M?&#(>!'A1MIY@)UB?&_6O\6_+?+7'&I+F^$JK51LE4$XBY;Y!QW'F>/'?B.:
M=IPW29+'6MIWNZ>QQVUQ#WUY!L!%@Q;.)Z##?+]2M5AP/'6]#-E\H\P<G<@<
M5?O7"_(W+%9B[;"\CXPSLMI-5_@+["/_`)+C-!!.R5)GYN';6@&VM:_V@B29
M0FRAC(8:.:M@@3X:T5E<_?+9/H+DR5<_$L=R:CFZ3\6<D?13Z'Y\M9.OU6HB
M9_-3:C29,>S)S->\?WS;:%76<QU+)9^`%#3!_MT5QPM708Z^$ZV'Y%Y`^)@<
MG_-/(DO(\0<E\H<B2\74</<AT-3@-!I\OQ_J<YNM)D.28VCDE990>,F1\Q9!
M@6$4A&"/*(D9$:^0Y&J`-!^&L2S,K_&QRKP[RQQCPMOOG;BG%<V0IF-YDL>%
M8'$&>F[WCZGR%SK=KC9QIF?EPDS=]Q-'NI26``>4>I+-LZ\XR-)*:U7S@B9U
ML?R+S[\.DXR#E>3^4?GZ;Q'K,WCHH:#37^1LL3<8_6Y\>GQ4A:^2635$S$[+
M1!VD64YJ1`0!LE^Q@D83IJ@#3M,ZR/FN'/FOA.KG;C*<<<.<74M'77VGL]?4
MYS)9.LJ*N;GZ*)J]'.OPQH46##L<UCJY+.:0K6R(M:!TA[FA:K6J23MOK!/&
MW,'\=?!W'UYR-Q1KOFKB?CW5;9:/27V,;D,776NWAU/[VE7=`K(U?)2=59F;
M^XL$<31PZ@WYC4'#?[5:J0Q,&=7'RO0?!O&3>.N8^7LW\X9=U9<3)O%>\TF=
MQ#)+;F^M+CD^?/QEE^"63,D'N9MAIBGB^Q`2'R+1SF.]LCIH.1V$ZQ)I+G^*
M#CYNYXTT9_B[-,Y.C4>LWN.+&XNCCV@701<DXRRM:R,%S+8\Z-/_`'S/,1KB
MRBD?+KVO*I']/EJOGZ[ZNTX_XT;*Q^=<P2N^1)DVV"#9?,=,&GXQ,)8VVT!+
MJ!>\:Q8\-8E?%VFS`Z1#?'00[6\!Y`]LT/\`0U3S[]=>LKR;_&N'=\G<ZXW5
M_)P>2,=6GT_*/*]"?CH>NJ:VYEID9]O;:^(QMH1EO<1V5$QXCO=)LFCAF\I7
MK%TTA^F\:QM"YQ_C1Y;N+'GC>5WSS67X^9Y_%67Y4Y)@\<)<;C5\)RLU+B:_
M):4IILXE7CYUK""VT,2.:H<U@)+HZ>MBM5AQM\M7_K>1/A.?RSAOCPF3X6W^
MTW$6?P'8\:TU'@+@>#Q7'?'VDYJA9+64)/`U9CZ$.1"Z+7Q0E_;+2;`(X(%(
M,J-4AHY:S=M"?)WS%P\?,;B%PIPSP;>RK+,FR%I3Y3,\?Z&9K`V$R]I/\32&
M&IOI&@B-FRK`"1C.D1V29$A%&TST:H.1.W76`>$-G\5GY9Y=X`X9XHXGIJ?Y
M\XOSFZT^PS%)QZ'($HOH^A9?V<2@;3ND6MM4Z;#8^IEVMBHTKY\1((6D.@&M
M$U4\HD^.L)<0?0/\57./(>*L*'"<#4FKV^$^?-QQ/J=IA^.\Y=Z\6W3=8#CF
M@RK9#'W<'49-G&S\\0;F`;V/"K(Y9'DP#6JD.!XZWSXDW7RQ<:+D'BCA'0<.
M2M)EG0HG(^&X]-F63(*9NHJ^,HH[NII6C;*#F*C*P\X]?$C*YM<*N>HE`T+6
MK2&ZF=:2XZ\^:97^=8+B[^.I+?Y4VO+XN$.1>4\-Q=P\G'NIW>&V[^.271>)
M:R>/D#2<4\9<D0SUI-(&H=&IYL2581PI7@-9(U=YNI/FULM6<U?`U=QER)Q7
M6\B?-%;P[Q'6MQW)F%9<X*!QQC*2_P!`3'/J-'2D>'-1Z.VUTLM497L=&+:N
M+%(Y9/L8C5(;KO.J1;;/^.WZ$T%SQA?7/R_RKIM6:#R!H<E=?X'?VMQ9X[%0
MI$#07$6P&60319OC68$C?<J3XN>(KE:V"KEZ:0PWW&K>M^0?XQ>0.,YMU>7W
MR)IN*C;W%YB3(LA\;RLQ)Y&S6/+&XWI@1Y`/1)T<?CRI>&@$%CB2*(:CA>R&
M[Q5I#SXSJ4Y'^E?XY:G@^_PVBT'!.PX0PNFXHXHN^,,Y4Y74Y+,R=KR34\;\
M>BBXN"!]1&S=)M$_M3805C5SZN0X#D/$5C6@#SM,ZDPG_C<MO^B%#NL-\I9C
M1I/V6`X*Q.H@\-7%A!B4?*EQC#0\@E26YJ8$.^Y#H_.,%I6%_?BI'>QENTH6
M-5\_A,:D9G%?\?GTK+YCXDX4TW!^=Y*VRQ9?-UGP)#XN!REH,Q0<J0KG>4US
M9AI+.0L>ZW56Z#HI0V/FQ+(Z.,0,_P!!&M)803TUN(#YP^?8^FWVS%PCQ0W5
M\JU5E1<EZ%W'^6):[VDNFB9>U&MF$JW%OJV_:`?[@"2I!SO4-3H16,[-6R=1
M<?\`/'`W'H\2/"\-\9Y%.-I.IFX!^=Q6>J3XZ9N8S8>UF9V1"@!D54K7QF-9
M9D$YKYZ,9[U?X-[-))UZV_SUP1R4;52>0>'>--G*W-=F*C8R]+B\_;S-/78J
M;866-BWDN;`+)L69.PM9)ZQ2N<Z"4[W!5BN5>FDD=-7%8<4\8VO'3N(+'CS%
M3.*74,;+_P#38V8IG88><A#".#1ARR0TI054!D<?H`P+1@4;%8C5:U4:I)F?
M'5BT?RS\U9J%/K<_P'P_3U]HR:.SA5_'>4C1;!MF'*1[19H!U;1RB6P\)2_E
MN>CG2G5,1Q5>Z.)6M5D_'5W\H<,\2<VTL+.<P\9X3E"AK+,5S74^]RM+JZZ!
M:A":,VPAQ;J',#&E/B22@(YB-4L<I!/\AD>US0$CIJZ*3(93-3;FQSN:H:&?
MHGU1+^;3U$"ME71**HAY^E?:'A@"2<ZHH:\$*-[5=Z(H6"9XL8UJ-4U8<3Y_
MX*@QM3"A<.<818>XAZBOV40&&S0HVJK]O=R]+LH&@`RM05M!U6BGGGV(3H\<
MR88ABHXCW.5JLG4U3<&<+YWDF^YCH>*..Z;EC417P]%R168^AA;:ZC%;$9(%
M8Z6/!';2DF#KXS3JXJJ=L4*$5R!$C6DF(\-94Z:IITTTZ::TFTO!U[:?6&1Y
M>@YK('SE9/F+<SDS<NIVL>PB8RGK(M]_E5S?Z_-WM),_,9%+$K*3,6T@E>!Q
M;&0*K&&2U=/ECQUNSTU;ITTUQ=Y5^J.9N/\`^43(\*P>?\'AN&MO(XCSIN).
M6\EI]=;[[27U1>2-`/@B5@>+H#\G-G0W5#%FZ3:'K(EA'GO=6/882C:D`'"8
MWUFOE71?B_95+CV27?N.CU'!5S&RU;$S4_`W]5G)L\\_3\NRB6K==0\EYIGY
M!<HD8`8TPD&M]K9K`O=7M4'TSK)7VE>7><RE5;9J6:%H8_*W%0Z:2!R-*.=)
MC:V,/U]WL5[W,*Y$:GDKE7LC7=^R][[)HHR<MZ<D!L<XE_('X`UG7CWYIY>7
M@]NKR<!BF:.XX@0CJ&(N']O3Q^!Z:Y&\P;F=K^2J7,3LAC]227=2<<>XFPI>
M)O-;>MNI\?230V&=2L2CMZZP26UJ?MLV-(AECR'%(JN[^O\`9L!,/MCY5=UU
M0%8L"@BQ:UX@H"'Y<E(X_P`ZL&#+`U\V^YN[W=R[[5@78V-D%K3279319=9S
M86L&KX>FZMS`^Z=60HY9B3J\-KQSP)IY%$:9RGK.%8TN-9U64KM?DJ?98?.5
M]).K)%5;-W5:(1:(+M$PQFS+>*^3,/+,U5:]@W-PL+N7?\5;`F)3FL"K6&NQ
MJ[7+!@R^DWUGA`XUM"A5.X)ULNZ]D]G9]E+6]PR>U(RLE*W4I?14M;*4?\0H
M!K'J<B'N0L[.PV(!%_:#@B]H,C2PN.K;%7L6X/YU-A5ZNLS-6Z'954^%M]S$
M,M6*BE6L"(PAXT<$IC'N3S</M&0?6!C]_HR,QW[DE];H/,&K9VE6!JJ(Y<@I
M,`DJ2.@/FG6XS?:.7A]MJJ[)9BW5VGR,ERU)Q9&6_(4\!674`LJJX!.Y7[OC
MK`NHPMYPU6BJ[:ON6VK64\;(WMM8VI(UE.B!T(9%S8GCP*K-Z!"T!HKD4#[/
MW_HG]2"8]V_Q,^CO5AMI9/2EC8BA94'A"@$LZ><-U"1^LC7']P[1E^UZ!C9"
M6_B`$%-CL\,RBP%V(5*K)K*'RFWE\PH)PY"M[>GH=<[RL2R--^-'NFS3(=#&
MG:FK\9,KLY(9Y$-T=);0">J!.Q&(CQL1).Y>FJ[(I'E"U25C;85ML/$`SQD]
M09V)\O,U9.3C8>3]9>^!9R,R6M3<_P`I(CF%!V81NH\]Y<@[C25NKWT.#(+=
M.N*K%CM(H,VVEF6,BID7RU4>>UL=TY(L"SL6/)':WQ.K_P!5:7T=87;\'&LQ
M,=[`$"/9Q)?D`&"<B-XDJ-CX1\.6MGWGNV=1W',JI8VFVN@.!5Z;,4-G`-MR
MA78$J-FG?S<-5;+2S<B0866+#KY9R1YV=KZR2*GN1W-;<6]/(O&SVV<1EG(E
MT(P`:CHYVJ^.P4@+'.*5XXLI%[<[989@LARPY+Q958+'$\0'D]1L25)V`.5V
M^QN]U)V]E1G*M6J$(X=7=#9RYCD37"B5;=0KJ"68C8SA[A/E2\_>*6^H)!6G
MK[)]')OF9:FA3L_9@C5RX]]:R>'0--@L^X$EI4#ZO21HT]16*CN;[SWSM5!2
M_'L`AEY!.;$.I)]3E'"+7D1,R"=P=NV]L^U/<.7ZN)F4D@HWIFSTD5JW`7T>
M/(63CU\6GC'$A1Q80<93OFO!<8<FPHI?HO#9X]<V19Y'#XFEE[G;QZRBBR')
M2WB?N%5@@24823(G#ES6K-\S"4#FO\6;2OW-W#NG:V<=MOL5H6RVUA546<CS
M+LUI'0*57RP#R!$G07>Q>S]@[\E9[WB4NDM3CT(U]X6L'R6>9,<&.36!W'.6
M4H08$AK^1\=@]TM33<6TALW(%'L&PMM>K)DW%"9QY"RCU%*L8%/!JK![R'DS
M(=@&&UK55YQM7SOP^VYF?@>M?E.,H2)J2`KB!`9I+%AL%5D+?!3TB[GWSMG9
M^[_AL;M])P2`W&^R2]9DR42`BHTEF=+%2`9<#?;/A3<Z;5<L[&KM]&/14%-\
M\S+'%DABJHE-&S>CWO$TFK6C@4\*%"A0)=5$C$<QB$[&\T<]7HY&\EWS`Q<3
MM%-M-9KR'[B!9/(L72K(#<BQ))#%@#MM&T:]&]J]VS^X>X\K'R;Q?A5=E9J"
M`@056Y&&4]-45552BJ2!/FF3(,=H^O$]?4^G333IIITTUIM]R$<WY^Y;&-[6
MD=P_NB#14<YWF*[PB-(C&-(]S!N*GDB,<OZIV1?]%[3V(`?<.&3T_&5?^&W7
ME_YM,1[,[DJD<CVS(/[+,??]4_`ZX?\`+IXP.3;>5Z;`'<]-8`-5VU74Z$V8
M+6YYDN3!T\B22LC<8.$\37T#5!8RYA72/)R/:G7N?9U9NV(DJ=F!Y*S)SY/`
M*`<C?,Q;NBJ`L"-?)WN5ZT[_`&V0Z[HP*.B6&HK7R*VD\1BQ`./Y;7<EY((U
M<W-[FSX=*VNAUY5J-YJSJRMI)@9,&1-ID2+:0[$8Y=5QZ'V,,3\JQ9+A':Y#
MKY(WQZQ>Q?=N_J%ASQZQNP@@-NI&S7>`XH58?3K.]V'UJ:A0J'TLRX^6L@J6
M39U8<DQA/(\[0Z,#SWB-4S#4^UE9//S.-BZ9\RJLK<EC9YPQVP03+2QI"PY?
MO(YC)BRHYP*&8629LQK'&$)HC($,N?=A)EV)W,5<'585XDA0P(CP@@RH`X[*
M22LM!VC&[K9VVFWL1O-E;OR:HGB&=JRID_5(*\7+-S@NJA6XKEO0X_Z,KCNO
M;F\MAUT1G:;=YA:FMR8)8)I&6KS3(Z5]7*.*^&0DI#G\2$*Y['$'YN73X^9[
M;L7T**T-IZ*_)K""/+`,L!P@+`V``,&!KI,SMGO>AOQF5;8*%'FLJX+2"&/.
M6'%"18"7Y-!))!*R=>(^NXU9C[5G+1,7H[YE/=NA$QN4D1M^MC(J+5L>1/Y`
MI)F6Q%=*):`:4AI8KP9X37(O^WPJV'W,YB'M`OJQ^:SZE@-4!ED"E@]K#B8`
M4U$-'ZZ)W+L0[98/<9Q;\P56<3321D<BCP6R$:JA27`)9Q>&2?U6E@HV)N[3
M@X'+-Q;FIH?#.F#F(VEK;6DH1W;:S"OK0S]#0UUW>NRYF/(T<B&'\KW#"QJH
MTG9<O/;-HJSV[0B"YLU"Y1E9^/*V2$8JG,;2&/&"3U&M;V>OM.5D=I3W';8<
M5>UVBH6J]=8LXX_$-96MEGI$2`R+SY!0-FUD?0U.BH]!8VO#U?D?Q:N2:=1R
M^,),6_LX40_Y+5<85D:9R#63&1%$8?M:`1C)ZW,[.1SM;CW8U^.M7>6NYL(8
M7@HI(CH5BEA,@Q)`WG;;>9N-FXF8^1[93&].MBU;8I%CJ#/4.6R5;C!$\0S;
M$;R<<W^N^J"Q364V-8PXY1UUC(MZ1L)^V7RAS(`XUL9A[#05U<"N'*&T<E8\
M-I&E<K4(Y5798^'[4#"I"K,"0%:?3Z@RHA4+$\3*RT0)C6DS.Y?F$U9OM6Q:
MR%8O7Q]?HR@.06L50H<0_%)#$B2=:_<K%69HY=Y9&%^[GJZ:;=GMIT^C$RU/
M5PY)WV-["[:.E#,F$8YK:QTLLZ4I'6*">B/=T/:1PQA14#Z(=@H4!O+R(V4^
M1B!/U\0JQZ<C8<9[B8V9S9=Y'XDUHUA=FK',HI/*Q?O4#,08JYFQY-W$[G:;
MZ*,A,1&(R'=AMEV\*1)CT_[793$A3<U/_P`G_-'*"6NI\F88V*ZP'XSY"H4C
MO)PT5_*^W!&<1R0U>@0"W)1(<<(C=K.OD/E&PZ';T'WNT]I5@MHR?Q:DA.#-
MQ:IO5Y`CBE)`$V#[QO,QDC>Y/EPP6&^9PJYAF.Y^E0J4\5&+0?MK<G1V0@8Z
M6?T6\_,1V^UH'S&FD%,AWN[*CG]8WNI25[FW0_T\%@?KY>HP^\`E0YVD+``X
M@>`UG?E^RANPKL1_62J$1Z?'T:V`I)AVJ&X4O+%N9/0G7=S'*JY7/JK?%5JH
M:JWP4?BOI;W;ZU1%9V_W?[.O!<W_`)NS_?.OKWM?_NZG_P!6O\-7+UBZS].F
MFG336@_UKQGS[L>=OC?:\"QL3'LN,='SE8:+4<D9N;J\7G(6KX@LLM6)9U=)
MJ\AI@R[:RFH*/(KY+GM5KPE:@3O>UJY2((.L)Y+^,^QXQR,>%Q_RM1R-EB]9
M\I[OC>XUV`?,H9-_\Q<3CXP2LY!IJS21)=GG-B.=9RX@H$J*_-R90"Q?<Z(U
M"M5YS^_5=RO\<TZMY(XBY.T/*M?+L(/(W(7+?T=E\_C)-/E>9-A;\OZ+Z$X=
MK*`$K3V4W'9?@;F;53+2N;)?:R[/S<^25IBE>K3EM&L5YW^+[DK*_P#3ZEH.
M=LQ1T6>XYQ^*VN@SV2W]'JM^''\>W^#'GM;EP<JFX?VF>LDNO?&M;C/R=70Q
MD)#@631_C$B-.8^&KDK_`.-;>P,Q`XG3F?'$XB#I,UR[,+_TVM&\GDYDS7SE
M3<`@BQ-.NV?41^-)<JB!<O"L)ULR$I*-)*PGH9C3GX^.JOM/XYM1.BXR9DN0
M\0VZP?#WRCQ?1ANL[R+E71)WS9G^?<V35Y3?\/\`*/'W)W&-U=1.<7+$-2V+
M'`BQ),"4V7$L"H)IR_MUGB[^6N41<1?*E/GN8*;2\W_*%Q4Z6EWW)V*-89#D
MBZ;Q3M^(-(NORF7OJ*PJDL<WR!-/!EPYQ)D":$#R.EM60TS5)$GX'4Y\H?(<
M[YIT&GT$SD"/LY&PXSP^5N00\RN8KQ:^HYC^E>:MC>TE<RYM8]-E;;1?1DB+
M4U#5(ZJ@US&/DR7$5Z-&:=:T5'\9FDB8'F#&6?+^;FRN0>";_@7.7@./9HS4
ME!-^CN7>=JFZN0R==*)9SVPN3A5TV/'+%CGD5Z2&>MKVA'352^\ZR+\]_`=E
MPESX3DN=OZ_5XW,:3Z&U?&\"8?EN=LX5C]);Z;O]7%N!:3EN_P")Z.-0'M)$
M)"Y[,5<B\&D>1,<,P"?DUT+2(U<(/E;Z'QNFY*R7$//^6P7`/,'-MQSII7_X
M#;3N>\+:;?35NRY9P_&VS;K@8EE#R-I(T\P;*QI)%A0#NY;`LE.'#)':I((W
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MCK]!557[LEM(UI$RW/\`P/K^&WU]7AJODFOX+Q4KCG_((Y(A*/+PC7<6.J3#
M#*Y[RTU7F/AJ\./OXX]CF^:\MR9J>3LMHZ0>]XJYOV5."/S3%*G+_&7!^-X7
M8'$9HO-A>*:_)S?\(BV<6=:YZTT%>(TBO2483PGC5U0MM&LQ<C_&^WV/,NUT
MM+R3DZGB7F#EGYOYKY3H;/"S[+DZ'L?F*RP-EDZKCG<Q=16U5+FM8_B^E;-2
M;6S)-8[]P+#?[;!'1&@81'CJXJCX_L:WY0X&^:R[^))G<,[SYQV<K8IG##C:
M%G`W.6&YADUX*-;HA:Q=+'Q[J\9%E'2(XZ%5I49ZW-4Y;D_'6O\`>?QIW$W%
M\)TE/RW1U^AX)%R[>YB=+X_--SMYNMO]?\*_7.4D:B@%J89IV1@7G#C*NZA,
MDLDV3)ZR@R(Q@L1S5>6Y^>IC:_!O.F]#R5)N.9>&HMO].<73^&/I5U7P26'`
MK<-(W'(6JKI7!PXVSC2:W9UU+R;95DBTTC[HEG-%"MC-82&V$1IR`^.QU3-G
M\E<\<=\B?-,W@.;@;2USOT]]O\YZ3:;[$3;7'YBN^B:KDZYI:S1UE-M<]JYM
MS&/M8]2RVA2U-)?&5"B''.]HVG($&?@-3&`_C9U/&,',\8YKF'-3^$#:_P"7
M^3^1TNN.9/\`U;L.0?EN%QL.B#@=7"UPZ'(8K;6/$].8\(T":>CCNGQH)E;-
M8^(TY@[^.K`Y#_BYY1T7$7%G#>7YZS%9F,!\Y<1\.'BSLOR)4TK]CQ!LY6X;
MN!93C_E7'T6KA\B321HDV!J&7@*)D/\`*KVK(E2T*U7F)F-YUD6__CHW=UHY
MNJ'S'DHUKF^1>8>4>+!'X\N)]9%T/(/V9Q5]JYNNY#@OW`/\CH:#9X&91S&0
M7UQ9==+CR@.BS(WD1JG,=/TZ1J*S^.;5W3?H/2;'E;)DY!^E>!/JCBW:GS?'
MLROQ^:U'TL[CB&VVR-3.U,RR3,9.AXQKQ2XLB2LN^L7&GF/'>5`CIISZ?`:V
MYT_&W,G(O!_/?#]CKZ#CRTTM=I^/N&]_GJ!+F=28N?@Z*GJ-+JJ*UNI\*TT(
MM06T<1@2PVD@I'5K(Y_)R5U20"#KGG)_C'YI(W>W`.8.-AZW;\BPN1Z^W/\`
M^)Z3J<!<2^#,WP;>/RW-#OI%O-DV1%K,=$F>$^Y/4W@94BOL*Y(XH1([5W,:
MVQY^^2.5.5\!P#BZ#G-8A^+,U99+?V=[6:S-NY1_><#!Q4C:S)/"FYXKT51;
M5LF,>?\`L,6Q#G;-9Q`2PJP,9PFK00#.L1\+_P`;]SQK4<3@ON3,O>6O'/+7
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M>..=\9::.RS,K+DC'BZ.?8U.G#):6='`4/\`<:KS'ZM9HA?#O,O'FZR&DXZY
M(XPGX7@OD;Z5YVX6Q]]QG;2=]:<C?0/&?*N?+E=OOO\`J%6UTC'9[:<DEE"?
M&B1)D^N:"+(.)\1LLM=4Y`_KUG+Z7^=>8/H//<*I6\ETF!NL@MP?DJABIR)`
MS>IDZS$OS5D:LT7&O('&_)$2/E+&6>1$KOWAE=<!(H+%CT:(@VJ`@3K7'C#^
M,RVQW%53QWH^5*"TFQM=\/W=I<T&)FTJS:7XYXYXXXU6LB*732YT&=N*S`.E
M`/[GMJ)$]Z-8=&>3VJE]_P!O[]9?^6/CSDO@[DZAW&^Y-X^V-1QY\M8+Y'X[
MJ\7QK9XNV/@^,]-)N,YK=O;6.TTP9^FL:\S`R8,&/%K8AV$+&1K9#AL:H6!'
MZ]8<KOXS](+&<WY.SY>S4L_)?"^^X1S%R'CZ:R1GZ#5_2?+7/]=:W8Y.NDOM
MI\47)S:V8".2)'DEKVR&(-'H(=-5Y#;60OG_`.`[+A7G\G)L[?UVJQF9U?T/
ML^.:^:;EN=LX5K]*;JRW>LB6XM'RW?<34D6@/<RH33Y_+UDJ[$D8\QPS`*LJ
MNA:1&L:'_C1T<SG+8<AET?SQ`IM1]:4OU/%Y)K>`)K?K3..H[W&7_P#TVS?.
M!.0FPJBAO1Y$E)/D)4E]V<M)L+\=?>I$IISVC?I&K!X3_C\W6FRNHTT[27_"
MLUGTG?WO`]/J<C27&GXO^8\-F^?\QPMQT7-)>6-#&-G=M]!:/10!2BRANJ"P
M84N.PC2,%752PG]6H4/^*#D>YKM>S:\]T:76M3YI$^\J*CE/6VD*!PTSECC_
M`)2IBW'+/+>XMYE7SCP)S9HZ!T>.:!!SY[!'QHIA!5IJ:<QX#5R6'\6>MH^/
M/\3XXY@RL#21^1N8K/,;>VS'(V9U?&W&.SS>5XVXAQF"UG$_+6#T;`<(\28*
MGI35-D:=E]@@'/L:X7B#U5U3GOK>FUXNYPW7S]S7PKH>0ZG,:2[H;SC7BGEF
MKS%?-N69<_'F>HH.ZVN72P7/2=5,USK8\B/7I6Q?PW`0(8I$[M:I(F=:"2/X
MRN:'CWEN'E[C9-9M>3*KDZNM)*_3TC38.Y)P72<%W:Y?FK_Q(,YQ-+CU>7BS
M&NEW1:VZCRY5=/KTC,ADCM7<QK:GGGY%Y5Y3X[^?</0\ZK'D<49>?C^0+:]J
M]9FG\IK;\?P</(V\R1PKNN+=%36U?)C2+#]ABV0<[9K.)'EA488SA-6A@)UB
M/AS^-RYXZI^+(U]R;E[NUX^Y0^2.0ITFLP,B!%N(_P`L?,U?\\0JJ.V9HYLF
M$;1$K6W(#/>5M:0CPM85?[RM5+SK'N3_`(I+O(ZW)V`>7JF]RTA_#Y>3*JUB
M<NU22#<%\R;#ES($QN9R',^;X[FNM7Z<,5_^3U-ZVGG1%LH:.(98S&J\]7V_
M^-:_A93@"%0<LYR-K?G7"SH62GS^/YALW?<B1?J#AOZ;SEUI:6#K8$U^4+;<
M3.K;.&&4V87]Q6:"2*1'8CFJ<QOML=8KT7\5')>GG:77VW->#D;CE.?](5W*
M-?7YCF7%\;LQOTKI\=K+V-GLSQQSOC+71V69E9<D4\71S[&ITX9+2SHX"A_N
M4U7F/AK-,+X>YEX\W60TG'7)'&$_"\%\C?2W.W"V/O\`C.VD[ZTY&^@>-.5*
M`N6V^_\`^H5;7R,?GMKR264(D:)$F3JUH(AS"=$;*+75.0(WZG6R7,G"7+?(
M5C\]\N8O6<>97G;A`6G*Z'L,K>['BBZ?R7B097=Q$K:G2YC4ULFMEA')J9X)
MWO:`1HAFN%-*0;5`0)'AJC?(7Q^WY072Q(V\)M:RXXYX&P<))%"VCDQ3<.9.
M[H+*V<(%G/A`B:6PNWR(L".P8:J,QD9CBL8U_31FG6O/'7\<>HR7&-KA+WEG
M,VUI(Q?P_P`?5U_68*RKV,H/B?G?4<K44N?%F:^RE%L]O074>$=HY`X]?8L-
M)"UXB-`RD:J7D_M_?J[OD+X$L_F/D<&ELM_7[7-X7(\EX+BI3&Y:F[`6<Y2Y
M!HM_<NTZ[/EK6\=T4F&3-0HQ@Y;/TL:WDC6?(:-Z"C"KHS2-5[&?*OT3QQ.?
MQ;@/H#*Y3Y@=S?HN:H\2JP%L'GZNJ=ARK9\SZW@^#NG:U^.3"WNVNYL9UPZG
M_>`YJ6^L8W\A!VC&J<@=SUUAFN_C5V\RCXSQ>SY<P-ECOGK.<=\;\(AHN*9-
M7<6O'61^D_GWGRW?S(>5L)]?J-=95GSQ54H"0`08#)DJ9;%`0LAL6.U7GO.K
M43X+Y<YWOOIG'<M:"BXYX%UGU?S[RWDHE%D2)S!H9?(7SF?@2GT+-J+82<Y_
MA[86ULYZ,/4-LSO@AKRJD'V>UJO("(ZQK.65^'N2;/F#CGG;F/D[C6YW?'VP
MXI."JXVXKGY#%S<3PQQ']-\=91&55WL=-+B;NRT/TM,MC35,6)7PZZ-710*C
M72WM4Y;0-8#S7\8G-U3/F7US]"X_1:</'O#^/K;NXS'*MVZTON!_IWCSZ/RF
MJMZZ_P"8[2IRM3N)61EP+7.92/14U/\`DC?6L\&>I&JEP?#5\I_&WOJ^MW>0
MI.9<8F)YZCMH>=UM^-;.=K(F8J?I+F_GZA_Z.VH]J&OS%^:!S?-I9![*-8AB
M3(@+B(-A_;&*U3F-9JX^^--MQ2_B:\Q/)6077<1XW["S].?08*TF9RRN/JGG
MS`\T?NUE5U>RJ+)8N7!CC0I(1S&%LI,EDE2A]:B>U0M.NA'35NG333IIITTT
MZ::=--.FFG333IIITTTZ::=--.FFG333IIK\Z_.6?VH/Y>LYR%E+'+9M(_)G
M!N*T530\VBX\Y*Y!R#<]PVPAM#AJ2SI[/DK'+'Y)O#!KK,5E%<'&ST1&^P2,
MIJ4?Y>N@?+L?94GV9Q]=4=KI\!@;.UXY9O[@5[7,R7(MY92I.4SF6_PZIYGS
MEQ+OI!BP8LFXM,_*`**D:,"/8=E?!KJP1QU=OVT!I\]CE+^/^,'GK@LDS\H2
M'C?BOEZ6,5\@?DQ[HX?>CR(QS%5C515\55%]`]CMQR+HGD>WY41L9A#M\S$"
M?'7C?YKH&PL7EQ],=XP"W(2(FT&1\!,F"-@1TG7$ZL/.@<JQ(DJ3<EO"Z)C[
MMKY->!/W1@"`IH&X'.--#K;A9#$2H!`>@JZ(X8)`T>PK1^WVK79VHN@3T!7Y
M=F/EF6-4`&M8_P`PN)=@64P1/RGCO;3[B6NQK3EF_P`^ZCSQ"+?R+"YY_P`E
M:S%:%4=9#!:=R\=IK/.2'UPHL>/D1U#Y45LQLN.R+K+1I84C5$*VBAP9"GBM
M?3H,4T@O$(Y(WJTG4G9UBJQ0Q+&[E!B#-:[BN.9(\WWDE09)4C;4'N9P]]#E
M`J+C!)'*1%SRIM)]-5,H#1`L*PH<&&UD>MHN5!_X4+C^++C!MZ#/U);,D05/
MFQ'#'F1IU!9KH0/J(Y8!02`RXDA9"A:1[3^;FN<76VW]J/KGN!4E+';C/)XD
M$..!Y$&0581,`K`@#>TXGN%1BKV965;*:T+D!*@0&#5OZ@X`J0RNC<N,D/)!
M+5&33<WTL_\`>[BXN*;-34DC#(FV-)G,AH(YJ,9*ZRJJ2UB5]'.@E@%4?H&,
MWJ\?(B^+FLZB6[L=]?H4HCY*QL`SV(>6ZLRDL#.\DB?#H3J9\7W9B7?B\JVV
MK`>0"S)538#7Y62MU6ME*F.(#1U8P0-53<:3A>1P_,2QCXVTY0+&H`U=CQ?F
M+FC?!MAZ[-N&EE=DN*?%WE*M$/LR%!IBND3'!**2G=CG18.-WM>\KZ9N3M0+
MEA>ZM*^F_1>+6*W+^9K!"R"O4:R.[9WM9_;+"Y<6SW`5K"-B5/7Q?UJHY6<T
MHLK],;)72>3E65^A-UYR%QSH^1.5'<O3"ETD.EX\?EDY"??XVKFU0%V7[@^?
M:8VLL[N1;@D1V*..\L6*<;9!"F;X/1N)DOW+&[;B?T=1^&+W<_1X6,&/IQ"V
M,JA3.Y`9@>("[C6QPJNQYW>NXGW*Q.<M6-Z7XGU*$9!Z_+D]".Y<$"%)1&`=
MF808LXP.5\D:U7CVFK80IA9[4N^'15=M50DEQXBC#^\YR1<:H"39KE:59,Q[
MR-:Y"-1'D3K,#=HS`G]1=F(`\N1R5C!._%PM9@=.*@#PZ#6L9/<7;6L_HM5:
M*Q;SX7!T60('.HO<.3;'DY)@R-SJ"^^^D:^=5#L)SZFI?H^]FF6="EGD7LJ[
M<_3.U4ZB*<,O0'M8S7R&39)"!`]&M!Z6L:EPQ_;5E;&M>=PK\O.0`H7R>F&@
MA`IVX@`D3RDDZL.9[YINK6YS7CF_S>CQ)-AL^]]9JR0;"X!8.Q*J8"<0!K`U
M'&!5<YYX\`I)<.3R/3UP2BEV,9)3DL)<)8`FUGY9)]S"KS$"^N*,U,(0T&&0
M]BJB=!>S7=BL6P`.,9FZ`QL#/FB%)@AP1829*@ZY#$1,?W;2])+5MG(H(+"?
M,5XCC/)U4E340U(`"JY$QE'Z+@0&&Q96QF?@#A:(6D2Z:"#7!2+?RXM8/D6Z
MKD-9YAYYPR,B1JMQ`/?ZVM[_`*+UJO;=EA%X)^\+)PXR290%O15H5]H+,\$"
M2=;_`-[TTAL5@H]$):+><*HBQ@HR766JEI"+5*D\0/#6V?S`:2_7,',2Q_*_
M\)!2G)<(,5J7QYJR\&,ME'CLBQ12V0(`4_0#'^KP1SG-1B,Y'W2JC#E./'^L
M#Z?I_P"6<GB3)B2?$B9V!F?1_8#6'N46\_4_Z;))?9S_`,=4HY`0`0JK_*#$
M22(CN?UX1KZXTZ::=--.FFM1/M*O?9<&<F1`">:7,XPU=7&$WU*A266CP0&A
M\3.8-Q#%:Q&^2HS_`%\E1.NP]DV"KON*[&$7*K8_^BEIG;7FOYITF_VEGUH"
M;&[?<@&VY>W'$;[23$3M\=<J^1N!I0HT(>]O<?B+YQ(-1>TMH]N@MSTU97O-
M2:FSR^<AZ*'8:?-4I`1P`NE2,!!,DB\B%(U/5^V]_0NQ[?7=?C[LK+Y%#,?,
MBNY0A':235YC)4[`:^>.^>S[%K1>\78V)F2J6(_WCE$6:[7JJ6Q6MJKXJJW^
M58#K)9AJ@3=?Q#C,_6"E8:#RJ41ZD-]9[>_L:S/5MY2-L[QUG8Y/$5<VTFVM
MM1A<:O)(M8\>?)*430#5KQ.R$P^\9N0Q2]L0$,46I%9RC<5XBRU@H56V<!"4
M4`EC((P[>Y>VNUX5:V8B=Q8,@L>^QEK6ROD_-J:%9V=ZP6K+6JMC%E"""IR-
M5?2>IVN?M,M6GRO&YZK\>!?4_'%55BJ\M,MA0)&<M,]&N,M(!(O*6(=7D.9K
M%'.<)CT17`?UK;?;6+A9"95@MR5>2C7,Q:P+(=7*N"%8B`!,J"1T8:W>/[Z[
MCW7"L[?0<?!>N%L3&1`E1<*:GK#U$&Q%,EF`BSB#U0ZPU9<B7.J30Y_D=3W-
MO*JY<R;4-U%#+NK2C$2)"P&IJIEFOXE>&^LCB4B1"PRQ;%6L*KHR%`NZK[=3
MB>GD=MA*0X`;@P57W-M;!=R54&.08,FX\T-KF+^]97<?7PN^<K<EJR63U:V=
MJP57'M1GV46,1/`H4M@--?)-8I9Q_H+.9=98#0FEQZ_0V!K,3&UT1L.NA2CS
MK\LVT25&KJZ-`C/E(]2G''(!6_H0#D)MCW#'J1,II"%D'$[F20`D+!))(7H"
M09Z-MSB]FS;[;>WH`;`EC%QY1Q526L+/(50H+S+!2I'U(>54=G)TQW$?XHKQ
M1TO$]KH5?,GUUI$'5K58N+)L*&":/[5B0H]@CR`5'/&+LI$<!I%6+\36GXSD
M:Y?+5-@5/+E80'(/4D;'Q/2&C61^!NL/;>`MBKMSV>9E<!>%`+5J1,*&DKU`
MZR@;7K)CEU\@.@(8BSA6;Q9T+*^;93"Z8.>MK,!R5D,K[V=7Q5J_;,.7T/D%
M>,?DUT@S64RREBG'`'IE?/N`.!=5(Y'R@GE"@2``3'E4FO;A90XS"Q]8616.
M+,QM%;L"4!]1E'"78\2Q*K(+N!LSB^<^3K2W;*LK1EAE<S(@RQS[',4$XW(%
ME?(=:*MS]]/MRW;*WCJTGL+,D-*208ZH%&HPK$ZYC-[#VNJGC4G'+M!$*[CT
ME2.1=0O'E<HA1``'FF0==YVOW;W[(R?4R+`_;L=E(9JJV.0UD^FM=C.;..,[
M`NTEBT+$,-4'D[Z1X9TF@I++9<'U&KN*+S=:\AX;=`PNM+J:.5`E[+.QV!D3
M[2\JJ\DIDF9'M&%B2.Q1J[Q[>61VOVUWK%QWJP<YZJ;/IIMJ-M81@16YV"JQ
M@JK(0PV,?#$[_P"^O:^?FU7]T[37DY-/UY-&0,>XVUE3=6(+/8BDAG6T%&\R
MS'7[RWG\UR@7.5^5T0L=-HBRM'=9W8P(`K6FV=H4*>P>PQ42[SM5?UE:QAR@
M6NBL#)>P9'M<AO6[1D9/:A99EU&Y+`$5ZR>+5J#_`.7:5=D9I`/-I62!$2]R
M86#[@:BGMUXQK:2;7KN50]=[D;BZ@/6EBK#%?20*Q"DSRC.N(X;N./M=\O$@
M2*_18VDY5JA%UU-/%,JKG6::+I;/06J,%=6)8DB3*D!C!"9SW_C`\W#&JM0>
MASN]4]QP^ZBP-7FOB-%;"&6M"BHOTB0`"21`DQ)WGKNT^V,KLO<O;[4LE_:Z
MNXH#<C`H]UHM:Q]G8@DE553)XK)"[1UPP<C\O%Y>4C%&DFCKCHQ6D8K/;&&_
MQ5A>Y6*WR[=G?U)_M_7KR#/7AFVIUBPC]^OI+L[^IVK'LZ<J5/[1/CO^W5V=
M8FMEITTTZ::=--.FFN#//6$+QKK/Y1KS'<M_2%?/X$^%\?S)Q1#G_57T1:T.
M,Y&Y`R7V.N@T8**XY*LZ8HSFPM2^,"3&D1:TE>,D,07L[]-2`SQF.O\`=JO\
MA_:7T)QCLK7%[>9PII-YQ#::Z=4Z@-SON%^+KAMY\,\A<Z9FJY#A6G)-_5NK
M*#8T"PI5K<220'5[QST!6R@K)&TX@_I\]7Q=?<W)\_X,^N^08=[5_P#B,X>A
M<CY'/#SO&[*BSJ]/#XRS>YJ9XLC3\D<^X;47N=I]8RP$^CU6@IIS1QV$<&02
M1!#DX^'E98<XZ%A6LM\A^G@-]:_-[E@=NLJ3-L6LW.%0&98DQX#83U)@#Q.M
M?]E]G_-'R30W.V^8>>.9^>=K.X.I-!,Q>^Y>U/T%Q7?1]3RIQ?B*KZ/Y&T>J
MW$\''EU2LU4R:2)7762K-'6,FL<P#*\4NOSG[+EK7ZJ&MU"@GBTP"0H)\`"3
MM)\#\#K5T^Z.W77"BY;J6+E1SK*RRJS%5'5B%4DP#$KXL)JV*_E`YKY`UF5X
ME6?Q7B[56?3CM;R=:\<SKY-!6<.1."28]<=B<!S_`+/.9?5V%CRS85]U&DZJ
M[%$+4#,-K5ELBBDI]O=SR!]T*RT.8#J3"<>4Q/\`B'C\?AJ'*]X]@P]\AKE3
ME6H)K903;SXQR"DCR-O'PZR-:\\?_4'._,>0^:9Y><XM\>MB?/NMY=O:*UY0
MI@\NWS?XTOI?Z$L*"?$RW,--6XU(.TXY$ZR%4-9#L[@(ITN.1(OX;]19592P
M6P02H8?,'<';72T7T9*L]!E5=D.Q$,K0PW'A^PCH=9BSW\M.ER>3L-!MM7PW
MQW28##QZ`/%O(5!RAI^4=-.KODW*<SUG*L;95.[U.CT5#=:N_"C8)Z(KI>81
M\\M]^XN_&78T]HNR,0Y=5E!0$CCR\_E7D3QB8`DS\OLUH\KW#B8?<5[9D49:
MV,%(?TQZ7G?@HY\HDM`@;[C;K&.+7^7'EP>VRK+'0U!&\+\Y<H5>\Q^<XZI:
MJUY]R4?X8U'.>.Q!:O.<\\RU>%U3N11$K8;8MS;GD$#$DFC"+'DU\B^OL>=8
M"1Z8*L5(Y`F16;(VD25!@3).VH[O=/:*&53ZQ5ZPX;TV`XFY:.1Y!2`'822(
M"^:8UM[\B?R=:+ENIY'3F&FJ)8JCCGC3D7/ZCC6FSE96QG\CTNHL+#'6U;0<
M]\S2&`HEI(YZJY//JIEM"F.<2LAOBN>6;$]N=PS0WI&H%0#!<29!(V7EX#QC
M6)W/WIV;M107KDE69A(K,`J0#)?AXG:)\28&K7^1_P"1'D/D#6_,&3OC8.)Q
MOR3AN'<?7PX#K/DO=6?(>B^8*WEVVK]1M)O-=WR=B=>._%(2&/3XZ73VV>:.
MP)J739*`9IK*7IL%=D`D*?E#`$?N.^VNGIOKR:&OI#$!G6-@248J8\.H,;ZK
M?+/\E_*W&O-O*+4S.0G<-\3_`$=QCP!*X_=BM*SF?5_]1OGS/\HS;F-K'[\>
M:H[^@V=LD.%6K12QV=>]?(X3>MZ[1>QYCB:FK>751Q),EE#+&V\@_;.M`WNK
MME6UZ7UD5/8>2@<0CE&Y`M((()^$;SK7&[_D]YKU7_06!!Y<X?C!V>V^)^5M
M5L>)\'93Z#)8OF_?7V;UWSAM$NN5[5LNYFBBQ75EW[ZB;9#!,&2IA+Z2K8O9
MLER@5ZO/QWY;#F8`8QL9!G4K^YNWU+:SU9(]/U=BF[>DH9B@GS`@B"-C(\-;
M>\S?R=R>/N;*[B*@H:HS>5*SC:QX8M]!GKI7Q09G:W)/KN5M8E1HRR9T7BKA
MB-!T-6D(0#%E27QRL*C4[Y.5[;[CB6+59Z9=P2L$P8ZB8'0;_9K![?[V[)W+
M'LR:/6%5+`/*@$<ME,<CLS>7[0=:OY_^13EKG2RPU&_69V%"/OOB'EFBMN/!
MBX[L=!A^=-CS-1WW'UU15G-/)VEG8Q\3`5Y0R;T.4NY3)R_F4D3^PJZ*Q'J;
MBX@P#^H[@[?$:ZZIZKD]2HRLL/UJ8(WB"#M_HUC.D_DUY'WT/Y#JUW&:XXI$
MY^^'<!>\<1Y^NE\Q\@4>MX+P/+FPUTCD&^Y3GV&@Q.EL]0:M97V=38$LZVMD
M3)ELZ8YP&;BKL>3:@8/4"SHH4L>1YCDI"Q)'Q(^!US>1[JP,>UZVIR&5*KG+
MA1Z8]%BC*6F%:1(!B01TG6[G+/\`*O6\:\K<F\<R:_*UTBBY&^&<KQW6:!ZQ
M]%JZ/Z0Y+'E>49BQAZ<*39F:S\:82I)'$P`I8%65[1M<U)']O9:.4YU%@R")
M,DV&%@$2=^L#;6-3[Q[=;4MPIR0C)<T\05`I7DW)@2JF.@8B9'QUJ')_E!YO
MUF4X+G\B3LQ25_,$KYPYHIV<(46LS%]F*.G^X>'.,MGQM<7-MR!IF;VIY'P.
MF5IW,BU#!2"'@D'*CG:1L2]BS'-85JYM"D;D?4ZH.H^+?LUD/[K[94M[.EW&
MAG#&`1Y:GM)$'_"AZQO`U7<'_+W]"[SB_3<@1,-Q3`2\S7'6JS<2SF<=4MKQ
M6NSYBJ./+''6E';_`%,(O*.F!G;"1^VNNC\7I,U-7)KR!&CV##BCMUWJI2Q0
M66+*@D;[QQGH&ZP"1TCJ0-;%N[X@HLR46UJ*7*N0I,#CRYQ$E.DE`T`SN`2+
MAR/\PVSO]OP?&DCPTC#:6;Q]C=K(HN/)LS4W_(&PYCVW$LZN=E$YR/MN*(QI
ME!`902X=-R#G[.R?.&:X!!`.>N0.S7&";*@FTDF.)+%?,/JV(.X#+\XU@M[D
MQ5#`4WFT!BH`!#A55Y1AY"2K`\69'Z>63&MP>??N'D3C+G#9Y6OD<59'*\15
M?SQ:VW''(4"UE\N\]LYRMM7#LX'$$RHV-;'@66:_QYE75CBTNG2UTBFCRG5\
M,3IC</&Q!DY7X5;$5B84GE#&8`$`D<O"0!\8UL<W/.#V\=PLHN=0.3JO'E6L
M2S,"P!X_S!23\`=:<XS^8K9M+Q'.ULW@_69OEL'SGM='<86MMZN#\^T?+W);
ML)JN+.0[&PY)O8T[958CL94V\QM![[&MLF2:D;&"1,_^A91:M0]1-@0]=EYD
M`<C&W7]QUJ3[K[>J76&K(`I:T1Q!+^DI9B@!EMA_]$-XU3KO^8'F:[@<I;?C
M6HX7D\?<-8WD[E&<LVCTN@G<G9G$?8O+G`])GL]?U/(U?493]]XSP,:<2[='
MMQLO'N4<)\-_@RU>RWLKN+*^**2>N\.4VV^*G]4:D;W+B(]534W![751/$06
MJ6W<3.RN!'69^W5F5G\J/T?F6;S#U%EB>0M;F-S]\<C2M1N,UBLM2`R?"7T%
M_B7&_`4DVH^D^,Z[+RF9NX8:;>CEWEC4U1(",I)_]R86#-[9?@@-<R%2S"1_
MLL5/6/$3\8(.LOMG?,3NS%<:NP.$K:&@?YE8L7<2.AXS,<E(!,:OW=?RQ_0L
M*PY%)34/$&7K:;G;8<6Y_-6V<9?\DTM#QSQA%WNEL;.LTWT'Q!F.0M,[0VX:
MV=64]A"E5E/"DV,85F4B1(V8_M_*6@9(>LU&QEV.YXJ&+"8D01TW^6M95[O[
M?9EG!-5ZY"TI89&PYN4"MQ#%6Y*1)''PD>-W9K^2+D/6LW=_A-%PSQ7G+F3R
M/R=6\E\^FY&M>/\`0Q>-/D;X[Y0K^,\Q07W(6'GX"RWEAS+86B,9^+^!04\J
M9^SR;(TXS=3DT?A[/2Y!C`,B?$!AUCP/[M=%A9(S:/7X,@Y,L$@GRNR$[$CJ
MNWQD:I\?^6#FVDBYSD349;C'0Y*=MLOQW(X?P^2VK.1KF?I_@K+?63+ZKY`L
M=M.HH4[_`*@W#Z"#3)02R2JLB&?)9)8UA,O%[5E9>.<JOB*0_'<[D\2VP^P?
MOUK^X=^[=V[-';[N9RC4+-AY0IL6L$L8`W8?L.K#X[_F"YNUX<7G]!'X8QY>
M2M%PZZ-S1;4="?`<:57(_'/+/(%GF[W&9CZ>UTJ]FR9?&T6LSEK8Z#,.L4M2
M&DUP"PVQY>31V+)O=5YUJ&X[DB`6#$`P3$Q`F))`&L#,]UX.)799Z5[M7S\J
MJ>3!&125Y*I,<Y;B&XJI),:I5/\`>N_+\(?'.LF<L/S7(>S^M\%!T7--]H+6
M]XQL\W??2^_IK.!93/\`+<_H--@5H0BB5]9*LH;)L4<6.20,7<B2CV[D-AKF
M5VU%&<+!)&Y8J#)$08ZSJ!O>>#7W:SM=V/D"Q*39(4-LJ*[``'ER`/2)V.MJ
M..?Y&.:]7=\?<?+2\5:G2<[;Z3QO\\[[,4>IB8ODQ>%/HS8<?_4W(/[,;8VL
MJ%1YS@2IKM?4PA6)D%-)*C.ES8XQ&=H[JGHM:FR.:DC8R#&T@C8CX$:ZK&NI
MR\=<FF?390T$0PD`@,IW5M]P0"-8Z_D5^K.>^%?JL7'N0Y4A9_,WN2^%])A\
MFZGF@!`T=S]N2<CR!=:2SJ=K2WNBS&CQ\1M7;5<<(A3XIH\4AHOF\Q\_M_:[
M>Y<O1=%96K$&9/J-Q$1\#N?EK4=X[_C]DX'*JM='2YN2Q`%-?J'E/0L)"_,?
M#6'M]_,SSIC3DR(L;QK,TW'0^?)&KV,NEJJ#$\P3.'^:YW&5!G<U'V?T)C3<
M6/OJ"&*7=3(\S=2:FQLH315YXY$]LS]CR5=T#*36&GP^EN)^HCQ^T[ZQZ_='
M;WJJN9;%6XH!U:/406+/!6VB=S`D&#K<SZ\GTO,4_P"9MA4Z3G_C6;HOJ?@?
MA35Q,1S_`,N<84]]AMG_`)A:WE#(HN,N0J'/R+*40;&EL4`EH@QC8V0T;6-2
M'N?:[>V%%L=69Q,"=H^,C61V'O\`3WQ+7QZW1*C$MQ,D_""?#^.^M#]+_+[S
MEQ%P\RR2#QB6PR&%YQY#ILQ)SNJTLB?Q=P;R8?AW&UNPY1Y1^BLQ,L;?8FS<
MN1<WT=UY?CL)0!`I)Z#/+/*W9KEPZ\P65E;*V?CT*A3!DF!,]`)/RZ:A3W+B
MOW.[MIIN#U7I5SV*LSKR'$*&8`#<E@JCX[&,Q7O\MO-M+>[O0LH>#R86-RE]
M8<08G+WPK[+3ZJ9P?Q!J>4./][R!RH;>6>>91Z"PRQ8%S'!2QHT2"9DQDYBL
M*),BSV]D5UBWU*S6SNH.\$HI8[D0.D?OZ:PJ/>.#?<<<47B]::K&'E)`M<(!
MQ!))$R8^P;ZUGY)_E9YDD6W'O)SIAKV?\X`^KKC=\446/N^/:;=Z7/\`$W#U
MCQY*VK<7]%<BXBVI<('E299RWP]!J*5]4-)CDB3NS8$+]DO1.7-.4-(^'$*>
MHE3(8;@P/&-9=/NC#ML](56A24`;:#R9UZ$!P0R$$%03(XR.NX/%G\FWT'R)
M?<?8^!1<<6"2.7^0J7=;86,A29]GQ7Q_PWA>7[`^<P&#^D>1Z/-;M)&CDU!4
MEZJR""$^+:.C*KGP%)V/(.:F#994CNQ4%FVY``Q*\H)F!\=66^ZL)>UV=UII
MR;:JJU=E588*S,O("P(2%XDMM('QWBP/N+^1O94W.>)U_#-;S_*XK^/:K%\O
M\]Q^-(U%)PNP!R1I:^%K,+S2A=+%D)4X;YF@Z34UH`1ISVWTZIDO&S\<:ONR
M/;^=CW/288U`%R)A1N3,QT4<H^&H\'WCVG-Q:LD<D&0Q6H-`+D0!$$[,Y"`G
M^:1X3J6Y5_FDWW'UCH]QGJ7B+=8@6]^H,90\&U\>UC\WAHN!.%M]R#BN0I^E
M;OY$"52\GVV<K["4U,U'CU>;LXS@29DARD6MG8,FMF0V5>HI<<1)8^FI8D".
MA`!4^((/CI3[NP;U1TIO%3+2>9"A!ZSK6%))V968AQX%6'4:O_@K^2;Z:Y]Y
M`X\X'SC.&,_M=_R%:5`^6[W"`N\W"R8/G+3<S2(@>+^-_J'>>&OI-12Q8@OR
M]<%EC06`YCHT8X_6;#S.V7X=1NL9"GJ!-B#N5+`[$B"!\?$:V7;N^8?<K_P]
M26K9Z)L\RE1`<(1YE4R&/^'P.^MC_@OZGY4YWU_.'(7*>WR8LA)^>/CSF?-<
M54E/+&G&K^2^'+;4[Z976SKFUO+W,VFCKI'H>2O0J^E!M<X@WM=K1K=L`-A\
M3K4.O_ELYH,-E$)_#=IH]VSXRT_'-R[$R8\*-C?I[E#<X?5RO\&SOT'K]3=0
M,CG,S#LZ,]](Q-Q8'FM#/J(+2#<W.P,"_N-PII*B6598P`7,">IZ_`'6K[QW
M;#[+BME90L8+78X5!+,*UY-$P!M\3UVUA+GK^6+G33_/'.-7&U_%G$&FXWXQ
MY';9Z^/7:/+Z?F&^H_I/D_@&/8<(.;RL*?QE;4M-@(=E+$YVL,&\OHL+NV,U
M),C.L[%?6UJV65!JIZDCD5<H0NV^X_81K54>Z\.Y<>RJC(=;^/0`\`U26J7@
M[`AH\/I;K&M[OK3^3O9\-ZC-KQ?A*>\R%=\Z\_\`T)N:[0T]A;;/0IP[+XYA
MT.%QAZ+6UU10+IINR.*?:RPVBU[`L<*&=SO%,N[VMG4VO2;*S8E3O`Y;A(D#
M:9,R-H^>M7B>_P#M.5CU9/I7K3;D54R>$*;N4,QY1Q4J0T$F8VUC[AO^2GG7
ME5F:RLZ\X"PIM-RCD\Z7G_4YZI3C?,5&@X'W?-1,E:X/(?3^YCMU%K-QHX%)
M82]G7LGU4Y92P$DQT!*T.3BW8C\+HD[B"#M^HF/LUV.#FXO<*C=C<X&Q!5E,
M_P#I*)@[$@1(C6N3/Y<><J[+5VZ9F^-ZW0\E9WA76W-W!M;/D/&!J[/@>\WE
MA)XHXPW/T!Q5'LJNSN8T1TEM5:1[45&\LYT*TD^+A9>)VQ\VHV465\EB5)AO
MI))$P#QCP,GJ!U&M?W'OE/:[THRZ;N#SQ=1R2>:JH8J&9"W+8E8!$$B1/H?\
MN'-M7M-S%JK7/:"KY@YIX^?QI8V&#J3U?"/',_XAXSYO/2KFMQSIP;*T4K?:
MJR*M;^[6U"=@QVLIHI!6MKHN0>QVD37:C`O'B.J"P'S1`(.P)!D';6$ONG&Z
M7475L*RQ$AI(N:EE'`,2599)4$0PWU=A_P"9/G*90W.F#@^,J2*&F^0<N"E@
M5;]K*H^0?IBLSMKI]Q9;`W,F*X\M.-\)%))93Q%L:_\`?9=I"'(MX#`D))J?
M;^:,<Y4IZ8:L'??[P2I^$?$S_'5J^[^U-FK@%;1>R7L-MON##KM+<CX`+.Q!
M$C5,Y:_DMY\Y+^6^>#UN]X8X"ON/^`N5+TFLMS&J-5S3?5O+/(/$<!."+'%\
MV:.GXXUN7JLO!FSP@M-J6)I+V!!:Y(ZI(/J\G%MQ;!7;$D2((((DCJ)'4'QV
MUT&!F8_<*S=C\N(;B005(/%6@A@#T8$&!(W&MZ?N'Z$Y,X,^DL7,Q7,_%/&M
M14_%/U1RK/RO-A;J;C.0KSC#=\`V-545%%5;G#-9K)-?83(7[NC["550)QW`
M@R5*YJ8^LM0"-_CJS.$?Y0]/R;S,;B&_X[B4=GQW`W^[YKCQJJQ%94W'NG#B
M;OYBB4`[;1QF"TFHSVTFCO2R6/"Z?D;)L8(6%&@=]C^W<^^[T"42SB"9)VY0
M5F`?JG;KT:8C7(YWO+M&'B_BU%MM)<JI4+YBA861R8&$X[S'U+$SK24'WI]0
MKS1R/+S?,>>M'<;:7^32W@9S;8.WD91F$XF/\QZ3B[&7.1S'+M$ZQNH4:QEQ
M8=U*E"?55]M*(*/*>=J)1O;^4EAJ-E1=?4F"=O3CEX?,1\=7)[P[;90EZTY`
MJ?T>)(43ZW+C!Y1MQ/*)@P-S.MC>`OY<=MSC]#X;+MQ.>R_&.NY+H^*CY>WC
M9H&TA,M>`JOE@O(L35%YJ;IK-C=38I$!2BX^6*;/_P#M']W0K7@;C6]GSJV*
MPK,/@PD^4/(!@D<3,Q'PUFT>Y.TW5BSDZJ9W*M`(L-1#%05!#B""TCQ`UA#^
M0?EKF7&\O_R$Z7+0N<+^#Q!Q-Q1.P6KP'V'R+PW4<!W<KAK3ZVQUT;A&CL1X
M[DQ($N&VZE1[`!!6ZQT@&1!/5R187;LC/2UZ./&E.328VWZ?$P"8VZ:R>Y=[
MP>T68U.6+"^3;P3BO(3(`Y&?*)($[Q,]-7-._F5Y3I-COW5/'57OL5@YO*V)
MK,N>LRN;Y`U\SBWY]LN5*OE!UH#FN=HTC[_250U=1Q./UAP\[9AF1[:48*@/
ME-V/,6QJI3FA8=>O%>6P^HR.GEWZ]-:]/=7:WHKO`L"6*AZ&%YV>F`S1P6&D
M,>>Q$;G5%T7\L_)5!KEK[B[X)Y;/@8=-LJ#9<966SXWX]EV&W^._J3E-U#R;
M%C<O;NE6DSFGP=,GG.D30#I3NLW1XU@(#X]?Z'>;#6MM!@=>7EW5G&\0)"G<
M[`D3MOJG_5&(,<9#X^8LDCCZ8+[6)62%!DPSC822`T`D0:+H/Y7^;$FXK5Q]
MGEQS.,*K[()R/QZ?BR/EZCD"\P7RUEN:>**2VFTG/?*N;$Z!:6,@SI6:TM\&
M36>LCTC2G'BQ[/Z-D0>3UA@&)!/BJ<R`1()(Z03/RU)_U+A2`M5S*[5@$`=+
M+?2#$'BRA6^KDHC:)ULEK_Y*N:>'.5^+<ER;:<+ZFJF<F\$\3\M0L-AK'*LJ
M]!SSAF\E`_QJ\W?/":N799'/:"G2,&ORM_5V$;VEF65;*D+"KL'"Q+<_)3%I
MXBQV`!)@23`G_0#K:=T[AC=HP+<_*#FJI&8A1R8A1)@;#I\2!K/GR-_(;,Y.
MX&P/(G-@LJ7D7D?.T7(</%\4UBUD;-8O6>FMSH)435;V]OKE2VM?,4ENYD"&
M8BN`$"_C/*7>XOM;,RPIKMIDIS@EI"D>(XGX']>VN2[C[^[9VYW6VC**I<:P
M0$AF!`/$EQ\0?C!!B#K:>U^ON/Z8,>7.S^P6$8T<!),6)3R6@60KD8Y6-N6/
M.G]"_H-'K_I_O3J>KV=W"YBE=E/,`F"6$Q_Z.WZXUA9'YE]FQ46VVG)](D"0
M$,3T_GW_`%3K-G'W*6/Y,B'E9><8KHK0$/$F1W19;02&(X,E@U<]AXSW=V>P
M;G-1[51>WZ=])W'M6;VMPF4H`,P09$CP^1\8/AKJ^R^X>V=^K:SM[DE8D,(,
M'H?F/"02)$:NV^O:C,4UEH+Z<&LIJB(6=8SY"N04:,%.[R.1C7/<O^B-:U%<
MYRHB(JJB=8>/CW95RX^.I:YS``\2=;+,S,;`Q;,W,<5XM2EF8]`!^GVG6NUO
M];<7TSXWY$/6$B2G^`K(53!2O1O;R8\AC6PB-]K5\F-\%>]/]&_HO;HZ?:'=
M;@>)I#C^7D9_8%_;O&N(R?S(]OXI7FN2:V.S!%X_M+@[^`B3\-4^Q^P>.:AZ
MK8T&W!$5GD.<RLJC1R*C'D=_2VZ0Z-:UJ=W>"HBO:G^J]NI*_9O<KA]W907^
M')I_\,:AO_,WL>,9OIRQ7'U<4(_]I/[O$:OS$_0W'^ZT,#,5G[W"MK<,N33L
MM*U`1[,$$#I,E\>0"1)8-XX[?+P+ZW*G^B+V7M@9WMWN&!CME6\&I0@-Q,E2
M3`D$#Q^$ZW':O>O9>[YJ=OQ_53(L#%.:P'"B3!!/AO!@_#QUEK07+<_4S+@D
M"?8@@!+)E`K61R2VQ@"(8IF!D2(R&\&L_P"%BJ]>_P"B+^O6HQZ/Q%RTAE5F
M,`M,2?#8'^[729N4,+&;)9'=$!)"P3`!),$B?L&_RUKC+^N>.8$V'"F5.J"Z
M<SN$RQ:CT^[R)WCKY7+".?ZV>2*UKD7OV_UZZ1?:'<G1G1ZCQ\);]OTZX:S\
MR>R4VK5;7D`N-C"1/P^N>GP&LT:'D*!F<4F\LZBX!2C@AL9P2,KPV==&DJ)D
M?\F(6>UKCE(=C?6-[WHYR(J?Z]M+C]NLRL[\!4Z&\M`._$D=8,=-CN0-=5F]
MZIP.U?UC(JM&*$#,#Q#*#$2I;J20(!)UB2K^HLM<Z*!EZ['[B5:VGN_!""%3
ME<?\<2ED.]3+GW"&!%;YN(UC6HY'*J-_7K;V^U<JG&;*LNH%2=22VT]/Y8W\
M(US>/^8';LK.3M]&-EMD63Q`5#,"3MSD1M),#>>FME(Q2FCA*>,^&8@V/+%(
M0)21WN3NX3R1WE`]S%_158YS5_V*O7,L`K$*>2@]?C^W?7=5LS(&=2K$;@P2
M/E(D?L,:C]6ZOTZ::=--.FFG337Y]?I&BDZ_^4_CK7W()]GQ=Q;RO\_<=W>N
M#EJ2/E\)R-JV<>\A8KC:]T$'C<F\G:?7[*+D[*)-#92ZZ*DF)729T&'-G1'-
M2#Z/GK<#GNKM)'U]QZ6[EP(M:_9<3V67B2?G^/H(EA7T6[XHC_FFYO#Q-<VF
M:L8.BOK".T::6"(4J55"<UHY,AI&J#Z=9/\`N'/WFLQU1F<W7$M;N[Y:XIBU
M\,21O8XH(>QGO(-\QXXXGA##<Y'*]CNZ=F+YJWOZ![%R*,3,?*R6X45X=Y)W
M\36/#?J?[]IUXS^;.%E]R[95@8-9LR[>Y8@51$R!>TCE`$!2>H^1F-<I^1.(
M(,&\-<Z':XZFN'3)=Q<9O)Q?\\T>=UD27)/=%K8577%R$2?K+HI)A)DF;"G1
MP&'#(C$C*Y_K/;N\664"G'HN>F`JO8?21ZR`%Y%CZA%:@*%"LI(+B>4#YV[W
M[:JIRSE9N5C597,N]5(_$65W`DN55%-(:YR7+LZ6*I6IHX$FKVO(G%>*DY]^
M7XAH>620`.FY73<MZ.W-'!:2&55%^S1L;G*`-;16;;MPVS06D^P&V/#&9'N]
MR$2&GMW=LY;!E9EF(&,6)CHH)4<FY&QWY,O&>)1$,L5@<8UDY'>_;W:K*6[?
MVRGN+(.5-N9:Y`<A*^`HJK"UOZD>HMME@"HK@GGR%Y+]!:7=T09F9UM5F#@G
MRFPI..C4-%35]SDHT]]EG:65=U(XE%2;%SF0BDBJ)Y:[R,K!D4['87_3V-@9
M!3*I>U2HD6%V8K81Q=@K2S5_4`TP\"2.)UM#[SS^[X@MP,FO'<.>)I%=:*](
M;E6AL0"M+MD)2":Y:%/,'#*7%IR7*DT^K\H6BK)4>'+&EY3Z:5DM)+_?-);1
M9XY;X%K,407%0L<!CBDPD0`@>YZ/%NO1J[8@NQ/-C,"1Y606(.**1$J-X@D`
MJWF+<1!Y895_?K&Q>X^3-K8*WG2TTVGU+7#3Q=H$RJE@R>14YF5Q#&R-JF>U
MB$KY#JW+.HY6BE&LS1(M373]?00*F#6EDQ`F=:2#S5'%$-'+(0CS,[M)(:NX
M;,J_$4PP]6WD$'$$LPK<L3!(X@"6)^F`IW"G7-IVW(_!9(9&]#'],V$L0$5K
MJU15)`/,EH0#ZI+#9G&L@:_.Z"+J>1[\<$KX5548:OG,EV4>UGUX[9VCEU,=
MEB-#28T>?)BO['3V"`^.Y7=G-\2:_#R<=L3&QRPYN]I$*5!X\`QC8$@$;;$@
MB.LC<=RP<RON&=F*A]*NO'5N3!V4/ZI0<MR`Q!\VX4J9W$-4./+:WQ#&Z,;S
M1[NTC.F0Y_A(CQ:.FBWU1776D*R#*BMI!0H5B7\523D'%3^X03WH1SH^XTTY
MQ_#$`T*8(V)9BC%4W!Y20.4)+=`0(`G[+DY/:1^.4E<JQ95MP*T%B*]I"D>F
M%5CPFR$^HJ3R)V,XX^@N1WR@:NZ9"DCC?F9[+U^LR%<"?^[4RP;;4\CWMW%L
M(LR?3WM%":*&QQ"^_P!+Y!W,(C2$YON7M[MH4XE$@F'<UV$CBTK72JD$!E8R
MQ@1(501(';]C]Y]\-@[CE\6"\JZENI4-S3B]N38X8,R65J`@D\H+N08+8T#S
M=P5J^2X4B'\_LB:V2:3`SF^XFWU102;[]ZJ;&'4W$G%6<65EKIL>2R3"BEL6
M"4'9"O<U['N9LV['W[$[8ROW"<,`%ZLBIG"<64LHM4AUD<68(3/0`@B=$ONS
MVCW'OJO5V8+W)B5JR,/(2LV>HC*CFA@:G@\D0V`<?J)!!(:S%4'(7)5:F2Y3
MR]?"@U--C*B;L:EU#/HH#Q.*5D"ZJQV&?OJ2VGN+[A+)A/D#+_8(/NSS8F=D
M=N[8WXS$M9V=K&%;<PY^:M#HRB(/%H(\P.\4[CVK#[UWVL=M[ACI4E:4(UR>
MFU:Q)XN@:NQ':>0YH6!\C+M.VG$7'6@Q?)E_*FYJ1G<E(^=IN:Q!ELH]K`FY
MW);SB6#5'BRH4VSBRBR:LX9!C#.;R>?Q<J.8OER/>.Y8^;VRM$M%F6.Y![?*
M5(>RK(+`@A2(8$`$#83T.O2/;79,SM7?KK+:&H[<W9&JH/(.K54Y&&J$%68$
ME"K$AC):#N#/8GKQK7TYITTTZ::=--:?_;AHXOG[EA)!I`!IQ3L#E+#8TLT4
M8%YB/R9$,3R":64!A$4;5>U'/[(JIW[]=E[&#'W#B<0"?Q=8WZ25M@'Y'Q^6
MO,_S79%]F]RYE@O].N)*[L`+*)*C:2)VW&\;C7&S564N>LNFCD)&]DF1&IY1
MK>>8CIZE_!EYZ2:6=8P4O+-/0-R>162Y$=$&W\IY1^SXE25@7,`=@6'$=.H<
M`"3P7<^!4-N>(!^7^X7V7<L5)$L0A+L3RGB:R28'J-Y0=R'9`%'J%EQS3VU6
MK)D&<!;>@O*^767=6]70YUG4=@G59!S#2;#LJPPG.!*14D1)D5'-1/7X+LKJ
MK9%E9X9",&5NH5NFP&Q5@=UZ,K?.=:3%R<>'JM'JX5J,MB?2S)L=R1R5D(/%
M_J1TD#RQJB:"5J>.;Z+/#)NK=U?"WVSJ)@=05\/:UNIDT6?#"GT-VP5L)8+)
MGXQACD>B%-8JM<Y7"<Z?'7$[E0:R$0,U5;`H)K:L.\AU\N\2"1++X=0,3-L[
MAV/+6Y6MM*)D7H1:>-ZVFNL*U=D../+BP#<4<&"94G,LB*2^`V\KYAH,REDT
M42I`*!G+"V-`S`'3M/Q5=6DAT9H`7MN)@VM(%S4D/&<;U%(?WTJL,=OP]BAD
M<.6W<*"YA+U43)5=]CT!4B5&NH>MLQ/Q=+%+:FK"`+6SE:ARMQ'<Q`L<`;@C
MD0ZGBYULARA4U7'GSFL%)\:EWFUH%LM)7RFU$2\K0S')H+'#*6GC!AQXU=.E
MR361R'$A[$?J,3P?V;S7:KK>X^Y/4XE\"BSBA'(JQ'D6WS$DD@`(`#"&0)&N
MX]P8^-V3V/Z/-:N\95/*U3P%BAOO&HE`%`5BS6L6'*P<6:#MJ;FYT7/ZSYON
M*<-172'XPS;*UCV,JV1S)$##1;;]WK9`3DB,="+)C26!:HSM,\3.Z]D7K<FM
M\C$[G3<79?7'%2`O0VE>+")WA@3N(!.O.<&ZO"[CV/)QA4EGX4\G#%]BM`?F
MI!(\I96`$-R*C6<>?>*+2LO<W:8Y];5YN[4I*B(D"1<9["?X@63::(4F34V,
MRN*6RH=$JYMST9^9^5XO<LD**/1>W^[56T6U9O)LE/J,A7M]2%2`P!@,GWT?
M3QD#B=^M]X^W<BC+HR.V&NO!MDH.)>O']$EK02C,I+5V?\,3'/G!/-?+B796
M-/A**NPV.J#44N=5WV;XW=%RLNTEYV@$R5?)J+`EF\+37.DE*7\8Q?2PZL.]
MGBY`=;?"KNS[VS\UQ8BLCW38%#OLG`<9A4$2!)$J#MRUSG=+\;M&(G:.V5FF
MQZ[*L:*BYJK$V>JW(B7M,\6/$-#D00FK,Q-5+H8,3D4T*<\TE]5:X3W4U/4#
M-HBXJNC['46E54CF&6OS4TJ$`*6IR$N&^37(*(YK\W.N3(L/;59>(Y+;YF:$
M]0FM%9HW<""5@"L[[N"-7VK'MPZE[XR.68H^/*(DV&A1=:Z)R/&IC*A^1-PV
M/&L@V]4V-M/O+,UE.2-`CQ2Z/4VS93I<D-9X"<8Z#DO/-/:3)%F`45"`?[;.
M6%'M<,;GLR;JJ:Z%6M9L)X(L0.7@-H`4!26@B$5H()@X./?DW9=CWOQI53;:
M\R0NTF#+%V+*$E3-KJ""H)&WO".KGV_,?#42:4]1#7ERG'7XYD@Y:RJ;55=I
M#_!CO24USY4<Q7E_)*PKI[X\@I$:YX?3Q_?,2NGLV:Z`._X-N5D#DW)E,G;H
M=AQ$<)4"8;EZ7[4[C=D^Y^UUVDU5?U).-$DJG!'7B-]R"2>1!]0J[-!*\>Y>
M,1$R>=1J>+4J(2-3Q5G9$"U$3P<P;F]D_P!BM:J?[DZ\)S?^;L_WSKZV[5']
M-HCIZ:_PU<W6+K/TZ::=--.FFG336B]#]L_->UUG!>*=3Z$&F^M97.V(H(&A
MQ$,3@ROFBWTV9Y"S'*LA94L%&./?5UI7U8)+I`9\GW#%^KG=VKN)@GX:QK)_
MD%^>;KC?7\S9O@SF'D>@R'%6(YOVK\_QO@5T-5P_R-DN59>>WTV+K-QG73Z6
M3B.,K/V!CED3OP)\4;8[V2'M&U7B9UJ3R5]:<00^6/GOA&EX?V7SW+Y?XZTN
MNXPXSV6)PN+HYE=67L>6>9$=QUI]7FJ70;-;13U<(SQ2;-($I5:TP&L)WOM*
MW&%/X5RRY-MC%6`V\JKY2?#8R/U_'7D'YC8^><G^HUA+,''I06*6\WG=_.HB
M3!`#>`V/AM8GSYR5\^\@LU51Q+\W<X\C1M5FJ?E/4Y_A;BC@^EJ(E-J]9R=Q
MU!=NEVF_Q`K*[T=]Q=>-;#5DU!Q0>;WHV0@VU[G[@_`FM<.FL<ZR22(Y>8KN
M%@'H=_$$3JWL/LT]U%]G=,FT^E<JJH;EP/!7\I8$J/,L*(XD&/"(NXWG$W$'
M*$CBCC7AOD:_XTXTTN5XSW.NJ^.,:;+\&\@<BUF5O0X`H*"^_P`G!5@9LJ4M
MW.J*2335\B8U9,E4"<P=IV?O)[C2++*FJO#BL-6`*Y,0&`,K)(!,<>A)'AH?
M<GM?^BY1JJR$R,0U&YJ[V8W0O($H2"K@`$@$AR.04'QV'_CWYUXLTMI*Q&7X
M:W0N,MQL]A6<1<O_`/2[)BXET&DP==M*O9T@++.7%EH\JIZRLN15<K0TU+&M
M8P90(QBN*,1N;]V7U9-M-M590A74F`%?BT2L?`S,Q)W'77;_`)>8>5@8^5CY
M%ZVCG6X26+UATY!6)`&Z\2(F!L3MJT/M;Z3^3L]SI6Y!;OBX>IQ4G_H1RRZ7
M59"M9BPW'&-CS#19[7:BS6L)#R!\)32D'%_(+!6<C(BB]_DQN7[2R,*FBY,@
MJE[N`KF-O*S$,3T4\?V[:UWYC87=LG*QK,(/9B5U,SUCD2QYH@**N[.O*8&_
M'<;@`WM\^X/Y)U%Q69XNSX@HKG6Q<Y<\/8ZKL.*ZVZT$*OBW4J!;<>T;H[K2
MX@T<.5*=#-6C(.*V3(4;T1[^^?W[NMG:O12BJD,9),1,1Q(XD?'9OV:T_M'V
M_5[@&5;EY&4:UA0"T\>4\U/($^$,A\3N.FKENLY\8\1<TZCYWB[FOXFT=5Q&
MO/W(LN;8<38_C.DSFIV:XFLM-LV=89NP=I-9=A,U"`BD8H!L69("Z1#;)TE7
MN[+00U%!7E/E!4S]H,?M!UU5_P"6^!9YZ\K+Y\>,.P<$?81,"8\I`WUM%Q$G
MS+Q=4<._F:OY\B[/6UDC(<+:\-[QZ"_Y#R\F>DFLH>+KTDMMSJJ-1V86!AUI
M3"1'L:@T[M3K2]WS*^X9[YE8A7`,0!$``B!MX>&VNG]M]LO[/VA.V7$LU3,)
MDF06)!DR?'QWUHGSWRWQ"/EG<6^4V6#V@X?+.<RVUCY"WQ.H+E-BVA0S96G-
M^_A?G[JJ@4L@;U[%LQ*)PQ!7U$]/?]@LIL[714P4VG8$%009:"WCM&WB!\M>
M/>\*,NGOV7DHSK0(8J5<AEA.0K\-RVX'E))$\B-9#X"Q7P?R!05`J+DWA;_(
MN1]9;1EPN7V_%1&[#:U#TN55<<U)I[[:0(*`L'N]19HV>L_]+/!W6F[O[ARL
M7+?#J7'>H$&>()+0"3R4@$_/K^O73^V_9F%W#MU7=,A\VO(964+S90$!90`K
M@E1'@(!^$:UVWG+'!JW>PEIH:W$EXTK.-=*FNY5N,/D(M2;FS'LU%%7!U<;2
M66>L+*PJ1J">Z%,4,IP&"\RC_5-]V;O%67C#)RN*(IXM,0)Z<2W21X3M)B=<
ME[H]L9/;L\X/;^=MKJ;*^,AB%V/-5^J"=S$$`3$QK?+Y[E\"<<<%2N0M]6<'
M<2T%;H9HQ[*Z_P``QV8'^_I47,.3&U$D554@'>VQV2`N8;_F#>)6J]ZH[KC_
M`'3515W5300:VK4R`!XGK\3\_'7I'L#(S,KV^XRU87K<ZP26/TKTGH/``=-8
M;X?X>X+U6PSP.2MKPM_E>QSX)?"F2C3^.&<H:?CJN)-G0;?)",(FBD8J+^`^
M1!=5M+$\1$.QS&HBKN^]>X<?#M2KMM:?C$4<F(V4[>58,_;T`V'77*^U_9F=
MW/'MR.]W6?TRQSZ:*8+"2"SR(^0ZD[DD`[ZQ\L\A<`93D%9.6LL!S770^5LM
MP337M`7%\EZO$Z?96X$JLW>:2&29.HJMEM%D$<Q[D>$H5=X*X;G-W6!F8N?A
MTY>1P7-8JIX@?4Q,;3*]`3O\P-<QW;MG<NT=RRNW80M?M2*[@.6W2L#EO$/L
M6"['X$@:W0QG%GRW9T_'%9<[?&8+DCD&FG?X3@[B[P]9<6T.CT$R4<^+PET*
M-=R8]?-J5D*D!OJ!(`TW9'C14Y[NGN'-P.XOALE+UU,(V\VZ@QR!Z3!Z:[/L
M'LWMO>.R5]SKMR:KKT/+S2DAF4G@PF8D?5K`G%/._P`@Q?B#Z+YHM6<=U_">
MWY5NN,K'3VN7PC:WE'2'V$/B2AF6=?72+D=U"O\`5%8>$ZV>LP$`RS)`HX_-
MR8F9F8V;W;"S5`2M^/+E'7F02T2#OL9W@;[:V7;>UY_:O;_=.U.S6WU!N'#D
M('I`A:^4$;;J%VD^4DSK#_`'*/SEM=;B+_,FXT.WCC33ZQ::YA8:'ON",_BM
MS:X:YLCQ5/(N,%@5NLQ(]<ASX43\-1E1&M>K>NLR;,3,PKS7Z:Y-5-@_E$@<
ME,`=)@Q&Q'7KKSO"H[GVSN>*+_7;!R,F@F>9"EN#CD3LY$@,#NIZ=#KL1KN0
M?G&[XNO?IHFHXEUF+XRQ'(-_$YOJ)6:VL#(4%/36*[670[2C2Y/#%&B0"CFB
M@&]A%&HG,<[^GKRBAE2Y';Z0P/[#KZ&RJ[+,:RE/K9&`'3<@@:X><>\B<3<A
M2Y5;:<':/A:BV&?L>5+@G,/%>$S>"Y/QU/)J`Z31:HM-=Z&CK=34NMHLN3#V
M#8%W'`7V*!S0G]/K2Y52K9CY%+)S0MYU`D?$G<=(Y*T&#,?#YS?`R&:C-P\I
M+O2M%?W3NW$_X57RG<@\73DL@@'I/4*OXJ^%G4>0TM3R?QB/*;>/-HL//K.1
M>-A9#9BAVK0SJG.)%:VCTS(&@L6^Z-'][1SC-1[/8Y$7AC[K[EQ*<:"IZ^3<
M_*9Z?IXZ]8'Y>]E-BV\\P.O3[T@`_&(B?[@.@&J;F<Y\CU>CL^6(_('S?NN*
M\-8R)^SW5MH^(K:KXUY(EI1NJKG5:13OJZ73SQ`B,C3S%CV'_=,5RM42NMS>
M]5]P[8U%JJF2+%;8;-U!/R83O/4:D[9[7O[-WZO+QW>S"-#IYCYDD@A2-I0D
M;0-CU'0G4'E'9_-.JT>LI=G<\(6-7>:'0\AUX-+:8"TJ-53Q2V-R/DJM)9&-
M7WE<6GJS267#'&8C(SW>Y?2Y6]QBFJK`H9VKX-2C0Q7_``]2I^&\F.GRUY1G
M#(O[OEI57>+4RK$Y('_Q]`Z_&1"\NL""=9=Y:N_BKE;B7@W"Z;F([Y^JXJY-
MY/R&=X6WW'I"\NY?CBIRF,Y*(2;I/S\!9:.DC384>#:ED0-#4DB2EK+&&Z/-
M5OF?=W%G<[W!!#6$[=-_A&T?#7NWMNIZ>Q8M3!E9*54AID$#QG>?C/CUUCOE
M+0\!X_F#=<0_NW$=54\8AR4D-(+1Y`<_CBKSV.SN7STG41WS/WC-&ATH(T*/
M8SU&98CQC<9S7IUZ/V!J%[-39C6*,BI"761(ECYNO2(DZ\1]WIEO[GR:<ZFQ
ML/(M`J?B>+$(OW8(&YD$@#K\_#83YS^=/E+E7A:ZT%>7C;<\=WNHT\N[C9DG
M'E[@`6]/,;'N27;ZV#8TTZ\A2(/MDEFN><7=JO\`^%'+S_>/<5]&4<?#6@5<
M1R(4$.>I)`/$[QX=1KL?;7LO&RL!<SNEF6<GDW`,Y#5*/*`I8%P")C>(:(UJ
M=RUK/E[$I<18&_X0W/SC).V'!NY>UXTT.&JK,L4TR\SK9CIQLY(G062'F-$;
MV...1"/;XO5R]-VK.I[GVM,J]J:LD%@1LJGCXP=@8WW^>N%]P=IR^P]_LP,2
MO)R,)E1E(Y/8H?8@$#DP!VV\`!K.W%NE^4>)+;A[D37<@5<O;5<ZCXI^?>)*
M38X^=&I:3Z,Y#X_X\!R%QWQC$-6V2UUK8W$&!,MXGY$*OH8QVQ1L:^4A^']U
M%6[DK*%`-*]``-I`.VQVC?X:]7_+U;5['96Y<G\5826))W"D@SN-R=O`ZH?V
M[]-\(T?TX'B+5MQ1+[C+@ZNY.V6ETDS"0HV'SVSW;*7/P["WT=F"U@2K>UI!
MR1Q@`</^V`Y2">^(A=M[37#%%@M<5Y)/(,W$*%78;D\I+3$"`0)W(US?YB-W
M-LJEL>I[<!1Z91.99K''(GB%*\17`,GDP8P"%:,;Z>;P%5XGBW3W-IPS=Q>2
MN0["=Q56W-A@[.3;2WTE=,+J>,X<N3+D7LL]B]4)-IV$+YD:U7^2M[]'5DX^
M5W+\(6K%ZU!T/E\SEC])_P`1$;S)ZZXJ_!SNW]D/<5KO.(V0U=BP\5UK6I\Z
MB80,"""`%Z0-;/?+_.W#SG6>;BZ_)\F@3D2AKUDU&IP.A-QYJ75>DGJ?3_D7
MT9]$^FKZ0GZ#0ED+L[PCJP9GCY;W<*[C7D)PY(QK8*9`/7??8['7H'Y<^MC"
M["M]3T[$6ZLN""5^DQ($@2L>&K*P'&_R#S'HH4;6<H?.FILI>YVU9Q;ELYO.
M*=7J)5E,4E_H*_,Q_?9%A2CU4Y)$BN@">0L$_OD-1IE5TN=[F3&2O'P4K=UK
M4,64<0>,$`>)_P`1VWVWC6/VGV'=FV79O=K+JZWN<H$=@[+S+*6;P4'Z%WVW
MVG6N>FY;^7:S1[*KC.I.+<U@87%%@Z]Y%3`YNMI;#F3C>#L*.JBZJ%=2,C83
MC9:8Z+)4$MP'#\@-)("BNZW7:.X_B^VC)R#6H5B'!A4WZ0#XD;&-R9UR_N7L
MA[=WLX&(+G-BAJV7D]GEB>143"D2)V`C6UV"XG^;:3@VMY'W%WQWP%64UA=T
M%9J+"=@\)Q]"??,%'03X]@*HS'ITY5:\H@'&^P8UK?:YJ]DU7=N]V=JSOPE"
M4V8!56B(V;<\6'21XQ'C!UT'M[VK5[B[2.X9EF35WA7=.7(G=-AS1NL'>)!'
M0,-QJV,+>\)<"8OZ3HKW_I7Q1!PC<S1YV<6TX\RV#T%MR5CYFKHI'&$H5K%A
M1R[VHG?K#8*',EE$]5"8:,*^W*S,7.R^W64$+C"TB2%7B?(6!C_#.Y/7J-M]
M7=O[9W#M7;^]U9:L^<<<-`+V%P/4"LLC^>#"K/'HT-MK%>%V'#UQR5E,5"WG
M&=S-Y4M:=DK#5NIRA[K1U5C!K2S+J!2Q9I;&ZBGS$T)G^8GM2M(QZ.<+P\^C
MR\G'&-:`U8REK9@94EH60"/YM@(.\CY=.*[=V_,.=0S)<<![T1AQ<+7R>&*F
M(0\B94\8:?YNMT3>!?XQ\%RC4?0TOGV!?3K7EVIX7RL&#RQB=AB,9S#RK32L
M-592+&H*N7/I9<C/?FQ8E7:32U5)#D2WQ(L1A"NZ\['N#N'X@7G@;`?+MTD1
ML9Y1'0$D"3Q`U[6WLWM'X-L,"U:2HY0T<@IY#D".$S!9@H9N(YEHUM)Q)QSP
M/\W:Q+W/[OB&MXGM\K>[3.'=+PV>@95UKHJ6FE:*OL:]T*B927YK@<!]H)1+
M*F&8![G.*U'YG<^]4]V[6M35)5EU6`GC`5P5()CK(/7J(/76J[#[7RO;W?[+
MTOMR.WY%+`>IR9ZV#J0I;<%2L\>AD';6R>;Y)^;7:2=6Y#?<'NV%3QU37UE`
MS>JP2Z2LXECQ&7N?NIT6KG_ND/CH,&];,AR2-;6-%,0HW(TR.=R^N^@_.-<[
M^<M/P'_D63V'#=;PSIN/'Y2]LQ;'B\&$GYJ/:!U,ZQTMB#59>-,JDDQ[.N&>
MP<DAC@R&,,7N]K7-]']G8=.1VVVPE1:+XDQTX@_JCJ/[->(_F9W/*P^^8]`%
MC8YQ)XB>I=@3XS(@$?`C8[:Q/QSL/BK=Z'A1VBGXCDJUYSY9N.-.%X&&LN+M
M'3Q-K'R-YK.1]4RRN)T.-`#7U-/Z+):]36,^9+`'\62:0)O5GN#O%F"*J<44
MV*>1YD*WB)`()'C)WG4WL[VU5W5LC*SSE4NH0>F&>OJ#!(902!$*(C8F.D3'
MT5L>%^`N=Z3BI+J)'L-;*N,UG<YL['.DG3IU=BZ;E/42,]9LLYUC#HVT]F!\
MAEC'KW$F@8P0S,=&*_8=B[TG=ZPN:5J[B'*HX$<QQF/E`'Q@ZTWNSVM=[<N-
MG:ELO[(:P]E;$GTR7X\O]H%F^$KTZ:R-\Z<*_/7/O&&MH^/-W44G&M9JZW8`
MM^`[[C@^4C:&-$O`74*[@)1Z[C?1A&*P20\-O6S"0I0HLT"@E1HT@?/^[+:[
M:L=J^'$%Y*Q!/EDGCM/Q^?778_EW1D8M^6F1ZO,I40+.1*@\H`Y>;C'3P`V&
MJ/O-I\3VN&R7S=P[&XQY&PG#S>*:"*]).-Y,R5ZRVRN\9C05>DD3=(W<:S.T
MG'%P:R(1SI\)J^USE:8CDA]H5)=E75MQY^F"`8W(/A/B.O\`JUD_F5?=B]OQ
MKQZGIFY@Q4D<05B6CHIZ22!,#QU1>`:7YG^B.4N5.#=&;*ZX$#*8>\(&;$Q%
MF'6LLH)[[,$S-Y.2[)R!#R=*R0]54+VTZO1!N1'O5=[WSO`Q:ENQTJ.3S4-R
M4%7!4D'CL#$?J_9KDO:OMELZ]L?-MR!@>DYKXNRV5L'56'+<@-.P,3'COK;S
MD[A'Y!C<8KJ]CR3@\?Q_LXM7"B\@ZS88&-B-5%L*Y4IX4BZNEA9_55UE51^P
M0.D$8:,/^W_2U%3G:/=F?59RL2EZC]2E=B/VGIX;&-=IE_EUVC(J"4VY562I
ME7#RRGQ/0'?JT$3UF=]5GA/&<28_"2LWRFG!=A$XPV(09&=+'A7T&8J=K0TX
M<B:B;,18F7?KZ20-D884COE@(UC4(B]UQO<67A9V35D8`XU&D`KM*M)E8'2/
M#P\1MK/]E]M[MVG!OPN['ED#)8AQ,6(57BTG<D^,[@['<'6/K?Z_^)OIO-3*
M>BV7%>MN;?BG&\C\/V6W%BT77$Y)=R&#(Q^+XVKE-NK7<4ESQ?.6;`BQASZV
M2R/W1"N3PUW:N![GC\]T]9)_^*&MU[A%R]AS/2D6?AK8CJ#P.M%.*G\,Q.1N
M6[Y>3L[_`-19^RQ@N9;V_P"4,O<SL?5PGIF<UE)\,-C7?X3DZ!LZ4ROK;%K?
M38S3*0I#E5>O4KVQ,07WTV+9*DL"1*D`\%/^$#H/$[^)UX#BIW'N1P\3)ILI
M"L%K(5H=68&QU$^<D;MU"P.@`UN03-_#=?`T>J-R=QWQW9VUM?5-#M=KR3Q!
M2T?)Y_\`$<?:2]!12F6\F'J,I/JKZH&=Y/7)<$0?,:`6,\O$)[MS38/62DT$
MCE">8CQ\TR3'Q/VZ]4M_+KMBT-^%MRAE*"4FP\`V\2D<0.6^P!&Y!W.L7!XU
MS@^0+^S@$X(A<M<89=`\GQ8O(_%(-AQ]QQ'8&<:3K"1K!=%F<O%AB$4"3?PX
M;6.&Y_9K4[=)_P!0]B`9#9*QY6],\ODLQLOQ$D?#KKB#[-]W$I:*"&Y^9/77
M@9.[1,%]MC`/3D=M;!:;=<6_5-M-J>&+?&ZNFR&Z)A.4-N!N?O\`$::N/Q-@
M>1'V5=IJ>?/J=?0U>3W<2,\AB*)DK\B*K>S%5>9]OYN/A59>3?)`1>('BQ+0
M/U[S\M=U[R[5F]SR.VX6&5#&Q^18$\4"KR;8C<0(^)UJ7]-:K^/3@OB[*[VJ
MW>)U<CF_86'`U5R#QQL>.K(XZZLR=UJ]S$'M:.XK)&<SO'>:IBSW"KYKYD&:
M2&&,!\@\8:Y_;O<.7W#N*UY`K4-6P#*`K`!3ULD'IMUGI`G6I[S[*P.S]E>[
M#:YV2U'*.38A+,`8J"LN[&?ICKR;C.M;_@NN^/*N#,Y(D;/_``WC#D:LQ%]9
M[_GO:</9RQ>N@PEC/X\IP6=!81\14&=G[>8AX[X\>SFRK&:Z4^7(=((F?E9U
M&-VELW%6<@E#R?@>0.PV7H8)D;'K,R=:C![3F9ON).U=Q>,-5M'"HV*493+;
MO)(Y`03(@*%B!K>W1<3_`#WP_P`BYK%Y*_X/EU,*R@;E_$@IW&$+1<?9:T]8
MK+D:/A$4$EN9M(-B85A:18H`?A%5QE<%Y7)#A=\Q^YX;X=Z5UYBTN5@>5R%,
M@1])`W$]=]^@UD=T]J9W8>YU=SQ;;K^V69-2O+$O4"Z@$D_4I;8Q$>4\>I$Y
M]:<A?,VDVW#LJCTWSMKM#J!7M9$D5]KQII=?>U>-NX365]3Z#3+JXKLOH:\_
M@&,YZ0+*,YR,:03_`!Q_9J8U@R$<K^)(7@#$F.1\L^(ZF/`>&VLW\S;,^@X=
MM0L_`*;/5(#0.7!1SC:#)`GQ/0@D:N'@'@/!<B6.AF3ZP-/6P::LJFPJ:#`K
M)CX[)ML^!'!("`PH%3#>625D4;48PY_8WP<KT=MN^]YR.TI4,8(;B3YB-@H`
M/'P)ZB/`;[:YOVE[:PO<=MYSFL&*J@\`=RQ+#EOR"[`S`DF-]HU<O._$V?XD
MKLW+JI%G9Y^SF2JR9&NOQ[`M=(#'%(KY+);!1F#A-8(J$5XWO1_@J.[JO>/L
M'=\CN]EJ6A5R%`8%9$@F"(D[](@Q$[:G]W^V\+VW119CM99AV,58/#%2`"IF
M!Y=C,@F8@SJM_)E5^T[[1BKWH.FDY13)$]\@JCG,MH:.>U#%*WT$&3NGCV\7
M=_\`?U#[NM];M];6?YPNB8'3B?AXZR_RXQ_PW>;UI,8K8TQ)/FYCXD[$'PZ&
M=;+_`$40#.(-6V4CG1#)51Y3$:YZ/`>X@#>UZ,15]:^7]2_Z(GZ]<O[<#'O%
M7#ZQR(^T*==Y[W9%]M9'J?Y9X`_874?L^.N=7'&*@7^WHL!9`DNH-+-(3]P7
MVFD1GQ:PTDP6-EH<<0WB'Q$[M_0YW^GDG=?2.Y9UF/@V=PK(_$5+TZ`RT>$3
M\_C]FO$>Q]JIS.[4]FO5OP5['S;DB$)(WF#M`/A]NMJ^0OF[C_$\<Z*TJY6C
MF%I@,GPQWL^/=1@M:8,=P?4:"QR1Q@(O9?+NQ$[]U3NB\GV[W-W#.[E75:*E
M#F#P!4])\#UG]NO1.]>Q>S=I['=D8[7LU0Y+ZC!P-P(@KT`/ZOVZU9XGF-J.
M:\'1)6J*$[3U[ZJ8#\@OXI#@(T@7*9KQ!BDBJ\?83F]E[(J*BJJ=5W9/6['D
M7EI?TCR!C>#\NIF#OKSWVY:,;W5AXG"*?Q"\&$[$@R-]@")&Q'\==;+AWC46
MCD=XJVNG.1W;OX]HQ5\NWZ=^W^[KR*G>Y!_M#^.OI#*,8UA_V&_@=<9J8D&R
M=5TE\%)<Z'8181WS1*#WS/<P\=\+N,;2LF10JYOK7NC$1/U55[>T7"RKG?CF
M*V4D1O`Z&?L)\=?+N*:;S7B9@Y6JX4\A$M,CC\>0$[>'VZVA^G^5I%K:IQY7
MP"R<I7N8R^M(<L#V3;Q',<."^-W1&1J5&*[V.\F+,5G?Q]7=>6]K=I%-7]1L
M8#+;Z%(.R_&?BWPZ\9^.O0/?_N)\G(_HE*%NVI_F.I'FL\%CX)$R9'..G&=9
M:^6<M01,]9Z4;VSM&2:>D/(/'[2:FICN'*B58I97F-*;)0K3&+Y_W']FJB*/
MK4>Z\O(?(7%/EQ@H8`'9F.Q:-HCH!X#[==)^7O;\*O"LSE//.+E"2-T000@)
MDF9Y$SN=O#6U_7):]%TZ::=--.FFG333IIKA?S%I=SFOY9<-1$T>8QO''(MM
MPFL',<C?.>WYEF<M[7#Y3=I.O>']CE>"XL+BBQQ^=V"0ETMCR$>MSQ5LED5O
M:P:C::D'T?/6?^8PBD??7&5?+BYEU^0N'O<G.L<]'N;4M#!DB'>4T3\S)V<F
ML!&C0;FP/.BV$='V(Z5_<*54I9%=4'TZR?\`=IB@X^C/`XK9#N5^'Q1W!1_=
M)!RZ0(5*\:M(",A'I[2,5",%Y*Q4>C>O0O82ANX$-''\)D3]@X3^OX`[$]=M
M>+?F\[)V52D\_P"HX0$?$FT"?$#XD;@21O&N,>SM;F?8UTIMT2QT=/$):7,=
M"HQN@HAQ'R;5P"QCO)-L<VQYXYD1Y5/&A_DO<)0%]GM6%5176R%`N,[<5/\`
M@:869&P?8CI#-Q$\A'RYW3)RKKDL%I?.J7FXG_,K`)>"#+-5YE;<\E3U"5*-
MRE\N^JE1[%EM+BQHA"0KA;=!28<@=U'`/]GT,9:TK93RUP9`WRV!(UDNM<0+
M6H[UO;=EBU&4T@EX*\=B.)/F0\MMR"%D2KPQ/4:C[><>Q'&2RK4>+\X*GU`!
MPL'$S*@@N`0'JE`)XD4"LLM%B;XU<^+83)Q:S#8FUJB[*CT]:7]RB6EN?6"2
M4"),)^$83I,>5*4CC@,B#5!E>],BVK&SL<6<E6L-;:K>FZ$0545[$C?H56((
MWW`&L.B_.[3EF@J[7&NBAT-]=JGD'<W"0&\I!97>2RMMY6)&>J_-WNFNJC0Y
MUB6\VV(1+:FHXU!*D<B1M@=<M5V[I1W-0T["5GMGM<00Y/XHRM[M>'^K069.
M/BTOCY'DK0>5F+@4FL<V6!X6M"[$KR(\#KL*<'+S\JK-POO;;#YT05DY(N/I
M(\GJV.LV20&X!AL5WR7]2&SN`X[I,-F$HIH9M]FY%]+@20#71"!H:6#'-?I7
M!C0(E750`A@P8[2N1L?RE(WN=//6>U5R>X=Q?/RO45EK<("#Y)1B0DR2S$EF
M,=82?+MOOS`;![-V6KM.!Z+J]U1L92!ZH%B*#9Q`5410*ZUGZ9L`\^]H\>OH
M&?1VES-K1965FM=D,O4W]+36,I:&RK;D6L(VI2SE3(\=;`10C=$5SV>FR$$K
M53^MJYG<1D'VU5E566C)IN=D9@.09?3\W$`F-SR^*%A\#K6]D.&/?%^!D4X[
M8.3C4I96C'TV5Q<>',L!R!`*21QM"L/$:E>4.''0>02YZVD1[#'RZ.-8W=C9
MT4[]QM<MK"/@U64I)M;)/#J;ENLS96WP0-8L40'$\E1_<MW:N\A^W#(I!7,%
MA50K"%>O=K&#`%E]-QZ1,\B0(VVC]P>V#5WDX620_;&I#6,U;<GJN\J4ULI*
MH_K5$9`4#@%+3OYL7<C:>74OD96FDV@YZU.7L]))K\B6\@"IJVPA9T^.!'FR
MA1XDIH'L)-]A6.`@A#&GK][5VO;<5+@,NX(:^;J@-G$\F!<6$@21,A8&\DG?
MB=<_WS/LQBW;\5K!=Z=36E:38H166LT@,0%,07D@K"J/+S&I*M@MX]RMFPA)
M<+37L2UJZDHG5M4//<;ENK2P@RGQ*&"UL:ZU51+<J/55DQZA6,+Y.L'L;?;9
M_4<M2.+8J%6;ZFYW<5!$N=U1AT^EK)(@5@ZBHJ'9>W.&+)GW*Z(1Q3TL8N[*
M8K79[D/7ZEI@-)N(&/\`%QY_Y9+^V?(+7TA(Z$KH9I1EU%W-')_;J4YFR?9$
M6P,(;SO*C7PH3#*CF22QO+89K5\1CTP++)W(`X*(Y,-MX$P!]31U4-K3=J2[
MU#F9$FFHCRJ2?5=@>*$S(Y$`L3NB!C(L:N>A/RYI;*^WFR-9VTF9-7@:SG^D
M@2C@N9*Y)XWBO/6`8_\``@0XDJO+%!$0;'`@BC>/=J_IYW[JQ:\?`H6I`J?U
M!1UWVIN,,>I)!#%I,L6G?7M'Y?Y]^9WC*:^QFM_H[-!!"[Y6*)43Q505**D#
MC6*XV.NYO7A.OK?3IIITTTZ::U!^W!$-\^<LC")AI!.*M<$`B'%&&8I;O%M&
M$D@[7QX["D\6J0C7,&B]W(J(J==C['('N'$+&%&7628GHMO@-S]@W.O,_P`U
MU+>R^Y!0"Y[=<`)`!)LH@2=A)\3L.IVUQ"T\0]VXLL$$D2/.GRD"&0Z54C%:
MN;+@:*NMZ^N0;V75'=521R^F2)S)(7N15;ZWN]RQ76B$9@651N(;R[%"I/\`
M*RM(E3Y2/F-?)^?6^63:B%4=S`,H`^ZV*ZK_`#UNG$\6$,I/3B3*5<(]W'E6
M57"'93Z@C/\`)`1X0"%+7"="L4UM<966UE+2.&T-"MT<?W2YTELYJ+[CD'?:
MZT,*[6XUN/(23]6X]-OI`DJ&KVA57A_*H,>/4^4C7XZ![JC]Z`H)XCBWK*8=
MC`=DNEN3V,+A/)V7)=/Q^W<.#C-%,9'J[&RB5=?=65<EQ^V2JZTK(_O=7SQA
M&"FM1TT5D\*^M_B!)`_(D8;2:R[N)P9S<99M52Q56X\@58]1/F7DW`[C?B8#
M&-]B]F'=B.UYK!<>RP(KLO/B5=!/%@`$?@@L&Q\O-9:M0UU\#\;$XLN-WRCR
MA66-?B\1<5B.QD&GI`6VYY@UEY(M:&H@-?:VD6P,RHFUSI,@CV-;_61/ZO%1
MXG?^YCNM./VKM;*V;>C?>%F*U8]:A78^52!R#P!\A\9V/M#L3>W\G,]P>X$=
M.UXEJ?<*E8?(S;K"]:+YW#'@U?)B0.I&\<<.ZKDK2\LW&AT/(K&%N'15J8P\
MHZ,V%2R+/-FU='B(4-X$2QNG0*Z2$BQQ@%[0(^3)<\Z*FYQ.V8W:*:\?MQBF
M>1]298*_IM:3.RR01))@PJ@+KF.X]]S_`''DWYO>Q.3QX`4QQ0M4;JZ%!'FL
MXJZGB%65FQR7G5-AOR09G"<AE[3UPJ_B^=+DRZVF2.:+/C5F*5A95L0D4([1
M1L.K/,PF&E-2,/VDD-COD<9;)G*:W8ME``,TR"UO1=SQZ3L2%\Q@+R&/4W;4
MM[4XMJ14[>Q+(D$,$HW9R0`_U1+`,XX+R9PAVXX>YCR6A?)X'UE>,=+J[(];
MF-=:/**93[JL2"E?E=D0!5L:V!;7$B1`\3L80)`26%,=A/)G(=Y[-EXX'?\`
M$:;JE#/6L0U33-E<[,54!]B005(52-_2O;/N?MN:6]H=Q0#$R7*U7/(9,A>/
M&J\@\E5W+5^8`J5L#,X,C6>)P_IM5MM8SDP)ZUF7TM07D:>-VRA`6TS]CK,U
M(S^4C3#@J`V6BI)5:K!C=*`*.PLER*P`U=T[]YQ<7!I/:R&-M3>B/NR>+BMP
M]A`+0C!]SQ),*-V.N"K]LY_<.ZY([\#6,>]#DM]^HY5M=4:Z0Q"!K4-4`%U5
M0UAV19\ZZKO;*8E/5YRSK84="U68J*JCE0Z^'3$2NI*>I`TQ$2#"K8#"E:;V
MHC!,4I2L1'*C#MHJ3UK;%9SYG9F!);S,S'XEC`B.NP!T[ECYE]OX7'HLKJ64
MJ1*RJJAXHB"?I55DAIV`Y,PWU8\@1'B;2TXJ>PCQK0EI;%_(=,/I[V*ED9\U
MM78RI<E^>S4(#H$"4!Y%/%>^<C>TIOISU(!]:XNK%.*B("(>(CDH`YN3S=2!
M#`5SY#.I=6*_A<45.BV%W,\C;8.1G@Q)].I0:ZW4GDI-L?>#CLSP'7!K>5>"
M*H$,MG+JN5<=.L98`K#J\A76=#L!5KI)K176\[0:RS)+:&$B-)'C`E'>OJ1G
MGS'N"UK.TY]S,%1\2P`=6L*O7R@+Y0E:\9;H6**-YCO/9U"T>X>SXZ*;+:^X
MT,Q`XI2K5W!9+^=K+GYA:^JJMCGRQ/=C!2&R\5E93%*K)-%6G8LAO@=6FBC(
MU3-[)XE[._J3_8O7@W<%*9UJ&)%C#;IL?#7UWV=Q9VK'L$PU*G?KN`=_G\=7
M;UAZV6G333IIITTTZ::XV\F_QH\HZ%_VQ=<?<PY7+;#E[9XK<?(UW8T=Q*_\
M/5T'52N5N62W213M?:_]2N7-5?RC?A^'_LZ4$;^[V.ZI&I`XVD?;K.IOABPI
M\I]=X3#Z//5.4YR^,^)OE/BR%-CV1"XM.+>+^9..8-IIG`&K)54\/(L![&1?
M(R,B&[IW<SO75.72?`ZU`^ROD^PV',?'LN9HZN*/+_'=!Q".RJ2RXVOS/).7
MY4Q_(W'W*^.*:-+BQCY#3X9DB.AAK["+ZC->!Y&]=O[:PTR,)WO8BODRJ0-U
M?R,&!V^GC/6?U3KRCWOW2S"[I75B(K6E4>P,?*]0%J&LCS'S\XGB5`DG<#6M
M7R;_`!N<O"I:;4:/C_Y+YWTE!Q'D.(-0WEFVY;P$:MW65Y*YEY2N]9AA8S+:
ML!\OL1<R1`^B4K9$,E3XL5XW(YVJ]R8UF)=CTNZV%<?ZEF-W<G8[CKTUT?LG
MN%/<,;,R::K*0V8?*T%MJJU$D;-L.HUN1SC\.[/?<_Q^1M1+^5\5J;'=\;;*
MH^B\]IMSQ9](9#CK'S,E,UW$,G,Y2HI,AS]0GCU%C1U]SJ+0304=NT4JN.^(
MW\C5XG]1`]3"6V%8244F#X`D`]?@=C\-;[N+=C8^CW5J.3H0%L=1*^)`8CI/
MU`2#T(U</S_\.[?"_1^9Y8H)7SEAX^9W&YT/*O)GSOH.0,SK_J/.:2DV-7FL
MKS7P)71*[A&@LOW*^K[RSNFR[V8>XHAE@,@ME%05F4<QF#9BL&,Q*\9^)Z"?
MGJ7M_P#3$K:OMS(R``$*_/C'0268@1,#;;[-8>^M_D[7`^TH?._[QQO89"QY
M6Q'.,'*6-+93=+)L<G\YZ3YZL:V7'=5GJC'CV%E"M8$ULCR",DM'C$\02FZS
MVGCI=66N4&E+PQ/C_ENL"=NI!WZQ&O.OS$SK,6Q4QG895F&4"_R_Y];DD@\N
MBE=A`!DF-:+</_!_-^0FYE<MO*V=5Q)'S=8;<5?9\AUY,KHOF[33M%FXN?QU
M!6/JM-7VLP,:56R)]I5)4R33"+&L`O\`0_.N[)BI?5^.:MZ0JB2S+Y5.X0;`
M@C:#'$_$&-:O&]V9UN)D?TE+J\DNYA:T?SN-C888J5:3*@\UB((D[TS^!.:_
MHWGG=<B9S3T-1L(.*^?:.SI-V*USFCF0N*.5>2]O<`H^1P8O96'&4JP+NH!*
MVVJ:P]I%?5D$Q(Z2F2@ZWW1VVG#HIOQ/3_"N8'".HY&3'R(WWWVUNOR_[]D]
MRRLG#[CZ_P"/K!9O4!V#<%`$QM*DP`!!!U?_``M_'=S_`,0`JJ\T[Y=Y"CZ"
MFAX;;3.3,_N]_P#X-E\Y]8<S_2--I^-*O0Q#2=+J;^#S(Z)-B6UE!;#OZ"MM
MTL)JC6)UQFO42P/QUSIV?P#R?0<IWF=;R+Q5E(F1T6%-1XZAN=YL:5`9W.<D
M#)-S\W=U1]Q@:9XN2`_AX\MQI:NI>DE\>=XJ-B^C=FP\E^U4V6`'%,$;2?*U
M@^J`0#RV62.IV),^)^Y^ZX-7N')HI)'<`"I,PIYK20"G(JQ`3=^*M$+!`$7O
MQM\Y;+$UE159DO$6=OLM5_QR4L0H\8K7*7X@WEGN-'.KK$=9%F*+<EL')`:Q
MSE:SR;)5K7N[S9'MC%=DMM/*OA4)4D0$@.(\)&R]-]SK%P_?_<*Z[**%X7>K
MD-#@-)MDU'D=SQ;=P)E0`-:^Q/AOFEY>-R3]E0/W.`'QA5Y2N#?ZW#Y^]!C.
M!;3@^PCBUE'G=%=TUI$+._/I6#K9;)4-9,4PAN.IF2IV,86.MF)8C5UP6666
M?(59B0-MSU@P"02)UCV>[CW3,>GN5%M=MP9:V*HY`]8.B*"0#L(B1)`(#0==
MA<G\*<HP?B7YYX/K"Y<VXX6V=7JZN5<[?E#BR?5-K\+IL."PX^Y!R(];J,);
M08^E,V.&XJ=/#DTI#UTN-W.R3&XCOM^-;EHF(0U55*)(F"5ZQ)8D28DDS&O5
M/:6-FX_;[;>XAEOR,FRSB8Y!7(X@A50`P)(`$$ZL?'?Q@\V9W?8V]N^6L/J(
M@B?-&OTVG&_7XUF6WOS=QQ0XNDK\9P=AX=!QOH\M+LLI%EQ'R[&H!!9860C5
MDT4E1=:4DL9/4ZZ@%54*HV`CX_O.^N>@OA[GGC3FZ#=;/186QB9&S^62WY,[
M>Z^]9)/\W;#775H3,T;\3C\YE:/5P]P<E=GZV%#KLWZ61AK,&YTIGI/9>WM?
MA4VM8@E:X!)GR,S>.PD&!'PWZZ\0]T=\JQ>YY6,E-K`67RP"Q]]6B3L>3%2L
MF=R#MTUU"C_'_(O*UD;:9JSXWC<?<V6?R_J-I?[&'>)S/Q2;Y>Y"34PZOB9(
M-9,IID39?M3'QEESJMV;MI]A/:RR63^.SCO<"E.\7J2###IT^D:]*]FVK9[9
MQ'`82C;'8[LW4>'V:R#R'\>ZZF_CFN_G2NLN/IFZS6@@\DP9\F!80L3:S,E]
M)1OH&%124#7R;2"*TK*]*ETAL<R@,92HQ[$\78G;E9\ZBL$#[U>O3ZAUB?UP
M-;'O=J5=JRKB"?\`AWF(Y'R$;20)WVD@?/7'B3\&6W)^;R./S.SPN*UA[3Z;
MC:Z6*FN(9='/^A/HC)\R9J%='AQH%W-IZ^'FF5EZ_NXY`E58Z/\`!K4]%[AV
MNRK!>NT@UK5>0R_%V#CY1Y8,GQD:\6[+[CIO[M5?0I]=LC$!1SX5(U32.H/G
MY(0#$0==F<W\.6<KY,^O.$^5;Z)377U1_G]EH[+):_<\HNRA[OB_,\=5%NFG
MY##G+#8WT$&.BSCJ.JHHAU1D90.<PDR3YA4I:Q5&Q+#^.O><BT5U/9$JJ$Q\
M0`=MM<F]'P?]&\U8ZXAZ_?<*XR!"S>6F1,7@&:O:X7E+D/(;O$\@AT/+T?75
M-;?Y[$VB8Y]6_.UK[`@X]Q,?(F2U%'$[U[*3N>2AQ<\UP(`@&&8,I!)($+"Q
MQ$_4228&OF[`N[#@VCN'9Q?R,EI99K4UNI50&:7EPWJ-!FM0%66.KHT/S5S\
M:WY!^@=4W-Q-9;Y3ZTTW^`XG'W$NDR.JYDXMX*P%7#XZLKK(TTPEU8T_`[BW
M5JR%43)]M;*\`D:I5+H:.T=L6\FQ:')5P$5IAB!PXR=R""=QU:(C779?N3OC
MXBI0^94JO238Z<956<V\X!XA@P4`'8),R3.Q?SU\+\]V_%_S%S58U'SUD^0N
M*.'?C>JQ7"#(.S@<7;&LX6XZY5K)1^8RDS*VV4WT8W.<DU,R'5WH\K:402(6
MP_(?^/P.0CUWO78(=6((^8\->P8E]5^+7;2>5+H"#UD$`@_.?CXZTMT'PUJQ
M2>;(@-3PZ7DS155-GPM@9AT:DQ<^O^N>6_HGD'%X"?<9_466,Q!(/)`:*BG1
MX!IT$\`,YT)KFB"WT?#[;?3@I;7`]3'0`D;;LUA'0P"#`.\$<HD#7B7<^_8>
M5W6S'N#DTYEI8*V_^6E*L88%F4KR994,#PF&,[7<??QE<\W'#$JNF[+A\UAR
M!2_:D61.M[;D?4SJFH^O8G!VHJ)I+W043KJ_T&.V?%,F#8J90"LZ^Q6:)T8O
M>`G`]T4KW&Y?_DA\2?WG<_KUZ_V"X/V7%<"/N4\`OA_A&P^P=/GUUJU]0?">
MSOMQR[Q/=:KBX6173?3^QP^[DT6E-O-?8?4%J?4W.4Y5*2J=6)18\-^81319
M=BZ[/659E!"2,\/7<=K[=D9O9:37Z2JJN-OJ;DQ'G$#;K,3RVZ1KRGOO?<+M
M7NG*]8Y#V/94V\!*_34'[II)Y$Q$A>$M!,P.L_`GS#IXOS_]ITV#U>(IC?55
MWK+7C.3/RL;39_%R)?`>$X3$[:Y:?"_QS3@?H,,:9(CC":'(@&8(C'JA!]<M
M[ED]YN)4*3QV`B/*/#7>^QB![8QE#&P*;!R)Y$_>,>OC^K;X:UNX]^#HV'Y]
MK.2/HG7<`VM77<M9GE6;E=-M]1RGJ([*CY+WWSR//%T&_P`GEXLYT:RN:RY@
M20UU5&!$0L,$$'XXBR<;"Q^\,JV8"7%`T@J"1RW4D?J)&L_NN=[91GI[M;C+
M::^#!V4'C(<*9,Q(#`?'4EP__&SN,ICN-,?QUI_F/6X2+R5\1\J<@;\E=I96
MUSNO^0;WCTMUF^*DKZV36/IMM0803X9YDV`2EFVMFUT66R<I`XN8F97:*\X.
M+50`!P00HV4"?`=!\M;'MU_:[Z&N[4U38[V.2:R"I=MW)(V+$F6\2=SOK#'V
MMPIR-R5],\@<S96ZQKJ6U/PQEP0C_N%=>S:WA37<GW,H4/<UN3V,SCZ9,E:Z
M"6';UT,T\:UIP(^/[VG9Z+@=I=\*C\.RID+362&\IGD[F&@D$AQ!`D1'0SKQ
M3N_N.FKN66,U'MPGR;@K)YP!Z=5:\JY4,`:FD$A3,G<09#C+XLVO$?"E'`%M
M_EKD$-AFL)6[5-E"VNYO\/2\=?4',G/=9;<8T%O"/*T.BT=7S*X,^#8V5>E3
MH*2/;,F6"HL9FAP\#N5?>RME<ULQ3DRGC$R")CQ'E)\8.NO[GWKL61[6%E-\
M6HJVA$<!R>/!@>,[026"CH"(&L3?/WP%RW5\EXB&[:\7YW%!N:,-/F*:=M=C
M7Q'UO'?..8BV%)?;&@'N,E13;3E<"PLN^SO*^N1DA[)O=[4=L>[X-I[3;6Y6
M:^)`W.R,TP2)40VR%F58/$[QK2^W>\8P]Q8]M:N5O]168PN]BIQY!3Q=N2'E
M:$K=Y4,L+(Z@8_\`C5LL@S+NK;#BBOEYJK_C'K(TJHRIH!XX?AC86&AW0X!P
M5XC10;6!8/!4-:K?2KG-D=F.5%\]U[*6G]_[]<K>5_X^>4\-K,5FV[C+%O\`
MC.@X4IJU(EULL3CM(7'_`"K1\&7]A,TU-0Z&WS]O%L8SIM:CZV7'D5QY$*1Z
M7RD,+O\`L7:[7[;7G4.K.')X2RF(*'<`GYB/`GIKQ_W9[AQZ^^7]JRJG2IJU
M46\$L6>2VCRLP'R/(@2%.^NE6$^/]]I/B/YMXCQLO%3M7\]Z]AJNZF;?E#C`
MXVU7'FFX_'=\>\AYE=_?Y><*OU1`+%NZ?3UUE3DDP),=JE'*!S_N.I*<]:J_
MI6E!X]0-^LF)F)),=3KL/9&3;E=ILR;XYV95IVC<%@5.P`DB)@`3,"-:Y<[?
M)_,/S!E@\O3:K*?0^[D965AI]?3\&ZNRX_/$+\:\5<$W=K;9#B7+Z"9@;A^A
MXI*F;=$I'9[]MMI-7,DT[9R21ZWMY;\;2O51:"!!(GIT&YF`#&Y&MWWI:CVO
M)?Z7-!!;DJF`2?K:`(DD28!WUISP+\1;S.\:<6&K9&6R_*T7D+Y0VEG&CYA]
MM=Y&TX6^9L7Q#.S-@P8WNE6`-54RRQPQSNKC0)C@.(YI2=_1T[<Z87HY1J5H
MJLY-N`M=81E^!Z':8V(G7B=W?:K>[?B>WB]UG(IX*2"7NO:U'@[K,CS!9W!`
M.VKMI/B3[#XWO\?K-S8TN@J*O0_%KY=;:S.1[2G"ORMR%K;LE?`9(PU+1Y6@
MT-/OYCZ:LKJL$&@D#;"8AA$=);@87;<"XMZ-F*,I50B'DDH6Y'H(#*=@H@0`
M01)UN.[=][OCHOXFGN)P'>U&FOB%6U4%8/F/(ULNY<DMR8@@@*>@F=_C2YNL
M:/CS"\CZ?@.WX^XBXTXAX<RL.#4ZZXE;[(<9?9/!_P!'3M!O*F_JA4U3-U6'
MXD6K=21_W&)&LS^QTP\<G@#SHC??7M(<1(\?[M3]Q_%[N[+?<TGD:#C?28'9
MZ7ZHW^-#M-+S%*$:V^F,CH<N?CS4<88^VQ=#19+-5^KD5I+FNOI4Z545]>T$
M&#*C#DL:KS_;K#?*GRGR7"XIYL^>N5>0J$5[SI2W5MDI<:QF<BLQ%?94U!F`
M4FSY%N,OQEL^<'V=QDW&E3+B`.T_9I252RI#(H3/[SVWC/?V6\(8Y6D$Q,>5
M?W>!Z;:\A][]PJQ/=.([@$I0K@$Q,6/L/@W0J8,$3\CD3XD^0^0Y/,,7G[:R
MN)Z"TSWT`[D2[P?'M=;$R4.G%\IZ[@6E7)S["DH#2-+8V^A#,L))8$(;:^MB
MQ6>YT9A7ZWW6C_BZ[W"*[U[JDD#CL-R`23U/P$#PG6\_+V^O^FWX=)M>JJW9
M[.(9N?F(A20%7H-Y)Y,8F!CC[X^/=K;?2&GY4BVW&UGG^2[_`%EO.H-=3:27
M$@935_(=)\P6([TU*L.9+(*[IWSB`C3(7OK'J-DH$E&.ZRO;.$<W#L52G,6'
M9IW#5%2`!!)DC:1(G<1K7^^>[)VON-#6"[TVH7=.(XLF0+`26!`!4,)AH,>4
M@ZR'\/?(NYE_.OV?P?MN0JJ#'^A<:7(YB3E9]EOO^G5/=<7SN-FR9G(>CH,1
MM^1C(039`8]LUYX4`0X*32M12-QO<E-U"5+<1RY-M))'E0;L0"W3:1($"2`-
M9OLC+QLJZ^S%!X!$W@*I\]C>5`SJFS00I`8RW$$G6.N<_D#Z&R_(]']!V\3Y
M1S>WM.2>)CU/'N);R#4\;'A\>?//._"-D>VTBY6-<?Y!8Q>68\ZM`*J08H%2
MRJ<=W@R<^+VO3>^8V1C\?4I`:#.XW4]`2(F?W'XC)]_9>'7VRO"S0_X?)9J^
M0@D-Y779B`9XQ$@[R.D'GS'^,_HCAO#YO,<5W4RZYPL;G@'"8WDCC7"Z*9`P
ME?%X]W?#OT'I+XSH<U,IBK'BWE&XG09<DPFLM(4(*O?+0(W]%G=NJ."HR70W
M$UJHWB5#*Q))``XDL))W4=9&N+[3WS(7NSMAU6KB@7NY\O*&9+$50`Q<\U"M
M`&S,=H.NHVF^?^;N2-/P)Q7QW=1L_@N'\KI:B@H=7-O..UJ<J+CT?&E!!QVU
MQF1NM;0OSU))\9T"&ZJ+H(1'Q26<87FTF#W[![=5V<6=O%2,MP#A?,6!!@DR
M8@SL-M;7VAW;O5_N9Z.]'(L2S&9JRPXJC!E+`*``9$06W$;3.KIXT_CO^D<)
M6<48D^OX&F8NHLOX\]+R;:I_GTG2/MOAROQ&9L:/%59Z8%7,JN1Z7CV#.CSK
M&4(]5)/(AOC2V**:SA(UZV6!WW\?WZ@T/\8G(]=P;L<+:W7#AMT?A_XKXGQ^
M@IJFY>./#^1?H+?<L2K4DVQJ8MA42>0*'007,C1U>*#=-*KC%$P9W9&*ZU95
M=K[(MBD_8""=8?<4;(P;Z*A-CTV*!MU9"!UVZZT2V'\6W/=UFJ;`7U'@8]/Q
ME0VV*R]Y59346]WRW2Z3Z"XRYAO;'FL2TZT<B6&KXW?'6-$-;Q;>[L#6)2`&
M[\=W>4VX5E8K;(Q_1"P-X+`V*YY@[@PO3?S$F1KR3)J[I1:UZ8>:,MGY-MR6
MMEILJ`J*R&')YF%^[4*`=7_RQ\L_6!+/1%BP<'H^"]!]$Z/Z$WO%>Y9O\E$U
MMH#*\3YWB[#Z.568;45!\/G+SCYUE:5:!$"W,&NC$>L4)@&JN#VV_+X4G#:M
MK2P4G<B!`E03Q&[$#J8G:0;6[OWK#[<+,D=S2^O'6LN%)4-+<FAV4<V!5%9I
M*B8`;B1@\/QMSK9VFB/-Y6JKVD;KN6=1G?\`*;C=Z=]Y;\S\U4'--[G.1\$:
M+1YV)C)EA4!J].V//NRW<,3#B##(QPENL]LX?&RIA6KE'*."TR=U''Z0!N)`
M\PC9=1T^_.Y<Z+ZVN>L65+;450`*!QL(?ZV+2&@D!"&$OKM)EOB_D/0<*_>&
M'Y'M>*N/=3]JZ757\9.%8%]993CP.FX!XPX<>&::_@9*RV<R;8\?/L+8S8U4
MVU'+<SU@<JN3SJ6`*^&O:I0LM@W(&Q/6#O\`OV_9K5WG/XPY.D=N:N25X.R%
M]9\J8T]CQYQ'5Z&PX^K*'._+W._S[27,.PO:#/S)>LNKOE^/+L3%@18\*@H:
M^`PDDD1DE^[]N8[9'<PJE016YW\?*1M\]]<I[USDPNQ%F#D-=4NWA]X&D_`0
MI_6=]M:E_-?PCR_QSS+QQH\)-X/W>AR7'^=S,+(<J`T@.*KZ14?*V8X$UUY9
MMK:&[NX]U$L\Z2;4L'%*.71V$^`=T-\E)`^@[_AL.V&\LO)#6O&#T"*DSTZK
M\.AZSKC_`&AW5&[\,-:[`EHO?GR7JUCV\2.I$/&Q@%00(`UN/$_BTY'B;76*
M;:<>6>)O;K4<B54H%IR+EX6<VN@^6#?.<7(YW@NF]V`IL30%.Y]=-+<V+H>9
M\*?]L*00[%.$#,IY(2&^6O7'X6+PL`9?@0".L^/Z3OK#'/7PMM>+^1?F"7C)
MO$N0S62X]X%R&KM,U'T\%+@?S]6_C6E)<<76=5H>-;W_`")UQ,9GM-%=EK[-
MML)*N=.>P"==9[7Q[K39;25`KLK8@^,<NBP03\Y!7J)UYU[^S\7'%6/DH[&^
MJY`0`()X_4_($+\5XLK]#&QUTL^'JJ^JZ_3MTIJ)U[)J,K(O8N=/:RZ*'?.'
M8_NS,]-O$;=2J,LC^L3YC6R7=T5Z)W1$S/>%SW58QM`%PY`QT/T^&W3H/EK5
M_EMC5XV3G+CLS8IX%0WU#=^IDS(@G?K\HUD+ZV6+_CV19-6.L4]Q81BC,_LI
M/R(#1L:UJ?JYKWJC%5.W97)UB^T.?XBXUSS"`[?(ZSOS(]/\%C+;Q],VL#/S
M7]!^L:QS\HQDC[K0*,K'Q9&:-)CL\4;Z7DL:U"C"GD[^A6M1SD[-[.7O^JN7
MMLO=K<L"N1YQ:`?GLVM'^75?#O%W$@UF@D?*660/EXGY[^.VQ_T2P9>)M$(P
MT*`IZ<4ACF^0W!+;PAO:9/T1!.1W9>_Z?KUS7MPD=WK*[,`T?_$G7<^]PK>W
M+E<2A9`?A!=1O\M:1<$0BU_+V.C1E),K)LV?*52R'/+`D1ZNR(JC_1WY,8WZ
M([^I%$Y$_145>W==_=;.SW,VUJJ!TZ@LO[#_`!UY/[0I:CW-BUI+4.['<[J0
MC';X@^/PVUTST$6CG4MG$THX!:`\0C+8=HX3*YT+MW+^8\[F":!$3^I7*B=>
M7X[WUWJ^*6&0#Y>/6?E'CKWK-KQ+<6RO/"'#*GGSCCQ\>4[1]NL8T>;X+#/J
MGT`<*ZR!*`^F=!M(,B9^8UKS1W0?":0Q3^#'.;X]U5$7_9UM+\GOS5N,@W^D
M0>4J0(\9VZ:T.)@^T5NK.&,3UPPX<74GEU''S$D_9K*UMX?M=E[%5&?M\SS5
M'H-49^.3R5"*CD8O;_:J*B=:FF?56.O(?QUT63'X>R>G!OEX'QUQC$%'%CQ+
M1BK*\$D5EDJCCN-^,U60QM6.0;A2`JY'_P!"^?;LKNW9KNO:B=B]7T=&'6)Z
M]?#[=?+B*"RUY'^9$HVPF.@VZ$==M^A/@=73!@7,G,/O;:NE0:Z1;'SA+"?)
M$4L^Y2"R9-=Y>7F7R:57-([_`+S]/]51>L6RRE<K\/2P:P('@#HLP/\`5X:S
MZ:<JS`_&9*,E!L-19B#R?CR;^/4]=;`?)=M)S.KN<-)FDEU=[5I8T2%[^V'(
MI7O_`"8IBN7N=YX<WNU?U5&1^W9$3KGO=U*Y6(F>JA;:WA_F&Z$?""/WZ[3\
MN,E\#N-O:78MCW5\JYZ@IU!/B2K;?)==`^O/->S:=--.FFG333IIITTUQ;Y1
MO./*?^26%9P?C;::#E7_`"OA/):;Z%K>1^=,N!W'MQ#R<#)WK:2CH'\3:O.T
M^HV-@W]EEV+(SX^/T,N9ZY:5T>P:D$\>NVLP\LK-_P#'+CLK7R9TO/ZBPXJV
M.TI[JJUM+DX=OE+!967N*'3T_']T+5[MTO)0FLKWV<2KKH0#.E28JS2`GM4'
MTZO?[X5O_3?^Y!FV80\E<8RI5;7,1]G-@P(&QL;#]KCO>']PEPH$0DE(PWL-
M):!PAN0KV+UZ+^7\_P!3V958XUX!/T@DU@<CO`)(7D00)D[`Z\2_.(C^A;H]
MBC/Q257ZF55O9N`VY%5!;B""P4JI#$:XKWH)T:[BVU>UJO>LJ[A3H3/.AC.@
M1X>FK+"$U5KHG[#((CU>PA2B.PJ-5KVO*QWMM#5M0:;.@A2#]9DE&!ZGF-N@
M!!'40#KY7S$NKRUR:>IFQ67_`"QQ"VJR_2/3)F020P,006!JE+0_DL2\I(TD
M%/\`F,C7D/-CD$)1ZM+0C!T-;-@U<MB4EM$DBD5:>$A@88'1#(-T<OE%?D<3
MZ%Y!NXRI>/-7Q^M@6'F4@A]Q+$.L\A&1BX?J+^+Q%9<7E%BU`S7=R_RU94/W
M;J0U6S!44UO!1IR@G&$G75H(LB,V9LL_67%SD!6^=@74C3MJJ'3?_>N=)$Z-
M%<>3,L7FJU<\4@2(435&.2GJU7]47#M+J8PK'5;.+E0G)T\X@$P`H#[$'8F2
MN^__`*!9W*@5.O+NE-;O2'J6PV\*[?NC+`268FK<,/,H*BSRY1XBCF^?N,;3
MDZ]IAW=[-LM#C?GO"MBUM?7-B8S/V43;:VZC&LK#]KR$&;4SB.(LIY2*<C48
MQAGN=JN\,ON'NB]KH<I0JI9EVRQ:;'!JK4\1RL(91'$`0#)*B.@]M(_LWL%G
M?\NH6Y;/91V['A57C16ZWW."S<*59+"3R)/)A`#DG6_;:MFXJM7;ZF3(M=-+
MM?R#7U>T"5UFM?OH>8T-C!COC!E+44=L1CS/=Z`EC21CB@5B'1W2X.(<&VJG
M%`3%5(XF>2S470$R1R9=AU(926:>.N'[KW$=VQ\G)[@S6=P:R38L<6XY"U6,
MH@'A6\$GRJ595K2.8-Y/D96/R?M9/[REC(?E\##B"J,HVLE64DI]'&F0HPP%
MB.>KV3T0@V(8Z1HSI;@-$%Q>L,+EMVNA>'%1;:3RLY!0`A!,S\-CL.3!`Q+1
MK9FSMR=_R[/5YN<?'50E/`L2;0R@`C_%N!+<5-A0*I;6QN!Y-?\`0>!TG'F>
MI8-'R]EZBQU/#%HV669#Y'JXP*XUK+G6E6R,.VUK1CCG4#6`*_R&Y&-)[E=S
M?<.U_P#3W<*NXY+L_9[7"9*Q!I8D\0%:>-?43)`WWCC'<=G[\?>?9[^RX524
M^Y<>MK<%Y)&2@"ERSH!SN@*W$!2?*0`W*=5N/>,($P#MIJ*V)-H8DRUD9S(7
M2[F3)T^@NVY+4,JF4]\&KC3:/,VXC)-\_:"05!1&&&XDCPZON/=+$;\%BL5R
M"%#V+Z0"(OJ5\N2%B&=8X]"!+D$!9\\[+V"FQ#W3N"*^&KN:J7]<FVRST;>'
M"P(&KJ<-SF58\:@REGBEW%7)T,XH)I9[9!2!=97OI5*VEJ"S#6-]96KS60F5
MSH<(!')&1'./[@B`Q9!&,?+3<N/6&0+Q`\J^+-`"*OEWDD;^$$L>()$&3CV9
MMQ2TOS)'*R/+6A):QG)8<>*@^7<MR54!=@#:OI9</A$KV=X4*1*CTD:26-*L
MVA,!MW*OKB,0O[C7V^MLYH)<US7%:!0!CC<@8@7NRN1I#"S_`#&`+$2%F>(1
M3'$K6H*KTF2Q\SL!K>`R2AH'W2$BL$@M!',V.)Y*]SLKO$\>*HIXUJ3NS\E1
M1QMCMPLK#J^NX4OZB5H5*P<$]C%Y+XSD3,[!CHQ'6!:&/*C?E3D<X;CF6.G8
M@#=<1[N8MA4,7$-G(P3Q`--P#D^'(AN*]8'+HPUZM^7%:U]SRT%9E.U6(;)A
M2PRL4M6H_F-89>=DP6;A]2-KN]UX)KZ^TZ::=--.FFM.ON;Q_P##ES&CWO8U
M>(]IY.$5P#-9^[8Y'O$9B*0)&(O='M158O94_7MUV?L2?^I,*/\`Z\K^?\MG
MZ1XZ\Q_-N/\`HCN@)@?TR_H8/UT]#X?;X:X_[ZO`:_E5>7K8-56Q7#KLW`"*
M61T=84<6<H8==(&7VN1]U/<CCR$(\B!+)/\`JI%=[%V^QEQQ;ELSV'=SMO)Y
ML2/]T=!`$A5\-?,_>:4;,;'P*TKH4A:E`.W$"JM5,SN[;LTDPSOORFPY$J4Q
M1Y^$:59P8=C'FZ&:A0R0::VBB=7L16ME*DNCRM!7+&K),=HUD!D$EJY4D(UN
MP55,Y%@"N5(00044[_#9K'/)U,P0$_EWT[V6",*HM94KAK&D$6N!Q^.]=-:\
M:G6.09K"?/`R"333N/,])O*\LB/N9N<995,FEJ3VZYZKF:2DJ+C8(:66NK`V
M\MMSZ*L2R!,`6*:6J$]#1OUPQ:^XY`HL`.`MG%@S!>;!&9:X$L5'&7,$D,J;
M<I&Z.=;V3";+I++W9Z.2%$+^FC6HCW22J!SSXU#D`I1[-^`4W#\OB!4LUF9Y
M"@29W%'(+B8>ZS=W1P`"M;_)W3QT7(,2;63)(8X:.F;'5)0D84)HSE1SG"(/
MK&]TEKC3D]N8+W;'^]5U8GBEB^:HA@">33Y3((;PD'6;[`5,89.!WI&?V[FS
M0]5E:@/92\5Y"LK$`5IQ\P@J5.Y*E=4SF+C[/<0FT>59`;J*UM+?5@-+HB*R
M-<U]51UK7U+8#7?D?AQH5-`$<,Q\]3+%1X6-"7Q?-V;N.3WA:LLMZ5O-6*)U
M4LS>:>DDLY!7A'*"2PD8_N?LN%[::_MRI^(H]*Q1;9T=4K64X]>(5*PP<V<N
M$J`K0<;5YJ^;-XC!=DL[>"7BBUC?A6<']E<&0:KQ$,G[7,%7V4:S>POK+%,H
M'O`1K#,=[VC<NRL6Q$S&H"I8,M3*GE(#6GS"5*^(82`1*GRSK14-3;;VU,LV
M64GMSCBR\()2@>1@K!C,%#Q)4@,/.%.MQ.)>/J/BZHG\\Z>0*SE'G3B<;YV<
MJH*'MKC]QE"VFVKHQ'/FSY#EGV0UERB(T,@RN:,KH[7<;W?N-_=;E[!B@J@4
M>LX\:E@>G63T`\J'BHW"P2.6O3O;G9L3V_C/[P[@1987;\-4W1;WY$7WJ#YF
M/WEHYN?*S2%8H#JAF.5=#D=;I';BU(05_H(%)RM`;"W,Z5"UFD/N]?:Z#*WD
MU]M1LN\VKXZJ5&A8:.TL9[D&\3&];E=IQ\S#J&"@FNLM09J`-:>E6J.HXMQ?
M?;<@PP$@D^=8'N+-[;W*\]WLE;KEKRUXWL5NM.1<]E-C<Z_4JE=X4,H9"8*@
M3FK0E/9-LZ[10[,0DA:?/W]*.361;"#+DPKJIL*J5&A'+8`N:UQG!]WZ$C%5
MGB]%5C;,2+JO2LK9291T:&((!5@P)$%3$QT83(ZZD[B&Q;Q?3>MBCC;78@*A
ME)5T9"%)8.O(KRZJ8@]!C*7.@7$@TX'_`+.2%?P*F]CAKUC#I[6.^XJ8$ZO'
M8LA1Z[(:Z%8!/5ACA?'%^">-_P#:AN?LTKLI45MYN5993,\E/%B#$EK*R"')
M,GDK>)C0V6TY3FY?)PN5+`%@(XYHK*&XA:;E96J"J5'ING\JD[0_/L2(WEC@
M^V`Z3!E3.1,57SHHI93!LQ)6Z.:(=RV07Q/-I[:-.)%((3"1TE2`N<X3F]<M
M[A9_Z1G5-#(N-:08`*^9`>,#8,I4,"8/%3$C7H'LNNL>X^TY*<DL;.H5@"2'
M'&UASD[E'%A0@`KS=22I&N[."$T&+RP6(U&"HJT;$:Y'-1K(PVM1KD>1'(B)
M_KY+W_WKUX-W`ELZUCU-A_CKZ[[.H3M6.HZ"E1^[5V]8>MEITTTZ::=--.FF
MM9\O]E?+6TY-D<-YGG3CZTY.CZ/3XYN/;<MC64[78N381-;EJ=\T<:'>:/.2
M*B6DR##*>4!(AW/8C0D5K5>)B?#6PUK<T]%%'-O+6MIH1K"IJ`R[6=%KHI;6
M_M(='15@Y$LH1/L+JZL8\.(%%4DF4<8AHXCVM5JFM!/K"O\`R^1J/T2CUMJ3
M+Q%K)0!JKI38]E9J>&]JM04P".(GF-RKXJ]%3LJIUZ/[1<KVUY7E3ZQD?`E5
M@_(_9KQ/\QJE?OE7%S7D_A@5(\0&>0?`CX@_'5/^:/H_CG-5>_RFQNP5M[D]
M>E-H30QR+.!%TR4%'8FS9U@1S$@WS*FSAS/QBM:JQY@E1>Z^/4/N#LN3W/(6
M[M46HHX,L@,A^KS`QM##IK(]G>Z,+L6$^+[@Y8]MA%B-!9+1'#R%0=Y4[&/V
MB-6O])<C8;DC19N3"CK<Y&+2RH9M$\!`QXEC(-(+ZD3Q_,&!\?LBO5!M\_\`
M7OVZV?MGMN?VS&M6P\,PV`A)W(`'ZIGPWUHO?7?.T=]SJ+*AZO;5J*FR"`&)
M)C_%!'CL)UG+XV%.#5[P<P82,989]L2TB(-(MF#]OE.1S5;_`%J6.CD:OZJS
MQ5OC_MZT7O0UFW'*$@\7E3U4R/X_QF==;^5ZW)CYBV@%0]<.(AAQ/[Q^R(C5
ME_9BT[]1AXUD+\4Y\]>)7WKS?C!KIC)<=T9/R!D;(";S[N9V3L[LJ)W_`*NV
M;[*]88M[5&5%BRG61!G;H1K5_FC^&/<,1+QQ<T6<;)@*P81O,@^(^/[=4[YR
MY?RW'U5J%Y"DFH'3#T[85BVOF6$&YCPHDIG[@.;713M"PK2HK6%\>R*JI_M[
M2>Y.S9?<;JOZ<!9Q#2L@%22-H)'[M0>Q_<W;^RX^1_6F-)8IQ;BS*X4'S!E!
MB9Z']6MA;3Z6X4KR#NTN94N4./)KQEAT=@K7H<D4JQ9$\L04:.KS1V(U"%8W
MOW_1?]G.U>V.^6`T<`%D&"P\)W`F3L3T&NUR/?GM2EAE^JS6`%05K;Q(,%B`
M!N!$D:OGAC9V/(&0D:RRCAB+::*\6!%`7WB#4QI+8M6B&[-4SGP@L>YWBWR<
MY51J)V3K`[WA5]OS!B5DGA6LD[2Q$MM]IC6V]K=TO[SVQNXWJ%-E]G$`R`@,
M)OX^4`DP)/AKGSS_`&7;F/>5<B!#A>9X)ZZYGG`*.8PZ2H>OBK?6;S"<:=VH
MY7*C?]GZ=>B>WJO_`)RX]JL6V(*@&0.3?V:\7]YW_P#W3YF.Z*DE2KL0`2$3
M[#L1\9VUN%P=GEUOSQ&SN@)&,2ZK]73R)E<K6,:*9/LXPI,,S$\F/&,C7M7_
M`&.3]4_V=<;WW)_">XSDXX("-6P!^04D'7IOM+"_J7LE<+-*EK4N0LOP9F`*
MG[-_MUSC-^\X>R+7WUJ^965ER2N?8J(JRZVTJIC4C-*03(YPO;("KGE15<Q4
M145._7I*^CG5BS'3C:Z3'@RL-_B.G0>.O#G_`!7:;S3EV%J*[2O*#*NC;21!
M&XW/4:['8750-OD,]JJV0*5%NJT$I"@<KA_D-[@FB1RC%W6/-$0;OZ43R:O;
MKQC/Q+,',LQ+00Z,1O\`#J/VB#KZ?[1W&GNW;*.XT,&KMK!D=)Z,/#HP(_5J
M[.L36QUR1YB@WT7EGD>=0V8Y8BZ93GKI:^;&2OQ(@CB"UCGJ!C([FN7NJ.<Y
M$5&_JG7KW9K*'[1C5WI!%4!A\),$_'?_`%Z^;O<].97[CSKL.P,IODJ?C`!`
MCIM^L_#IKH)\\'ER>(,B:=%2%+<.V0T9I7&:-S+NR8U6O=^OB\;4<B?[._;K
MSSW&J+WBX5GDGEWZ?RC7L_LE[']LXS6KPLAY$S_YC?Z]7+R[X+Q?O6D+Z&OR
MUP)#>:,43RPR#&]'N[M:K2.3LJ]^R]8W9Y_JN/`G[U?XZSO<L?\`3^8&,`X[
MB>D2"!^_7+;#&]^VQ4>S*L&Z@Z6@'#L7!``ERR+;0T,)ID<5KVN1S?>(;VJO
ML56HC?U7U3/7C@WO6.5#5/(W/&5/A_`D>&^OGWM#\^[8B7GAE)?7Q:`"\.)$
M[S_M`$=3&VNOESV_:+7O_I^VSN_?OV[?BE[]^R*O7CU'^<G^\/XZ^E\J/PUD
M]/3;^!UQ.K7>PT>?$@U]9K:Z<^NEPW$1@YX5*`\M(2B55*Y`?U"=XO<Q[E;_
M`+4;U[?:(4UNS-B,L@_`P0)_7UWW&OE.@\G6ZM$K[E6_$K.S"06XQUVW!@P3
M^K7;P/B2,+R17M(!GDA6KY.:X:=T*UZ=^[D7^I%Z\-:0Q^(.OK!(:L3T(\?[
M=>8D2+`B@A0HXHL2*)H8T8#&C"`+$[,$(;41HQL;^C6IV1$_1.CN]CE["2Y,
MDGJ3I55736*JE"U*(`&P`'@!\-<;.2ZZHMM_O!5\DM?IQZ?2_P#,(0@_W!@K
MR0QS6(\D<<QJF8C!*Y%:U6^/ZHWNWVCMEEU/;\<V`-C&I-OAY1]L?$_I/R_W
MZC&R>\YBTL4SQ?;O)'*+#\P&WV$["(\-NI_#"R%XGX]_+>XDI,G3,D/(X;RJ
M=D0;"^Y1*X?O1[50B(OZ/[IUY3WL*.[Y/#Z?6:/LGP^7PU]">UBY]N87J&;/
MPR3,3,;S&T_'YZYX<T7,0/,G(5+>1QQF_GQGQ#R!N4%C%FU\%Z,8I&-]CQI(
M[*UB/1.RN\NZ]NO1NR4N>RX]]!D\3,=003_=\M>*>Z<JM?<^;BY8"CF()&S!
ME4^/PGPG[=;`</\`-V#X[X_BYZ[#:0V5,B<<!*^`^?#)"G27ST*BA5GX+`_D
MN\T(B,1K?)'?KV3GN\]BS^Y=P.3048N`#)@R!'ZYCP^S79^V?=G9^R=F7"RQ
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MRF8YSFJB^:?W/^+O;;:JJ3^)4#TD._C"CH>IV'0_JZ=/(:,>_(R5.`Q87VKM
MX2Y@LLP-R3R&_P`?JZ[/5WR1M:D\YD30Y!:T\I900N9<_DL\QD4HD\HSHXV(
M=&.&UJ(QC5<WMW_K7EK/=^#<J\Z[O4`@GRQ_&>DSX_PUW]/Y;=UQW<5WXWH,
MT@>>?&1T@;P0!L!(^>M6C?O65O?SLT>.1*2Y+)MJN4]#+6SX$X+CDKAJB&$1
M#1B.<)7HSO\`Z=D[=NK'H9='#)!^\2%8>((VG]HWZZ\^<97;\SUL`J?2M)=#
MOQ96$\?$&021,:[,UT^-:5\&SAE8>)8PXTZ*8:^0RQY86'"1CD_U:\9$5/\`
ML7KQ6RMJK&J<0ZL01\P8.OJ*BY,BE+ZB#6ZA@1T((D']FN97T4>>/E_5>X,6
M3GS@J`3&F?$1(SV4L+N\R3"`$<1G/1/6G9R.;_YW=.WJ'MM:SV:J"1D`L1UW
M\Q^$Q]NO!/>SW#W+D%PK81"!I(V\B]>1`(/PZR/&=;8?*T<$/BW\**Y7Q(ND
MN6Q5[^;4CG2)*&QA>Z^UK$/V1R_JJ=<E[L9G[KS?ZS4L_:)']FO1OR\1*O;W
MI5[UK>\?88(W\>O761>9TD+Q/R(D3_UM<E=?C=G,:OY'X1/3XJ16L\_9V\45
M4[KV3_5>M;V3B.[XW/Z/66?LG?6[]U!S[<S17_F?AGC[>)CK\^FN5^-FPA:G
M-:4!BUUK76E%-T4%6^V2^+'G`).<2'(0'D5@XZN"Y'(UR^*?HG?OZMFUN<2W
M%8!JF1PA\)(,;B=M]]?/7:[:E[A1GH2F0EE;6KU,!@6E3&\#RGQVUO\`S?J7
MB&8&TKI,736#1`<R=6%RY7K)BE<X)%6/**-A8SF?JJN[-5O^G=>Z=>?)[4[P
MC)8IJ63LW/H>O4>.O9;?S!]M6K90ZY#@#S*:CN#MT)$C[=HU2<-S+.Y/Y@I(
MM(%L3`PLS>2HS2F8LV;;I^*`9I(@/*-JLAF=X#5?[;5<O=7.5$ES^RU]K[,[
M7F>X-:H.VP7<[3\QN?'[-8W:/=%W?_<]5>*./9DQ[")/F9]A)`D?2=AX;[R=
M;:=<CKTC7._[`%6&VM''O*^26`7*QC!L&1GGCQI`+BQ8YJEBHZ5&.GN;V<Y/
M!4<O9?T<B^C>SC:N"[4,!8+3(F"05'QV/3[=>)_F8N.W=:DRT8TG'!#02`0[
M>(W!W'RW^W4I\[<LY_C%M_G=>>Q)'NI<>=F;<0@S'3*^%%5L@4]6R6R23!EE
M,1CVC?[F+Y.1O9>K_<?:,CNGIY.&%#("'62().Q&T1L9$[?/4?LGW'A=@%V%
MW,N4M8-4X`;DJC<-O,R1!`,C<Q!U3N=N4JG<:RL/30;$=#24<C\BYF"``<ES
MC^\Z-BD(Z4D>,CF]W>*.5?U1%;U)V'M5N!ALM[+Z]E@A1)C:!OTDZ@]W^X,?
MNW<JWQ4<8E5)EV``.\G8F8'[?U:RM\?5<>`W?'@J](,Q^;((**;\0#E%:F[1
MF%>J#0PSH]R-:U$5>W_8FI]Y6M8<=7CU%YS\3]/7]D:Z+\LL=*1F/3/HMZ4#
M>!LYVGXS.T:K'V`V%(RV2@SQ>P$N]G-<11#(D-$J3L2<BD$;UO`8K&M=V\6J
M_P`G+V3J'V;S7+NLK/F%8_7YAM^O^S;63^9@J?M^-5<)1KFW@'CY#YNAB"1O
MT$R=8N^3`V$#D.WAEG$GUSLG*?"E'>'WN\+&J[QWJ#LTXV-=W:YWZ]VK^G;M
MUM?=S5V=N1PO&SUA('3HV^_36@_+A+Z>]6U,Y>C\,>),3]2;;=1\/LUT%-"C
M2)$.64?G(@/,^(3S>WU.D!=',OBUR,>CQ/5.SD5$_P!4_7KSQ7959`?*T3^H
MR->SM56[K8PETF#\)$']VIKJS4FK,Y$MK2AP>ONZ1S&V]1GK6RK5*)IQK,A0
MRR`,>%Z*TC2$&C53_;W_`$_7K-[;35D9]-%_^2]BAO#8F#K5][R<C#[/DY>)
M'XFNAV61(Y*"1MXZT4KOI[DYCZB59H*4`-A`70U5;1U_[A^V_H^P9"65)BM0
M[AJGK_57(Y41R)^JIWMGM;M9YI5()4\&9C$^$P#M\?W:\AH]_P#?P:[,B&0.
MOJ(M:\N/\W&2-XZ>/@=;#:;Z&XVM,S>PJZ1;39%A2V<(`OV:4-J2I,4L9H)#
M9#1N$X;R]WHK>_BGZ(O=J+SF+[<[G5E5O8$55=3]0Z`S(C]VNUS_`'KV+(P+
MJJ&L=WJ90.!&Y!$&>G7?Y?JG0=C7M/`L&1I*G4L2).$YC1N-$:;NYQ!O>X:^
MIRJYCVN5%1W97*S^I/0"1Q:LD<8)'R/Z?ZIUXZH(=+PIYR`PCJ)_LZ@@_KC<
M=BP]O2+MV5/4/LJ?Z*GBG;M_V=NO&6^H_;KZ=3Z!'2!K`?TIY+QPUC5_X]#5
MHK?+LI&H*:YS43]%<O9O?LGZ_IUT'MG_`-Y3_P#(V_LUQWON3V,`?_'T_@VM
M8_GJ*HN6*9[I7@+\&X1D0HW>QTE8$M7*PC!(UC6"5&HU_;^EO^JKVZZCW$_+
MM#B-^2[_`"D?V_#7`^RJ^/N.H\H7@_E(WGBT[Q\/`^`^.NCO7FVO<=::_5H_
M*9BG/<Q`/AZ$14(G9'.4E2YC?9YI_P!XGDWQ\5\E5/U3_;VGM,^2\#ZN2?\`
MTVO+_P`Q%FS%)C@5L!_:GZ1'[-8[X#W6(XQDZ8]_*G0`W`JF-&<$#YM>$D(L
MUKA-8!A)$8IG2VI_4JC[M1$\5_UV7N#`SNZ+4N.%9D+$R8)F/CL>GVZTGL[N
M_:NP/>^8SHEH0"!R4%2VVVX)D?+[-5KG;DC*\BQ<_#SZ3#K5R+"3,D3HJ0`L
M`:,-6M&L@C2/>A(R*O\`2B(J-[=U_P!(.P]MR^VO8^1Q',```R9GY?;K*]W]
M][=WNNFK"Y'TV8L6'$00.D[^'\-0?E2O?$WN@4#VM@?XJ]S@N17$_,-<17/*
MQ41HPB]:(BM3_B<O?LB]U=7W98'[?6&_S/6Z_(*=M6_EW2:^\7%(]'\/T\>1
M<21X`?+Q._QG93G^(6;Q5HP#`Z0WSJBG&C4>GXX+6&8SWM7OW&-@^[O^Q%ZY
MGV^X3NU3$Q]4?:5(UW?O*MK?;UZ*.0E"1\@ZD_Z=:*8/7UF/WF8NK"-,9#A%
M,2<^$%QF*PD>;%10!9ZF->X)6JK$[-1457+UWN?AV9F!;161S8;3]H.Y^W7D
M/9^YX_;.\8^7<K"I22W$3X,-AMX$;?;.MF.4.>..]/Q[?5-++L)\BZAQ01?*
MGELCO:68![G$>=HT0?K&J=^RIW<GZ+WZYCM78.XXO<:[;PJJA)/F$]#\-=[[
M@]W]D[AV6['Q6=WM4`>1HW(ZS&T?V:U=XA.>OY<PM<*N8L*1H&&#(C,*K`))
M9,)X*-2&5$:C'J]R>L8U5.R=G(G74]X5;.SY%A;SBN(/C$?Z(ZDZ\^]M.]/N
M7$H6O[HW`@B=ID])/SGH!]A`UU,M48ZKLFD5J#6!,0BN;YM1BQR(Y7-_\YOC
M_JG^WKRJJ?56.O(?QU]"9`!Q[`>G!OX'7&YE?7CBCKK10@K62XT:OF^2#6"$
MQ6_C$',1S'BD",W]$:@V#3Q8ODG=5]G-EA;U*I-A!)'Q^.WP(^V=SKY@%-*U
M"C(@4!@%;IQ!.QY;00?A`&PWUTMY'XTSY.%KG'PH?:'25#[2N?[7-E-L:IKY
MZV'Y3&J_\^0YI%4B?KY$7MV_3MYEVWN>0.]IF.?.[\3\(;:(^`VV^6O=^^]A
MPV]JV]LJ3[JJKFN^_)/-RG_$=]_GK1+"Z%V5T^4N9#G>==8UKS.(1CUD!<,0
M;!%(WS3V>F0]BJY&^9$56_HJ+UWN?C?BL6ZE>C*8^1ZC^`_5UUY#VC-/;^X8
M^4YW1U)D]1`#;_82/"3T\-=71D84;"B>T@RL:09&.1['L>U',>Q[55KFN:O=
M%1>RIUY*008.Q&OHM6#`,IE2)!U[ZIJNG333IIITTTZ::X7?3MT_6_R`\=8>
M76:R(;*\]_,5O38L7-GU2FDY,KJV5D=;.YBP/"<(<_Y.?P_QK+]L7429L1;)
M"T5G)69!L&U;9;4@^F?[O]>ME^5^+)%M]?4^H=Q766\YVWXAN:/5GXXW%S<E
MI*RSX^EZFYK^5ZJ$3`X:)C?\!8Y:RU,R7)8Z2,'=;02(U0'RQJ_/N0D(>,JO
MW2,>95%Y7XNB6D4,U]<V7!GUFV@&@39@B"DLJK3\E(LP0E1\J*<@%5K2N>WT
M'V('.:_I$"T8EY4Q,$-49`Z<ECDI/TL`VY$:\8_-MJE[77^(4MCGN.('`;C*
MLMZE68$'@\\'`W=&9-@Q(X]VP[^^M9\-2UM.LV7;"D6)T&.'3UZRHB399Y<(
MY&1ZV'5Q+&2B)XC5P_4SR(Y@R>R4G'HI6R&>`L*.K&#``(W8L47X[R=I(^9<
MA<S,R'JFNKDS@L8"HLCDQ93LJH+&\!(XB6(!M04Y\LD(%?7E;4U@3PJD,\@2
MF.>YGQ+VYT-I%D3B,AW=Z9(99[>SAA5K(XWL9'8JY;5A`S6,/68@L1X!045%
M(&ZJ.03Q.[$$L=:Y;C8R+2A_#5@J@8@DEV%CV,"QXV6'@;!N!`0$!!.4]E?6
ME'0S\3`=;?OFCB1\QN3#HGSX-'2Z'-Z.91YN/-OUK0,L+>=!C%FG5"=A%%#5
MK7$D.;JL+'JOR%SK.'H5DO4.4%F1T#.0G(\5!8*-MP7DPNN@[GEY&)AOVJGU
M/Q=ZBK((KY+6EE5K5U!K.(Y.RJ7;?8K5`+.1F[@'*UW(O&][Q)RHVP@TFJN6
M;SCPDFC%&MN'M))A$DW)(T6J++<(.CN12(Z``=J2V'8QK?9*8Y='[@R[.V]R
MK[OVKBU]2>E=#RN0@,+):-T6#)'E@D[(==9[-[?1WOL5WMOW"'3$R+?Q&,36
M`^%:5)>`A,"UPR\58<PP`$V`ZUTY'KX62I=#0K2#++?=Y(@='8E<:3I9(=M5
MQ(.MK*MKXD0-B8LR;)B&_&4XCR7B.=7JB/Z/MMCYEU>1S(3A9*#8(#4Q-;-N
M2-E5AR@A056.G#]\IJ[;BW8?I`V&VDBUC)M(O0+<J;`,2SLC<.09RKO.QG3A
M$;DCD>9;!N)UQ&@Y&;6+8`)7W3SP!:%8875\>*=XHL\?Y$0WX:PSFA>X2E8!
MY5!8I([9C)246DM8&C=8/"3)(W'E8<N0#08+`<IG0-WS.MR1:^2J4LG(%7)4
M6<1Q`,!AR1N'!BG)>04L4VFJ<#:?//#LBTR4RIM^<>1\L6EQ8G39,*MXWS*5
M%)66T2GA05$V)H)9($2'*E*1\Y9(E:PJHPQ$Y2[N%7N+O(JS`Z=BQK>5FP+7
M/R9E+$]4$LRK'&#N-U&O0L?L^1[*]L'([:U5ONW.QRE`Y%5QJN%:.J*L18>*
M([R;"P@,89M:G\=\BPX<%N1T&A!79&_L+O\`P^UMHVR=.SEC0KF,-%992]#^
M17)C=9(_Y>2CI`D9(]4IB)_S!'=;W'MKO9^,QZRV96J^HJFN'#\[3`2#ZE8W
M78R)4_RC7G/9.]U5U#MN;>$[;<[^B[B_E6U?I8XY&R5]"X^5_,(;C8!];&WI
MTR?0VED<U<TDF`^16V$28$;@6<*N.L&SH-!GTAE=*CS(EK*&\97*HR"&1GK(
MP9>LE$KR*E56A6A@1U4D2KH\B""JD$=02#()&L*VR[#R+'9)="58,!#JIXO7
M97!D,'8$'H0I'%@K:H#9$(`J:PKCR8E79ME%@,D1VI>0RNAO@2\[86AWDE'O
MZJ121@RB,`..5LZ-('W9)8Q,@J[%Z[`&M6`8/E(F0X4;!&#$J))'%E.ZDZPP
M]2+5?067'L!*R/O%/'B:V<[FQ"BAR%"GU*W&S@:WF^4!C#L]Y,$>0V-:\-VU
MDM*B_P#L8ITW/%,3_)1M<OY<>YOZ\$9LQ&J$1OQAE]2$<][^#]VDMA8Z$#DF
M:J\OYO\`*O/#X%4)/'J1)$Q`'K?Y=*J=SS+5+<+.UNW#^0G\1B#U?B'L4*'B
M`W%6XAB2>YW7A.OK?3IIITTU",84<)9!R,$``B&,4CD:P0A-5Y"/<OZ-8QC5
M55_V(G554LP51+$P-6NRHI=R`@$D_`#J=:)_5FZR?(?SMS6W.2UM!P>,M)"G
MQ9,2RK2/%9W&06$_PD`CS%@VH!/]91(JJU%[=GM[)WOM/`R^W>X\'\2.!;*0
M@@JWTK9/0D2IZ@_PUY#^8G=^V][]D]V&"WJ*F!:K`AEV9Z>/4`\7$P1_$:YH
M\E9ZZQ5Q9AMHD^BUC@$9`B2T45IG:%K#UBZ&,9'!>RXN$LI/H>OK(,$DS^S6
MF&@O3>V9-.=2K4LMF).Y'TN^S<"/\*\1(W!*@;D&?".^X65VO*L7)5Z>XQY5
M;9ZJ]U]0';SOR;B=B%9CL&7C8,5*.CHK;<7S8DW-9>!/5E*R]KZL5[;S8,@T
M"DK229C%+&+6UB%F&1Z,CUX"E5WD@VNV#^O?>F!CRN5:P\W`MQ4$2S0.O)H4
M1NY`Z2=::L8F)B6=VS.+X&.C>3U%46.RDJBDMN"J2[3"UJS3/$&P*O,NYGU]
MU(NCYBS@`LKVAVLJ9=:R]-79N]%1RL-3Y888M;F8T@H@-CUD)HU[A@]@F(HR
MJNQMRAV7#1:!:MA5'K`6M0SKR%K626<@3+M/5MP)&M-CX!]T]SM?+./92MEE
M=Y9[K"M5@K..E4!:@2`%J0#Z:_*S<6G)6LNA2'_X/%KA5LN92Y@VECR\U+)4
MU7'J^[,6&%K[*3)`^-I=>*4,3GN*`B16JY[5>1SFZO$I*C\<S%D5W"$..37;
M.+2`#*5P3T(Y;#8`:WW<<I7/])K05V-54;0:B43'WJ;'5B01;<"`22IX"2"6
M)%]<D:NXVG'EUAI5FW_*,G0PR#A*.00PLC30[F@C)%C?F+7PM#2U<1S?R&E6
M18TRI):J.$O?![;B487<4SD7_A;K#OM_F,5<R8DHS'I$)9Y3L=;;OO<<GNO9
M;>T66?\`'XU*^7>136'K$#EQ6Q$!\P/*RGS@@J=8\XXK!7F^^=P3XA@L9@R6
MWLUW:3G0UE7`PTF1;Q!"&X0:*MK:]2R/R/8SU)X,1I'-<FQ[E::.W]R:M@3^
M(X_=[.68V@*?'DS&!$&=SMMK2=BQUR^\]D6Y2`,,O]]O6%1<<EU`$"M566Y2
M(V$,0=;!?0/(<S66V9EXM($VIRM4VH8-UU/@TFVRFHF20:^^NX5;7P*B5MVU
M&5%+AA$KGPU1P_Z2%0/7/>WNW)B4VIF\ENM?E](+56(`:T4L2PJY6%6)V;8]
M!RUVGO/O5O<LFBSM?!L?'KX1S94OIM8BZQU550W\*0Z*NZ;KL6XZUPU'KV\2
M+N,=9S+=*VHU-[A$SFDL:8FQC3(EM1@%8R216+'OL[*F.=$4XR,9X'C(I'^K
MKI,6<%S@YJA.;UI;S0-Z9!5C`G='`\T$$RK;"=</W".[5KW;MEC6"NJVS']*
MUD-X(>L!C&UE9:4Y`@0Z;GCJBY32);5_^`VIY4M(1*^OS%HMM0VT4=[29"FG
M:7,S[:G4<MT:XM6*]'3H@F#ME5$<P,UZ=3Y>-Z-G]0J`'*2Z\74\6L8(X5MI
M5=O*QFOXE!K%[=G?B*?Z/DEF"E5J?G6X%E=*-;4SI#0[[_>(`+IW"VG4C^TS
M(5I%LZ^N+<-:&;27XB')6CL\\488\@%A.&L>3^7%`,"QVIY)&FQ$,]GD%X^K
M_61ZC58P3<,FW+B_4$#<03,_XE;B#!!U#^&MJR%R*$-H`9+`3QYUF`0S"#(`
M7B/Y70,1*E=;E\,X6VI^0.'+\U62?0?]7<_&K]8T8VQ/W"0ELR0BABA;%@7M
MJT'>=%(_V12H;TH^,4)%XSO6?3=V[-QU<+D?@W+5^,#C&YW*+/E8"&''E#@C
M7J'M;M.3B]Z[9F/67P_ZE6%NVCD><[`0MCQ]XA,H>7`&ME8]B^,"D-QSAC%<
MYY"Y6C(1[E5SGO?7@<YSG*JJJN<O?NO7C/=`!W*\#H+6_B=?3O8&+=CQ&;=C
MCUG_`.A&KZZP-;?3IIITTTZ::=--<7*3AWZ,TV1I/FZ?\ZZO*@SO\A^O^G#?
M0.JUW$3L!3\;T?VOK/J#.V/'T3/;W4\F3=IO\L^-GV19.?KAPFW,Q\LK1"<*
M0U(2)F?#^R-:G4WR+]8:M-$SE;@/DJWR]P+Y+Y-U6`_ZB4GX-ES1PI]FXOD/
MF-U)=7OU#N;S<Z.3PY8V8:C4V,O.LTD>"C%AUSPP@-:KR'Z?9]FJ7?\`P/\`
M:^]D\I3=D3E*3NHZ[Z3O[ZDU&7S%-]$T=I]&8C74^7P>ME\[Z>W9<R>!:RYJ
M:`YJ+CR)F&34JCN>(OMC;+MW=,CMW-:MZK``RR1(D$B0=I`(D08)@ZT/>NP8
M'>Q4U\+D4L6K?BK%6XL`2"/,`Q#A3*EE!(.MDOCKX/T&2O>0I6KXJY5XPH-G
MSIS%MN,!:G89'5KAN.KSC3@*EJXW(%'6<O:N/*LM5=YJ<.FKT;>?XZ"H<)30
MF$$AMM1[D_#V-971$N2!ZC;`JJQTD_3L3N)C7.YGLC\;2E-^7RXU!6/HI+$.
M[!NL#=]P(!(!(\!T"J?CJ'5Q"15WTF:IRF,<I<U$CH9QB(5WF"+9C`Y4<W_B
M5%=V_I[^/Z=9]WO-[7Y#'"P`!YR>GS*S^GQUI<;\L:\>LU_C&>222:@)DST#
M1^D=-M;'<8<9T7%>>)GZ,ASLDSB6,R0=&#]LHH0@5L>,)$%#B#%':C!-[^/Z
MJJJJJO7-=T[ID=VR?Q%\`A8`'PW.Y\3ON==SV#L.)[>PCA8A)#.68G:20!L!
MLH``@#Y^)UC;<_/\CD+065WH-Y-,&2U8U;4LH('X5/6C4BQH4=SI2F.]A"*0
MI7KY%*JJB,3LU-G@>X5[=CK1CXZAANS<S+-XD[0/@`.@^/76B[O[,?O699EY
MN8Q5ME3TUXHHZ*-Y.^Y)W)^'06+&^/JJ-'+&;O;8@C!8U1&HZPD<4A&JPAHX
M%+XA"5BHWT]U8UJ)V_7NJY[>\K68-^'0$'_$TQ\"?[>NM0GY98]:&L9EA4CH
M:T@'Q($[`_X>@U+U7QQ5UT!:TN]L9L3LC/!^=J@?V_ZD>)WHD-:\;FN5$[HJ
MHB_Z]76^\[;+/4&.JO\`[['^(U;C_EACT4^@V8[U_P#JD&WPV/36P_%/&\7B
MG&QL97V\ZXB0YME+BR[`0!F"RQE/E?BM''\1(",\BHQ$[?T]<YW;N;]VS3FV
M(J.RJ"!.\")W\3KM?;O8J_;O:U[73:]M2NQ!8`$<C,0-H'AK#-_\LQ-3,O)M
M_O+6Q/?3)<V8XE)5M5A)+&(,8?$G@@8CV-]:.1RHQJ,551$ZW6/[K?%2M,?'
M116H`\S>']I\?GOKELW\O:^X6VVYF98[W.S--:=3T`WZ*0(F=@!K*/#O%1^(
MJ$^7!K;#1T22C2JN)90(L<M2Z28AI(020$>\L8CG(J#5$:QR*Y/U<O6J[SW9
M>\9`RFI6J^`&*DGE'20?'Y_W:Z#VQ[=?VUAMV],E[\3D2@90"DF2`0=P?AX=
M?$ZQ&;Y,KYUE=VMMO[RPDWMC-LY+75%6(`9%A,D39`@!12,;%&4Z^EJ]W"[N
M[.5'=F[@>[K*ZZZJ<>M5K4*/,TD``"3\=M_CMMKFV_+BFZ^[(R<VY[+G9CY$
M`!9BQ`&^P)\HZC???;)_%W#CN*230TNQMIM'9'67,SLZ#!2J%-\5:Z=4L#X%
MJI,I%3\GP<X1U:URL1Z*Y=7W7O0[L%:^E%O40'!/*/@W^(#^7Q'QC6_]O^V#
M[=9EQ<JQL1S+5,J\`W^)(W0G^:)#0#$[G,YFD>$K`E]!7C>T1O!I?21S51A?
M6Y4:3P<O?Q7]%[=:12`P+"1/374N&*D*88C8]8/QCQUJG+^4J>PO;;1S]QHI
M=K=273K`SXE<QDB>\I'K*(,36-=ZPO0(V)V:P;6IV7LG76I[MNKQTQJZ*Q4@
M@;G8?#]NY^>O.[/RZQ;LRS.NR[VR+6Y,87=IZD#Y;`=``!X:SIQ[B2X&E=0-
MO9-U7C.\\!LN'&C%@(=[RR0M+&7^^$IW^:>:*YCE<G=45$;H>XYP[A?^(-82
MPB#!)F.AWZ;;:Z[LO:F[-B_@Q<UM`,K*@%9W(D=03OON-]XV$/DW".Y)RDK)
M/OIM!!L)$1]F6#$ARRSX44[)#JPS9K'L;#EE&U"^/9[F(K>Z(J]Z]KSQVS+&
M8*ULL4'C)(@D1R$>(\/"=]6]_P"SGOO;F[:;GII=AR*A264&>!Y?RD@3&Y&T
M[ZP9+^2<O+9'1VKOFEA%!)@2DBUKI<&;%(,L6;%,\3D:>.0:.;Y(YJN1/)')
MW:N]3W?E(3%5<,""):"#U!$]#KD;/RW[?8%!R;@R$%3"RK`@A@8Z@B=YWZR-
MM;%7&>GW60EYF1HIT>?/J$JYFCA1(`9Q'D"T$R:.&X)(`"S&^?=K6>#/-?%$
M[)VYRG)KHS!E+6IK5^00DD=9`F9,?OC?7;Y6%=E=M;`>]UN>O@UJA0QVAFXP
M5!;?8"!.T:ULL/CS&6@&`F:?1*HV*,<@`Z^-*&-SQE<,1Q`1XF.(%B]D_7LU
M$[]=-7[RS:FY)57OX&2/V3KA;ORR[7D(%MR+Y`Z@*".AV(&VX&MGLU4SZ.IC
MUEA=GOR16M$&?*AQ(4C\88QC"$K(3!A(X2,_X_%'.[_U=U_5>6RKJ[[C;6@K
M!Z@$D3XG??\`5KO\#&NQ,9<>ZTW,NP8JJF```#Q@&/CU/CJMF:1X2L$7TE>-
M[1F\&D]1'-5&%];NS7^MRHO9?T7MVZ@4@$$B1/364P8J0IAB-CU@_&-:DV7R
M)FK24E@?9Z-EBDQ9[IPX5*X\B4KU>AIKCPS++>-SWJSR[-:YW?M^B==?5[PR
M:E]-:*_3XQ$M`'R@B/GKS?(_+7!R+/6?*O%_+ERXI)/Q:5,^,?`[ZV`P&++@
MZ9:%F@L;RN"17US+(49I:YA'/>:,`H&M5\5Q7^3&.[^I>Z-7Q[-3GNX9HS[O
MQ!K6NP]8)\WP)GQ^?CX[Z[/LW:F[/B_@Q<]U(/EY`2OQ`(\)W`/3PVV&/N5O
MGG&\K2OW.?*L:2X4(P%L*M(9/R&#<)&O/&G1Y`OR&QQ^M",\'^/;NJ^+438]
MI]Q9O:4]*L*],S#3M]A!&T[P9'[=:7W%[*[7[BL]>YGJRH`+)Q,Q'4,")@1(
M@Q'P&K'C_)68C1?Q6:R_(WR1W>3&KC]U16>+511M51L:-$1JKV1$_P!O6<WN
M[*9^9IK!^1(UJ4_+?`KK],9-Q'S"G^SIJ6K?D'*P63HQ=1<'@3YYYA88Z^N`
MQ&2&A0D=JO;)9XJX:KW\.W=W_#V3LM]OO'+L*L*D%BJ!,D]/'PU'1^6G;J@Z
M-D6M2[DE0JCK$CQ^'P_5K+$WABC3#5O'6>L[+,YB"8IY,>$@94JT*62LUSYT
MN6UY'(^:]Q7M;V:YRHG9&M1O6G3O5_X]NY9"K;E,(!,@+M&P'RV_TF==';[6
MQ!VBOLF%8^/V]"20L$N2>7F)W^J28VZ>``UCG._*N?S%B&TJ]=?MF1[0%M']
MD6M=&!(C&;(`(,1!-`&,TJ*JL8C?+R7O_KUL\GW9D959JMIKX%"IW:2"(,GJ
M3\]:3"_+S"[?>,C'R;O5%@<2%@$&0`(@"?`=9,ZV<_'F+6K%=8.2>L-0?N@X
MP&O24H5&DYL1R$C(]"_U^M45G?\`3MVZY?DGJ\^/W?*>,GI/2>ORGKKO>%OH
M>F7^^XQS@=8^J.G7>.FM5H?R+EH<JRELUNC(:TDNERGG#7%<\S^ZE(KG`[J0
MSE[O=_YW9._?MWZZM_>&6Z*AIK"H($$]/VZ\]K_+7MU5CVKDWE[&DR%._CX>
M/C\=;%8O*-Q>9K\M&LY=A"J0)#JS3!162(D`;&LBP_\`EA"&9D1$[,<YJN5O
M9'*O;OUSF;EG-RFRV0*[F6`F"?$[])\==MVOMP[7@)V^NQGJK'%"0)51T78`
M'CX$[QUG6#;3Y<S%W,M+"WU.FL)EW,D3;0LC]K=^665Z_8BHD)%$-%$WQ:Q6
MM8GZ(B)V[;VKW5E45I5354J(`%CEM'Z]<ED?E]V_+MLNR<B][;6+.3PW)C_9
MV&VP$1X:O3B_A6#Q/(D-SVIT4JGEA8.316CXLF`I@B:($H"M"-\0XF-1O<?;
MS8B-?Y=D5,+NO>[.[J/Q%58N!V=9!^8.^X^WH>D:VGM_VK5[<=AA9%[8K``U
MO!60(!&VQ'RZC8S`U>7(&*7>T;L^6^LZ2`<HR3DJV15)/&)[2,BR'R!$<D57
MM[N:Q6JY43NO9.RX7;\[^GW_`(@5K98!MRG;YB/'[=;3O/:CWC$_!-=9522.
M7")8#P,@[?9'AOK`$SY"R-B6(>7JM)[H!??$)%;"B/:1'?\`"9XQN<8#F(B.
M9W;Y*G?NB?IUT*>\<RL%4JJXL(,R?T.N-M_+3MM[*]F3?R0R".(,_/;<1U&J
MHGRICT,V3_D6D]Z>(W$\J].\5K7=H[6I$1G=2KY^;D>J*GZ=OUZA_P"K,R./
MIU<?U]?CU_NUD#\N^V!_4]>_GT_EZ?#I\=Y,ZN;CKY\S?&NKDZNEN;>0>9$+
M&DP9;(21'O*B-=)9Z`"((BHUO=J+X*J=^W?K%[E[AR>YX@Q+T0*ID$3/V;G6
M?V3V7@]B[BW<<6VUG92"IXQOX[`$?PUG[KG]=EK'V\XUSO(0H#;O\P,BK<9T
M*7`.T!QI(>!QAO\`,96&$1(Z)XN1?'NJIV=V5-CV_N>3VXMZ'$J_4$2-IC[.
MNM+WCL6#WI4&7R#USQ93!$Q(Z&1MX_JWU@5?CS%OBLA'U&G/'$4IA/<VJ;+`
M\KR$[QI#8/B#UO(OAV9V1$3_`'=;_P#ZRS@_-:J@Q'^U!^T3O^W7'_\`P9=J
M-8J?(R"@)(^B1,G8\=HG;;59%\K9%&H,^DTAAHU1JJ)5#,X7;LB>Q(#FH1.R
M+W1OCY)W\>WZ=0GW9F3(JJ!_]*/XZR5_+SMH'%K[RO3^0&/MX]?U?JUFG`<=
MYKC6E=1YJ.4<<TATN7(DO825,E.&P:F.X0@B3LP:(C6,:U$_V=U55TG<.XY/
M<[_7R2.0$`#H!\!UUU79NR8'8L7\)@*0A:23N6/23``_8`-6OR+Q!#Y(L8,R
MUT5M"C5\<D>-7P10_2-#N:Z29'G$1_Y!_!J*[_8C41$_3]<KMO>'[96R55HS
M,9),^'3IX#6O[Y[9J[[>EN1?:B(L!5"QOU.X.Y^/R&J+D.!JS!W@+S,:2VC.
M"`L184V-!GQ2PS^"GCO<X89+4<X;7M<CT<UZ?ZJWNU9\SO\`;GT&C*J0@F9!
M(,CH?$?NZ?/?6-VSV?1V?+&7V^^Q2`1Q8*P*GJ/`_.9D'Y;:SWUS^NPTZ::A
M'`*4`T8XVE!($0)A/:U[""*Q6$8]KD5KFN:Y45%147JJL58,NS`R-6NBV(:W
M$HP@CY'6N$_Y?Q,DK21+;0P6C>BA$IH4QL8+O)3`COD0_:UIGN5RJYSE1?\`
MX^NEK]TYRB'2MIZ[$3\"8/AKAKO8':K&Y567H!T$JT#Q`D3O]IU(-^5LFQKE
M9HKYIR%:0QT'7=R(UJ-\%9^-XHU$[JG^U%55_P!J]Y#[LRR=ZZX'AYO[]0C\
MO.V@;7W<R9)A=_W:K%1\S86MLJ^SDS]!:/@E<5T.5,`RNF]BL.%LR**,U7(`
MC/T\',\FJJ.[HO4-WN?/MJ:I5K0,.H!D>!@SX_.=96-["[11>F18]UC(9@L.
M+;@CD`/`_`B>AUL7US>NWUB_DCC,?)(8$.PT%C6UL$CI"0(,:$\<B4YCAI(D
M$D#(1[AB>YK6HJ,1'+^BK^O6U[9W0]L+/76K6L(DD[#X"-<_WSL*]]5*KKGK
MH0SQ4+!/23()V$@>&^K&J_GJNH;2KNZ+6W59:52L<*2*'7$;(>G=AOR0O'ZR
M#E`<X9&?HU6N7K/M]QV9%3T7THU3^$G;[#\CN#K4X_LJC#R*\K$R;:\BOH0J
MF?C(C>1L1TC6PS$>C&H1S7O1/ZG,8HVN7_>C%>16_P#R5ZYPQ.W37:B8\VY_
M3[=63NN/J'D"!&B7`W,/`D))KYX6B=(BN<K/R!>!V%`>+,$SP*(C7,<G9>R.
M:U4SL#N.1V^PO2?*P@@]#\.FX(\"/X:U/=^RX?>:5JRA#HTJPB1\1O((8;$$
M0?M`UA65\L9:2\G;06XX[V*J1EBP#C:;R>]I.YV$56,<K>S?]4\?T=W7]-VG
MNO+4#[M"WQDC;]6N5M_+WM]C'[ZT(1TA2)_7.WR_?J`_Y7HE4:#U=J,;`#&Y
MJU\,KB&9_P`1WN>147V?[6]O]?U[]^_>X>Z[]YI0F?B>GPU8?R\Q#'')L```
M^E3)^.YUEOCWBC.\<DL956>PGV%FT8I$ZQ*-[V1Q^#OQ8X@""(07G:I%_1SE
M543OV1$34=Q[OD]R"I:%6M=P!\?B9GPVUTG9?;F%V-GLQR[WV0"S$=!X````
M3O\`'YP!J_K>J@WE9-J+(+)$*?'?'D">P;T5CT_1[6E80:$&Y$<Q5:OBY$7_
M`&=:ZFVRBU;JC%BF1K<Y.-5EX[XUXFIU@C;^V=QU'SUKG9_+^9F3#2(6AMJV
M.1RO9#'&AF8!5\D[#(J#=X(Q43LJ+_M7O^O72U>Z<E$"O6C-\9(G7$9'Y?X%
MMI>J^VM#_+"D#[.FJ67Y/SCV*!FGLFQGC09Q$K(!G'_I[/<4BN;YJ]ZN7^I%
M[(J(G^G4H]VY(/(U+RG;S$1K';\N<$C@,BS@1!!53/V_']!J_</P%D\3=`OA
MS+*VG0U>^`R;^,*%!.1CAO.&+&"S^MK7*@T5RM$B_HG?LJ:_/]P9>=0<<JJ5
MGK$R1\"2?V_'6X[3[-[=VK*&8&>RY?I#0%4])``_9O`UE744AM'16-(&UE4R
M64<D0\Z$,!)38IV.'($'\ACQC4XW*U7(GDU%7Q5%[*FIQ;UQKUO9`_$R`9B1
MTZ?#71=PQ&SL1\1;&J]12"R@$P=B!/21M/7X;[ZUR_\`"?EE"L9=/?K%5>R!
M4,!5:)'^;1H5XGD56]OT<JJ[O^J]=+_U;E3R]*OG]IUP_P#\'/;^/I_B+O3^
M$+T^V)_7UUL,.@ELRRYM][823_MSJS]]ECCGM"`<Q0>^0KF("1-_'7Q4CF]W
M._K5%7OWYPY"'+_$BM0O+EP$A9ZP/$"?#]6NU&'8.W_@3<[-PX>H8+D=)/@6
MCQC<[G?6!G_+&/)Y-=?7RA<KF^ES:Y[/0OAXB57Q'$<J>/=7=^ZKV7LG;K?C
MW7F#I77/Q\W7X]=<>?R][8=C==Q^'EZ?#IK/66HIF<JH]1(NY-W'A";'@GG1
MP"FBC#<_U`,:/X,DM`%6C8Y6-=X,3R5RJJ]:#+R$R;3<J"MF,D`F)^(!Z3U_
M7KL.WX=N#CKC/:UJ((4L`&`'0$CK`@#:8&\G5R]8NL_3IIITTTZ::=--<">=
M+K+1/Y4<KC2YC7VVSO\`E;YRV$3GZIM,O*B<#9ZIR:UTGYZM=.WD6)(XUH/H
MF=`0\/-V-0.9IT-?+%#.).K31&I!]'Z?IMK<'D_9:>M_D!XXSE!R1HJVOL,_
ME1Z7CC";;%/%8U<R3<N32<LYCDC7OJZ*D,^&L*O;G:--7;JC_P`20HXYE"U0
M?3J\OMR);7>=HJ2IKY\F0?F3B=?""%9-@=E?2[F_9+IHD=SY,V54RZP<AP?#
ML5@'M?V$KWM]"]CO31DV7W,H4861UV`EJDAB=@&#$3X$B-X&O%OS7KR<O!IQ
M,9'9SW3$^D2QXUY%DHHW8HRABL;A2#Y9(Y#;&KM<BLC,'4$6XMRG@Z@\@$KR
M+!4SQ!Q$$R^LR&C.0)+="&:*3:^*(C4A(\WL.%;5EQE+)I0`H`1U\;3]NXK@
M2M?QYPOS3W/'R.V\NWO"Y-A*VD@_3,"A3L9'E-TD![8B!4"WRBL08>(FLG00
MNE6-D"FQ-5(E5V;]]_+EA`Z_<"<?UNI<],43!M\"+.L/0%B*Q"L:OK.<_P"$
MK8\%4M:P!>$`^B0/J<23TX)R8[P=,.]>T5_U*U!ZKN$H0E:IL+`>I#&.%;0`
M(/J6<$&W(:LKC?*&VL9^PO8M)H*AD;/V;[>7;["WT5QR5C"3Z\HT)*](KC]O
M25^18FCQD/X2&M>Q4-W;G=RRQ@M^#H+UW2Z\0M:HM-D'PGC,0@+1(V/EWU78
M^W/W1#W/,6J[&"UMS+W/8^5064[F`_&>5C*O*&`(\^V6K/32[362Z2N='/(Q
M.FLCW=6ZA**1I]K"+&VF)9G;@%A'5*K&30I,(U91!K(4:-$X7B[K458J58@O
MLD+?4`K<]DJ,UV\U@^:P>4>4&)W!D:Z._/LR.XMBT07Q,AC8GID&V]2+Z/2<
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M`$&'!=V_R_$F28"@BUN:N69Y>0;39VR5M/F8\,4?81F7=NZ%D(&)8"MR%YC,
MP:,D8PY.FOWALS#1XYO9CT:JM$;K+[)VBL=O7"IY/E%IK/%9L-OFL6QYD0B2
M@.Z[B=RNM?[J]QW-WFSNF3Z=6`J@7#F_&E:`%ILHJ(@@VV%;6$A]C!A6UA;;
M9B\F.=?02V#["WK<IG-+`I]8V@KX=9;6M9I;#3@#81RPI[S/1O[DCXKG&9)8
M5%8TCGIN\'*H0?A[`OIHUCH6KYDLJL@0D&1'\D-L5(WB-<MW7`R[3^,I+F^U
M*:K52[TU57=+6M`8%6G_`,V5E@P;8$G42-I3[RI&Z28LNRA-TEF![WT[&V.&
MD75MGZ]8\RA(>'86=-GZAGL5ZNDR*U@2*U7QCN6C8JX%IX@"IN"GZMK0JN9#
M[A6=C'@KEAT9=75Y[]XQ@78MD*+6'T>;'-CUK#5DJS)6@F99J@K;FMSJGTM%
M+BS#A?&E0JV;,8EI+5&*R)914D_M&MAQHQI#Y\L+!B)XO0:%#[6.8I71',DO
MO1T!!#6JOE'Q4QRK),0.HVF#!!CF#!BXEE=I0JR4.WG;;9A/"Y0">1$`[Q*\
M@06-9&^GS9GK>DO]#,NZ0`'77$NI,"[=[TK[>/$WO$CFQJ26P`(<F@A.GJ]A
M`M>]'F43U;ZF-7@/<N13?CUI0Y/#,K!7:5)JR-V$DAS&X,"!(F2=>P>Q<+)Q
M<R^W+J`]7MMQ#[\7`R,/9&@*:UY2"LF6XF.(&NS77BVOJ/3IIITTU#,,9A%"
M4;"B*-XR"(U'C(-[5:\;V*BH]CVJJ*G9>Z+U5258,#!!U:RJZE6`*D00>A'P
MUS&Y@G1;/Y5YXNHM&M-/?@==7R0O%?#,C*>5@EJZ]"WLF9,?#JVRR"C,&@QQ
MVJHVC\FN<_U'LU;U>Z\"A[.=?XBL@^3^86\CY`!+0"29)ZS!`'@?N:VN_P#+
MSO&573Z5OX*Y2(L!\AQ^"S86;BDD*!`42H602=/N7N>=XW]BSK[*/ICU5,#2
MV(K:B#K+>:RT1)$8,.#80+J\LLQ50SQ8]H^LCM-6R#$*<B-1C$['L_8,#[S)
M"FI7<H.+>FHX[&2"JJ[$,:PYAP`%$R3YG[E]X=X^ZPF=;WKJ%K!ZQ<[<]P`K
M*]C5("BVFI0U3,6<P`!-Z(7!<7,9#_JOF]=06F8)75`0<.WM;#@6-]H0V1=/
M(%FM8Z0">/\`;WF#8/CV;+#\>,`8XX^PVI9C'OS95W])MILIM!8G(5B0B<>`
MYUP1O!0%"DEB6.^I,U?:->!C?]149-.1CE4`PK%56LL#&TBJZ0PXRMA6T6<5
M10B^4:RCG>-.-4XR!9<(<EU&KFU,2&E59[__`"*LLK75C6O+DY.\K0)^^.K*
M&"X,<P$B-]$=J/,KT<=4U63W3N?]4-7?,5Z4<GDM7!E6O?U!43Y>3F2#RW.P
MB%UT&#V+L0["+_:F?7DVUJO!LCU49[AQ-)R%'WG"M85EX>50"TR^L.7G`-QB
MLM<W)JBOW4";-O;ZPF5-_9Z,.ATVM4D660PBEEFHZRCMV.BIV@JK!N=Z3/D>
M*+NJ/<%.=EI2':BQ51`&14X)7N/AR9E\WU=?J4+.N7R_9N3VKM]N2]:9=3O9
M8S)8UHLMNV,@DFM*W'#_`"]@3Q<O&M=#S+UDZWM2RILFV+:6II5FIUJIIYJ1
MW%>26A'39(WSB,5QHS49'@11*!PG`C#23T:ICE$J`44A5A8Y`"?#H-O`]78\
M@0S'CQ+VY8NMR69FR38Y+SP8M$RT\B.1ZKLM:#@5*(O.&&>2L9PR.N?6R7Z#
MCB[J9_[5H5FR;:L?68VPF5\F`UY#T2+'BO\`[86^"O1[E11#5CJM6+3FFSD!
M7DJPY)`5N5@!!Z/N1N?EXF=6I<V..UK2:V-V#8C<+.1=.-#,I7<U[`[*(F3!
M58-]XBPN;"R%GW@G2GR%D2<Q^W&O:<+=6R':1H4@RYX<V0X1!2W)*4L.86'*
M57,1?6(A<#.KHKK.0"H`@//!ONY4D>>!X>6&4,NQZD#<=JNRK[QA$.Q,FKB;
M$'K!7"D^F&,$'SRCE'W'TJS9XR?!_(%7KHS)3#UT6YG#4$:_TU-0_P"'SZ6'
M(K*:1FLC7ULRWA0^19;&FG$.*.*,$+92/>B(SK09G?>WVX9*0SHNY1&?U`Q!
M8/86"DTC90"Q8GA`ZZZ_MOM/O./W)18#77:X@66I7Z+(I5#52JLZKDG>PL%"
M@"R3TU;?(O#WSYFM6>JWG+9I5^:64UOQEQ?AJ/76`+N?;Q#;"YFWDJD_&SX-
M%^*.+.,U"B@A:Y7L85S&CRNV]Y]PY6(+<##`QP(6^^UJP5"D5J%#2Y22RC8L
M>A(DG![W[9]EX/<6Q^\=R+9A8E\7%HKN86,ZFYVL-<5BR`EC;BM09`8@+2>2
MMR3/SLU*S.5AQF35+GS:C7AJ=QR+=7L#\DSXDBO2&+CLDV^B_CC6?+CPXT9X
M7J4CGM522]LP!D):N5:Q(\_"LM52JF-P9]:$,G@I8M(@1TQ^^]W;"NHLP,=%
M#S6;;@E^2]BR>)7B,;E8.(]1U14*GD21OL#C>3=+M.0/G.7964F37Z3E*H#+
M@14L!Y:NTN970"O&YP7ZUQZZ5)$P\68/V!)%*U@3N%ZUD<]F]KQL+MW<DK4"
MRK$8@F/49'X<>?B"!(93!#"64&>/9]K[]G=T[SV.R]V:F_N"`J.0I6VKU!9Z
M0^DJ2`R.)!0@(Y7CSZP<8*U>.<.K7*YJY:D5KE[*KFK7@[.541$[JG^Y$3KR
M7NO_`+RO_P#6M_$Z^B^P1_0\2.GX>O\`\(U?76!K;Z=--.FFG333IIITTTZ:
M:=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::Y0?1?UYR!QW
M]:\=_/>2T7`-%`W'+?`;+FHT61YJ_P"JNBS.@U6'J-C)J[\O'C^"Y4]L*=%A
M19#[[\J,A(X&^-@Z(!S5X4<9WUD/ERBPP?KO"RK[DJ%1Z"]O..;JEKK&NYM2
M]A$S5K5UX,QD9]%>1.'"T.WLY,6%8NLHI)$<EH0;_<^5#2.U0?3J[?LF7>5%
M%2W>?DS(]Q7<N<6'K9-8X0;*"LFHVU1,D1"D9V<1L.P*KD56JHU<U'(JIUWW
MLM*+KWHR`II;#O#!OI,-4P!_6!^N->/?FA9EXV)5EX3,N2G<L0J5@,LI>A(/
MQXL?U2)UR_Y8Y3W>QY+AX5L>HT,N!+A<>!?J,H&=:3I+IK&2+787T6/_`)K6
MPK6VC$FUMHLBO@3(3AJCO:UYF^H]H[3@8?;#GDO6C*;O)9"@1LM:$^DQ52%=
M(=U:=H(77@'N/W#W?N??D[1QJNL1EQAZM09V/+=[K`/757<&RJWE76]94@\@
M6%T\F1OG*7;P_P#.G\K<;RM)5V&?BWF#N0ZS/45%4%HP1+,F/L!?Y9!JH=L'
MWPWU4JU61(/+,9>Y%5,7MC>Y$I;\!^$R4J<.5M7TW9FY$KZ@^[+%3#>HM<`(
MJ]-;#OU?L>S*7^KGN.#9?6U8LQW%U==:&L!C2P]945QR0TO=R9K&8RVLI;?A
MZCEXF%+XVY)P\K/:-C&"GWDFZA1XF:?72(?(6IFDA?E38FJFQX_L"64**T<A
MA51H6M&WK58/>;TS63N>->,BOP0*27D&E!,`U@F"%+2I'4DG70]V]LXEG:EM
M[%GXC8=XV:PNH%14KDVL5EEN8"5+A`&#&%``UA77<07/%^<'*2HC38]5$@T^
M9T$&5/T#XSZ\4H+=9*T))$@]G)L:V8GXHW`BF(Q7O>@P"8-F[P^\T]UR2O,J
MSDLZ$!)F#Z82`%`8>8RP!@"6))Y7N?MK*]OX(L%2LE:JE5BEK(X@CUC9)+EE
M/D!5&(DGBB@#5R<L\=?8E"=PPV"T4<LEDH?[9-CET=,:0Z6,I'R[6+'(P3#2
MC*]"RW^37-4L0:=57Z9L4$;KS,1Y@>#`1X*3N0HB%$;PYUY_<;EI=E,*_I@F
M?*P-J$S/F<`P"[3+F01RK760+RV)4[O<YN'-@0*Z778VS(S-6Q[*E6SC_P"2
M!%9QC$>9K#QPE(T8S(0+1$<PG]I3%%KJ*A=@49+JS6!K%\Z@-Q/`\2/@3$D0
M9`(WX@[G+R6Q^[Y>#4R)0R4N?2<M7R'J@."2=P"0`TJ`2&\O)EO'C6%>:B1)
MRL.IG6>K_%0%?!65:RXY<\MG#->4@Z<$2WK+B(.MCHQCSQXB&C,BAD/::*=K
ML+N=E&*HRW=5Q)DF%!Y\2%;D2K*>1W@M#%V40ZG6S[%5E]P=NWU5/9W'C"K+
MD&OFILK"`.KJ%``+*G)16KD-6X.6L5P7O+-DNCMY=2P<!]M:#=J]G1VT^1&M
MS(V^X[LZBK@R&T$;(4\AD=C9!(THDB2^.X;A#:K-3G=^P*B+Z0\MQ7[NME`*
MCR7*S$<S8P),`J`H:029Z3M7M+O%X;$R6KA"[_?7UNQ#G[S&9%4^F*4(4!BK
MEF*$%5$6D7`?/V<W+257)>FVNRC2(MA4Y+AS%9>-48@0J6>W+4DOE&ZSBU4<
ME*(TN?&,R&8MA(8O=KD*K'YB]P]PY.!%N+51A$$-9D6N6M\PYL*%?D>7E1@6
M`0'PB1K6[-[,P>[\L?/R,ONBL&2G"HJ"4`(WI5G+>K@/3!>Q6",;&'0\H,GH
MN4[;);QG^/8/`5$<D7_)Z<%O7LTIK#.`F-AVTF_M]`@:S-U,"6`GF:J&R=*5
MOC"C,>X",NQNU4Y>!_Q&1D.P/!BIX`.1*A%26=B"(%AXK_.Q'*8LWW!D=M[P
M/P6'AUUE?50.HM+5`\7-CV0E2*09:D"QXBI`2@&T?#&AO+W?:H]C>7M[4V?!
M5AJ,[*TDF:2R93:#7<-2:X*5TAHX]%^/!8,$B*,8&_E!(Y&+W54Y;O6-1C]O
MJ6NNNNY,]4<(!')*\@'<;M)DAB3Y2!.O0?:V;EY?><A[[;KL:SM#6U&TMRX6
M7814<3`KA85D`7SJ3&^NQG7C.OIW3IIITTU\=_HO?LB=E_5?]/\`3_;^J?IT
MT/37+KEN2DWY%^A'#BS@^..W$1BSX%)6LFH`'&@AS(4"F8R&ROF,\7L>5Y32
M/)2$*_S\E]4[0OI^\.W`E3]]4=BQB3=L2V\CI`@#H`(C7S][D?UORV[T55Q_
MPMX\RHO*!B@,JIMQ;J"26:>18S.N;'T*2*#?W2R88!TW[?BKVR'8:6SJ:\40
MN7R$"-:66TAJ:VQT]B1E@Q,Z16U]TD;\CN\OK1?2_;H=NWIQ8F[E:@A%8R++
M"56LPM@WY-<//7RX["=>%>]36G>+>:J,;A18P:UT4`U4J':]9>AMO33&/W=_
M'GNW'5Y?1KTL*.))JG3)0H6Y--*QT*,!LR+;Y^82BOYI2%C'Q\0(0N$"SH?;
M9$_J<K6F>O6%[;'IWLML`M0`-R8*N.:#J+#O)2V$'Q*C6T]\'UL17QN3*F66
M/E`E7K8UV,9!I4`$+;CS:=S`9M4W&XOD#8\<5%WC:FQDP:*^N&S[M/94A?97
MLS.EAVCY\Q80EEV'91,][DL[!8J$GC'+,C7RYN;V_#[D]&:ZBRRM87ZO*H>5
M@3L.ICR)RBLE%V@[7VOO/<^QUY7;*W:FFY^5GT#E8U95BS<1+=!R/JV<>5RK
M8P!R+M>$.8\[7@TNKW#3.KH4>N303]7851(D@4AB^OSO5K[DPQRHACM2O%*_
M-&-']U9W7K6X/?.S9%AQ<2B.3$\!6&D1_L2HV('G*\28ZZW?=?:?N?"I&=W'
M+DH@7U&N9"I!Z?><7,$%ONP_,"9B=3D;E/(9W`6E1R-=6W+2RJ.V5H;;+4LD
M4D=K17-?&0W*=C'J]G3G;:B:5SX$8\ERQW-<G_F]6MVK,R.X)=VU$PXL7Z78
M$<64G[@%JV'$QYV"[R-2U^X>V879K,;OEMG<N5+[/2A!YUNHG+8)>AY@$FM6
M;RD'X:QIQ[?8.'>\.MY(E1[^K?P_H*FI`+*VX*^DT:0L%-A2=%35E[E)NJ@A
M'&.WUP[!IF*UIU_H%^FR[CC]P>C-/;0:[?QB,Q]1262;00C,E@K)D;LD'=>I
MUH>R9?9ZLOM@[XRW8_\`3+$0"IPM=O''938BV4M<H`80E@8;/T7;(.TD::YD
M$C<7RLS,AR;=D")G<+VP1JV,-AXH8Q*"[IJ2SFV,*.UHCG;+M#*YO97-3NB:
M_"7&H7EW06APDE[?O>1V)/-690I.X'%!'AK<]T?/RG-?8&QVJ:WB*\?_`(<J
M!(`].Q*W9E$*S<[6GQ&K/MLC]`P*N;46L2_B509=6^PRR+'9>1YTN!!#!6RI
MHH8DVX9)APY(A/4AT9V(/P:J^+LRK,]OO:MU1K-I#19OQ(!,PQ)"P2I.PG8R
M>HUN3VWWG3COC9*W+CADY5;>H&*J%Y(`&>55@#+1N($P<#\N#.RSMJ>;#F,L
M$I:0]M2V]2Z=YV=35UE>ZPM<K"#&N="D"4UH_.O2"M*X:K,?((Y&)O\`LY4U
M)<C+Z?-@K*T>5F8PMA)5)&\/R]2?(%&^N0]R*XR+<:U7%WI5EZW3E+(B+R>E
M0'LXF!-?I^A'WI<D`9GYHG09-`V$T=DXUAR!21#OI;@.=A6(X=-<1[<;[*6J
M$MJ<;A,&M"P:2WL:\3^[WM</2]EK=,CG*\5QV(Y+S*RRE=A]+>/JSQ!@C8&>
MH]TVU687I`6<GS4!-;BM6`1PXY'=T$`?AP.9$J=R",H_-QQ!NOE\JP&F/+^@
M+V)%DCAG@4JUP<#5!<?,9B>&1,PM(%X6"96*Z,:/)CD<5SO:T+=5[E4FCN@Y
M0J]O4D2"TFUMG<0+6W)+^8,I$=)UT'L5U7*]OG@"[=YL`(4JG$8Z":JF!;'K
M$`"KRE65BQ/(*.WG&#GOXYP[R/0A'Y6C>]Z=NSWNKP.<[^E$;_4Y?]GZ=>&]
MT`'<KP.GJM_$Z^L.P$MV/$9C)./7_P"$:OKK`UM].FFG333IIITTTZ::=--.
MFFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG
M333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333III
MTTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::TNR'T1O+3Z?ON#;C
M/03TE?\`NKDMJVD/$-5`BUAK:KE3YC]=;&='FA:,3GGKX2%?)CD$GK,U%:N@
M1.N;'-5O&G?R_P"+I+B-POJ*&OE\&A@OYO\`I*WXHU&.U,V#,T+J/@?B^MYW
ML(W,%B:=F\Y?QJ&9QL*'/T`EE.MAR*J(1*>.KA]'CK:[F:HT%M]IXB[/MH[*
MO+ZCC6IK<S/JM[9Y2'$N+OCNQ=76^DAD)QUD=;J90+.;`KISX\JPLJ:B(,12
MOC*ZNJ"..LE_8Q46)F4.)IH<;Z`X`/-1TLR(&)'=HYI#*T;7_B*UX&]G=Q*B
MK[&.]B,1?0O9@\]O$PY[?E@;#<G@/U]?G\"(G7B_YG&:Z.8FI>\]N+;G91ZK
M$[=.GR_Q`\@)Y"F:ZCYZJUOU`Z-$Y5G5_L346`(57=3[*U2)2P;\*D!R?<EG
MJR0>)*(JYE'.B>*#9W;["OW_`&!_P\\FQ`?H!+*`LL4ZT+&P91]]L\R=?-+#
M\)[PK_&1Z:]Q99]5@J.S/"+8)&4Y:&9'/_"R:H`&U+YZ::?;X[1D62R`[*7M
M8)$>1(U<.#K2GE-?:U4DFC'.GQK1DA*@`G5AG$]97^A'JDO8"M=-V,(]3U5;
MYF:X'E8<(!6/4)YB)`Y1K']X!KLG%S6Y"G\/8@ZPH6XD^=";>3!PWHJ/2,\6
M/"3K*]3QSR==U''1L<&VR().?IZ6LTEC)/5BAR<M`FMN611@&XDUU1'B/(=E
M.V2&.R0K`>8FHBZB[N7:Z+LE<TI<18S,B@-(L(XS\.1(`-G$F):"==%C]D[_
M`)>-@OVP68R-2B+:Q*!34K<X`$MP"DL*0RJ&A)4:I&CXMY=PFC'I]#L8N7E2
MXOY]?M[K36(GE`X(Y#(T.%`:+6.`&(CF*(U>B1OZ0^2*J)U-C=U[/G8WX7&I
M-J@P:E0=9B23]W,[R'WW:-8V=[>]R=HS1GYN4N/8R\EO>UA(@$!56+H`VAJ_
M+LLZK/)G)/'DGBRUS>A='W^VG'SP(&T=@<GCX]#/C["B*:^9J8LQ-QJQ1:D4
MH*P9<439?8SU:J-<YL/:^V]Q7NJ96-./@J')K]6RPN#6T)P(]*N6XGDK'CL/
M&-97?^^]EL]O68.;QS.[.:@M_P"'II%;"ZLFSU0WKW`(''IN@Y^8D;$B>Q>F
MP8.1N3![;]NLKTM/QX7,Z#0X^^L<M`BPW[`%G!M,EF+JD-#N#M8(HK(S+"&$
M0GL>%7.7J/-QL]NVXIP>2T![@Z)8HL)/IE2MCJP*C<%`48D@@ZE[7G]G3OF>
MO=>%F8:L8U664V-2H7U@ZO34]95SL1:18B@$%9)U1),/DNXM8\#*VM3K`OD6
M!Y$#C.3`J8L^-#)!;&)$QL2ESMK65HDC#:1"PA>U_P#2U[T;W2=7[934;,M'
MI:``;P6()F9L+.K-N8AC'4@:Q7K[[E9"T]OLKR5+,2N*50,%*P10J5NBB!,H
M).P)C5.M:+F*3.R=!)-=RP5FJE1/V"`:&R=`F5UI-?H7R<G#CPY5%,_=Y?Y!
M3.%(_(4R$5ZM(G4E5_9EKNR%"!GJ!YF8(*CA%A)#CB(`D1$1(U!D8GN=[L;#
ML-K)7D$>FI7DI5V]2:5"M6W,\BQ#<N0,P=82H/Q]!RG")`5\R!5\G,*%9U62
MZA50I=G/E6,\S*%J'H;!8(G%-=R52LFHQ61XK!L[KO<CEC]J86>6Q\7>&XEH
M4!0.>SB3`J'G699R3KE,/AF^X4-,M37W"1R3FJ!G8LQ]/>MN()-[?=61"5@#
M5U\CI%"++O:TC&DAW4F2MI9+>Y=\?]TCMK).IQ+9,F_Y,\)X3$[00L&`[DD.
M56(YJX?;2S&T?`J!Q7B\\3R"6P$HV('F,D>7K&MCWSTU7'(D2KD\V]2J.8X&
MZB39E>8,?NP`K'F=I&MY_F6,I]\P)1W<=\WY>GDFQ[V['H9(I!>9LC+CHZ\&
MLM\URULP+VN8=0>EX_6-/ZBFX3W.P7M_(>F0O=5@HO`0,:P'R[1Y@>HF09/@
MOKGL).?>>#"U2_M]BPL<6$$YU)'W@GEY64R&X\2('5F[6]>(Z^JM.FFG331>
MFFN:O,E22O\`FSGMC'5K(EAG]HC'55W1Z4#219'%=.\CI='29R`R2LB$92`?
M$$1%[*Y7H[RZ]-[+:+/<W;R>7-;*_J5D.XO;HS.8@B"&(^SIKPGW/CM3[%[P
M`:Q6]-_T65VB0<1)FNNI9E6E2@/QF9UK?S!P'1B@5$#6;N%FK:D4H4C4M3+T
MYBY:V--DQY4FV@!H:XMU5$9*CQSRY\F$$9G?VTD#:]W2]G]P7M8]F)0UM+[R
MS!`+%@$!3S/%O*2%16)`W*F-<-[F]G8:TU4]RS$HR*I$(AM)J<L02ZBM2Z'F
MJL]C(H8^4.H)QY;[:DP6%J_\;X^H^3&U`8M=I[OENN=J?V8,,KYM5HUP]08-
M#<A*"I9#C2I9)LMMB,;7]V$8XFQIP;\_/?\`$Y%F*7)*+CGARG9D]5O.I!8L
MRJ%7@21N#&DR.ZXO9^T5_@<*G/%8"VV9B^KP"GDEOH(16X(0(CN7<6A0=B"U
MS9_Z6Y4Y>I['-7=S,RVGJ:N)7Z"ER=5=XN-^V:P$&5"LLA,6"MA6VV(K9(GN
M,P3Q1I*,.JC5ZJF+D>V>T]GN7*H06XKN2C6,MAY5D@K8)@K:P.Q,LLKO&L_"
M]]^XO<N*^#EVMCY]=86Q*4>@<+@I5J6X\E>A2"6`(5H?RSM@N/O;";:2\UK;
M6+>3Y5%8SX*CTM]&-L,+22(N7QM[)NK*NL3@N!3`'2:V.]SHLU$E]T2/V3?-
M@5I4,G$0UH+`#Y$(KM8%[$"J0"I!'&1YE\G\VN13O%UN0V#W&Q;KFI9EBVP&
M['K(JIL+LK$.&#>H%/D?[S^35NR,'93+._ALGQYM<Z!H+%FF9Y#K`U=+$DDN
M+.W/4(KH31%IRL/#:CRBF@&`?BX,55R%SZDJK<J5MY(O#^8LQ'%5Y=?J$-L"
MI+&0SZPG[/?9D75AP]'"QO5Z*$0$NSE/I@H0R;D.JHL%:]0*RIM]`/@T%/,T
MOY<+A[06XH]["APVNB0JS'GMAY,1AD2W_:*L;I(A*KRB&)QFL5C7C==9=3CG
M/:X5<&S$64).Y:P+ZD?3R;RD[`D\9D@BS'QLG,7M*8S7^JG;+'`L51LJTEQ2
M"#SX(.8&Y`!8"`5-;R5?8@#*UDZO(>`:3,H:2'$6O(DN=)K[)*SP713XL(E#
M4V-7Z&(X)VFL5#[T*,,EY8,NRMF&(C18`'8F=@".7T`GFP:3N(2>,%E`R^VT
MW(K=QM0FDLU=:CCNQ5N/^:P7TT9.(\K!K>//DJ6%LO9/G;D`MI^?1Z2P'AZL
MY)&68>^QT^DY,M]-YAD&;73Z.6M?4\>7$PC8:QE"\DY!JY4:%S6:?+[#V]:O
M3R*E.<XBR$L#4*FX$AA+7*!RY2`L_$3TO;?=_>6R/6Q+W'::R35-E+)E/;L3
MQ:MN*8SL0G&";.,[*0)'8?6=)M;*MJ=+Q+QWS6M%8C$0MD.V9M7\@9.962=#
M74<[)5"2&QD!(::"KO<&?(`K&`43QJR3#]HWX-378V7DX7J+,+Q]+TK`P0L+
M&B9$-T*@R6D&8>Y_F-B=UO3&S^VX7=32\$L']?\`$4LIL6MJ4F(/*N>2V,L!
M.)6*9R7&QFZM*&D2SLL9-H4GV%]26WEL<S'N9=B.OELK]75P\WM4NZVI0(V6
M,&,Q(<L*L0A6]R$E[8^;@567E5OKL@*R_=N5`D36Q>KB6D\&;S*9@'88_?:^
MU]WR*<06/BW4\FL1_OJ@[-Q;C<@JOYJG$"VM1P=8!826V6Q7'\+/ZKYNM*&S
MR^ARE=RS0"99QCQ8E_;7]Y5ZF7?:*=4_AQ;&/9SKJV:LE_K152.K#F(1Y$)S
M&;W!\C$[G5D);7EMAOY2"45%9`B!I(*A5\HGQE5``CO.U=FJP^X]BR,.S'O[
M<G<JQR!`L>RQ+C9:R<0P9G<<C'\L.S,6GJ9QB-XN.L.(@G`(/+48R!>CFO$]
ME>!KQO:_^MKF.3LJ+^J+UY5W0@]RO(,@VMO^LZ^A.P`KV3$5A##'K!'P\HVU
M?76!K;Z=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITT
MTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ:
M:=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTUH9Q390'_:_.\:7/KF73<U%@Q8?A7P;J37HS)SHS+2"'T-?&C#
M&5]7)`Z;(FQUE.F_B.!'8=JX_2-<[><+K4G_`)=<0:)+O+"QR&MX;I*O-Z;D
MW&%R,#C;84>5AW5KQAC=543US6WO+&_T4ZZ6I>"Y/4XY(Y2JE_4^AXZO'T:W
M/Y3J[%GVKG+F-E-;/K'6?%<:^1]5HY.0-$;<4@:_6B,6(?%);`TTJM03O,5@
MH\Q,,4C%KZP<IJT?3K*?UKFO\MAT.:A.C`L+OE;CU!R"%9!&TU3D.1;U$F37
M2(J#&:)4O$A?-/3[$=W3Q[IW7M'*_!O9E/)K3$NVZ_592NP@]"TQ&\1XZ\B_
M,C`_J55.!45%]O<<:"3QW2G)LW:1U"$3/EF?"=<^N8N(<>"Z'<Z3?EJ]@,,<
MNIJ\75^YJV\1ARSDIK2>_.409-Q+":;82F-LI;Y!WL0K0.&SKT/LW>,UJ#3C
M8X;#)/IM8T>4Q')1S8A1"HIX*``8Y`G7B_N;VUVQ,H9.=F&ON8`-J4)/G62W
M!V-58+D-98X%KEF(Y!"!JV-GS7_TU%GI7&G$.&T`7"*:@W/(%-9;RY@[(KH5
M9^'#@,""BR<ULRV4REAPWH6`YB*Y'"+Z\K"[)_4S8G<\R^MI`>JEEJ4U[F2=
MWL$+$,VSSM!$X'=/=7]"6FSL7;,2Y2":[\A&R'6_RKQ"P*Z6Y/RE$,UQN"K<
M;DD<Z[+F/&R;2?K-!1)3_F$MW5<:QQK(EOGH\AC;!&P:X=FF4V=W&6(6.11L
M+&80+/<HEZQE[#A=ES157379SCCR(LE7(VW,>I6IY`B2&@F)UG/[N[I[H[6V
M1=DW5>ER+\`U$/6#YO*H;T;[!P*F`4#*.7'6&X.EF;2/<9G63W0-O22:B)IX
MPK*8K:S;6];?W\NV8MB)&SHTP"N<!Y3"%+\U`5RL(YQ=U9C)A,F5B+RP;`Q0
ME1YJE9$"[="#U`!*_4-P(Y>G/L[HEN!W%^'=:F06@,WEO=;+"_F'F!&ZEF`>
M>#&&);&5KQZ>=AM9HGK7P8F0E4%N:9[7380"7&KJH--"K9`GL_?C37=G0R=A
MO+7L0AW)X&>_9U=Q6O/IQO,SW!UCH3QK8L6'\D?S#<!]EZJ!HLCLKV]HR<X\
M$KQFK<M/)07N1452/\PM_(=B:QR<B&)NO4U5A+UG)5TT]V=(M1QI&NX-_(#'
MOY,.S/I10;9@1P2'@9YTZ$)A3!8][%&)&N<1X'MQ,6VM,/%I(02]Y4H"4!4)
M*]=W@F`8&YZ`,-9_<,>ZSN.=E`VD+7BBQ;"!858VA7@+*U\E`+*"1"@$L4(F
MLPYO']5!L+Z2&/)M:P5K%L3MB0*BCS%7853YMB25>2T%&M[&*47XX617&CPN
M_H1'`8Q;<H'N%K5XX)5&XD"2S.P:%A1NJF>1Y06^KZB=2X!_HN.E^8P%EE8<
M,>*I74C)R:;#`=@1Q4(2J?1N@&LMXGE[DX<.;L=!<VY?P::RK<97ZXF0N/\`
M%<K`<"Q9L8KAT"6429K\^%@6Q`O5K(X45Z%(8;DU&=V?M9=<+'1!R=38:_47
MG8=O3/GXD5N2>1\3M`!&ND[5[E[^*G[GFVVGA4RT+<:7]&E8;UA]WR#75@*$
M!@*LGD64BF2/IJBY/V=,>5P;Q=LC62F)D-K16NER6WA9ZRK;Y)%M<:"KJ+2L
MK?P+&HD_G))#-_!KFD<][D8CG2+[8O[5A.JY^70JQZE3JEE1=62%5&96:0R\
M>)7D\``3M`_OW$[_`-TJ>SM';\IK)--];VTWK6RV2[V(CJO%D;U.2OZ=7(DD
M`$V9KZ;CS;<F/MJ[DS287)K+K<U!M;['NGGJ*Z.%1,/G];3^BQ6JO91C'*"Q
MA#@2@E5L@?=SQ#S<.[N.#VST;,6O(RX+E5L@,3_CK:5Y((`*,64B5.P)U7<\
M7LO=>_')HS[\/MW):E>RGD44")KN2&X6$EBME8K93#C<JNZ?$F5GYSD:SNAL
MR@\W:_/%Q"QL3,V,.9#AYJAWW#T*FAN@ABUTF$P-60/ZEBQ?:Y55H^R=UXGN
M^77D]M2@^J<E.XJ;"X()=ZL@L9)8&6GHS1\=>J>V^W78/?+,H#&&#9V1UI%3
M!E6JO(PE1>("E83CU5),D#77_KQW7TQITTTZ::\O[>+N_P#IXKW[]NW;LO?O
MW_3JHZZH>AUS"Y0F'_\`"1SI9V#C@:F/UTD3G!C&EQJF,SC%:\?H_!%$*Z#7
M"8,0?`P6L&T?=[4[=>H]K1?^K\"JN"?6K'B`6/KSO,B3N3L9).QUX%W^U_\`
MX-^[WW2!^%N(V!(0?A>.W$`\5`"K#"`!N-:%:30S9(3T5F<L,,J4KZ=\P!G5
M%-:$$^&(1YS4>1]5;."^LLD%&<U#/B3&L]@RN?W^+C(I%]0!8#S01R9>NP_Q
M+/-)/3FDP0!X[G9MMBG$O)56;R<@>%;D<0"W7@\&JV%/F-=H')6)LN@T\>/+
MF0YU&^_B.2PJ+O+6$`TP4B+ZG):4MV(GJA.=+B>Z*8;E*]DB.1K.S^SNLW(Q
M69%>M_3?9EL!`@_RLOCL88'8003MMK5X>>B6/5=4;J_,CU,I8$1YT<;+NO)&
M&Y#*0-]]6%R)6RN+;:OV66DQS09$?D7D#,2!:.QIFHD@6:S7^,:"IMEL:&PF
M9X4ML*:!KPC(CV%"'U%5K=AVZQ>ZTMA90(L!IJ<<%;H7?FC+#@/')3!(W#&1
M)T_>Z+/;^2G<^WL#25R<FHBUDZBJKTK$?E6QK!"6*"`9#(O%H&8TK'[4<`M#
M:DK;>KNH;R?MVHK3RZG2Y:I#<S,-)LG`E]Z&]MV1X\@;C/*X:LEJ,;AD`[3>
MJ,(L,A`U+H>J-#([%1:%D>=%DJ8`F4D@AM=/Z![JJ-AV%,FNU9XVJ2EM2!S0
M6@_=V/Q5@6)(BSBI#(=B^7Y4;#\%`RGM2IY&TV?9=ZR$LB;(LJRXK4'=3:JK
MOXT1*U^3ICN.PTCV&'-LQ(5W=B.1G-]G1\[OQRXY]MJLXUF`%96\H9D)Y>HP
M@@0"J&.L3V_N6ROM/M`=NGTN^9%'.Y98LCKYV1+`./HH>09I(>T<CM,:EX>Y
MG9[4_*UL*GTU`4.+)Z)Q[(UA%EL6'B9YY=1`<UDJ(%`N(4L:.KW.85J.:UGF
M].NSJ$R<7NU+/58#?N`H!&]HACT)Z`,WB-C,#7G':,JW"[A[>R5JOI88IABY
M8-Y:&)1>JB))59D$`@"3K;SG7B0B_LFHP;X-0'0+,+;V>?IZ[04F(K\_+LKB
M9`:6Q'$EQJWD.IMY,:IBJ,@X9I,D:]U9Y]<?V'NZ^?$S^3FN.*NQ1K2X"@[2
M"U+*IL:06"J?&->E>[O;;?==P[04K2[D7>M%LKH6LL[++00N2CNM*P0C-8OA
M.M9^39J9F)#RF'K[C.L6/ILY"/EJFBI8N!R1Z:=>T89))DAT"%8ZE`&_NE1Y
M#`>\AA,.82MZ?M=?XISEYS)891R+&=C;8&"M$"2$D;"`#`!*J=<'WZT8%2]N
M[0EE`BVM34E:#'I*-96"6/%6MAO,9+*2S*'98M7'0/VBCK=U;GDEL]+%HYG'
MRGTP9LJEEEQ<&AUFN''K$@TT8[)AGB@L8T\<AV&G">B#C]96;9ZU[8%(`JJ+
M"Z$@,/4+UURTL1`EB8($5D;MK7=KI_#8B=WR2QOO6ML>;0Q0FA:[KH7B@,DB
ML`,I8-<I\J:MN`!_[B24>T-4T5+^,>T2,@H-AXR8L5[:RIL?)S3ZJR(8$.&U
M2N\&&-)<,C8I&IDV,/3"*@?(>0L[C8GS,OA6L%FVZA5!',:P:4/KFQ[#7AU0
M7B%;<#R(WC<TJB"3`+V$$5L-;B\!$+9\S\-6UJ^(UTWDD<:EB1$C38"-I,?L
MH?XE;(*UWX=0%D*0:(H6B>1(?F]OMDD<O&^X`M79<VFF?+C2Q,@^:RLR1XMN
M`TR!R@;*!KT[V:S7^Z.UY.25E\^*P(9?)3<.*D_2@XLR<8)X21RL8Z[/\>OC
MDPF-?%&HH[\S2."-41JL&M='\6JB*Y$5/_+UXKW$,.X7!MV]5OXG7U+V4H>T
M8IK$)^'KC[.(U>/6%K9Z=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333I
MIITTTZ::=--.FFG333IIITTUSUX<I+")]N\YR]'(HAZ.5D*VP8;)5\)X-!1A
M?2U\$>NL;FMDZZLG44>6!T&M'/)7B?)EFCO5IS"1J\_3K0;ZDTLC7_R:<39F
MVSOQ^KN.N8>'*C+I>7%91?5%K36]]\M\ARM'4.?S#42[J.Z[CSU@#7,2R"K<
M;/B,5[;7OU350/).^ML>?[>7;?7V`RUA-XTAPX._X7LJBAN.5MC1\A7R4^SX
MZMP75!AF<LU.)M(HI=K8_P!!<O.,5*,C/-32(KPUU0?3.LE_:%M,A9R0J_U!
M'R5QM%B^2#]0BS,EO?QED*<+F?@DMG!;(<U"O8!SW-\7HBM]$]E5)9D@?S'%
MN)_595,1X\9CH"8G;7BGYIY-E6"T_2,_%`Z0"U.1$R/I+QR.Y"DD00".7EQ>
M7MT.!"<YL^Y&!)E,YC)$0NDH/1).F?2,PBF=*J`UTIT0:"'YI$(UI?+\,/7J
M=-&/06?Z:28;H>#R///2&)7D9,<@8CF=?/\`E9>7E!*C#Y064Z@VUP3Z<3,H
M%?@($\&`:?275#R=KF[@MG4:V-`N:>;$B/!8#KV%2GGT34OZ&XKWD?7-DV,.
M$K)3/!PU.QQ1J_Q<]>I\NK)I"7899+E)D3]0;R,IZP"97>8@&)C6'V[(P,EK
M,;N2I;BNHAN,\&K^\K=9XRRK#B".0++,$ZQ;#D3N,]<N?%(AWLDE9@>/VPX6
M[MX5-H,Q=K:WUYH:R/>C,X39!J]LF&\,M\ACT5KU1!F&NU=:^YX?X@AJU#6V
MR:E+(Z\55"4CH#Q:5`\1U!US];W=A[E^#5ENL->/CPN0ZI959SLLL46`Q)7D
MA#E@=C]+#6=X5!:;6?D])QI8EL;::GE`2DOJ:NC;/,ZRR/GS&NR.9#*"PQ5$
M"9*`)GF&(D4@/>]6IWT#Y%6#7=C=S4+4O7DK$UO6`X"]=K6*J3L6Y!N(UU]6
M'D=UMQL[L5ALR7^GA8BB^JYC638?*0U%8=E`D)P9.9C64_L70TE#C:W#X^Y;
M*B5=W4KHTC%."99?N-_5PW2K\QZR(`=C)5SHT$",<\%8)CF.1Y'KUJO9N/?D
M9K9V8D.];<)`(6$8PD,=AU8]"Y((@#70_F=FXF'VNOM/;+>5==R>K!(9N5B+
M-A*`<C]-:@$K4`09)U;/%EDRD^C+NOL:YM'66&5Q5/=U&EL2W<6RK)5=M(4N
M+..C91_\?G/"P8CM8X$$C&&5S5&J+D]UJ-_MM+*V]2U;;65D'$A@:R".@YB9
M(ZL"5C?6![?O&)[WMIOK]&A\>A'2UC8&0K>I#'<^FT`!HXUD!I''>;Y0X08S
M?10.+8WV*O#BU<UAJROEU^X!H8Q*`7'DRVC3!>RPQMI5NE6*E$K2"?%(Q[%>
MCV6]J[Z3V\L`M>;6/3$,0:BAY^L%(Z6*W%(.Q#@@Q!D]P>TP.\JDO=VJTBY@
M54K>+!Z?X9G!$M0Z<K>0@@UL""9&%>6=;HQ%GT5:+0UT&N7-Z'2WE&W(U&?M
M['(W]=GS9$4^;-_:#P<VV1["`#[_`/F45P'*P+'$W?:,3&(6^TUM8W-$1O49
MU%B%_4@#D"\0"8\OU"6('+>X^Y9JL^)0+TJ3TK+;*_12MVIL6LTAF;@5JF2J
M\O-NAA06I^QK9_%^!L8BSS"V.B=H*DDO]]DZ`E)F3Z:1H:S+G&%@`P)%\R<(
M]JJQ6EAA&&&[R]9T))A65]T[@K\0<*O@T<0G)P@0OXDA((K\T,2SCJL0=SHN
M]O\`9WKYD=SO-B%O4-AKJ-IL6H@0%-G(-=Y910M1GB_*B9Z-$2&*^OB!*]LH
M((%.4[HT#1ZAK(LQL8H)+62)65@6$Z-^:0/O%_0R,YK?S5*R?(9N9HQP8B2T
M243<3(V%A`;B#!ZM/D@XF%76*AEY9!/(!4)A;;=C!!W-*LR\R.0V%9`]7D-W
M?E(YK/D[0S+-"V$ZXX#OK.1)-!)'):,E<M\?M?(DHP;[1TXTL17N17/;^.\#
M6M8K7(O#^[5%7:ZTJA:T[@B@3/&,>[8?RP!`^T-,R->L?EVS9'?[[+Y>ZSL]
MC$E2.<YF/),>?D2"3U'$H`!!UW!Z\+U]9:=--.FFOB_Z+_M_1?T_W_ITT/37
M*K>%L+7X^^@&2I\VVG2:#D2*.7=1XL"0]#R>.!P8)H%%?7Z0X%>$@XX5&8<@
MX!H96>PGF_UCMXKJ]X]O**J(+*3"DD;"Z2"RI).Y,@@$\9@0/G?N[79'Y9]Y
M%CO;<U.2)<!3N<8*I6NRSBJ@A1!#,HY$<C)T/U=3/N*6UM_V\U1;QIVHI;"*
MD^,Q8%_FYOXFAKJ>T5YJU]15Z'-N04]K229L;_5/:AT9WN)=73>E/(/251@8
M.Z.)1F79N3(^Z;!6^7&?(.XXUV5BV9/`UY*O:C#D/+94T6*C[IP2RHQ9!:Q.
MOF#Q;$+)6]O$/*..1'G4,:*LK\IXX5=>XN)(KH<$JV5U(HJ:HN:&JOGPP`<Q
MTFY`J*'V&BN:_+?,II<*L&NPF(W9;""3Y5#,RNR<B9XUGZH5Y&!5VW)R:S8X
M9;:5$SY5LH!55/)S6B/6EA15(+7+],M60<UY+BLFVJVX*]EP(U-H?P:9I:.[
MSMU?4UW#LG1X,^-6P;2]A%.`;$;+$1"!EPRH!6,)Z7"T>9W88-O]0H#&^N6\
MRNJ,I62"Q5#O_*1!5ARDB0>J[=[>;NN/_1\QD7%NXI-=E5EB6*T*P57L60-G
M!D.AX$!N)5P9AHG%$_EOFG?RB6F5X?LZQ&T%3-R+*S4\D;C3R)M1.CVN9C"K
MX5="'.K563(<OBTBL\/8XC4=]SW[M7A]D[>`N5F*WG86<DIJ0!@5<DDF'V'P
MF8`.GM'M%?MVWN7NGO+>IV_MEB_=HU/"W)R+2R,'J`554-5YFZ`Q$EAK"%WR
MK?;>]V-UNX@]-8E'#AV4M)!J^FS:&SMA=4L*AESPC@_L$581Q?G6/X,$49U>
MYIU(]AG[RCM5&#131@$U5R2!`+/#A6+@;\S(/%.3$^H.,`J.3R_<.9W;+RLO
MNZC(N(56,E4JFIG1:RP"^F.+#U+/3K"FDAR2&-OYJ[H,K)X<M;:LDTT&+Q?;
MODVD6T6V"Q&UN+(R<=OYXXU(17,];?<KPNER!A<@D=YLR,FC(RES::6#V'*6
M%*\?YK=AM+?';?B"V_0X>!EX?;[.UY&16U52X#RX?F/IH/(^8"OX>:1S95(6
M9&[O"7-->>8_@_4Y.8SC[63#YJ"<D*9HK#CWD=OX\:.73!0+7AJ)%Z>7#5M>
M0E4/]O*091HXR=</WSLEJI_7<6Y?ZC4`Y$A!=3N3P^+!`K><"P\P"#"Z]7]J
M^Z:6M/M/N&.P[+DL:E/%K6QLG8`VB-D-A=(K)J'IL599<:U\I_GJZ=KM?.Y:
MIHDR!AM;%B[2^%G/RDV.HR-I?0*6HK;*#>6$://TV>T<1ARMBA6+709'9JF<
M((^BN]Q4?@Z:^T.19?236G./32Q4+,P*@D(Z-`Y'D[+X`L>+Q?964>Y9-WN2
MI6IQ,D"^P53ZUM+V*B*RV,`UM=B!B$7A6C[<BJBL7^/W.OMGCB4ZF#:/E0HB
MQ8@H=;21R$KZ"/7,/!A?M5715='!<@6C&H(86O[L[*YR0X^9@X=,N\%()DRS
M'=R8)Y,[,=Y,L8W\-9.;VSN_<LDBNJ4L)40`J5@\:PLJO%*TK7R@#B@G:"3K
M$US"C%GY^FIYKS0D1]]&-`]0+/5:)U;974BR;`KT.%T,K!0V4<B1%$Z)3-1Q
MF(0\A5VU%C"NRZY8L^DSNM:2JA9,&=V]4!CRLV4PJZYW*J1KJ<7&<FK_`#`5
M@-=9Q:PMQ61QV04,R`I1NX#.\[6?/\<,#EGA:GDPV65A0[K-6UU8%.Q&T'^4
MXW>5V:JZR!$[OL9]K-!-E2#/:./7PXSD<I#&8Y.3]PLUG:,ZY3QJLH=5$?7P
MLJ+LQ/0*.*@;EV81`!UZ'[,1*?<?:L9U]2ZG,J>QB?\`+]6G(6I%4?4SL'9F
M,+6BF>3,".R/%[U)QSAGJ[S5V4HE5WBC/+_V='_7P;V1O?\`W?[.O&.Z".Y7
MC_Y,_P#XCKZ@[`9['B$[_P##5_\`A&K[ZP-;?3IIITTTZ::=--.FFG333III
MTTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTT
MZ::=--.FFG333IIITTTZ::=--.FFG336N?T9]2\3?,&7E7O(=A8V.@)BN3-Y
MDN+\?&B7/*?)M/P]EUVW(T3C/(RK"L+L+S,Y-CIYH0#(=8['.:B]NW350"=<
M?^3_`+_^R/HV9R1Q]\5XN+"GQJ#EZBQ&TQU<'D04F_M.)L1]6?`O/2[&[KHV
M+K.`/KKBZHT>+LUG5[5SNLDLCNL&E$Q[J:D"J/J_3P.O7(WP/]__`$/6<S1=
M)S/_`(-4<@YW[>QV&A;?E'9:"WS&-^D;#YPYP^>85I6Y(<VI99?-_+>.U&6[
MBEN+'S/I;!,4)W!1IR4?NU4.5?XHOIO6#YPE8_Z+RE%;<H2_Y%)N?D?E\AT9
M,Q(^XM=\Y2:8P[*H)-E19/'&)XHOXS"QQHYDRUCNBH)B&=TC5`X^'P_=IR5@
M/Y8^%[WE#6<4VMIN!Z75_5NDXWH(.MB<AX^JV'/7+W!?`_R#G]%EM4V%>U?&
M/S-P347?(^D#"9'J_P!U?*#[)+GO<6N@*'K^GQUECB;^7S#DNM%5<\Y>TPF<
M@%Y`U]5N04MXDNEX1B<XT/S'\VZCD_"D@?YC7<I?9'+<70RL7EJ:MFS"T5<R
M0\36JYR-"GP_3_5KLG76M7<`)*J+*!:10S;"N+)KID>:`5A4S9%9:P"&C$*-
MDVLLHI8\@2JA`G&\;T1S51&H]3_333IIITTTZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::U"SN^V51]/W?%H\C09;CJYC7>ACW]GF;6!I^0-*RJJ;2>?
M+6\?7W%=;4E(2<1LZ7,@5JL.K8T<#D:LA[5T;3XZY^\T\@_'NL_E"P_&7)&D
M^I;#G?$WO$XLCF,Z+/6?`M996(LOR7F86@K<W63MSG*2RTV8H[I;.Z6'%L[.
MFDA@RBPJV\C":N`8)(B-9DYPNKN?]MX*++V^094YG4<8TE=QW;ZW10;2?$T&
MFXONB3HU56\@TN?67.N1/LHX)U3+.65D8S6>;)GK(U01QUE7[B2^7"SW455!
MNIH=]QY+%73I+Q?D0H&<W$^T2$O]$4-LD*,7\1TE[(C9'@\[FC:Y>O1/8OX?
M\<HO=DK./<)`Z$O4%GQ*R1RX^:)"B8UXI^;7XP]H?\)6EMHS,9@K&)5:KV?C
MX!^(/#D0@:"Y"@ZY4[G-@E1Z':5H718[H@+:KDM<>KDS8<B35Z.BD0JY(EC<
M!D!D2W-(T8F>)51O='.[KZO@9+(UF%:9:2K#9@"`R,"TA2(&TD[;Z^=^[8*6
M)3W6@%:^(=#NA924MK*KQ9P029``AMIDSJCOP\FRBQ]0%\44%]X6KNZX[*ZI
M"L]+274OFT@M))SC9`+Z/-9)+"BQ>U-)8\"N&(L-JS#.6ISBM)L]/DI$MMQ#
M0W`/!0@J&9OO`0VY#ZQCVFR^M>X(5%)N*V*>*#ES*<D%IJD6!@YK1/N&!0E5
M:H:RH+C>7R9F>SI(H]SE\S=[#&W,4N<%&AC@9B8EWEYS;`<RJKJ.Z'[Y;32O
M%(-FU45XXYI7?5-W).V970FFVU:[%(>3+CBXB&9EV6%^I/`LJ:Z)>QV=^P(+
M!<K'H>ZAP:P%"U-SJ;D&1:W\S\GCT[0=PC63.<5SS_-G"%ERDQ2VNJY%UN@X
MYX.H["9$CY^G;CZ*91W6GE"K6$`U;4N<(D:LCHZ3*,1$&QS"JBQ]UK7W-WQ>
MU;)B8U*793`$NWJ,&5`6W\O,<G/E4#<@C4GMZY_8OM.SW`)L[AG9-F-@5L0*
MT]&MJ[+2%V\YK/&I99V.P(;6NVJU[+_,Z&1<A_?Y)KYBDU-BZ7139%C6\DQ<
M_:QDBSC_`(U.2<_V3(@5E?N$Y&2'+%\8KF]=)B8?X?)K6@^FHK^@0X`-)=3(
M$M&RL>/!94<Y>=<3W'N0S,"]\I?6L-W^:W*MBRY(K<0QA"V[H.7J60Y].*R-
M7Q$LLU#Y%VC)E+:UDFTI,%255'568)4"UGE-IC$B?Y!:V[4#-F0U-(D1Q_UL
M@P"&%W,,;4P'JRG[=04=&5'M9F92"HA-^"KN`8`)ZLP!\I.MM7?@5=[RA;59
M7995CUI6C@J[$VGCZCOLQ7DS*-Q7666651K;'CCEJR^@\-=<0Q(%=7[-^-MM
M!\Y[J-'E6<0G[=70;"RH;:1/2#*B:,.?L:PS26"L1DDC'(1?4`C^2[EVBKV]
MGIWAV9L+UE3,J)"G<D*Z@2"A<.(2=@=MV`]&['[CO]Z=IM]M5HB=T.*]G;,@
M`N#Q56:MRW$BT5M4P-D0Q!GRH3K)Q?Q!5U$6HY,OZ"$QO[[*=A::=E8_:9;W
ML''ZJ;>R3-MKZ,_.Y6Z@F]32HD8\T[7*J#C$4W4=U[S;<[]KQ[&_RQZK"P[*
MILK"CRH>=BD3'F"@^+#CP7M_VSCXU=??LRE(]4_AT:D>9[%IM:PGG8/3I=3`
M/E9V!V6MN=*N\)>VZBFS"V%94#8M]J;^V9*D0XU,6;*#9V$[]TBR%N9!A5:,
MAM159,FR!,<\;G.+U+1GT4RB!6N/DK18!+0.('$CB/-+?X5!(!``UC9?:,O)
M(MM+UXP'J6V/)4(6(=FY@\R0D)X.[*"5)+:MPGX][9PCADUD#]ABPXM)4+*`
MUU1#537IUGAC-F5<RRLIVG?+N)(2`%(F(]XVL1L=&Y(Y45,K!V]0DLT'S'Z1
M$PP50G&L$$A8!)\VL$\,O(5U:M/14!$D>0;V'D!R1F9K2]S*5#/)4"$C<CY@
M1P>1-@UDH1F4W"VGSBVZ%8,I;2KY)XHD6D"NB04DLB4N>#8Q(C2/5"&E(9K1
MM$)KG\9[IW[=3((YYJ/Q_P!EJ;PI8F)9X9H&P7C)DD#U#V`"O>\H!@15VNVK
MG,$NF5AEU4+,)6&1`3NS\@`%4$]O^O#-?6.G333IIKX[_1?T[_HOZ?I^OZ?Z
M?KV3]?\`MZ:H>FN:_.&>U6+^/^;:W:1I()D7$<FRX88]_+LIY*%+K$O@/#:N
MGV#JZ680W*$,=1!K^[1A8C1M<[TWL63B9OO'!MP2"AOH!E`HY\;9\L"0/$F2
M^Y)W@>%>[,+N/:ORS[M1W56%JXF45`L+,:^='&'Y-Q)$PJPM>RJ(`)YW[XM@
MR!%H,M&DPXY0CS^8I*)A#'="LQ#HX,*'$'[?W4YHS+"0\A'/.91N(1ZN57M]
M%[>*S8<C*(+`\W9^DKYB2?Y1/``#82`!X'Q/O+7"E</MZLB$>G4E8)/%ONU5
M1OS)`L8DRS068SN+3+-DQ70<M03D?GZF:"?=7099V@U5DH&W<\'Y]6QC296H
M:6+$J$EQDDQAO,9R-62X8\L(K<LK(6,AU(52!]VL\08;_P`QO,UG%N+$*O\`
M+)US6O7P[?AO.%6X:QP3%K1S8<DZU)*)3S7D@+,8YE1>NPY)L>&,'";7NL0<
MCZVF+(S]K72JJ+!R=)%GP#3-%(LK^QB_A6=]`FD#!*]BHH7EF,:Q?Q2)A8?;
M*^]Y[>IQ/;:7AU(8FQB"`@5%,JA`+#X@(2?,-;7N??;O:W9T%/,=\R:B:W4H
M%I0,I-A>QAQ>Q6(0D?26M`!],BY_E]S\?9WNAWJ1S\9<@QM3QS>T-G:9!])H
M*.IO)-D[D&1^(&I:.!35LU0PFJI)`_QW.:YJ,]AL7W2!F55XV!([ICE+E=5L
MY(S(%]$26W9A+=`9WF87/]@$]LONS>\0>PYJVXUE;/2:[*TL+_B3`2%1&XIU
M8<201$M`YAX\@\$/MXV6HQ6^0C9ZU_Q;8:2N_>G6<0=3`**GC2"19M97"_9X
M<)$:!%#:@C",Q'>:B?7LW<;._A'R["F8;%]2M#QXGD?,1(9O,6Z[H6*F(D6^
MYNR4^T&MK[?2+>V+2_I76KSY#@I"`PR*.`KV7RVJJL)GB=>JF752R\,@+69A
M1P.*;R'*6I%*A2Y0Y-/C:V0:WEC-&DBG206+QJ2.9AGO4@QM(YPVDZ*U+4&:
MP:V6RU(Y00(:Q@%$$0"`8(B()(@QQ6/9CV-VM&KQX3MUBG@"I(*4J2Y!!#$,
M1*D,3R"@D@'?#AOBK-\59R=S5;&-.UHG7,#B_+SH4BPA\?VM@$KIFY-#%$&"
M3HB0@).1\J.Z>U\@C2(I)0O7P7>N[9/=LE>R4@+B'B;W!`-JCI5,R$GR^4\(
M`(V4SZ_[7]O8/MW!?W5DDOW(%UQ*F4LN.[`\KRH4`VE1SEE-@+,#)L6--Z+5
M;WC/6W)-#$M9RZ:SS>=WXQ98K@[,NB#L=]H[FCNJ^=,F-+629T23'G.CR%%.
M:O=54Q6-[3(Q,#N>(@QBB^DCO5Y]Z^!KJ164@"&`92LB5_W03YAB=P[QV+N-
MK9JV/Z]E5>0!48O-@NR+7K=69I0LC+85;C9UGFP%Q;D8I#*FVS9V2J>4&/HL
MO9.IH,>$:O21`T%))C2C!&2))_(A&$2++01X1_)G92,>Q<;`)4O3DB+@2CKR
M),P48$>(@@AED,-^A!UG=W"N*\C!(;&8"RIN"A2LK8A!(E3*D%'AD:1]0(U9
M<R?.O2"MA%CML9%[$%L@.['`X\C\V`'057[>UG@'15UF,LQHA-BU4X+$:C`'
MB-ZS4KKH!I,^D*SZ9Z&!!*-/BC*0LGE8I,RRN=:FVZW,(R5(%QN47CJ)/)18
MG'PL5@7@<*K%`$(]8UM9\[O@R>6^!YYX[EN4VA*IEA'G.CEDQRYO4S["!8@`
M]G[S&!:UA)"-(A&QI+GD8K6F(G7)^XPZ]GSZU/W'H<H(F#SK`()^DE6`VCD(
M!^D:]%]DFFSW)V>YU/XK\5PY!H)!JM9E8#ZP'4MO(5B6$!CKMED7*[*YIRM:
MQ74-0O@UKVM;_P`A'_1&D&)Z(G_:UJ_]G7B&8(R[1_\`)&_B=?5G;3/;J#$?
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M!C$S^S`%'"&(!1*6FKRT>5>OZ;?W:P-S]]>_4&:W5?\`)?QWB<-Q7G>+OH7Y
MYWWQC;?*8%O.%OH3YIVV%W>APO'7,*5,.QKL[QMRUR'13JE^CI71,Z&356$4
MY@E%#+:-5"K]3?#?6SNQ^$OK_P"A\/H\O,V-IP1@QV'V-H.!:FPY2V'&V@SD
M[Z?R/#?-/SG-U^?X5N!-EZ[Y@^A'ZW/S!V!Y!E@C=+C+-63Y.KUU3DHWZG;5
M(Y7_`(X>;-=ELUQY\T_7.6S_`![6\R_3/+V-XYR/.6UP#,=D.64XYK,OJ,SI
MZBCY5G7<WYPY*J-46MAN@QZU).B1$EPY$=1F:!AXC?4+D-GV3\>[CZ'^A=M0
M\R['C3_Q`\E_26TEQN702LWIN(.">(^-^&OESC#/3*JW=)XR@\S\D[1^IWHY
M]<E)34F6M%)"=$8$DEH.+0!$ZV7F[+YN^MJCCVE^A;7@+@3ZRVFWTL_Y=Y(X
MDYAP_+55R'N>.<1<8CC[Z/X)TQJVFJN6X_&4_F"QBYJ%L*1Q:771Y#(T-9(@
M22M4$CINNM/\GKN9OXEN4J;C*^JK2Z^;+&;69'CC'YT.CV4.^RC;#D")Q7Q!
M\VXN(E3R']/_`,G'U;R?8V.]Y7TUHV/FLW4>+9!ECH"4E-7$!Q/C^G[AX:_1
MACMEF][GXFFRES5WE3*-/A/DU-M4W0(=M3SY-1?T<N;23K*M;<YV[@R($\##
MD6--CE"Y?-CDZKJ'IJY^FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FF
MG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTUI#]*?3NTX3Y<
MX;PN1S66VD3D$%D73U-_82<B>@KX]K65<+1Q]NDFUAC&218/$E;^QRSRB"3Q
M.%%<J-7`2)UN]TU;ITTTZ::=--8%HN#HM3S!8\P'LJ%]W-A3ZTLRCQ-=E=/>
MU<SUI$JN0-13V#&;VMH$"Q:UDJ$,D-[$>UZN4BO:K.T:TEYY^LR<4_7N*X>P
ML#XYA[;D;DS@?):R9=\NRZ[Z?N<'KK[,PM,H.*G<4U=;<L@49FLKROVIG-`@
MC,BD,T4(C5P65G?6\5UP737W)<;D29>WX!#M\_=6&/KKG0U^3T5EE(8_\8MM
M+1QK]E/;7U!=1(LJ-*6*QJCAQQ&$98X"B:MG;6IOVW(A.@5L6]C%N*0O.G"T
M&52K(D`BSHTW*;UKZVQ4!8Y24MA)>ULX#"-;+BN(!_=A'M7TOV.M@L9Z"$O&
M!DD-`)!%E7F$R.0'TF/*T,-P->%?FN]1J2O+4VXA[O@J4D@,&IR/*T$$HQ@6
M*#YTY(=F(US;V,FTV%RM..4VNJ#U4NXOK0L0@X&2K5N67$V?91?Q[`4RGJZ"
MA1ZB&,+COD1PM=Y&\'>EX2U8=/K$<K@X5%G>QN/$`&1#,[Q))@!FZ"1X9W.S
M([GE?AE;AC&MGL8B%I7GS9F$,"B5US``Y%D4&6@V>EMJ=)/%71"V<2LKFRP4
ME*&2.ON#^!Y%_/EW#X7>B)J+.\F#?82``1"E`@_%1@$Q,STL3&K-CA&L:"S$
M2HV"`+/G]-5!"`G8&9EB=:P9/<,Z\45FQ:$D5U@\7.YL8OQ^[]5[&!L95W*\
M8A%&KLY5WUGF*)G$M"^1&N+6$M7R1=2K"@J(+2:6CU$BKP@#VTWTS_P;:)&D
M6Z@$AS2AL@N_H;(87$[3V^K*O_J^1!I1N5*@.Q\C(&M(4;2I(KDP%)?KQ(V/
MN+O-^!ACVYA$KE6)PR7+5HOWM=I3'!=H;BZJUW$<F<"H[!PV<?G7(TQ>(K7B
M+FHX8E!S!*I=?5P+&5G)]OQ]M;L0X6=E5GB6$.1H=+J(SFH)$]TE)@8[D57&
M1FB]QYER]X7O'9`3D88:MB`X6ZI=W#=81$/7HO$MX+/6>R.VXK>V[/;7NHA<
M/N;)<BL:V?&OL'&LINH-EMHB.K<U0]7C7CFO/2.-X5IDI5#%BC--RH8UM>0Y
MEC8:W,Q=G2P(-O+F642QG`,YLF6\S6NC+`*8Z,5'N+Z^B[)D+W-TRUL)(5Y5
M2`*W-;$J`I`(V6.O,!9V`GBO=6$_8ZK.VV4JH+4@/8K,UU0OK57+,&8'=RWT
M^F6>-RW&EV#:Z5O=R$$&BL)%I6\?08L3)GGP8TJ1[+J57!BHZ/!LI+TL(Y'D
MBC8<)W+V>U`N>TDM9L7M]!9K%5&N)-@!('E!)W(&Q$,8(\#RB(+A19WC+5$I
M=[*\90*2R@GSE0-E8^8$E`&5O$<20VV#N/YW!G#4F-AY<67SMR=GV9]=%:15
MEP\1@7NJ\^[)4/XSX=97QY!XL:*:3&<V),+%>Y2HP*.?R8[A7WWO0;.!'8<6
MSGP4P;;?,_J/,L2`2P5O,H8;28'HI[+;[1]KLG:65O=^?3Z?JN.2T8_DK]&N
M.*J"0JEEA'*$\@%DZBXC:3*"--QEJE[G,!>.NK\896++5)EY&4N\]QUFM).C
MU<B<,E19,7\2W"6.)"1QA,OBL1$)U^=A)D,N;3Z=G<*^*2+.7,6*]SH"P'F7
MZJR"8)*_S[>:]I[I9AUOVO(]:CLUW.R#04](TV5XU5K!"PX-]%P*B5"L8]/>
M/;3;#.W@+JJ<&G+32[$L,RUE8:*1:Z3)):UZEMPO4\:10WLT!?%BH<"N1CG,
M)YI;2E>30:+9=743YFGS`<3Y>A#*I&^QZB1&K\BV["RQEXT5-4S%3Q4@\22Z
MRX,@UV.I@>99`)!G5EK(+828,NL]R49F/AM%^4>XM,_>`C`J)&0=8+)80H`-
M9$6/-E_URH$YID8A6R&CS>(K5DMCUP9Z!5=22PLB.I\TJNRLL3!6=7ZC7.EF
M/(Q".,27>NP`(:>4R0/)Q=]WKL#1R#A=VOBF&)>9](24/\DES\_%ESXC#Q)$
M:6@.2N.X,.2>'$&.(2T2%'9$/(=_>*V&P1.Z@15XCWNY'9*@A@)W&`8((FFX
MD`G?C)Y`=!R)'U:]6_*JI3[IO-@Y-;V8EED$&,K&4$JH`+\0$9OJ/`*?HUW3
MZ\'U]<Z=--.FFO!%>UCW,:CWHQRL8YW@UST15:US_%_@CE_15[+V_P!W51$[
M]-4)(!(W,:Y\\][^PY$^6^7;\0XC+*+C=O3QQUL28D5EE776`1T4"VR(EH^'
M9E='<9&,`8@E3Q1$<G7H?M_M]?;O=6'CDGTC?4QY$3Q*W;GC],KO'4`]=>+^
M\.\W=[_+[N>:H7UUQ;T'%6CDMF/L.?U\7)4F`K$$1UUHERAQYL>-PV`+J@LZ
MRRT$637PILN2&NB9:D4*CF?ML\9)HI%G>5HC0@JQ?R(<'\IZ&&>4U&][VON.
M'W(JU%BM5602`"QL;PY#:%5H8^#-P'$JAGR'O_9.Y]C5TRJ;*[[E*JS$**:X
MAN#2P+6*"BQYD3U"&5[!&OE'*B9^LL]AJ8["U]0.XL!0IDQE(79Z4H9EE`RH
M$A)*FD%/6N618/$)_P"-!CE5SGKXJO17J^1:N'B&+'*B0.0K20#9O`VF$!(Y
M,1TUQF)95AT6=S[@)IJYL%9O3-]I!9:1QEH;CRL(!XUJTR8U8.1S,SG'F*WL
M]5+KS4CY<JUULZ-G+VR5U/L:NM'G\O4&L42)!A&6,"+%:$#:^O"!&O8U@4ZS
M\S*K[%V9*L0,+^(6L%T7S5LW-V"[DB2S2>;DR#)UINVX-ONSW/;?W%D.*6+W
M,*K&\ER+Z=2%ME4PJ(%7TZU6"`%UEWD6]L;V;&P]'!F184*GSTS36$*BJ15U
M51T$EN8'Q&-ABST`ME721I,8>09L>(YHGKZ2D1NH[;170ASKV4NSN$!9I9G'
M/\1M$P0>,`2VX\P&ND[WF7Y=J]IQ$=:EJK:UEK0*E=9](8>Y:.:D<PS,%3RG
MRLT9IM-7%Y+XGG\175BXW(66J$920GQ(Q(-QEZP%@M7DW^C\X$RVJ:.+[X*?
MTE?73DCF\7JP?6DJQ&[9W9>\4+';K7\QDRKM'*S>"%9C#>'->2R).NJR.XU]
M]]N/[:RGGO6/5]VI4%7J0-PIVY!G2L<J^A-5@1H,+K"_'D"7>;7Y<C6%@J0*
M;C^;<S/WRB_8:&DIZ&#CY]U82K`Q)0KJLAPXQ%*XCFND#$T3552L:[==QL2C
M"[JU:_>/D!1Q?D[,YL"J`(XL21$="9\"=<KV2BW+[K[?2Y_N:L)G;U*_3K1*
MUI9V+$D6*J@R3]0`4;L`=@.?]K*Y)L*/3XU($D&7A/Q^/E:BJU4VKN,U=S9+
M]K47`X)Y,*;JKROS33*52O,!X1(B*1[R-Y_V_@KVRNS%S>0:UO4L"-6&5U`]
M-ED`BM2\1`!!/@`#V?O+NMG?;JL_MG!EQT]&DVI<RO58Q]='"DJUMBU!IDLI
M5=N1+#`6@7/\IYNAW-`R+,M05.HG\;&OI6III,NUMC2,HF6M),(JGB6L4SE=
M%\I*O&][?4$097L9O\?\1VK)LP,B12707!!6P"J!9S4'8J1]7EW\6)2#QV;^
M#]PX-/=\,*V0*[6Q38;4+.Y-/HN5,JX.Z2T@D<55;)%B<>Z>"3PPEQ/A0&@F
MAIZ*RDZQ);,?H\KB*1VJ9-%;LC6\.CM9T6/$EL(62\,U&3'>EOO1=AW'%<?\
M?2K,2O)E%<>HEEK>G'&5+*"66`LK*"3QUJ.RY]1CL^4Z(%8)6QNGT;::$]7D
M'AUK=@J."S%;(M/$<]77#HI]=<)[X#6'@C=27@K@!1PK.$>2^LFU-RCHXCLK
MI->KH\D?@]\=&#D-:]PF/;AO?793Y6\K'DO$[J0.09=XD'=3T:2I(D@[&K$N
MHR9=/.@X6!P>+J3Q9'V!XE?*P@E85P"5!&[W!O&MI0;KBC7_`(ISYR;R9$#2
MZ:T8U9J-G9_2-=3,1KXH?W"0V.S\J2P1`RWM<8'BV2YH^'[[W.K(P,O#D#)7
M%/)%Z;.GF\3`GRJ2"NP:>()]7]I=BR,/N_;NY\6."^>`EK_5YJ[?)U`Y&!S8
M`JYET@.0O6/&213<AEY07*X4C/TY1N49!*K75\=47UE1",_\COUZ\DS5*9EJ
M-U%C?Q.OHWM5BV]LQ[%W5J4/P_E'@=7+UBZS].FFG333IIITTTZ::=--.FFG
M333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG333IIITTU9?(NXJ^-L1IMQ<((L3.U9Y@:\EQGJ$UY:O\
M8U'F:ZUUEO09N+=ZFZ/'KH'YLV+')-E"8\K$=Y(U4"3&OSZ_+O$$_P"WOH[G
M#F_Z+J)H>,\W<PA<NX#?X37<0R]?9Y%A-/Q3Q+]9?(?,E3O,%3\M_,T.946^
M4YBXMTXHVBJHS!%>1ARM2FI">(@=?T\?G\-96Y3YAU_W1SC7<#9VUG9:BH^:
M>(^:?EGD'!<0W7(.7#QSC>)K;E2E^RMKR?HYTCYZYNX$Y'U=LS"`QU<2NOJJ
MUD#FI-2:$2QJZH`%$_I]FLQ\%T-QC*JI^<?BVDJ)E-Q\:UC<S_:6]R%9G\S;
M8WZ(C<Q\Q6VL^-;['YRZXKY&E<<?0%QWF8QR0<QFAE2"OFYGETU0_%OV?WZQ
M-O\`0?%O$UUK7<]<@<P?:7TOPK<_(V\VT/2S=1GLY'YTX+GX+AO'\Q<=X<<K
M,\-8"_9??05+<:V!G/R(QFWD<Y8DIS&L1JH#'IL#.L::[8_Q<U%!J^/.1O@Z
M)QK@:S@J\XIL,]'JLKAN5H-+R!:\4?3VNX%/A,_K<UM</2ZODWEBE*EB6PA5
M,_8*>.0XF.">335?/U!_3IK<'&4VMLL7$YA^$OHB[ULKD&D^C/H2H^4OI[5/
MN,[R_H^2AT&3Q4*3L+^%JN3^&N`N(M=GWMJ8V3!(H9;;)?68T<X3$KJT_`C6
M#=+\Y\9_1OT#B>=LCQCR-5\N<(\NY[B_DKY>V9LWQ)Q!N8/$5W1UMKSEB6[O
M,2]]9<"X2VN07M%/RD,57M=1EL^X\:/)@_G`:K)`CPUNC]&<C_,'T1OYOP3-
MT&RUO,FES%])TYN"GZ@>E^=\[/S]DA[GDKF7`^N9\\#Y)JF&SX&K8U]Y=P[0
MH(PG1RF,-JT`CS>&M`?X]>7[[Y.YT)\1<VR,O@Z[26,_'<.91`X/@GCT.KQ[
M2/C\??#7R-GP;3G2_P#GH-,VTL+OEGD.YB$U%TP9Q(1TER-:O8<AR'Z?;_=K
M]`_346G333IIITTTZ::=--.FFG333IIJ7ERXE?$E3Y\J/"@PHYI<V;+,.-$B
M1(PW&D2I4@SF!CQXX6*][WJC6-15541.FFM)H/\`(_\`&5W?:?,Y'F$O(=QC
M["=57P.+.-^6>58H;&ME,A3HD&UXYPFHJ;LL:6_UN_"/(1'HY._]+NS5W%M9
MOX3^DN%_H@&J)Q)L7W\S#6L2EV>?N,SKL+L,M86$)ME6-O\`$[^@R^OJHEO!
M<I(4DT%D:8T9/20BB(C6J$$==9RZ:IITTTZ::=--.FFG333IIITTTZ::=--.
MFFG333IIITTTZ::=--<\_L^?<9[38VSPL.=$Y)TE.;+Y2VJKGZ7I)%_<P)4Z
M_H<E8LX5R-UA='&!ZI\P,32S88PL62_R%$)++TU<O[M=#.FK=.FFG333IIIT
MTUPQYKK3ZG^4+$LWL[84U/F=UP]7\8T9X'T%O<7NHI<[1\CRSAD8KF'-\,<7
MGC[_``K9[ZVYS=A+),QP+D[C0WL$UJ0?1MUUW.Z:CUH1]@YN[U<?-YVIB?E2
M[OE[!1H8&1H1RG$/COE,\U0,DF$Q98!`>\+W*CQ%8UPT5S6HO?\`L[)HQ&LR
M;C")AVDF2(/K41,#H9$CH1L=CKQW\S<'+[BE&%C+RMM[GCA1"DD#&RRT21N`
M"5/4$`C<#7+WEG/WG'X5R,R*2NN+`OYFL&L=P$E$B_CO;F(9"(H)]96.A"][
M0$:PQ1/\G&:$!.O4^T9%'<&_&(0U*B*]YB9\Y\0S28D;`CH68:^?_<F%E]F3
M^FV*4R7/*X1$Q!])?!E3B.04P2#)8(C:QM'TK.,<U_F,>973]A>3R5V5KY4D
M9"M0DR-66^U:&`(GOAU-M8J*(PZC%*L7(QW9D>0B;-L8]TR?P;!EPZUFP@?(
MLM6_0LJRT253?JRZT:9P[!@_U2MD?N=K\:5)WW8*]\*#(1VA`T!K=C`1XM+@
MGCR+H3KI;:/4WD6CC+&C5,O.2[&_O>0\I)/("4Q+HX)A:FD'8>\WY;`$,BHT
M97J0B=9G?NXOC+^&J+UO89+!PJ+38`#'$$!FB!QD#Q`@:UOM#LM><_X_)%5M
M=*P$-1:RS)I)()-A!*(&Y-S"D]%8\CK)^IV%QO-^6LH9$F9F,YI9T:N]D"$R
MMW^UM8LZ^I[^%9H$,=*O`2X!#1Y1C.(:8SWO=_J\>JQ<.C`[<+;P%RK:@3N>
M552D(R%9GE:"`5`@*>('@=_W#N>5WCO)Q\0LV!1>P7RKQR+W#6)8K0!PQRI*
MN6DN.9/4K>W..DK.7<)-LX-J=^PXXT&?G;8((A9D.X+9:_."!I:-`'E0Z\4F
M7_:L!H5/.SCB=X.24YR8/8L:WL^>*G0##R:W%1)@KQK>4:0"8&Z&/H)W\NMK
M[LSJ/<G9WR*;">YX-U;7@`LK\KJ@+:X)503M8)WM53!]0Q6.(Y58#FOD3D?4
M:>P%F,;1XPU[<'J1T]L\AXNH@TN>J55Q6BT%E*CR(P_2B/$'WR'HB,:HX>\)
M:W8\;MN+4IRKK+`JAN2[%"SM_L*"&,]3Q4==\KVU90GNG-[YW#(<8&+50;'*
M<'W%JI6G6+&(91QW"\W/0<:?S+R,5>1+KF"?'J`0"1#Q-Z.+0:63[LOCZNI@
MXNPQ$4LET1K<OH-$12/"1S9,9Z.>]!.8JR=E[:/Z<G9JRYLD&J700]C,;!:8
MGSH@@$;-L!(.H?='?&_K=ON:X5B@J1D17:9JI1%H:@$Q]U9:9*F&0R2%(UB+
M=9(T^/&T$.!2IIK&OQU3H)4:QUU-/7`=ZW8V5V0D2<<WLH5CB6<9&R'20/:\
M[VH,C2;C`RQ6QQG:S\*K6,@(K8>KO6%W`^N3P&T$0HW$<UW?MS7(N;4E7X^Q
M*4L(:Y&_#^6]K"0Q/W<#U&ABRD%R.+`_,W<UO)5)$I9L\9[R+"LM9FI8M%3R
MTMJ&9?Z2+39;VQ`U=S)DP*>L[P`O:55AH2(CGE`/S9--G;+S>BD4%EK<<&'%
MPB%GWY*`6;SD1YH>`&,4P,K'[[B+BVN#EJC75$6(>=;66A*I`1R51?NU(/DY
M5R6034L]F_4Z156WX2YS0-''G@8P:S!SW1W-AZ&("4@F_NT1P&D&KFJ4BM*-
M7L%*(\<>1DR!;3R_$U[@^$3NA(_E,P?`;&"4`,^%@\2V/D</P-T!A_,&C:P`
MQYQ$C:2>2R%L8C>'YYX_N\9MSK*K"N9=<$:TE5>*UXG:(0.4^+))"5J.E!;%
MJF%LE,P+01_7(E'1SGN_5.%]Q=PHS<$<&$IGU\E_P31>/-MNT+!,F0JQ&O6?
M979LOM?=CZE9(M[/<4LZ>J!EXA/'<0@+<@H589WDDZ[&]>,Z^GM.FFG334([
MO`!G]G.\1$=XM3NYWBQ5[-3_`&N7M^G5RB6`^>K7,(3\`=<RN59KG?(7-UC$
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M&AE8UK$OP4[I9W&S^AY(J5B[%;:_7`1!Q4EC%H5C'$\@`68Q,G4?=K.P4]DI
M/NS!.0Z+6H?'N.(S6V'U'`030;$$\U],LP1%Y0`-90R.<^?)W%L<7"F^LL_(
MC`L:RHK.4ZTLW2"T]HH+&/97,5MG2AO)F1GB`R0&.Z204=K`-&BJC2ZK,R?<
M-?=2>]XZV*2&9J#"<%D$*>+%18)*D\03+3\-_P!MP?9=WMY5]J9EE+J&5%RU
M+6BUX8,XYH+#2P4,JEB%A0HZ-BFUX8LL)F+-M7(RVZO&W6@E6%;!6,:YT^QU
M$9:#839V3TLU="<$"V$,B?BPV/+&.P;6^)?:FVJ[W7GY2FT6T4<$"DSQ2M#S
MK`L0<`2LCS,0&!/41KGLGVO?VC`L&.V/EY?JV%E6"]M]H].YFIM;U"%<`^5`
M2K!0(;EK5J7/V^8TGNM/W>/=GERY$D]G'G5YVR+$CDGK(&^+$(6=:6H7O(2,
M)7D5[FM3NZ*-O5)7@Y6-QJX&@``<2"(7I&YV58`#&!$GHQ/GUEW=L#.Y9'JC
M*9B26#*98^:1`EG<$DJ),D#K6!?H)/X4;A=]:^6.9<\<6,2P"N@C6L.8U(>)
MEAC2H58)TREISRV,<B%8KE*J-1A'L:(F`4]1\T6QP3)4@\"I&]H)!;9F`^!Z
M;R`9&X1_23M1HY"VW!8,/4#JWEH(!51R1"8.XZ[0Q`4UG"_Y)^^NSE566%P&
MQF!$&#&2VEK&LI5+H*V-)M64AW&5K06I8\APG)%01%(Q'>N,]8,_\-Z'XFUE
M1E7<GB)`9&(7D(_E!$^:1!B6&LGM/X[\6<''K>U'8`*.9ABEB@OZ9GHY5B#P
M@EA/&LZV[P7`>UKKVQM;>RH**MOIT9VH@VFRN;<]=/J82Q,7H*Z#1QQTU,*V
M='<2]%,D1P3(D?W.1I!L:G(9_?\`"LH6FE;++:U/`K6J@AC-B,6/)N,Q45!*
ML>(V).O2NS^SNZT9CY&39331<X]57O=RK(L46*M8X('@G(#LJNB\C#*!JR.9
M\O\`*F0U-;'UV[Y)Y!UB1X]3HLOQNM948_W@NH"WFFEZ'3/=6`6YL^S9_P"V
M_FR#L84:":YSW]9W9,KW9F8C-AT8V/B261[N3605/%`B>8\5^CGQ`V,]!K4^
MZ.W_`)>=L[A6G<LS.S>X\0EE6+P2F0Z^I:;+3Q'-]K/2]1F`9>())U3.2^1+
M^@D4]QB*B!3"K6R,B=!PY.TU:V&9">P@DN-S?5EO*KJI8!7#=<GBPQQ61W/'
MW1C'-E[9V['R%>G.=G+18-Q77#['C4C*"TB?3#,6)`/4C4'?N]9F$]63VFI*
MEKFDPIONY5`LI?(L1RJ<20;V1`@4E>@(SEP]R!?[WE'YRU<S2V5S&V&WGCM4
M)^1^P3++-XO4QW3\H,MK9@903Q_B2XY`O1AT*KD8G]30:'O/;\?M_:NY8B5*
MC4T#CTYA7LK,6>53S'F4@](B>A;K?;'><SO'N#L?<;+[+4R<MN<SZ;-51:.5
M(+N!6PX.I4PTDQU"=><BX+\KFG`5JA=0U"C5B>+%9^!'[>*=D[)_\77C^8",
MNT-]7J-_$Z^ENV%3VZ@I]/HI'_Q(U</6-K-TZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIJRN1^1\'Q#@];RARAK:+"<>X2BL--L-?I9X:RCS]%5@=(FV-A-
M.YK!B$-O9K4[O(]6L8USW-:K50"3`ZZY'?)'T;]7?R1\X93Z;X]?:_.?\8>`
M/>3.)H=Q3QXG-OW9H2UT_.1MMIJZUBRI/&/SIG)AY$NIB#4%OH9@0'.K8[4&
M-J]E5!Q.[_PUVFZ:CTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=
M--.FFG333IIITTTZ::=--<C_`.7#8:"3Q'EN$\KFM3MC<C6-C=;;+9#ASYM^
MJ$M</E@"[TG(/R;S?R+@=QR_QSH+JR$0QL(]^AJYU8!XRB<]C2M7H-Y_3]NM
M>>2=H3XY^4N+?FGCGD/YUQB4O'.?L.<./W_6&X^0>9L5<\P7,B]X_;\W;?Z$
MN>8:WBL5U?9[11:?&[*UBC=!AN@0IT8,0B=-5`Y&3/\`'^&I[BKACGO@G&UO
MS)P=RWSOG:/Z]LLURSE6ZBZ^3MA]!?`[;1^BWOT'LK_&L=7<=;KA?=;;]FSP
MX.7K;F)3WNAL9@Y+EF1V=-"03)'3]^MC/H#B^_H*S+?#W!?!-;QS\UW]%QJF
M)=QEPT2ZX[I]4_G5FQWX-S'KK&JXQR7$^)HJ9MKH<M>1`_\`4R#?3*N!81)3
M"M,U0'^8G?6Q?S]\+\'\(4D%T[(8_<[])D>TLMI8900(L>962+X>8KL7G;BS
MU*XO+X/,W8\]10AS91X=!55T4LF0Z&(J-4+$_9K:BPPV*M[1UY:X_+V5VY:1
M77,^@JI=LJYJV%?9QW[D>(29Y9^]`R;!7S[Q);&F%X$1'=-6ZY3_`$'\)<>\
M'1N2/HS@V^Y3XF:#C#.T/*7_`$IFW6TY6J^(>(;6-R&"B^;PZ^[F4^*TUE)P
M^=HQPI"NRE?G8!D;6.,1[W-7AB=CJ/*=ROS#Q%C_`+KSW`>QXK^LN'X084NC
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M[S&YS60;"MAZ"OK9H+RJBV"2:Z%JZB@T\:`53JH66$&',0?C[@C?Y,1J,B#&
MLA=-4TZ::=--.FFG333IIITTUJMRS])GH-RG!?"6,+S-]!R*^LM+',!L7T7'
M_$N?O%EMJ=OSOR`R#:!Q&?F-@F?!K8D6RTMT@E_`KBA0TD#5P&TGIJTA?&E#
MR5:0=C];:B7]):B(:%/KL1<QY.?^<\7-C>!O5D.#(]E-H+M12N[FV6M-IKE4
M7Q;*$'Q`QIRC8;#6Y<"!`J8,.LJX42LK*Z*"%7U\",&'!@0H@F@C1(<2.P<>
M+%C`8U@QL:UC&(B(B(G35NM&^`)5;RKSCSK]G!FP8'%MKALE\^\4WCK.'^V;
M'`<'Z[D[2;/F"1,$5T$>9O\`?[NR@TI7F>,M-2-LF.:&R1$:N.PX^.K!M?H/
M[,^CZ2?KO@["<!T7%D25WQ?,OU;)Y&?5\\@@3S1;&7QGQWQNE3I*#CJQ6*]M
M7KK>=VM1JV5!J)5>6/..U6%'U3/RUN7\_P#,55S[PY@^6JFO+2?Y;4/==YF5
M+C3K#&;*EG3,[N\);2HBK&+=X3:U,^GFJS^E)<(B(B?Z=-6D08UF+IJFG333
MIIITTTZ::=--.FFG333IIITTTZ::=--.FFG337*S[XMZRIY3X>E:&XNJ<T""
MMGQ,6JO!U.9?RG'MY+);^7S3;ZI)7\?@R3R]Y5*B6[8Q+'R)X-`$K5Z]-=4^
MFK-.FFG333IIK%,'G+B"UY"%Q13<CX^\Y&<+1FDXZBOJZYO:EF3)`!H/WVOK
M9$J11/KI-F`3VRVA52O\$17(J(U6#U\-<OOHKY:V4K[6R/.N=^=='R!0V?-7
MSC9VVZ7FK-I0XU:[3<2U^SY#K.'X?'0=Z*?6T_&&?%/,NI=!2+1-*V..-)MH
M]@U<&\L3KLOTU9KFW]OR;*)!IC5\V;'FKSMPV"J<&62$X4R5C^0XH0QY2D&T
M#94@R,>K?)5\E3Q<J^*^E^QEJ>QUL52GX#(+;3L+*29'C`$C^SKKPO\`-FR^
MNFIJ7=;?ZOA!()6&-.2``9$23!CXQ!.VN;_,'+W)>@Y7I>,JC6R),;*V%=@:
M^FT-/1ZJ17F<]:VZVU[`L&3ZN=0:`DI\F%,24&3&8Y!OCJT8W$]*[/V?MF/V
ME^Z74@-:IM+(SU@^*U(5A@Z1#+Q*MU#;D#PWW-[E[]F^XZNPXV2S5X[KCJEB
M5W%3]+WV*W)&KLDM6_,,H\I2%4F9Y(LOGMDS.5?*W%>GAS]1&NV"O>']Q-K;
MBFRM3%KZUUR'CVT)9TLM'FB>(&5BQ`^Q9)_Z7$)U;VVKW$4LM[3EU-745\N1
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M-C/<]Y'H1[E3;XW<:L[*-_<VNI!=BP>5#NW!>)("J0&4QQ8SL`(&N:SNS9':
M>WC%[%7C9)%=8K:OB[5UKZCEP&9[%8HX!Y(H4DEB&)C5$5G=5E19T`!K1MO9
M%=`!Y^81)"L;>$!S+`<J/&,:L%Y-5?8P+"*]YBN8\I"1NL-5%MRY#?>>F"3X
M[A2=H)'+["8@*`0`&\[7(RL?&LPD'HBYE4>`XLZCS2`2@VZA09+,069J\OZ"
M2D:^V-;$#.?`=5XNR<C[J*>)^8V+IPEG/;#$^MC6<:$]2C][W."@B*K%&A53
M48R\L>FQROJ![%^D@Q*;;^8J3L8`F1O,:Z7-<)F95%8?T?3H;ZP5F+06\HXA
M@NXY$\8;8CEK)7&.<V6W<;'#H9<]8]:MQ36CHUE7P8U/`L:Z=)JI;Y,R3G80
MIGJ$2/\`DD.(0'I&>KDC":36=TR<+!`S38%EN++*DEB"`P@!S&X/$`DCD/J,
M;WL&#W/NI/;!2S\4YH\,JA%96*&6-8#0"O(L`I%9GTU#;"<:_.>BKZ\59H>0
MLS05]NP]E%DV^EOM2E/KI-G"/O:.=-DQ:O*/IAM,V+71'2GREE(K6]QO<]>=
M[G[DQK+#;C8]MEB0"%1*^58!%3``M9RVY.W'CQ^8C7:=B]D9M-`Q\W-HIIL!
M8%[;+>%Q<'(K9B$IX;\*T+E^<@;$G6+5C_*=-R8"#EM5R?R5K3R3SZ*-6VC^
M/^-\I80:DT:AAU=X>')VIXE;$;*;7?MD=XT.Y'*1I4:5-IR]V7]K-F55BXN&
M``Q9?5NL4L"Y9014"3QY\R#&T$;:Y_A^7>+WX4]OR.X9W<BQ:L*_X?%I94(K
M5+"IO(4<_2])2.1DL&AM4+D/F7;8K4K990V4QU3+$S1(^'E10ZJJER91:JXA
MZW7366AF38D]QF!B,L8DBT]K4_LD(YKLCMO9L'.Q/3RQ;=<#PWLEF`')376.
M.Q$$L48)!^H`'6'WKW1W7M7</7[<<?%QV'J>6D*B$DHZW7-S/(-(""U&MD#R
M,Q!VP^>9$F?S?=291="^MTO`<S7U4+4NL9E_65^BWO$\MM;-6YERY2$KB^45
MXU>Y$)'=W7O^KN2]Q*E?8T517ZM7<!6Q2`C%*L@<AQ`'F^J?@1KT?V2[V^[+
M;+#?^'O[.;D6WDUBK9D89XMS)/E,H02=U,_/L#UXYKZ8TZ::=--09"HT!U5!
MN1`D54+W]2HC'*J%[-<OK7_SOT7]/]G55^H=>NK7V0DQT/7I^OY:YE\Q2H<S
MX[YR6#3U5&-F&WS/QJ%VF?7/0R<:RP2(<G5I$L#C2')$-CA(*(QHVL"J,9Y=
M>H=F1T]Y8'-WL/KU;OPY?^>""*Y`W!)F6WEMSKP7W/95;^6/=S3572HQ,C:O
MU>._X4@J;H8CB0`1"``!=A.N6'T8^"NF.<SJ0D"TQ&"OCUDX<N51N'1YBDIH
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MJD-)0/RDJ8\>33"L>4#P&J[5[2[_`-X]LI9CXYK6NYI=E9>(M-?$A6'*!Q*(
M!+(.$G<EOM]\U7N6,2YU6]@1AY\\.J832V$^)<S!AF102"U]00MIHG5,V<)L
M:')+"AJ=\7S16C<Q$IC^YJ,I11B8[$V`MY`"HD$B6\J<@/,P#-'*.LZ9GL3+
M[>_XKN.8BK253[UF#L`P!*H2]O!F`5&*)R*3LI&KJR7.6=Q>;OZ2=-V/*D*?
M$FJ[)ZE*B'QQ7D?52:V97DJ[.OVVM6&I;`$WQ@OI9CI*M[D7W#\\3+[%DYN3
M7>BTXCJ1]XG(W'S`@\E-5<[%?,+%CPV,;'MONW![5@W8EKY7<:W5ON;>"XJ^
M0JRE'6^[C+*_W9H<M'F\PFTN,M9Q[E;KAVVV6?S5W!_Z2:*L$ZCJ9$VTH;^3
M4XM*[0S<_JB-SNLL(/K,S\1[DCD\B$55\&=\SNF)W'+HS:<*RU'_`!B-YF`5
MT#62@>OSU@['D-QL/$ZUG8>X]E[=E=LR>YTT6T_TVQ!Z:%GKL*4<;&KN/I7,
ML,.!/$^9CT&LFZ^T+RA;R/\`$^68IF6LE7U&4T\.+QS"`CCR8G[<E;&6;Q[)
M8(:^/@DP7BC7)W8O;MJ\.H=JI'XS$(*#S6(3<3L#/(Q</MXGPZZW_<\AO<&2
MW].[BI%C>2FU1C*-R./$<L8Q\.8Z$2-0K3YQ^E8E#6);V9%A0)=?^5@8]A-D
MPH=S+<``H]79"`7-7)K*95*(@(\M'-<HQHBM*-O5U7N3VR^0WHH.;`Q:0`2H
MDRRSS7B&D$K\3X$ZMR/8_ONK#K_$V'TD9>6.&8JKF``C`&IRS)!57D'BL$,H
MU@'GZOOZC1-R-W46L;61LW1Q+.NGY\+RV$J%15E6J@II88U+N65TA&@;&FN;
M%KG,\JXTA3%5O0>W[,>W&_&4.AQ#:Q5@YV!=FW82U7(;\E\SS]Z%XC7&^\:<
MS&SAVW+KL7N*T5JRM6)8K6B;(0$OXF%XO"5Q-#.6:,S_`$%$@P,C'K1$JY!)
MG(>>KJR)(O;>@A75U29J:VT9&LHA9%@:RK9DJ.HJ:,Y892$8S^I4:SK2^WG>
MS,-K<P!CN6(57*JSCC*F``P!FP^8`$[;G74^\ZZJ>VBA36S-FUJ@-CUK8Z5-
MSA@2Q925BA?(20-]AK*WRA.G&ON`915+.+:_16H=(ERFQ:RUF.KN&OVB9,N,
MR'SAXJUB%C-C'J(CU")(#7*QKB>;M3[MKK7'[@@A0G;4@"643D\@%?K:IGD+
M&$GF1)`C71?EU=<V9V:QI<V=\NDF$=N.%P8O4-J'!'%J4,#TP8!,GM[CO+_$
MLQYN>]_^/T_D]_=7N7]OC]U<JM8O=?\`M1.O#<V/QEL=/4;^)U]8]KG^FX_(
MDGT4_P#"-7)UBZSM.FFG333IIITTTZ::=--.FFG333IIITTUY>]@V/(1[1C&
MUSWO>Y&L8QJ*YSWN<J-:UK4[JJ_HB=--?CI^EN8M+_\`"$OO2+\`?.NSTU1_
M&E\QVL'8_7W+>0*^)5\Z7E/:HM9EJ6Y5@_R:HNBK%KL\+^X&40-A?>)AP*U5
MIJ<#TUY'ZCTU^NCC[C_%\4X7'\9<<YNKQ^!P&;ILAC<M2@_&JL_F\_`!64]3
M!$KGO2/"@QF,17.<]W;R<YSE55KJ`F3)ZZO#IIITTTZ::UXY/^L_FSA7E?AW
M@SE?FC"8'ESZ`F6-?PU@])<,K[WD&?5R*^'*AT0GL4#Y+YMI'C@84@G2I!$$
M!"$16HU4*2)'0:V'Z:IITTTZ::E+"P@5,";:VDV)6UE9$DV%C8SY`HD&!`AA
M?)ES9LN0\8(L2+'&YY"/<UC&-555$1>FFK!L>8^)ZGB61SU8\CXN)PI$PG_4
M\_*Q='5_X`WCI:5-&S;-U+9+J<N9+0N26.8TK@DCN1[7*BIW:K!F/'5N?.7.
MN<^F>$>/.>L?FMUDLER?3%TF7I^2<\W*[!^=)93HE)=V%"V=8K!@:FMB"M*Y
M7%5YJV9'*]HW/4;6A$&-9LZ:IITTTZ::Q]RKROQMP=QWK>6>7MKGN.^-\)32
M]!K=CJ;`-92TM5"8KRGD2"KY%,5W88`":21).]@@L>5[&*U4`DP.NL)?+7T-
MM>>>';'G;D_AFU^:<5<6ES=<:TG)NBBBWD[AF%#CR*+DSE*@)75L/B>RU`&2
M)[:*1+F2JRL4#IQ0R7FC`:$`&!OJP>&/LZP^FN7HU9\Z\26F[^5*B'>-UGV1
M=:`.5XWU6FA"F1*_+_.V>D5<W0<Y007L?TVFE!^VY:.QA&P9]D=JB:U4K`W^
MKX:OS@K[9^=?HKE7G7@SCK9R&<S?..OL\CRIQ=KJ*WQFXJAU\Y*Z/M*C/Z*+
M`FZ7C>]E*C:^_@-/6RE5$0B.<UJM"I`!/0ZVPZ:MTZ::=--.FFN!'\FW'_\`
MUB^O?GO$W_&DC>8^+&XY@E=IOE;X6^@\#7ETG)<IMU-%JN7^;^,?J?C6V;7Q
M`)*DYJ+,KQ!$&1&!+EL.%::D38$_WZSK]2_QU<N\X<C\QQLMO?G]>#/IC19K
M6<H1>6N&[?;\R\1:JJX:A_/.CT_S[J86LK,JZRT7#T1\*N'H:Z2W,6TR58Q'
MF][HB5U0,`-YD:V4X\SC=-]\\];.WI)AA\.<)\/\4\=6^J^78&3-3Q-\6]WF
M]'Q3]82IA[CEW)WY:NG'>YZ,`$/.VU:/S5Y9#NFJ'Z0-4S^2W5<A9CYH'&XL
MY@S?#&XV7+W#.'J;?1[27Q<NYC:'?T[+SAW,\OQ<EN1\/[GEN@CRJ*DTIJR0
M.NLY@511$>,K&B1._37#?4_0O/TZQX)^?LYR?]B5.DH_LGGKC/E[B_6?57"F
M4Y(ST2L^0<WS=E..ZO[,K$T^4Y;P5-+O!Z"%.MU%IV).=3SQM)%$KZ:D@;G;
MI_;\-97^L/LCZ`X6I?GC"<-Z#Z6M=%\L</$^SOI*FSC;+Z]O>28).4%ILE\X
M<W\U<5XVXSE3FMOQM2\BV3;B0E6`1\]4HAD8,JJU15!DF-]OAKIM\>?3]9RG
M]'?=L*QYII]/Q\#E7YOF?/E38Z>E9"CX#D[X]X)Y&BMQ4(A8\R15ZJ^UQ[%.
MR%4LJ6]&KW_I2NK6$`?'_3KIH6)$/$)`-&CE@FCOB%AD"-\4D0@U"^,2.YJB
M?'>%58K%3Q5J]NW;IJS7)CYQX('H^+,)B:#+0J.5\8_;?)N:XX=2</[KX2S>
M"XDK=%H*>THN(\I2"U0>5L43B[:.JF6?>+0[>0AI:FB2!,DL:O)_>/MU7?Y`
M\9COGCX"J\[QII9'!V(X+F<3T..M*_Z)E?.'^-9FOL8&'@U4KGFPXJY[U5$"
M37VJ!*6-5%M[(JH-)@7%>56B[MOO.LV_QO[R'R-\<\3:&%L:;>B&FOIR:JCY
MVY*^F`6AZ?;:&$5\WG#EW%\?[_>6XG#\)9YM5&;'.UT<'G'")[FJ.(;]!K>7
MIJW3IIITTTZ::=--.FFG336KWR3POJ.#.-;W)[HV?O\`<6?)W)&MTO)=04Y+
MCEY^FU,ZTI.0=RR370"5^WE9H\.OFP1/DP8'[>R/!(D$<8(FKF()VZ:VAZ:M
MUI-SY>7W.NZD?'_'=A94U3(HJK0_47)--/FU=AA.*[\\AE9Q?D+:&!S@\I\V
M1Z^5%]@S`/G\PDNR1XIAJCWM7#;S'6._HRCJ.9.2.*?X[,E`;FN'R\;#Y3^F
M*?-U3JBD;\SYFS9A./\`Y^KI=<L&-GJ[G380#P)88?\`6['9B[A-0"R@E:T&
MWF\==$X,&%60H=;6Q(U?75\6/!@0(0!18<*%$"R/%B1(P6L#'C1@#:P;&(C6
M-:B(B(G35NM&?AM%@67VQEHKG#HLG]U\PAS]?W[`K`;3%\5<KZ&/$"WQ!'!-
MW7(5M-5@V,122WN=Y$<][FKF\/LUOATU;ITTTZ::=--.FFG333IIITTTZ::=
M--.FFG333IIITTURP^[K>0'DC)K>?YDN&QN$;J5@9:]L3_Y'K;^_M\M#STGC
M^#K<Q+OZJ[I4E4]I8Q(UX2LA72-E04@G.<35Z_OUU/Z:LTZ::=--:-\#?1/(
M.Y^B.8^&M>_!,H\B_17.&')?/S/,L_-5U]3T3+2XP48VEH9>+9=2Y\.+>/GU
M$F6.-%<E:13G(!JX@`2-8KX>ULW4_=O*F:N][+CV?';-LE=Q/I]AH-5<5U3:
M"Q\INCSE=(XWJLI0Y^\J]#5SF?A:*=)A`DCA%`KE*X+53](UK_S#*1OWP?2I
MH>;$CYGZ.^5,+(Y?IYFM%QIPJ[78_/K,^69N,C<WTM'J8//=AI*`Y[MN'M(E
M639R/SI*R(=<2"U4?3^HZ[<=-1ZYL?<QWQZS/RIIW@A0?H#@Z:`HT03QLBY[
M=2#>!'NCH17&9V7LXO9%5%8].XW>F>Q%#6V*@EV[=E`_K>H?/^S[1UUX5^;;
ME**;+214G><!@>D17D$_"=_F?L/TGDC.%%H^>J21-?!"VGYAM8(S14ER*>KN
MK32SASJ_#28409W7LZ1(;,OOW5HXT<LASXGD-&>7KU9>_L%BIR)?#4P8#,JH
M(-H)CB`.-7IRQ`A]YU\W6K7B>\:GM*`5=S=9$E$=[6#+05`/J,2'R/5A5+$U
MRL3(_1L-;.PP<1D2RGO6!>9B/6H@YM<2RAZ$=J=85*!@K^\M2PK)GK-%<8)'
M,_JC*UBM=?[;?TJ\AR57S*Y;H>)3B);Z%65W#01_BWVB]\5?B+L.L*[GA94%
MV92RV!SQ0198Y5A#*64D;I`@Y0E_+W(FE@<=/'!G8VNG5==3?GV,68&P_P`C
MHX<^PL$I@TJR+J:R#%A/DFEQ8\0,E"]PJU'B&W5)[I[=C/D@LM]BN6A2".#$
M`<BT*))"A6+$1OT)UO[?8'>\ZG"*H^+0]:IR8,&]6M69N`27;B%+,ZJ@:?+`
M*J+&M^"KC$1G:;6[NFJ)$Z9*&.3:7+":H5K&A!B&K+"DJ)]E*K[>#!:J20RI
MD;U(US?8+UDZSZ>^TYS_`(7$QW=5`V5?NRI,A@S``J3])56G8P9&M3D^T<GM
M-?X[N6756[L0"[CU@X4*4:M&8JZK]2NZQN)7BVK[Y`Y;R\OBN5Q^:1JN2K0!
M,RD;0[P%%$A4LD&IK3Q;;/`@UUQKI9H<*!)@B>6];!6(CO9&:1OBW`[=V?*3
MNH[@HJQJB'E*BY+`UM*N2RU@$E6(%7+E$-!WV_>?<G;[/;S=F=LC/R`:HLR!
M6%0BU2'K"J]Q(56K!.0*^$S6"(%V\<;'C6@WW)#=;G*$L]:7!2L[>4./@Z^'
M7Q!/T[-!4LRN^E0H7E;M?%?)LW$<^,L<;!IY/%Y8?<L+N>1V_&_!VV!.=H=7
ML-9)\G!O4J!/E\P5(AI)/0ZV78NZ=AP^\9P[E12;O2QS5972MRJ!ZOJ)Z.05
M7S^0M;,KQ4+N5F@WM5L.2],*%QOO\KOIQ8;_`-NH;NTF9&W_`!S%BS01Z/.Z
M@4:B@FG,:TKGQ#D"X;E8-"JC>V11;A]LQ2_<\>['K#>9U46+.X)9TEB!TA@"
M#N8UAY>/W/OV<*NQYN/F6E?+78[4O!(8"NNV*U+"#*,0087EM%>LOG_Z0C6E
M"RYFV.U/'F,!3555.LI)ZN-4-5QTKZ^^]4>>*,28*5^1&,=5%Y&[HX7BR"KW
M![::JPTJM"D2S,``Q;I)3<3!6&`W\O0R<S(]F>^4R*1E/9E,&A$1F)0)UXK9
M`8`L'Y(S;2W58&M\(4Y.9*ZI2KF1)5'R;#>D(L5LU\*"^[EVIYYJ>[2N_8XI
MX#S2%T$=4N9/;RDQ@K^G72N:SV9KN:E'Q3O,2>(6.2SR(,#TC]VO\K'7#5+:
M/<Z8WINMM6>OE(Y%5]1G+%+./I@KR;\0OW[=71=7SSK*@`E<85L<\EMHM/J;
M!LN`:POIT.%.EMAP[:CQY',7D3VC@F(Z79^@`D\B>37(Y6X'84L9,JU@/2YH
M(("`D"2K6?\`D]0.*23TZ:V_NZRE+.WT(6&1Z5K2I:QE5CQ5ZZ?_`)9D*Q+V
M\5&YD&2-V/EM@(FHS/L8&&+_`,*%G)5*^Y)H42--YNR=A&/'O#3"'L02HTQA
MA.5C6(TO9CWIW:/B/=19\6V))_JRC=>&XQK`05`@$$$'QVW`\?5?R^"5]PQ^
M0"I_TXQ\K^ILV?2P(L+2P((8&`(.Q/AVCZ\3U]3:=--.FFI6=^D*9_Q?^JR/
M^!S6N_[I_P#PN>K6-=_N551$_P!O5]?UK]HU'=_E-_NG^&N7NHC1P?&_*\&H
M8^HBAS.RC5[`2JBRDUQGRN+E/)<>B*^,6P=:E+)(US_>T[W,?XN3LGJ>*S-[
MSQ++O.YMK)D,H(B^!#"8XPHVB!(D:^?^X(B?E?W*K%^ZK%%X6"C%3.))FLP6
MYDN03R#$@P=AJ]RCQCF*^EHP;[=-MK[/E/!S,OC_`,+BO)3OO'1;V`#4Z$5)
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M>W555X_*8@.R,FZL>8.UC`&2=H`(@[8_:?>O?/=&$^#WK(R+LTI$@FM;$MV=
M5]-E\U"DK`&Y9F4\AYL.P9U[EM%8Y.U?&MVR\I?6-%#G.TD>-;X]E>[*Y*KL
MY\9Z&6[HT>1DL4B*K7HJ26,<5@2=;FRNC+QES*92+D5R.!*V3ZEC*#MQ;8J0
MW^R2`2-<S3=E]OS;.W9'&P/CV-6&]4!Z>/HTH[#?U*]PX9(/^8`6"MJ%7<>6
M$^]O1R2*[/1?W^67220F=71Z*C)80K65:QQPP$E6$7\8D401C$2=)5J"8J$$
M@JV]QKKQZRH_XD\1P'4L\%0IDP#(8DDA1U.QFVCLM]N7<KG_`()?48VD'B*Z
M^2N7'$$L(**H`-C1Q!Y+QO\`H<E(UZ<,5,67IOW)>'='.HHEG710/LW5]-B+
M`M7GI=(\TMTV15%)^.0K.Z.:T8G,DHQS-??F+A_C;G6KT_QB!BI)XRUHY.&V
M@,!(!^),K,[C#[:_<OZ7CUM?Z_\`2[6K5U`Y\4H8I64D\BA/$D=852'@BB9.
MGL,[,EZBUK!S8RJVOI*9\Z+GK&+.MZV\@0-:T2H\(:RAL8@QQD,QS!20O.C5
M'$C]3Y=U>2@Q:6*MU9H+@A64FOXEF!):-RI"]7;6+VW%NP;6[ADUAZ_IKKY"
MM@SK8JW?`)6R@+R!`=2\<:TUD/B_9<HZ+1P-15;_`$1,E4FER\0D&[NW4^PG
M6)14'(E_>1(E?&CEH*">QYX8WQV`'(7VO(BB(]==W7"[7C8S8MN/7^,<`6RJ
M\JPOGI1223S<0&())&P&X`W78.Y^X,W.3N&/F7GMM99J.-EG"YF(KR;+`%`-
M=;2R`J%#>8M*L3/[#[2Y,T=K$QM?@<'S'1YRPB451%Y`XW+H)&HWU4>-*325
M)X[("0%OVR7-K7A+'*\RC>USE>]&QX?LGMF/4<VS(R,+(L4NQJNX"NI@1P8&
M9X1YP00!(C83-W/\TN_9V0O:Z</#[GB4.*T&3BFPVY"$'U4(X\?4F*BI4EH(
M)D@7/RM&XNY0+45FK-=<8:VFA64?5-Q1CZS!2M+-D*V\K"5]]8Q+V6E:%D>,
M68Z?^IF>4='!8-5Q>TMW7M8>W$"96&[`U^J!7:$`\IE`5'(RP7AT,-N3K/\`
M<2>W^_M5C]Q-O;^Y5(PN]`F['-K'[Q"MC"P\!Q4N;.HE`5`UL+QW@:&CY)^6
M[3!;2GT&#H]_*HX`9KCUFUNI<WC_`)!F3]#,IWQ8L6>"3:3#.6:-7-40D8U7
M>'=W.]R[AD7]L[K5W"AZ\^S'#&(:I0+:0$#22"%`\I\3.TZ[7LG9L/$[[[>R
M.SY55W9Z<PUJ&E+W+8V2S6,D`,"[-YQ.P@3$GK'EE1V9SJIW[+15*_JBM7_U
M"/\`ZM<B*B_^7KR3+_YJW_UC?Q.OHWM^^!0?_D2?^$:KW6/K,TZ::=--.FFG
M333IIITTTZ::=--.FFG337YE?_A"_P#(]R1Q)QQ.^#_D4;[WZ1YQP:R>4[JB
M..3:\1<-[C1U'&-!30@B8=T;D[G_`&.ICYK.B7QDA')+*$C2K%*E#J6I`3R;
MIK>?X(^:/F;^$;^/?,YOF#DCC;C/]N@?Y[]%<R:VXKLU5:SE:TJ&2KP,&;92
M&RK.!GX%>VIH:^.A)!($!BC`IRE\JZM8FQMM=1N+.3<7S1QSBN6>.;.5=X+D
M3.5>MR%Q-H[_`#4FUSUU&9,J[%]%J*RET%8V9$(TC1RXH#>#D56HBITU:1!@
M]=7[TU34-I@O*0+2C<8+1N,)KVJ432^?J<0:*KV-+ZW>*JB>79>W^G336GOW
M#]C9#XKX87D"SH+3D;DO::.HXP^?>#<LY';GGCG#7D?"P_&F4#ZSJ!]E-13V
M$][%CU=8`\HO=HT8]JY5Y&/#7#WY5^:]9]B??]%RI]#6=/S3MOBO9)R+]&<Y
M1(4"RX[K/JNQ@6\SBGX#^5[8D`<B)P)\1PM9.OM/-&8D^]WD^$^R<AXY(X*:
MD8\5@;3^D_KU^HCJNH=.FFG337%'^3OE&+SMNLQ_&YGN0(7'V'U&(D_0O\B?
M+9+A:*!PI\-8RS1UMD+/3.0$#-Z7Z9N*T^?CO+*"6+FXMQ,<Q1H)7-2)MY_V
M?;K'O'&#O?Y;;[%ZK48J9Q7_``_<3/S\KYXX*D5S\G8?=-ECC1V8SD_D[',!
M$D9[Y'RR5@9&/R,D8/\`*5''LK`'X+8T5::J?)_O^/R_TZ[V"$*.(0`"&$`1
ML$$(F-&(0AM1@Q"&Q&L&,;&HC6HB(B)V3JNHM1.FFG336+N:N:N+/G7BS;<U
M\U[:CXZXOX[I).@UVOT,G\>NJZ^/XL8QC&-)*GV4^20<>'#C#++FRRC``9#$
M8QS50"3`ZZXQ&=6?2-8#^3;^39)_SW\9_/4TW*7RM\F<J-!70*F)7#`W'?4?
MT]EV)-EZGGW2GE=\5B%&=N4;)CM8"5>R7.`U?T\B;D]?[M5KCO@[Z`_E4U,;
MG+[AS6EX7^#*^Z%=_._\?5T):?5<V5T-@C9SF?[<=7S_`,F7!L2K^=4<9$<M
M=$3TDN&2#"41&A(39?J^/]VNX];6UU-70*>G@0JJIJH46MJZNMB@@UU;700#
MBPH$"%%&*-#A0XPFC$(;6C&-J-:B(B)TU'J#^RTRW":):FL70-K74K;W\"+^
M\-IWRF3GU*6?J_-2M?-&TR@\_4I6H_Q\D1>FFJGTTTZ::=--.FFOS^_R;86)
M1_8W`O.5EQ;67E+F('%UK9\ER_D3X0T=?E'8WE"RLW"O_L?ZVY?P6DXZ)$BF
M23&K,]72["M9Y3815E2&L:U*FZD?VG^&OT`,>PC&$&]I!D:U['L<CF/8Y$<U
M['-56N:YJ]T5/T5.FHM<_P#!6.8P/\CO/^+F3..:?5?0/`O$O+N>J6\O<J:3
MEC:5W$,^YXQUEZ?B"_AEXGXTP>3=?U$0,N@DAG7<Z84LT1'"1XVKMROR&MV-
MMAL5R7E;K"\C9#,;W$Z2)^!H<ALZ&KT^8O87M&=(EO0W46;5V,9#A8]&&$]J
M/8UR)W1%Z:MZ;C7*VQWO\;8N/=WQ1;?%F=)F_GWD#CZOS'`5_P#)F"%(TVN^
M@MIHN,>-M1Q#QWHZL%4DGEC3Y*R""=.;3S3P8WY\M!UYXTH[5_FF9Z_/64>)
M?HSX/P]]PYQKP=Q308:C^G^/>+-14VG&_"%!BN/`4/*59R5)X4S')Q:6NITJ
M+C;CP6KBU-<>)(;'D0903K&60'\AJA#>/AJ<^?,K_']]$Z_:7F(^/^*<YR3\
MV;7)8*;+WWS%QUD=[BK',YJ@O.,SYV8?/2+C.1ZG)NKC5,-Q8-K21V`&:'"<
M@A]-#R'4]==&),F/#C2)DLPX\6(`LF3(,]!A!'`-Q3&*]RHU@Q#:KG*OZ(B=
M-6ZT2_CJF5&KX-UG,6=L,G=YOZ"YYYKYJR^EP//?(7T)A=7EM5M)D#,:?*:3
MD6%6SL77W-#1QRFRM='%44$Y3@C-:GDU&KFZQ\!JT?Y5^3`<7_(]Q:%W@^-2
M7F]P6>C:TG-_+7S@V`1UL^^.->:N'.*.9-%A4D0*$S7&FTZ4\EO>-,D!89/)
MH@DZRG_'O,L;7Y!X<T%GL;/?'T]7=Z2/K+/Z-C_6?[Q5W.HNYE-*K?H"+C>/
MQ<@TI:EX'0R_M$1\,"MB/1[P.(YHWU?H-;G]-6Z=--.FFG333IIITTTZ::=-
M-<^N8OM2WPFVYZXWQV(!JMQAG<#\9<.4B_N,E.3/HOZ`K=?>4F4M9-8KDH,?
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MN'4CJUK2H`O!^;S)%:7^ZPCWM5&HB,:U<W6/AK>OIJW3IIITTTZ::=--.FFG
M333IIITTTZ::=--.FFG333IIKF=]H\83]GR/2S1<6UVW67@(U3G9\WC;>;R1
M+U`9NXIG9NOTN.E`J>(C-I=\:5^]7B?MSBJ$_?RKG->U>NNF/35FG333IIKG
MK\V<6<M8;Z`Y3T&@@ZV)G]?.Y%NM>>]ER967LKZRV=9(X[EXBSE\L[2SO@,Q
MHI`WME5-<RH`T<0+(C?^5Z:N)!&K!^:[F.W[&YE".U="K-%.Y.D463R.JV*8
MQ)E?NWPK:]VV2N8DR)+Y4N34IY3I+9<6'65A@BCQ&I-860U4CRZY\_1T^L#_
M`#>\-2+.YI(\F'=\,5%-%H+SY%@[#VV><DB]&JI^6IKN6K//2"7!!A+G(O\`
MD@V2B#K2M854<U</\O7Z3NFHM<Y_L7.2-DQF:%=0*-T[EOC?U6ES,=$IH*1.
M+^4K%ZV,A02V1Z\_XO@;N)[7->J.:J*O7I'LS)7"/XDHU@7#N\JB6,WT#RB1
M)$[;C7B'YG8+]T`P%M2HOW+&AW;BBQB9;>8P84Q!V(WW&N?/,_&W&\V4.SO=
M1J;K:!H8\&[%DVCJ:O1S*^(\%%*J=YHV#NHU-/:1LN8Z-7&CV$AWM\U<9K7>
MA]E[GW-$-5%5281L)7U/,R`F6#5)Y2P^E9<%%VC;;Q?W1V+L=M@OS,C(M[J*
M0M@IA$M91%93(M\X1I#N5J*V,>4RP!MG<?1/(6.@P3<,Y[)8MDF7#@6&HD9V
MKTFZJ]6VOJL_7L+>Z:591!K,?-)8@D0X54T\<:@8C5&[VY6#[<[=F6,O>K+K
MR`2$#LE35RSF%0*=H"$,UD$\C,B,#NWO;O7;*4;VO3C8H9@K6FM+<A+N*5K-
MEI8#ER-JLB4AE!000>4N7=:+G_%6:Z?3ZF<M;'LDUC+2TN(\B=*K(KDSVP;5
MU5K'BQJK2Z-K52&H9`CH%`N5HE"1;A@8WM[.3\+54O(KZ?%5(`8^>ODRDED3
M^:01,[F1JQN[YOO+M5GX_(R'-:MZW-W!9D'W=W!'`"6V1Y.+!N/`PO%M6%5'
M)84^APUK,ASM34#I*>VE#B6@PNN9PK#4NUN;BD%9U=@-XF^QDQP0%:=!#>4(
M%<TFPM`KNKSZ59<1RS*)7Z1">FY\K#X<9(B2`6@C3X[&_%O[1DLK]PJ%:.8>
M.;!K?6J!#(PC</Q4\N*EE20U,-Q]+B8/5WUX5D6DH(V'%#L@UKFQ;AUSILR>
MEKJR.7R?7&FPT2P"U7>$."%C#-'^*-[I1W!'SZL>@3?8;94MNO%'#%B.L'R'
M_$Q)4GF1K'?LME?9\C,RSQQ:5H"L$V?G;445`?I+#[P>"5@!POI@G*=[E)][
M<<JS7%M+<M#G^.K:SA:01)=U+I9,W7@C6JI73)4!U)3V<MCCC4HB&83_`&"(
M]S=3CY=>/3B)"H+++E4H84,!62NX!Y,HV,$`CX@`]#E]NMS,GN-LV6-33C.Z
MVCD[(6N`?RL5]-'8%A*D@_X6)%`J53B^GF["W,T<^T@2K>ZM`64:%;YJFA7=
M'-LX%JA!J]EQ<5UB\A1QXZH15=';ZT*U!Y%W_P`]+AATB:T8*J\25=BK!2O^
MRK"`2=MF,P9P\:.P8S]SR3%UB%W<,%>I%>MG5]OK=6)(5=]T$<AQRMQOR)R%
MGPWFV/M+J`=D!:_/9LFNMK:FRN#K(S+3'W\B+815CFU^VB/_`!1^]8Z,C^L(
MFN]RA;J>Y=M[=D-7@K2C+REW]-5:RUCQL0$&174?,8G>6)''D>B[%WOO6$MO
M=7RK4<)QKJ-SNE6.@YTV$,(-UX\@Y<86%4'GQ%$K?KCE?F3D&N:G&?$FKB&C
MR9=%/W&*MH6@PV,L(\^#=W$O=4YZ314\2N?"++L/PR.1(7D)K/$@F+/;[0[3
MV7MS'\5F5."`PJM4I;8""JBI@R,3(5.0^K<G8G6)1^9/N+W/WFL?@.VY%14F
MMKZ'6RBA@RV.<A#7:@7BSV<#]$J!#*-0-WF>`N5.2P:F1K]OAZ>)+SE6>O;!
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MFI>61`Q9)5=XH*.8BN_3^E&#<[R_J:]OZ=O]J*G_`&+U<@EP/B1JRQN-;-\%
M)_=KF3R%;7=G\6<GVNC*R;9%PF[E%AU^4HL9*CQEM\!(B5ZT]%+EPEG'B.80
M<@C0%.TS'.").S4]0[=315[VQ:L8<:AD5"38U@)XW`GDP!@'8@2!!`8]=>"=
MZR<O(_*ON&1G$/D'#R"56FN@@<\<JO"LE>1$$,>);D"540-<Z+"^9#F6=7:_
MDQJR\L!#`\TB;;2<UH!^R+G2O")"2K.#&G"/66HQM]L^M(/Q[.`%4](KQ^:+
M;5!M1=]@H=.K[]%)$/63LC@^#-KQ"[,%=MF/D\EHN<`26<U6=*S`W=0P:JT`
M3945C=%UC.CNY%7KY"6L**.96$GUUS76,B-)CRH@J\<B3%=(CQ9$6TK)E*8H
MGE$UX)H&*U$\555V=]"VX8]%CP8`J0"(,P#!(*L&@@'=29ZZT.)EMC]R(R54
M6UEE=6(((X@D2`0Z%"02`5=1$1.K:Y4JH_'VAB<J8Q(JU$B?JMAEK"/!M:R9
MF=774^;B1,[Y5A(D(+ZDB>R%,DL>DV"T;QL]HI#6Y/:;6[CC'M6;/K!:ZW!*
ML'K+.2_FD^;HRJ?*T@F"I.#[AQT[-FK[A[7Q_#%[KJF"NC57*E2BKR$*.!W1
MV!]1`I`Y*X&6'LJ.3<<:`,JP=+3W=-!LS54Z:LJBY+S518V(`TR?AFDS:2UL
M`!`8`S`>C'*I7O.%B]:D&[MF:+".6*];%>0$-2[!3RW`#*"2"01\`%)UT;#&
M[_VLTJ>.=5:BN49IKRJD9@$V)9'8*K*&4P3R)=1K87E)R<5\50.*;.0B\AWE
M1076[J:]]S.B,NT>.=^7!L2S'&)G*B<D\$04>$9LHYFR&([U?U\[VH?U7NS=
MVJ'_`,[JW=:F/$'CT@B/K8<"Q+#B!Q,3MVGN`_\`3WMU/;N0W_S[NKK?(1>;
M#GLTJQ:?21O45`J-S9@XGCOJIG[]U!)^<;BM?2P+"#F#NER<Q;*6YDP0UN1M
MI"V(CM("%+$Z!W$QI`.<;S3OV16KU>1CC(7N5-O-JVM$!U\H):Q1$;D;[F#M
M&O.\/-.'9V/*H-27)09-3RY4+2YY`[*1QV$J29\-M;P?4V"@\@T>%Y'R%U-2
MHL+<$?:ZG+GJX@,[+A5I+.MM:@%G$@.27NY'L@$8J^JJEF<O9!O7OPWM7N#]
MOOO[;F(OK*A-:.&)<$\2K%2=JA#CQL4#Q&O6?S![/5WK$P^^=LM?\,]H%]M1
M0"LJO)70.%WR#-9'2EV.W$[ZH<MW@,I6T&(S[I%;(T$:917,2@V=%GFX+):J
MG=9YK/#97N]L>RL9+%/+4K#D'$>K4*1DOS;UO:*&R[;,[(AEK(92];/ZME;<
M7??8J!LL$`L)@%(UYU[DRT[=13VG")K>Y6K<5WUU_AZ;DY55CCN&8^9Y#$(8
M#,+)%M<>U;<AEJ[E"[A/F;&]H\K*PDL5E.N)N7J09@U)-VYY<F2((I6@'YQ:
MTL9@%<QAI7@GNCD3)[C;^,RF[70>.'798+1Q"AV+AA4``3"?4X8GJJ3Y6&L#
MLN/_`$WMZ>X,M2W<[::3CD,SM4@J*->22`#8)2HJ%D!K(\R'5O5#QGOK'0W4
MU$H:X=>DY1!/'FV\XS6RJ_&4_@T<<5S<32EC.:I45M6*:9")ZT1<FX%:%QZ%
M_P"(8F.A"CH;&\>*B&Z?64$;ZPL8J^8^;E/&(@7E`(9V.ZT)X!W8E8G_`"A:
MW(<1K<[YUTI[;F_ADMLAAR[3D@@X0H<7\2MBC@<?;857"2,<1GQZU::KDK%:
MPR$8,4='JY5+Y<5[CQ5I[%FBG=$QMY,DS=7R,CJ>3#E(B2T1M'J7LC.?(]V=
MK;(D669Q"A1"@+C7A%@@PO!&*`-(`0$GS3V]RRJN9SJJBM5:*I_I7MW3_D(_
MZ+XJY.__`,?7AN7_`,U;_P"L;^)U]8=N_P"0H_\`5)_X1JO=8^LS3IIITTTZ
M::=--.FFG333IIITTTZ::U[^K_I+C_X_^<.9OIGE"0H<3PS@KS:VT<96AEW!
MZZ,K:?-UKWL(W]VT]V6/7Q$5JHLB2SNG;OTU4`L8&OR<9WY[^F^'/E'CC^:_
MEWA>5]`_1._^DG?R#?7'#@[J!FME6<&9KBGDO._*>*Q4ZQK+F%78CY\_RJFU
M]M6I&_/_`!PHY/[]6)&T^>II4G@-A$#6/-'KMWL+W)?;7..?O_YB/L/DKDS,
M<2_+7`W%$&ZRG\7?SCR!H*R[Y"K\/E]KKG5.8^AM7FZ7"EG6%I5@M889-2I+
M&4`[134:J`/I'E7Q^.NYGP[RS]B_+_%7*O/G\VGUGP-QA9\LZH.@XOX+/8<<
MYBDX-SP/R$E9FGU$`K;?;W%L6RB@'3QY5\2"R&-4F2I,H_A74;!28K!UCO[-
M_F+Y<SW"5IR)\6_*^\M,!9;#CWC*']F_5--8\`?->0M>6]U5<9YOD&KRFV#5
M\O<DXW-:*Z&>RGOJ*2BCQA*5T\C%1CVJJ@GS']6ME.`(_P`??QB\5[[D;Z/^
MVL)K>9N<=!`Y&^D?H[F7E++5MYRWR%$J@4T2'BL<*V=&S>&S$15@9K+444C*
M^$Y!-0Q7O(]JT\G,`;#7*[B+2\Z?R_\`\BO/?TEP1*L<%\M?.E(#Y3X`^BMT
M&?1;#AR?I\O$N_I7?<"<&Z//QKB']+\C1+ZMJJG5Z1L.)E<PGL6'/E2&0QM7
MF$4`_4=?IFX'X+XP^:>),3PAPWFA9/CO`U;JVBJFR95A,,65+D6=Q>7EQ8&D
MVF@T^ENYLBPM+*64LRPL))I!WO*1SE:B)),GKK+O35-.FFM6/M7ZJR7Q7\S<
MH_1FNJ+/4MQ%5#BY/"4+4+I>2N2-5:P<KQMQMF8Z(\LB\W&VN8->'P81PD.X
MJL<T;DZ:JHY&-?F^^O/F;9<#?)_S<_[#M8]WI/Y*_P"2CYCT?\MW*[[M]%DL
M[QY:R9-CF/GI]MV8V@^>N/5I:G(QTD'9#1K)!'O8MDK4:F5I8\?`;:_68,F;
MRN;881*/-X_-T;2#*-T"GS=#FZ>`CF$8]JQZNKHZNKCHJ*BCC@CC_P#-8W]&
MH/XZEL;M,=R+EJ+<<?:S-;K%:BO#;9K88Z]J]/E]#52458]G1Z"DE3:FVKSH
MB^!HYB#=V_15Z:1&QZZN7IIJ1L[.MI*VPN;F?"JJBI@R[.UM+*4&%75M;`CD
ME3I\^;)>./$A0XHG$*4CFL&QJN<J(BKTTUP!XJM:'^4GZ0X^^J>:YUJOR3PS
MN:,_Q)\BUH3:Z?REI;8VI;BOY`/IW&9^+93<G@KV+03W\91-"&+6PHL%;@I?
MR)<<;J:D/D'$?5XG^P?VZQ=_*)Q5.H?Y%/XPN8?L3GZ]U?Q/<?5FRIV<96=)
M08GYXX?Y(J^,/\A^84Y&`LZP+N]#I.4ZB:63I-#*;7Q4CQXT:'!&\ZR:ZJAE
M"%'FC_7KLKS#_(5\2<$`$G)7T_PU67DZ*V30X:EV]+L.2]<0\5DNOK\3QID)
M5YN]C;W`RC2#$K:^2>8\K&A:]7M16K`K'H-:=?)/WISY]0?R)\\<(Z3BVQ^>
MN"N(/E_B?E/%<<\GY^/"Y[Y(F\UZRY#1\E;**.VD+QC64=3B9D),L01;,!;!
MA+-\:4B00-7,H"3U,ZZ,_0OTSP%\H\=V?*WT5ROC.),)5L)Y7.NMP02V<L8U
M(RHS=0SVW6IT$I$[`KJV/*FG=^@Q.7IJP`L8'75K?'OUOQ']Q\!9+Z4X+77D
MXPW$[40LW+VV2L\9<V#<EIK7*6%@*GM6H=]7*LJ<SHQVJYAA=E_I>CV-:,I4
MP>NMG>FJ:=--.FFN07\N7`"<B\>\<<MY_C^+KMUQ??V%/%L\W\O?.'T-S#3Y
MW7`CEFFP.I^KM-2\(_/]/`M*.--NMA<0[85=%CM<@$7NY6KT.\:W'^'>?Z+Z
M1^:>.^0*G2YW4VM=`=A=Q.S')F/YE@1]]BFBI-/!E<H\=T6:X\VUXR4!I+";
M0PPT[II2,B=PL:O35K"#&I7ZXQW*SZK`\T<&CV>GY-X-U3='7\-4G+6;X6P7
M.%#HP_XAI<QS)K[_`!NN?(QF+H[N3J(<(*1OR+FGC-5_=6JUJJQT/36O^X^W
MM-=AX>^BN"96.UWP=9Y,G(VTYYCQDM*?0Y6!<WM+NPE/87>:T^%D8FKJV2:&
M/!H])8[712H]6,,`(94DC50O@?JU"X.^6?EKESB'?'Q6HYZC!^A-_EOJ"W_S
M?>7-=S1@N3X.VF:C+<C4$ZU%)T-',@:?/I$KI"GLZ4M?3!@0G%K8S1=-"6!\
M-M9UJ_@OYRSFOX-VE-3Z>G_\/.)P&(Q6=C[2\;C;"IXBK]O`XIM-O22))1:S
M0<;,Y*T1JR=*>I6R;@YCJ9[0N"U3D=_GK4C1[/AKXWV.\X7^:;V]VGV#]19N
MBY`PD_FK<7>BR^H'5P+BIXQQX>3M/(?6&/,SM#<5^4)(?.%)N&PHES8,6=`4
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M_P`A`KV/F2Y$>(,AV5U8%),#6HDKE:JXR^M>$OITQ+"G^</Y`>"^*.(SW%Q"
M/!3#<_T5A?[WYV7:`$25"H7<RXCE&[S3I9WL"*_I*:M]KS6$9O35T;1X@ZR3
M]<V\CZ!OF?`F!M)T6PY4RK;WZ=UU0(I&\6?,,ZP_:M'GS60)</\`:.0_H@`9
MF6SK&D_+C5[[:Y&U?VIC2M47;S'6^E765U)65U-3P8E94U$&)65=;`CBBP:^
MN@1QQ84&%%`U@8T2)&$T8QL1&L8U$1$1.FK=3W333IIITTU:FRWF'XYHY6GY
M"V64PF:@L0DW0[+15&8HX;%*("/E6UW,@P([%,=C$5Y$3R>U/]53IIUUJM:_
MR$_*`9(:[%\B67-]Q-BFDU=5\Y8#D'Z#=:>AYF.CQK?B',:_,QI+G1W=FRIT
M=%3Q7OV>Q7-7<3]FHTKZ+^@M0&I=Q'\5\FR!6\8IOW[GC?\`&G!]!4/?'82#
M^[U%==<G\I`8\Q/$[$S7O"C'?VW+XHYI`\3J;9F?NK7)$+><J_.?"L,L-!VM
M)Q]QEMN9M!'EJ5?8>DY%W>RXUH6=HZH@_P`O%2&L(WR<PC5\$:>7YZK4;YAL
M+.L!`Y'^C?HWD!Z2@39SX&XJ.&H\^0"QDV'K<'Y_S/%<P4&3^1ZI(/R7,EB;
MV-['*YRM4GX`:S3DN+<%ARFE9S/!!8R3OE2+FRFV>AOY$@D6/"*8^@T4VUNS
M$+$BC8]72%\D;^O?]>FJ3K('333IIITTTZ::=--<U/M"^V%5REQW#H=AMZ.@
MG9X)M2;'VM_7!Q`8^@E1JC8Z6;3Z.GI\YEI%Q8!E2Y=T/\.6;/1HOM_"=:QS
MM7KTUTKZ:LTZ::=--<IOEZCOG_8G*>YM>.!Y*OU4#D=]994E5!J8Y$9ILC'C
MBU,<`'S63;RNK&V(T.=ZFG$EG;_21K1M7MTC5R\-BL"_8^JTU5Q_RWA<MJ'\
MFLDSKK=V>BP&MN*O13:"?=1\G*L"Q<Q.T$G(,EL<T;E%&C1`M\!E1K6A^F-:
M@?26VLM%_+9P=AM+JN'0\?XRWXHAY_/\O\F,XFTUQM=(K-[+S/$U/QUJS:3G
MBRK;?%9?14]+K\^ZNCWL6:0,\``,85JH'DG7?/IJ/7.#[:<Z#229:-$9\KE#
MCV/&:K_)D:3*XUY.KHTF:`2ND'A1I,AI3A8U2%CM>UOZJBIZ5[''.\)N`,6X
MGY@74D@'H"0(!.P,3KPW\UB:<5K-B6[AC`?(G%RE!8#<J"06`W*@@==<GY\\
ME]"_QBO]'^0LFDN,3$[NKRS)$F08UGDYDK\?\2JC6$Y9GX;O[48,X#FKV=.1
M1^M5UC'?\59/X;CQM/6`!"V`3+$#CRZL5/\`L;_.EUQS*?P%,?C0Q>A?I+$D
MEZ28A`S<^'118I'6W:T,#9U;Y$R))45_6V4S\&TK&,AED28@9<8\*=#C2!HP
M=I%(./9B.0+TCD$GFBHC_/,SZK0JNDUV*)5MX!@@@D?RG="`1(.WA&L[/?CE
MVKLBZBQN+KL20&!5E!&SB%M#$'B5WVF:#.RUMP?NVP0+F+(XDQ^:I;B<*YJ*
MC39*_GZ*PN7+7MD'J']_VE[#QV*A(,L*L>Y',&K\BO*I[[@<V]55^\=E'%F2
MQ`@7>`W\P()V93(V)C#N[?D^TN[BE/P[N/1J1V#HEM-C6L_EDI_(0RC>MU()
MD*3GP.<D\M6_&NBX?,^RNKBWO1U'[C=2ZN/94.LD3H6K@Z&2PP2%@T]..7)0
M@O,3/!6C8\#E<WGVR5[13E8W>1QH1%Y0H8J]8!K*#XLW%8,$^)##78K@V>X\
MG!SO;)+Y5ME@3D[(&KN++<MAD$JB<VD2!$*"A)%Y_7]YGX5!7<;90-J<.:NJ
MV7=UYTG0@"D6EO%%;6%Z>3+FFF6UBYC1/[#\P5S6,5R-:Y&87LZC(?(;N>65
M!M0A2()A5/$(```HZ]8+R8GKM?S+R\*K#3L?;A8RT6J;%/)0"[@.UA)8L[=#
MM*U@"8!`MWB'7`P?T9:W9[NB@5AZS-EM&53YUE0**SC["IC0[&)^T36NIP?E
M"ARE>KW!CE]B,<]6=\GO&&V?[;2A4L:T._'E`>5-;$J>0\Q@LL1)$2!.L'VU
MW).S^][,I[:4QS747X%GKAA<@5AP;R"0CS,*>4$QK+W.W$L(_*62T,@MC.X[
MTSJJZB#ARXP@[.[L_P`2LE<=G#(`VPLZ#(^N+:.D.:@Y<.8$3&.151FG[#W=
MQVJ['4*O<:N2F09K5987"#"O9YDCJK*Q)'CTON[VW4_N#&S7+OV2_A8.)`%]
MC<5.,01R>NF$MY$0Z.B@'PU%YUV+E#+QU).LY,&CA5EW?6=;N:"NB66UI+F)
M2.IHXZ]AG3JFM%,15$`3A2)!?)[1D:Q_77]APQ(S+U066,RHK5.2*F4MR,]&
M:.I,@"`2)&O-O=W<SP;MF(]C4U*EECKD5J&OK<5\`%GDBANB@AF,D*P!U<4N
M#'X7RUE06D,)MI?K.F;"<0MU,/3Y=+6RMZCC\LJP=^0D4,R.*79^OV1G2.P4
M3M#[+C([=ZRER*F(PJX%8A0&?B%:V!M)!*I,&/-_/K-LI3VMV]\/(4'NMW(W
M,2[%*N;.F,2V\`@/;$J6A!_E:HN4::*:LV.D%7V!XMC(#@:*:Z/'AWM]'>L&
M?IY\4KA)*H*"VEHR5ZVJOY88X"B?'=*\9\LAU;#QBRJ5!M822J'<(#X.ZB5G
M^4LP(8+K%[<'K:ON><$=U<C'K:`ME@\K6L#$UUN8>/YU1&4H;(W9^0K0:<CZ
M2?.G&+8)PSH+03FJ(I7UMGR;QK(+(L+<PU?(NS6C"R3>7DWM,3Q[-1J)Q'O"
MH_TVJM%`K_&HI_WEHN``4=%XPH_W=>K?EID*.^7W6N3=_2[''0GBV5BDEG(W
ML+RS3(\^VP`UVZZ\-U]7Z=--.FFH,GV+'.@?^]4)?5^K4_N>#O#]7(YJ?U=O
M]45.KECD)Z3JRSEZ;<?J@Q]NN6M]!-#^-.5Q_D(LL]1R/(/8-SWX,<UL;2\?
M?N4Z+2I>64RQC+;H9R/-)`>P5%(K(Z%:QGJN/8K^],0QY`](`YR>/"[B"W%0
M#QC8*0G26B3\^YE+5?E?W)>7WK59)+>GQ!<VX_)A7ZC%ASDRSJUGU0G(`<UM
M'0VMY5:B:ZQIFDK)^MICE@6!9S"7&>LGU\ZPS4Z/(C&EYVTM,][HCW(1`^WP
M55)[._I>-D4T6U(%>'6MA(CRN)`<$$!U5X8;3$](UX3G8>1EX^1:7JFM[D)5
MBPYU-Q9JF!!-;O7R0F>,QUY:EX6(@W]1Z1R2U%KQY&APVWUZ]U8&942+Z/!@
M9BTF,>P<.7&;.<'/C$(OYC1R(Y#M0,56WOG68]O(@/5DDGBOFA@A)=1X@Q-I
M)'$E6"GD^HZNU4YF-Q5C5D82JOJ6>4,AL"K4[`PI'*,<`'F`Z,X"5QF+CW(Q
M]-`)QWKIAIM!M?V;/2&5<V1-LPR@D?&IKNBCUSY3(>@KYGK7N@$;(0IX[R/]
MGDNE[CEMC6#N6(H7(HY..0`4@[LKDQ*$3X[0K`"-=1V7MJ9])[)W-B^%E<*S
MP8LP(,)96%GC8K1_+YI9"3RG5L<"9^AXJTG/O.EB^%MZ7@=\V'48_/:(]C7Z
MC3[O863*#2V,H->,U9D\V%@6EG*-SD,QK$>Y1D\\OW!D9'=L;M_8:^5%V?!:
MQT`*)56O-%!,-8^\+/0DP)$8'L[#P_;N=WGW==PR\7LY94IKL++;;D7-Z=K$
M*"M-0B;(GD``3Q:<,2.2MOJ[O5W&XE1]39WK?S'7UC(EUBTE=9U,ZQ99YJT`
MWUP\31,K`,,0B2(D&-9`>P:JGZ[I>V8.)133@@U55[<``W)E8#BZGK:W(P!#
M,R,"=<J_?>[=QR\C)[LRY&1=YO48LOIJR,W*IQLM%?%0Q/)*UM0A3&JHZ]K(
ML+A.5=ODS:ZIX]M'.CT=*ZB-!BMIL:DDTN0)A;#2QQ1@O$J0@2R*]S3(/U^9
M&1#'M>S.2B%L?)7=FY`GE9$#HA)(/F*C;C,P#D',HKJ[59E2]%>$^U:>F5'"
MB2Q$M:``1Y%<R0P'&2-EOG_Z1LL_M@<9Z/-H3C'6ZM<3=YJLK?WBPQ/(TF;1
M0L]JZV2=RPM=(AWD]D:7^&GD,$(,A(P_6Q7\Q[A]M59&">YXUO\`\]*:?55V
M/$6T@,7K8#>L%02O+J6*\C)CO/9GOF_"[L.PYU$]AR<CT'J5>;49):M:[E)\
MMQ6Q@K\.BHKBM8$XTR?S??+S#R9$WMI0:RLXMTXSZ"ZAOH+2?M+.DT4NPH*J
M4R(YMK3QK`&I='L'M8/\4$9P&*PZL;UM,OW+CCLV*_;TLJMRJH13S45JR`.P
MGRL04E!OR)Y&5DZT/;?8V9_U-GU]XLIR:.WY`-CKZ;M>Z6,U:&/.@86E;#`X
M*A00\#4YM<=H=OHBLB2Z*5+N9,+/"@FNL'71TAN?)%""E$.S$ZN="@U!`L:T
M#'HQK0#8Y_9BQX69CX.,"XL"("\A;29VD\N.\E@9F/YB8WU)W7MF;W;.(J:E
MK+66L*7QU''?B/3YCCQ5"``H,0B@F`</RZ`=O=0\]!*C:?,ODN`^SBEC'MK2
M56DN+/7G#:5<=KC:`S1+!BR"-?$KHS([^Q/8Y^Y3(--+9#C[ZV)XF0JAN*U@
MJQV03R8"&=BPVB.:MPUR<I<*D_\`"T3',$%W*\WN(=!O88]-&,I6@0^:2=R_
MG:"ZOY[XES=2&ME!S.MKKS37,ESUF?@W>0Y`SN5KJ",WS]1RS*>6:T,JMBQV
MH&,-?87PZXOW'8+/;^9DW%@UM)5%'25LI>QG/PAE"#ZCYF.PG7J'LFDT^\>V
MX..*V7'R5LM<_5QLIR:Z5K&\$LCM:WT+Y:U,M&NW&5_]V,Y^KE_]A5/ZO;XN
M7_D(_P#Q-\6]E_\`B3KP[+_YNW_UC?Q.OJ_MW_N^C_U*?^$:K_6/K,TZ::=-
M-.FFG333IIITTTZ::=--.FFN+O\`(_@$^TOJKXC_`(^+*IN;/AL6CM?MOZT0
M()X,Y;<5<$RA4O$'&-]8!0,67'Y/YSO8AC0D,A70L]()X*B(Y*:O4\5+>/0:
M[/($*!_'00T`@_2@$8WTH'Q\/5Z^WAZ_#]/'MV[?IU75FL.<V?//#7T5@!\8
M\PX:OUN-BV]1HJB$.;;YNTS.ES[WDH=/C=/E+&CU&+T]*XKTB6-5,AS8[2/:
MPB->Y%:J"09&L2\.?`?QYP-H7;3CO@G)_P#4%2!*G*&[D7_+G+`W1V$&)L?E
M/EFXVW(,0#&E=V$&R8+]?^']$Z:J68[>&MG=CC<ER'E=!AM[F*#:8O65,VAU
M&3U-1`OLYH:2R`Z-/J;JFLP2:^RKI@'JP@3#>Q[5[*G35O3IK4/B3^-#^/7@
M?2AV?#_Q7\S<?Z^(Z.2!J*#AW$`T%66*_P!H#5%P:G/85!QD_7SC$$]51.ZK
MV3LU<78]2=:HI\N_<7RM]/?2.[^((OSAO.$_M'=5W-/(.8^A]IR+CIW`?/K,
M["RNYVV2AX/(:AW)>.Y/JZ6NF2:DDFFEQ;6*]&2V`-Y,:NE2!RF1KH_P3D><
M\GEYS?H'F//<P[BWM"6;IF-XQA\5XO*Q##:J9C+T2Z'8:&;602JY&S+6VFS3
MHB.<H^ZMZ:L,>'36;^FJ:=--<YOHGY:Y3^D_MCY-U>TFYP?QS\KPKSGIN/2Q
MEET7)?U[^1+R_%,G04B!;!3&<+Y>9-OH)GE5Y=!,CJ@U2-Y-:N!`4_XC_#6^
M6TQ6/Y'R>AP?(.6SVWQ&NJ9E#J<CK*>OT&:T5)8A<"=4W=):QY5=9U\L+E:0
M)AO8Y%_5.FK02-QUU3L?QI@,!Q]2<48[(45!QKF\X'(4>(A0`KFZ[+`B+`%G
MPUAT-'6H9!<H?0Y'#42^*IX_ITTDDSXZK67RV8Q&>J,EB\Y0Y#*9^$&LH<SE
MZBOH,]25T=%0%?44M5'B5M;"`B]F""-@V_[$3IIUZZKW335K[?&9GD?%Z_CS
M:58[S';S+W^,UE*4\N**XS.HJ9='?59)4`\6=&'85<XHE($HRL1_=CFN1%1I
MTWUA3YB^/?F3XRPQ..?F#A?%<.Y242(>TCY>`5]MH94"*V#!FZG46LBQU&JG
M0H34"$UC,E%$+^ACD;^G352Q;J=9AY`XZX_Y8R%UQ_REA\AR1A-'&2'H,7N\
MW3ZW*W<5I&&9'ML_?0Y]58"88;7M:43T:]J.3LJ(O35.FXUA'A'XE^._FR2^
M?P!\N\!\.VA#S)#[KCSBC%9>_>2>_P`Y2.OJNFCW*A(O9$'[_6QB(UK4:B)T
MU4LQZDZQY]7_`,>'S5]BZ#*[SDNNY#Q_+>'J)&;R7-G!O*V_X0Y=I\M,M`74
MS)/VG'5[23+S*R+6.DA*ZS9-B`D.>4+!D(][FJJQ78=-<3?M?X"^;^*-5P=\
M:_)]-J]/]\?:#+[$!^H.=^4^1?HGF+Y?^2\S&27]%<Y92_Y6TVJ7CVV/0RW9
MRC)4"J'3+N^\!E10JU*:D5B02WTC]YU^D7A/AW`?/?$/&O!O%=%&S7'/$^+S
MV#QU+&&)C8=%FZT%;#=(<$8FR;"4T"FE'5OLDR2$*]5>]RK741))D]=90Z:I
MITTTZ::L/D_C7$\Q<?:WC#D;+9G;8G:4\BET.6V6?K=7EKB&;Q(R/>9NX">J
MNX(Y0AD='D,<(BL1')VZ:`D;CKK@9\U<U[?X/^K]QP#S_L=!I<E>T1+FZT.O
MU%!=Z//<=X9QZ^O^J;OCSC>QQ/R)_&]\#YN)!L*6AH2)(U^HLCL*9A"Q'LZ:
ME(Y"1^GR^).OT4QI,>9'!+B'#*B2@BDQ948K#QY,<[&E`<!Q.<,P3#<CFN:J
MM<U45%[=-1:T!YE^5-;4ZKD#E;@0]+H`\FL2W^@_G#E);'78#Z#J>-^%]3C^
M)N)N.2:O1'POS*RSV<FNE6]S6TDH4UPU-+`1[?)6K@?`ZU,UMEG;$7)_&'(I
M?IGXMY(^FJKY-^4+R='X]D<I\:CW>MXKL-=)P'S1S;GJ`UG;4&1S0=+GKO3V
M+X-'57\\T\2"F2/,C5P^(@@2=80@\C?(P]-Q;]$6O\D>GWV&Q/RMA-Y?\?Y+
M(\G:JIY%S$0E[\;W/.D#(U;[ZV@5M[S0S-E2&&OFE@VM'-(521[*5)&U6&Z1
MX_Z=;"\1<5\BXC"5/S[\<\+;_'/XFC?27S]0_77V#5UDN5PGHLI`XROL=H>,
M^')YJ>[YK^;^:-_5#FUB4UE55-3(JO(,<48,:,-JA/B?'72G@S@/.<(PM>>)
M;Z75ZSD7=ZKD[::36Z31:DHM9NWU<W5U.%;J;:]G8+C+]VJVGK,Q"D_ME6CE
M:%G=7.5JPF=2GT_]&8?Y;XAO.5-S:9VN&.5`S&/C:[2"P^6T?)&H(^LX_P`=
M?\A3ZZQS_'5=K]02/7+>V[155<^2TDDC6?ZM`),:Y/?QJ\)<A\C\]\N?7W*5
M;LL5?S=/;4FFK;:EW7SMR7KMW#`L*5QW];_/-2ZZ^7>=I_"5*6G=@^8,/*#^
M_P!<@%)Y/`3IJ]S`XC]/L_NUWDZ:CTZ::=--.FFG333IIITTTZ::=--<;3?,
M^Y^D?B;[`^<:*3QE2:/=_:_U.^TC<PY$_(&/-B[SZST7(LJLLJ:ENJRTJ9^U
MXTLQK7V,:0*QJ4L@S(_IDC$0;5\PP/R'\-7)SQ\;:K#?'GTK>YV1:\X_55[\
MZ[+C/.WV5RE5CF9;C>761H\_A'Y@XIK9YJ#BO'#S\!15M5'DS+2WGBC.M+"R
M.P+F-`VX\!/Z3JX>6/I;-_47$UGP3\P?,>@^G(W)E,7!Z`/._$_(O"WS!Q]G
MY<9D:9,YFNN5LAE=%=0Z2,B.;G\I67%^:2,8_&!W_,"T`XF28U9O`?PE]<_%
M,'0$^>?IS$\_$Y#F46AY2IOL'%WIM1?;6NSE3E77.:Y^X]MI6[K,A0YS/0*F
M@SM_4ZI*BHBC`.?Y-<0K0LK=1'V:V8!K/Y*6!&R3P+\1R)#&-8:1'^K.<XD<
MY6IV><,4OQY++&$5R>31N*5S$7Q5[E3R5JGD^)_9_IT-HOY*YJ-;&XB^'LZY
MA&*0\OZ&YWU[3A<CT(@XL?YFQBQBA5&N17&(A._CV9_Q=-/)\3^S_3JDAXU_
MDDUABEU/U/\`,_$]>^8HV5'$7S!K-K=,J_Q8HG'!M.5.<"50;<LAT@H_9F9$
M<#D#YLD,0C'M)3X'4=_Q#J]48!>8/N/[4Y+AM7REYVAY!P7SUG9RHTXT84WS
M)QGP]MDCJ(ZH\/[XX151%>U?%GBTY?`#59X__C=^&>-;F'J*+YIXWN]G"_,<
M+?<E0)O,'(99%BJNL)LO>\KS]GKIEA.<Y5*<LQQ7>2IY=E[=-"['QVUNG"@P
MJV)'@5T.+`@Q!-!%A0HXHL2,%B=F!CQ@,&$(F)_HUK41.FK=37333IIITTTZ
M::=--.FFG333IIITTURV^W@_F<]\!T5>4M/9ZBJLH%K;W\_'_P""7&7A7L,=
MIE7Y'6<J\9`WVPL:ZZF`CA]AV5E?-E%4<GWK!E-7KT.NI/35FG333IIKE[\L
M"K0?37(`C&KEF^CEZQS]U55`::=K\[>\EU;ALVMP/*Q9N\N:HU*27!DSK8YF
M0YZG#'2+)"56KSTU<W#5%PXOVIR_:0.2*2+S-"35?O?$`^+6\<:(=5(?F)*Z
M7]]D3I9>1Z(]7?5LN3.C.*$\NPC2"_C$[1^FJ&>/RU@?E#`\BZK^17"\P\=X
MGE&WRF/W6,XVY&Y2B\T:_39SCZOC4-?96>/IOEZ\J\=5Y&AW!;40KW7T-Q;1
MU'XGG0934\8C5P(X1X_IXZ[*=-1ZYF_<[+)^8T"U#J=EA'Y&X[L@OOGM!5H*
MGXTY*N)K)$QR*RM<:!`*,<MZ.%$(]#%:X3'HOIWL0U#*K];GZ9QKE\N[>:ZE
M1`\8)!*]6'E!!(UX-^;@O.!<<;TA<N=C,/4V2$Q<IVEOY952`YD(2&8%01KE
M%K*8EQ256G85*&:9CK]!RSD?<^^<.JOJA2QF/3TV#6R>Y&A8K8YW,<K1O_N)
MZWB7"F]\4CU$'DV'E@<D;?X;;2=Q.Y&VOG3N.*V3B5]P!]&T_>;GSRP2Q)'@
MV^_$>5H,`^;41^`K0U55JPH-+(MU)SMY/-,C22ZR_6UE5-EHJN?:'%8RYUK'
MN&$NP$:']LD>HGD\,@2AM_J%IM?$:?2"!U$$>FG$,$8*.("E2*B)YB1LRF;C
MV:A,>ON*QZYM-=C%@3=9S*-:C.0Q9PX-ZGCZ3<3)5U*YE@\<?YK@+VEM-`6#
M+RF6O]AG;63.C5E?16=?F;$ES7RII6W;A9&WKV*28]R_CADJ*0UOL`5C]-9W
M+\#W"N^JL,MUJ5NH!8LI<<2!Y?O%.R^)65F&!'3T]C_JO9KL6^XI9CX]EU;E
M@BUNM3%U9CZD4NN[D^57XN!*,#XXDD6?SU\]Z'EB'(AW6\Y+UFHXLX^G,E)*
MR?&P\#GK99NDGH!DD`KV[D9CSB0E3^\XPW%\F_VT=W6KW%[AK[2X9,#%I2^T
M1%EWJNL()@\%#^9O"#$'?3VV^1[+]EW>XZBEO=\[)MQ,=IFG%_#UORM:)`LL
M-4HGB2I:1Y=:FR=/,=F[EEJTVCD.T@7_`.7:HLXEJM@S9&I_R+IK#E`DV[;7
M*:!&()TB8^&=4?W8'MURXM?XE#5%:^F?NZXXQZ8:%V!A9AV!A0R[;MKSA^X6
MG`M7(F]_7!]:TMSY>N4E]R.5G'E6I!9RCP=DUFUUM6,Y"UZ3*^QN+&S@82/3
MN,R%F0?NC5U#Q19`8HY$B%&".3(/^:0$2(D:*X*2!E>T)M'Z5I[=3P94K5K2
MT2YX^3<3`)V`X@LW)@W$@$CJ_P`3CCO63ZJ/;?8F.$GC4.?WL`@`E0)9N95$
MXH5YJQ"ML#PIS#?\_P"8M^`I*.BSM-B[ZXX!VT:,=5Q,FLJ6V4FEM_W9AIPZ
MZ73V,5X[,CI+(\HKE<0B()H>>[WV?']O92>X%WKJO1<NHD?>AFXAEXP)#*P*
M#C*@;#<MV?M7W-F>\L"SV;9Y;<C%L?MUX!^X*)R-;\Y8*49"+3R"N3+$<0N%
M^$^+7U-0WEVQBTZ'):2*S"5\H.9E1":FRJL?8W6JL;.F)(*$]-95KIL"(=R.
MDEDCE.&08AJ7=]\[KZUW]'K+\>`:T@N#Z8:P+6%:-F!XNPZ!2D@DQRWM3V^<
M;&_ZEO6KF;"N.I%14VLE+66LR$D%&4O6C'S%A9Q957E0;+`S==9$%I=,,,.M
MB`NM"?\`>JB_LX].C9MQ-AQHHYG[L2S.VN&T/JCE<Q\A"&\8;3%9/5W"O#JG
M&J)=F*H.+(I;9028X\1)F6&PA9<J#B7]FM[E>5SL@"JM0]AYI8X3S.R@<N9<
M\0%A206Y-%09A0X]--U.D#+.R/3GC-@5M)0CAN$E32U-:UY8CEMZZOC::3")
M>%-,,PJDL)1#&>U7&<C9VN3%QBBRZF69Y^IF;KY22@/$!01"*`!LN^'7C6]P
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M@_?]2$K!($$C@-]>`^Y*,C'_`"P[Q7DU65G\)DD(];5$@_A>BFVXA2W(*18=
MO@1KESH&V&FF-RF*&VM$:35T47/170?VN7#DO9-KG1`W1@#'`@4=.C5*8S6A
M$-7/<K/)Z^IXYKQD_%YOG(#,7,\@1L9*@[EFZ`;DP-]M?/V:+\^T=N[4!6I9
M*Q6./`@^98#D>5:T@DL``))B3JW[63.:3/X[/&_'HZ*T2Q?83&2V&T^L``TJ
MSOHW[FH2QZ4ME91XT&$?R0(@J_Q:8YTZR:E2+,S($WV)$"/)62`J'CU;B"S,
M.I,20JZPLBRT&GMF$>.)39R+-(-MP!+6#G!"%F5:T:>(68#.^KNU.WM.*L3+
MI(DYH=;JLS)DQ)W^01*E^/SD*'#EODF._P#)/'OM-$N^X$"BLAQ"E)V:0T=6
MX>+@U=USEO=9PZK0".!;U')(B-@40KO/U,`-PK:V7<>[9'MWM38E;QW+(QR5
M;U`GHU*H)).Y%EHL\O'9$+-L72+H^5I<_C;6%Y1NS#7$W==IL]*S<R?)L:/2
M<8'=::*1:78SAD$AQZJ`LQD)#L]9OQW*BJUC7KB>ZTK[EB#M5`/XY&1PX`#)
M>.*!5B)+'CR@R)'B8UL/R\LN[%W$]_RR/Z3:EM1J9BU=N*>=A=Y!*A%YA.0A
MN)\`#J[.<.-(?!!3WW%<21_TJTL*NF9&WFBB6LICI<2-?4P339,B2L>%,KX4
M5]642Q'RX\8:&<IPO*F)V/N;]^`Q^ZL/ZM6Q%BB5&Q*-L`)()86`\N))XCB0
M-;+W9V*KV@QS/;RM_P!/7HK4NP#GS`6("Q)A654-1'`NJ*&)=2PPP$W[;#^?
MI5O4V<5Y\).C0RW$];%EQ[JG+L(>B`;TFK!3H\]0E&-W@417"1?ZGHNZ9?5?
MN"4NIB\$A1QXPS[,=PQ!$@GH0#X#7+(_H5=FLR:[%)PV"EVY!Y2J36#!4,&@
M@;$$KXG6]G&?'N%X5JR<KW=<6)RI/@2Z/C?.6L41HN0BE@1)JZ3-P+;U-'90
MLY71"G<(4@T!SFN>XCYB-ZX/NG<<_O=W])H8'M*L&N=3!L,D<'*SY2[,!)`?
MP`"3KUWL/9>T>U<<^XLI"ON)T->+4XD4@JK>K4KQ#K4J%B`QK)!))MC6AM5<
M<D<,<K/;.?+O5LI]74W(HPJ)&<GYGD*3I]AIB#1SHEP^-*`43&RVE<:).B">
MQQ##<[KOK:>V]Z[3Y.-?%699+?</2$K3XK(,DK$,K$&%.O(,?)[Y[6]Q$6\K
M?4=$<`5_\55DFVZV.CD$$`."2EB*02RDZNWDZ$VVHJ:^ST^XDY[1U*W\&99%
M."PE!'-D3@UUA$_(&Z)H*%WE%FQ7/<2.7NY6JQS'OP^UOZ.0^/D*@R*WX$""
M!L!(,;H_U*T01M,R!L>_U#)Q*LS">UL*^OU%9B0Q`8L%82(LKW5TDE3)B""<
M8V\F[OBQ;DKQ+HXD^$37NB2_R7V>>A&?6NV!$9&2=*DR8<^."^E$5K41`24_
M[^1ZMK2M%`-`!_#%3Z<B.+D<O3ZP`"":E'^TO\JSH<E\K,9<IB/QRNOK0T\Z
ME/#UCMR)*LJY#G_8L_G?CMC\PV,>QYH^=I)XZGFNVL\5=/:XB,:V9C]@>XCQ
M5.8,J?7`6C:QXB^;(YV#(QGF/OUR/NBIJ^R=R53">@)'V65A28$`^:01N02"
M8.O1O8-R7>Z>R.ZS;^+8*W^]3<7`D@LH],`@R%8!@)77>;)J1V6S:E8T9%H:
MA7C:3VM8[\"/W:A/`?FB?[^R=^O`LR/Q=L;CU&_B=?8';23V^@L(;T4^?\HU
M<'6/K-TZ::=--.FFG333IIITTTZ::=--.FFO/@U'*_Q;YJUK%?V3R5K5<K6J
M[MW5K5>JHG^B*J]-->NFFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG
M333IIITTTZ::=--<7OY;OY4KWX!I:/)<+8;C_E'G*=QYO>>=C7<EZNRRG'W$
M_P`]<7A%'O>0MO84<:5<DL=UM)T'*9&N`C"W&AFH)KNP7M5J1$Y=>FN>7\<W
M*?\`(/GOI'D?[+^S?XR/H';<J?<5;QA6X#E?AW<<-W6+^>_FV,VE+B>&9?&N
MTY&S.JXTI:NTMYNDT,N5)D6-E)<QYHB2`N3IJYPL<5(@:_5=TU#ITTTZ::=-
M-.FFM(_N+X[IOK;C053%3+!Y%QUG&V?&K>1H%[IN%YO(]!"M@<?7?.'%5)<T
M,'FW,<:W-V6\J*&Y*:K%>!#(>)WBYKFKE:#\M<N>`ONGDOXFO-3PA]70.3M%
MQ[Q]46.K/JM]:/Y!Y\PG')]S?\>8/E?G"ZS,K24VXYF^_OI*V/%XPXDQ<9"9
MG*06=G*(*QQM7E0PE>OZ?P'CKOMC=YB^0ZR9<X754&MK*V_T.4M)F>MH-N"K
MU61N9N=U>9LR0#G;`T&9T%;(@V$,JMD0Y8""*QKV.:C44$==4?E[52L+Q/R?
MMH-MGJ"=C^/-IJ8=[KH=U892EE9_-V5M'MM/`S8C:*;GJXT1#30P&/FDC,>T
M"*16ITU4==?E@_AG_EN^K_KG[GY`X9YHH>-\?B=C(T6NS`[++\LUAB5V4X@P
M#1<>?,G[C@,]%H<7.L1KR+.C;64ES^T:J,R.-SFH1]-2NBJLCKK]<?5=0ZTV
M^G/NSY[^5J:XF[_4%MKNBR]OO;G(XV*W2ZBFXTR&QQ&-Y1Y0LJ:)(9+)B>%G
M\@UUKK71$DV572*66V(9HU:K5P4MTUR1XXXH^G_Y$.='<E<X0O\`IQD<')M\
M1H8,0-3?YC*>,7CB)S#\Y1:F^RL;B_[K_C^^[^(IM;M,SII8/\@Q]XU?(S#@
M%'&U>2$$#]/[B-?H&X]P&.XIPF.XRX]HHN7PG'^:I<=CLW!))+#H<SG:\%52
MU$0DT\J6^/7U\48F*0CWJUJ=W*OZ]-1$SN>NKQZ::=--.FFG333IIITTTZ::
M=--.FFK=JLEEZ.ZTNCIL]3U5]LY%;,UMO75\:'8:693UXZBKFWDD`QELYD"J
M".*(IE>1L<3!HO@QC4::N+IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG337,[[>R\'D/D'%9*K:&QW]3BI]WFHFAS_'%_DLR>ZT4
M>IKM>V-RQRY@L_\`OH["N5C9%93:&V@,"PK1C<Z,P[5Z]-=,>FK-.FFG337-
M+A2UB#^T=QEJH%91CI:WF&5HJFNXZX;SKK:[O[SB>UAV\K3\?\E[386TA*5`
M*5;BMJ'2%(Q2L;)%Z&-7GZ=6K\NW\&/]8\LT]=^=GI.AUW-5GHI0JOD(E!S`
MM?MWU^:NVNO<108?.W>295V4%O[5-DOEQX9'$+-]B'`T;IJ:=O-W<_=O(V6+
MR!]FVF5QG)O%=!5Y/B+C_C,WS-DJ^TX;X]UMC2<P;#1X27N#3;6VT1[2P)66
MK6QJ^=#&-XR(1C6D#CX3KJ;TU9KF/]XL@1Z`<N[K8ME6.YSX0<D.>\OXDDR9
MK;1XY3"CN1T@<"<0<AP2J@CH)6/1S'*UWJ'L'U&R"M#%;?P&3N.H\]1,3TD2
M)&XF1!W'@?YP"E,(69=:V8_]7P/*TP3Z5X!('4*Q#%3LT09!@\DK*/;Z_6R(
ML[0R:&I#$6UUMT48I=15U4.P!?6UFZHD#CS!RD#&C,]0E(23+EQPL9_6G;UZ
MIJ</$#)6++B>-:]&9B."KR$B)+&3`"JQ)VU\WWUY/<^Y&NV]J<8+SN<@,B(&
M%COP(!F`H@26=T4#?5(K]!?Z>^AAIHKH=730?VG+0`L9<6+*\-HHXCC3'1E%
M=69K^YF2),IK6OD&5Z([MZ6)-9CX^+CEKCRM=N5A/E$E=X$^50BJ`O0"-NIU
MBT9N9GYBKBKQQZDX5*/.W$/M+1#L;'=F<;LTB8XC5R<L[YN<B+Q;F[1X+!LG
M.47)DX-^&N#9S+F!=,=A(!(@Y3_V2@LP#+.17K^3:$51N]49['8O:.WG)?\`
MJN2DUP[TC@6XA2OWIF/,ZDA?\*#?=@1G^XN\C!K_`.G\&SC=RJKRF%@4.SJ_
M_#J0#Y*W`-F_FM/E/%"#L7\PT])DL)><2\\OBR>/N;7T\N[@OMU:S#::RF?L
MN1@UM@OBVOU-GH$"TYR^MS32QM*B>LHUYSW1=?EY]?=^P2.XX(8*>/\`FHHY
M6%AXHJ3`$[*8Z@Z[?V#BXG;>T7>V_>!5NR]V*-8O/:BUF].E5;^6U[(#,8W=
M0WTL-8<YQS6DX@I[#"KFH$"GFV6:!3R'/[6TVD%K8<&PC3;2<.29+5T,S8\^
M.R6C(Q'D*QJC7L[<]BR<;O%RY_JLURJY8?RAO3)!"B/+(E#QEA`)G7,>[,#/
M]M8K]H]!$QG>H(?YVK%P5@SL">?$A;%#PI+,!'6`2N=:\F;;.1L^0MA;46''
M7U(9YKJ;),Z9H),>/"NX4@BNDQK"O%(C1CJ47O8B^*N_MGN%HI[71DM9%:66
MRT!0!"`DJ1T()#$08/6-UL:@Y'?LO!KI)NMIH"H&+L3-A`6Q3U#*&56D<ATG
M9]Q'X"HX=X3TN,Q5X>'R_P`S5HX>AT\QM?66V)I[15AU-6!LXJ6,+,V4H#H:
ME`%C)PH95:BL`#RXT=PN[SWRK-SD#=GPFE$$LMK+NS&-BZ@\H))4L/%FCTT]
MFQO;'M6_M?:KBON;NE86RUN*O0C^5$'(\EJ8@I*J!8$:-D2=)N-MM8\=W^BQ
M6M@VL/#3Y.H;=TT*%G;&USDS,IE\31:RJK\V^)-?8Q832>T`>_[C!(5BJSU1
MW-[?N>#7W''KSL-D;.4)Q8EPKA^=K5L7D03$$_0P!WEM>5=B[I?V3,O[5W)+
M%[0[6\T5:F>HU>E17<BU0W(+,JO^966!(XH14M)6Z[CK2(^-?)'MZ@()L:=0
M'?(ES`P9R+'G5LPXW5<D$VCLB*CPJWSC/[O8YKR>V+&MP^Y8T-7-+D@AQ`!(
MW#`>8$,HV/B-C($3YU'<NR9TUW1DU@,&K)+$*VS*2.!#5L=UB5.X(+<L=)$E
MS)<:WHWQATA;^)77=7$1`Q,=JG1Y=9(J42(R246?E$#'D5SWR%.>*TD=SG&A
ME=UL^:(AIODW>F2K'K97(8-O'G$D.`(#0T<7&M'Z5MMBY.)Q&(;@MB#84VP5
M*;2162%:HEN3)R0DM4QUO]\?GK7<S:>W2O<RQE<$626,H"*P]C!A\H<=LJ&N
M@)YB8D(92@"\GF=1,1CGN8,?;S[WDMH[+53R^[&>(!Z`FB[EO\X!,0),@`DZ
M]E_+)Z#[HR,KA]^W:&Y$=65<O&X>7_9!*J3+0()(5==P>O"]?66G333IIJ!*
M\OQI'@KFN]!O%S'.:YKO6[LK7-81S7(O^BHURHO^Q>KD^H3TG5ED^FT=8/\`
M#7,7?WQ]+\9\LV@K$U@,F3Y#BUL]O[XUCEBWF!C&+#+K3W,HS%N&'>IG$D1B
M&5[T8-JK''ZCV_'7%]Z8E14*?6I+#R^*VG?TPH^F-H!`@2?J/@?><Q\_\KNY
M9"N7!QLD*WWGA9C@E3<7)\_(\B64M)@`E%THY`X;Y#X[IM"<M%8VTB_\XTB[
MIUA6>8ILS-EQ(4C.UEM",:H5VC``*3?)Z`B5K5A,:\T@SV=MV_O7;NXW5J+%
M1:]PK2KLX!(=E(#>0D\?%G\Y@*H/E/>?;'>^R8MSM2]CW;%TXM4E3%5-:NI*
M?>@#G)XI5]T`6=B,,P24''>=O-3H6ADR8BR792CMXTXP]EK8T258I1R5&UC4
MKTLQ)(M'-+W'&CL$CG/,-7;NP7]QR4Q,>0C1ZC*1]W62!R'SXF$VW8D]%.N7
MI.'V3"N[AFPSK/HUN&/KW!2WIF/Y>8Y6D'95"@DL)QYCJ:5R]R%97UW<%-0`
MU"Z?522YVJCK9#Y,J*Z)(S=?(;()(<U%@-C%0+!"KHXFHH4<,?EL<V].S]N7
M'H0#(-7"L<V/'T6)#D1'C(DDN3U@G6E[9BV>Y>]/F9=I.$,CU;B:T'(92*#4
MIDG^7B8`%:@>4%5F^][L27REX]A339[,U];4VNLGUEK";GXLW(.**KXRE1VL
M;'APUIVC).8I3B"!'^8F(A6I@=OPACQW%U%F4S,M893S(L^J\'J3RD)L"3$$
M['6W[QW1LL'LM3FG`1$>YE=?3#4R$Q2.BKP@V"6"K,J(8:SY;ZR+J<1=_.FH
MGA9NJRLD2*2UB6*K"("OM)UQ!X_D3/P_Q>\VN!$E5+?QA,A%DI#:C_<[OS].
M(^)G)[DQ%/X!W`92-Y*A3:!,[$LMFYY!>>W'78Y/<:^X=IM]D=P<?U>NLFMU
M;RPKLZXY/&/,H1Z?*!66](`\SK#W'&6B6MY\XRPI4U3J+)3=38V4.T=>-CUN
M:K,I:V%A=UAGN6ED1(<9Y1]O!IC/9&1%(_P7<]RRGIH[DC<W%EP0`KPDNUB@
M*P^H$D`]8`+=!.N9['V^O(R^QVKZ5?HXS7,ROZD+4E+LUBGZ"%!(Z<B16!R,
M:S)SGI)7,QZ:\P\D-<#&V(*S`6UO3.T\FO?:2SPKS/6I)UL\LPM]3U8G3#R8
MQ!*"7%:QRB1SVZ7L6,G95?'S@6:Y2UJJW`-Q`*NL+L%9CQ"D&5>1.VNF]VYU
MGNAJLOM+!$Q7"8[NGJE>;%;*W+/+&Q$'-G4CB]8!X@D8IFP8O-&0I)H*PM7<
M0X^JO<9$T%,6*[(Z^64-`F4OPL(4O[9?S4\Q']8R(C@%8X0W/&FW2QNR9CHS
MAZ2:UL*-/J5B7]1/]I!L1)&S`@D`ZYZVI/=/;*K4K->4HMLH%B$>C<Q%?HV#
M<\+&W#0#NC`JI(UB[C+:56)%><;[8,2+DK*X@9LLI[+B,#"[#+9@0+K71:NW
MKIA!U=8565]RZ.?V.BL'(*KR1&H[:=TP;<XU]RP23EJA>/*3;78\K664CS-N
M]<B.4J(#G7/]A[KC]I6WL?=0J]M>U:B?.!CW55`/<$=6\B&*[RK24`=I-8FX
MC82[HM2)]8.$<E+^:%ZW!9!XDJ&5CH<BLE1G`-^YT]G6'*`W8CD-#.U1,3R8
MY<9<^B_%(MY`/!\L`@]0P,^5@P!&VS#?H1K.;M&7A]P!H"LU7(><DJ5.Q0B#
MS1E)4[^9&'$"0=;O<$\1Z?&<J<';5*XU9C]'R0V*,=[&*MZTI>/MI)K8(#W8
M8ET9C`Q?8^P")PIX6,4CV%4K'</W_O&+F]JSL+D&S*\:?*?+_FUAB0LJ.L<"
M90DP"((]8]H>V\_M?N'M/=0AK[9?G0/4!]23C7E5!<!SL)-B@BQ0.1#%@>R&
M65'9G.N:J.1:*I5%145%3\"/^J*GZ+UXQE[95L__`!QOXG7T]V[?`H(Z>DG_
M`(1JO=8^LS3IIITTTZ::=--.FFG333IIITTTZ::=--.FFM6.>N;.2N.>0.*,
M%QGQFSDBRWM/N=%90T-91CQZ[$:3BBA-%98QHQ:G/#FBY)(=UG9/;#C.A-&Y
MCU.BL:N`!$G6DT'^1[DV9.XZIIG%F4S,SDEF7T%5;:2;?5=>#)ZFCY%MHA8D
M&Y=1.T`Q$P7@VT!+%&/^2Y&QT47];5>&KGTO\B&GSUAK:EV,X\?.AZV=3Y^0
M7:3"T<'.-L-]45NGT&BIX5Q03:]\G%L-+8*5"L8"ED194$#XK3R::<-2LC^0
MS?NO>1Z.MP?&LPW&7&>SU:2O\UF_L')NAS$_FFIKG8G0.CBDP\;>SN*P(DQM
M=:D"Z5('V)^,TAJZ<=9?XZ^N>0^6.5\CE,QB,=G\E/W/(V!VD?6VNB3D#,:/
MB7*X2\W=*VOKJM:(MC7W.Q-6#<XZ1RK`_)&0H9`^S5"`!JQ;O^1P%7JMQ61N
M+IT[-8CE"WJS7[I.A@R+S@S-8#E&;KN:\K$GY.-#V,/)\D\264:7%J),X#\Z
M0$X4I\LK:]6J\=M5_BO[HOMO#TEU88;+VT*#QCS+R17YGCO62]'MZA.&WYL+
MJ375I:D8(A.1W:+RHY`U;YJ!6>HWG[&-..J)8??&FS$<L:5BL-RY.9A-%MY-
M_P#/^REZ[&9U*^=Q&.OK=A8W5=3OJ@`A\H*63*AOL2.CQPR/QPK)6,%H%G5G
M57\AW).E@[J?0<9Y$DS.S>'J"@R@[>QM]%>7?*\W@J&DH`(LB!.FQJ=>82N;
M$%!8LE*]O_-#]KO6TXC6>M;]2[_*<N\1<26=%@J&9M.)8?(VNN]18SJ6)36$
MFWDU)Z8,*;919-9'KGQ5?(*1TX@^ZM4?]/FYJG$1.L%9G^1W7:NXP0A<6T>?
MBZ.EW&AN,S/O9=AO``PEGE*AM/`J9`\WXV7(C+I]QEW^N2ZQSUC3RW`&^:\(
M6J\1J^XWWC,JLM.O=)_T/OI1>'N2N4*)./>3Y]C6FTN:S''.GQ_#<Z9<9Z$(
MW(.C#MSL8"$^3+E`B,DCA"]J@&TX[Z^V'VCR=@[S6,Y*Q/&_^)8G:<D0M3H<
MKH=7[L_QOQ%)XHD\A;N;"M:!WY)*#*\H/M211.\4CT\A$(Y2,\6G$>&KIX3^
MO-[R7R+OLKJ./J+*AP^1KM,N6K;4UWO+$EWQ=Q[RK65H`'DUG>U95<@"AGC-
M@.8V7'?XR%1>R-4*P)UC&A^[.5M5KN*<+E\!QOK[7E*)F->6[X_T.AW-#@LK
MJ*#073\EKF1(55)!O<NZB:L\GF(*Q)0S_BB7L)S5>(_5K[2_=_*LK*\9W>BX
MRQV.)S3^ZDQUSJK304.0R%9'U'%6?@:;86LF*9UOEI+.2>PID?\``;*GCC14
M0*2O>%IQ&H)/OS=FL.2HE/E^+=&F#9QM459,CI;S40]O?;]_$L1;K)2$C4]U
M<YN-)Y,(2*$55YS0PD\)2>U'I33B-<SN$>"OK+^77ZZ)SK]]?/''W!OQW\H\
MJ\B93C/C6/26L'=?7.EXPY#L*G#1><X&@N;.;<\2<.;&DGWT:OEQX5?+T<OQ
M9$D#$8Z-]7$A%A3YC^[7ZA$1&HC6HB(B(B(B=D1$_1$1$_1$1.JZBU]Z::=-
M-.FFG333IIITTUB#E[@OC;G"!F8^^H(]C98/60.0^.M"@HQ+?`<ET5/H*?)\
MB9QDZ/-J7ZK&,T\R15$FQ9D>),>TZ"4C&JC502.FN-AOXQ^;OF+2Y'5_*N^N
M=!C^.P<6U,+&Q=7*Q/(]EPG\U\;\K<M@X?/H'2@4>^WWVG]Q;(=YR1H)QZ./
M*J3_`(Q&.$QZ*U?S!^K]/]0U(X[Z1_E"X93&Y#F;"2^1FU3^'\5M]?><1S90
M=#+Q?\?7+'TM]2\@5UYQXM11K36OT,'/8*A-Z/P72X,J*!AY,ACD:K"'I^F^
MVK7X&^N_H:+J'S\M\E\=<;[/Z`YQ^`Y'..II.+^5D+8:OZS^"Y.TY`Y$NV3K
MEWJ/Q1R?ELSER23O4$"CC+$GK^7X&930JOQZ`_N.IC)3?Y3OKJAXZ%R-2[WC
M+"[O)_+-QRKG::%#X(E0,']`_.G,W`_VCC*VPL2QMY`Y!^>N;851R5F6/E#L
MF1Y<6,`QT\&I73R+TZ_I&MF/FG^*J%DY^4Y,^F-M#Y'Y;CV?'/*>JK<4R=6X
M=_T=6\$6WS;]!\DP;.:"MNK_`!_UWQBRF+N\I90OVJ?<U?Y3T,\BN1JTO\.G
MZ?PUUNS>;SV-SU%D<E1U&8RN7IZW/9K-Y^NB5%%GZ&FAAKJBEIJF`*/!K*JK
M@1Q@CQPL8((F-8QJ-1$Z:LU6NFFG333IIITTTZ::=--.FFG333IIITTTZ::=
M--.FFG337-GZD^UMKP)M]UGJ?/X:WKLW@/WFF!.GI,NYNE)F[W2N)?Q8FJJ[
M;-4<&+4L5A956.BF#4OGH(4H:0GM7A9&K6F_=.\@4VCM5D\(R)V4XWMM3`R1
MY5LFLY>M69'D/4`G\9@Q6NY*H&YC,S,@.LLW-L+4+I8)_OG5B@$,K3B-0\M]
ML<V77-^<X.T63PF`NYDR;`GSM?6Q:BQL99X^%ET(H>5L>:J\T!90-JU6CJIV
MLE2AL&3T1G%]#&A41(U9TK^0KFO+5EL+4<8YB^M(^!Y1GQ-#C\QR/%QD7E?/
MW6H'QQQE8SK0TVK=:ZK(<>6MJ<#[6),5UE4@"/P,62C?3B-;%\)_2_.7(G(]
M+QYJ.*J*A',MN4WVVD?(F5$BFSW#=Y!RFIB7&2);:`E;L=!=[?*RJ<$>SLZ\
MM1.FG)+::(,$AJA``G6_/35NG333IIITTTZ::=--.FFG333IIITTUR:_D1MX
MDC>\44ZU&B>_+Q)&LMM332M/*'F*RSKMLZ-)_P`>@;++T4B37-Q4R_:4H9I9
M!,\."]K0R_UIJ]==9>JZLTZ::=--<L/E*R'5?8?T3EG7+X[IEKO+&#A<^G$%
M_E,]''=8V=)FR=7!Y!VO-D6UN)5PZQ)`E0Z*B!.LY@%BJ>/'\6KV^D:KG#ED
ML#[6VM/>:J(5MF/E@/'W'V8T6VLZ#/P:G1TUCH-%I:_9<24$&-KK63<O\64F
MA)5P&23!&":XI)W30_3J[M?\L\T6WTO8\Y9OEVRS\$_+'">@J:^NY$Y)HJ*%
MQ#E\D.EYDXWTO#5,K.*.1KW=V%*'\'07(CVD./;.\#1_V*M%):I(B-=!>FK=
M<\_KF@F:QP<O5ACDGWG+_&<%5ES8%<!(W_37DN5-<DZ=%,"(5*^,9&D>K58Y
MR.8\;D1W7HOL_(3$G*M)].O#N.P),^M2!L#)W(V\?$$:\5_,G#M[D1V_'`-U
MW<\5=V51'X7*+>9@0#Q!`)B#N"IWUREYLX\U7'HI.9M*FUK*\!8-SHK6UJFE
M9L;)9S8\9M3/_%"&US^7_%8V(T3ED26H4K&?CO:T'K/8^Y8G<2,FET>T@JBJ
MT>FL2>0D\7>?-.R[`GD);YV]U]E[CV56P,BNRN@%7L=TGUFY0.#0`]=4`)'F
M8<F`X$!+-K]Q2\.YRGO:Y0NY%L71HV6BRPS2%J<=-<&OTN]G@8R,L:7-/.<*
MI3P5BJ\DEW@R(U79MF#?WG)>BV?Z:LFP@CS6#=*@=Y``FS]2B2YC5T]VQ?;&
M#5F40>^/`J!#2E+0MN0P@0S%B*=HW9S`K$VQP%QN^88>TM7QR5U0Q*?)UD^G
MC177&PS#9DT5W9NF2/.+6T<&2XP'F-(;+,H^Q$<A$;D^X.Y!`<*D$6.>5C!B
M>-;P.*P-V8B#`'$3MTG7^SNQ&UAW3(*FFOR4HR`<[JN3!VY'9:U)92S-S;C#
M`\@+LM-79<A[LPZ+1S5QE3HIP<R=MM^*+<:&_',M`:=B>IIGU.6FUSF0U#'*
MXI0O>U[BJYBXE6)5V[`!R*E_&O6.8XSZ2)"E/AR<&6DB`0(`WUL<CN-_>N\%
M<2]OZ77>PJ/.!?98&<6])X5,L)Q4R5)!+$C64>;-WF^8^+I-I`MS2MQQI,H7
M;EIH45T352$OZ:!-TL2=&"_]:NR:@+$[>Y9$<03-<UPS.75=DP,GLO=158@&
M#E*WI;F:QP8A"#_B7=!T!)7>5&NA]U=WP?<_M]LBFTMW;`>O\1*B+CZB*UH8
M#^1O+:W5E"L""K'4;CJ%G\OS)O.2;M\6'FN/,[F77!<M:32CGMMF:8$/-T%Q
M^;%EDN;YS7-<Q)"NCQ`'DJSR0:I;W%\C*[+C]MHELG)L?CS4;<>$NZP1Q7[-
MV*K,3J[LE6%V_P!SYG?<OBN!A45<S4[$-S]4+56_('G9XCEY45WB>.I+E;46
M-[O'\SE>RUB/@E?>U])FPV@=UB<;74ZT]?2M;920#+GKR[-(8U[0%<%WDO9C
MFHLG:<6NC`'9!Y'Y>4L_'TK;"W(MY0?.J@'J)VZ@ZB]Q=POR^[_]4,197P)L
M6NH.,BBA4X+7YB`:[+"P!"DJ9V!&K6Y`P0=YD(5SG:^LM=/4YW)UEA++1V0)
M&EXXB-@Z6W=(/`D,EEL<F>O]+VHZ,]@6O:5RD$SOE]O[@>WYC4Y+,F*]EC`<
M@0EQE%@$1%@,CZA,0()UKN\]G7O';4RL%*[,^NBE&/IL#;C#C:\E3):DKQ(\
MI"SR/)1JSN.MO6[C,U_'UJ<S;:Q2YN>.[1DZ?)`Z#?W=_#C\;'=*0!ZPLZ$,
MQJ97F.QI7OBA56DCN;F=RP;<'*;N%0'HKQ6Y8`,HJ$W;2&`,"R`#$.=PVM;V
M3NN/W;`3LV0Q&2_-\9^3$<;'L`Q3,%2R\FHEF`)-:[%"+KR.2M7WTJ&.D+:4
M]Z^)37\"J&0;IHJ]A1QB0V.APB0;Z"<:$"08W$:\+7J]1$D,?B9F92*`YL"7
M5RR%O">L[F4(V()B#$2%(V';>VY!RVJ6HV8MT)8J`CD%F"OE4K8IW!`)E02>
M)<'HG\T<4Z3BKDE\>^_%!%O.(=/85PPBCQI)E'R7Q@Z6:SCO$RTA/"Z4SU!D
M*C6D+(<QO9ZN=YS[G[MC=V[9RHDO7F(&F2!]S?`4_29C<CP"@](U[=[#]O9W
MM[OO#,XA+NV6LL``G_BL62PCFL2(5M@2Y`WD]9>O(]?1NG333IIJ6F=_Q)7B
MU7K^,?LQOZN>OJ=V:U/)G=7+^B?JG_E3JY/K'VC5EO\`EM&_E/\`#7+7;/%-
M^*N9"PFC.^=E>3E=#K#2)E?'G-N<!$-5U,PU3`).&*0)1J5$F-+(]CFR)"+Y
M+ZM@@I[WP@\@+=1NT`D<;B&8!C&V\>6!'E7IKY[[J5N_*KNC5`$OCY7E0EE#
M<\=2B,44M!$3YY;D0[]=<[.>MYK\*_$X_%75E2QZ^L#M+PU#>BK17FHO9,<\
M(.C.(L']AL**GF07QAS9#HDX<LOB$GG[7>C=@P,//%^9G(KLSFM>2\N**""4
M&_(.P8,5')2HDB('B?O#O'<^T'$[9VJVRI$K%]AKL"BRVP@J+2"OIM6C5E18
MQ2P.T*T\C>VQUN>SN`SD;F/C7-<T6%!_BU'3S;MEOB]-%M[^473VIAZOCX4"
M5!B111)!$+-@$;*<%G]Y['O5<'#P\C([A8W9LFW"KLYLP7C:A5!P4>G=(),@
M0K#C)V!`UM>Y]RP\+LU">Y\&CNMU/I5HUG.BT/8QM<^MC!2H`#&;*R&*CS$$
MS.T^C^6KKC6N;Q4+7\1V9)EK3TM-ICY[11VVEJ*KL+*]CS[4\ZEO8V3DG$X+
MCR:]S^S0-9V8Q$LNQO=5/<V_JQIS*@JLS('0\5Y`*0L,IL`,PK_XB=SJ7&SO
MR^RNQ)_TZ,GMMY=T1+37:.;A&:P,Y9+!22"O)ZR=D`V&J#.XSH,#&@_XMO:R
MRTAY-_(-G]*.MR-]IK^9!L:#7:NWA2BDA:.'-EF@R(1!VC0&C+W:)H3F:Z>O
MNF1W!F_%8[+C`(`Z38B("'KK4@2A`#!@4D'J254ZP[>PX?9JT_I^979G%K":
M[>--EMC*U=USJ25M5B:V0BWBR_RA68'6`^2V>>D+KM)G;>M<5TB=^^V=8<HK
M"V$;TDM8UJX<:#9#')C^;I#I#F%5[WL];SG>#J5S,+)7\'C6(P$#BK`$*1/$
MKN5V/2)$`&0JAN!?MW=,*S^I9U%J$RWJ,A(9P8YA]E82)Y<H,DCB7<I?=U.D
MU.5X99&-$1O^"VLMI*JHD5EC+;+S^9,4MG)L`(V]+&F/:)XT4C?%KGC[D\&]
M8%%:W9>:6!G\0H\S!@(=_I`/ED;@[?`[2=;?*MLQ^W]K%96/PCF40HQFNHDN
M6'WA!@$;[`E?-`U<_%F?UDN>6)$SDBXI[::`4J2>+!LZS)6,FMLZJ/J),RQE
M5U?"_;8LY_\`<'.CAE0#F"%S4*)08O=<C$2L.]@2Y%,`$JU@!5B@`!)DCH5)
M5@K-,'EG>WL+N-MQKJH:W&L<`DA66EBKH+2S%57B&.X=5>MG52.2E,U4_!@\
MQM8N@E\G9*OK9:4-9LCU,FVU'YXZX;`Y27(NA6T#$0;>MEPS2#HZ2LAT4:M0
M2H9C^M)=WTY6$<9,6YK1S:L,%2.7^8`O$VE6!`'ECD9G8C758WM%<#NJYEF?
MC)0WIK>4+V\@HBEBX=:%=2&9O/R*"./F!U*<R$^-J+1QYVD'R3S)L8X:N+I[
MJJT,/!<=RZS\^/8?Y'8W$D;3S)EO$034&PC2VD8+0CDD[/*^[LH]YWXQKQCC
M86&2Q160VW!H(X!1L`IG<B$8R5&P%GN=ORPP\X79PSNZ=S4(+72Q<?&9.0;U
M6<B2SB-@0;5`4.T%C3N9--N<S7YR9QC9!PM-1329"+0<?L&^^;`AQID_,WMI
MM+:QMM7`S)8"J/VMF2G)'CM&$(FHJ,E[+BX&398G=%-]]B^H7M^B20'5:U"U
MEYWCBNYDL3U@]SY_=L"BBWL+C$Q:7]$5X_\`F<5#-58][L]RU%=I#MY5`55`
MVSGP1IKO?[SY,Y(MIMA.G:?D.^I[VVGNCM#J;/-\<;%8^@K`,ER'@CV$*8,J
ML<T)T+[G$$U7.:+0]^Q:.WX'=^VTA5KJQE95$RBO=7*,8$D$$3N(@`[;];[0
MS\OO/>/;G?<EW>[(S;$L=HBUJL:^+$$F`RL#!"M/(LHDA>S^6[_XSG?)$1?V
M.I[HB^2)_P`A'_T54;W_`/D)UXKE_P#-6_\`K&_B=?4O;O\`D*)Z^DG_`(1J
MO=8^LS3IIITTTZ::=--.FFG333IIITTTZ::=--.FFO"C&I&&4;%*-A!L*K&J
M1@RJ-Q6,>J>36$<)JN1%[*K4[_Z)TTU1[#,YNV"&/:Y^DLX\?U>@%A50)H0>
MCV>CTBD@(P?I]S_#Q1/'S7M_JO337S_&,UVM&_X]1^-Y()*NF_M,#M;RBQUB
M%DVB?C]K"02*JC<\OFY1KXJO;].FFO+LKF'G@2GYRA?)JHC:^KD.IZ]QZV`U
MCQ-A0"K'4D.(T97-08U:Q&N5.W95Z::JS8L5I5,V-':97D*I6A&A5(5@Q%(I
M$;Y>9!B:UR]^ZM:B+^B)TTUX2O@(H7)"B(Z.)X([DC!10!(BM($*^'<0B-7L
MYK>R*G^O334&%3U%:>9)KJJNKY-@H'6$B%!C13SG11J*,Z84`ADDK'$Y6L5Z
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M]NFFI5M#1LMG7S*:J;>/`D5]RVNAMMG1D:UB1W6*!28X",8U/!7^/9$3M^G3
M37V!24M6IW5E15URRI\NTDK`KXD-9%G8>/Y]B=8XAJ6?-\$]QG=R$[)Y*O;I
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M6,5%=Y*GBG97)V[.5.WZN3M_KTTU]1K4551J(J]U541.Z]T1%[K_`*KW1J?_
M`".FFOO333IIITTTZ::=--.FFG333IIITTTZ::D9%96RWD)+KX,HA0)%*^1$
M`9Y8S??XQR.(-SG@3\DG9B]V_P!QWZ?U+W::GNFFG333IIJDP:&BJY)YE;2U
M-=+E>W\F5!KH<23(]\E\P_O/'",IO=+*XK_)5\B.5R_U*J]--3Q(<0TB-++%
MCEEPT.V'*(`3Y$5LEK624C'<U2`20QC4?XJGFB(B]^W334QTTTZ::YO_`&?'
M?(BH`9',?*YFX@AHHC%"]OYV)Y`@*UWI$XY6E;)\58-S'.1W_$B=T7TKV4P5
M^1Z#"R#T^%M1^SPZF?LUX;^:2&RO@I@MW3"&Q(^JC)7P$F9Z`@GX^&N47)^H
MY)O>:B8/(:_49RBI;6%QQF*NKTD.7G1U$.T_!L-%7LG,)2:>=<(-94J&T$Z;
M$F&]1/4T2";ZUVO%[91V,=PS*:K<AT-SLR$/R*R$,>9`OTJTJK*)$S)^=._Y
M_?,OW4>S]MR<BC#JL7&J1+5-?!7XM8O*:[6>.;IQLL1VXMQ"\1>7)FQX3B%S
ML;F7@O.[2=K:>R/-U^2M[GBW>KG*U]5F1&8.L[9"QOC@C":L.8.N0"0W-5&*
MK57"[7A]\<6/V7/LHKI=0*[%6^KF>3_S?>*@D^92\\@=];3OW=/:E;45^Z.T
M495N34Q:ZEWQ,CTEX5`^3[EK"`/(XKX\"-NNLHZO,\`\C9'*0>+-UI<&?45%
M1&%53ZN%+NZS.P:F?$'6"J9,@"'F[R%#)'503Y4MY'L54:KR.758F5[@[;F6
MV=VHJR%J=CR#$*SE@>18`P*B0=U50)^`UT'<<#V;WOMF/5[>R[\-LBI`$9%:
MQ:U1@%"$B6R%!7RV,Y)!VECK$EQQ\')48\EQ3M*C8V\NBA4*U=8<%)H<WFOS
MY=[3"-G)L:'H(NKMW2G,.2,2<T2B:U?(HF*_;T]Q;,O.7W:AZ:187Y,"R.\!
M6AP2AK6-@P69)Z$QS>5V9>VX@[;[=RJLG):E:^"$5V55<FL0&I@+!<\PQ4V<
M8`W903K>N6UV!HY4:TI;W*3Y*P(P:RRH9,)[H=E+APRH*!)%&4Y)T,#!H$;C
MD4+E3^YXF?(Z7\7A]PO#5O7=6))97!W4$]1,023)@3\/*%X?^G]R[/B-7D57
M8]K<0%>LKY6*J84@264`<1R/$^,,7RCRU?7"Z731E.@(\^EQ83R"5+LQ$@RS
MNT@!QB4#(:EE$(`SBI(&_N![$\57Q1A=5VC'I_#5-$LKV$#ES)`X&><[;B(/
M4?;(Z#W)F9)S\A.4(]5`)X&H*3ZH@UA9)@D\@?*1L=H:^.%>,N0;=UY1W.<K
M(-+-6)*SN[NHM94UM!`2\KKF;`!:64VI*V/9_A.#X1IDEP#N5[0D\1=\'O?=
M.W4BN^FUVO60]2EF+GB5!*J&W69W42-BPWUMO:O8>]9)MQ,JBM,1^)KR'"HM
M:^HKLH=F0P\%85VXL20K0L[)\><&5?'MH:MO^6<GE*B[)87P)%?!OWK2;>VG
M"=H9E=J+.]@TLREL#,'6,BUJS%0K5-_2K3MZYGN/?;>XU"W'P[KK4A""4\U2
M@\`45"P8;OR?CMMO*Z[KLOM''[+D&C,[EC8^-:6L!5;/)>[#U&6UK%1D8Q4$
MJY[@MM#C6$+&T^);'E>+3YSC_DK<WUY>SZ^$;3:`^+XZJ=<.JEP:VDS^3I9=
M/H9@"'@M&,$<L,D0YF.5@W(C6[VNKWQ7VDWY.1BT8]=8)"(++FKY`LSV,&0&
M#))#!@#N>NN3OR/RIO\`<2XV#A9^7F77,JFVPT8R7!"JUUTHR6,"5@*K(49@
M8!V#F;E[F#';*-H*+9S<3G9L.IU*#R=3$HX&;FLLB5EQ7:\R`+:Z6WFI6_VH
M,EA6&4BMFR.R$>]V7L_9LS"./?0M^2I9/O&+%Q')36)XHHY;LI!$2B]`'NCW
M)[F[9W1<S#RFQ,)U2V*4%:U,&*.MQ@O:[<-JW!#3%KQR)W(^>(QQ\X6ENZ!:
M5L;3\!.US:6Z)`EV%0?2<@\;S)T.1-KY<X)G,NAS8_9BD1JP_%[W$:J-XSW&
MZGL2T\D9JNX>GR60&"4W`$`@?R\3O'U;`#KZ?[)K=?=MF24LKKR.S^MP<J60
MVY.,S*64L#YQ8NTQP@DD;=<.O(-?26G333IIKRYJ/:YB]^SFJU>RJU>SD[+V
M<G947]?]>@V,ZH1(@]#K6CDKA>LL^/=%QK60-K/H=M5:N!9V%199^UOJ>9=S
M,Y-!*:3<6\$$R*+]F\&#(Z1XL:@U1&=NW3]L[W;5W&ON=K4+D4/65#!U1@H<
M$?=*2#YMR(^/77!]]]K8]_9;^Q8Z9;X>77<KLC5O8C6-4P,WNH8#A`!Y0!!V
MB-)-!\!.U-L^YOM5SS/E&KJZMDQB9;YJ2JF#IHH85+-GU"3_`-OGW-+%C"9$
MFF824!@FM:_Q\D=W./\`F#^$J]''J[>J!BP/J9O(<C+`-$A6))900IGI.O*,
MW\F_ZADG*S,CO#V%%4CT>U\&"`+6S)RXL]8`".P+J``#$@S6P^$+'=M\=)N_
MH@[76YKN0V#0_.%7^?//')#<EFL"Q`^T@,AE<)D20I(K!N[(-.K,/W]7@&<:
MCMH/#B);,:`#/ED'B9$EA#$^.I.Y_E#?W@1G9G>R/5-AXU]L3DQ!7S\6'->)
M("-*`>&K1_\`J:]6M6"F?KOHTM=%F%G1PGK/GD[PE-'C1"B88MJ\WX:Q(01-
M`JJ(0Q-:-&)W1<O_`.$RT6F\4]M%A$$ALL3N3TX]9),]23)G6M_^`K'..,4Y
M/?#0K%@"G;3!(`(DO/&%4!>@````G5-C?Q?9>%())BZ'Z)`8GCXJ.!\_HT'B
M9#M6,S]Z\0O81O=KD_K;_JBHOZ]2O^:66ZA'K[:5'SR]]HW\N_\`#4%?Y`=O
MJ<V5W=[#'X+V[;>=O/MOX]=9%P?PS>\:->#&<F?4-772)A)5C1%7@ZQS=V,P
M7`)6WN<L-))I;:I>-[NX#`<U7.5555ZUN?[[H[F>6;B]J>P"`W_%*ZP9E7"!
ME;Y@ZW?9_P`I,OL(*=KS_<%=#,2U9_`-4X(@K94UI1T_V67KOJ#1?!;L[-SU
MA!TG.4N3DJ>=29A+_*?-VGAT<6>"'&+(KZS0VMG5BL0A@C0)E"JA_56IW7JZ
M_P!__B4LK>K`"W.&?A9F(6(),%D56B29$[ZMQ/R?.#;3?3?W=K,:IJZO4I[9
M:*PP4$JMCL@8!1Q;CMO&IO5_"U]LIA[/5<K?3FBFG$Z$QTL'`WA`CBE!L0I5
MPQVT6OK(PYG9PA!&T3',54&GZ*MF)[\Q\)!5B8G:ZD!G8Y6YB#R/$EC'4DR?
MCJ7N/Y1YG<[3D=Q[CW^^TCCN.W^4`AAP4.%4<N@4``CZ=6,+^-:M%%B04VOT
MR2'"4JQ(TEG!$J/&<9`M<\`9%\44<C6QV(QPVL<-&]FJB?IUGG\S+2YL]#M8
M=NI'XH$Q/6$WZF9Z^.M.OY%4"M:?Q7?S4DP#^`($QT!L('001!$;:G;/^-2F
MDN@//L?H*82-7LBQR`@\%^<,*125[@'23<#'),2+_P`:$:<7ZHYO9RN5;*OS
M-O7D%I[<H+29.5N9F1"[">D0?U1J;(_(G%<HSY7>F94@$+@>41Q@RXDD=9Y#
MQ&\ZNV^^"'[>O=0:C9<X3*F5=UFDD"FY_@0(%NZN(L&'/(ZNMO<UX0HJN8-O
MJ5SE5&_JJ=8>/[_&#9^(Q:<`6A&00^63Q8R1NOC\3O\`/6RR_P`GCW:C\'W#
M*[LV.UJ6D-7V\#U$'%6/%YV'@-M^FLD\8_'A.+=OD-.[5<Q[06>UUAOW0)];
MPM71K/5S\B;#+.T-E5S:RVE>JD.U4&+^VKP,=_Q)^NL[I[R'=<&[%]+"H-E(
MJD-DDK6+!;"!@RCS#J=X)&M[V#\LF]O]VQL\Y'=,I:,ELCBRX*AKFI-'*QD9
M',5D;#:5!ZZZ`4$8\.BI8DH?IDQ:FNC2!>;">HX(81&'YC<X;_`C53NU51>W
MZ+VZ\^R&5\AW0RI<D?83KV7"K>K#JKL$6+6H(ZP0`"-MM5;J'63ITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333I
MIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIIT
MTTZ::U9YCX2+RG.L(MD[75D(&IPVWSF@Q4O')9P[S(4U]7,9)B:[W0R!\[=5
M1J@>UZ^*JJ(CD7J^R]\':D5ZO19S5;4Z6BSB5L9#L:]Y\OQ&O/?='M1O<-SU
MW_B:ZER,>^JR@T\ULI2Q=Q=*QY^G$SMO$C6L</\`CIQD&\33Q]KSPEV*RLKF
M!((O!94I;2Y0R7$N@B/SZP*(]JX[GR%BL%["HA%_N(CNNH?\R,UZ/PK48'H%
M54C_`(KS*L<0YYRP6('(F!MTVUP-7Y(]KJR_QZ97>/Q8L9U)_`'@[SS-8]/C
M67F6X`28;ZA.J+K/X[\9JY4.?H;GZ,N25$*12U\9DG@$<(8#'_.-:"KUCQX;
M[*18$_(68]OY:R&(]5_I;U-B?F-FXB&O'3MJ!V#$QES($!9DGB!MQ^F#'QUB
M]R_)/M?<;%NS;>^6M6I11/;PH!/(N%@#D6/+F?/R$^`U!G?QU<>7<2AJ;-O/
MQH5)7K61?R#\&.&6.=!O4MJC9!/S)P"`\ED(SW/*1SWN(Y?)MU?YC]QH>RZK
M^GBQVY&!E=1_AVV!GI,0(``VU;=^279,JNG&O_K)JJ3B).!$&#+[GDP(GE'(
MDDDD[BWJS^,WBJF]KH<7Z,*:2YQW29%EP::4(QA."3^\LX;B=Q+XN&3VA7LB
MJU53OUD6_F?W:^`Y[;Q&T!<H`QOTC]X@_/6%C_D-[=Q9-2]\+-O);`)!(@[\
MA.W4&5^6LLM^1)"9F=BS:SZDGY"PK!UI\U:67`5K3A>&RAVH;BMBV$F3^T:(
M$N"-!SHJA,(:*QBM:JIUJ/\`K!?Q2YRT]J7,5N0=1EJVX*E20!R0@F5:03N=
M=$/RV?\``/VILGW"_;7K"FIV[>Z"&5PZAB>%@*B+$XL!L(!U\I/D$.<L[F_I
MYW//^2W<6L@&TUU3_-&GO8$&J;8M!%H[#1I9FHFR$M">]\51%(K!_P!:>MO5
M;_>+9-28]R]O_"UEB$5LU%):)+!./..(@-($G;?5<3\M$P<BW,QF[Q^/M5%-
MKIVNVQ53E`K:WD:YYGD4@F%WV&K=M_ABLTD]MCH-']/V]D62DF9:VUIP=/G2
M'HD?R1TDD\QQH7\5B/<Q%(1._DY57OUD4^^[<:OT\>OM:5@0%5<D`=?"`/$Q
M.P\-8.3^4E&==Z^;?[@LO+2SNV`S$[>)8D3`F-SXGQU)1_X\<R2Q_=R['Z)6
M0)`)''>FX=N#@8CB/],22OY:QXXY!WD*-KV,(B-1J*K>ZR-^8N4*_1%/;N)F
M>/XA0?M&TF!`/4;_`!U"GY*8!O\`Q+97>^8B!8<)R!N8!W@`DEA(!VCIJ=@?
MQZ8U-`;6/T?.$'2-MAV*3%A\,)7RWQY;YT=JTHHEC7NAH8G8GFT<DKF]U?V1
M.H[/S%S?PXQ!5@MC<(B<F1(@^:5,QTZ@?#4U/Y+=K_&GN1O[LF<+.7+C@\6@
M\AY`&7C/60&/QU4-/\"U.K3)FE\@<T1K/#"LH^:M6U/$JR:=;56$L950@@,0
M1)1D5W_-?DJW_8B=NZQXOY@78GK!,?"-5Y!=>61#<>@:3X#_``\=39_Y.8W<
M?PSV9G=5OQ`PJ?AARG/ZBD`02?\`%RCX:ROQ%\Q)PY:)84]GMM"UN0C\?U=7
M84W'M%5U=0;91-;*M)IZ27&FV,X<T954KU(11E5B,<U@FLU/>/=']:J].Y**
M_OC:S!KF9F],UA0&!`$1ML)$SN2>C]L^P?\`IC)]?&LR[Q^&&.B,F-6B(;Q<
M78UL&9@T[F3!@`@*!O-UPFO6].FFG333IIITTTZ::=--.FFG333IIITTTZ::
M=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--
M.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FF
MG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG33
M3IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333II
MITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITT
MTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ:
M:=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333I
MIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIIT
&TTZ::__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g572031st_p73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g572031st_p73.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!``````$8`1!1`0`!`````0`(`!%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`(&@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`$P!/@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?J***`"B@D`$DX`KSSQ3\6=,TB
MZ.EZ)"^M:PQVK!;?,BM_M,.OT%`'H=%>'"?XGC4#J@UFP;5`-Q\/^:N1%_N=
M,^V=U=?X5^+&E:S<#3-8B;1M84[7M[GY59O]EC_(T`>A44`@C(Y%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!0**!0`5S?B[QSHO@NT674YF,\H)AMHQEY,>GH/<UTE>4>
M/HXY?C#X(25%=#ORK#(//I0!@:MJOBOQM;_:-7N_^$7\-2?<B&3<70]%7[S?
MH*CL3:Z+;-:>';,Z;"PQ)=.0UW./=_X![+3'FEO+F2\NI7GN79@99&W'&X@`
M>@]A17T&$RR"2G4U?;H?(9AGE64G2H>ZEI?K_P``C\B+&-G\6[<"=V[USUS[
MU/?M::Y;K:^)+,ZC$HQ'>1X6\A_X%TD'L>:917?7PE*M&TD>3A<PQ&&ES4Y;
M[I[,LZ5JOBSP1;?:=*NQXI\,H?F3GS[8>C*?F7'XBO4/"/C?1O&=FTVF2L)H
M@/.MY%P\9/KZCW%>403RV=[#=VLKP7"R(/,C;!(+`$'U'L:Z7X=QI%\5O'21
MHJ()EPJC`'-?-XS"O#3Y;WN?:Y=CUC:3G:S6C/5J*HZOK.FZ#8/?:I>16MLO
M!>0XR?0>I]A7+K\5?#6Y6F.H6UNQPMU/92)"?^!8KD/0.VHJHVIV:Z4^IK<)
M)9+"9O.C.Y2@&21CKP*?87UOJ>GV]]:OOM[B-9(VQC*D9!H`L4444`%%%%`!
M1165-XAT^#6DTJ1W%T^`/E^7)Z<U482G\*N1.K"G9S=KZ&K1534M1M]*LGN[
MIBL28!P,GGVJH_B&R&@-K*^8UL!P-N&)SC&/K51I3DDTM&[?,F5>G!N,I*Z5
M_EW-:BJ.D:I#K&G1WL"LJ/D;6'((ZU>J91<6XRW1<)QG%2B[IA1114E!1169
MJVNV>BM`+KS,SMM38N>?\FJA"4WRQ5V14J0IQYINR-.BL:;Q+9P>(8]&9)/.
M?'S@?*"1D"MFG.G*%N9;ZBIU85&U!WL[/U"BBBH-`HHHH`**S;+7+&_UC4-+
MMW8W5AL\]2I`&\97![]*TJ`"BBB@`HHHH`*!10*`"O*O'7_)9/`__`_YUZK7
ME7CK_DLG@?\`X'_.@#DX?]6?]]__`$(U)3(?]7_P-_\`T(T^OLZ7\./HC\SQ
M'\:?J_S"BBBM#$1NL?\`UUC_`/0A75?#[_DK/CO_`*[+_.N5;K'_`-=8_P#T
M(5U7P^_Y*SX[_P"NR_SKY_./XL?0^PX;_@3]?T-&QLXO%OQ.U>[U)1-::`8[
M:SMG&4$K+N:0CN>@%=OJ%UIMO"(=1N+2.*4%=EPZ@..XP>M<7K$.H>#/&%SX
MFLK&:^T?441-2@MUW2PNO"RJO\0QP15?6O&WP\UR")[R-=6N8@?)M!:.\P)Z
M@+C@\"O(/HB^FFZ#HW@[Q'9Z%?I+!):W$XMEN!(L.4.0@'W5SVJAH&O7NC1>
M![68Q_V/J>G);@[?F2X"!EY]&&1CVJEH7A273O#OBSQ!=:7'IEQJ-E*D%A$!
M_H\*H<`X_B)Y-:,VB2:U\&-,BARE]:V,%U:L1@K+&H8?RQ^-`S;U_7;Z/Q9H
MGA_2C&)[EFN+QV7=Y=NG7Z%C@"LM=6\2^,-2O4\/7EMI6CV<S6_VV2#SI+B1
M>&VJ2`%!XSWJ/X:FX\0/J'C74(?*GU/;#;QGGRX(QC`^K;C53P]KEM\/9+WP
M]XCWV=J+F2>QOV0F&:-VW8+`<,"<8-`C?T:Z\6:=KHTK78X]2LI8R\.JVT7E
M["/X94SQ[$5F6FJ>*?&T]U=:%?V^C:)#*T,%P]N)Y;HJ<,P!("KGIWK4TKQB
MGB;6S::+927&DI&WVC4VRD>X]%C!'SGU/05S_A?Q):>`[)O#'B=FL#9R/]EN
MW0^3<Q,Q8$,!C=S@@T`;>@Z]K-GXD/AGQ-Y$MW)$9[*^MUV)<H/O`K_"X]/2
MN2UR2>?Q)J.HP#*VDZY/I@X'ZBMNRO6\8>.;77[."9-$T:WF$5Q)&4^U2N,'
M8#R5`[^M/\+:6VI:/K9FC96NV*KN&/4C]37I8":I*=5^2^]ZGBYO2E7E3H1W
M=W]RT_$7QCJ+:O:Z58VGS-=*)RH^G`_G4>AWK1_#_4T`4O;N1AUW#!QV_.H?
M`VFW$VMM<72.%LXRB;P>"<C`_6H[:&:UL_%%AY;X^\GRGG#=OPKM<81C["/V
M6G][_P`CS(SJSE];EISJ2^Z.GXIEN?7[_3O!NDW-JT<3R2,K!8Q@@$\8HU#6
M?%6E);:E=F'[/,1^Y`&!WP>XXJE?PRGP3H:>4Y(G;(VG(Y-;_CV-W\-VZHC,
M1*O"C/8U-J:G&+BGS2DG]Y=ZTJ4YJ<ERQ@U9];&;J&L^*K:SBUEVABM)&&V$
M`'`/3/?FM;7/%<MGIE@;2-!>7R!UW_=0''/YFD\51NW@6-51BVV+@#)Z"L?7
M=)N)='T744MFN(X(%2>$9SMZ_7UK.FJ-7D<XI:M?AH;5I8BA[2-.;?NQ>NMK
MO6WR'RZYKVC".[N-1L+Z$D"2&.12P_*JWC2XN[VXT^[1T-C,%:V'<,0,Y_&H
M4N/#MS-%#9>';J:9VPR>81CZ?_7Q6IXSLA;V^BV]M`XCB?`49;:..,UM%0A6
MA[MF[]$M+=DSFJ.I5PU3W[Q5NK>M^[2T\NX^.[OX_&VFVM\MNT_DCS7$8SG:
M3P:=-KVN:[JT]IH(2*W@.&F<#GGKD_RI;Z.0_$ZS<1L4\L`M@X^ZW>J-E>W'
M@G5KV&\M));2X?>DL8Z]<>W?I62C&24HQ3ERJRZ;NYNZDX.49R:ASM-]=E;7
MS.@T.;Q+%?26VK01RVZKD3J0.?08ZUS]OXA\1ZMJ$QL9[9#')M6T?`)&??K[
MUT6A^*)M;OIECTV9+15RLQ]?0_7VKBM<O;34;B1HM*N;/5A+\NS^(9ZD?WOI
M2H4W*K)3@D[+M9?*_P!_8>+K*-"$J5635WW3?H[=.E]SU:/?Y2>9M$F!NV],
M]\4ZL(ZTVEP:3:7D4DU[=!494Y8'`R36[7DSIRCJ]F?04JL9Z+=6OY75SRMM
M0N-)\0_$K4+1U2XM[>WDC9EW`$1MV[U=TJU^(&NZ!::TWB.UL;J>!98K);-6
MC((R-[$YR>O'3-9>JP3&]^*.(9#YEG"$PA^;]VW3UKT7PNI7PEHRL"K"Q@!!
M&"/D%0:G+1_$29O`UOJ8T\/K4]T=.2R#?*UT&*D9_N\$_2I3HGQ`6W-Z/%5H
MU]C=]C-D!;D_W-V=WMFN9M-%U.Y\,W&H:;;&6_TGQ-<WT5LPV^>H<AE&>Y!.
M*ZG_`(6IX>-EO5;YKX\#3A:/Y^_^[MQZ]^E`'2:!?WVI:-!<ZEITFGWI!$UN
MY!VL#C((Z@]16G7*7GBZXT#P?#K?B'2YH9Y'56M+0>:T>X_*#[XZUU,;B6))
M%!`90PR,'F@!U`HH%`!7GWQ$\%ZQKFH:9KWA^]CAU32PWE12CY7R<]>Q^O%>
M@T4`?/8UFSFU%K#7[0^%]<)^9G0_8[AO4C^`GU7BK=U;W&GRI%>P^49!F*0,
M&BE'JCCAOYU[)KWAK2/$UB;35K*.XC_A)&&0^JMU%>5:CX&\4^"(ICX=D&NZ
M`V6ETF\&\@?[(]?=<'VKNPV/JT--UV/+QN48?%>]\,NZ_7N9F.<5):6MSJ$C
MI91"7R^9968)%$/5W/`^G6LO_A*/"?D^:;?63=[MG]A'KO\`3S?O;/;K72:=
MX&\5>.8X6\22C0]!7!BTFS&PD>X[?5LGVKNKYO>-J2U\SR\+P[:5\1+3LNIB
MC6K2+45L/#=HWB?70?EE$9%I;GU5?XL?WFXKT3X=>"]7T"[U/6M>OHY]4U0A
MIHXA\J$<]>Y^G%=5H/AS2?#5@MGI-E';1#[Q4?,Y]6/4FM6O&G4E4ES3=V?2
M4J5.C'DIJR"HU@A5]ZQ(&_O!1FI**@T`@$8(R*Q_$^FWVK>&[S3=-N8[2>Y3
MRO.8'Y$/#8QWQG%;%%`%73=/@TK3+73[5`L%M$L2`>@&*L/&DB[9$5AZ,,TZ
MB@!%144*BA5'0`8%->*.4`2(K@=F&:?10`@4*H4``#L*4`#H***`#`%)@>@I
M:*`$P/04I`/4444`&!1110`T(BG*JH/J!3B`>HHHH"P8&<XYI&56&&`(]Q2T
M4`(%"C"@`>@I-B[MVT;O7'-.HH"Q3;2[5]634F4FY2/RU)/`'L/6KE%%-R;W
M)C",;\JW$P.>!SUI:**10``=!3?+3?OV+N]<<TZB@!"H888`CT-+110`4"B@
M4`%%+BC%`"44N*,4`9_]B:7_`&K_`&I_9]M]OV[?M'EC?CZU?I<48H`2BEQ1
MB@!**7%&*`$HI<48H`2BEQ1B@!**7%&*`$HI<48H`2BEQ1B@!**7%&*`$HI<
M48H`2BEQ1B@!**7%&*`$HI<48H`2BEQ1B@!**7%&*`$HI<48H`2BEQ1B@!*!
&2XHH`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g572031st_p81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g572031st_p81.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````@$8`1!1`0`!`````0`(`!%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`/^@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`%\!A@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?J***`"BBB@`HHK$\2^+-'\*:>
MUWJETL>/NPJ09)/]U>IH`VZ*X3PQ\6O#/B:[-I'-)97)/R)=X42?0YQGVKNZ
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`J
MKJ&I6.E6C7>H7<-M;KUDE<*/UKD?B)\01X(ALXX;!KR\O"PB4MM48QU[GDC@
M5YEJ'AS4]6NDUKXBZRUO'(=\6DP-NFQV55Z(/?K32;=D)M)79OZ[\6=5U^\.
MD>`=/FN)&.UKQHLXSW`/"CW;\JPSX9TC2[K^TO%&I/XFU]_^7**0M$K?[;]P
M/3@>U:$VI2/9KI^CV:Z%I.!NBMS^]F_WVZU7B@AMXA'"@11Z=37I8?+9SUJ:
M(\;%YS3I7C2]Y_@1ZA8>&?$)*ZWI4>B7+`+#?::I\I?02)[>M3V?B;QK\.#"
M-3VZ_P"'BNV.Y@?>%4>C]5..S48!!!&0>H]:DL+N\T:4RZ:ZB-QB6UD&891Z
M%>Q]ZTQ&5N/O4ON,,)GBD^6NK>9ZCX9\;Z#XKM(Y=.OH_-;K;2L%E4]\K_45
MT6:^>]1\.:'XAU%;S29_^$:UW<&2%B1;R/ZHX^X:Z;PY\0O$>A:U9>&/&>FR
M/<W,BQ6]ZA'S@G`)QPP]QSZBO)E%Q=I(]^,XS7-%W1Z]1112*"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\5^.:DZWX5P,DSD`#_>2JFJ0
MQGQOXBN"N9?M80,>2`$7@?G6A\;@?[>\($'!^U\'T^=*I:KN'C/Q*#C;]L7'
MU\M:[\M2>(5SR\X;6$=O(C%!QGFFGM2]LU])8^+N+P#0N::3WI`>*8F17L$=
MQ97$<R!T,;9!^E,U"1Y+OX522.SL40%F.2?G6IYN8)\_\\V_E56]Z_"@_P"Z
M/_(BUX>;KWH_,^GX?;Y9KT_4^A*XS6_B?X=T:_?3HWN-1U!3M-M8Q&5@WH3T
MS2?%/7+C1/`]R;)F2\O)$M(74X*ESC.?IFK_`()\'V7A#08;2&-6NW4/=7!&
M6DD/7GT]*\<^B,.#XO:%%*L6M6.J:*[GY3?6K*I'U&:[)]9L_P"PI-8@E6XL
MU@:</"<[U`SQ^52ZAIUEJMH]I?VL5S`XPT<JA@?\^M<Y<^'=-\+_``\UG3M*
MB:.V%I</M9RYR4.>30!M>'M:A\1>'[+6+>*2**[B$BI)C<H/8XK3KR;2O%%[
MX2^$'A/4X+6*>S!CCO2Q.Y(B2-RX[Y]:]-N]3M;/1YM4>0&UC@,^\'@J!G(^
MHH`N45P?A[QY-)X`N/%OB.*&UM3([6\<()8QYPHYZL3D56L-0^(_B6SCU&T3
M2-&M)/WD$=PC2R2(>5W8^[D4`>BT5Q_ASQ'X@EU^70?$6BB"Y2'SH[VT):WD
M7..I^Z?:J&K^,]8U/Q/-X:\'6MM-<6H!O+^Z)\F`_P!T`=6H`[^HYYH[>"2:
M5ML<:EF/H!7G6I>*O&7@KR;KQ)96&HZ0T@6:\L`R-`#QEE.>/>NI\47T1\)3
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MZJC16&F1/<*-S,&R`/H>]-M_'=Z0;673@]Z6V(J$@$],$=:/J-;565UYH:S7
M#.SN[/K9_<=[17$0>+M4M-6BL]8L8X1(0/DR"N>`>I!%;7B+Q''H<2(L9FNI
M?]7'VQZFLY86JI*-M]C:./H2A*I>RCO=:_<;M17-Q':VTD\I(CC4LQ`["N/E
M\1>);&#[9>Z3%]EQS@D%<^O)Q^57M5UEK_P?)>V$!D$JE9%/_+,=&S]*?U6:
M:O:S=KW)6/IRC*UTTKV:=S3L]?L;[39[^!W\B'.\LN",#/2FZ'K]KKT,CVZN
MAC;#*XYYZ&N2\&7=U%87<0LEEL0KN\K'N%^[COFMCPAJ5K)I%W.+2&RCA<E_
M+)P>,YYK:OAHT^=)7LU;7N<V%QTZSIN32NG=6?3MY'5T5Q"^+]6U.ZDCT;35
MEC0_>?)./?D`5HZ)XAU&\U&2PU#36@E1<EU!VCZY]:QEA*L$V[:>:N=-/,*%
M22C&^NB=G;[SIJ*XW4?%6I-K4VF:58I+)"2#OY+8ZX&16WH&I7>J6)FN[,VS
MJVT`_P`6.XS4SP]2$%.7YETL;2JU'3A>Z\G;3?4UZ1V"(SM]U1DTM177_'I-
M_N-_*L#K,WPYXETWQ5IAU#2Y'>W$C19="IW#KP:UZ\>^&>JS:)\&=6U.!$DE
MM)KB5$?.TD`'G%:7A_Q5XZ\;:3#>:39:7IEOMP]W=;W\UQ]X(@Z+GN:`/3Z*
MXWPCXHUB_P!;U/P_XAL;:VU.P1)`]LY,<R-_$,\C_P"O5+4O'&K:GXFN/#O@
M^PM[J>U&+N^N7(A@;TP.6-`'?T5YQJ&K?$7PM:&^OK72]<LHQNG%FK13(.^!
MW_*O0;2X^U6<%QY;Q>;&K['&&7(S@^]`$U%%%`!1110`4444`>-_&[_D-^#_
M`/K[/'_`DJCJF'\8^(R`1_IW.?9%%2_';=;:QX9OW#&WAD);`/&&5NO3.!3M
M0MY=5OKWQ'H5Q!JVF7K^=)'!Q/;D*!AE_"NS`U(TZRE+8\_-*,ZV'<8*[*?X
M4G(XID5S%<`F)PV.HZ$?45*01SUKZ=24M4?$RA*+LUJ-^E)2D=R*!@`L2`!U
M)IW1-M1LHS!+_P!<S_*J5[(-_P`*H_XE",<=,&11_2M&UM+[6FDATN$,FTB2
M[DXAB'<D]\>E9VKWFDR>*?`6AZ/?KJ4NERQPS30I\I.]3P>_0FOG\TJPJ2BH
MN]CZO(\/4I0G*:M>UCU'XJZ)=:UX&N!8HSW=G(EW$BC)<H>1CZ9K3\&>+;'Q
M?H,%[;2K]H50MS#T:*3'((]/2NCKA]6^%>A:EK1U>VGOM+O&.YWT^;RPQ]2,
M'FO+/=+'B_P=H.KSG6-9U"]LT@AV,\5X88PH).2/7FN'\#V*GPIXYU.UFNI-
M*GCFAL&N96=FC1&RW/J372/\(M.OG0ZUKNMZI&C9$-Q<_(1V!`'ZUVKZ/9G0
MI-'AB%O9M;M;A(AC8A&./SH`Y+P+I=OK?P:TO3;M`T%Q8F-@1G&2>?P/->?I
MK-Y/X5M?AC*)6UC^T/L%P<[L6P;=O!]-O'L!7M'A_1;?PWX>L](MY'>"TCV*
M\A&2.N37">`["V\1>//$/C<+F'SS9V+!<*ZJ`K/[GC&?K0`?&'2FM_A]9I90
MD6&GW4+301K_`,LEX_(<5Z)IE[:ZEIEM>6+J]K-&KQLO3;BK$L4<\3Q2HKQN
M"K*PR"#V(K@XOA18V,\[:3KVN:9!*V[[/:W6$7V`(/%`'9'5M/\`[6_LG[;"
M-0,7FBWW#?M]<5YQ\'I(M.G\1Z%>8BUB/4'FD1QAGC/0CU'^-=;X6\":3X4G
MN+JW:XNKZXXEN[N3S)"/3/85#XH^'VE>)[Z'4C-<Z?JD(VI>6;['QZ'UH`D^
M(M_8V'@+5S?2(JS6SQ1JW)=V&%`'<YKF+J*ZT_X6^'+&[5DN!%&)%8Y((7H?
MSK2L?A3IJ:M;ZEJ^JZEK,UN0T2WLN44@\';74ZSH-KKBPK=/*HB8LOEMC.?6
MM\-.-.K&<MD<N-I3K8>5.&[.0U^PDL=$T/48QB2V1%8^G<?KFIO",;ZSK&I:
MI=+EF4H#C(4MV'T%=E?:;#J&FO8RY\IU"Y'48Z$5%H^BVVB6C6]L78,VYF<Y
M)-=/UM.@XOXOT;N<*RZ2Q49KX%:Z\TK''^%'-K#KVFR'#(C$#Z`@_P!*?X-"
MMX5U8-TPV?\`OBNC@\,6EOJ-W>K+,9+E75P6X`;KBI-+\.VFDZ?<6<+R/'/G
M>7//(Q3JXFG)2MN^5_=N10P-:$H76D5);]]C!^'2#^S+M]OS&4`GUXJMI2*?
MB1>9`.#(1['`KJ]%T.WT.WD@MGD97;<?,.3TQ3+?P]:6VMRZJCR^?+G*D_*,
M^@J98F#J5)?S*R-(8*HJ5"#M>#N_Q.9\>*/[4TM@/FSC/_`A5/QE;R?\)/;2
M33-#!(B!)B#B/'4_UKLM6\/VNL7%O-</*K0'*["!GG//'M5C4])M=6M#;W:;
MEZJ1P5/J#3I8N--4_)-/YDXC+YU75?\`,XM?)=3B[G1)$LO.N/%2FW<8R6)#
M`^V>:UM/TD:3X4U%5O%N8IHFD1E&`!MQQ38_A[IBN"]Q<NH/W<@?TKI#80?V
M<;!4V6YC,>U>PQBBMB8M*,975]=$@PV!DI.<H*+M9>\WO^AR/@SGPEJ7U?\`
M]`%9NA0R3^"=:CB!+[@<#N``3^@KM=+T"UTK3Y[.%Y&CFSN+GGD8IVC:';:)
M;20VSR.LC;F,ASSC%.>+A>;CU::^0J>7U.6E&72,D_F8?@G4[!=$6V:>*.="
MS.K':2,]?>N@M]6TZZO'M8+J*2=1DJK9./ZUDWO@?2;RY:?$L)<Y*Q,`N?H1
MQ5O2/"^G:-*TUNKO,1@22')`]JRK.A-RFF[OIYG1AHXNDHTI1CRK2]^GIW,#
M7]+T^[U*>;3]1CMM3B!>2/?C<?KV-:/@O6;K5;"=;Q_,D@8*'QRP([U)?^"=
M+O[N2Y9IHWD.Y@C<$^O(JY;:/'HFE7$6EQEIF4L-[<LV.,U<ZU*5%4[W>EKK
M;OKV,J6'KPQ+JV2CK>S>O;3N:D-Q#<*6AD2102"5.<&DN?\`CUF_W&_E67X:
MT;^Q],"2<W$I\R8_[7I^%:[J'1D/1@0:XZBBI-1=T>G1E.5-2FK-]#Q+P5S\
M!/$H]&NO_05KT'X7Q+%\--!"_P`5L&/U))I^D>`=.T?P??\`AN&XN'M;TRF2
M1R-XWC!QQC@`5L^']&B\/:!9:1!*\L5I$(U=^K`=SBH-#CE^7X^R8_BT,$_]
M_*H?"&Z@LY_$6B716+5TU*69XGX=T)X(]1_C7<?\(U:?\)A_PDOF2_:_LGV3
M9D;-N[=G'K6;XH^'^E>)[Z#46EN;#4X>$O+-]DF/0^M`'1:AJ-GI5E)>W]S'
M;6T8R\LC8`IXO;7[)'=?:(A;R`,DI<!6!Z8/O7"O\)["_O8)]<US6-8CAY6"
M[GRA^H`K>\6>#-.\7:#%H]T\MO;12+(GV?"XV@@#D8Q@T`=$""`0<@]"*6JF
MF6$6E:7:Z?`SM%;1+$C2'+$*,#)]:MT`%%%%`!1110!!>65KJ%L]M>6\5Q"_
MWHY4#`_@:\EU[X07FF:F-9\"Z@UC<*2_V5G('T4^A]&XKV&B@#Y[F\3V5[>+
MI_C33)]!U]/E&H01[4;T:1.X]QFM*]L=1TNTBN[I8KJQD`*W]HV^(@]"?2O6
MO$'A71?%%J(-7L([@+]Q^CI]&'(KR35/!7B_X=I/=^&+YM1T7.Z6QE3><=P4
MZ,/<8-=-#%5*+]UZ')B<%1Q*]]:]R"!Y+ZY^R:="][<GD)#R`/4GL*34[S0O
M"US_`,5)=)J=VIPNE6#Y$9_Z:M_2JUAJ'C7Q=-_9_A/2!X<L3@W,L:&,%CU+
M.1GUPHKTGPG\*?#_`(::*[EB.H:F,EKFXY&X]2J]!]>3[UIB,=5K:;(QPF64
M</JE=]V<+%X;\<?$987NBN@>'&8!+)/D/E_[@'S'W:O4_#/@?0?"=L(],LD$
MIQON)/FD8_7M]!7145Q'HA1110`4444`!`(((R#45O;06D(AMX8X8EZ)&H4#
M\!4M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
H%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
